<SEC-DOCUMENT>0001570562-22-000143.txt : 20221108
<SEC-HEADER>0001570562-22-000143.hdr.sgml : 20221108
<ACCEPTANCE-DATETIME>20221108170222
ACCESSION NUMBER:		0001570562-22-000143
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221108
DATE AS OF CHANGE:		20221108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolus, Inc.
		CENTRAL INDEX KEY:			0001570562
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461385614
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38381
		FILM NUMBER:		221369773

	BUSINESS ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
		BUSINESS PHONE:		(949) 284-4555

	MAIL ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>eols-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:9907a7dd-9da5-4da3-a916-5b93970552d6,g:d423565a-304b-425b-af42-a6f72195e86c,d:dfe4cc3337b24bc380d09a49794cd329--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:eols="http://www.evolus.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>eols-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80L2ZyYWc6YWE0ZmM3OWI5NTZjNGY0NDkyMTY5MzAzNmUyZWY5NmEvdGFibGU6YjQ2NDQyZGYxOWRkNDRjM2FkYmM1MDFkNTYzN2FmNDcvdGFibGVyYW5nZTpiNDY0NDJkZjE5ZGQ0NGMzYWRiYzUwMWQ1NjM3YWY0N18xLTEtMS0xLTY2MzUx_e1d73f59-b7c5-4d27-b0cc-9730a4aa9eb4">false</ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80L2ZyYWc6YWE0ZmM3OWI5NTZjNGY0NDkyMTY5MzAzNmUyZWY5NmEvdGFibGU6YjQ2NDQyZGYxOWRkNDRjM2FkYmM1MDFkNTYzN2FmNDcvdGFibGVyYW5nZTpiNDY0NDJkZjE5ZGQ0NGMzYWRiYzUwMWQ1NjM3YWY0N180LTEtMS0xLTY2MzUx_a378f7ab-421e-44e9-8aef-1f880b97d0e4">2022</ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80L2ZyYWc6YWE0ZmM3OWI5NTZjNGY0NDkyMTY5MzAzNmUyZWY5NmEvdGFibGU6YjQ2NDQyZGYxOWRkNDRjM2FkYmM1MDFkNTYzN2FmNDcvdGFibGVyYW5nZTpiNDY0NDJkZjE5ZGQ0NGMzYWRiYzUwMWQ1NjM3YWY0N181LTEtMS0xLTY2MzUx_51ddc4a4-406d-4555-856c-9a3921b2dd44">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80L2ZyYWc6YWE0ZmM3OWI5NTZjNGY0NDkyMTY5MzAzNmUyZWY5NmEvdGFibGU6YjQ2NDQyZGYxOWRkNDRjM2FkYmM1MDFkNTYzN2FmNDcvdGFibGVyYW5nZTpiNDY0NDJkZjE5ZGQ0NGMzYWRiYzUwMWQ1NjM3YWY0N182LTEtMS0xLTY2MzUx_3cdb1727-e765-4202-a440-bc34670feb2b">0001570562</ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80L2ZyYWc6YWE0ZmM3OWI5NTZjNGY0NDkyMTY5MzAzNmUyZWY5NmEvdGV4dHJlZ2lvbjphYTRmYzc5Yjk1NmM0ZjQ0OTIxNjkzMDM2ZTJlZjk2YV8zNA_0fef1358-277b-440c-b76a-b15049c3c961">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0wLTEtMS02NjM1MQ_10a43e2f-3e60-477c-96dd-c813c9ca153a">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0wLTEtMS02NjM1MQ_41cadcf3-4b1a-47e7-9c8e-6ea6514114cf">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0wLTEtMS02NjM1MQ_42d06fef-136c-4320-8d1b-5576fedb6eb4">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0wLTEtMS02NjM1MQ_d46a4bb0-fbe7-47e2-be47-adc7a74bafa6">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="iee5500851309496fb43072fa4dccbd43_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzU1MQ_69856644-a55a-4627-8d51-4a7ed13cffd0">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="eols-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5d4379a4158c443fab6596315f543818_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39ff6d4019914c7fb0f58a9c69af0da7_I20221104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if255f3612ce24011914ed9f9fc5283c0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b0a77f15c444c19f759b3deaef409d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd30dda6fae047ba8fc0f4931c1cf694_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie045c20cf6bc4a46bc1cd1a0cb076bd5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22f3e32c1ab94b0382fce87da10b1f25_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i519de1da8eb84a708ab6875c547d1cb9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7a96d1a07754c188b0a005f18255480_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57cb5111d30d40a68b4e495a42bac87d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i325d14c124e140b2af640417dd708743_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19b70069ec2b4bc88563acac780cb0fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie933be957e064dbf9e19c7a328a5a3a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icec2119209b14768b574684aa088fd0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbfa32b8bceb4d85b8d585d6362e9ead_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d107be2e3b249e3a47304c93fca1cf8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b2a587e790f4e898dff40a08b249f56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9ad3bd07da14e6e91626d72417cbd26_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14697910a2c7431d8e843fa9e6047c3f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i089a8fa6f6594b3f9738d50bda403e59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d310130bd084da3ac0de405205ba752_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2006f8ecb5641f4ace06a537399080a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i322856dfc9674ae588e828493d27d95e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia31b6cb915184194bff3d93618626fd2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i111481324b7843119d6ff1bdabd0d80a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1769ef3b028f40ceb603ef14511541b8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7727dfd31c3944fab9afd583ea30a2d7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29999457232e44aeb12a5ace34004e44_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29512e75fcde470fa4dc860e639a878e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5492be0135c14a0aa71f49ae2531d9a3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i173b74f14d1d431b99aed7270421b1ec_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib97a0827a3aa4c1e87cc2994ec2eedf5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5af4588f76d4ab8bd0886c2f0f3080f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65e3e596ba3f464aad3607fcd5ad2218_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i490de831fccb414783dc72487430e05b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e4cc38409b74c9b8c6c73ff0a0b3ddc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if314cfb6f75348ed94b97148ad316c5d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96c5b48b38fc4cd6814bfde2d6a09765_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddd953d7c6a94c3a9fbeca055456caca_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15763c0703af45cbaf1faa81f158530e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic940384570964e689ab795df4e66ccb7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13db4b6383624d5097720364e94a31b5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c628e554673429f919660de503a710e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide79544f24324f7b8502d4f715dcf188_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia80760aeda834165a0bd09ccfcabfa32_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48b21d372773402dbf5d667fe310b72b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideffba28e2bf412cb0e77892da2aa722_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2512c22190594595845dd6dc9d382f8b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b5a39a32eeb4cab9368027d10b64144_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e42c0d2b5a8488e921290035592036a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5cb60ec41f240cdbd130979758bbe33_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8398583e0d2541f0ad8db5defad16243_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbb65d439c414edbb7040d29388dad05_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i458f436d90584702b2e171f24fc2ffd9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54b5f0ef22bf4fa9839716763e9e8209_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2d7f6a0cb1b497cbfc385cc704bccf2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1fddad6db8d4551816b8c9aecd79504_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b12284fc5ce4b21a29b45a18ae68685_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff586361777d462b9327912ebb0fdc8c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41a3e5c8a1c94c8488ef9e164b01e0cf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0566f63895a44386a854828b2eacdf90_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a862462206439c8bc023adde6f54e2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib29835257f2c4dd18c50418dd8adfee9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c84c79944be420fb608efbdf8406369_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id470dada4c0e4d9f9665fcb85a0e6d32_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2398dc3c9da43c4ac481b18ad745499_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47b462307ce144bc832c08ae7d8df5c1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b7351c853c140558b8a86c3ba8db24b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf8b55b81fd54639927f832aefd0c105_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c698504400444cad7bd76a594cae6a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38daf97bf6b54a5d9f36afcbc66faad1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe0af0b6fdac41d79d91b5cfebd2f064_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7690b2a3bee42b0adbdb700c288530e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i483c0c81c82a4127a108474382234dae_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia70412995ddc4b699370638e386fbd7d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a4f256b4cc8459bacffb1ecf8154425_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i986ed2aacf8249efa66cfd1e39a120f5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i711c0ec8101d43c2bf551aec2015fe93_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i517b67724cfa4e4a9a9d6760c1b208ba_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie47683c6c9bd447d932d1f3f3b371104_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41fd4a2cf7cb49e6a38c2fc9b0df76fd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i696aed9396534e69a8f395b92916dbb8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86e69b86a1f34f1f860a8d0303c3f93a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb5cba7d4b31433baac45503a471e4ed_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d9bfad2231c4ef9be095f3e3afb8838_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaff2091727e4bbda42ae97fb2c0ca83_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eda81fe6f4443b3840b17e1ed17844d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67e38e0bc0df4e4d88a289133b9464f5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ca472192774250bc53a843ace80459_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68b52e5c01fb45b685329d95b6300084_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19e324736d7a4b58bee7bebe0815ab9a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0788351e9e084ee681884fb575fce218_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a3343570b8b4e2da7fe85c347c87365_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4b79303cf634cad95d0ba5d12c163ef_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e2257ed337439eaac012b86d0a396b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ee94ea6704b4637b072dc991661fa7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf185154c94a4f079a63adb078d887d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafb5504b024a49c98e5b98f03ed55642_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>eols:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i74d2705a944e47df928e202fbe73806f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd37f700914349598839f80a5c3ac5fc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39e0aaab2daf4a1f9ae49292e3fa113f_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7982c1b9a3ab4239b877aa1d02a5459e_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f6eead0dce949398cd5a205a8b761a2_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id23cfd7dc1564cd6aaa76f53b45ccf4f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0997749416bc4e028361e395d1f8bf92_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6fd11493b9d4a18967f5147f5eb25fc_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6f902c0f3cf4c5f86905379573f1883_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84371b8801da47da9efba13175f076d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if066a834ef404c0da380ab9066a249ab_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd893c426cf344bfb3e70e80a9717b85_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa3b589eceb84e1c94c3c2c4af20ab72_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib29f2936ca6c4e15a73ecfb1e92029f6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8813e5b8a70741dc843401ec024d4735_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib956a75826f1489e9a25f9ab19425726_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i107ea59f6dc34340846131488239195e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b9df72617243df82a84ee6f7a17e88_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33badbda974443e1a5a538c1d41eb1f2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de66ce7e4cd487684e1ec075b96e8c2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib955eea1a8f64090909d07cf0f04a443_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc3b4cc897fe4b31821dca208a7264a5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iead433642b5a445d83074f84bb63c628_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03eb03f09bcf4e01b9c6fba2243bb8aa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b9d9f3ec3d401cab72265246433b66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11377a43f27c4faba7aad6793f724743_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8509a6d0797e4a1b8fd1d32a15d74377_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84d7dc8ca08a4da6a6c642d9a973ff92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7373271b2dde4aba839209bce8d0292e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib746515f688d46d7934e1ac056024bba_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74ba879b9f0b49eeb45d7c48810743cf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefccff05ba3b424ea7695cd478bcf8c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d5a4bd9076b49e990faeaca86303ea1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b7b2f262aa04bfebf9a790343dc73ff_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d84afa1250640b198c1fb1a6169c85a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieab10e4bb85e456c8270ad88c92f573a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a097741d79a4319ba97c97d46d0a539_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eae918cd3a1458f8f5c7ea81225a697_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492a93cfde634638aead055c0ca3b153_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8be82e572d441889a4d6f6934c06888_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic324d34859d240ffa67a43c66f937f95_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87008557f7394da183cb13535fff98b5_I20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>eols:tranche</xbrli:measure></xbrli:unit><xbrli:context id="i9f70375f5d4e414ba6839f26fe0ddc44_I20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i681b2a7d205d410ca672bf2a337a55b0_I20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie655358ab82b4cf3933d54db2925cf4b_D20211214-20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-14</xbrli:startDate><xbrli:endDate>2021-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0931e5250f9643efa1a3ac8af4f22859_D20211214-20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-14</xbrli:startDate><xbrli:endDate>2021-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="payment"><xbrli:measure>eols:payment</xbrli:measure></xbrli:unit><xbrli:context id="id0259e20c7b64238ace67075cd4ebde3_D20211214-20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-14</xbrli:startDate><xbrli:endDate>2021-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb4a33cd285f450c9199ba56c40498b4_I20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39eaeea68ce4b2b873c2e7097ffad4f_I20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb4fee43c2d44ee2b2e15ef341def13b_I20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bfea5e3671f467c9abe90444ff80e16_I20211214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12401c3106e141e3932d964c36466a9c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32423b3783a74a82a50b52069242757e_I20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="advance"><xbrli:measure>eols:advance</xbrli:measure></xbrli:unit><xbrli:context id="iba0b2ad793844b26a191ac3cd34f31f2_I20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoanFacilityTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6b945adff8f46008df2b4591b66e2fe_I20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoanFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de13a38f24141ecadd52a63c397047d_D20190315-20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-15</xbrli:startDate><xbrli:endDate>2019-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f2553d528c41c3ab5ae3858f5fda13_D20190315-20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-15</xbrli:startDate><xbrli:endDate>2019-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d21558b1b844fea9ffd52152f5a0b6d_I20190315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ea01d8678a148839f20dd947155b9a2_D20210104-20210104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9984dc72d84a433bbbf2c8e4297d8ab3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcabd9d8120a4b52ad4211b9b2779160_I20200706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfb737bacd0248fc910875d3a4549e77_I20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4504c78963354d1badb28c7c64e116ec_D20210323-20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>eols:position</xbrli:measure></xbrli:unit><xbrli:context id="i671a3057546c42ba9908a766f27874d3_D20210323-20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b2b0c3bea3a4f22ae04d9279885dafc_D20201016-20201028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-16</xbrli:startDate><xbrli:endDate>2020-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="complaint"><xbrli:measure>eols:complaint</xbrli:measure></xbrli:unit><xbrli:context id="id4a4bebb895c49d0bbdd0bf38322e752_D20201127-20201202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-27</xbrli:startDate><xbrli:endDate>2020-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>eols:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i32d51cd4bd6f4489a4adb7b2aa247e44_D20210228-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-28</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8fb36cf68884af1a7d8744f3d77a5ba_D20210325-20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia933b0ab944743ada651aa08e01c3fa0_D20210326-20210326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2021-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib05b2ea5b15449b3949c409f13302aba_I20210326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39845926fd4c4a7185d0ad1aec0a9125_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d569b52d5c4b558d7fce708c55c3d1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5451817e64c44dda2476fee6acbac53_I20171121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5823e0351234f7f9b1f20c5fe18cbe0_D20171121-20171121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-21</xbrli:startDate><xbrli:endDate>2017-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47a9787376af49c4af38a5bd745283ea_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i848b50e6e7d3430995e3db062f15f819_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa10e78f3b4c4e968e52a77f68b4440f_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i239833aec97149198fa33cf47989aa8d_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc7da1566164597b0db01be97552e79_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f7d73b878d64950a8425ead93d94a97_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5500851309496fb43072fa4dccbd43_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ed1c49defa42e594f5fe2cb8f08e35_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0fe33cc353c4425a6f61687288e7219_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsMarketConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39b3ec4c69b340288a1cd5b5320c3f95_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3807d087dad4368af0d30e4e6ea552b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd6507cc4bd4d85bca970b83ba305bb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a44426e14f4cf68658b6c28359fe8f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61c0058713f24095b11a013badcef8e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b27e8a6feca4241b642ac4baf127f19_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8faa1fb37e374acb85de383e56577e09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ba6f3c5b4314563a0f6c2b8e9485876_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0df63e74062b463990c0a0996e88bf4d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7000885be6d948baa6c2a16a20a9b3d0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5753737be3a4d78816715ef5956b5f1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide927851f3d44d388940de49dc572cbc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab36228520640d2af7899d4d89c4119_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16951a5be9bf4007b7826543c19fc57c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie70ba7a39fbf47b5ba3502a70a32b3cf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1894854da2af42638a40edaec631c6a8_I20210218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i748d6131bd954dc9aa10faa24cb00d27_D20210218-20210218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-18</xbrli:startDate><xbrli:endDate>2021-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d8448ecaa3a48df85d5889b9d36144b_D20210218-20210218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-18</xbrli:startDate><xbrli:endDate>2021-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1bd190fdbab49dabebbb80e51c1f276_I20230915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e475107c9e4c7997018cc44ab1d86f_I20240915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia06093115e034c0794719bee09423007_I20250915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6c9bed41b124f498f1b2cccdadacc84_D20210218-20210218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-18</xbrli:startDate><xbrli:endDate>2021-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie66d630b4d65447f8c7f52dd587c90cc_D20210323-20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongSettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3389f3c7fed74caf844e5cc2688cd6f0_D20210323-20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idfe4cc3337b24bc380d09a49794cd329_1"></div><div style="min-height:9pt;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzIy_25453bf5-8126-4906-a1b6-c1a5b3790fc0">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzIw_40a4a3e8-3a82-4489-8b92-05977454fbb8">&#9746;</ix:nonNumeric> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8zNTY_d2380ef6-695b-456a-afcf-bd9799555b91">September 30, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzI0_2b3ed0e4-011b-4b7c-930d-d499348ceae3">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from ___________ to ___________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzE4_43d58ba5-9313-4031-a255-e5ea7a8627cd">001-38381</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:23pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzI1_6461d4e2-7a13-4034-98e8-45015344c2db">EVOLUS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_________________________________________________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.839%"><tr><td style="width:1.0%"></td><td style="width:9.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV8wLTEtMS0xLTY2MzUx_57ff5b9c-bd95-4ad2-973a-d1ffe9787be8">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV8wLTUtMS0xLTY2MzUx_474a1b89-2c4f-4a84-81d8-af78fafcc041">46-1385614</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification Number)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV8zLTEtMS0xLTY2MzUxL3RleHRyZWdpb246OWJlOTY1MDc5ZjMxNDczNmIyZDNhYzI5YzFmNzgxMTlfNA_b57e4c30-5d86-4276-8ec7-e8707fbf2cf8">520 Newport Center Drive Suite 1200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV8zLTEtMS0xLTY2MzUxL3RleHRyZWdpb246OWJlOTY1MDc5ZjMxNDczNmIyZDNhYzI5YzFmNzgxMTlfNw_10cf0663-dcaf-49f9-b241-7c67fd0609b8">Newport Beach</ix:nonNumeric>, <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV8zLTEtMS0xLTY2MzUxL3RleHRyZWdpb246OWJlOTY1MDc5ZjMxNDczNmIyZDNhYzI5YzFmNzgxMTlfMTE_bc27c196-c73c-4c3c-832a-2b80e94ba571">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV8zLTUtMS0xLTY2MzUx_26abc399-f609-4882-b13b-9f2de3b178fe">92660</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV81LTMtMS0xLTY2MzUxL3RleHRyZWdpb246NTgwNGEzOTY1NjA5NDM0NDgxMTE3M2ZhNDMzNTFmYjNfNA_2d4466ac-1b43-491d-985e-678a1e457e17">(949)</ix:nonNumeric> <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV81LTMtMS0xLTY2MzUxL3RleHRyZWdpb246NTgwNGEzOTY1NjA5NDM0NDgxMTE3M2ZhNDMzNTFmYjNfNw_aad767e5-aa3d-4d2f-8f88-0dd549d65ba9">284-4555</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6YmQ1YTM5MzAzMDg0NDBhMzkxZGE0MmU0MDNmZGVkYzIvdGFibGVyYW5nZTpiZDVhMzkzMDMwODQ0MGEzOTFkYTQyZTQwM2ZkZWRjMl8xLTEtMS0xLTY2MzUx_0ac10feb-9bae-490d-aeb7-e36273447393">Common Stock, par value $0.00001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6YmQ1YTM5MzAzMDg0NDBhMzkxZGE0MmU0MDNmZGVkYzIvdGFibGVyYW5nZTpiZDVhMzkzMDMwODQ0MGEzOTFkYTQyZTQwM2ZkZWRjMl8xLTMtMS0xLTY2MzUx_d67f5e80-5a35-48cb-95ee-609fbfb9cde5">EOLS</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6YmQ1YTM5MzAzMDg0NDBhMzkxZGE0MmU0MDNmZGVkYzIvdGFibGVyYW5nZTpiZDVhMzkzMDMwODQ0MGEzOTFkYTQyZTQwM2ZkZWRjMl8xLTUtMS0xLTY2MzUxL3RleHRyZWdpb246NzBhMGRlNmZmM2U2NGJlNDg3MmZhM2Y5MGM5M2E1MWJfNA_3238ae08-7a58-4b55-9f8e-62e75ac5f6d4">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Nasdaq Global Market)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzE0_c35a5879-0304-4fc4-9920-7546e5e75765">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#9744;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzE1_0660c01c-1a54-4474-9326-13b99958e7b0">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6ZmNhMDA0NThmYzU5NGM3MWFiZjNiYTc2NGRjZjA4MDUvdGFibGVyYW5nZTpmY2EwMDQ1OGZjNTk0YzcxYWJmM2JhNzY0ZGNmMDgwNV8xLTAtMS0xLTY2MzUx_315b7ac8-7ed3-4ca4-9f65-cec6d405041f">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6ZmNhMDA0NThmYzU5NGM3MWFiZjNiYTc2NGRjZjA4MDUvdGFibGVyYW5nZTpmY2EwMDQ1OGZjNTk0YzcxYWJmM2JhNzY0ZGNmMDgwNV8xLTMtMS0xLTY2MzUx_e0eb4206-727f-4b4d-8d1f-447c7eca12f6">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6ZmNhMDA0NThmYzU5NGM3MWFiZjNiYTc2NGRjZjA4MDUvdGFibGVyYW5nZTpmY2EwMDQ1OGZjNTk0YzcxYWJmM2JhNzY0ZGNmMDgwNV8yLTMtMS0xLTY2MzUx_fda46882-243b-4b4f-b983-066aa15c008b">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzE5_c8578240-b09c-44e8-b572-103f2df33704">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:4pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzIx_55cc75c4-84cd-4014-8fea-24863b7349fd">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of November&#160;4, 2022, <ix:nonFraction unitRef="shares" contextRef="i39ff6d4019914c7fb0f58a9c69af0da7_I20221104" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMjMy_5297f55d-74d8-4799-911f-199a51f13ce9">56,246,570</ix:nonFraction> shares of t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">he registrant&#8217;s common stock, par value $0.00001, were outstanding.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.494%"><tr><td style="width:1.0%"></td><td style="width:7.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_10">Special Note Regarding Forward-Looking Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summary of Risk Factors</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I - FINANCIAL INFORMATION<br/></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_16">Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_22">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_22">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_25">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_28">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_28">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_31">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_70">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_85">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_85">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_88">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_88">46</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II - OTHER INFORMATION<br/></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_94">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_94">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_97">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_97">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_100">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_100">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_103">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_103">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_106">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_106">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_109">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_109">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_112">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_112">79</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_115">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_115">80</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Special Note Regarding Forward-Looking Statements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve risks and uncertainties, including statements based on our current expectations, assumptions, estimates and projections about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, or other comparable terms intended to identify statements about the future. The forward-looking statements included herein are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to those made below under &#8220;Summary of Risk Factors&#8221; and in Item 1A. Risk Factors in this Quarterly Report.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider these risks, as well as the additional risks described in other documents we file with the SEC in the future, including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which may from time to time amend, supplement or supersede the risks and uncertainties we disclose. We also operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements included herein are based on current expectations of our management based on available information and are believed to be reasonable.&#160;In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.&#160;Except as required by law, we undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should read this Quarterly Report on Form 10-Q and the documents we file with the SEC, with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by the cautionary statements referenced above. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in our securities involves various risks and you are urged to carefully consider the risks discussed under Item 1A &#8220;Risk Factors,&#8221; in this Quarterly Report on Form 10-Q prior to making an investment in our securities. If any of the risks below or in Item 1A &#8220;Risk Factors&#8221; occurs, our business could be materially and adversely affected. As more fully described in Item 1A &#8220;Risk Factors&#8221;, the principal risks and uncertainties that may affect our business, financial condition and results of operations include, but are not limited to, the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently depend entirely on the successful commercialization of our only product, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If we are unable to successfully market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we may not generate sufficient revenue to continue our business.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history and have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We have only one approved product, which, together with our limited operating history, makes it difficult to assess our future viability.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may require additional financing to fund our future operations, and a failure to obtain additional capital when so needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate the scope of our operations.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or our counterparties do not comply with the terms of our settlement agreements with Medytox Inc., or Medytox, and Allergan Limited, Allergan Inc. and Allergan Pharmaceuticals Ireland, or, collectively Allergan, we may face litigation or lose our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which would materially and adversely affect our ability to carry out our business and our financial condition and ability to continue as a going concern.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The terms of the Medytox/Allergan Settlement Agreements with Medytox and Allergan impacts our profitability and may affect the extent of any discounts we may offer to our customers.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business, financial condition and operations have been, and may in the future be, adversely affected by the COVID-19 outbreak or other outbreaks of contagious diseases.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable global economic conditions, which may adversely impact consumer discretionary spending or cause our customers to delay making payments for our product, could affect our ability to raise additional capital when needed on acceptable terms, if at all, and may result in supply chain disruptions impacting the availability of our products.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on the license and supply agreement, as amended, with Daewoong, which we refer to as the Daewoong Agreement, to provide us with exclusive rights to distribute Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in certain territories. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect our development and commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> faces, and any of our future product candidates will face, significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may fail to achieve the broad degree of physician adoption and use or consumer demand necessary for commercial success.</span></div><div style="margin-bottom:10pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to market Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is limited to use for the treatment of glabellar lines, and if we want to expand the indications for which we market Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we will need to obtain additional regulatory approvals, which will be expensive and may not be granted. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party claims of intellectual property infringement may prevent or delay our commercialization efforts and interrupt our supply of products.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or any of our current or future licensors, including Daewoong, are unable to maintain, obtain or protect intellectual property rights related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our future product candidates, we may not be able to compete effectively in our market.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to increase the size of our organization, including our sales and marketing capabilities, in order to further market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and we may experience difficulties in managing this growth.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on our digital technology and applications and our business and operations would suffer in the event of computer system failures or breach.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to extensive government regulation, and we may face delays in or not obtain regulatory approval of our product candidates and our compliance with ongoing regulatory requirements may result in significant additional expense, limit or delay regulatory approval or subject us to penalties if we fail to comply.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context indicates otherwise, as used in this Quarterly Report on Form 10-Q, the terms &#8220;Evolus,&#8221; &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Evolus, Inc., a Delaware corporation, and our subsidiaries taken as a whole, unless otherwise noted. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EVOLUS&#8482;, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are three of our trademarks that are used in this Quarterly Report on Form 10-Q. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the trade name in the United States for our approved product with non-proprietary name, prabotulinumtoxinA-xvfs. The product has different trade names outside of the United States, including Nuceiva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada and Great Britain, but is referred to throughout this Quarterly Report on Form 10-Q as Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Quarterly Report on Form 10-Q also includes trademarks, trade names and service marks that are the property of other organizations, such as BOTOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BOTOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cosmetic, which we refer to throughout this Quarterly Report on Form 10-Q as BOTOX. Solely for convenience, trademarks and trade names referred to in this Quarterly Report on Form 10-Q may appear without the &#174; and &#8482; symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_16"></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except par value and share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:66.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNC0xLTEtMS02NjM1MQ_76ea5e77-d7fb-486f-9b74-bd153c26a05d">65,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNC0zLTEtMS02NjM1MQ_de4d85f3-eb93-49ce-b26b-44b7e78bec10">146,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNi0xLTEtMS02NjM1MQ_2b234b90-e9d2-4835-8403-19932656b1b9">20,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNi0zLTEtMS02NjM1MQ_e8fb5805-b46c-40ac-9598-4e33dccafead">14,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNy0xLTEtMS02NjM1MQ_b5a057a2-55f1-4b61-9847-506d79ddc0dd">21,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNy0zLTEtMS02NjM1MQ_f88db08e-e518-4abf-aca3-ce78050cff04">1,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTAtMS0xLTEtNjYzNTE_fa262c52-2ab4-444e-8fbd-9168148b85cf">3,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTAtMy0xLTEtNjYzNTE_0b3e8e0a-74b5-447e-8d84-59218048b412">5,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTEtMS0xLTEtNjYzNTE_ea1dfeee-9e1f-4309-b7fc-c69437a5c91a">4,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTEtMy0xLTEtNjYzNTE_41dc589f-1d41-4278-9f9b-54366e7c4e99">11,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTItMS0xLTEtNjYzNTE_ab5ac0ea-82d9-4a73-8662-bbc408cad314">115,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTItMy0xLTEtNjYzNTE_96c5ad57-87b4-4877-869b-537cdad17eba">178,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTMtMS0xLTEtNjYzNTE_ff9d0064-4371-4d6a-b8ba-530f738d9b27">1,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTMtMy0xLTEtNjYzNTE_b90a571a-e734-406b-8b0e-d86e384b098a">1,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTQtMS0xLTEtNjYzNTE_19f99e29-1a2a-478c-b203-f630e584e110">2,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTQtMy0xLTEtNjYzNTE_78a51504-9c36-47be-9c30-3ce3d2b8f7af">2,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTUtMS0xLTEtNjYzNTE_90a3b6a0-984a-47d6-b84e-1340b966f822">49,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTUtMy0xLTEtNjYzNTE_1b3109e3-e525-4e45-88c2-b0e4113b77b7">50,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTYtMS0xLTEtNjYzNTE_ae9aa570-4ead-4249-b9cd-49f126e4fc15">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTYtMy0xLTEtNjYzNTE_c220b412-a84a-4301-a37b-facc19edfb74">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTctMS0xLTEtNjYzNTE_7da24dda-1329-4e7b-beae-952861d83e44">2,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTctMy0xLTEtNjYzNTE_f56d88f4-ce31-4d13-a914-7cf9fd7ee0a4">2,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTgtMS0xLTEtNjYzNTE_232cd75f-6524-4bc3-88a0-ab1a08a349a6">192,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTgtMy0xLTEtNjYzNTE_6de172c9-71ec-4db0-b0f2-095aa3c08702">257,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjEtMS0xLTEtNjYzNTE_fa087a16-2a35-46e3-ad9b-b4836bc7a701">8,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjEtMy0xLTEtNjYzNTE_a7a02fcf-f90f-4c34-9a07-fe6aa71897d5">6,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjItMS0xLTEtNjYzNTE_ba3d4c51-d1ef-44cb-a888-1895560712c0">29,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjItMy0xLTEtNjYzNTE_9dcfc841-0526-49c9-b401-0c06f9458edf">29,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjMtMS0xLTEtNjYzNTE_8a51efe4-8990-40c1-aaae-6b31a2f5b213">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjMtMy0xLTEtNjYzNTE_760badac-66fc-4251-9a40-68b2014dd54a">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjUtMS0xLTEtNjYzNTE_9ee154ab-c75d-4112-a6c8-f9bf24e7a19b">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjUtMy0xLTEtNjYzNTE_5da8845a-7f25-47c2-bf6e-c5b457955821">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjYtMS0xLTEtNjYzNTE_e5d18847-e2ab-40a4-9a3c-22740222b103">6,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjYtMy0xLTEtNjYzNTE_df416392-dfce-4180-bfde-273cac2ff765">5,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjktMS0xLTEtNjYzNTE_2f5574ea-2c71-4256-a06c-8938554d7814">51,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjktMy0xLTEtNjYzNTE_4f935fef-6aed-440d-858f-1632b848fb09">57,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LitigationReserveNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzAtMS0xLTEtNjYzNTE_09c6f2ca-5084-4664-af15-4ab5f72b1d4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:LitigationReserveNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzAtMy0xLTEtNjYzNTE_647995fd-ee4d-4e49-928f-c40963e4ea9a">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzEtMS0xLTEtNjYzNTE_7ba03427-ed83-4827-a10f-757e90de110f">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzEtMy0xLTEtNjYzNTE_27b8b970-ca12-4b0b-ac78-8e8acf394b21">2,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzItMS0xLTEtNjYzNTE_7494df01-6659-4caa-b1cb-a6def63a4b40">39,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzItMy0xLTEtNjYzNTE_2ec32947-8b1a-4762-b097-1d67fd9ccb64">39,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Term loan, net of discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzMtMS0xLTEtNjYzNTE_f99c362a-d05b-4626-aaba-798d390e63bc">71,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzMtMy0xLTEtNjYzNTE_6e5b8de1-5f5d-4f85-b284-325bce78cc50">71,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzUtMS0xLTEtNjYzNTE_6fe866a6-1069-4918-9708-9f6414d51f41">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzUtMy0xLTEtNjYzNTE_b3c76c1d-29b4-4a1a-97fd-4e46c8ecf87d">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzYtMS0xLTEtNjYzNTE_f918c59c-084b-4bb8-a789-c51e13bedb61">163,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzYtMy0xLTEtNjYzNTE_476dea63-c92c-48bc-9fd8-63e600a0df39">175,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzctMS0xLTEtNjYzNTE_90f11ec5-5b45-48d9-92dd-5532ae4bf522"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzctMy0xLTEtNjYzNTE_dfd06d3a-8787-47ad-b4b4-cef1ab6e274a"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV8yMQ_6cd615b8-aaed-4705-99af-6d0f33e846b3"><ix:nonFraction unitRef="usdPerShare" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV8yMQ_c7701fac-70e1-4b40-9c72-e668a3e8d193">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV8zNQ_3fe21a35-8323-4d6c-9ad1-a3e316c21323"><ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV8zNQ_71c2f5eb-acfc-422e-a58e-5c60d562540a">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV81Nw_02989ebd-76af-4a22-a5a1-e247127827c1"><ix:nonFraction unitRef="shares" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV81Nw_160a6188-705f-4dca-be51-539d86b39df3"><ix:nonFraction unitRef="shares" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV81Nw_7b36b307-cf22-44bf-a3ff-7bd3b05f7dfc"><ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV81Nw_9507ef07-c963-4846-aef7-f5156afc5d5c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMS0xLTEtNjYzNTE_87d0c319-2e99-4212-9557-c7a9d9375342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMy0xLTEtNjYzNTE_167ff144-b8ea-4866-bed6-a3e79695ab86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N18xOA_74b3bd52-a95c-416a-a237-7b373d9e5ac8"><ix:nonFraction unitRef="usdPerShare" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N18xOA_d75c741c-e679-4683-b306-21980b74cd33">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N18zMg_074b64d4-9a44-4355-a670-b3cf35d82712"><ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N18zMg_e900bac0-cca7-47d3-9871-2d6799396b0f">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N181NA_13ac0631-5f36-4754-ba26-7e3f6d3c17c5"><ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N181NA_69e8a0ea-e11c-4d21-b167-3ea3660791b7">56,183,414</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N182MQ_ba5d130b-8e6e-4556-b9e7-357afdd2fb05"><ix:nonFraction unitRef="shares" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N182MQ_efdb60d1-ab2e-4e3e-ae01-aa05734b5057">55,576,988</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMS0xLTEtNjYzNTE_8c76e9ca-d7b9-4032-8fd9-2a07958f85d8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMy0xLTEtNjYzNTE_1ac617c4-81fb-4421-94e5-393c91ee03a7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDEtMS0xLTEtNjYzNTE_8624ae3f-da81-4dcb-87b5-7b5c1903005e">513,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDEtMy0xLTEtNjYzNTE_bfa68098-7354-4b91-bb4c-b138311570e0">504,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDItMS0xLTEtNjYzNTE_cac83027-3b81-4110-8146-da3ced575f36">368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDItMy0xLTEtNjYzNTE_9ec47e65-4de9-4cc3-b1ed-61f5a3d10128">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDMtMS0xLTEtNjYzNTE_f9a28612-78d1-4688-8ee2-9c8bb107128b">484,130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDMtMy0xLTEtNjYzNTE_fc314f53-b77d-48a1-b74f-86a40fb86cf7">422,882</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDQtMS0xLTEtNjYzNTE_814628b2-5034-49d2-b9bd-abcc8adaa2b5">29,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDQtMy0xLTEtNjYzNTE_68d230ad-3eea-436d-a3ad-0c6d592b1264">81,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDUtMS0xLTEtNjYzNTE_fbdb878d-1e4b-4639-9165-13a5e85dff25">192,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDUtMy0xLTEtNjYzNTE_e1192aa0-02d9-40e1-aa8c-e44393180c62">257,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if255f3612ce24011914ed9f9fc5283c0_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMy0xLTEtMS02NjM1MQ_6ed0d91e-3e97-4cb6-899b-9f2ec3aa8d71">33,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b0a77f15c444c19f759b3deaef409d_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMy0zLTEtMS02NjM1MQ_0ce19be5-0e2c-40bd-8c55-d1828c286f49">26,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd30dda6fae047ba8fc0f4931c1cf694_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMy01LTEtMS02NjM1MQ_e0cbab37-9a8e-43fe-bbef-2cf864833b32">103,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie045c20cf6bc4a46bc1cd1a0cb076bd5_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMy03LTEtMS02NjM1MQ_f5d1fade-b5cf-4e17-a636-7f17e8e4798d">64,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f3e32c1ab94b0382fce87da10b1f25_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNC0xLTEtMS02NjM1MQ_3de11afd-f590-4c5f-b215-b1bbdec3cecc">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519de1da8eb84a708ab6875c547d1cb9_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNC0zLTEtMS02NjM1MQ_b945b761-6172-47c1-a4b5-8578b202ba58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a96d1a07754c188b0a005f18255480_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNC01LTEtMS02NjM1MQ_2db130cf-020e-4dd9-a2c7-c882095918ec">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57cb5111d30d40a68b4e495a42bac87d_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNC03LTEtMS02NjM1MQ_894a9f85-7eb7-4c25-953c-746a43094a9e">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNS0xLTEtMS02NjM1MQ_fc8a0309-f646-44ed-961d-45a48bbca9c3">33,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNS0zLTEtMS02NjM1MQ_568efe0f-a54a-4549-b3bf-f5452699a7f6">26,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNS01LTEtMS02NjM1MQ_c652f3a3-6466-4e40-aadc-46bb8eac0b92">104,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNS03LTEtMS02NjM1MQ_d8e5d5c0-3d42-4e62-980a-97773a107e0f">65,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0wLTEtMS02NjM1MQ_10a43e2f-3e60-477c-96dd-c813c9ca153a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0wLTEtMS02NjM1MQ_41cadcf3-4b1a-47e7-9c8e-6ea6514114cf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0wLTEtMS02NjM1MQ_42d06fef-136c-4320-8d1b-5576fedb6eb4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0wLTEtMS02NjM1MQ_d46a4bb0-fbe7-47e2-be47-adc7a74bafa6">Product cost of sales (excludes amortization of intangible assets)</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0xLTEtMS02NjM1MQ_cb51bd9c-4150-4406-b850-e0fa67eb3463">13,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0zLTEtMS02NjM1MQ_3639d9d5-a78a-41f1-bae0-b29ebc677c26">11,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC01LTEtMS02NjM1MQ_49bad24d-b976-4399-aadc-065689c7e609">42,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC03LTEtMS02NjM1MQ_51d2c9f0-5814-4d57-b6fb-34d929a59648">27,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement payment from Daewoong</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOS0xLTEtMS02NjM1MQ_e88347f6-00f1-43a7-8bae-dfae7d0d4d4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOS0zLTEtMS02NjM1MQ_e15c2dee-56ec-4df9-956a-d894ced41b96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOS01LTEtMS02NjM1MQ_dae46367-6011-4c5b-bfce-059186fcb7db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOS03LTEtMS02NjM1MQ_6eba1fa7-2333-4104-a3ec-9fe31c44a9bd">25,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTAtMS0xLTEtNjYzNTE_9b0971b2-fc43-4f1f-8985-63bef25c320e">34,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTAtMy0xLTEtNjYzNTE_9b2e99f3-77e0-4db8-b6b0-9e3bfad0429e">31,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTAtNS0xLTEtNjYzNTE_c8b7508d-a8be-4d95-b598-67dc073f1859">105,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTAtNy0xLTEtNjYzNTE_a0d35876-2910-425d-bb9a-ec006c4b55fc">78,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTEtMS0xLTEtNjYzNTE_5201ee8e-d285-4e51-958b-7e4b984c82f4">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTEtMy0xLTEtNjYzNTE_4b56782f-4617-4669-8538-a9302e3ec6ec">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTEtNS0xLTEtNjYzNTE_4259c3e3-6765-47c8-97db-0a391adb623a">3,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTEtNy0xLTEtNjYzNTE_c1412e31-660b-4bfd-8c54-1a3f8d9d826f">1,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTItMS0xLTEtNjYzNTE_287164dc-ea2c-4f2d-801a-2b4ce6a4ad85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTItMy0xLTEtNjYzNTE_b83ce1d7-94f8-4cfb-a787-c6c6d052e44a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTItNS0xLTEtNjYzNTE_52ed679d-070f-4c09-a8d9-6d410fd88fda">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTItNy0xLTEtNjYzNTE_0e568363-1c86-4fa7-9b42-9775261ab25a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTMtMS0xLTEtNjYzNTE_58c8c8b9-7176-4fe7-bffb-a078ca548d73">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTMtMy0xLTEtNjYzNTE_39b34c4a-aa40-4eb5-9aaa-ffddfbdc69f8">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTMtNS0xLTEtNjYzNTE_984a5e7a-8528-4636-a6e0-f049249b7ebe">3,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTMtNy0xLTEtNjYzNTE_d4888a99-d3cf-4800-b86e-09480ebb9b42">4,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTQtMS0xLTEtNjYzNTE_91dbae26-8acf-430d-bb58-dc4eff35cf63">920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTQtMy0xLTEtNjYzNTE_38f192c6-4e3c-4c74-941b-05d80ed65d4f">923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTQtNS0xLTEtNjYzNTE_80652e59-fadd-4488-b4d5-3b300c41d777">2,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTQtNy0xLTEtNjYzNTE_9fee5bec-f130-4941-8290-f48d0c4a3a84">4,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTYtMS0xLTEtNjYzNTE_92306da1-0d0e-47d1-9785-437e93744d3e">51,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTYtMy0xLTEtNjYzNTE_0ed7797b-6b3b-4c61-85d9-45308b3fd9e4">45,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTYtNS0xLTEtNjYzNTE_eeb7b189-df1f-4295-96f3-58f240452e7a">159,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTYtNy0xLTEtNjYzNTE_43c8d8d0-a0de-4224-b001-39fdd2be8e19">91,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTctMS0xLTEtNjYzNTE_7aa92dc0-1b02-454d-a3a6-347e96e1440b">17,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTctMy0xLTEtNjYzNTE_9bef3a2b-5e26-44c1-840e-4a271561f8cb">19,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTctNS0xLTEtNjYzNTE_fb6ffe3c-de84-42c0-9194-d567b0b7e737">54,693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTctNy0xLTEtNjYzNTE_b3dd322a-ca5a-42ad-8cf7-91e5ff67d943">26,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTktMS0xLTEtNjYzNTE_ada4e28d-bcfb-4e15-84a4-ac12b37b7146">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTktMy0xLTEtNjYzNTE_e70fa8f7-8005-4fe5-b2c0-92bdf396b2a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTktNS0xLTEtNjYzNTE_5c715133-88d9-493b-8078-f57617464d37">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTktNy0xLTEtNjYzNTE_21620ac6-a80e-41bf-84d2-5900e72f1123">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjAtMS0xLTEtNjYzNTE_904c781a-4f47-48b6-922d-671f616c2622">2,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjAtMy0xLTEtNjYzNTE_a6b82d2f-ae45-41d3-ab82-52579ca14d6b">311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjAtNS0xLTEtNjYzNTE_d3a54bd5-e92a-4379-8e66-2e4a24e4944d">6,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjAtNy0xLTEtNjYzNTE_54eda735-a042-497f-8f45-dd254e23c84b">1,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from extinguishment of debts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjEtMS0xLTEtNjYzNTE_2bd3c039-0a46-48e2-8864-0c7f68c93fc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjEtMy0xLTEtNjYzNTE_0c6ddad0-731f-4693-bb36-550be18875c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjEtNS0xLTEtNjYzNTE_e727ea6b-9779-4afb-b513-ab8a9cb888dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjEtNy0xLTEtNjYzNTE_89b09a80-20ac-442d-81cc-6f149e979d63">968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjItMS0xLTEtNjYzNTE_263dcde0-840c-4f26-9c40-7f7384532780">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjItMy0xLTEtNjYzNTE_dc9dc950-b97a-42f7-bcc6-29dd09c10587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjItNS0xLTEtNjYzNTE_f6575941-96b6-4d06-acbb-7880de917ee6">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjItNy0xLTEtNjYzNTE_20881cf3-28e2-4106-b6b1-db4e4b1d483d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjMtMS0xLTEtNjYzNTE_35129cb3-450b-4706-b673-512980ac1876">20,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjMtMy0xLTEtNjYzNTE_685d930b-07d3-4c25-9964-f2c46e8f6f7b">19,421</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjMtNS0xLTEtNjYzNTE_2accf076-9236-4fe5-9821-879e110edad9">61,210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjMtNy0xLTEtNjYzNTE_eb59a0db-37e1-4090-a82d-b52aaf708eab">28,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjQtMS0xLTEtNjYzNTE_42d1d2b4-173a-4c71-aaeb-67a58abb30b0">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjQtMy0xLTEtNjYzNTE_dc656361-ab1b-4dfb-81ed-637eaffbd142">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjQtNS0xLTEtNjYzNTE_63b0a84e-1f29-4b75-a65d-68314a8d3995">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjQtNy0xLTEtNjYzNTE_c22b8092-1f62-4528-9609-b07c14b8bba2">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjUtMS0xLTEtNjYzNTE_a3c44d69-8fd5-4dce-837f-65f5f2e3b575">20,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjUtMy0xLTEtNjYzNTE_e1420182-edf5-49b0-8d5e-c2dec88e826d">19,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjUtNS0xLTEtNjYzNTE_ecf55072-a682-491c-97c0-ed1ffe6a5c40">61,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjUtNy0xLTEtNjYzNTE_2f2969d5-a763-4bfa-87b6-172b10a052d4">28,633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive gain (loss):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjctMS0xLTEtNjYzNTE_fc4286a3-99e0-4414-8dba-4d326ac8a764">203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjctMy0xLTEtNjYzNTE_09e23684-030d-4fda-a15a-c9b8e5286228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjctNS0xLTEtNjYzNTE_6de18dc7-6285-40bf-b0b2-8b70d7694fac">368</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjctNy0xLTEtNjYzNTE_35f76a8a-8310-4e06-86b8-8dd255746855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjktMS0xLTEtNjYzNTE_d380eb06-ff71-40a0-bebe-c6b85acae301">20,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjktMy0xLTEtNjYzNTE_30c6669b-28b2-4a93-b3c8-fcff39ee7a52">19,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjktNS0xLTEtNjYzNTE_949964e1-4886-48f2-98b4-d92662353d62">61,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjktNy0xLTEtNjYzNTE_de3cdce2-9e08-4c2a-8c67-ce88d5c6fbb6">28,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtMS0xLTEtNjYzNTE_26ff5649-b9b4-46fc-9cf0-37ec02df7bfc"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtMS0xLTEtNjYzNTE_bf6da31c-fbd8-4b5f-9ff9-235316131136">0.36</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtMy0xLTEtNjYzNTE_12da1125-3d8c-4ba3-ba4e-7dfb518509d7"><ix:nonFraction unitRef="usdPerShare" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtMy0xLTEtNjYzNTE_92a2ace7-35b0-4f07-a8cc-c0f9146c8cb2">0.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtNS0xLTEtNjYzNTE_78192884-7b53-4926-9bf9-01b06f8a4d35"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtNS0xLTEtNjYzNTE_fb92fe43-8288-4d74-8ce0-39479212f455">1.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtNy0xLTEtNjYzNTE_a43b3158-209b-432c-b8e8-021f5e7d3272"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtNy0xLTEtNjYzNTE_bc8f977e-92d4-4a49-831a-fbcc6010480c">0.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtMS0xLTEtNjYzNTE_805e04f6-3693-4b56-9758-80ea5762a86c"><ix:nonFraction unitRef="shares" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtMS0xLTEtNjYzNTE_9f1fbc71-8f41-45b1-9cfc-032348816f52">56,176,949</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtMy0xLTEtNjYzNTE_652bc86d-8fa2-4f3d-b5ff-9b9586adb6dd"><ix:nonFraction unitRef="shares" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtMy0xLTEtNjYzNTE_c7566884-8b54-457d-9e72-bfcf6ffbc4d4">55,007,132</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtNS0xLTEtNjYzNTE_3c30d1d7-1331-4b17-9d64-ac45cdce38bf"><ix:nonFraction unitRef="shares" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtNS0xLTEtNjYzNTE_4517f56c-4022-43f5-a381-d1d644ae94af">55,997,545</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtNy0xLTEtNjYzNTE_33fb4d54-c1d0-4524-9b52-ca4e89a929d1"><ix:nonFraction unitRef="shares" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtNy0xLTEtNjYzNTE_a6d1fbb3-2fd0-46d0-b5c5-2d0a343cba95">47,818,288</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_25"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:10pt;margin-top:6.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.780%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.383%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.148%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid In <br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19b70069ec2b4bc88563acac780cb0fb_I20201231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi0xLTEtMS02NjM1MQ_08125a68-2028-4e0c-9a22-a8c9c0a52b07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19b70069ec2b4bc88563acac780cb0fb_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi0zLTEtMS02NjM1MQ_450957b3-2d0e-4b0c-815c-dce90e786c32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie933be957e064dbf9e19c7a328a5a3a0_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi01LTEtMS02NjM1MQ_f1515d16-8f54-4814-a1c7-0fd24d415085">33,749,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie933be957e064dbf9e19c7a328a5a3a0_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi03LTEtMS02NjM1MQ_21116319-af39-4de8-9009-2e651d0d3857">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icec2119209b14768b574684aa088fd0a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi05LTEtMS02NjM1MQ_4d5c9a4c-8a30-4b0b-9ef1-60a0cd43182e">303,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfa32b8bceb4d85b8d585d6362e9ead_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi0xMS0xLTEtNjYzNTE_e08684a8-c36f-416d-ac0c-4ea896a45aa3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d107be2e3b249e3a47304c93fca1cf8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi0xMy0xLTEtNjYzNTE_abc3d5e9-45ba-4175-ac41-23810c0fe759">376,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b2a587e790f4e898dff40a08b249f56_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi0xNS0xLTEtNjYzNTE_a9a49596-a8af-4828-b821-d843f3d1139f">72,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9ad3bd07da14e6e91626d72417cbd26_D20210101-20210331" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMy01LTEtMS02NjM1MQ_085ad566-889b-4157-8637-c77d49d61d08">6,762,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14697910a2c7431d8e843fa9e6047c3f_D20210101-20210331" decimals="-3" name="eols:StockIssuedDuringPeriodValuesLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMy05LTEtMS02NjM1MQ_f388b65a-b94c-4d44-933e-0e2fca9f47d5">48,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331" decimals="-3" name="eols:StockIssuedDuringPeriodValuesLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMy0xNS0xLTEtNjYzNTE_38e4c322-4fbb-421d-bf7c-4966fac0fae0">48,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for conversion of convertible note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9ad3bd07da14e6e91626d72417cbd26_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNC01LTEtMS02NjM1MQ_9d18c9a4-d18c-4082-8532-9bb1cb6502e9">3,136,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14697910a2c7431d8e843fa9e6047c3f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNC05LTEtMS02NjM1MQ_df17d8ce-d784-4ba1-b4f9-6e9b1356f037">39,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNC0xNS0xLTEtNjYzNTE_a72bf501-077c-430a-8d49-c9559a05eb0b">39,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the incentive equity plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9ad3bd07da14e6e91626d72417cbd26_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNS01LTEtMS02NjM1MQ_85adf86a-be5b-41cd-bed3-ac8df39be294">88,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14697910a2c7431d8e843fa9e6047c3f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNS05LTEtMS02NjM1MQ_7737e360-3d62-4fd5-b23d-72df77c0fb96">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNS0xNS0xLTEtNjYzNTE_4b698e22-33b6-48d4-ab72-62cbfc200a41">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14697910a2c7431d8e843fa9e6047c3f_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNi05LTEtMS02NjM1MQ_c957e89a-0b93-41a9-8f7e-f8725b0df7be">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNi0xNS0xLTEtNjYzNTE_63a1882f-7175-4c94-b3f4-8e3bc22c8e5c">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i089a8fa6f6594b3f9738d50bda403e59_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNy0xMy0xLTEtNjYzNTE_18959e5f-67b6-4d0c-a4e5-94c15c9185e5">6,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNy0xNS0xLTEtNjYzNTE_2eba76c1-5c42-4b9e-b288-d631c5051ae7">6,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d310130bd084da3ac0de405205ba752_I20210331" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS0xLTEtMS02NjM1MQ_f3fefa62-38f7-45e2-b3a2-815c0e38d764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d310130bd084da3ac0de405205ba752_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS0zLTEtMS02NjM1MQ_4dd7bf88-0ab1-4bd0-b27b-c2b04bfadcc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2006f8ecb5641f4ace06a537399080a_I20210331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS01LTEtMS02NjM1MQ_73358981-c048-4735-9dd1-9b497a442cb0">43,736,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2006f8ecb5641f4ace06a537399080a_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS03LTEtMS02NjM1MQ_56c21433-9f9e-47a9-acc3-acca4cd58b80">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i322856dfc9674ae588e828493d27d95e_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS05LTEtMS02NjM1MQ_b139dc0c-0ce6-4f66-a204-186997dfa34a">392,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia31b6cb915184194bff3d93618626fd2_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS0xMS0xLTEtNjYzNTE_3160ec08-d85c-4020-9f5b-2a9a85e35c05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i111481324b7843119d6ff1bdabd0d80a_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS0xMy0xLTEtNjYzNTE_9cdb97c8-84ef-485d-a6bc-d351dcb1795e">369,671</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1769ef3b028f40ceb603ef14511541b8_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS0xNS0xLTEtNjYzNTE_2b8f130e-89f9-4824-af9a-0361788bdb2d">23,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon follow-on offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7727dfd31c3944fab9afd583ea30a2d7_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTAtNS0xLTEtNjYzNTE_85b381b5-6f47-4ee3-9b54-86aa12eaecfa">10,350,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29999457232e44aeb12a5ace34004e44_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTAtOS0xLTEtNjYzNTE_aa2da3a7-0a65-4df9-9e67-3843746a2b90">92,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29512e75fcde470fa4dc860e639a878e_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTAtMTUtMS0xLTY2MzUx_35fe8f42-23dc-4730-a9ed-1a9087819dbf">92,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under &#8220;at-the-market&#8221; (ATM) program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5492be0135c14a0aa71f49ae2531d9a3_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTEtNS0xLTEtNjYzNTE_22edddbc-8d06-417e-85fb-7d07333bbf44">209,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i173b74f14d1d431b99aed7270421b1ec_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTEtOS0xLTEtNjYzNTE_468394bc-3df1-474a-9394-2d4b6ce22641">2,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97a0827a3aa4c1e87cc2994ec2eedf5_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTEtMTUtMS0xLTY2MzUx_f10940e6-c871-403a-9dc3-a0bcabb35f2c">2,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the incentive equity plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5af4588f76d4ab8bd0886c2f0f3080f_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTItNS0xLTEtNjYzNTE_c86c41b1-c935-4e3b-ab35-7dc233bbf281">76,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65e3e596ba3f464aad3607fcd5ad2218_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTItOS0xLTEtNjYzNTE_7e4082e2-d0d7-4b78-a73d-5f936b08deba">644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490de831fccb414783dc72487430e05b_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTItMTUtMS0xLTY2MzUx_23d50256-c9f2-4363-946d-a96210a94538">644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65e3e596ba3f464aad3607fcd5ad2218_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTMtOS0xLTEtNjYzNTE_3256cb8d-8466-4910-8a86-c81c4fdb897d">2,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490de831fccb414783dc72487430e05b_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTMtMTUtMS0xLTY2MzUx_d9a80a86-0cfa-44c8-a294-36a2481049ed">2,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e4cc38409b74c9b8c6c73ff0a0b3ddc_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTQtMTMtMS0xLTY2MzUx_aea46bc2-b068-478d-b2ed-47db452b813d">15,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i490de831fccb414783dc72487430e05b_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTQtMTUtMS0xLTY2MzUx_7325ad3f-931d-4472-9707-df1fdb4c9f53">15,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if314cfb6f75348ed94b97148ad316c5d_I20210630" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtMS0xLTEtNjYzNTE_89320255-d709-40e9-9fa4-0e53df40d5c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if314cfb6f75348ed94b97148ad316c5d_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtMy0xLTEtNjYzNTE_1af6797a-d814-4b50-a657-92c08c583d1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96c5b48b38fc4cd6814bfde2d6a09765_I20210630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtNS0xLTEtNjYzNTE_afe88fb2-6b4d-4ce4-9606-d2ae9570da48">54,372,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c5b48b38fc4cd6814bfde2d6a09765_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtNy0xLTEtNjYzNTE_c33b357f-2d43-4229-80c9-18db07a35742">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd953d7c6a94c3a9fbeca055456caca_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtOS0xLTEtNjYzNTE_be55ac08-3659-416a-a7c1-4451f3b5e011">491,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15763c0703af45cbaf1faa81f158530e_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtMTEtMS0xLTY2MzUx_2ac410f4-b434-45b6-a4e0-efbac44acfa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic940384570964e689ab795df4e66ccb7_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtMTMtMS0xLTY2MzUx_32c21aa2-19f5-4dc1-9a49-f93dbf302852">385,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13db4b6383624d5097720364e94a31b5_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtMTUtMS0xLTY2MzUx_5746ae37-4f39-4ae8-aa95-0ac7c8914fc8">106,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under &#8220;at-the-market&#8221; (ATM) program</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c628e554673429f919660de503a710e_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTctNS0xLTEtNjY3MTA_b411572e-342e-4262-aebd-8822eee670ed">724,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide79544f24324f7b8502d4f715dcf188_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTctOS0xLTEtNjY3MTA_c6f89404-e740-44d3-97fa-16b2a2559f66">8,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80760aeda834165a0bd09ccfcabfa32_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTctMTUtMS0xLTY2NzEw_eee35e72-e2a6-42fc-8b75-b11c47448715">8,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the incentive equity plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48b21d372773402dbf5d667fe310b72b_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTgtNS0xLTEtNjY3MTA_e759365f-a97e-426f-9129-655f316dfded">456,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTgtMTUtMS0xLTY2NzEw_403b48b9-bc03-4a9e-9867-770acd01d9c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideffba28e2bf412cb0e77892da2aa722_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTktOS0xLTEtNjY3MTA_7d270400-da2f-4c48-87d4-4c6281c1c7ca">2,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTktMTUtMS0xLTY2NzEw_e38f786e-4c8d-4c9c-b168-05e1c07129e6">2,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2512c22190594595845dd6dc9d382f8b_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjAtMTMtMS0xLTY2NzEw_fe01a0cc-c8c7-4aea-85f3-36a522935737">19,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjAtMTUtMS0xLTY2NzEw_d5674c1a-8b0d-41f1-a78a-6ef70dec7c20">19,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b5a39a32eeb4cab9368027d10b64144_I20210930" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtMS0xLTEtNjY3MTk_6151b793-fcb2-4e13-8fbc-bd734e17465a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b5a39a32eeb4cab9368027d10b64144_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtMy0xLTEtNjY3MTk_091651f2-66d5-4829-8f8d-ace611d972c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e42c0d2b5a8488e921290035592036a_I20210930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtNS0xLTEtNjY3MTk_d90ff9c6-55d4-4df8-a756-1237489c5bde">55,553,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e42c0d2b5a8488e921290035592036a_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtNy0xLTEtNjY3MTk_145320cd-d556-4cf6-928d-10f4da3da96c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5cb60ec41f240cdbd130979758bbe33_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtOS0xLTEtNjY3MTk_a5a566ab-9a63-49c1-9e67-5f9677ae946f">502,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8398583e0d2541f0ad8db5defad16243_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtMTEtMS0xLTY2NzE5_e94470e5-c4aa-487b-b7bd-bc57f4b4d5a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbb65d439c414edbb7040d29388dad05_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtMTMtMS0xLTY2NzE5_0cf7d923-309d-470a-bb5f-4dea45b9df8c">404,705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458f436d90584702b2e171f24fc2ffd9_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtMTUtMS0xLTY2NzE5_e34110b9-8b14-46ed-9ddf-2770863524df">97,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.780%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.383%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.148%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid In <br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54b5f0ef22bf4fa9839716763e9e8209_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi0xLTEtMS02NjM1MQ_095d5824-ed35-4c68-bebc-4f84269a623a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b5f0ef22bf4fa9839716763e9e8209_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi0zLTEtMS02NjM1MQ_ce876ff0-3b19-4b67-951d-985e3baafd2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2d7f6a0cb1b497cbfc385cc704bccf2_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi01LTEtMS02NjM1MQ_fbdc17bc-b473-42a7-aa9d-45e2393487b4">55,576,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2d7f6a0cb1b497cbfc385cc704bccf2_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi03LTEtMS02NjM1MQ_90977ab0-bd07-4cde-b210-e9ff68071ac5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1fddad6db8d4551816b8c9aecd79504_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi05LTEtMS02NjM1MQ_f59a1595-741b-4b3d-96fb-93cb0da06c94">504,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b12284fc5ce4b21a29b45a18ae68685_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi0xMS0xLTEtNjYzNTE_f293a026-98bd-42cf-9435-447b08f8af99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff586361777d462b9327912ebb0fdc8c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi0xMy0xLTEtNjYzNTE_9e0b4c59-372c-40df-a631-652f140330e1">422,882</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi0xNS0xLTEtNjYzNTE_34690262-82aa-493f-a4a9-a0cbc8d34b39">81,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the incentive equity plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41a3e5c8a1c94c8488ef9e164b01e0cf_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMy01LTEtMS02NjM1MQ_412d588f-1a6b-4bde-89e2-ec4fcf80f52c">464,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0566f63895a44386a854828b2eacdf90_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMy05LTEtMS02NjM1MQ_c723f862-4114-4feb-be15-e9101dd8b170">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a862462206439c8bc023adde6f54e2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMy0xNS0xLTEtNjYzNTE_4388e3da-f0a4-4042-a9a6-a05a786045a4">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0566f63895a44386a854828b2eacdf90_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNC05LTEtMS02NjM1MQ_86395702-6d5b-430d-916f-62dafc773ce1">2,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a862462206439c8bc023adde6f54e2_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNC0xNS0xLTEtNjYzNTE_a3bd5a09-fbfe-4763-a74f-771534ba24ba">2,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib29835257f2c4dd18c50418dd8adfee9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNS0xMy0xLTEtNjYzNTE_d083d8c7-f498-4c81-a0e9-d8da2d17f3f1">17,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3a862462206439c8bc023adde6f54e2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNS0xNS0xLTEtNjYzNTE_9fabc88f-f5f9-4579-85b7-6334f24550ea">17,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c84c79944be420fb608efbdf8406369_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNi0xMS0xLTEtNjYzNTE_88e04dde-8461-421a-aba4-085b9289cda8">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3a862462206439c8bc023adde6f54e2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNi0xNS0xLTEtNjYzNTE_ff477909-0469-43ff-8a80-d8d2d9924eec">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id470dada4c0e4d9f9665fcb85a0e6d32_I20220331" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy0xLTEtMS02NjM1MQ_6007f45a-f18c-464f-8f1b-c4dd70b4771d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id470dada4c0e4d9f9665fcb85a0e6d32_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy0zLTEtMS02NjM1MQ_8c055e44-e316-4210-b6f7-e0506f22ea27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2398dc3c9da43c4ac481b18ad745499_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy01LTEtMS02NjM1MQ_6cc6e78a-15ef-4418-a31d-4434e5ab01ea">56,041,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2398dc3c9da43c4ac481b18ad745499_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy03LTEtMS02NjM1MQ_c812c48f-42ae-4100-be74-9ca402c264f2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b462307ce144bc832c08ae7d8df5c1_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy05LTEtMS02NjM1MQ_67c36263-dd24-4ef5-bad2-d85f483b8f55">507,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b7351c853c140558b8a86c3ba8db24b_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy0xMS0xLTEtNjYzNTE_697a01d3-b0f3-477f-825a-d3d2328c2d19">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8b55b81fd54639927f832aefd0c105_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy0xMy0xLTEtNjYzNTE_1bd46d59-cea2-4092-b5a6-5bd6c20d72eb">440,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c698504400444cad7bd76a594cae6a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy0xNS0xLTEtNjYzNTE_16a52fe4-a5d2-46f1-9778-1b78a6c4a09c">67,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the incentive equity plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38daf97bf6b54a5d9f36afcbc66faad1_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfOC01LTEtMS02NjM1MQ_80103f69-806f-4d93-9448-028d3d77eab4">22,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0af0b6fdac41d79d91b5cfebd2f064_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfOC05LTEtMS02NjM1MQ_beb2466f-9774-442a-81dc-391349a4b688">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7690b2a3bee42b0adbdb700c288530e_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfOC0xNS0xLTEtNjYzNTE_ba552e0c-722a-4d5b-8137-3cfa34e49b75">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0af0b6fdac41d79d91b5cfebd2f064_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfOS05LTEtMS02NjM1MQ_9ba19a41-6ee4-4a81-ae9f-ff4cf7ccef1c">2,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7690b2a3bee42b0adbdb700c288530e_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfOS0xNS0xLTEtNjYzNTE_559c260b-4291-43a1-89ee-692aa8149b7a">2,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i483c0c81c82a4127a108474382234dae_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTAtMTMtMS0xLTY2MzUx_4c27be0d-2be2-431e-aa45-d89825be7f0e">23,471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7690b2a3bee42b0adbdb700c288530e_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTAtMTUtMS0xLTY2MzUx_7b7da86d-525c-4cec-bd93-5cc327c0c0fe">23,471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia70412995ddc4b699370638e386fbd7d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTEtMTEtMS0xLTY2MzUx_b5663288-127f-4782-a375-1ff97494eb1e">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7690b2a3bee42b0adbdb700c288530e_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTEtMTUtMS0xLTY2MzUx_1ab23e92-b327-4c3b-8137-cd0f2496e9a4">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a4f256b4cc8459bacffb1ecf8154425_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItMS0xLTEtNjYzNTE_eabc175b-0a90-41d5-bb44-5763450135a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a4f256b4cc8459bacffb1ecf8154425_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItMy0xLTEtNjYzNTE_984350c1-fcc6-4ec1-8763-b92497e50b95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i986ed2aacf8249efa66cfd1e39a120f5_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItNS0xLTEtNjYzNTE_ce1027ef-46d1-43dd-9023-e8d24cd9100d">56,063,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986ed2aacf8249efa66cfd1e39a120f5_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItNy0xLTEtNjYzNTE_5c54ca46-5629-49bc-bfbc-5b07d4e408a7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711c0ec8101d43c2bf551aec2015fe93_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItOS0xLTEtNjYzNTE_6acdc531-efc6-4fc1-a04d-aeff244f838f">510,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517b67724cfa4e4a9a9d6760c1b208ba_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItMTEtMS0xLTY2MzUx_64cf2c63-1919-4b49-9fa0-e063dcc98b22">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie47683c6c9bd447d932d1f3f3b371104_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItMTMtMS0xLTY2MzUx_1672cde1-6256-481a-80bc-8845dcc8432f">463,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fd4a2cf7cb49e6a38c2fc9b0df76fd_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItMTUtMS0xLTY2MzUx_344293e7-e23c-4f58-bbbe-85ac774d543e">46,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the incentive equity plan</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i696aed9396534e69a8f395b92916dbb8_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTMtNS0xLTEtNjY3Mzg_f70c4e4d-f5b7-4881-b5af-a5d074df2a5c">120,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e69b86a1f34f1f860a8d0303c3f93a_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTMtOS0xLTEtNjY3Mzg_75cf91f9-0cee-49b3-a5d4-07d63e84167f">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTMtMTUtMS0xLTY2NzM4_3f655750-1986-4392-a5ed-6f4a90c7b48c">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e69b86a1f34f1f860a8d0303c3f93a_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTQtOS0xLTEtNjY3Mzg_22f0af7e-7523-406e-94dd-02489b6ea37b">2,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTQtMTUtMS0xLTY2NzM4_c19c45e0-e0b9-4149-87d2-521ffa8c6170">2,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb5cba7d4b31433baac45503a471e4ed_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTUtMTMtMS0xLTY2NzM4_12b3b4fb-0344-4319-94e9-1671def71482">20,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTUtMTUtMS0xLTY2NzM4_9e02a6d4-2692-4d1c-9c78-aa1cb5cd8451">20,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d9bfad2231c4ef9be095f3e3afb8838_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTYtMTEtMS0xLTY2NzM4_7cd6dd16-c6d8-47eb-aca9-d4dd4cfbb810">203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTYtMTUtMS0xLTY2NzM4_ad60e529-f2ff-4ae0-b291-da171967ebc2">203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibaff2091727e4bbda42ae97fb2c0ca83_I20220930" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctMS0xLTEtNjY3NDU_3e5aeeae-a8b5-4b37-aa94-84f439eaed35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaff2091727e4bbda42ae97fb2c0ca83_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctMy0xLTEtNjY3NDU_0e5a9e32-4005-48f2-8ff5-39b541c265b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eda81fe6f4443b3840b17e1ed17844d_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctNS0xLTEtNjY3NDU_d2303433-3b7e-43c3-bc5d-dc8abf3d57bc">56,183,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eda81fe6f4443b3840b17e1ed17844d_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctNy0xLTEtNjY3NDU_fd3675e0-473a-42dc-bcab-634f98eff784">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67e38e0bc0df4e4d88a289133b9464f5_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctOS0xLTEtNjY3NDU_f4013969-e2ac-4bbb-a066-79e003013d0c">513,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81ca472192774250bc53a843ace80459_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctMTEtMS0xLTY2NzQ1_5d972e77-1a0e-4dc9-9206-6f00ed6ea64f">368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68b52e5c01fb45b685329d95b6300084_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctMTMtMS0xLTY2NzQ1_4b84a4f9-2373-4ed3-88b0-95a0e37a339d">484,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctMTUtMS0xLTY2NzQ1_7ad057b4-d6cc-4059-8e5b-8c5ee4785602">29,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.385%"><tr><td style="width:1.0%"></td><td style="width:71.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMy0xLTEtMS02NjM1MQ_934a6df5-11b5-47f3-9435-e636e75332bd">61,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMy0zLTEtMS02NjM1MQ_ffb17dbd-bfb7-4d49-a502-8e63d9824c66">28,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNS0xLTEtMS02NjM1MQ_864cdabd-a733-47e2-b0de-b5db72d94c15">2,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNS0zLTEtMS02NjM1MQ_52b5dac6-8ab9-414c-8f6c-bfbb1c9f3766">4,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNi0xLTEtMS02NjM1MQ_dc8dfd8c-53cb-485e-a554-85b0910edce0">8,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNi0zLTEtMS02NjM1MQ_106fcd72-0333-43ec-b7f2-28c36eff6d76">6,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNy0xLTEtMS02NjM1MQ_4a47994a-2d3c-479b-abd2-58ebd45a4d70">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNy0zLTEtMS02NjM1MQ_31ec0de6-99f2-415b-864c-8164f8d975d5">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfOS0xLTEtMS02NjM1MQ_32ec4a44-4c3b-4f17-98a6-476f66947e43">573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfOS0zLTEtMS02NjM1MQ_f88d8835-09a3-40e4-9d5c-4d5d03e9ed71">512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTAtMS0xLTEtNjYzNTE_864ea6bd-fd34-4088-9c5f-00aa881e6b65">805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTAtMy0xLTEtNjYzNTE_021bf288-ef72-46ef-8112-cacdf1c5bd1d">882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Paid-in-kind interest on convertible note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTEtMS0xLTEtNjYzNTE_eae6c54b-b81e-4cf0-943f-98e77190720e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTEtMy0xLTEtNjYzNTE_d8e230c8-0bee-4c50-b137-c525449613ef">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTItMS0xLTEtNjYzNTE_605df42c-0f55-4876-92ed-32089c844e11">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTItMy0xLTEtNjYzNTE_c966ad6c-01d6-4b89-93d1-a64543bf06e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTMtMS0xLTEtNjYzNTE_34c13c2f-9240-4409-9c87-75100d1b4d8b">3,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTMtMy0xLTEtNjYzNTE_e5342d35-7b53-42e1-9f03-cabd499ac14d">4,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from extinguishment of debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTQtMS0xLTEtNjYzNTE_300a3af2-08bc-4e2a-9231-535d0976107c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTQtMy0xLTEtNjYzNTE_47ff34f1-039b-46f3-86de-3524b0508746">968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTYtMS0xLTEtNjYzNTE_d6dbb23e-ff91-40fd-9695-9393df5dfb65">7,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTYtMy0xLTEtNjYzNTE_7a4c0746-1a87-469f-bffe-51b0a2bfb28b">4,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTctMS0xLTEtNjYzNTE_c7cd378c-435b-4565-9518-2675295a6ff3">15,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTctMy0xLTEtNjYzNTE_9b192fdb-f45d-433c-9ccb-5698d9f0de51">7,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTktMS0xLTEtNjYzNTE_bd92450a-415e-413a-b28e-3d140a66f5f6">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTktMy0xLTEtNjYzNTE_a1bfb3cb-730c-4b4d-9ba2-6fdf7eb5fe6f">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjAtMS0xLTEtNjYzNTE_1e7e32ee-d83a-4cfe-9b40-d6d95e4ca3cb">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjAtMy0xLTEtNjYzNTE_daa87dba-69f6-46b6-919f-1fab112199ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjEtMS0xLTEtNjYzNTE_2769f07b-9b90-434e-b777-a21c1eb0c14d">2,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjEtMy0xLTEtNjYzNTE_c0d7458a-ea88-496d-a1d3-760b0bad7ac3">2,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjItMS0xLTEtNjYzNTE_5acacf7e-24db-41ba-bd43-9ca582e682b5">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjItMy0xLTEtNjYzNTE_6d00dc07-3bf6-44e5-b719-d765a6e563db">14,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="eols:IncreaseDecreaseInAccruedLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjMtMS0xLTEtNjYzNTE_d3e82aba-9191-4d16-912f-157f0c7208e7">15,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="eols:IncreaseDecreaseInAccruedLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjMtMy0xLTEtNjYzNTE_36919ffc-2604-471f-9103-8faf6d83fca9">15,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="eols:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjQtMS0xLTEtNjYzNTE_a30e1401-c6aa-4b69-997f-61d4fb76c56a">723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="eols:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjQtMy0xLTEtNjYzNTE_11c26016-d0e5-4d01-bd82-d13541bc0f1f">619</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjUtMS0xLTEtNjYzNTE_4cfa5486-326b-4ec1-bcab-6e7bbc1c5d76">76,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjUtMy0xLTEtNjYzNTE_a8f1dbe0-23ab-457b-ac49-f58e9109e1fe">24,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjctMS0xLTEtNjYzNTE_2a9ec1c0-73c8-4c60-aa8f-d663525c0bef">752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjctMy0xLTEtNjYzNTE_dc1f5457-e7cd-47bb-823b-339234fa9da4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsForSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjgtMS0xLTEtNjYzNTE_bf81ae22-4d5d-4e80-b228-34a0c34e7a35">796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsForSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjgtMy0xLTEtNjYzNTE_7a7b457c-c420-4c64-90b0-546ab6958fb8">580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzAtMS0xLTEtNjYzNTE_13b3e66c-f958-431c-951a-803f303cf15e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzAtMy0xLTEtNjYzNTE_f0d5e392-0d1a-4e52-a03b-20a4c4119e57">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzEtMS0xLTEtNjYzNTE_d6f788fd-9e9a-4fc2-8db8-553fc1fa51dc">1,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzEtMy0xLTEtNjYzNTE_b5293345-5eb9-4d4e-800e-9ce4b5c6ba2c">4,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of long term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzMtMS0xLTEtNjYzNTE_8e5ae5a6-24f4-4b19-a94c-72afdc0b4c12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzMtMy0xLTEtNjYzNTE_6736dd26-fb37-42fa-8075-9901b4e08ef8">76,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of contingent royalty obligation to Evolus Founders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="eols:PaymentsOfContingentRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzQtMS0xLTEtNjYzNTE_ef845d57-8572-4b26-a145-b094e96dc7a0">3,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="eols:PaymentsOfContingentRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzQtMy0xLTEtNjYzNTE_20a75d4b-ef3f-456f-8c59-4ccbc3a6f0fa">2,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from follow-on offering, net of underwriters fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e324736d7a4b58bee7bebe0815ab9a_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzctMS0xLTEtNjYzNTE_3d7b825c-9a43-47cd-ae07-db37f9daca52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0788351e9e084ee681884fb575fce218_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzctMy0xLTEtNjYzNTE_996e39a9-da4c-4a6e-aac6-db24d7b786b2">92,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzgtMS0xLTEtNjYzNTE_91291540-e016-4d51-a481-34c904378351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzgtMy0xLTEtNjYzNTE_4227686d-bcf0-4f1c-a873-71787c821e60">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from ATM sales of shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3343570b8b4e2da7fe85c347c87365_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzktMS0xLTEtNjYzNTE_7dd547ee-850e-42fc-9f38-dd4931ffc740">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b79303cf634cad95d0ba5d12c163ef_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzktMy0xLTEtNjYzNTE_c487cda8-6c7a-414f-b67a-3d24bbd80f6f">10,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with incentive equity plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDAtMS0xLTEtNjYzNTE_fead8275-ebf7-46bf-a752-d88d3b07b204">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDAtMy0xLTEtNjYzNTE_01968a51-4fa7-4e27-930c-246f4ba6ed32">654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDQtMS0xLTEtNjYzNTE_cfa86c92-41c1-4a0e-9412-0fe37f0e3af9">2,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDQtMy0xLTEtNjYzNTE_91bd2f1a-557d-4d80-8b91-e721dec0f14a">25,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rates on cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDUtMS0xLTEtNjYzNTE_929ae8af-e081-40a2-9c05-c9671dc4ec07">368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDUtMy0xLTEtNjYzNTE_25ef85be-99f2-4063-9d2a-d6db04384f80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDYtMS0xLTEtNjYzNTE_6238060d-4a6d-4e7d-910d-45c13bd39588">80,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDYtMy0xLTEtNjYzNTE_630371ce-0dc5-42eb-83f5-2f8583b2353b">5,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDctMS0xLTEtNjYzNTE_6f47d72e-3e05-432d-a912-e7f1ad88eea3">146,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2a587e790f4e898dff40a08b249f56_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDctMy0xLTEtNjYzNTE_0372e676-f0b0-47ac-afde-f89b46320257">102,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDgtMS0xLTEtNjYzNTE_f00fabae-6be4-494a-af00-3cb184341766">65,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458f436d90584702b2e171f24fc2ffd9_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDgtMy0xLTEtNjYzNTE_73e00a9c-158a-424e-a5ee-7af3b70b8789">107,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (Continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:8.7pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.632%"><tr><td style="width:1.0%"></td><td style="width:73.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfMy0xLTEtMS02NjM1MQ_ed012286-8607-491b-8240-4ee3a42917de">5,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfMy0zLTEtMS02NjM1MQ_17d8d3e5-8430-4fa0-a259-7dc1c4fe2b7c">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfNC0xLTEtMS02NjM1MQ_e6d124ad-a85c-4ac2-87a4-36a042b65427">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfNC0zLTEtMS02NjM1MQ_78255216-aea2-4c14-90a9-2f7a5126b1eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing and financing information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of convertible note to equity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfNi0xLTEtMS02NjM1MQ_6b931691-1872-4a8b-85d7-2d43b09c08f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfNi0zLTEtMS02NjM1MQ_35044c54-759e-4098-ba4e-1a7759233f6b">39,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in exchange for accrued litigation settlement expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="eols:StockIssuedForAccruedLitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfNy0xLTEtMS02NjM1MQ_eb3f5cd6-e994-4f33-82ff-05079c4ff27a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="eols:StockIssuedForAccruedLitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfNy0zLTEtMS02NjM1MQ_3da86d96-1a7d-47ea-9780-a627f9c46d17">48,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized software recorded in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfMTAtMS0xLTEtNjYzNTE_06e872a0-0073-47f1-82d5-1ece29bde053">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfMTAtMy0xLTEtNjYzNTE_78b363b0-f85c-44fb-9686-cdb40d24c941">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_31"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_34"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMzc0MQ_42ecfb10-a203-419e-aebe-2febb589a342" continuedAt="i4934a93bb0d54d1ea5262e063f651cb9" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="i4934a93bb0d54d1ea5262e063f651cb9"><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolus, Inc., (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in February 2019. The product was also approved by Health Canada in August 2018 and the European Commission (&#8220;EC&#8221;) in September 2019. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019, in Canada through a distribution partner in October 2019, and in Great Britain in September 2022. The Company currently generates all of its net revenues from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is headquartered in Newport Beach, California.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements&#160;have been prepared&#160;on a basis that&#160;assumes that&#160;the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company&#8217;s assets and the satisfaction of the Company&#8217;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has incurred recurring net operating losses and negative cash flows from operating activities and management expects operating losses and negative cash flows to continue for at least the next 12 months. The Company recorded net loss of $<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMTg3NQ_a3c44d69-8fd5-4dce-837f-65f5f2e3b575">20,276</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMTg4Mg_ecf55072-a682-491c-97c0-ed1ffe6a5c40">61,248</ix:nonFraction> for the three and nine months ended September 30, 2022, respectively. The Company used cash of $<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMTkzNg_1a29897d-f780-464a-bc1c-8c5d7845eae6">76,138</ix:nonFraction> from operations during the nine months ended September 30, 2022, which includes a settlement payment of $<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="eols:IncreaseDecreaseInAccruedLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjAwOQ_d3e82aba-9191-4d16-912f-157f0c7208e7">15,000</ix:nonFraction>. As of September 30, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjAzOQ_18f8ab4b-2f14-472e-adea-da5a233c46c1">65,572</ix:nonFraction> in cash and cash equivalents and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjEwMQ_c7917478-89d5-43e2-84ab-404f10fb6952">484,130</ix:nonFraction>. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a $<ix:nonFraction unitRef="usd" contextRef="i87e2257ed337439eaac012b86d0a396b_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjE1MQ_857da5b3-4a1a-4383-a6b3-1aded71c195f">125,000</ix:nonFraction> Term Loan agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC (collectively, &#8220;Pharmakon&#8221;). The first tranche of $<ix:nonFraction unitRef="usd" contextRef="i1ee94ea6704b4637b072dc991661fa7c_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjMyNA_6ee20c45-8483-4360-9c23-9104fc1378e5">75,000</ix:nonFraction> was funded on December 29, 2021. The second tranche of $<ix:nonFraction unitRef="usd" contextRef="ibf185154c94a4f079a63adb078d887d1_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjM4Mg_75db7f88-993e-44a5-8581-25045c543a11">50,000</ix:nonFraction> may be drawn at the Company&#8217;s election no later than December 31, 2022, subject to the terms and conditions of the loan agreement. As of September 30, 2022, the Company has not drawn the second tranche. The Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="iafb5504b024a49c98e5b98f03ed55642_D20211201-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjYwOQ_3d6cc1f1-7a07-4f7a-bed7-26f15aa0c604">68,695</ix:nonFraction> from Pharmakon, after issuance costs and debt discounts in December 2021. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its current capital resources, which consist of cash and cash equivalents, will be sufficient to fund operations through at least the next 12 months from the date the accompanying condensed consolidated financial statements are issued based on its expected cash needs. The Company may need to raise additional capital to fund future operations through entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its scope of operations to reduce the current rate of spending through actions such as reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.</span></div></ix:continuation><div><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_37"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5NDc_5316931f-eb80-4c9d-a931-a135ba872a86" continuedAt="i7d4623f778664dc5b501ca832a794e05" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i7d4623f778664dc5b501ca832a794e05" continuedAt="ib142c8bd51d0448bb7ccfe9c9a43677b"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5NDg_69386e05-5b9e-4eda-9bc7-38148e8f5cb4" continuedAt="i056d07eff11d4c7eac5ca3df66e23c3d" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the annual financial statements and in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. Pursuant to these SEC rules and regulations, the Company has condensed or omitted certain financial information and disclosures normally included in annual financial statements prepared in accordance with GAAP. In the opinion of management, the interim </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ib142c8bd51d0448bb7ccfe9c9a43677b" continuedAt="i08d1e0630fae4ee2863cb1c79437cbfa"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i056d07eff11d4c7eac5ca3df66e23c3d" continuedAt="i1c9fee12a11d4704a9231545e1dc1d44">consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, considered necessary for a fair statement of the interim periods. The interim results presented herein are not necessarily indicative of the results of operations to be expected for the full year ending December&#160;31, 2022 or for any other interim period.</ix:continuation></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1c9fee12a11d4704a9231545e1dc1d44">The accompanying unaudited condensed consolidated financial statements and related disclosures should be read in conjunction with the financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on March 3, 2022.</ix:continuation> </span></div><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MDE_b15575ab-5929-4194-bbd9-673f6e410eda" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly-owned subsidiaries, Evolus Pharma Limited, Evolus International Ltd. and Evolus Pharma BV, and have been prepared in conformity with GAAP. All intercompany transactions have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5NTA_1e7a45df-971d-4ed0-bf1a-d0a2768d3d02" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements, inventory valuations and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#8217;s actual results could differ materially from those estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full impact of&#160;current global events, including rising inflation, volatility in the financial and credit markets, the COVID-19&#160;pandemic and the Ukrainian-Russian war, is unknown and cannot be reasonably estimated. However, where possible, management has considered the potential impact of rising inflation, volatility in the financial and credit markets, the COVID-19 pandemic, and the Ukrainian-Russian war, and their respective market impacts, on its estimates and assumptions, and there was not a material impact to the Company&#8217;s condensed consolidated financial statements as of and for the nine months ended September 30, 2022. The Company&#8217;s future assessment of the impact of these events, as well as other factors, could result in material impacts to the Company&#8217;s financial statements in future reporting periods.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI4OTc_7f5923f8-875b-4e2e-bcea-1b2d51fd3d26" continuedAt="iefdc78de12424032939da27bf769b817" escape="true"><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (&#8220;Daewoong&#8221;) entered into an agreement (the &#8220;Daewoong Agreement&#8221;), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the United States in May 2019, in Canada through its distribution partner in October 2019, and in Great Britain in September 2022 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#8217;s business and its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i08d1e0630fae4ee2863cb1c79437cbfa" continuedAt="i76f1ce8c0fe54ff4886d99f0a581130f"><ix:continuation id="iefdc78de12424032939da27bf769b817" continuedAt="i7661a2ee49a6474e8e9feb29bd8d1519"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve, and the severity and magnitude of future outbreaks, or other similar public health crises, could result in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets caused by these or other events, such as increased inflation and rising interest rates and the military conflict between Russia and Ukraine, may increase the Company&#8217;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and cash flows.</span></div></ix:continuation><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI4OTU_57523f9e-e1e0-456d-b1a5-692b900d5e65" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it operates in a single operating and reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</span></div></ix:nonNumeric><ix:continuation id="i7661a2ee49a6474e8e9feb29bd8d1519"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#8217;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#8217; ability to pay.</span></div></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MTU_42622644-b0fd-4dfa-9994-ba8c3735e19e" continuedAt="id855c74cf0024289870d585e27ae3bbc" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id855c74cf0024289870d585e27ae3bbc">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.</ix:continuation> </span></div><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MDI_1e76037a-6c44-419f-bed8-bcd57d83e2b8" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed consolidated statements of operations and comprehensive loss using the specific-identification method.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i76f1ce8c0fe54ff4886d99f0a581130f" continuedAt="i1027e6efcd794b6dbf4cade94c28094a"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5NTQ_9e00831a-4701-4a34-b94b-e0ef8443f946" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of finished goods h</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eld for sale and distribution. Cost is determined based on the estimated amount payable to the Company&#8217;s supplier after accounting for any reimbursement receivable pursuant to the Daewoong Settlement Agreement (as such term is defined, and such agreement is discussed, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), using the first-in, first-out method with prioritization of the items with the earliest expiration dates. Inventory valuation reser</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product cost of sales, excluding amortization of intangible assets, consisted of the inventory cost, and, for periods on or after December 16, 2020, included certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox and Allergan pursuant to the Medytox/Allergan Settlement Agreements (as such term is defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Settlement Agreement with respect to such royalties. In the nine months ended September 30, 2021, the Company recorded a one-time settlement payment of $<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTE0ODY_6eba1fa7-2333-4104-a3ec-9fe31c44a9bd">25,500</ix:nonFraction> from Daewoong in connection with the Daewoong Settlement Agreement as part of cost of sales.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MDQ_3f19560e-d16a-43cf-ae07-e53df129548a" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</span></div><div style="margin-bottom:9pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MzA_d5ab6a94-dc95-46b0-9667-97a4d1d5ab47" continuedAt="iff51c1fafe784ae48fd91d0e2c426d9e" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iff51c1fafe784ae48fd91d0e2c426d9e">Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTMxMzU_edafe925-e952-4969-8170-4bc6a8b2e9be">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease.</ix:continuation> </span></div><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MDk_87307185-da32-45ff-904b-b7603fc7f2e1" continuedAt="if9c1a05eff804811bce0b7ee9a90b2ef" escape="true"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i1027e6efcd794b6dbf4cade94c28094a" continuedAt="i7ef434b47b2b459f8c0b4e63046d32dc"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if9c1a05eff804811bce0b7ee9a90b2ef">would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has <ix:nonFraction unitRef="reporting_unit" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTQ3OTk_01a1ab5b-3b28-4aa1-8e66-f564e255aa67">one</ix:nonFraction> reporting unit.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTQ4Mjg_07ae2e05-8cfa-4fef-8380-9946c60989fc"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTQ4Mjg_c274b429-bd58-43a8-b761-e0b8932fc97a"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTQ4Mjg_cd5bb5ab-3c95-462d-8e8f-b44af0040eab"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTQ4Mjg_e3598c40-71a5-4ef3-b798-3f2a5631a257">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of goodwill for any of the periods presented.</span></div><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5Mzk_0a395f88-ada2-4201-a259-cf755cb755ac" continuedAt="i98d7231d57674792887ed1a152cffc09" escape="true"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution right intangible asset related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="i74d2705a944e47df928e202fbe73806f_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTUzNDc_0bb45564-b6c3-4bcd-8e19-3a3e6caef17b">20</ix:nonNumeric> years. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying condensed consolidated balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="icd37f700914349598839f80a5c3ac5fc_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTU4Mjk_48689d4c-e6cf-4a85-86d1-7adaa1af6351">two years</ix:nonNumeric> upon being placed in service. </span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i98d7231d57674792887ed1a152cffc09">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTY3Nzk_6c412bfe-7982-4c39-acb7-9b6d7150a78c"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTY3Nzk_b2a2ecfe-483c-47da-b318-94525cb77a2e"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTY3Nzk_b6132a1f-d829-4dfb-b12e-6a6ff2615ed9"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTY3Nzk_ff97063b-f86d-4c78-ab05-c4be59708bf1">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> material impairment of long-lived assets for any periods presented.</span></div><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5NDE_8e600dd3-0aa2-4a8d-b9a4-ecc330c1a99c" continuedAt="i11cb91c4df664e0b94bb52d1898d2b0c" escape="true"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying condensed consolidated balance sheets. </span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i11cb91c4df664e0b94bb52d1898d2b0c">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the condensed consolidated balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term.</ix:continuation> There were no significant finance leases as of September 30, 2022.</span></div><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5Mjg_efbc3464-cad9-47b9-b183-c747c9d6d1b1" continuedAt="ifeea56f3d58046708928bd22ff739d00" escape="true"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Royalty Obligation Payable to Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i7ef434b47b2b459f8c0b4e63046d32dc" continuedAt="i7c59d251f88a4ba9b8e2066168aca5e7"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifeea56f3d58046708928bd22ff739d00">are determined at each reporting period end and recorded in operating expenses in the accompanying condensed consolidated statements of operations and comprehensive loss and as a liability in the condensed consolidated balance sheets.</ix:continuation></span></div><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MjQ_d9b65dca-c9b0-4f8a-a154-9d81cb3ef509" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt represents the debt balance with Pharmakon (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), net of discount and issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MTY_6eb360ba-f145-443e-a8fa-b37b804fb9a6" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated into U.S. dollars at current exchange rates as of balance sheet date, and income and expense items are translated into U.S. dollars using the average rates of exchange prevailing during the period. Gains and losses arising from translation are recorded in other comprehensive gain (loss) as a separate component of shareholders&#8217; equity. Foreign currency gains or losses on transactions denominated in a currency other than the Company&#8217;s functional currency are recorded in other expenses, net in the accompanying condensed consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MjA_843febbb-91ae-4c9b-9f34-ab6ffe86b409" continuedAt="i1ea313d6fb8c44379df3ade72f049d3a" escape="true"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates product revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Great Britain and service revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i22f3e32c1ab94b0382fce87da10b1f25_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjMwMzY_96e24696-e3df-49cb-bab8-44ea4722beda">684</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib7a96d1a07754c188b0a005f18255480_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjMwNDM_fe6544e7-635c-455e-84c2-ebca88e54f23">1,366</ix:nonFraction> of service revenues for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i519de1da8eb84a708ab6875c547d1cb9_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjMxMTk_4dbc8683-4f59-44b4-9b07-62e652e80e37">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i57cb5111d30d40a68b4e495a42bac87d_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNTQ5NzU1ODU2ODUx_894a9f85-7eb7-4c25-953c-746a43094a9e">702</ix:nonFraction>, respectively, of service revenues for the three and nine months ended September 30, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i7c59d251f88a4ba9b8e2066168aca5e7" continuedAt="i1332aa9ce9eb4a6390f50b987802aaa6"><ix:continuation id="i1ea313d6fb8c44379df3ade72f049d3a" continuedAt="i2c85cbbfe60b4d5192b1bc74824b1529"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Revenue Adjustments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume-based rebates, consumer loyalty programs and co-branded marketing programs. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Volume-based Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Consumer Loyalty Program &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company launched a consumer loyalty program, which allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and redeem the rewards for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#8220;Reward&#8221;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on historical sales data, estimated average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of redemption, expected customer and consumer participation rates in the loyalty program, and estimated number of qualifying treatments to be performed by customers. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-Branded Marketing Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company offers eligible customers with a certain level of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#8217;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of September 30, 2022 and December&#160;31, 2021, all amounts included in accounts receivable, net on the accompanying condensed consolidated balance sheets are related to contracts with customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract assets nor unbilled receivables as of September 30, 2022 or December&#160;31, 2021. Sales commissions are included in selling, general and administrative expenses when incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and deferred revenue associated with Rewards under the consumer loyalty program and co-branded marketing programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December&#160;31, 2021, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program and co-branded marketing programs, were $<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjcxOTM_5bbbe947-ca23-4f7e-a6ad-a15eb74987de">10,188</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjcyMDA_f929764a-9342-4d2d-8949-fef9cf735529">7,934</ix:nonFraction>, respectively, which were recorded in accrued expenses in the accompanying condensed consolidated balance sheets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjczNjM_adcf7eac-dda1-462b-936e-bd0b91564a5a">7,566</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjczNzA_7d4092d8-2650-4563-9562-6a8fcca2c1db">2,802</ix:nonFraction>, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collectability</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i1332aa9ce9eb4a6390f50b987802aaa6" continuedAt="i3d2c9ddbcf8142faa8e365d2c23a52f7"><ix:continuation id="i2c85cbbfe60b4d5192b1bc74824b1529"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of September 30, 2022 and December&#160;31, 2021, allowance for doubtful accounts was $<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjgzOTM_d4055cf2-a2d0-484b-b1ed-0762a96ff36e">3,271</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg0MDA_a9af2ced-7d2b-408f-80e3-bc1c34cfbdff">2,385</ix:nonFraction>, respectively. For the three and nine months ended September 30, 2022, reversal of and provision for bad debts were $<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg0NzU_cec92107-15fc-4979-bc10-9ceb24aaa3f3">623</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg0ODI_e1e320e4-3502-4489-b6f2-cc99eace2bee">1,363</ix:nonFraction>, respectively, and the write-off amount was $<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg1Mjk_6e027b85-bd43-46e4-8d32-b55f3b32b5ee">392</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg1MzY_78ddbbb4-1be5-4789-9f61-db6c6b3987dd">477</ix:nonFraction>, respectively. For the three and nine months ended September 30, 2021, provision for bad debts were $<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg2MTE_106e1643-ff59-4726-9e1b-6f8d8f6e57b9">188</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg2MTg_3c67007d-4bcd-49e3-8a3a-2dc594767514">501</ix:nonFraction>, respectively, and the write-off amount was $<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg2NjU_b9a6be23-1e7b-4710-b06a-94104f68ccab">23</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg2NzI_a3ea5b71-7058-4892-9119-e006aef06528">214</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical Expedients</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.</span></div></ix:continuation><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5NDU_d4f40e75-4063-42d8-9972-1848cdb70e7d" escape="true"><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MjE_ab8652b4-560c-4f24-a6ba-3ed28f5d8433" escape="true"><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a License and Research Collaboration Agreement (the &#8220;Collaboration Agreement&#8221;) with a 3D printing company with biomaterial capabilities (the &#8220;Licensor&#8221;). Under the terms of the Collaboration Agreement, the Company was granted a license to the Licensor&#8217;s technology to develop and commercialize any aesthetic product or non-therapeutic product that is created through the use or practice of the Licensor&#8217;s patents. The Company paid $<ix:nonFraction unitRef="usd" contextRef="i39e0aaab2daf4a1f9ae49292e3fa113f_D20220601-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzA1OTI_d93a1175-a638-44bb-a7bc-7ec58d901f85">2,000</ix:nonFraction> upon the signing of the Collaboration Agreement and has research funding, ongoing milestone and royalty payment obligations depending on the development plans, the success of such development and approval and commercialization of products. The upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i39e0aaab2daf4a1f9ae49292e3fa113f_D20220601-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzA4NTg_22d057ff-d357-4156-817a-1f8289e3e540">2,000</ix:nonFraction> was recorded as in-process research and development expense.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Settlement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, upon entering into certain agreements to settle intellectual property disputes relating to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company agreed to pay to Allergan and Medytox $<ix:nonFraction unitRef="usd" contextRef="i7982c1b9a3ab4239b877aa1d02a5459e_I20210228" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzExMTM_a008a69f-c114-4e1c-88eb-2d9746a2fde1">35,000</ix:nonFraction> in multiple payments over <ix:nonNumeric contextRef="i1f6eead0dce949398cd5a205a8b761a2_D20210201-20210228" name="eols:LossContingencySettlementAgreementPaymentTerms" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzExNDI_e255329f-7126-47b8-9132-9e646924cbcf">two years</ix:nonNumeric>, of which $<ix:nonFraction unitRef="usd" contextRef="id23cfd7dc1564cd6aaa76f53b45ccf4f_D20210701-20210930" decimals="-3" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzExNTU_66c66259-461a-4351-8763-8e157c4dfdfe">15,000</ix:nonFraction> was paid in the third quarter of 2021 and $<ix:nonFraction unitRef="usd" contextRef="i0997749416bc4e028361e395d1f8bf92_D20220101-20220331" decimals="-3" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzEyMDA_0f73203c-4279-4219-a051-4881a354a15c">15,000</ix:nonFraction> was paid in the first quarter of 2022, and issued <ix:nonFraction unitRef="shares" contextRef="ic6fd11493b9d4a18967f5147f5eb25fc_D20210201-20210228" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzEyNTM_dd73c8b9-acea-4e3f-8e3f-e4ed9ea400dd">6,762,652</ix:nonFraction> shares of its common stock to Medytox. In addition, for the period from December 16, 2020 to September 16, 2022 (the &#8220;Restricted Period&#8221;), the Company agreed to pay to Allergan and Medytox a royalty on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a certain dollar amount per vial sold in the United States and a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold in other Evolus territories. Royalties for sales during the Restricted Period ended in the third quarter of 2022. For the period from September 17, 2022 to September 16, 2032, the Company agreed to pay to Medytox a mid-single digit royalty percentage on all net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The royalty payments are made quarterly and recorded as product cost of sales on the accompanying condensed consolidated statements of operations and comprehensive loss in the periods the royalties are incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement agreements resulted in an $<ix:nonFraction unitRef="usd" contextRef="ie6f902c0f3cf4c5f86905379573f1883_D20201001-20201231" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIwMzI_2a6a1904-758b-4772-b9f6-5c2e77e9f797">83,421</ix:nonFraction> charge for the fourth quarter of 2020, which consisted of $<ix:nonFraction unitRef="usd" contextRef="i84371b8801da47da9efba13175f076d4_I20201231" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIwOTM_5234eac6-eb18-411e-be71-3a9e661242d6">35,000</ix:nonFraction> in deferred cash payments and $<ix:nonFraction unitRef="usd" contextRef="if066a834ef404c0da380ab9066a249ab_D20210201-20210228" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIxMjY_6c77ce6c-435e-44a1-91ba-63095034bb8f">48,421</ix:nonFraction> from the issuance of <ix:nonFraction unitRef="shares" contextRef="ic6fd11493b9d4a18967f5147f5eb25fc_D20210201-20210228" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIxNTA_c3b0dad6-dcc0-4429-8157-445bf864c365">6,762,652</ix:nonFraction> shares of the Company&#8217;s common stock in February </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i3d2c9ddbcf8142faa8e365d2c23a52f7" continuedAt="i784d19359c9e4c5e953f654421125e0f"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021. In the first quarter of 2022, the Company made the second cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0997749416bc4e028361e395d1f8bf92_D20220101-20220331" decimals="-3" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIyODI_0f73203c-4279-4219-a051-4881a354a15c">15,000</ix:nonFraction> to Medytox and Allergan with the $<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIzMTg_8a51efe4-8990-40c1-aaae-6b31a2f5b213">5,000</ix:nonFraction> balance due in 2023. As of September 30, 2022 and December&#160;31, 2021, a current liability of $<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIzODI_8a51efe4-8990-40c1-aaae-6b31a2f5b213">5,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIzODk_760badac-66fc-4251-9a40-68b2014dd54a">15,000</ix:nonFraction>, respectively, and non-current liability of $<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LitigationReserveNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzI0MzY_09c6f2ca-5084-4664-af15-4ab5f72b1d4e">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:LitigationReserveNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzI0NDM_647995fd-ee4d-4e49-928f-c40963e4ea9a">5,000</ix:nonFraction>, respectively, were recorded in the accompanying condensed consolidated balance sheets. </span></div><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in March 2021, Daewoong and the Company entered into certain agreements, pursuant to which</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Daewoong agreed to pay the Company an amount equal to $<ix:nonFraction unitRef="usd" contextRef="ifd893c426cf344bfb3e70e80a9717b85_D20210301-20210331" decimals="-3" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzI2OTI_c5c08d22-d59e-436c-bf25-38eb80982e45">25,500</ix:nonFraction>, which was recorded as a settlement payment from Daewoong and included as part of cost of sales on the accompanying condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2021. For the period from December 16, 2020 to September 16, 2022, Daewoong also agreed to reimburse the Company certain amounts with respect to the royalties payable to Medytox and Allergan. This reimbursement is received quarterly and recorded as an offset to the related royalties to Medytox and Allergan in the product cost of sales on the accompanying condensed consolidated statements of operations and comprehensive loss. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the details of all litigation settlement agreements.</span></div><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MjI_fb521103-5bbc-40e6-abe2-d4a6141c048f" continuedAt="ic3e8bb080d6d4c01bc737fa2868c521c" escape="true"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value on the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic3e8bb080d6d4c01bc737fa2868c521c">The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the condensed consolidated balance sheets and in the selling, general and administrative or research and development expenses in the condensed consolidated statements of operations and comprehensive loss.</ix:continuation> </span></div><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MTE_6e0807ea-c228-4334-aa64-25e70e53e042" continuedAt="i8491628dfeff4ed885c977df28079fe7" escape="true"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies an estimated annual effective tax rate (&#8220;ETR&#8221;) approach for calculating a tax provision or benefit for interim periods, as required under GAAP.&#160;The Company recorded an income tax expense of $<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzQ4MzU_42d1d2b4-173a-4c71-aaeb-67a58abb30b0">12</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzQ4NDI_dc656361-ab1b-4dfb-81ed-637eaffbd142">12</ix:nonFraction> for the three months ended September 30, 2022 and 2021, respectively, and an income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzQ5MDc_63b0a84e-1f29-4b75-a65d-68314a8d3995">38</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzQ5MTQ_c22b8092-1f62-4528-9609-b07c14b8bba2">33</ix:nonFraction> for the nine months ended September 30, 2022 and 2021, respectively.&#160;The Company&#8217;s ETR differs from the U.S. federal statutory tax rate of 21% for the three and nine months ended September 30, 2022 and 2021, primarily as a result of the impact of the change of the valuation allowance to offset its deferred tax assets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i784d19359c9e4c5e953f654421125e0f" continuedAt="ib15398f0f7f24393b5541680ad3035c2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8491628dfeff4ed885c977df28079fe7">The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect that changes to state tax laws through September 30, 2022 to materially impact its condensed consolidated financial statements.</ix:continuation></span></div><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MzM_9cc6cf31-dbac-4ca2-9e39-f8802a15e969" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. Excluded from the dilutive net loss per share computation for the three and nine months ended September 30, 2022 and 2021 were stock options of <ix:nonFraction unitRef="shares" contextRef="iaa3b589eceb84e1c94c3c2c4af20ab72_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc0NTc_7bb65e99-b602-442b-bc88-11726fbeaac6"><ix:nonFraction unitRef="shares" contextRef="ib29f2936ca6c4e15a73ecfb1e92029f6_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc0NTc_840f4933-6573-4c90-afe6-2a0e484d900d">4,932,632</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8813e5b8a70741dc843401ec024d4735_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc0NjQ_3d76e1ef-915d-44cd-bba9-1b82af9e8320"><ix:nonFraction unitRef="shares" contextRef="ib956a75826f1489e9a25f9ab19425726_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc0NjQ_71473a18-dcb6-4df9-babb-27faec502e45">3,873,352</ix:nonFraction></ix:nonFraction>, respectively, and non-vested RSUs of <ix:nonFraction unitRef="shares" contextRef="i107ea59f6dc34340846131488239195e_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc1MDU_5f92939d-7c3c-4186-8e52-987e2f4bb135"><ix:nonFraction unitRef="shares" contextRef="ic4b9df72617243df82a84ee6f7a17e88_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc1MDU_88428e63-bb38-4e42-b9ca-b7400c690df5">2,638,803</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i33badbda974443e1a5a538c1d41eb1f2_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc1MTI_26e9a0b4-5e8b-4ca3-be60-d658dbce3c16"><ix:nonFraction unitRef="shares" contextRef="i6de66ce7e4cd487684e1ec075b96e8c2_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc1MTI_8976a696-154e-46df-ac9b-d93df1b64682">1,771,938</ix:nonFraction></ix:nonFraction>, respectively, because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5Mjk_0d4db9df-5bb8-4004-8a70-c40467c18a05" continuedAt="i9515fc624123429c91a71896a7e25c3e" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update will increase transparency of government assistance received by most business entities by requiring the disclosure of: (1) the types of transactions; (2) the accounting for the transactions; and, (3) the effect of the transactions on a business entity&#8217;s financial statements. ASU No. 2021-10 is effective for financial statements issued for annual periods beginning after December 15, 2021, with early application permitted. The Company has adopted this guidance on the effective date of January 1, 2022. There are no material impacts to the condensed consolidated financial statements as a result of this adoption.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Issued But Not Adopted</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU No. 2016-13, the FASB issued ASU No. 2018-19,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU does not change the core principle of the guidance in ASU No. 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04 which did not change the core principle of the guidance in ASU No. 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January 1, 2023. The Company is in the process of determining the effects the adoption will have on its consolidated financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the consolidated financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ib15398f0f7f24393b5541680ad3035c2"><ix:continuation id="i9515fc624123429c91a71896a7e25c3e"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in January 2021, the FASB issued ASU No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope (&#8220;ASU 2021-01&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Both ASU No. 2020-04 and ASU No. 2021-01 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued because of reference rate reform. ASU No. 2020-04 and ASU No. 2021-01 are effective upon issuance for contract modifications and hedging relationships, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company does not expect adoption of this guidance will have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_43"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfMjA0NQ_91cb3871-3bb7-4885-91ab-28557437092d" continuedAt="id642feb28cf54c6db19d015b94f253e9" escape="true">Fair Value Measurements and Short-Term Investments</ix:nonNumeric></span></div><ix:continuation id="id642feb28cf54c6db19d015b94f253e9" continuedAt="i01e811f6607c47388d79ad21b9abd447"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfMjA1MA_d23952f6-0581-4906-88ca-8a2d94c0e1af" continuedAt="i5302863ea86c432ca3a9ece31a0a7204" escape="true">The fair value of these instruments was as follows:</ix:nonNumeric></span></div><ix:continuation id="i5302863ea86c432ca3a9ece31a0a7204"><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:47.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib955eea1a8f64090909d07cf0f04a443_I20220930" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmFhNmI5ODhiYTk4YjQ4OThiNzY0MjI1ZjMxZDI2ZjE1L3RhYmxlcmFuZ2U6YWE2Yjk4OGJhOThiNDg5OGI3NjQyMjVmMzFkMjZmMTVfMy0xLTEtMS02NjM1MQ_956f85d5-ca9b-49a8-845c-0bb1b425dd2e">45,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3b4cc897fe4b31821dca208a7264a5_I20220930" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmFhNmI5ODhiYTk4YjQ4OThiNzY0MjI1ZjMxZDI2ZjE1L3RhYmxlcmFuZ2U6YWE2Yjk4OGJhOThiNDg5OGI3NjQyMjVmMzFkMjZmMTVfMy0zLTEtMS02NjM1MQ_63af9be5-c26d-4b68-8565-7ae0b81cad46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead433642b5a445d83074f84bb63c628_I20220930" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmFhNmI5ODhiYTk4YjQ4OThiNzY0MjI1ZjMxZDI2ZjE1L3RhYmxlcmFuZ2U6YWE2Yjk4OGJhOThiNDg5OGI3NjQyMjVmMzFkMjZmMTVfMy01LTEtMS02NjM1MQ_c462640b-5bae-44d5-8ab4-b3c646d0c1e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03eb03f09bcf4e01b9c6fba2243bb8aa_I20220930" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmFhNmI5ODhiYTk4YjQ4OThiNzY0MjI1ZjMxZDI2ZjE1L3RhYmxlcmFuZ2U6YWE2Yjk4OGJhOThiNDg5OGI3NjQyMjVmMzFkMjZmMTVfMy03LTEtMS02NjM1MQ_b2291dd2-805e-48cc-aef0-12a625f3319a">45,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:47.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b9d9f3ec3d401cab72265246433b66_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOjRhZDIzOTIwMWU2MTRmMmZhZWM1NTQxNmMwZWQ4YmZiL3RhYmxlcmFuZ2U6NGFkMjM5MjAxZTYxNGYyZmFlYzU1NDE2YzBlZDhiZmJfMy0xLTEtMS02NjM1MQ_c9604c8c-69dd-4224-bcfe-461351701987">44,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11377a43f27c4faba7aad6793f724743_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOjRhZDIzOTIwMWU2MTRmMmZhZWM1NTQxNmMwZWQ4YmZiL3RhYmxlcmFuZ2U6NGFkMjM5MjAxZTYxNGYyZmFlYzU1NDE2YzBlZDhiZmJfMy0zLTEtMS02NjM1MQ_b7642a7f-91ab-4378-bc5e-d7d32ec86f46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8509a6d0797e4a1b8fd1d32a15d74377_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOjRhZDIzOTIwMWU2MTRmMmZhZWM1NTQxNmMwZWQ4YmZiL3RhYmxlcmFuZ2U6NGFkMjM5MjAxZTYxNGYyZmFlYzU1NDE2YzBlZDhiZmJfMy01LTEtMS02NjM1MQ_a47ba7da-0f3b-4ae4-a495-ad9d4af68086">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84d7dc8ca08a4da6a6c642d9a973ff92_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOjRhZDIzOTIwMWU2MTRmMmZhZWM1NTQxNmMwZWQ4YmZiL3RhYmxlcmFuZ2U6NGFkMjM5MjAxZTYxNGYyZmFlYzU1NDE2YzBlZDhiZmJfMy03LTEtMS02NjM1MQ_a91f188c-eba4-4e0d-9e37-916768f787e6">44,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the nine months ended September 30, 2022 and 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable to Evolus Founders based on Level 3 inputs using a discounted cash flows method. The significant unobservable input assumptions that can significantly change the fair value include (i) projected amount and timing of net revenues during the payment period, which terminates at the end of the second quarter of 2029, (ii) the discount rate, and (iii) the timing of payments. During the three and nine months ended September 30, 2022 and 2021, the Company utilized a discount rate of <ix:nonFraction unitRef="number" contextRef="i7373271b2dde4aba839209bce8d0292e_I20210930" decimals="INF" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfOTY2_a112823c-0989-48cb-904d-8a87ad95dd52"><ix:nonFraction unitRef="number" contextRef="ib746515f688d46d7934e1ac056024bba_I20220930" decimals="INF" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfOTY2_e194ecad-1cdd-4641-b4e2-7bd73164ed34">13.0</ix:nonFraction></ix:nonFraction>%, reflecting the Company&#8217;s risk profile. Net revenue projections are also updated to reflect changes in the timing of expected sales.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfMjA0Nw_99065f11-7716-45d1-beb5-0f85a7c80a76" continuedAt="i41877df6d4384d4f934bc39a70a269c0" escape="true">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i01e811f6607c47388d79ad21b9abd447" continuedAt="ic1dcb9f30c3c4aaf878c8220c4666d4c"><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><ix:continuation id="i41877df6d4384d4f934bc39a70a269c0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.452%"><tr><td style="width:1.0%"></td><td style="width:44.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fd4a2cf7cb49e6a38c2fc9b0df76fd_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMi0xLTEtMS02NjM1MQ_0e108687-cac7-4929-8ddb-9341df499bc7">45,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13db4b6383624d5097720364e94a31b5_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMi0zLTEtMS02NjM1MQ_043cef8c-f23f-4814-8ad7-5fb81a9223a8">42,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMi01LTEtMS02NjM1MQ_0a956e60-baab-499a-8d1f-d1c680193a35">44,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2a587e790f4e898dff40a08b249f56_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMi03LTEtMS02NjM1MQ_32dac41b-8fad-4bbb-acd5-518b84187bfe">41,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMy0xLTEtMS02NjM1MQ_3512cedd-1570-45c0-baa4-0931573e8d3a">1,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMy0zLTEtMS02NjM1MQ_073aa864-0a3c-40bf-94ca-26f2cc0fafd1">783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMy01LTEtMS02NjM1MQ_9e3f5c7a-3ccc-43c8-a262-d1025dfe0065">3,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMy03LTEtMS02NjM1MQ_aca7b9de-d228-4d23-865c-2255f56434c8">2,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recorded in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNC0xLTEtMS02NjM1MQ_d10be86d-9d3a-4d74-9d86-7a0b9968cea2">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNC0zLTEtMS02NjM1MQ_3347cc1b-f8ed-4356-bc01-09e7eb067773">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNC01LTEtMS02NjM1MQ_984a5e7a-8528-4636-a6e0-f049249b7ebe">3,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNC03LTEtMS02NjM1MQ_d4888a99-d3cf-4800-b86e-09480ebb9b42">4,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNS0xLTEtMS02NjM1MQ_90f59a19-31a9-4ef1-85a0-bb66bfc6899f">45,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458f436d90584702b2e171f24fc2ffd9_I20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNS0zLTEtMS02NjM1MQ_013749e0-0e2c-415d-b533-af26bdfe2482">43,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNS01LTEtMS02NjM1MQ_5c7c94bb-e1f8-4860-a684-5d62daf4e969">45,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458f436d90584702b2e171f24fc2ffd9_I20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNS03LTEtMS02NjM1MQ_90e58054-eaf7-4345-8f00-37f2c4cb729e">43,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Assets and Liabilities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. </span></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic1dcb9f30c3c4aaf878c8220c4666d4c">The Company estimates the fair value of the long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of September 30, 2022 and December&#160;31, 2021, the fair value of long-term debt was $<ix:nonFraction unitRef="usd" contextRef="i74ba879b9f0b49eeb45d7c48810743cf_I20220930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfMTkxOQ_22cd16ba-680a-4766-8f82-a1a11d98793b">70,360</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iefccff05ba3b424ea7695cd478bcf8c0_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfMTkyNg_dd5bab8b-f28b-4683-8d1c-08ec6e2c9045">75,448</ix:nonFraction>, respectively. The fair value of operating lease liabilities&#160;as of September 30, 2022 and December&#160;31, 2021 approximated their carrying value.</ix:continuation> </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_46"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTQ5Mg_04e9f554-50a9-44c2-b44a-800dee5f02fd" continuedAt="icaf3e9cae0e040449d45bf95ea73d493" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="icaf3e9cae0e040449d45bf95ea73d493" continuedAt="i6b4dcf5939824c798db6208a3e8aafcc"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTQ4Ng_a94fce32-d144-4fb6-bf17-1ec8c62c5192" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:40.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.891%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i74d2705a944e47df928e202fbe73806f_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMi0xLTEtMS02NjM1MQ_c9546f90-d43d-47dc-8d65-13cd20121bea">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5a4bd9076b49e990faeaca86303ea1_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMi0zLTEtMS02NjM1MQ_5bbf2587-3f27-450f-86c3-13a819a68e39">59,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5a4bd9076b49e990faeaca86303ea1_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMi01LTEtMS02NjM1MQ_e0d4e97f-f523-4bf6-bd76-7836f28fb76d">10,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5a4bd9076b49e990faeaca86303ea1_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMi03LTEtMS02NjM1MQ_9e882eaa-0ad4-4a0e-8a00-35d13fd399e5">48,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7b7b2f262aa04bfebf9a790343dc73ff_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMy0xLTEtMS02NjM1MQ_150a9533-d211-4b33-89d0-868b71d9a5b5">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d84afa1250640b198c1fb1a6169c85a_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMy0zLTEtMS02NjM1MQ_d48df789-028c-4587-b616-b65f890d8d2e">8,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d84afa1250640b198c1fb1a6169c85a_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMy01LTEtMS02NjM1MQ_460f9f6d-55f3-40b5-98e9-03112fcc019d">7,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d84afa1250640b198c1fb1a6169c85a_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMy03LTEtMS02NjM1MQ_9bd1ebaa-6ee0-448c-8ceb-ab3b3bfd34c9">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNC0zLTEtMS02NjM1MQ_a76f9ed1-bfd2-4a1d-83bd-ccf3f71895f3">67,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNC01LTEtMS02NjM1MQ_760aaab0-ad6a-42a3-975d-343342fa6018">18,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNC03LTEtMS02NjM1MQ_996422e2-657f-4314-8cbd-3d6342c60c2c">49,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNi0zLTEtMS02NjM1MQ_66d82b49-0bc1-41cf-9fa2-979cbe153a76">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNi03LTEtMS02NjM1MQ_ee5af62f-9318-4e2e-8c75-c98d70fd6136">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="eols:IntangibleAssetsGrossIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNy0zLTEtMS02NjM1MQ_3a1d7159-8851-4749-96ae-c7f9e082265d">88,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNy01LTEtMS02NjM1MQ_6beef29a-5e35-4bc4-b95a-4cb169a1f19b">18,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNy03LTEtMS02NjM1MQ_fe94bef8-3b2e-4c45-b6fb-f2f13c0e0441">70,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:40.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.891%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieab10e4bb85e456c8270ad88c92f573a_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMi0xLTEtMS02NjM1MQ_6ea2e678-6952-4cd1-aecc-680307d9ea00">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a097741d79a4319ba97c97d46d0a539_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMi0zLTEtMS02NjM1MQ_ec26b0d0-5252-4f46-a0f1-866bb39ed03d">59,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a097741d79a4319ba97c97d46d0a539_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMi01LTEtMS02NjM1MQ_ad8f315a-8d61-452f-af5c-11bab4f04919">8,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a097741d79a4319ba97c97d46d0a539_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMi03LTEtMS02NjM1MQ_4bb3e56a-2b82-49e7-8c4b-7fe37bfa7706">50,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1eae918cd3a1458f8f5c7ea81225a697_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMy0xLTEtMS02NjM1MQ_fb09a6da-73c6-4ff5-acb7-ba5beb908b40">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i492a93cfde634638aead055c0ca3b153_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMy0zLTEtMS02NjM1MQ_62c45f67-906b-40aa-8434-42dc631fb312">7,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i492a93cfde634638aead055c0ca3b153_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMy01LTEtMS02NjM1MQ_dec08cc0-3d90-4ebe-9075-c94bbb15f5be">7,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i492a93cfde634638aead055c0ca3b153_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMy03LTEtMS02NjM1MQ_3a76ed2a-2718-4b8e-a26f-72eb873db803">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNC0zLTEtMS02NjM1MQ_d725d837-3efe-4000-a513-aabba61abbb8">66,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNC01LTEtMS02NjM1MQ_75f6a447-a8d0-4a31-9e8b-749dfad508ba">15,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNC03LTEtMS02NjM1MQ_f25e54ff-8808-4f54-b0f5-9d92862a68eb">50,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNi0zLTEtMS02NjM1MQ_1fbe6a88-10fb-41b1-be37-f70f04ee3198">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNi03LTEtMS02NjM1MQ_c8e601da-372d-4987-8d23-49eb0e3745c3">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="eols:IntangibleAssetsGrossIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNy0zLTEtMS02NjM1MQ_fdc17a08-7983-4e4a-b359-0fa0178b4049">87,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNy01LTEtMS02NjM1MQ_9007a003-afb3-404d-9cda-d29ffdfce59c">15,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNy03LTEtMS02NjM1MQ_e87fdbd6-35ab-47df-a500-4ec82afb5b5b">71,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*  Intangible assets with indefinite lives have an indeterminable average life.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i6b4dcf5939824c798db6208a3e8aafcc"><div style="margin-bottom:9pt"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTQ5Ng_b25120d7-37d5-4ca8-a78d-ff12bbd5450e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;September 30, 2022 that are subject to amortization:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.173%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining in 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfMS0xLTEtMS02NjM1MQ_ba079011-2a80-4efb-b52d-951aaec68182">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfMi0xLTEtMS02NjM1MQ_8e537559-9d74-4f4b-91a3-09c212f65f3c">3,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfMy0xLTEtMS02NjM1MQ_2aee7d3e-bc79-4274-ad7f-c79ebadc7a20">3,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfNC0xLTEtMS02NjM1MQ_14964109-d6d6-487a-af26-5853539194b6">2,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfNS0xLTEtMS02NjM1MQ_5fc80d27-0444-4cf1-9dd4-b4a690928eb3">2,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="eols:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfNi0xLTEtMS02NjM1MQ_8f5ada91-e296-4100-920f-e124db5253da">35,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfNy0xLTEtMS02NjM1MQ_be626f34-6a0b-4500-a845-65f33f8da879">49,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution right represents the license and associated distribution right to develop Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the initial term of which expires in September 2023 and is automatically extended for unlimited additional <ix:nonNumeric contextRef="ia8be82e572d441889a4d6f6934c06888_D20220101-20220930" name="eols:AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTQ4OQ_ab4d0973-3347-4582-822a-133746c4b9ce">three-year</ix:nonNumeric> terms provided that the Company meets certain performance requirements. The Company paid Daewoong $<ix:nonFraction unitRef="usd" contextRef="ic324d34859d240ffa67a43c66f937f95_D20190101-20191231" decimals="-3" name="eols:MilestonePaymentsForIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfNzM4_2c92019d-7a0f-4156-a102-031af532e0ae">3,000</ix:nonFraction> in milestone payments in 2019, pursuant to the Daewoong Agreement, which increased the cost basis of the distribution. Under the Daewoong Settlement Agreement (as defined in Note 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), there is no additional cash consideration due to Daewoong. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:CapitalizedComputerSoftwareAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTA0Mw_2f011860-1e73-4d4a-9fab-b5e80b7499ed">531</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:CapitalizedComputerSoftwareAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTA1MA_7c455d74-cf87-4478-905f-37be823766ad">0</ix:nonFraction> for the three months ended September 30, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:CapitalizedComputerSoftwareAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTA5MA_92a1277d-0e32-4683-a62a-0f9734c67ec2">938</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:CapitalizedComputerSoftwareAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTA5Nw_8f3fbee5-bbe0-4ab4-b6e0-455f74608434">633</ix:nonFraction> for the nine months ended September 30, 2022 and 2021, respectively, related to costs of computer software developed for internal use. The Company recorded total intangible assets amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTI2OA_6542e857-0e9f-432a-a66b-582c0774ca16">838</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTI3NQ_671f3e62-b70d-40a5-bc7a-9838cb7cd9cb">843</ix:nonFraction> for the three months ended September 30, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTMxNQ_aca933db-e978-43e9-b2bc-c08a424c285c">2,454</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTMyMg_044099e7-541a-4eaa-96ed-155798c13b75">4,463</ix:nonFraction> for the nine months ended September 30, 2022 and 2021, respectively, within depreciation and amortization on the accompanying condensed consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_49"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RleHRyZWdpb246ZDY3ZjIwMDRkZTE3NDVjNTk1ZWMwODgyZDczODE3MmJfNjI_6f1a6ce3-9cca-4526-9723-32d4ae8170cc" continuedAt="i5731d200490a47049d23b5f3b1a5efc7" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i5731d200490a47049d23b5f3b1a5efc7"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RleHRyZWdpb246ZDY3ZjIwMDRkZTE3NDVjNTk1ZWMwODgyZDczODE3MmJfNjU_0088945c-5612-4fb2-b5af-56206283af1e" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:57.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties under the Medytox/Allergan Settlement Agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfMi0xLTEtMS02NjM1MQ_f44191e6-2c58-4875-94bb-2c6351f48722">7,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfMi0zLTEtMS02NjM1MQ_e9fff7bd-4ffe-4b93-b14a-66e435a56dd8">12,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfMy0xLTEtMS02NjM1MQ_89b4e252-ac1f-48c0-b33a-16be62a12f60">7,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfMy0zLTEtMS02NjM1MQ_728fdde1-e56a-413b-a584-15b09d10e4ac">6,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued revenue contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfNC0xLTEtMS02NjM1MQ_5bbbe947-ca23-4f7e-a6ad-a15eb74987de">10,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfNC0zLTEtMS02NjM1MQ_f929764a-9342-4d2d-8949-fef9cf735529">7,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfNS0xLTEtMS02NjM1MQ_0a4fa0a5-3599-49ef-ba91-31ee48c8a609">4,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfNS0zLTEtMS02NjM1MQ_10d4548b-d2bd-466b-85fd-20970f1cc5f9">2,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfNi0xLTEtMS02NjM1MQ_3f35284b-866d-4816-a466-b4de6a8736b7">29,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfNi0zLTEtMS02NjM1MQ_aa6aebca-81e8-4004-8a74-52ade90cc0fb">29,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_52"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjcyNA_e9099cbe-0328-44e9-85c8-153ae3c816a9" continuedAt="ife2bfc12f13145648c70836f2a9f72ff" escape="true">Term Loans</ix:nonNumeric></span></div><ix:continuation id="ife2bfc12f13145648c70836f2a9f72ff" continuedAt="icb015ce02b2c49ea89047692dcd48170"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmakon Term Loans</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, the Company entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to the Company in <ix:nonFraction unitRef="tranche" contextRef="i87008557f7394da183cb13535fff98b5_I20211214" decimals="INF" name="eols:DebtInstrumentNumberOfTranches" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjcyNQ_088ef551-4821-46a0-86f6-663e9af13685">two</ix:nonFraction> tranches (&#8220;Pharmakon Term Loans&#8221;). The first tranche of $<ix:nonFraction unitRef="usd" contextRef="i9f70375f5d4e414ba6839f26fe0ddc44_I20211214" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMjY0_7a7342f8-d719-4e44-aefd-228293f68528">75,000</ix:nonFraction> was funded on December 29, 2021. The second tranche of $<ix:nonFraction unitRef="usd" contextRef="i681b2a7d205d410ca672bf2a337a55b0_I20211214" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMzIy_f9b17967-5a33-4621-ab0e-0db41e25c4ca">50,000</ix:nonFraction> may be drawn at the Company&#8217;s election no later than December 31, 2022, subject to the terms and conditions of the Pharmakon Term Loans. As of September 30, 2022, the </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="icb015ce02b2c49ea89047692dcd48170" continuedAt="i385294e2f2f947458e0a76885dacb6d6"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has not drawn the second tranche. The Pharmakon Term Loans will mature on the <ix:nonNumeric contextRef="ie655358ab82b4cf3933d54db2925cf4b_D20211214-20211214" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjcyNg_a8cd08f7-a3e0-4f84-85fd-815059f97b41">six-year</ix:nonNumeric> anniversary of the closing date of the first tranche (&#8220;Maturity Date&#8221;). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans accrue interest at a per annum rate equal to the greater of <ix:nonFraction unitRef="number" contextRef="i87008557f7394da183cb13535fff98b5_I20211214" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNzI5_b9df53d1-d57f-451f-bb90-8c41f9f275f2">1.0</ix:nonFraction>% or 3-month U.S. Dollar LIBOR rate plus <ix:nonFraction unitRef="number" contextRef="i0931e5250f9643efa1a3ac8af4f22859_D20211214-20211214" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNzcx_268eb433-9fa6-41bb-bd3f-eb2ad0be535e">8.5</ix:nonFraction>% per annum. In the event U.S. Dollar LIBOR rate is discontinued, the interest rate for the Pharmakon Term Loans will be based on an alternate benchmark rate established in the manner provided under the loan agreement for the Pharmakon Term Loans. The Company agreed to make <ix:nonFraction unitRef="payment" contextRef="ie655358ab82b4cf3933d54db2925cf4b_D20211214-20211214" decimals="INF" name="eols:DebtInstrumentNumberOfPeriodicPaymentsPrincipal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMTA0Nw_221d8ff0-e165-4ef3-9cc0-56ec7ce64599">12</ix:nonFraction> equal quarterly payments of principal on the outstanding Pharmakon Term Loans commencing on or immediately following the <ix:nonNumeric contextRef="id0259e20c7b64238ace67075cd4ebde3_D20211214-20211214" name="eols:DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMTE3MQ_10a5b3e9-9d5a-4903-a7f0-974fefa1adfb">39</ix:nonNumeric>th-month anniversary of the funding date of the first tranche continuing through the Maturity Date.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect to prepay all amounts, not less than $<ix:nonFraction unitRef="usd" contextRef="ibb4a33cd285f450c9199ba56c40498b4_I20211214" decimals="-3" name="eols:DebtInstrumentPrepaymentAmountThreshold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMTMzMg_4b2a3d27-a69f-4729-bda5-10c58f79f265">20,000</ix:nonFraction>, owed prior to the Maturity Date. Prepayments of the first tranche prior to the second anniversary of the closing date of the first tranche and prepayments of the second tranche prior to the second anniversary of the date on which the second tranche is drawn by the Company will be accompanied by a make whole amount equal to the sum of all interest that would have accrued through such second anniversary. Prepayments of the Pharmakon Term Loans will also be accompanied by a prepayment premium equal to the principal amount so prepaid multiplied by <ix:nonFraction unitRef="number" contextRef="id39eaeea68ce4b2b873c2e7097ffad4f_I20211214" decimals="INF" name="eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMTg4Ng_4d6d3fa4-36c3-4aa2-9bdf-6655fc1b3e68">3.0</ix:nonFraction>% if made prior to the third anniversary of the closing date of the first tranche, <ix:nonFraction unitRef="number" contextRef="idb4fee43c2d44ee2b2e15ef341def13b_I20211214" decimals="INF" name="eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMTk3MA_8e7df458-a656-4f90-8502-1d1375bbc6e4">2.0</ix:nonFraction>% if made on or after the third anniversary of the closing date of the first tranche but prior to the fourth anniversary of the closing date of the first tranche, and <ix:nonFraction unitRef="number" contextRef="i3bfea5e3671f467c9abe90444ff80e16_I20211214" decimals="INF" name="eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMjEzOA_4c01321a-a5a7-4e34-b5c3-87a1c57664c2">1.0</ix:nonFraction>% if made on or after the fourth anniversary of the closing date of the first tranche but prior to the Maturity Date. If the Pharmakon Term Loans are accelerated following the occurrence of an event of default, including a material adverse change, the Company is required to immediately pay Pharmakon an amount equal to the sum of all outstanding principal, unpaid interest, and applicable make whole and prepayment premiums.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans are secured by substantially all of the Company&#8217;s assets. The Pharmakon Term Loans contain customary affirmative and restrictive covenants and representations and warranties. The affirmative covenants include, among others, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. The restrictive covenants include, among others, incurring certain additional indebtedness, consummating certain change in control transactions, or incurring any non- permitted lien or other encumbrance on the Company&#8217;s assets, without Pharmakon&#8217;s prior written consent. The Pharmakon Term Loans do not contain covenants requiring the Company to maintain a minimum cash threshold or minimum revenues or earnings. As of September 30, 2022, the Company was in compliance with its debt covenants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing date of the first tranche, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i87008557f7394da183cb13535fff98b5_I20211214" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMzQ3NA_be8ae292-a65f-4f61-b591-ccb35175babe">3,042</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i87008557f7394da183cb13535fff98b5_I20211214" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMzQ4MQ_72b52083-37ae-41d4-a0ce-7840cde5ccab">3,263</ix:nonFraction> in debt discounts and issuance costs related to the Pharmakon Term Loans, respectively. Debt discounts and issuance costs related to the entire Pharmakon Term Loans have been allocated pro rata between the funded and unfunded portions. Debt discounts and issuance costs allocated to the first tranche of $<ix:nonFraction unitRef="usd" contextRef="i9f70375f5d4e414ba6839f26fe0ddc44_I20211214" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMzc4OA_3171ee88-e73b-408b-8635-5e94d1244070">75,000</ix:nonFraction> have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. As of September 30, 2022, the borrowings outstanding under the Pharmakon Term Loans were classified as long-term debt in the accompanying condensed consolidated balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately <ix:nonFraction unitRef="number" contextRef="i12401c3106e141e3932d964c36466a9c_I20220930" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNDM1Nw_da96da10-a005-47bf-9dfa-ca2ebda5bdb5">12.22</ix:nonFraction>% as of September 30, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjcyOA_ba14765e-ce2d-44c3-8c3c-c22a797aa3dc" continuedAt="i7441d11f168d42c6a6b5d63d5503be13" escape="true">As of September 30, 2022, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i385294e2f2f947458e0a76885dacb6d6" continuedAt="i60e9bb6629cd49d88c4fac49c5b3821e"><div style="margin-bottom:10pt;text-align:center"><ix:continuation id="i7441d11f168d42c6a6b5d63d5503be13"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.299%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfMS0xLTEtMS02NjM1MQ_87cf0bc8-3c76-4113-8afb-92239de53e5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfMi0xLTEtMS02NjM1MQ_733212b5-88bc-4e69-a671-14f54fdb2da2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfMy0xLTEtMS02NjM1MQ_c1c87aec-c8f4-42ce-93a6-992a93ebce11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfNC0xLTEtMS02NjM1MQ_eda9669d-bc3d-4f48-b37a-35dd4f50a833">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfNS0xLTEtMS02NjM1MQ_043e4ac5-6233-450a-b6fb-03298bcf7e83">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="eols:LongTermDebtMaturityAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfNi0xLTEtMS02NjM1MQ_14cf9d81-6da0-45ce-878e-90663e4ee624">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfNy0xLTEtMS02NjM1MQ_e9f2c799-56b9-4d17-8ec5-bbd4505e0389">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfOC0xLTEtMS02NjM1MQ_df7de65e-0b93-4159-9445-4b85a7a597ff">3,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net of discounts and issuance costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfOS0xLTEtMS02NjM1MQ_14e7d7a6-0944-4f0b-9412-881af8fcb6b8">71,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oxford Term Loan</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2019, the Company entered into a Loan and Security Agreement with Oxford (the &#8220;Loan Agreement&#8221;), providing for a credit facility of up to $<ix:nonFraction unitRef="usd" contextRef="i32423b3783a74a82a50b52069242757e_I20190315" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNDY1Ng_eb1cb27f-08dd-468e-8c1c-e5e2a07f4da3">100,000</ix:nonFraction>. Pursuant to the terms of the credit facility, the lender extended term loans (the &#8220;Oxford Term Loan&#8221;), available in <ix:nonFraction unitRef="advance" contextRef="i32423b3783a74a82a50b52069242757e_I20190315" decimals="INF" name="eols:LineofCreditFacilityNumberofAdvances" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNDc3Ng_6ea1b0b2-0933-4373-8edd-71f7ba8b597f">two</ix:nonFraction> advances, to the Company. The first tranche of $<ix:nonFraction unitRef="usd" contextRef="iba0b2ad793844b26a191ac3cd34f31f2_I20190315" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNDgyNg_fcae83a0-26f8-484b-80cd-d4d573c89e71">75,000</ix:nonFraction> was funded on the closing date. The second tranche of $<ix:nonFraction unitRef="usd" contextRef="ie6b945adff8f46008df2b4591b66e2fe_I20190315" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNDg4Mw_ede08a16-02c2-43ca-aa30-5bef743cfe5a">25,000</ix:nonFraction> was not drawn. The credit facility bore an annual interest rate equal to the greater of <ix:nonFraction unitRef="number" contextRef="i32423b3783a74a82a50b52069242757e_I20190315" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNDk3NA_9f8affb2-9283-454f-b6b3-7b7e063c5e4f">9.5</ix:nonFraction>%, or the 30-day U.S. Dollar LIBOR rate plus <ix:nonFraction unitRef="number" contextRef="i9de13a38f24141ecadd52a63c397047d_D20190315-20190315" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTAyMA_d9139873-770f-4bd9-bdca-147f9fa587c1">7.0</ix:nonFraction>%. The Company agreed to pay interest-only for the first <ix:nonNumeric contextRef="ia0f2553d528c41c3ab5ae3858f5fda13_D20190315-20190315" name="eols:DebtInstrumentPeriodOfInterestOnlyPayments" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTA3OA_f17efaf2-05ed-425b-ab9b-846507c64c3a">36</ix:nonNumeric> months until May 2022, followed by a <ix:nonNumeric contextRef="ia0f2553d528c41c3ab5ae3858f5fda13_D20190315-20190315" name="eols:DebtInstrumentAmortizationPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTExOA_3873e736-a5ab-4929-8308-d07507100859">23</ix:nonNumeric>-month amortization period. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the earliest to occur of the maturity date, the acceleration of the Oxford Term Loan, or the prepayment of the Oxford Term Loan, the Company was required to pay to Oxford a final payment of <ix:nonFraction unitRef="number" contextRef="i4d21558b1b844fea9ffd52152f5a0b6d_I20190315" decimals="INF" name="eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTM0NA_702a3fc7-1752-4521-9a3f-5ff5f5b277be">5.5</ix:nonFraction>% of the full principal amount of the Oxford Term Loan funded (&#8220;Final Payment&#8221;). The Company could elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee was also paid, which would be equal to <ix:nonFraction unitRef="number" contextRef="i4d21558b1b844fea9ffd52152f5a0b6d_I20190315" decimals="INF" name="eols:DebtInstrumentPrepaymentFeePercentageYearTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTU3NQ_6c9e9527-3dd1-4e87-b033-959cf91791fc">2.0</ix:nonFraction>% of the amount prepaid if the prepayment occurred after March 15, 2020 and on or prior to March 15, 2021, or <ix:nonFraction unitRef="number" contextRef="i4d21558b1b844fea9ffd52152f5a0b6d_I20190315" decimals="INF" name="eols:DebtInstrumentPrepaymentFeePercentageThereafter" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTY4Ng_97d46e86-e4e3-45e7-9a87-85e456bdb7ad">1.0</ix:nonFraction>% of the amount prepaid if the prepayment occurred thereafter (&#8220;Prepayment Fee&#8221;).</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, the Company and Oxford entered into an agreement (&#8220;Payoff Letter&#8221;), pursuant to which (i) the Company paid Oxford $<ix:nonFraction unitRef="usd" contextRef="i2ea01d8678a148839f20dd947155b9a2_D20210104-20210104" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTkwMw_f3f30a33-e56d-483b-a23a-86f63b4d1b7d">76,447</ix:nonFraction> to discharge in full all outstanding obligations, including accrued interest, by and between Oxford, in its capacity as collateral agent and lender, and the Company, and (ii) effective upon such repayment, the Loan Agreement, and all unfunded commitments thereunder, guarantees and other security interests granted to Oxford in connection with the Loan Agreement and all other obligations of and restrictions on the Company under the Loan Agreement, terminated. As a condition to entering into the Payoff Letter, Oxford agreed to waive a total of $<ix:nonFraction unitRef="usd" contextRef="i2ea01d8678a148839f20dd947155b9a2_D20210104-20210104" decimals="-3" name="eols:DebtInstrumentFeeAmountWaived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjQ1Mw_beba1991-1c79-4f42-aef5-9100a3c9204c">4,300</ix:nonFraction> of fees comprised of (i) $<ix:nonFraction unitRef="usd" contextRef="i2ea01d8678a148839f20dd947155b9a2_D20210104-20210104" decimals="-3" name="eols:DebtInstrumentOfFinalPaymentAmountWaived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjQ4MQ_38be68be-43d3-41e2-970c-fb77ea4af63e">2,800</ix:nonFraction> of the Final Payment and (ii) the Prepayment Fee of $<ix:nonFraction unitRef="usd" contextRef="i2ea01d8678a148839f20dd947155b9a2_D20210104-20210104" decimals="-3" name="eols:DebtInstrumentPrepaymentFeeAmountWaived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjUzNg_b1d9cffb-00bc-4ff6-b6e1-f56918c31ad5">1,500</ix:nonFraction>. As a result, the Company recorded a loss of $<ix:nonFraction unitRef="usd" contextRef="i9984dc72d84a433bbbf2c8e4297d8ab3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjU4NA_7d15c773-0f15-4289-a8fc-4385127bdd01">1,939</ix:nonFraction> in extinguishment of debts, net on the accompanying condensed consolidated statements of operations and comprehensive loss in the nine months ended September 30, 2021.</span></div></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_55"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:continuation id="i60e9bb6629cd49d88c4fac49c5b3821e" continuedAt="i946977512ca04834b0f43e97267e7ebe">Daewoong Convertible Note</ix:continuation></span></div><ix:continuation id="i946977512ca04834b0f43e97267e7ebe" continuedAt="i683162899f7d4221b414006ff1bf3f12"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2020, the Company entered into a Convertible Promissory Note Purchase Agreement with Daewoong for the principal amount of $<ix:nonFraction unitRef="usd" contextRef="ifcabd9d8120a4b52ad4211b9b2779160_I20200706" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81NS9mcmFnOjhhNDBlYTZhMTcxNDQ2MzJhN2VlZGZkNGIzYjkzZmMyL3RleHRyZWdpb246OGE0MGVhNmExNzE0NDYzMmE3ZWVkZmQ0YjNiOTNmYzJfMTcy_5126dc3f-6c6b-4146-8ded-de6728551b12">40,000</ix:nonFraction> (the &#8220;Daewoong Convertible Note&#8221;), which was funded on July 30, 2020. Additionally, on July 6, 2020, the Company, Daewoong and Oxford entered into a Subordination Agreement pursuant to which the Daewoong Convertible Note was subordinated to the Company&#8217;s obligations under the Loan Agreement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Convertible Note bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="ifcabd9d8120a4b52ad4211b9b2779160_I20200706" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81NS9mcmFnOjhhNDBlYTZhMTcxNDQ2MzJhN2VlZGZkNGIzYjkzZmMyL3RleHRyZWdpb246OGE0MGVhNmExNzE0NDYzMmE3ZWVkZmQ0YjNiOTNmYzJfNTI1_e88469cd-41d4-4ef2-b31b-8b45b2d47761">3.0</ix:nonFraction>% payable semi-annually in arrears on June 30th and December 31st of each year and was to mature on July 30, 2025, subject to earlier conversion as provided below. Interest was initially paid in kind by adding the accrued amount thereof to the outstanding principal amount on a semi-annual basis on June 30th and December 31st of each calendar year for so long as any principal amount under the Oxford Term Loan remained outstanding and the Subordination Agreement was not terminated. Interest became payable in cash after the Oxford Term Loan was repaid in full, and the Subordination Agreement was terminated on January 4, 2021. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:10pt"><ix:continuation id="i683162899f7d4221b414006ff1bf3f12"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the outstanding principal balance including all accrued and unpaid interest thereon, of $<ix:nonFraction unitRef="usd" contextRef="ibfb737bacd0248fc910875d3a4549e77_I20210323" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81NS9mcmFnOjhhNDBlYTZhMTcxNDQ2MzJhN2VlZGZkNGIzYjkzZmMyL3RleHRyZWdpb246OGE0MGVhNmExNzE0NDYzMmE3ZWVkZmQ0YjNiOTNmYzJfMTI2NQ_299034d1-33a0-4671-a876-17119648a167">40,779</ix:nonFraction> was converted, at the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibfb737bacd0248fc910875d3a4549e77_I20210323" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81NS9mcmFnOjhhNDBlYTZhMTcxNDQ2MzJhN2VlZGZkNGIzYjkzZmMyL3RleHRyZWdpb246OGE0MGVhNmExNzE0NDYzMmE3ZWVkZmQ0YjNiOTNmYzJfMTMxMA_b0b1b307-680a-45f7-a5eb-2120661f46ae">13.00</ix:nonFraction> per share, into <ix:nonFraction unitRef="position" contextRef="i4504c78963354d1badb28c7c64e116ec_D20210323-20210323" decimals="INF" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81NS9mcmFnOjhhNDBlYTZhMTcxNDQ2MzJhN2VlZGZkNGIzYjkzZmMyL3RleHRyZWdpb246OGE0MGVhNmExNzE0NDYzMmE3ZWVkZmQ0YjNiOTNmYzJfMTMyOQ_8f9bf57b-f8c8-4b55-9595-521ea8a2b1c1">3,136,869</ix:nonFraction> shares of the Company&#8217;s common stock under the Conversion Agreement (as defined in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 11.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The conversion was accounted for as an extinguishment of debt resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="i671a3057546c42ba9908a766f27874d3_D20210323-20210323" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81NS9mcmFnOjhhNDBlYTZhMTcxNDQ2MzJhN2VlZGZkNGIzYjkzZmMyL3RleHRyZWdpb246OGE0MGVhNmExNzE0NDYzMmE3ZWVkZmQ0YjNiOTNmYzJfMTUwNg_d3f7b53e-fa5f-4de0-ada0-db5e60e9c865">971</ix:nonFraction>, which is recorded in loss from extinguishment of debts, net on the accompanying condensed consolidated statements of operations and comprehensive loss. The Daewoong Convertible Note was not registered, and the shares of the Company&#8217;s common stock issued upon conversion of the Daewoong Convertible Note have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the details of the Conversion Agreement.</span></ix:continuation></div><div><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_58"></div><div style="margin-bottom:10pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfMTg3NQ_5fc5bf2c-abf0-4c36-818a-7adffaf7d8d3" continuedAt="i4bf36c65fd9c4a4ca177b5b780dc9e76" escape="true">Operating Leases</ix:nonNumeric></span></div><ix:continuation id="i4bf36c65fd9c4a4ca177b5b780dc9e76" continuedAt="i03ab692ab9fe46c9b02eb01e7d53aab7"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate headquarters in Newport Beach, California is leased under a <ix:nonNumeric contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfMTg3Ng_9cc953ef-bbf4-4825-8f80-c04403569888">five-year</ix:nonNumeric> non-cancelable operating lease, which expires on January 31, 2025. Lease payments increase each year on February 1 based on an annual rent escalation clause. The Company may, under certain circumstances, terminate the lease on the <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="eols:LesseeOperatingLeaseTerminationPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfMzUz_dc3d6866-ae78-4668-aeab-39925b08c404">36</ix:nonNumeric>-month anniversary of the lease commencement date by providing a written notice <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="eols:LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfNDM1_266c8277-c695-4f25-bb1d-76b31a95d27b">12</ix:nonNumeric> months prior to such anniversary and paying a termination fee&#160;equal to <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="eols:LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfNTAy_2e7ffc13-c025-47f6-8095-77eb598a17ff">six months</ix:nonNumeric> basic rent plus certain other expenses. The Company has an option to extend the term of the lease for an additional <ix:nonNumeric contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfNjIx_04a90fe3-787a-4fef-8501-df5fc02259ac">60</ix:nonNumeric> months, which is not recognized as part of its ROU assets and lease liabilities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreement does not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.</span></div><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfMTg3Nw_7b4190af-6c09-45c4-8191-1d7e86d64cf2" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.690%"><tr><td style="width:1.0%"></td><td style="width:41.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMi0xLTEtMS02NjM1MQ_ba77c289-54a1-40bd-80d5-9caf638ad8c2">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMi0zLTEtMS02NjM1MQ_cbbca913-33eb-4882-b78c-66c3ff86368e">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMi01LTEtMS02NjM1MQ_d4757ece-8151-40ae-98bf-f51d56e57d76">811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMi03LTEtMS02NjM1MQ_c6e99c3a-6451-4ad3-8773-df0c1a39c0ac">797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMy0xLTEtMS02NjM1MQ_93ff34e9-7eec-4064-8408-31a10bcad799">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMy0zLTEtMS02NjM1MQ_ba11ca54-8444-48b6-a777-5dbccb529c70">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMy01LTEtMS02NjM1MQ_441c37bc-5dc9-47d0-8b30-0569f5e6752d">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMy03LTEtMS02NjM1MQ_31646578-3128-4f13-acd3-406f9fdaa7d8">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfNS0xLTEtMS02NjM1MQ_e5936e70-c830-4776-88a4-ed4fae14e5cf">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfNS0zLTEtMS02NjM1MQ_b914acc0-8ebf-4174-b084-3e1adecf6f0b">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfNS01LTEtMS02NjM1MQ_cf753066-bdaf-46d3-af9e-44e53d3f28c7">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfNS03LTEtMS02NjM1MQ_f4bb075d-2798-43da-a399-11e0f72b9368">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.940%"><tr><td style="width:1.0%"></td><td style="width:72.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.897%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOjMyNjY5MjhmYWM1MDRiNTRhNjc1YTc1YWZjY2QyMGQ3L3RhYmxlcmFuZ2U6MzI2NjkyOGZhYzUwNGI1NGE2NzVhNzVhZmNjZDIwZDdfMi0xLTEtMS02NjM1MQ_0c3b65e7-230b-4ed7-8cde-47858a42e0d6">2.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i458f436d90584702b2e171f24fc2ffd9_I20210930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOjMyNjY5MjhmYWM1MDRiNTRhNjc1YTc1YWZjY2QyMGQ3L3RhYmxlcmFuZ2U6MzI2NjkyOGZhYzUwNGI1NGE2NzVhNzVhZmNjZDIwZDdfMi0zLTEtMS02NjM1MQ_4bba5b37-d197-4cb9-9a97-79767e5f7e5f">3.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOjMyNjY5MjhmYWM1MDRiNTRhNjc1YTc1YWZjY2QyMGQ3L3RhYmxlcmFuZ2U6MzI2NjkyOGZhYzUwNGI1NGE2NzVhNzVhZmNjZDIwZDdfMy0xLTEtMS02NjM1MQ_98917b19-199e-4d97-869a-01d5d46ece02">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i458f436d90584702b2e171f24fc2ffd9_I20210930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOjMyNjY5MjhmYWM1MDRiNTRhNjc1YTc1YWZjY2QyMGQ3L3RhYmxlcmFuZ2U6MzI2NjkyOGZhYzUwNGI1NGE2NzVhNzVhZmNjZDIwZDdfMy0zLTEtMS02NjM1MQ_987fa586-bcf2-489d-a46e-6e966d3db54a">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease&#160;expenses were included in the selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. Operating lease right-of-use assets and related current and noncurrent operating lease liabilities are presented in the accompanying condensed consolidated balance sheets. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i03ab692ab9fe46c9b02eb01e7d53aab7"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfMTg3OQ_a19505ad-7f5b-4db1-b9a4-77c0732a9e4f" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of September 30, 2022:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:68.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfMS0xLTEtMS02NjM1MQ_c2366bd3-4b6b-423d-9923-facf012e7db4">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfMi0xLTEtMS02NjM1MQ_be45e881-066b-4aa5-b19e-aeaba6efe86b">1,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfMy0xLTEtMS02NjM1MQ_6b4cb663-5d9c-400d-9e4c-1b070e6ed428">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfNC0xLTEtMS02NjM1MQ_64c86a7c-def9-4a21-b5df-6919a61df814">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfNS0xLTEtMS02NjM1MQ_b85a1a8c-e0bb-4f02-bce9-16cf10794a43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfNi0xLTEtMS02NjM1MQ_b797975a-d2d9-48c6-83ba-f0eccccb07a0">3,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfNy0xLTEtMS02NjM1MQ_774fe63f-68e4-4744-92ca-e4e5c46533b8">332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfOC0xLTEtMS02NjM1MQ_7411674e-d8d4-467d-a8e6-ec3f76918c32">2,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_61"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82MS9mcmFnOjExZDM1ZmQ3ZDYxMzRhZDg4NGZmYTY3OWNkNGFiN2M5L3RleHRyZWdpb246MTFkMzVmZDdkNjEzNGFkODg0ZmZhNjc5Y2Q0YWI3YzlfNjc5MQ_f5683296-b38a-4263-8d3a-1c02fad4074c" continuedAt="i8a8cac7842ab4137a8f9e8189f159b2c" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i8a8cac7842ab4137a8f9e8189f159b2c" continuedAt="idadb6543df524848ac2a8daaccb57dda"><div style="margin-bottom:10pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately $<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82MS9mcmFnOjExZDM1ZmQ3ZDYxMzRhZDg4NGZmYTY3OWNkNGFiN2M5L3RleHRyZWdpb246MTFkMzVmZDdkNjEzNGFkODg0ZmZhNjc5Y2Q0YWI3YzlfMTkw_0e330c4a-a6b4-40fa-9a15-2da94ce0a7d4">1,074</ix:nonFraction>. Certain minimum purchase commitments related to the purchase of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are described below.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Supply Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Agreement includes certain minimum annual purchases that the Company is required to make in order to maintain the exclusivity of the license. The Company may, however, meet these minimum purchase obligations by achieving certain market share in the licensed territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions. </span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16 and 28, 2020, <ix:nonFraction unitRef="complaint" contextRef="i2b2b0c3bea3a4f22ae04d9279885dafc_D20201016-20201028" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82MS9mcmFnOjExZDM1ZmQ3ZDYxMzRhZDg4NGZmYTY3OWNkNGFiN2M5L3RleHRyZWdpb246MTFkMzVmZDdkNjEzNGFkODg0ZmZhNjc5Y2Q0YWI3YzlfODg2_5e14fffc-8541-4f95-b7b8-c356ae46bff8">two</ix:nonFraction> putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#8217;s acquisition of the right to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, three of its officers, and Alphaeon Corporation, the Company&#8217;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint. On February 10, 2022, Alphaeon Corporation served its motion to dismiss the amended complaint. Both motions were fully briefed on June 16, 2022. The outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2020 and December 2, 2020, <ix:nonFraction unitRef="plaintiff" contextRef="id4a4bebb895c49d0bbdd0bf38322e752_D20201127-20201202" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82MS9mcmFnOjExZDM1ZmQ3ZDYxMzRhZDg4NGZmYTY3OWNkNGFiN2M5L3RleHRyZWdpb246MTFkMzVmZDdkNjEzNGFkODg0ZmZhNjc5Y2Q0YWI3YzlfMjY4OQ_20ed0b69-44b7-4639-9c06-cebc0926aba7">two</ix:nonFraction> putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#8217;s officers </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="idadb6543df524848ac2a8daaccb57dda" continuedAt="iad9414bed2fd47408e7bd0f5ec852dbe"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-09986-PPG, and adjourned defendants&#8217; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#8217; stipulated stay of the consolidated derivative suit pending the court&#8217;s decision on the defendants&#8217; motion to dismiss the Securities Class Action.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Books and Records Demand</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#8217;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to the demand in December 2021. The outcome of this matter is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legal Matters</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, from time to time, involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. <ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82MS9mcmFnOjExZDM1ZmQ3ZDYxMzRhZDg4NGZmYTY3OWNkNGFiN2M5L3RleHRyZWdpb246MTFkMzVmZDdkNjEzNGFkODg0ZmZhNjc5Y2Q0YWI3YzlfNjc0Ng_a2a2800f-91fd-4fa0-a39f-5cb5473f9bf7"><ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82MS9mcmFnOjExZDM1ZmQ3ZDYxMzRhZDg4NGZmYTY3OWNkNGFiN2M5L3RleHRyZWdpb246MTFkMzVmZDdkNjEzNGFkODg0ZmZhNjc5Y2Q0YWI3YzlfNjc0Ng_f50db8d1-161b-4264-8b98-b9613d70f98d">No</ix:nonFraction></ix:nonFraction> amounts were accrued as of September 30, 2022 and December&#160;31, 2021.</span></div></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_64"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDg2NQ_6193a1de-7439-420a-a281-508ed49b10bf" continuedAt="i43bcf982f0244549bf273adb0fb74a82" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i43bcf982f0244549bf273adb0fb74a82" continuedAt="i9d6738fddb8943c2a50d28a1954aa1b3"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNjc_792ea7a7-da7d-40aa-a7b8-191f1cfaf78e">10,000,000</ix:nonFraction> authorized shares of preferred stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMTI3_ca66e6b9-ef81-41fd-9b28-f941aab9b288">0.00001</ix:nonFraction> per share. As of September 30, 2022, <ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMTUx_33249baf-d337-4266-8225-356685b91ace"><ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMTUx_40c6839a-9256-463f-abf4-7b21771331ac">no</ix:nonFraction></ix:nonFraction> shares of its preferred stock were issued and outstanding. </span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMjQz_c9a36e55-9f35-4f9e-a4c4-4ba90ec65569">100,000,000</ix:nonFraction> authorized shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzAw_ff577121-6e29-4ed6-b0b3-88ba9e09beac">0.00001</ix:nonFraction> per share. As of September 30, 2022, <ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzI0_13ac0631-5f36-4754-ba26-7e3f6d3c17c5"><ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzI0_69e8a0ea-e11c-4d21-b167-3ea3660791b7">56,183,414</ix:nonFraction></ix:nonFraction> shares of its common stock were issued and outstanding. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i9d6738fddb8943c2a50d28a1954aa1b3" continuedAt="i8a2f2c28aaa148169a0a32032b5d349b"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i32d51cd4bd6f4489a4adb7b2aa247e44_D20210228-20210228" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDI1_5fa8f839-d5b6-4a08-87ef-ed2a6a84a655">6,762,652</ix:nonFraction> shares of its common stock to Medytox pursuant to the Share Issuance Agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="ic8fb36cf68884af1a7d8744f3d77a5ba_D20210325-20210325" decimals="INF" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTg1_34426680-a92a-411b-a955-dc38e191775b">3,136,869</ix:nonFraction> shares of its common stock to Daewoong in connection with the conversion of Daewoong Convertible Note. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Daewoong Convertible Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;At-the-market&#8221; Offerings of Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2021, the Company entered into an &#8220;at-the-market&#8221; sales agreement with SVB Leerink LLC (the &#8220;Sales Agent&#8221;) pursuant to which shares of the Company&#8217;s common stock could be sold from time to time for aggregate gross proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="ia933b0ab944743ada651aa08e01c3fa0_D20210326-20210326" decimals="-3" name="eols:SaleOfStockMaximumConsiderationReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMTAxNg_14f3d443-72a7-4f89-a491-686c1f5e0d59">75,000</ix:nonFraction> (the &#8220;ATM Program&#8221;). The Sales Agent was entitled to compensation, at a commission rate equal to <ix:nonFraction unitRef="number" contextRef="ib05b2ea5b15449b3949c409f13302aba_I20210326" decimals="3" name="eols:SaleOfStockCommissionPaymentUponGrossProceedsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMTExNg_1351acb1-2c69-4d57-8450-32a78382b793">3.0</ix:nonFraction>% of the gross proceeds from sales of the Company&#8217;s common shares under the ATM Program. Since August 2021, the Company has not sold any shares under the ATM Program and the Company terminated the ATM Program in May 2022. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, the Company sold a total of <ix:nonFraction unitRef="shares" contextRef="i8c628e554673429f919660de503a710e_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxODg2_b411572e-342e-4262-aebd-8822eee670ed">724,835</ix:nonFraction> shares of its common stock pursuant to the ATM Program at the prevailing market prices for total net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ide79544f24324f7b8502d4f715dcf188_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxOTQx_c6f89404-e740-44d3-97fa-16b2a2559f66">8,203</ix:nonFraction> and paid total commissions of $<ix:nonFraction unitRef="usd" contextRef="ia80760aeda834165a0bd09ccfcabfa32_D20210701-20210930" decimals="-3" name="eols:SaleOfStockCommissionPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxOTU2_dc5d08ae-9274-4411-9d23-225c84bcdf87">254</ix:nonFraction> to the Sales Agent. For the nine months ended September 30, 2021, the Company sold a total of <ix:nonFraction unitRef="shares" contextRef="i39845926fd4c4a7185d0ad1aec0a9125_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxODk4_eb722adb-8b90-49f7-8d07-f08048cfd53e">934,367</ix:nonFraction> shares of its common stock pursuant to the ATM Program at the prevailing market prices for a total net proceeds of $<ix:nonFraction unitRef="usd" contextRef="id8d569b52d5c4b558d7fce708c55c3d1_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxOTYy_1b0cead1-fd3c-47ca-b668-b8893207737b">10,910</ix:nonFraction> and paid total commissions of $<ix:nonFraction unitRef="usd" contextRef="id4b79303cf634cad95d0ba5d12c163ef_D20210101-20210930" decimals="-3" name="eols:SaleOfStockCommissionPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxOTc1_ff275737-74c4-4ac7-bcee-0e2eae506074">337</ix:nonFraction> to the Sales Agent.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Omnibus Incentive Plan and Stock-based Compensation Allocation</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;) provides for the grant of incentive options to employees of the Company, and for the grant of non-statutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#8217;s officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is <ix:nonFraction unitRef="shares" contextRef="ic5451817e64c44dda2476fee6acbac53_I20171121" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMjA4NA_9be71c63-b2c9-49fd-90fc-062b6105eb5e">4,361,291</ix:nonFraction> shares, plus an annual increase on each anniversary of November 21, 2017 equal to <ix:nonFraction unitRef="number" contextRef="ie5823e0351234f7f9b1f20c5fe18cbe0_D20171121-20171121" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMjE2OQ_a7444ab0-33a8-41e9-9296-d34f6898e3d9">4.0</ix:nonFraction>% of the total issued and outstanding shares of the Company&#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#8217;s Board of Directors). As of September 30, 2022, the Company had an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMjQwMg_4ba06385-9c9c-4e37-b06b-8a2818ffe97c">1,447,855</ix:nonFraction> shares of its common stock available for future issuance under the Plan.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Grants</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company&#8217;s Plan. Such grants were made pursuant to a stand-alone nonstatutory stock option agreement and a stand-alone RSU agreement, which were approved by the Compensation Committee of the Board of Directors. Any shares underlying the inducement grants are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance. </span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company granted options to purchase <ix:nonFraction unitRef="shares" contextRef="i47a9787376af49c4af38a5bd745283ea_D20220201-20220228" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIwNzQ3_94e378fd-a9d9-4f40-ae15-9fc3eb0ea8f6">171,103</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i848b50e6e7d3430995e3db062f15f819_D20220201-20220228" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIwNzc4_13a59494-dadd-4575-9f68-5a00412b8cf9">39,012</ix:nonFraction> RSUs as a material inducement for the employment of the Senior Vice President of Corporate Development. In September 2022, the Company granted options to purchase <ix:nonFraction unitRef="shares" contextRef="iaa10e78f3b4c4e968e52a77f68b4440f_D20220901-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxMDI2_a29f948d-a415-410e-b451-76186b20db5e">169,158</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i239833aec97149198fa33cf47989aa8d_D20220901-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxMDI5_e5000cc6-c947-4c74-a45a-2fae72b47373">36,443</ix:nonFraction> RSUs as a material inducement for the employment of the Chief Financial Officer. As of September 30, 2022, stock options to purchase <ix:nonFraction unitRef="shares" contextRef="i0bc7da1566164597b0db01be97552e79_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxMDQ3_7723b9db-85a7-4d80-8061-f2f373b8a822">340,261</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i5f7d73b878d64950a8425ead93d94a97_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxMDU3_0fd58ca8-575c-447d-b07f-d0e025501e88">75,455</ix:nonFraction> RSUs remained outstanding outside of the Plan. </span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Award Activity and Balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options are granted at exercise prices based on the Company&#8217;s common stock price on the date of grant. The options and RSU grants generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzU1MQ_69856644-a55a-4627-8d51-4a7ed13cffd0">one</span>- to <ix:nonNumeric contextRef="i01ed1c49defa42e594f5fe2cb8f08e35_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDg1Nw_d9745e91-7dba-4183-92dd-8300141f31a1">four-year</ix:nonNumeric> period. There have been <ix:nonFraction unitRef="shares" contextRef="ib0fe33cc353c4425a6f61687288e7219_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzU5MA_c414c58f-7fbc-4fc3-870d-3fdd0ec4f1e2"><ix:nonFraction unitRef="shares" contextRef="i39b3ec4c69b340288a1cd5b5320c3f95_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzU5MA_e63ae0cc-a16d-4d1b-b152-0ca09f6fa2df">no</ix:nonFraction></ix:nonFraction> awards granted with performance conditions or market conditions for the periods presented. The options have a contractual term of <ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzcyMw_47a91850-c3d3-4a88-a711-ae4099fba015">ten years</ix:nonNumeric>. The fair value of options is estimated using the Black-Scholes option pricing model, which has various inputs, including the grant date common share price, exercise price, risk-free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#8217;s options as well as significantly impact its results of operations. The fair value of RSU grants is determined at the grant date based on the common share price. The Company records stock-based compensation expense net of actual forfeitures when they occur.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i8a2f2c28aaa148169a0a32032b5d349b" continuedAt="i58a84061665d4f3e8c9ffad4b5dd630a"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDg3MA_7ae286c7-a73c-40e2-9571-e9a3b4a4a14e" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in determining the fair value of stock options granted were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie3807d087dad4368af0d30e4e6ea552b_D20220701-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMi0xLTEtMS02NjM1MQ_dbc7e081-19c6-49d6-ae93-eb12dc6a6ab5">83.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fd6507cc4bd4d85bca970b83ba305bb_D20210701-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMi0zLTEtMS02NjM1MQ_048289e5-e08d-40da-80db-820b880566e7">79.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMi01LTEtMS02NjM1MQ_7985be25-118a-428d-98c1-70733fa491b9">78.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6a44426e14f4cf68658b6c28359fe8f_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMi03LTEtMS02NjM1MQ_b701bfd9-a8df-4a13-bcbb-295d903d9327">78.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie3807d087dad4368af0d30e4e6ea552b_D20220701-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMy0xLTEtMS02NjM1MQ_c60ad13a-f5cd-4b2b-8afa-e001b8de3971">3.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fd6507cc4bd4d85bca970b83ba305bb_D20210701-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMy0zLTEtMS02NjM1MQ_e1af62d7-2be4-4c53-9d6c-f453d64bcfb0">1.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMy01LTEtMS02NjM1MQ_57c2b555-00de-4189-9bcf-5a21fd9c7b3b">1.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6a44426e14f4cf68658b6c28359fe8f_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMy03LTEtMS02NjM1MQ_a22647e8-1f25-4d57-befc-848de36e5cf3">1.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie3807d087dad4368af0d30e4e6ea552b_D20220701-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNC0xLTEtMS02NjM1MQ_d3ab8d0c-29cd-432c-94fa-2b089a83e2fa">6.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8fd6507cc4bd4d85bca970b83ba305bb_D20210701-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNC0zLTEtMS02NjM1MQ_a09b8ec8-f861-48e9-8e42-f4275c38aa25">6.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNC01LTEtMS02NjM1MQ_06058f61-43dc-4e77-af75-a4e6c9610408">6.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6a44426e14f4cf68658b6c28359fe8f_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNC03LTEtMS02NjM1MQ_31ea3955-d460-480a-b070-466cb90fa14d">6.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie3807d087dad4368af0d30e4e6ea552b_D20220701-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNS0xLTEtMS02NjM1MQ_979be8e3-9383-4d12-9e0c-ec93d34f59ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fd6507cc4bd4d85bca970b83ba305bb_D20210701-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNS0zLTEtMS02NjM1MQ_a0ef608e-dc9b-4531-8fdc-93ab0f2c66e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNS01LTEtMS02NjM1MQ_d8656e0d-b3d3-4910-a928-335c43dcf704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6a44426e14f4cf68658b6c28359fe8f_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNS03LTEtMS02NjM1MQ_83b2d68e-4b71-492e-b079-a460ff694818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDg1OQ_f40997bd-422b-4fca-afa9-0bfb0d6b9c2a" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the nine months ended September 30, 2022, is presented below:</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:47.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terms (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61c0058713f24095b11a013badcef8e3_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNS0xLTEtMS02NjM1MQ_1c763ca7-d913-44b1-abb4-b1718554364d">3,922,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61c0058713f24095b11a013badcef8e3_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNS0zLTEtMS02NjM1MQ_d2b2768d-1f9f-4e23-89ae-0e9e70a0000b">11.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b27e8a6feca4241b642ac4baf127f19_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNS01LTEtMS02NjM1MQ_cf2517db-d8cf-4140-8f6f-40b99cac7718">7.10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c0058713f24095b11a013badcef8e3_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNS03LTEtMS02NjM1MQ_dbe911fd-337d-4a6f-85c7-b9e95a82df7d">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNi0xLTEtMS02NjM1MQ_54092561-3f28-46a2-a6d8-5efda8cc3d5d">1,665,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNi0zLTEtMS02NjM1MQ_6631c434-fa97-46fd-bfdc-5ef5758da1ec">6.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNy0xLTEtMS02NjM1MQ_60b322a3-d658-41c4-bcb4-53d0bad26dfe">53,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNy0zLTEtMS02NjM1MQ_28f73f38-bae5-437a-b6fa-9bff65881110">10.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfOC0xLTEtMS02NjM1MQ_75d2ef39-2756-4a5b-a365-b04cfb2e331b">602,342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfOC0zLTEtMS02NjM1MQ_4fc3838e-3d23-47a2-87b0-da24c25028f4">14.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfOS0xLTEtMS02NjM1MQ_c77fa7ef-97bd-4f03-9029-8dd7927f7eef">4,932,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0bc7da1566164597b0db01be97552e79_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfOS0zLTEtMS02NjM1MQ_4190fc6b-9fd0-45b5-b801-c68dcb5bc572">9.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfOS01LTEtMS02NjM1MQ_19ec2c59-5930-4c9f-a580-b705567e964e">7.23</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc7da1566164597b0db01be97552e79_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfOS03LTEtMS02NjM1MQ_a45214d0-9285-4199-87c6-8a3459254461">4,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bc7da1566164597b0db01be97552e79_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfMTAtMS0xLTEtNjYzNTE_3e937130-08ad-48d8-8f70-f09347190672">2,860,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0bc7da1566164597b0db01be97552e79_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfMTAtMy0xLTEtNjYzNTE_8187e57f-bc4e-460d-813b-f3c4b0b00dbb">10.35</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930" name="eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfMTAtNS0xLTEtNjYzNTE_9a777e9e-2ea3-48fe-a030-79ac865f557f">6.01</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc7da1566164597b0db01be97552e79_I20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfMTAtNy0xLTEtNjYzNTE_e5df229a-1404-4813-9186-1ea0cd5c7dea">1,338</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of outstanding and exercisable options represents the excess of the fair market value of the Company&#8217;s common stock over the exercise price of underlying options as of September 30, 2022 and December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDg3MQ_b8ab8a75-5e04-44a7-9e40-3a0eaacd9dce" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the nine months ended September 30, 2022, is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:57.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8faa1fb37e374acb85de383e56577e09_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNC0xLTEtMS02NjM1MQ_395b6866-b0ac-4ada-9e77-771be8838af4">1,926,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8faa1fb37e374acb85de383e56577e09_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNC0zLTEtMS02NjM1MQ_62a1d9c4-bc01-4b2f-be42-c4d06b6bbfc4">8.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNS0xLTEtMS02NjM1MQ_a2d5f52f-4c4c-4062-9ad3-f761afd7b39e">1,667,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNS0zLTEtMS02NjM1MQ_0e4b50fe-abec-4b90-bc1f-343b9627e5a0">6.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNi0xLTEtMS02NjM1MQ_2680a5ed-92e7-459e-880e-22034b2f1905">553,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNi0zLTEtMS02NjM1MQ_fe907b10-cd45-4ceb-9d26-68655fe9b993">8.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNy0xLTEtMS02NjM1MQ_a2b35f1c-24bb-4950-bbee-308ea4b4bcd2">401,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNy0zLTEtMS02NjM1MQ_59235589-f07e-462b-8b63-b0210172d30d">6.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfOC0xLTEtMS02NjM1MQ_81f11446-7926-4fc5-a30c-1fb00cfc4101">2,638,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f7d73b878d64950a8425ead93d94a97_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfOC0zLTEtMS02NjM1MQ_8170041e-4a63-4adb-b016-05588f2bfe15">7.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i58a84061665d4f3e8c9ffad4b5dd630a"><ix:nonNumeric contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDg2MQ_b4854981-2ba8-4f17-b035-e00b54e7612f" escape="true"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense:</span></div><div style="margin-bottom:9pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba6f3c5b4314563a0f6c2b8e9485876_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMi0xLTEtMS02NjM1MQ_8237d17b-aa04-4980-bec1-164e883a0e1a">2,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0df63e74062b463990c0a0996e88bf4d_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMi0zLTEtMS02NjM1MQ_8af92bdb-b692-4aeb-a974-7cf8f76af5f7">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7000885be6d948baa6c2a16a20a9b3d0_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMi01LTEtMS02NjM1MQ_93f14eed-05d7-4739-99d0-1cb8ffd20acb">8,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5753737be3a4d78816715ef5956b5f1_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMi03LTEtMS02NjM1MQ_d3732870-c5a6-4bf5-b46c-3049d9b67cc8">6,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide927851f3d44d388940de49dc572cbc_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMy0xLTEtMS02NjM1MQ_5ca3e5fb-3db9-4375-9e63-d2dbf4bc252a">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab36228520640d2af7899d4d89c4119_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMy0zLTEtMS02NjM1MQ_775d5bbb-c1fa-460f-a0ba-99a6a85ce6c0">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16951a5be9bf4007b7826543c19fc57c_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMy01LTEtMS02NjM1MQ_13583b1a-95e8-4a1f-b110-7742a95c5c0b">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ba7a39fbf47b5ba3502a70a32b3cf_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMy03LTEtMS02NjM1MQ_dfc9b652-246e-4a63-8b08-63f546f6b571">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfNC0xLTEtMS02NjM1MQ_b0090b78-1069-4bbb-9df6-e94e12adde78">2,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfNC0zLTEtMS02NjM1MQ_81ebe973-2817-4101-bcd4-38932b53ec11">2,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfNC01LTEtMS02NjM1MQ_2000c062-cc7e-4bfc-8565-5c8fcbd81add">8,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfNC03LTEtMS02NjM1MQ_32683716-af00-4379-9cc1-1f2a99ff7f26">6,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;padding-right:9pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_67"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:continuation id="iad9414bed2fd47408e7bd0f5ec852dbe" continuedAt="ib8fffa23374a41968d07dbfdeb25f7a1">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</ix:continuation></span></div><ix:continuation id="ib8fffa23374a41968d07dbfdeb25f7a1" continuedAt="ie853102572974de5b5cf2ad98f548f00"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medytox/Allergan Settlement Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Settlement Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company, Allergan and Medytox entered into a Settlement and License Agreement (the &#8220;U.S. Settlement Agreement&#8221;), pursuant to which, among other things: (i) Allergan and Medytox agreed to file a petition requesting the remedial orders related to the ITC Action be rescinded with respect to the Company; (ii) Medytox agreed to dismiss substantially similar litigation in California against the Company; (iii) the Company, on the one hand, and Medytox and Allergan, on the other hand, agreed to mutually release certain claims they may have against one another and their respective affiliates; (iv) Allergan and Medytox granted to the Company and its agents a license to manufacture and commercialize certain products identified in the U.S. Settlement Agreement, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Licensed Products&#8221;), in the United States during the 21 month period that, pursuant to the ITC Action, the Company was restricted from, among other things, selling, marketing, or promoting such imported Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States (the &#8220;Restricted Period&#8221;); (v) the Company agreed to pay to Allergan and Medytox $<ix:nonFraction unitRef="usd" contextRef="i1894854da2af42638a40edaec631c6a8_I20210218" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfMTI3NQ_882ea194-f1d8-4f3b-840b-3f345a05d3d7">35,000</ix:nonFraction> in multiple payments over <ix:nonNumeric contextRef="i748d6131bd954dc9aa10faa24cb00d27_D20210218-20210218" name="eols:LossContingencySettlementAgreementPaymentTerms" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfMTMwNA_a4d519d9-1952-44f8-b289-50307293874b">two years</ix:nonNumeric>, of which the Company paid the first cash payment of $<ix:nonFraction unitRef="usd" contextRef="id23cfd7dc1564cd6aaa76f53b45ccf4f_D20210701-20210930" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfMTM2MA_a9c489a5-d12e-4d82-b320-ba345918ad72">15,000</ix:nonFraction> in the third quarter of 2021 and the second cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0997749416bc4e028361e395d1f8bf92_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfMTQyMw_87888c29-429a-4d8c-a7f4-ebef1c5804ed">15,000</ix:nonFraction> in the first quarter of 2022; and (vi) during the Restricted Period, the Company agreed to pay to Allergan and Medytox certain confidential royalties on the sale of Licensed Products, calculated on dollar amount per vial sold of Licensed Products by or on behalf of the Company in the United States. Royalties for sales during the Restricted Period ended on September 16, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ROW Settlement Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#8220;ROW Settlement Agreement&#8221; and, together with the U.S. Settlement Agreement, the &#8220;Medytox/Allergan Settlement Agreements&#8221;), pursuant to which, among other things: (i) the Company and Medytox agreed to mutually release certain claims they may have against one another and their respective affiliates; (ii) Medytox granted to the Company and its agents a license to manufacture and commercialize the Licensed Products, in Canada, the European Union, Switzerland, member countries and cooperating countries of the European Economic Area, Russia, certain members of the Commonwealth of Independent States, South Africa, Australia and Japan (the &#8220;ROW Territories&#8221;) during the Restricted Period; (iii) Medytox granted to the Company and its agents a fully paid up license to manufacture and commercialize the Licensed Products in the ROW Territories and the United States from the end of the Restricted Period (the &#8220;Medytox License Period&#8221;); (iv) the Company and Medytox agreed to enter into the Share Issuance Agreement (as defined below) pursuant to which the Company issued <ix:nonFraction unitRef="shares" contextRef="i5d8448ecaa3a48df85d5889b9d36144b_D20210218-20210218" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfMzAwNA_9a3dfab2-a20e-45b6-b06e-57490b0d5427">6,762,652</ix:nonFraction> shares (the &#8220;Settlement Shares&#8221;) of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i1894854da2af42638a40edaec631c6a8_I20210218" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfMzA4MQ_42b413e0-1596-4011-a689-b79038b1e25b">0.00001</ix:nonFraction> per share, to Medytox; (v) the Company and Medytox agreed to enter into the Registration Rights Agreement (as defined below), pursuant to which the Company granted certain registration rights to Medytox with respect to the Settlement Shares; (vi) during the Restricted Period that ended September 16, 2022, the Company agreed to pay Medytox a confidential low-double digit royalty on net sales of the Licensed Products sold by or on behalf of the Company in the ROW Territories; and (vii) during the Medytox License Period from September 17, 2022 to September 16, 2032, the Company agreed to pay Medytox a confidential mid-single digit royalty percentage on net sales of the Licensed Products sold by or on behalf of the Company in the United States and the ROW Territories.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share Issuance Agreement</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ie853102572974de5b5cf2ad98f548f00" continuedAt="ic6e9658f279d463c9d7bb1e3cb333563"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox entered into a Share Issuance Agreement effective February 18, 2021 (the &#8220;Share Issuance Agreement&#8221;). Pursuant to the Share Issuance Agreement and subject to the terms and conditions set forth therein, among other things, the Company issued to Medytox the Settlement Shares to enter into the ROW Settlement Agreement and in consideration for Medytox&#8217;s representations, warranties, and other agreements set forth in the Share Issuance Agreement. The Settlement Shares are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates, prevented Medytox from transferring any shares of common stock prior to February 16, 2022 and, thereafter, prohibit Medytox from transferring more than <ix:nonFraction unitRef="number" contextRef="ia1bd190fdbab49dabebbb80e51c1f276_I20230915" decimals="2" name="eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNDcxOA_8d9cd107-1895-4614-80f0-ca02bfc857d7">25</ix:nonFraction>% of the shares it holds prior to September 16, 2023, more than <ix:nonFraction unitRef="number" contextRef="i97e475107c9e4c7997018cc44ab1d86f_I20240915" decimals="2" name="eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNDc4Mw_5fa6aad3-067a-4212-b458-0cedaee99eb1">50</ix:nonFraction>% of the shares it holds prior to September 16, 2024 and more than <ix:nonFraction unitRef="number" contextRef="ia06093115e034c0794719bee09423007_I20250915" decimals="2" name="eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNDg1MQ_ef03823a-1cb6-4e3c-8668-61a8164d0655">75</ix:nonFraction>% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Rights Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox also entered into a Registration Rights Agreement effective February 18, 2021 (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the Registration Rights Agreement, among other things, the Company agreed, after March 31, 2022, (i) to comply with certain requests by Medytox to register for sale, under the Securities Act, the Settlement Shares, and (ii) to include the Settlement Shares in certain registrations by the Company of its securities for sale under the Securities Act, to the extent requested by Medytox, in each case subject to certain customary conditions, exceptions and limitations as set forth in the Registration Rights Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Medytox&#8217;s registration rights under the Registration Rights Agreement will terminate at such time that Medytox is able to sell all of the Settlement Shares over a <ix:nonNumeric contextRef="ib6c9bed41b124f498f1b2cccdadacc84_D20210218-20210218" name="eols:RegistrationRightsAgreementSellingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfOTk2OQ_08a65bac-a39c-4926-ae55-a98fb3efe7b4">three-month</ix:nonNumeric> period, or less, pursuant to an exemption to registration under the Securities Act.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company accrued $<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNjA0Mg_f44191e6-2c58-4875-94bb-2c6351f48722">7,936</ix:nonFraction> for royalties under the Medytox/Allergan Settlement Agreements and $<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNjExMg_8a51efe4-8990-40c1-aaae-6b31a2f5b213">5,000</ix:nonFraction> of accrued litigation settlement expense. As of December&#160;31, 2021, the Company accrued $<ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNjE4Nw_e9fff7bd-4ffe-4b93-b14a-66e435a56dd8">12,447</ix:nonFraction> for royalties under the Medytox/Allergan Settlement Agreements and $<ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNjI1Nw_b12cab4a-35be-4c41-a2e8-95ab95cec266">20,000</ix:nonFraction> of accrued litigation settlement expense. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daewoong Arrangement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Daewoong Settlement Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the Company and Daewoong entered into a Confidential Settlement and Release Agreement (the &#8220;Daewoong Settlement Agreement&#8221;), pursuant to which, among other things: (i) Daewoong agreed to (a) pay to the Company an amount equal to $<ix:nonFraction unitRef="usd" contextRef="ie66d630b4d65447f8c7f52dd587c90cc_D20210323-20210323" decimals="-3" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNjYwMg_b623200e-39b1-4d83-9e3e-36d0f2257111">25,500</ix:nonFraction>, which the Company received in April 2021, (b) pay certain legal fees incurred by the Company&#8217;s litigation counsel in connection with its defense of the ITC Action (including any appeal of the resulting remedial orders), (c) cancel all remaining milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="ie66d630b4d65447f8c7f52dd587c90cc_D20210323-20210323" decimals="-3" name="eols:MilestonePaymentInConnectionWithAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNjg3OQ_a2c03f27-9663-43c7-a884-a64d471845c6">10,500</ix:nonFraction> in aggregate, and (d) reimburse the Company certain amounts (calculated on a dollar amount per vials sold basis in the United States) for sales of certain products with respect to which the Company is required to pay Medytox and Allergan royalties pursuant to the U.S. Settlement Agreement; and (ii) the Company agreed to (a) release, on behalf of itself and certain of its affiliates and representatives, certain claims they may have against Daewoong related to the allegations made in or the subject matter of the Medytox/Allergan Actions, or any orders, remedies and losses resulting from the Medytox/Allergan Actions, and (b) coordinate with Daewoong on certain matters related to the Medytox/Allergan Actions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conversion Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Daewoong Settlement Agreement, the Company and Daewoong also entered into a Convertible Promissory Note Conversion Agreement (the &#8220;Conversion Agreement&#8221;), pursuant to which, among other things, (i) the principal balance under the Daewoong Convertible Note, together with all accrued and unpaid interest thereon, in the amount of $<ix:nonFraction unitRef="usd" contextRef="ibfb737bacd0248fc910875d3a4549e77_I20210323" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNzk4Nw_299034d1-33a0-4671-a876-17119648a167">40,779</ix:nonFraction> was converted, at the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibfb737bacd0248fc910875d3a4549e77_I20210323" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfODAzMg_b0b1b307-680a-45f7-a5eb-2120661f46ae">13.00</ix:nonFraction> per share, into <ix:nonFraction unitRef="shares" contextRef="ic8fb36cf68884af1a7d8744f3d77a5ba_D20210325-20210325" decimals="INF" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfODA1MQ_34426680-a92a-411b-a955-dc38e191775b">3,136,869</ix:nonFraction> shares of Common Stock; and (ii) the Daewoong Convertible Note was deemed cancelled and satisfied in full in connection with such conversion.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the conversion, shares owned by Daewoong, together with its affiliates and attribution parties, did not exceed <ix:nonFraction unitRef="number" contextRef="i3389f3c7fed74caf844e5cc2688cd6f0_D20210323-20210323" decimals="INF" name="eols:DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfODMxMw_6bb2a50d-4789-4615-8187-34ceb77e2137">9.99</ix:nonFraction>% of the Company&#8217;s then outstanding common shares immediately following such issuance, as required under the terms of the Daewoong Convertible Note.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ic6e9658f279d463c9d7bb1e3cb333563"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Daewoong Agreement Amendment</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Daewoong Settlement Agreement, on March 23, 2021, the Company and Daewoong also entered into the Third Amendment to the Supply Agreement (the &#8220;Daewoong Agreement Amendment&#8221;). Pursuant to the Daewoong Agreement Amendment, the parties amended the Daewoong Agreement to (i) expand the territory within which the Company may distribute Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to certain countries in Europe, (ii) reduce the period of time with respect to which the Company is required to deliver binding forecasts to Daewoong, (iii) introduce certain limitations on Daewoong&#8217;s ability to convert the Company&#8217;s exclusive license for certain territories to a non-exclusive license in the event the Company fails to meet certain minimum purchase requirements for such territory, (iv) adjust the minimum purchase requirements and reduce the transfer price per vial of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> applicable to various territories, (v) require that any Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> supplied by Daewoong match certain shelf-life thresholds, and (vi) prohibit the Company from sharing certain confidential information of Daewoong with Medytox or its affiliates or representatives.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfOTY2NQ_4a7cdc67-c2ea-49cf-a53a-3c53ff77ceff">3,257</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfOTY3Mg_94d05df1-6122-48fe-aeb5-e596aa41b9b2">5,657</ix:nonFraction>, respectively, in reimbursement receivable from Daewoong, respectively, in other current assets in the accompanying condensed consolidated balance sheets. Total inventory payments to Daewoong were $<ix:nonFraction unitRef="usd" contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930" decimals="-3" name="eols:PaymentsForInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfOTg3Mg_4afca97a-2ee9-4c45-9eec-9a1417030baa">14,238</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930" decimals="-3" name="eols:PaymentsForInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfOTg3OQ_16ca1cee-4fc7-4cb2-b5bf-5a7e12c915e2">40,509</ix:nonFraction> for the three and nine months ended September 30, 2022, respectively. Total inventory payments to Daewoong were $<ix:nonFraction unitRef="usd" contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930" decimals="-3" name="eols:PaymentsForInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfOTk1MA_c4ef4de5-76a4-4217-9013-a297f99883cf">10,916</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930" decimals="-3" name="eols:PaymentsForInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNTQ5NzU1ODI0NDcx_38a82eea-00d1-43db-b804-81a395c6070f">24,576</ix:nonFraction> for the three and nine months ended September 30, 2021.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_70"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion contains management&#8217;s discussion and analysis of our financial condition and results of operations and should be read together with the unaudited condensed consolidated financial statements and the notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and in conjunction with our Annual Report on Form 10-K for the year ended December&#160;31, 2021 and other documents previously filed with the SEC. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs and involve numerous risks and uncertainties, including but not limited to those described in Item 1A &#8220;Risk Factors&#8221; of Part II of this Quarterly Report on Form 10-Q. Actual results may differ materially from those contained in any forward-looking statements. You should carefully read &#8220;Special Note Regarding Forward-Looking Statements&#8221; and Item 1A &#8220;Risk Factors&#8221; of Part II of this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_73"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. In February 2019, we received the approval of our first product Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration, or FDA. In May 2019, we commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. Our primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. We believe we offer customers and consumers a compelling value proposition with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader, and prior to the approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was the only known 900 kDa botulinum toxin type A complex approved in the United States. We believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we received approval from Health Canada&#160;for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age.&#160;We began marketing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada in October 2019 through our distribution partner Clarion Medical Technologies, Inc., or Clarion. In September 2019, we also received approval from the European Commission, to market the product in all 27 European Union, or EU, member states plus the United Kingdom, Iceland, Norway and Liechtenstein. In January 2021, we received a positive decision from the European Commission to add the 50 unit product to the approval obtained in September 2019. We launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Great Britain in September 2022 and we are finalizing plans for entering additional countries in Europe as part of a phase rollout. We received acceptance of our submission to the Australian Therapeutics Good Administration, or TGA, for regulatory approval of our neurotoxin product in Australia in the first quarter of 2022. We expect to receive full TGA regulatory approval and launch the product in Australia in 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we announced the initiation of a Phase II clinical trial designed to investigate a higher strength dose of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the frown lines. We completed our patient enrollment in the clinical study evaluating the &#8220;extra-strength&#8221; dose in the second quarter of 2022. This program provides us with the opportunity to offer the first multi-strength neurotoxin, giving customers and consumers increased treatment options. We anticipate completing the study in the first half of 2023.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of Settlement Agreements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we settled litigation claims related to a complaint against us filed by Allergan, Inc. and Allergan Limited (together, &#8220;Allergan&#8221;) and Medytox, Inc. (&#8220;Medytox&#8221;) in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;) and certain related matters by entering into a Settlement and License Agreement with Medytox and Allergan, which we refer to as the U.S. Settlement Agreement, and another Settlement and License Agreement with Medytox which we refer to as the ROW Settlement Agreement. We refer to the U.S. Settlement Agreement and the ROW Settlement Agreement collectively as the Medytox/Allergan Settlement Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medytox/Allergan Settlement Agreements, we agreed to (i) make cash payments of $35.0 million in multiple payments over two years to Allergan and Medytox, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of which we paid the first payment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the third quarter of 2021 and the second payment of $15.0 million in the first quarter of 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with the final payment of $5.0 million due in 2023, (ii) pay to Allergan and Medytox certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a certain dollar amount per vial sold of Licensed Products by or on our behalf in the United States, from December 16, 2020 to September 16, 2022, (iii) from December 16, 2020 to September 16, 2022, pay Medytox a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sold by us or on </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our behalf in territories we have licensed outside the United States, and (iv) from September 17, 2022 to September 16, 2032, pay Medytox a mid-single digit royalty percentage on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and all territories we have licensed outside the United States. We also issued 6,762,652 shares of our common stock to Medytox.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in March 2021, we entered into a Confidential Settlement and Release Agreement and certain related agreements with Daewoong Pharmaceutical Co. Ltd (&#8220;Daewoong&#8221;), which we refer to as the Daewoong Settlement Agreement, under which Daewoong paid us $25.5 million in April 2021, cancelled all remaining milestone payments up to $10.5 million in aggregate under the Daewoong Settlement Agreement and agreed to reimburse us certain amounts (calculated on a dollar amount per vials sold basis in the United States) for sales of certain products with respect to which we are required to pay Medytox and Allergan royalties pursuant to the U.S. Settlement Agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on the litigation settlement agreements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the royalty payments that we are required to pay under the Medytox/Allergan Settlement Agreements, after giving effect to the offset of a certain portion thereof that will be reimbursed to us under the Daewoong Settlement Agreement, our cost of sales and gross profit margin has been materially negatively impacted through September 2022 and will be negatively impacted to a lesser extent from September 2022 to September 2032.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Pharmakon Term Loans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;14, 2021, we entered into a loan agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC (collectively, &#8220;Pharmakon&#8221;). Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to us in two tranches (&#8220;Pharmakon Term Loans&#8221;). The first tranche of $75.0 million was funded on December 29, 2021. The second tranche of $50.0 million may be drawn at our election no later than December 31, 2022, subject to the terms and conditions of the Pharmakon Term Loans. As of September 30, 2022, we have not drawn the second tranche. The Pharmakon Term Loans will mature on the six-year anniversary of the closing date of the first tranche. See &#8220;&#8212;Liquidity and Capital Resources&#8212;The Pharmakon Term Loans&#8221; for further information.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Royalties to Evolus Founders</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the founders of Evolus, which we refer to as the Evolus Founders. These obligations terminate at the end of the second quarter of 2029. The fair value of the obligations are valued quarterly and are referred to in our consolidated financial statements as the contingent royalty obligation.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Trends and Uncertainties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, including the financial and credit markets, has recently experienced extreme volatility and disruptions, including increases in inflation rates, rising interest rates, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, and uncertainty about economic stability. We anticipate that the remainder of fiscal 2022 will continue to reflect a dynamic macroeconomic environment. We expect elevated levels of cost inflation to continue, potentially impacting consumer discretionary spending for aesthetic medical procedures. Markets experiencing uncertainty could have substantial high rates of inflation. We cannot reasonably estimate the financial impact of increased inflation on our financial condition, results of operations or cash flows in the future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Use of Adjusted Gross Profit Margin</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted gross profit and adjusted gross profit margin are not required by, nor presented in accordance with, United States generally accepted accounting principles, or GAAP. Adjusted gross profit is defined as total net revenues less product cost of sales, excluding the one-time settlement payment from Daewoong in 2021 and amortization of an intangible asset. Adjusted gross profit margin is calculated as adjusted gross profit divided by total net revenues. Management believes that adjusted gross profit margin is an important measure for investors because management uses adjusted gross profit margin as a key performance indicator to evaluate the profitability of sales without giving effect to costs that are not core to our cost of sales, such as the settlement payment from Daewoong and the amortization of an intangible asset. Adjusted gross profit margin should not be considered a measure of financial performance under GAAP, and the items excluded from adjusted gross profit margin should not be considered in isolation or as alternatives to financial statement data presented in the condensed consolidated financial statements as an indicator of financial performance or liquidity. As adjusted gross profit margin is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, has limitations as an analytical tool and may not be comparable to other similarly titled measures of other companies. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are reconciliations of adjusted gross profit to gross profit, the most directly comparable to GAAP measure, and adjusted gross profit margin to gross profit margin, the most directly comparable GAAP measure:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.765%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product cost of sales (excludes amortization of intangible assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement payment from Daewoong</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of distribution right intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross profit margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">54.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">93.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Settlement payment from Daewoong</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Amortization of distribution right intangible asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjusted gross profit margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">59.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_76"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended September 30, 2022 and 2021</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product cost of sales (excludes amortization of intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non operating expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenues</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate in one reportable segment and all of our net revenues are derived from sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Net revenues consist of revenues, net of adjustments primarily for customer rebates, rewards related to the consumer loyalty program and co-branded marketing programs. Revenues are recognized when the control of the promised goods is transferred to the customer in an amount that reflects the consideration allocated to the related performance obligations and to which we expect to be entitled in exchange for those products or services.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales increased by $7.2 million, or 27.0%, to $33.9 million for the three months ended September 30, 2022 from $26.7 million for the three months ended September 30, 2021, primarily due to higher sales volumes. Net revenues during the three months ended September 30, 2022 included $0.7 million of service revenue. We anticipate our continued sales growth will depend on our ability to grow our customer base and increase purchases by our current customers in the com</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">petitive medical aesthetic market.</span></div><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Cost of Sales</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product cost of s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ales, excluding amortization of intangible assets, primarily consisted of the cost of inventory purchased from Daewoong. In addition, during the period from December 2020 to September 2022, product cost of sales, excluding amortization of intangible assets, a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lso includes certain royalties on the sale of Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox and Allergan pursuant to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Settlement Agreement with respect to such royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our royalty obligations to Allergan concluded on September 16, 2022, and beginning on September 17, 2022, our royalty obligations to Medytox were reduced to a mid-single digit percentage of net revenue for ten years thereafter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product cost of sales, excluding amortization of intangible assets, increased by $2.0 million, or 17.4%, to $13.5 million for the three months ended September 30, 2022 from $11.5 million for the three months ended September 30, 2021, primarily due to higher sales volume. We anticipate that our product cost of sales will fluctuate in line with changes in revenues. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross Profit Margin</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross profit margin was 58.0% and 54.2% for the three months ended September 30, 2022 and 2021, respectively. Our adjusted gross profit margin, calculated as total net revenues less product cost of sales, excluding amortization of intangible assets, as a percentage of net revenues was 60.2% and 56.9% for the three months ended September 30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2021, respectively. Our gross profit margin and adjusted gross profit margin were impacted negatively from royalty obligations from December 2020 through September 2022, offset by payments we receive under the Daewoong Settlement Agreement. Beginning on September 17, 2022, our gross profit margin and adjusted gross profit margin began to increase as royalty obligations to Allergan concluded on September 16, 2022, and our royalty obligations to Medytox were reduced to a mid-single digit percentage of net revenue for ten years thereafter. We anticipate our gross profit margin and adjusted gross profit ma</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rgin will fluctuate as we implement various marketing programs that may affect the average selling price for Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as we expand internationally.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $3.1 million, or 9.8%, to $34.8 million for the three months ended September 30, 2022 from $31.7 million for the three months ended September 30, 2021, primarily resulting from increasing personnel costs and increasing commercial activities, offset by a decrease in marketing related expenses. Selling, general and administrative expenses may fluctuate in the future primarily due to potential changes in marketing strategies and future launches internationally.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $1.1 million, or 366.7%, to $1.4 million for the three months ended September 30, 2022 from $0.3 million for the three months ended September 30, 2021, primarily from increasing our clinical operations and research and development expenses related to the Phase II &#8220;extra-strength&#8221; clinical trial. We expect our research and development expenses to continue to increase if and when we seek to develop further product candidates and as we pursue regulatory approvals in other jurisdictions.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revaluation of Contingent Royalty Obligation Payable to Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the fair value of the contingent royalty obligation payable to Evolus Founders is recorded in operating expenses in each reporting period. During the three months ended September 30, 2022 and 2021, the revaluation charges of $1.2 million and $1.4 million, respectively, were primarily driven by changes in management assumptions relating to revenue forecasts, the discount rate used and the timing of cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization for the three months ended September 30, 2022 and 2021 was $0.9 million.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Expense, Net</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating expense, net, increased by $2.0 million, or 641.2%, to $2.3 million for the three months ended September 30, 2022 from $0.3 million for the three months ended September 30, 2021, primarily due to higher interest expense for the Pharmakon Term Loans. The interest on Pharmakon Term Loans is based on a variable interest rate, which will continue to result in higher interest expense in the rising interest rate environment.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes Expense</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was minimal income tax expense for the three months ended September 30, 2022 and 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September 30, 2022 and 2021</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product cost of sales (excludes amortization of intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement payment from Daewoong</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non operating expense, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from extinguishment of debts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenues</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales increased by $40.0 million, or 61.5%, to $105.0 million for the nine months ended September 30, 2022 from $65.0 million for the nine months ended September 30, 2021, primarily due to higher sales volumes and a slightly higher average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. Net revenues during the first quarter of 2021 were negatively impacted prior to entering into the Medytox/Allergan Settlement Agreements in February 2021 due to an increase in pricing during the presidential review period related to the ITC Action. We anticipate our continued sales growth will depend on our ability to grow our customer base and increase purchases by our current customers in the competitive medical aesthetic market.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Cost of Sales</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product cost of sales, excluding amortization of intangible assets, increased by $14.8 million, or 53.4%, to $42.5 million for the nine months ended September 30, 2022 from $27.7 million for the nine months ended September 30, 2021, primarily due to higher sales volume. We anticipate that our product cost of sales will fluctuate in line with changes in revenues. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Settlement Payment from Daewoong</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we recorded a one-time settlement receipt of $25.5 million from Daewoong in connection with the Daewoong Settlement Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross Profit Margin</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross profit margin was 57.4% and 93.2% for the nine months ended September 30, 2022 and 2021, respectively. Our adjusted gross profit margin, calculated as total net revenues less product cost of sales, excluding amortization of intangible assets and the one-time settlement payment from Daewoong, as a percentage of net revenues was 59.5% and 57.4% for the nine months ended September 30, 2022 and 2021, respectively. Our gross profit margin and adjusted gross profit margin were impacted negatively from royalty obligations through September 2022, offset by payments we receive under the Daewoong Settlement Agreement. Beginning on September 17, 2022, our gross profit margin and adjusted gross profit margin began to increase as our royalty obligations to Allergan concluded on September 16, 2022, and our royalty obligations to Medytox were reduced to a mid-single digit percentage of net revenue for ten years thereafter. We anticipate our gross profit margin and adjusted gross profit margin will fluctuate as we implement various marketing programs that may affect the average selling price for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as we expand internationally.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $26.3 million, or 33.4%, to $105.1 million for the nine months ended September 30, 2022 from $78.8 million for the nine months ended September 30, 2021, primarily resulting from increasing personnel costs and increasing our commercial activities. Selling, general and administrative expenses may fluctuate in the future primarily due to potential changes in marketing strategies and future launches internationally.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $1.8 million, or 112.5%, to $3.4 million for the nine months ended September 30, 2022 from $1.6 million for the nine months ended September 30, 2021, primarily from increasing our clinical operations and research and development expense related to the Phase II &#8220;extra-strength&#8221; clinical trial. We expect our research and development expenses to continue to increase if and when we seek to develop further product candidates and as we pursue regulatory approvals in other jurisdictions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, we recorded an upfront payment of $2.0 million in connection with the License and Research Collaboration Agreement (the &#8220;Collaboration Agreement&#8221;) we entered into in June 2022 with a 3D printing company with biomaterial capabilities. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revaluation of Contingent Royalty Obligation Payable to Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the fair value of the contingent royalty obligation payable to Evolus Founders is recorded in operating expenses in each reporting period. During the nine months ended September 30, 2022 and 2021, the revaluation charges of $3.9 million and $4.0 million, respectively, were primarily driven by changes in management assumptions relating to revenue forecasts, the discount rate used and the timing of cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization decreased by $2.0 million, or 42.6%, to $2.7 million for the nine months ended September 30, 2022 from $4.7 million for the nine months ended September 30, 2021 due to the decrease in amortization of internal-use software as most of these assets are now fully amortized in 2021.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Expense, Net</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating expense, net, increased by $5.2 million, or 400.0%, to $6.5 million for the nine months ended September 30, 2022 from $1.3 million for the nine months ended September 30, 2021, primarily due to higher interest expense for the Pharmakon Term Loans.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss from Extinguishment of Debts, Net</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from extinguishment of debts, net includes a $1.9 million loss from payoff of long-term debt with Oxford Finance, LLC in January 2021, partially offset by a $1.0 million gain from the conversion of the Daewoong Convertible Note in March 2021. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes Expense</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was minimal income tax expense for the nine months ended September 30, 2022 and 2021.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_79"></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 we had cash and cash equivalents of $65.6 million, positive working capital of $64.7 million and stockholders&#8217; equity of $29.2 million. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a limited history of generating revenues and began shipping Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in May 2019. Since inception, we have incurred recurring net operating losses and have an accumulated deficit of $484.1 million as of September 30, 2022 as a result of ongoing efforts to develop and commercialize Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including providing selling, general and administrative support for these operations. We had net loss of $61.2 million and $28.6 million for the nine months ended September 30, 2022 and 2021, respectively. We had net loss from operations of $54.7 million and $26.4 million for the nine months ended September 30, 2022 and 2021, respectively. We used net cash of $76.1 million and $24.3 million in operating activities for the nine months ended September 30, 2022 and 2021, respectively. We expect to continue to incur significant expenses for the foreseeable future as we increase marketing efforts for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and Europe and maintain our regulatory approvals.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of Inflation</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets in which we operate are currently experiencing increased inflation. While we do not believe that inflation has had a material impact on our business, revenues or operating results during the periods presented, a prolonged inflationary environment could increase our cash required for operations and impact our liquidity position.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Pharmakon Term Loans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;14, 2021, we entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to us in two tranches. The first tranche of $75.0 million was funded on December 29, 2021. The second tranche of $50.0 million may be drawn at our election no later than December 31, 2022. We received net proceeds of approximately $68.7 million from Pharmakon, after issuance costs and debt discounts. As of September 30, 2022, we have not drawn the second tranche. We shall make 12 equal quarterly payments of principal on the outstanding Pharmakon Term Loans commencing in March 2025 and continuing through the maturity date. The Pharmakon Term Loans will mature on the six-year anniversary of the closing date of the first tranche. The term loan bears an annual interest rate </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equal to the U.S. Dollar LIBOR rate (subject to a LIBOR rate floor of 1.0%) plus 8.5%, and matures in December 2027. The proceeds of the Pharmakon Term Loans are used to fund our general corporate and working capital requirements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Royalties to Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make quarterly royalty payments of a low-single digit percentage of net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Evolus Founders. The obligations terminate at the end of the second quarter of 2029. The fair value of the obligations is valued quarterly and is referred to in our condensed consolidated financial statements as the contingent royalty obligation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we recorded an aggregate balance of $45.5&#160;million on our balance sheet for the future royalty payment obligation to Evolus Founders.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Settlement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in &#8220;&#8212;Overview&#8212;Impact of Settlement Agreements,&#8221; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on February 18, 2021, upon entering into the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we agreed to pay to Allergan and Medytox $35.0&#160;million in multiple payments over two years, of which we paid the first payment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the third quarter of 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0&#160;million in the first quarter of 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and have </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due in the next twelve months. We also issued 6,762,652 shares of common stock to Medytox. In addition, during the period from December 16, 2020 to September 16, 2022, we agreed to pay to Allergan and Medytox royalties on the sale of Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a certain dollar amount per vial sold in the United States, and a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold in other Evolus territories. During the period from September 17, 2022 to September 16, 2032, we agreed to pay to Medytox a mid-single digit royalty percentage on all net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The royalty payments will be made quarterly.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in &#8220;&#8212;Overview&#8212;Impact of Settlement Agreements,&#8221; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on March 23, 2021, upon entering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Daewoong Settlement Agreement, Daewoong paid us $25.5 million in April 2021, cancelled all remaining milestone payments u</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">p to $10.5 million in aggregate under the Daewoong Agreement and agreed to reimburse us certain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts (calculated on a dollar amount per vials sold basis in the United States) for sales of certain products with respect to which we are required to pay Medytox and Allergan royalties pursuant to the U.S. Settlement Agreement.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Supply Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Agreement includes certain minimum annual purchases we are required to make in order to maintain the exclusivity of the license. We may, however, meet these minimum purchase obligations by achieving certain market share in our licensed territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and our future market share in various jurisdictions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters in Newport Beach, California is under a five-year non-cancelable operating lease, which expires on January 31, 2025 with an option to extend the term for an additional 60 months. Lease payments increase based on an annual rent escalation clause that occurs on each February 1 anniversary. We may, under certain circumstances, terminate the lease on the 36 months anniversary of the lease commencement date by providing a written notice 12 months prior to such anniversary and paying a termination fee&#160;equal to six months basic rent plus certain other expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current and Future Capital Requirements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our current capital resources, which consist of cash and cash equivalents, future cash generated from operations, and cash available under the Pharmakon Term Loans, as well as the public debt and equity markets, will be sufficient to satisfy both our short-term and long-term cash requirements for working capital to support our daily operations and meet commitments under our contractual obligations with third parties. This includes our obligation to make a $5.0 million payment in the first quarter of 2023 pursuant to the Medytox/Allergan Settlement Agreements (see &#8220;&#8212;Litigation Settlement&#8221; above).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based our projections of capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources, which consist of cash and cash equivalents, cash generated from operations, and cash available under the Pharmakon Term Loans, sooner than we expect. Our cash requirements depend on numerous factors, including but not limited to the impact of any potential disruptions to our supply chain resulting from the COVID-19 pandemic, inflation or other economic conditions, and other long-term commitments and contingencies. Because of the numerous risks and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertainties associated with research, development and commercialization of our products, we are unable to estimate the exact amount of our operating capital requirements. In such case, we may be required to raise additional capital to fund future operations through the incurrence of debt, the entry into licensing or collaboration agreements with partners, sale of equity securities, grants or other sources of financing. However, there can be no assurance such financing or other alternatives will be available to us on acceptable terms, or at all. The global economy, including the financial and credit markets, has recently experienced significant volatility and disruptions, including severely diminished liquidity and credit availability and rising interest rates. These conditions may adversely impact our ability to raise additional capital on acceptable terms, or at all.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of revenue growth for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States and success of planned international launches;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to forecast demand for our products, scale our supply to meet that demand and manage working capital effectively;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of any future product candidates we develop or acquire;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and costs of any ongoing or future clinical programs we may conduct;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our product or any future product candidates and any products we successfully commercialize, including costs associated with our supply chain;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amounts of the royalty and other payments payable in connection with the Medytox/Allergan Settlement Agreements;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amounts of the royalty payable to Evolus Founders;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates are approved or cleared for sale, including marketing, sales and distribution costs;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of maintaining a sales force, the productivity of that sales force, and the market acceptance of our products;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any product liability or other lawsuits related to our products;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of any current litigation including our ongoing securities class action lawsuit and shareholder derivative lawsuit;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expenses needed to attract and retain skilled personnel;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing intellectual property and any other future intellectual litigation we may be involved in; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of sales of any future approved or cleared products, if any.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-right:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:57.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #231f20;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #231f20;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #231f20;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #231f20;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #231f20;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:4.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:4.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates on cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Activities </span></div><div style="margin-bottom:9pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, operating activities used $76.1 million of cash, which primarily resulted from our net loss of $61.2 million. Net operating assets and liabilities changed by $32.7 million primarily driven by timing of collections from customers, payments to vendors and the second cash payment of litigation settlement of $15.0 million to Medytox and Allergan in the first quarter of 2022. Operating activities also includes adjustments for certain non-cash charges including $8.4 million of stock-based compensation expense, $3.9 million in revaluation of our contingent royalty obligation, $1.4 million of provision of allowance for doubtful accounts and $2.7 million of depreciation and amortization.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the nine months ended September 30, 2021, operating activities used $24.3 million of cash, which primarily resulted from our net loss of $28.6 million. Net operating assets and liabilities changed by $14.5 million primarily driven by timing of receipts from customers and payments to vendors and the first cash payment of litigation settlement of $15.0 million to Medytox and Allergan. Operating activities also includes adjustments for certain non-cash charges including $6.9 million of stock-based compensation expense, $4.0 million in revaluation of our contingent royalty obligation, $0.5 million of provision of allowance for doubtful accounts and $4.7 million of depreciation and amortization.</span></div><div style="margin-bottom:10pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities was $1.5 million for the nine months ended September 30, 2022 compared to cash provided by investing activities of $4.4 million for the nine months ended September 30, 2021. The increase in cash used in investing activities was attributable to no maturities of short-term investments during the nine months ended September 30, 2022.</span></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities was $2.6 million for the&#160;nine months ended September 30, 2022, compared to $25.2 million of cash provided by financing activities for the nine months ended September 30, 2021. For the nine months ended September 30, 2022, cash used in financing activities primarily resulted from the payment of contingent royalty obligation to Evolus Founders of $3.2 million. For the&#160;nine months ended September 30, 2021, cash provided by financing activities primarily resulted from proceeds from our follow-on offering, net of underwriter fees and offering costs, of $92.2 million and sales of $10.9 million of our common shares under the ATM Program, offset by the repayment of long-term debt with Oxford of $76.3 million in January 2021.</span></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have future obligations under various contracts relating to debt and interest payments to our Pharmakon Term Loans, royalty payments to Evolus Founders, a $5.0 million settlement payment related to the Medytox/Allergan Settlement Agreements, royalty payments to Allergan and Medytox, operating leases and purchase obligations. During the nine months ended September 30, 2022, there were no material changes to these obligations as reported in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_82"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosure of contingent assets and liabilities, revenue and expenses at the date of the consolidated financial statements as well as the expenses incurred during the reporting period. Generally, we base our estimates on historical experience and on various other assumptions in accordance with GAAP that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions and such differences could be material to the financial position and results of operations. On an ongoing basis, we evaluate our estimates and assumptions in light of changes in circumstances, facts and experience. </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies and estimates as discussed in our Annual Report on Form 10-K filed for the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued and Adopted Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We describe the recently issued and adopted accounting pronouncements that apply to us in&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2.&#160;Summary of Significant Accounting Policies-Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_85"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosure About Market Risk.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_88"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. &#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, who serve as our principal executive officer and principal financial officer, respectively, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure (a) that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (b) that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that, as of September 30, 2022, our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, there were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred with respect to the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_91"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II&#8212;Other Information</span></div><div id="idfe4cc3337b24bc380d09a49794cd329_94"></div><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Legal Proceedings&#8221; in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9.&#160;&#160;&#160;&#160;Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding legal proceedings.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_97"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The risks and uncertainties discussed below update, supersede and replace the risks and uncertainties previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2021, which was filed with the SEC on March&#160;3, 2022, and previously disclosed in Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, which was filed with the SEC on August 2, 2022.&#160;Other than the addition of a risk factor related to fluctuations in currency exchange rates, we do not believe any of the changes constitute material changes from the risk factors previously disclosed in such prior Annual Report on Form 10-K.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in our company involves a high degree of risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the risks and uncertainties described below together with all the other information in this Quarterly Report on Form 10-Q, including Part I, Item 2&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the consolidated financial statements and the related notes included in Part I, Item 1. If any of the following risks actually occurs, our business, reputation, financial condition, results of operations, revenue, and future prospects could be seriously harmed. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. Unless otherwise indicated, references to our business being seriously harmed in these risk factors will include harm to our business, reputation, financial condition, results of operations, revenue and future prospects. In that event, the market price of our common stock could decline, and you could lose part or all of your investment.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Strategy</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently depend entirely on the successful commercialization of our only product, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. If we are unable to successfully market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, we may not generate sufficient revenue to continue our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have only one product, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our business presently depends entirely on our ability to successfully market and sell it in a timely manner. While the product was commercially launched in the United States in May 2019,  through a distribution partner in Canada in October 2019 and into Great Britain in September 2022, we have a limited history of generating revenue for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our near-term prospects, including our ability to generate revenue, as well as our future growth, depend entirely on the successful commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will depend on a number of factors, including our ability to successfully commercialize Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, whether alone or in collaboration with others, including our ability to hire, retain and train sales representatives in the United States. Our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also dependent on the willingness of consumers to pay for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relative to other discretionary items, especially during economically challenging times. Additional factors necessary for the successful commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include the availability, perceived advantages, relative cost, relative safety of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and relative efficacy of competing products, the timing of new product introductions by our competitors, and the sales and marketing tactics of our competitors, including bundling of multiple products, in response to our launch of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant issues commercializing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Further, we may never be able to successfully market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates. In addition, our experience as a commercial company is limited. Accordingly, we may not be able to generate sufficient revenue through the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates to continue our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history and have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We have only one product and limited commercial sales, which, together with our limited operating history, makes it difficult to assess our future viability. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a performance beauty company with a limited operating history. To date, we have invested substantially all of our efforts and financial resources in the clinical development, regulatory approval, and commercial launch of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is currently our only product. We began selling Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019, through a distribution partner in Canada in October 2019, and into Great Britain in September 2022 and have a limited history of generating revenue. We were not profitable during the nine months ended September 30, 2022, and we do not expect to be profitable in 2022. We have incurred losses in each year since our inception in 2012. We have a limited operating history upon which you can evaluate our business and prospects. Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer operating history or greater experience commercializing a product. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in the medical aesthetics field. We continue to incur significant expenses related to the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We recorded a net loss of $61.2 million for the nine months ended September </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30, 2022, and we recorded a net loss of $46.8 million and net loss of $163.0 million for the years ended December 31, 2021 and 2020, respectively. We had an accumulated deficit as of September 30, 2022 of $484.1 million. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will continue as we commercialize Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our ability to achieve revenue and profitability is dependent on our ability to successfully market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, may adversely affect the market price of our common stock and, if needed, our ability to raise capital to continue operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may require additional financing to fund our future operations, and a failure to obtain additional capital when so needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have utilized substantial amounts of cash since our inception in order to conduct clinical development to support regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, EU and Canada and in connection with the launch of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Canada. We expect that we will continue to expend substantial resources for the foreseeable future in order to continue to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and for the clinical development of any additional product candidates we may choose to pursue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the near term, we expect to make a $5.0 million payment in 2023 associated with our settlement agreements with Medytox and Allergan. Additionally, we expect to expend resources furthering the development and continuation of our marketing programs and commercialization infrastructure in connection with commercializing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within and outside of the United States. In the long term, our expenditures will include costs associated with the continued commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, payments related to the collaboration agreement depending on the development plans, the success of such development and approval and commercialization of products and any of our future product candidates, including our proposed higher strength dose of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, such as research and development, conducting preclinical studies and clinical trials and manufacturing and supplying as well as marketing and selling any products approved for sale. We expect to incur additional costs as we continue to operate as a public company, hire additional personnel and expand our operations. Because the commercialization expenditures needed to meet our sales objectives are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We may in the future, also, acquire other companies or products which may be costly and which may require additional capital to operate. In addition, other unanticipated costs may arise. Accordingly, our actual cash needs may exceed our expectations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to raise additional capital through marketing and distribution arrangements, royalty financing arrangements, or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings or offerings of securities convertible into our equity, the ownership interest of our existing stockholders will be diluted and the terms of any such securities may have a preference over our common stock. Debt financing, receivables financing and royalty financing may also be coupled with an equity component, such as warrants to purchase our capital stock, which could also result in dilution of our existing stockholders&#8217; ownership, and such dilution may be material. Additionally, if we raise additional capital through debt financing, we will have increased fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures to meet specified financial ratios, and other operational restrictions, any of which could restrict our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates or operate as a business and may result in liens being placed on our assets. If we were to default on any of our indebtedness, we could lose such assets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the global economy, including the financial and credit markets, has recently experienced significant volatility and disruptions, including severely diminished liquidity and credit availability and rising interest rates. In the event we are unable to raise sufficient capital to fund our commercialization efforts to achieve specified minimum sales targets under the Daewoong Agreement, we will lose exclusivity of the license that we have been granted under the Daewoong Agreement. In addition, if we are unable to raise additional capital when required or on acceptable terms, we will be required to take actions to address our liquidity needs which may include the following: significantly reduce operating expenses and delay, reduce the scope of or discontinue some of our development programs, commercialization efforts or other aspects of our business plan, out-license intellectual property rights to our product candidates and sell unsecured assets, or a combination of the above. As a result, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and may have a material adverse effect on our business, results of operations, financial condition and/or our ability to fund our scheduled obligations on a timely basis or at all.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our counterparties do not comply with the terms of our settlement agreements with Medytox, Inc., or Medytox, and Allergan Limited, Allergan, Inc. and Allergan Pharmaceuticals Ireland, or, collectively, Allergan, we may face litigation or lose our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, which would materially and adversely affect our ability to carry out our business and our financial condition and ability to continue as a going concern. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, we entered into a Settlement and License Agreement with Allergan and Medytox, which we refer to as the U.S. Settlement Agreement and into another Settlement and License Agreement with Medytox only which we refer to as the ROW Settlement Agreement. Collectively, we refer to the U.S. Settlement Agreement and the ROW Settlement Agreement as the Medytox/Allergan Settlement Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medytox/Allergan Settlement Agreements we obtained (i) a license to commercialize, manufacture and to have manufactured for us certain products identified in the Medytox/Allergan Settlement Agreements, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Licensed Products&#8221;), in the United States and other territories where we license Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ii) the dismissal of outstanding litigation against us, including the ITC Action, a rescission of the related remedial orders, and the dismissal of a civil case in the Superior Court of California against us, which we refer to together with any claims (including claims brought in Korean courts) with a common nexus of fact as the Medytox/Allergan Actions, and (iii) releases of claims against us for the Medytox/Allergan Actions. In exchange, we agreed to (i) make payments of $35.0 million in multiple payments over two years to Allergan and Medytox, of which we have paid $30.0 million, (ii) from December 16, 2020 to September 16, 2022, pay to Allergan and Medytox certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a specified dollar amount per vial sold of Licensed Product by or on behalf of us in the United States, (iii) from December 16, 2020 to September 16, 2022, pay to Medytox a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sold by us or on our behalf in territories we have licensed outside the United States, (iv) from September 17, 2022 to September 16, 2032, we will pay to Medytox a mid-single digit royalty percentage on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and all territories we have licensed outside the United States, (v) issue to Medytox 6,762,652 shares of our common stock, which we issued on February 18 2021, and (vi) enter into a Registration Rights Agreement pursuant to which we granted certain registration rights to Medytox with respect to such shares of common stock beginning as of March 31, 2022. In addition, under the Medytox/Allergan Settlement Agreements we made certain representations and warranties and agreed to positive and negative covenants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we fail to comply with the terms of the Medytox/Allergan Settlement Agreements, subject to applicable cure periods, Allergan and Medytox would have the ability to terminate the Medytox/Allergan Settlement Agreements and thereby cancel the licenses granted to us and re-institute litigation against us. Any litigation may result in remedies against our products, resulting in either an injunction prohibiting our sales, or with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, any of which would materially and adversely affect our ability to generate revenue from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to carry out our business, and to continue as a going concern.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if Medytox or Allergan fail to comply with the terms of the Medytox/Allergan Settlement Agreements and comply with the covenants and agreements under the Medytox/Allergan Settlement Agreements, it could materially and adversely affect our ability to generate revenue from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to carry out our business, and to continue as a going concern. We would also be required to engage in costly and time-consuming litigation in order to enforce our rights under the Medytox/Allergan Settlement Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of the Medytox/Allergan Settlement Agreements will reduce our profitability until the royalty obligations expire, and may affect the extent of any discounts we may offer to our customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the royalty payments that we are required to pay under the Medytox/Allergan Settlement Agreements, our profitability has and will be adversely impacted for the period that we are required to pay royalties. We may be able to offset a portion of the loss of profitability by decreasing any discount to customers on Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to discounts we provided to customers prior to the Medytox/Allergan Settlement Agreements. If we reduce discounts for any customers, their volume of purchases may decrease which would have a material and adverse effect on our business and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, financial condition and operations have been, and may in the future be, adversely affected by the COVID-19 outbreak or other outbreaks of contagious diseases.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 has had, and may continue to have, material adverse effects on our business, financial condition, results of operations and cash flows. Other outbreaks of contagious diseases in the future could have a similar material adverse effect on our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak, and restrictions intended to slow the spread of COVID-19, including quarantines, government-mandated actions, stay-at-home orders and other restrictions, has adversely affected our business in a number of ways. For </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">example, the spread of COVID-19 in the United States has resulted in travel restrictions impacting our sales professionals and closures of our customers&#8217; businesses, which adversely affected our sales and operations, particularly in 2020 and periods of 2021. If similar or other restrictions are imposed in the future in response COVID-19 outbreaks or outbreaks of other contagious disease, our sales and operations may be adversely affected. Additionally, surges of COVID-19 outbreaks or other outbreaks of contagious disease, including closures of our customers&#8217; businesses, may impact our ability to enroll patients in our ongoing and future clinical programs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other negative impacts of the COVID-19 outbreak or other outbreaks of contagious diseases could include the availability of our key personnel, temporary closures of our office or the facilities of our business partners, customers, third party service providers or other vendors, and the interruption of our supply chain, distribution channels, liquidity and capital or financial markets, including increased inflation and rising interest rates. Any of these events may result in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets may increase our cost of capital and adversely affect our ability to access financing when and on terms that we desire. Any of these events could have a material adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is utilized in elective procedures, the costs of which are borne by the consumer and not third-party payors. As a result of the COVID-19 outbreak and restrictions to slow its spread, these elective procedures declined dramatically in 2020 due to closures of our customers&#8217; businesses and as many customers are deferring their procedures. Even after the current COVID-19 pandemic subsides, we may continue to experience negative impacts to our business and financial results if consumers continue to defer or avoid altogether elective procedures to administer Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to the continued perceived risk of infection or concern of a resurgence of the COVID-19 outbreak, including new and more contagious and/or vaccine resistant variants, as well as COVID-19&#8217;s global economic impact, including decreases in consumer discretionary spending and any economic slowdown or recession that may occur in the future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. In addition, inflation has increased over the past year, potentially impacting consumer discretionary spending for aesthetic medical procedures. Markets experiencing uncertainty could have substantial high rates of inflation. Inflation and rapid fluctuations in inflation rates typically have negative effects on such countries&#8217; economies and markets. Significant increases in unemployment stemming from the pandemic have also occurred which may impact consumer discretionary spending. Furthermore, for the discretionary nature of aesthetic medical procedures may be particularly vulnerable to unfavorable economic conditions. Because we do not expect Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of glabellar lines to be reimbursed by any government or third-party payor, our only product is and will continue to be paid for directly by the consumer. Demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is accordingly tied to the discretionary spending levels of our targeted consumer population. A severe or prolonged economic downturn or inflation in consumer prices could result in a variety of risks to our business, including a decline in the discretionary spending of our target consumer population, which could lead to a weakened demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates. A severe or prolonged economic downturn may also affect our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our products. Any of the foregoing could harm our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business strategy was developed based on a number of important assumptions about the self-pay healthcare market. For example, we believe that the number of self-pay healthcare procedures will increase in the future. However, these trends are uncertain and limited sources exist to obtain reliable market data. Therefore, sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our future product candidates could differ materially from our projections if our assumptions are incorrect.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> faces, and any of our future product candidates will face, significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved for use in facial aesthetic medicine. The facial aesthetic market is highly competitive and dynamic and is characterized by rapid and substantial technological development and product innovations. We have received regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of glabellar lines and launched commercially in the United States and through a distribution partner in Canada and in Great Britain. We anticipate that Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will face significant competition from other facial aesthetic products, such as other injectable and topical botulinum toxins and dermal fillers. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may also compete with unapproved and off-label treatments. Many of our potential competitors, including Allergan, and now AbbVie Inc., which acquired Allergan, who first launched BOTOX for cosmetic uses in 2002 and has since maintained the highest market share position in the aesthetic neurotoxin market with its BOTOX product, are large, experienced companies that enjoy significant competitive advantages, such as substantially greater financial resources enabling them to, among other things, market and discount aggressively. Competitors may also have greater brand recognition for their products, larger sales forces and larger aesthetic product portfolios allowing the companies to bundle products to provide customers more choices and to further discount their products. Additionally, our competitors have greater existing market share in the aesthetic neurotoxin product market and long-standing customer loyalty programs and sales contracts with large customers which creates established business and financial relationships with customers, aesthetic societies and universities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These competitors may also try to compete with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on price both directly, through rebates and promotional programs to high volume physicians and coupons to consumers, and indirectly, through attractive product bundling with complimentary products, such as dermal fillers that offer convenience and an effectively lower price compared to the total price of purchasing each product separately. These companies may also seek to compete based on their longer operating history. Larger companies may be better capitalized than us and, accordingly, are able to offer greater customer loyalty benefits to encourage repeat use of their products and finance a sustained global advertising campaign to compete with our commercialization efforts at launch. A number of our larger competitors also have access to a significant number of studies and publications that they could use to compete with us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the long term, we expect to expand our focus to the broader self-pay healthcare market. Competitors and other parties may seek to impact regulatory approval of our future product applications through the filing of citizen petitions or other similar documents, which could require costly and time-consuming responses to the regulatory agencies. Larger competitors could seek to prevent or delay our commercialization efforts via costly litigation which can be lengthy and expensive and serve to distract our management team&#8217;s attention. We could face competition from other sources as well, including academic institutions, governmental agencies and public and private research institutions. In addition, we are aware of other companies also developing and/or marketing products in one or more of our target markets, including competing injectable botulinum toxin type A formulations that are currently in Phase III clinical development in North America for the treatment of glabellar lines. For example, Revance Therapeutics, Inc. obtained approval for an injectable botulinum toxin type A neurotoxin on September 8, 2022. Additionally, Hugel Inc., submitted a BLA to the FDA for an injectable botulinum toxin type A neurotoxin and received a Complete Response Letter from the FDA in March 2022. With the approval of the Revance Therapeutic&#8217;s BLA and the potential approval of Hugel, Inc.&#8217;s BLA, we expect the competition in the U.S. injectable botulinum toxin market to further increase. We would face similar risks with respect to any future product candidates that we may seek to develop or commercialize in the broader self-pay healthcare market. Successful competitors in that market have the ability to effectively discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as the ability to effectively commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy of competing in the aesthetic neurotoxin market is dependent on the marketing and pricing flexibility that we believe is afforded to a company with a portfolio limited to self-pay healthcare, comprised of products and procedures that are not reimbursed by third-party payors. In the event that regulations applicable to reimbursed products are changed to apply to self-pay healthcare products, we would no longer have this flexibility and we may not be able to compete as effectively with our competitors which may have a material effect on our business, financial condition and results of operations. Additionally, as a result of the royalty payments that we are required to pay under the Medytox/Allergan Settlement Agreements, we may not be able to discount Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the extent that we previously provided discounts to customers without impacting our gross profit margins. If we increase prices for any customers, their volume of purchases may decrease which would have a material and adverse effect on our business and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competitors may develop new technologies within the aesthetic market that may be superior in safety and efficacy to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or offer alternatives to the use of toxins, including surgical and radio frequency techniques. To compete successfully in the aesthetic market, we will have to demonstrate that Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is at least as safe and effective as current </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products sold by our competitors. Competition in the aesthetic market could result in price-cutting and reduced profit margins, any of which would harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to less stringent regulatory requirements, there are many more aesthetic products and procedures available for use in international markets than are approved for use in the United States. There are also fewer limitations on the claims that our competitors in international markets can make about the effectiveness of their products and the manner in which they can market them. As a result, we expect to face more competition in these markets than in the United States.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could also be reduced or eliminated if our competitors develop and commercialize products that are safer, are more effective, have fewer or less severe side effects, are more convenient or are less expensive than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any other product that we may develop. Our competitors also may obtain FDA or other regulatory approval for these products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market, which may create additional barriers to successfully commercializing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any future product candidates and attracting physician and consumer demand.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> may fail to achieve the broad degree of physician adoption and use or consumer demand necessary for continued commercial success. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may fail to gain sufficient market acceptance by physicians, consumers and others in the medical aesthetics community to continue to grow our net revenues. The continued commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any future product candidates, including a proposed higher strength dose of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, will depend significantly on the broad adoption and use of the resulting product by physicians for approved indications, including, in the case of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the treatment of glabellar lines and other aesthetic indications that we may seek to pursue. We are aware that other companies are seeking to develop alternative products and treatments, any of which could impact the demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree and rate of physician adoption of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any future product candidates depend on a number of factors, including the cost, profitability to our customers, consumer demand, characteristics and effectiveness of the product. Our success will also depend our ability to create compelling marketing programs, training of our customers and ability to overcome any biases physicians or consumers may have toward the use, safety and efficacy of existing products over Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Moreover, our competitors may utilize negative selling efforts or offer more compelling marketing or discounting programs than we are able to offer, including by bundling multiple aesthetic products to provide a more comprehensive offering than we can as Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently our sole product.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in its clinical trials, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was clinically tested and compared to BOTOX. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the only known neurotoxin product in the United States with a 900 kDa complex other than BOTOX. We believe that aesthetic physicians&#8217; familiarity with the 900 kDa complex&#8217;s handling, preparation and dosing will more easily facilitate incorporation of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> into their practices. However, the ease of integration of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> into a physician&#8217;s practice may not be as seamless as we anticipate.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to consumer demand, the treatment of glabellar lines with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an elective procedure, the cost of which must be borne by the consumer, and we do not expect costs related to the treatment to be reimbursable through any third-party payor, such as Medicaid, Medicare or commercial insurance. The decision by a consumer to undergo treatment with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of glabellar lines or other aesthetic indications that we may pursue may be influenced by a number of factors, including the cost, efficacy, safety, perception, marketing programs for, and physician recommendations of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> versus competitive products or procedures. Moreover, consumer demand may fluctuate over time as a result of consumer sentiment about the benefits and risks of aesthetic procedures generally and Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in particular, changes in demographics and social trends, rising inflation and general consumer confidence and consumer discretionary spending, which may be impacted by the COVID-19 outbreak, economic and political conditions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates fail to achieve the broad degree of physician adoption necessary for commercial success or the requisite consumer demand, our operating results and financial condition will be adversely affected, which may delay, prevent or limit our ability to generate revenue and continue our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to market Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> is limited to use for the treatment of glabellar lines, and if we want to expand the indications for which we market Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, we will need to obtain additional regulatory approvals, which will be expensive and may not be granted. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received regulatory approval for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States for the treatment of moderate to severe glabellar lines. The terms of that approval restrict our ability to market or advertise Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for other indications, which could limit </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">physician and consumer adoption. Under the U.S. Federal Food Drug and Cosmetic Act, we may generally only market Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for approved indications. Many of our competitors have received approval of multiple aesthetic and therapeutic indications for their neurotoxin products and may be able to market such products for use in a way we cannot. For example, we are aware that one of our competitors, Allergan (now AbbVie), has obtained and plans to obtain additional indications for its neurotoxin product within medical aesthetics and, therefore, is able to market its product across a greater number of indications than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If we are unable to obtain approval for indications in addition to our approval for glabellar lines, our marketing efforts for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will be severely limited. As a result, we may not generate physician and consumer demand or approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on our digital technology and applications and our business and operations would suffer in the event of computer system failures or breach.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are reliant on our digital technology, including our Evolus Practice App, which allows customers to open a new account, order Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pay invoices and engage with our customer experience team and medical affairs representatives. In the event that our digital technology is unable to function in the manner it was designed or at all, we would experience difficulty processing customer orders and requests in a timely manner or at all which would have a material adverse effect on our business, results of operations and financial condition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The systems underlying our digital technology may not be adequately designed or may not operate with the reliability and redundancy necessary to avoid performance delays or outages that could be harmful to our business. If our digital technology is unavailable when customers attempt to access them, or if they do not load as quickly as expected, users may not use our technology as often in the future, or at all, and our ability to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a more limited sales force may be disrupted and we may not realize the efficiencies of leveraging our digital technology, any of which could adversely affect our business and financial performance. As the number of users of our digital technology continues to grow we will need an increasing amount of technical infrastructure, including network capacity and computing power, to continue to satisfy our needs. It is possible that we may fail to continue to effectively scale and grow our technical infrastructure to accommodate these increased demands, which may adversely affect our customers&#8217; experience with our digital technology which may decrease our revenue and harm our results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to disruption or damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyberattacks or cyber intrusions, insider threats, persons who access our systems in an unauthorized manner, or inadvertent misconfiguration of our systems. The risk of a security incident or system disruption, particularly through cyberattacks or cyber intrusions, including by computer hackers, foreign governments and cybercriminals, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Interruptions in our operations caused by such an event could result in a material disruption of our current or future product development programs. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, government files or penalties and other harm to our business and our competitive position. Interruptions in our operations caused by such an event could also result in a material disruption in our relationship with our customers. For example, if our Evolus Practice App were rendered inoperable, we would have to process orders by telephone or otherwise which may result in slower processing times and harm to our reputation.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, a computer security incident that affects our systems or results in the unauthorized access to financial information, personally identifiable information (PII), customer information or data, including credit card transaction data or other sensitive information, could materially damage our reputation. In addition, such a security incident may require notification to governmental agencies, the media or individuals pursuant to various international, federal and state privacy and security laws, including the General Data Protection Regulation (GDPR), the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Clinical Health Act of 2009, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. Additionally, the regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve and a number of states have adopted laws and regulations that may affect our privacy and data security practices regarding the use, disclosure and protection of PII. For example, the California Consumer Privacy Act, among other things, has created new individual privacy rights and imposes increased obligations on companies handling PII. In the event of a security incident, we would also be exposed to the risk of litigation and potential liability, which could materially </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adversely affect our business, results of operations and financial condition. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyberattacks and other related security incidents.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any other product candidate for which we seek approval as a biologic may face competition sooner than anticipated.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the enactment of the Biologics Price Competition and Innovation Act of 2009, or the BPCI Act, as part of the Patient Protection and Affordable Care Act, an abbreviated pathway for the approval of biosimilar or interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics. Under the BPCI Act, an application for a biosimilar product cannot be approved by the FDA until twelve years after the original branded product was approved under a Biologics License Application, or BLA. The law is complex and is still being interpreted and implemented by the FDA. For example, one company has filed a Citizen Petition requesting that the FDA not apply the BPCI Act to pre-enactment BLAs. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCI Act may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any of our product candidates to be a reference product for competing products, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found to have improperly promoted off-label uses, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, significant fines, penalties, sanctions, or product liability claims, and our image and reputation within the industry and marketplace could be harmed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about pharmaceutical products, such as Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or other similar regulatory authorities as reflected in the product&#8217;s approved labeling. Physicians could use Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on their patients in a manner that is inconsistent with the approved label of the treatment of moderate to severe glabellar lines, potentially including for the treatment of other aesthetic or therapeutic indications. If we are found to have promoted such off-label uses, we may receive warning letters from and be subject to other enforcement actions by the FDA, the European Medicines Agency, or EMA, and other regulatory agencies, and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management&#8217;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed in order to resolve FDA enforcement actions. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to FDA prohibitions or other restrictions on the sale or marketing of our products and other operations or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry. In addition, regulatory authorities outside the United States may impose similar fines, penalties or sanctions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians may also misuse Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates are misused or used with improper techniques or are determined to cause or contribute to consumer harm, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend, result in sizable damage awards against us that may not be covered by insurance and subject us to negative publicity resulting in reduced sales of our products. Furthermore, the use of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates for indications other than those cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and consumers. Any of these events could harm our business and results of operations and cause our stock price to decline.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any of our future product candidates may cause serious or undesirable side effects or possess other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of approved </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">labeling, result in post-approval regulatory action or in product liability lawsuits.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unforeseen side effects from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or our future product candidates could arise either during clinical development or after marketing such product. Undesirable side effects caused by product candidates could cause us or regulatory authorities to interrupt, modify, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or similar regulatory authorities. Results of clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or terminated and the FDA, the EMA or similar regulatory authorities could order us to cease further development of or deny approval of product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may harm our business, financial condition, operating results and prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or any of our future product candidates, after obtaining regulatory approval in the United States or other jurisdictions, a number of potentially negative consequences could result, including regulatory authorities withdrawing approval or limiting the marketing of our products, requiring a recall of the product, requiring additional warnings on our product labeling or medication guides or instituting Risk Evaluation and Mitigation Strategies, or REMS. In order to mitigate these risks, regulatory authorities may require additional costly clinical trials or costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. As a result of any of these actions our sales of the product may decrease significantly, we may be required to expend material amounts to comply with any requirements of the regulatory authorities, we could be sued in a product liability lawsuit and held liable for harm caused to patients, and our brand and reputation may suffer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any of our future product candidates. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted against us under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources and result in decreased demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates or products we may develop, termination of clinical trial sites or entire trial programs, injury to our reputation and significant negative media attention, withdrawal of clinical trial participants or cancellation of clinical trials and significant costs and diversion management&#8217;s time to defend the related litigation.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future products that we develop. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above events could prevent us from achieving or maintaining market acceptance of the affected product, negatively impact our revenues and could substantially increase the costs of commercializing our products. The demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could also be negatively impacted by any adverse effects of a competitor&#8217;s product or treatment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although most of our effort is focused on the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a key element of our long-term strategy is to in-license, acquire, develop, market and commercialize a portfolio of products to serve the self-pay aesthetic market. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is currently our sole product. Our competitors are currently able to bundle multiple aesthetic products to provide a more comprehensive offering than we can as a single product company. Because our internal research and development capabilities are limited, we may be dependent upon pharmaceutical and other companies, academic scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identify and select promising aesthetic product candidates and products, negotiate licensing or acquisition agreements with their current owners and finance these arrangements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing, sales and other resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidates that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical testing and approval by the FDA, the EMA and other similar regulatory authorities. All product candidates are prone to risks of failure during product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, any approved products that we acquire may not be manufactured or sold profitably or achieve market acceptance.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to increase the size of our organization, including our sales and marketing capabilities, in order to further market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and we may experience difficulties in managing this growth. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we had 213 employees, all of whom constituted full-time employees. Our management and personnel, systems and facilities currently in place may not be adequate to support future growth. Our need to effectively execute our growth strategy requires that we identify, recruit, retain, incentivize and integrate any additional employees to effectively manage any future clinical trials, manage our internal development efforts effectively while carrying out our contractual obligations to third parties, and continue to improve our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks in building and managing a sales organization whether internally or by utilizing third parties, including our ability to retain and incentivize qualified individuals, provide adequate training to sales and marketing personnel, generate sufficient sales leads, effectively manage a geographically dispersed sales and marketing team, adequately provide complementary products to be offered by sales personnel, which may otherwise put us at a competitive disadvantage relative to companies with more extensive product lines, and handle any unforeseen costs and expenses. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development and strategic objectives or disrupt our operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be materially adversely affected by the impact of the ongoing military conflict between Russia and Ukraine on the global economy and capital markets and other geopolitical tensions may also adversely affect our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the ongoing military conflict between Russia and Ukraine. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions, which could continue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the recent military conflict in Ukraine has led to the imposition of sanctions and other penalties by the U.S., EU and other countries against Russia. Russian military actions and the resulting sanctions have adversely affected the global economy and financial markets and could lead to further instability and lack of liquidity in capital markets, which could make it more difficult for us to obtain additional funds at terms favorable to us, or at all.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our business has not been materially impacted by the ongoing military conflict between Russia and Ukraine, it is impossible to predict the extent to which our operations, or those of our suppliers and manufacturers, will be impacted in the short and long term, or the ways in which the conflict may impact our business. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict, but could be substantial.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our international operations will expose us to risks, and failure to manage these risks may adversely affect our operating results and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have operations in the United States and Europe, having launched in Great Britain in the third quarter of 2022. International operations are subject to a number of inherent risks, and our future results could be adversely affected by a number of factors, including differences in demand for our products due to local requirements or preferences, the difficulty of hiring and managing employees with cultural and geographic differences and the costs of complying with differing regulatory requirements. Additionally, we may experience difficulties and increased costs due to differences in laws related to enforcing contracts, protecting intellectual property, taxes, tariffs and export regulations. The current conflict between Ukraine and Russia may also impact European economies and consumer discretionary spending negatively. We do not have significant international operations in Russia, Ukraine, or the surrounding regions that have been impacted by the conflict directly.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations will also subject us to risks related to multiple, conflicting and changing laws and regulations such as privacy regulations, including the GDPR, tax laws, export and import restrictions, employment laws, immigration laws, labor laws, regulatory requirements and other governmental approvals, permits and licenses. Additionally, we will face heightened risk of unfair or corrupt business practices in certain geographies and of improper or fraudulent sales arrangements that may impact financial results and result in restatements of, or irregularities in, financial statements. These and other factors could harm our ability to gain future revenue and, consequently, materially impact our business, operating results and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fluctuations in currency exchange rates may negatively affect our financial condition and results of operation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange rate fluctuations may affect the costs that we incur in our operations. The main currencies to which we are exposed to such fluctuations are the British pound and the EU euro. The exchange rates between these currencies and the U.S. dollar in recent years have fluctuated significantly and may continue to do so in the future. A depreciation of these currencies against the U.S. dollar will decrease the U.S. dollar equivalent of the amounts derived from foreign operations reported in our consolidated financial statements, and an appreciation of these currencies will result in a corresponding increase in such amounts. The cost of certain items, such as raw materials, manufacturing, employee salaries and transportation and freight, required by our operations may be affected by changes in the value of the relevant currencies. To the extent that we are required to pay for goods or services in foreign currencies, the appreciation of such currencies against the U.S. dollar will tend to negatively affect our business. There can be no assurance that foreign currency fluctuations will not have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract and keep senior management and key scientific personnel, we may be unable to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> successfully, or any future products we develop. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management. We believe that our future success is highly dependent upon the contributions of our senior management, particularly David Moatazedi, our President, Chief Executive Officer and member of our board of directors, Sandra Beaver, our Chief Financial Officer, and Rui Avelar, our Chief Medical Officer and Head of R&amp;D, as well as other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future products we develop.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we could experience difficulties attracting and retaining qualified employees in the future. For example, competition for qualified personnel in the pharmaceuticals and medical aesthetic field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information or that their former employers own their research output.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our strategy of focusing exclusively on the self-pay healthcare market may limit our ability to increase sales or achieve profitability.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to focus exclusively on the self-pay healthcare market. This focus may limit our ability to increase sales or achieve profitability. For example, to maintain our business model, we have chosen not to offer products or services available in the broader healthcare market that are reimbursed by third-party payors such as Medicare, Medicaid or commercial insurance. This eliminates our ability to offer a substantial number of products and indications for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, under the Daewoong Agreement our rights to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are limited to cosmetic indications. Daewoong has subsequently licensed the rights to the therapeutic indications to a third party. As a result, we do not have the ability to expand the permitted uses of botulinum toxin products for therapeutic indications.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the only U.S. neurotoxin without a therapeutic indication, although other companies may seek to develop a similar product in the future. We believe pursuing an aesthetic-only non-reimbursed product strategy allows for meaningful strategic advantages in the United States, including pricing and marketing flexibility. However, physicians may choose to not pass any cost benefits received by them due to such pricing flexibility to their patients. In addition, companies offering aesthetic products competitive to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, whether they pursue an aesthetic-only non-reimbursed product strategy or not, may nonetheless try to compete with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on price both directly through rebates, promotional programs and coupons and indirectly through attractive product bundling and customer loyalty programs. Our business, financial results and future prospects will be materially harmed if we cannot generate sufficient consumer demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials, and we and our third-party manufacturer and supplier must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development and manufacturing activities in the future may, and Daewoong&#8217;s manufacturing and supplying activities presently do, involve the controlled storage, use and disposal of hazardous materials, including botulinum toxin type A, a key component of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other hazardous compounds. We and Daewoong are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at Daewoong&#8217;s facilities pending their use and disposal. We and Daewoong cannot eliminate the risk of contamination, which could cause an interruption of Daewoong&#8217;s manufacturing processes, our commercialization efforts, business operations and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, manufacture, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by Daewoong for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, this may not eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use third-party collaborators to help us develop, validate or commercialize any new products, and our ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may license or selectively pursue strategic collaborations for the development, validation and commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any future product candidates, such as the Collaboration Agreement entered into in June 2022. In any third-party collaboration, we would be dependent upon the success of the collaborators in performing their responsibilities and their continued cooperation. Our collaborators may not cooperate with us or perform their obligations under our agreements with them. Our collaborators may choose to pursue alternative technologies in preference to those being developed in collaboration with us. The development, validation and commercialization of our product candidates will be delayed if collaborators fail to conduct their responsibilities in a timely manner or in accordance with applicable regulatory requirements or if they breach or terminate their collaboration agreements with us. Disputes with our collaborators could also impair our reputation or result in development delays, decreased revenues and litigation expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to consumers, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate, reduce or delay its development program or one or more of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates or bring them to market and generate revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. As of December&#160;31, 2021, we had $273.8 million of federal NOLs and $169.3 million of state NOLs available to offset our future taxable income, if any. As of December&#160;31, 2021, we had federal research and development credit carryforwards of $2.9 million. These federal and state NOLs and federal research and development tax credit carryforwards expire at various dates beginning in 2034. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Planned discontinuation of LIBOR could have an adverse impact on operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we had $71.7 million of outstanding indebtedness that bears interest at a floating rate using London Interbank Offered Rate ("LIBOR") as the applicable reference rate. LIBOR, the London interbank offered rate, is the interest rate benchmark used as a reference rate on our variable rate debt, including our Credit Facility. On March 5, 2021, LIBOR&#8217;s regulator, the Financial Conduct Authority and administrator, ICE Benchmark Administration, announced that the publication of one-week and two-month USD LIBOR maturities and the non-USD LIBOR maturities will cease immediately after December 31, 2021, with the publication of overnight, one-, three-, six-, and 12-month USD LIBOR ceasing immediately after June 30, 2023. On March 15, 2022, the Adjustable Interest Rate (LIBOR) Act (the &#8220;LIBOR ACT&#8221;) was signed into law. Under the LIBOR Act, the Board of Governors of the Federal Reserve System is directed to select the Secured Overnight Financing Rate (&#8220;SOFR&#8221;), published by the Federal Reserve Bank of New York, as the replacement rate for contracts that reference LIBOR as a benchmark rate and that do not contain either a specified replacement rate or a replacement mechanism after USD LIBOR ceases publication. In addition, recent New York state legislation effectively codified the use of SOFR as the alternative to LIBOR in the absence of another chosen replacement rate, which may affect contracts governed by New York state law.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOFR is calculated differently from LIBOR and the inherent differences between LIBOR and SOFR or any other alternative benchmark rate gives rise to many uncertainties, including the need to amend existing debt instruments and the need to choose alternative reference rates in new contracts. Furthermore, uncertainty regarding whether or when SOFR or other alternative reference rates will be widely accepted by lenders as the replacement for LIBOR may impact the liquidity of the SOFR loan market, and SOFR itself. Since the initial publication of SOFR, daily changes in the rate have, on occasion, been more volatile than daily changes in comparable benchmark or market rates, and SOFR over time may bear little or no relation to the historical actual or historical indicative data. It is possible that the volatility of and uncertainty around SOFR as a LIBOR replacement rate and the applicable credit adjustment would result in higher borrowing costs for us, and would adversely affect our liquidity, financial condition, and earnings. The consequences of these developments with respect to LIBOR cannot be entirely predicted and span multiple future periods but could result in an increase in the cost of our variable rate debt which may negatively impact our financial results.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationship with Daewoong</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on the license and supply agreement, the Daewoong Agreement, with Daewoong to provide us exclusive rights to distribute Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> in certain territories. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect our development or commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Daewoong Agreement, as it has been amended from time to time, we have secured an exclusive license from Daewoong, a South Korean pharmaceutical manufacturer, to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for aesthetic indications in the United States, EU, United Kingdom, members </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Daewoong Agreement imposes on us obligations relating to exclusivity, territorial rights, development, commercialization, funding, payment, diligence, sublicensing, intellectual property protection and other matters. We are obligated to conduct development activities, obtain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and obtain from Daewoong all of our product supply requirements for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, under the Daewoong Agreement, we are required to submit our commercialization plan to a joint steering committee, or JSC, comprised of an equal number of development and commercial representatives from Daewoong and us, for review and input. Although the Daewoong Agreement provides us with final decision-making power regarding the marketing, promotion, sale and/or distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, any disagreement among the JSC would be referred to Daewoong&#8217;s and our respective senior management for resolution if the JSC is unable to reach a decision within thirty days, which may result in a delay in our ability to implement our commercialization plan or harm our working relationship with Daewoong. If we fail to achieve minimum annual purchase targets of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Daewoong Agreement, Daewoong may, at its sole option, elect to convert the exclusive license to a non-exclusive license. In light of the COVID-19 outbreak, any potential decline in consumer discretionary spending and the potential loss of our ability to discount the product to levels previously provided as a result of the Medytox/Allergan Settlement Agreements, it may become more difficult for us to achieve the minimum annual purchase targets for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which may result in the license being converted to a non-exclusive license.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the Daewoong Agreement will expire on September 30, 2023 in any of the aforementioned territories. The Daewoong Agreement will renew for unlimited additional three-year terms after the expiration of the initial term, only if we meet certain performance requirements during the initial term or preceding renewal term, as applicable. We or Daewoong may terminate the Daewoong Agreement if the other party breaches any of its duties or obligations and such breach continues without cure for ninety days, or thirty days in the case of a payment breach, or if we declare bankruptcy or assign our business for the benefit of creditors. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages to Daewoong and Daewoong may have the right to terminate our license. In addition, if any of the regulatory milestones or other cash payments become due under the terms of the Daewoong Agreement, we may not have sufficient funds available to meet our obligations, which would allow Daewoong to terminate the Daewoong Agreement. Any termination or loss of rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which in turn would have a material adverse effect on our business, operating results and prospects. If we were to lose our rights under the Daewoong Agreement, we believe it would be difficult for us to find an alternative supplier of a botulinum toxin type A complex. In addition, to the extent the alternative supplier has not secured regulatory approvals in a jurisdiction, we would have to expend significant resources to obtain regulatory approvals that may never be obtained or require several years to obtain, which could significantly delay commercialization. We may be unable to raise additional capital to fund our operations during this extended time on terms acceptable to us or at all. Additionally, if we experience delays as a result of a dispute with Daewoong, the demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could be materially and adversely affected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely solely on Daewoong to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, and as such, any production or other problems with Daewoong could adversely affect us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend solely upon Daewoong for the manufacturing of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Although alternative sources of supply may exist, the number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for and qualify alternative suppliers, which could have a material adverse effect on our business. Suppliers of any new product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on Daewoong entails additional risks, including reliance on Daewoong for regulatory compliance and quality assurance, the possible breach of the Daewoong Agreement by Daewoong, and the possible termination or nonrenewal of the Daewoong Agreement at a time that is costly or inconvenient for us. Our failure, or the failure of Daewoong, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dependence on Daewoong also subjects us to all of the risks related to Daewoong&#8217;s business, which are all generally beyond our control. Daewoong&#8217;s ability to perform its obligations under the Daewoong Agreement is dependent on Daewoong&#8217;s operational and financial health, which could be negatively impacted by several factors, including changes in the economic, political and legislative conditions in South Korea and the broader region in general and the ability of Daewoong to continue to successfully attract customers and compete in its market. Furthermore, Daewoong&#8217;s recently constructed manufacturing facility is Daewoong&#8217;s only facility meeting FDA and EMA, current Good Manufacturing Requirements, or cGMPs. Daewoong&#8217;s lack of familiarity with, or inability to effectively operate, the facility and produce products of consistent quality, may harm our ability to compete in our market.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, although we are ultimately responsible for ensuring compliance with regulatory requirements such as cGMPs, we are dependent on Daewoong for day-to-day compliance with cGMP for production of drug substance and finished products. Facilities used by Daewoong to produce the drug substance and materials or finished products for commercial sale must pass inspection and be approved by the FDA and other relevant regulatory authorities. If the safety of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to successfully commercialize our product and we may be held liable for injuries sustained as a result. In addition, the manufacturing facilities of certain of our suppliers are located outside of the United States. This may give rise to difficulties in importing our product into the United States or other countries as a result of, among other things, regulatory agency approval requirements, taxes, tariffs, local import requirements such as import duties or inspections, incomplete or inaccurate import documentation or defective packaging. Any of these factors could adversely impact our ability to effectively market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure or refusal by Daewoong or any other third party to supply Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any other product candidates or products that we may develop could delay, prevent or impair our clinical development or commercialization efforts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, Daewoong developed the manufacturing process for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and manufactures Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a recently constructed facility located in South Korea. If this facility were to be damaged, destroyed or otherwise unable to operate or comply with regulatory requirements, whether due to earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, public health emergencies (such as the COVID-19 outbreak) employee malfeasance, terrorist acts, power outages or otherwise, or if operations at the facility is disrupted for any other reason, such an event could jeopardize Daewoong&#8217;s ability to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as promptly as we or our customers expect or possibly at all. If Daewoong is unable to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within a timeframe that meets our and our customers&#8217; expectations, our business, prospects, financial results and reputation could be materially harmed. Any disaster recovery and business continuity plans that we and Daewoong have in place or put in place may not be adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of our or Daewoong&#8217;s lack of disaster recovery and business continuity plans, or the adequacy thereof, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We forecast the demand for commercial quantities of our products, and if our forecasts are inaccurate, we may experience delays in shipments, increased inventory costs or inventory levels, and reduced cash flow.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong. Pursuant to the Daewoong Agreement, we submit forecasts of anticipated product orders to Daewoong and may, from time to time, submit purchase orders on the basis of these forecasting requirements. Our limited historical experience may not provide us with enough data to accurately predict future demand. In addition, we expect Daewoong to manufacture its own product, Nabota, a botulinum toxin formulation, from this facility for sale in the South Korean market and other markets in which we do not have exclusive rights. If our business significantly expands, our demand for commercial products would increase and Daewoong may be unable to meet our increased demand. In addition, our product will have fixed future expiration dates. If we overestimate requirements for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we will have excess inventory, which may have to be disposed of if such inventory exceeds approved expiration dates, which would result in lost revenues and increase our expenses. If we underestimate requirements for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we may have inadequate inventory, which could interrupt, delay or prevent delivery of our products to our customers. Any of these occurrences would negatively affect our financial performance.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our commercialization efforts and interrupt our supply of products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the proprietary rights of third parties. Competitors in the field of dermatology, medical aesthetic and neurotoxins have developed large portfolios of patents and patent applications in fields relating to our business. In particular, there are patents held by third parties that relate to the treatment with neurotoxin-based products for the indication we are currently marketing. There may also be patent applications that have </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">been filed but not published that, when issued as patents, could be asserted against us. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the technology, medical device and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter-party reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As the technology, medical device and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we or any of our current or future licensors, including Daewoong, are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, methods of manufacture or methods for treatment related to the use or manufacture of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to claims of patent infringement, third parties may bring claims against us asserting misappropriation of proprietary technology or other information in the development, manufacture and commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our future product candidates. Defense of such a claim would require dedicated time and resources, which time and resources could otherwise be used by us toward the maintenance of our own intellectual property and the development and commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any of our future product candidates or by any of our current or future licensors for operational upkeep and manufacturing of our products. For example, prior to entering into the Medytox/Allergan Settlement Agreements, we were a defendant in a lawsuit brought by Medytox in the Superior Court of the State of California, or the Medytox Litigation, and a respondent in an action filed by Allergan and Medytox in the U.S. International Trade Commission, each alleging, among other things, that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain, or the BTX strain, that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (which Medytox claims is similar to its biopharmaceutical drug, Meditoxin) using the BTX strain, and that Daewoong thereby interfered with Medytox&#8217;s plan to license Meditoxin to us, or the Medytox Litigation. Each of the Medytox Litigation and the ITC Action diverted the attention of our senior management and were costly, in terms of legal costs and the ultimate payments and royalties to be paid under the Medytox/Allergan Settlement Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us or any of our current or future licensors may request and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, we or any of our current or future licensors may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties which may not be commercially or more available, pay royalties or redesign our infringing products or manufacturing processes, which may be impossible or require substantial time and monetary expenditure. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research, manufacture clinical trial supplies or allow commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. Similarly, third-party patents could exist that might be enforced against our products, resulting in either an injunction prohibiting our sales, or with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any of our current or future licensors, including Daewoong, are unable to maintain, obtain or protect intellectual property rights related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any of our future product candidates, we may not be able to compete effectively in our market.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our current licensor, Daewoong, currently rely upon a combination of trademarks, trade secret protection, confidentiality agreements and proprietary know-how. Botulinum toxin cannot be patented, as it is produced by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clostridium</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">botulinum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a gram-positive, rod-shaped, anaerobic, spore-forming, motile bacterium with the ability to produce the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">neurotoxin botulinum. Only the manufacturing process for botulinum toxin can be patented, for which Daewoong has obtained a U.S. patent. Our trade secrets and other confidential proprietary information and those of our licensors could be disclosed or competitors could otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we or any of our current or future licensors may encounter significant problems in protecting and defending our or their intellectual property both in the United States and internationally. If we or any of our current or future licensors are unable to prevent material disclosure of the non-patented intellectual property related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could adversely affect our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by trademarks, confidentiality agreements and proprietary know-how, we may in the future rely upon in-licensed patents for any future product offerings. The strength of patents we may in-license in the technology and healthcare fields involves complex legal and scientific questions and can be uncertain. The patent applications that we may in-license may fail to result in issued patents with claims that cover any of our future product candidates in the United States or in other foreign countries, and the issued patents that we may in-license may be declared invalid or unenforceable. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are reliant on the ability of Daewoong, as the licensor of our only product, and will be reliant on future licensors of any future product candidates, to maintain their intellectual property and protect their intellectual property against misappropriation, infringement or other violation. We may not have primary control over our future licensors&#8217; patent prosecution activities. Furthermore, we may not be allowed to comment on prosecution strategies, and patent applications may be abandoned by the patent owner without our knowledge or consent. With respect to patents that are issued to our licensors, or patents that may be issued on patent applications, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. As a licensee, we are reliant on Daewoong and our future licensors to defend any third-party claims. Our licensors may not defend or prosecute such actions as vigorously or in the manner that we would have if entitled to do so, and we will be subject to any judgment or settlement resulting from such actions. Also, a third-party may challenge the validity of our in-licensing transactions. Furthermore, even if they are unchallenged, any of our future in-licensed patents and patent applications may not adequately protect the licensors or our intellectual property or prevent others from designing around their or our claims.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property or the patents and other intellectual property of our licensors, which could be expensive and time-consuming. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our intellectual property, including any future patents we may acquire, or the patents and other intellectual property of our licensors, including Daewoong. As a result, we or any of our current or future licensors may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or any of our current or future licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse determination of any litigation or other proceedings could put one or more of such patents at risk of being invalidated or interpreted narrowly. Interference, derivation or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to any of our future patent applications or those of our licensors or collaborators. Litigation or USPTO proceedings brought by us or any of our current or future licensors may fail or may be invoked against us or our licensors by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management or the management of any of our current or future licensors, including Daewoong. We may not be able, alone or with any of our current or future licensors or collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, or in-license needed technology or other product candidates. There could also be public announcements of the results of the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States and in some cases may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from using our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreign intellectual property laws. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, collaborators, consultants, advisors and other third parties. We expect to enter into confidentiality and invention assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts within and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at other pharmaceutical or medical aesthetic companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defend against these claims. We may not be successful in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Any litigation or the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could diminish or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold intellectual property, including patent rights that are important or necessary to the development of our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are using trademarks or trade names that are confusingly similar to their marks. If any third party were able to establish that our trademarks or trade names were infringing their marks, that third party may be able to block our ability to use the infringing trademark or trade name. In addition, if a third party were to bring such a claim, we would be required to dedicate time and resources to fight the claim, which time and resources could otherwise be used toward the maintenance of our own intellectual property.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may request and obtain injunctive or other equitable relief, which could prevent our ability to use the subject trademarks or trade names. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement. We may be required to re-brand one or more of our products, product candidates, or services offered under the infringing trademark or trade name, which may require substantial time and monetary expenditure. Third parties could claim senior rights in marks which might be enforced against our use of trademarks or trade names, resulting in either an injunction prohibiting our sales under those trademarks or trade names.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and products are subject to extensive government regulation. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the United States, the EU, Canada and other countries, principally by the FDA, the U.S. Drug Enforcement Administration, the Centers for Disease Control and Prevention, the EMA and other similar regulatory authorities. Daewoong is also subject to extensive regulation by the FDA and the South Korean regulatory authorities as well as other regulatory authorities. Our failure to comply with all applicable regulatory requirements, or Daewoong&#8217;s failure to comply with applicable regulatory requirements, including those promulgated under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and the Controlled Substances Act, may subject us to operating restrictions and criminal prosecution, monetary penalties and other enforcement or administrative actions, including, sanctions, warnings, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, or exclusion from future participation in the Medicare and Medicaid programs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following regulatory approval, we, and our direct and indirect suppliers, including Daewoong, remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to confirm that we are in compliance with all applicable regulations. Adverse findings during regulatory inspections may result in requirements that we implement REMS programs, requirements that we complete government mandated clinical trials, and government enforcement actions including those relating to labeling, advertising, marketing and promotion, as well as regulations governing manufacturing controls. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not obtain regulatory approval for the commercialization of any future product candidates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, with regulations differing from country to country. If we, our products or the manufacturing facilities for our products fail to comply with applicable regulatory requirements, a regulatory agency may:</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on the marketing or manufacturing of the product, suspend or withdraw product approvals or revoke necessary licenses;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters, show cause notices or untitled letters describing alleged violations, which may be publicly available;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commence criminal investigations and prosecutions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose injunctions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose other civil or criminal penalties;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or refuse to approve pending applications or supplements to approved applications filed by us;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to permit drugs or active ingredients to be imported or exported;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, the EMA or other similar foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we and our collaborators believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA and other similar regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA, the EMA or other similar regulatory authorities delaying or denying approval of a product candidate for any or all targeted indications. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approval of a BLA or BLA supplement, marketing authorization application, or MAA, or other product approval is not guaranteed, and the approval process is expensive and may take several years. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process. Despite the time and expense expended, failure can occur at any stage, and we could encounter problems that cause us to abandon, modify or repeat clinical trials, or perform additional preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for the FDA, the EMA or other regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. The FDA, the EMA and other regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be deemed safe, effective, pure or potent;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data from preclinical studies and clinical trials may not be deemed sufficient;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities might not approve our third-party manufacturers&#8217; processes or facilities; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deficiencies in the formulation, quality control, labeling, or specifications of a product candidate or in response to citizen petitions or similar documents filed in connection with the product candidate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general requirements intended to address risks associated with a class of drugs, such as a new REMS requirement for neurotoxins;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the enactment of new laws or promulgation of new regulations that change the approval requirements; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities may change their approval policies or adopt new regulations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain approval, our business and results of operations will be materially and adversely harmed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, limit or delay regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any other approved products are subject to continual regulatory review by the FDA, the EMA and other similar regulatory authorities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we or our collaborators receive for any future product candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any other future product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP requirements and compliance with good clinical practice, or GCP, requirements, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; fines, warning letters or holds on clinical trials; refusal by the FDA, the EMA or other similar regulatory authorities to approve pending applications or supplements to approved applications filed by us or our strategic collaborators or suspension or revocation of product license approvals; product seizure or detention or refusal to permit the import or export of products; and injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain regulatory approvals in foreign jurisdictions for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any future product candidates, we will be unable to market our products outside of the United States. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we are and will be subject to a variety of foreign regulations governing manufacturing, clinical trials, commercial sales and distribution of our future products. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive necessary approvals to commercialize our products in markets outside of the United States. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any future products may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so, we could be subject to sanctions that would materially harm our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some participants in our clinical trials have reported adverse events after being treated with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If we are successful in commercializing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any other product candidate, the FDA and other regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events that we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA, the EMA or other similar regulatory authorities could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may in the future be subject to various U.S. federal and state laws pertaining to health care fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not expect that Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will subject us to the various U.S. federal and most state laws intended to prevent health care fraud and abuse, we may in the future become subject to such laws. The Anti-Kickback Statute prohibits the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state health care programs as well as private payors. Violations of anti-kickback and other applicable laws can result in exclusion from federal health care programs and substantial civil and criminal penalties. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act, or FCA, imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. Some state law equivalents of the above federal laws, such as the Anti-Kickback Statute and FCA, apply to items or services regardless of whether the good or service was reimbursed by a government program, so called all-payor laws. These all-payor laws could apply to our sales and marketing activities even if the Anti-Kickback Statute and FCA laws are inapplicable.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our marketing or other arrangements were determined to violate anti-kickback or related laws, including the FCA or an all-payor law, then we could be subject to penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment or the curtailment or restructuring of our operations, any of which could materially and adversely affect our ability to operate our business and our financial results. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and federal authorities have aggressively targeted pharmaceutical companies for alleged violations of these anti-fraud statutes, based on improper research or consulting contracts with doctors, certain marketing arrangements with pharmacies and other healthcare providers that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices. Companies targeted in such prosecutions have paid substantial fines, have been ordered to implement extensive corrective action plans, and have in many cases become subject to consent decrees severely restricting the manner in which they conduct their business, among other consequences. Additionally, federal and state regulators have brought criminal actions against individual employees responsible for alleged violations. If we become the target of such an investigation or prosecution based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the FCPA and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. Our internal control policies and procedures may not protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or regulatory healthcare reforms in the United States and other countries may make it more difficult and costly </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">for us to obtain regulatory clearance or approval of any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is drafted and introduced in the U.S. Congress or other countries that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, regulations and guidance are often revised or reinterpreted by the FDA and other regulatory authorities in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future product candidates. Such changes could, among other things, require changes to manufacturing or marketing methods, changes to product labeling or promotional materials, recall, replacement, or discontinuance of one or more of our products; and additional recordkeeping.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationship with Alphaeon and Alphaeon 1, LLC</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our directors may have actual or potential conflicts of interest because of their ownership of debt and equity securities in AEON Biopharma, Inc., or AEON and Alphaeon 1, LLC and their positions with AEON and Alphaeon 1, LLC. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our initial public offering in 2018, we were wholly owned by AEON (previously known as ALPHAEON Corp.). In January 2020, AEON transferred all of their stock ownership in us to Alphaeon 1, LLC. As of September 30, 2022, Alphaeon 1, LLC owned 10.8% of our outstanding shares of common stock. Vikram Malik, Simone Blank, and Robert Hayman serve on our board of directors. Such directors or entities they are affiliated with currently own and may in the future own equity, debt or convertible debt of AEON and Alphaeon 1, LLC, which we refer to collectively as the Alphaeon entities. These individuals&#8217; or entities&#8217; holdings of debt or equity securities, options to purchase shares of Alphaeon entities or other equity awards in the Alphaeon entities may be significant for some of these persons or entities compared to these persons&#8217; or entities&#8217; total assets. Additionally, each of Mr. Malik, and Ms. Blank serve on the board of directors of Alphaeon and board of managers of Alphaeon 1, LLC. Their positions at the Alphaeon entities and the ownership of any Alphaeon entity equity, debt or equity awards may create, or may create the appearance of, conflicts of interest when these directors are faced with decisions that could have different implications for the Alphaeon entities than the decisions have for us. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decisions include corporate opportunities; the impact that operating decisions for our business may have on the Alphaeon entities&#8217; consolidated financial statements; the impact that operating or capital decisions (including the incurrence of indebtedness) for our business may have on the Alphaeon entities&#8217; current or future indebtedness or the covenants under that indebtedness; the timing and amount of financing efforts, whether they are debt or equity, and the amount of resulting dilution to existing shareholders; business combinations involving us; our dividend policy; and management stock ownership.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, disputes may arise between Alphaeon entities and us relating to our past and ongoing relationship, and these potential conflicts of interest may make it more difficult for us to favorably resolve such disputes, including those related to indemnification and other matters arising from our initial public offering and sales or other disposal by Alphaeon 1, LLC of all or a portion of its ownership interest in us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to resolve any potential conflicts, and even if we do, the resolution may be less favorable to us than if we were dealing with an unaffiliated party. While we are not controlled by the Alphaeon entities, we may not have the leverage to negotiate amendments to these agreements, if required, on terms as favorable to us as those we would negotiate with an unaffiliated third party.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AEON and its directors and officers will have limited liability to us or you for breach of fiduciary duty. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that, subject to any contractual provision to the contrary, AEON has no obligation to refrain from: engaging in the same or similar business activities or lines of business as we do; doing business with any of our clients or consumers; or employing or otherwise engaging any of our officers or employees.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides for the allocation of certain corporate opportunities between us and AEON. Under these provisions, neither AEON nor its other affiliates, nor any of their officers, directors, agents, stockholders, members, partners and subsidiaries, will have any obligation to present to us certain corporate opportunities. For example, a director or </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">officer of our company who also serves as a director, officer or employee of AEON or any of its other affiliates may present to AEON certain acquisitions, in-licenses, potential development programs or other opportunities that may be complementary to our business, if he or she was not offered such corporate opportunity in his or her capacity as our director or officer, and, as a result, such opportunities may not be available to us. To the extent attractive corporate opportunities are allocated to AEON or its other affiliates instead of to us, we may not be able to benefit from these opportunities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under our certificate of incorporation, neither AEON nor any officer or director of AEON, except as provided in our certificate of incorporation, will be liable to us or to our stockholders for breach of any fiduciary or other duty by reason of any of these activities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, AEON no longer held any shares of our stock.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medytox, Alphaeon 1, LLC and Daewoong each own a significant portion of our common stock and may exert significant control over our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had 56,183,414 shares of common stock issued and outstanding as of September 30, 2022. As of September 30, 2022, Medytox owned 13.0% of our outstanding shares of common stock, Alphaeon 1, LLC owned 10.8% of our outstanding shares of common stock, and Daewoong owned 5.6% of our outstanding shares of common stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This concentrated ownership position may provide any one of Medytox, Alphaeon 1, LLC or Daewoong with influence in determining the outcome of corporate actions requiring stockholder approval, including the election and removal of directors. The significant stock ownership by Medytox, Alphaeon 1, LLC and Daewoong may also discourage transactions involving a change-of-control of our company, including transactions in which you as a holder of our common stock might otherwise receive a premium for your shares.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities class action and derivative lawsuits have been filed against us and certain of our officers and directors, which could result in substantial costs and could divert management attention.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Part II, Item 1. &#8220;Legal Proceedings&#8221; we and certain of our officers have been named as defendants in a securities class action lawsuit and we are a nominal defendant in derivative lawsuits filed against certain of our officers and directors. We maintain director and officer&#8217;s insurance coverage and continue to engage in vigorous defense of such litigation. If we are not successful in our defense of such litigation, we could be forced to make significant payments to or other settlements with our stockholders and their lawyers outside of our insurance coverage, and such payments or settlement arrangements could have a material adverse effect on our business, operating results or financial condition. We may also be the target of this type of litigation in the future, as companies that have experienced volatility in the market price of their stock have been subject to securities act litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the claims asserted in these lawsuits are not successful, the litigation could result in substantial costs and significant adverse impact on our reputation and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, operating results or financial condition.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The trading price of our common stock has been volatile, and purchasers of our common stock could incur substantial losses. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is volatile. For example, the closing price of our common stock during the nine months ended September 30, 2022 has ranged from a low of $5.22 to a high of $13.94. The stock market in general and the market for earlier stage pharmaceutical and medical aesthetic companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, some of which are beyond our control, including: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public&#8217;s reaction to our earnings releases, other public announcements and filings with the SEC or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any termination or loss of rights under the Daewoong Agreement;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other U.S. or foreign regulatory or legal actions or changes affecting us or our industry;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning our manufacturer or any future strategic partnerships;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments affecting our compliance with the Medytox/Allergan Settlement Agreements or Daewoong&#8217;s ability to satisfy its reimbursement obligations to us with respect to the royalties payable to Medytox and Allergan;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning litigation pending against us;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introductions and announcements of new technologies and products by us, any commercialization partners or our competitors, and the timing of these introductions and announcements;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">success or failure of competitive products or medical aesthetic products generally;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of results of clinical trials or regulatory approval or disapproval of product candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated safety concerns related to the use of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our future products;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, new product approvals and introductions, joint ventures or capital commitments;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall financial market conditions for the pharmaceutical and biopharmaceutical sectors and issuance of securities analysts&#8217; reports or recommendations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rumors and market speculation involving us or other companies in our industry;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">short selling of our common stock or the publication of opinions regarding our business prospects in a manner that is designed to create negative market momentum;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of substantial amounts of our stock by Medytox, Alphaeon 1, LLC, Daewoong or other significant stockholders or our insiders, or the expectation that such sales might occur;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">news reports relating to trends, concerns and other issues in medical aesthetics market or the pharmaceutical or biopharmaceutical industry;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating and stock performance of other companies that investors deem comparable to us and overall performance of the equity markets;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel, including our Chief Executive Officer, Chief Financial Officer, and Chief Medical Officer; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property, product liability or other litigation against us, our manufacturer or other parties on which we rely or litigation against our general industry;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting standards, policies, guidelines, interpretations or principles; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic conditions in the markets in which we operate, including those related to COVID-19 and the Russian-Ukrainian conflict; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the market for pharmaceutical, biotechnology and medical aesthetics companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the overall market and the market prices of a particular company&#8217;s securities, securities class action litigation has often been instituted against that </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company. We may become the target of this type of litigation in the future. Securities litigation, if instituted against us, could result in substantial costs and divert our management&#8217;s attention and resources from our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our common stock by us, Medytox, Alphaeon 1, LLC, Daewoong or others, or the perception that such sales may occur, could depress the market price of our common stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by us of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could significantly reduce the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as discussed above, each of Medytox, Alphaeon 1, LLC and Daewoong owns a significant portion of our outstanding shares of common stock. Subject to the restrictions described in the paragraph below, future sales of these shares in the public market will be subject to certain contractual limitations in the case of shares of our common stock owned by Medytox and the volume and other restrictions of Rule 144 under the Securities Act for so long as Medytox, Alphaeon 1, LLC or Daewoong are deemed to be our affiliate, unless the shares to be sold are registered with the SEC. Additionally, the shares of common stock held by Medytox are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates prohibit Medytox from transferring more than 25% of the shares it holds prior to September 16, 2023, more than 50% of the shares it holds prior to September 16, 2024 and more than 75% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025. The sale by Medytox, Alphaeon 1, LLC or Daewoong of a substantial number of shares of our common stock, or a perception that such sales could occur, could significantly reduce the market price of our common stock. For example, in September 2021, Alphaeon 1, LLC sold 2,597,475 shares of our common stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed a registration statement with the SEC covering shares of our common stock available for future issuance under our&#160;2017 Omnibus Incentive Plan and may file future registration statements covering shares of our common stock for future issuance under any future plans. Upon effectiveness of such registration statements, any shares subsequently issued under such plans will be eligible for sale in the public market, except to the extent that they are restricted by the contractual arrangements discussed above and subject to compliance with Rule 144 in the case of our affiliates. Sales of a large number of the shares issued under these plans in the public market, or a perception that such sales could occur, could significantly reduce the market price of our common stock. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our certificate of incorporation and bylaws, as well as Delaware law, could discourage a takeover.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation, bylaws and Delaware law contain provisions that might enable our management to resist a takeover and might make it more difficult for an investor to acquire a substantial block of our common stock. These include the following provisions:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit our board of directors to issue shares of preferred stock, with any rights, preferences and privileges as they may designate, without stockholder approval, which could be used to dilute the ownership of a hostile bidder significantly;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the authorized number of directors may be changed only by resolution of our board of directors and that a director may only be removed for cause by the affirmative vote of the holders of at least 66 2/3% of our voting stock;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divide our board of directors into three classes, with each class serving staggered three-year terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice, which may discourage or deter a potential </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors, which may delay the ability of our stockholders to force consideration by our company of a take-over proposal or to take certain corporate actions, including the removal of directors.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This provision could have the effect of delaying or preventing a change-of-control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the&#160;sole and exclusive forum&#160;for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the&#160;sole and exclusive forum&#160;for all &#8220;internal corporate claims.&#8221; &#8220;Internal corporate claims&#8221; are claims that are based upon a violation of a duty by a current or former director, officer or stockholder in such capacity, or as to which Title 8 of the DGCL confers jurisdiction upon the Court of Chancery of the State of Delaware, or the Court of Chancery, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. For example, this choice of forum provision would not apply to claims brought pursuant to the Exchange Act or the Securities Act of 1933, as amended, or any other claim for which the federal courts have exclusive jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our certificate of incorporation. The choice of forum provision in our certificate of incorporation will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation and bylaws provide that we can indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Separate indemnity agreements have been issued with each director and executive officer.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as permitted by Section 145 of the DGCL, our bylaws and our indemnification agreements that we have entered into with our directors and officers, among other things provide that:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have indemnified our directors and officers for serving us in those capacities, or for serving as a director, officer, employee or agent of other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that we may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interest and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will be required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rights conferred in our bylaws will not be exclusive. We may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company,&#8221; and the reduced reporting requirements available to emerging growth companies could make our common stock less attractive to investors.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We qualify as an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies. These provisions include, but are not limited to:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">being permitted to have only two years of audited financial statements and only two years of related selected financial data and management&#8217;s discussion and analysis of financial condition and results of operations disclosure;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure about executive compensation arrangements in our periodic reports, registration statements and proxy statements; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemptions from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we take advantage of any of these exemptions, the information that we provide stockholders may be different than what is available with respect to other public companies. Investors may find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including exemption from compliance with the auditor attestation requirements of Section 404(b) as long as we do not otherwise also qualify as an &#8220;accelerated filer&#8221; or &#8220;large accelerated filer&#8221; for SEC reporting purposes and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Investors could find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our trading price may be more volatile.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts publish unfavorable research about our business or decrease the frequency or cease to provide coverage of our company, our stock price and trading volume could decline.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that equity research analysts publish about us and our business. If one or more of the equity research analysts who cover us downgrades our common stock or issues other unfavorable commentary or research the price of our common stock may decline. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause the trading price or trading volume of our common stock to decline.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future, and the payment of dividends is also restricted under our credit facility. The payment of dividends on our common stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant. If we do not pay dividends, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain executive management and qualified board members.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Nasdaq Marketplace Rules and other applicable securities rules and regulations. Complying with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources, particularly after we are no longer an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may need to hire more employees in the future or engage outside consultants to assist us in complying with these requirements, which will increase our costs and expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased selling, general and administrative expenses and a diversion of our management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_100"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_103"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_106"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="idfe4cc3337b24bc380d09a49794cd329_109"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. &#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. &#160;&#160;&#160;&#160; Exhibits. </span></div><div style="margin-bottom:10pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-top:5pt;padding-right:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed Herewith<br/>(x)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit318-k21218.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/12/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit328-k21218.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-38381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/12/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="sandrabeaveremploymentagre.htm">Employment Agreement, dated September 5, 2022, by and between Sandra Beaver and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q32022.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q32022.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q32022.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information in Exhibit 32.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report on Form 10-Q), unless the Registrant specifically incorporates the foregoing information into those documents by reference.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="idfe4cc3337b24bc380d09a49794cd329_115"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idfe4cc3337b24bc380d09a49794cd329_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.303%"><tr><td style="width:1.0%"></td><td style="width:4.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolus, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 8, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Moatazedi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Moatazedi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 8, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sandra Beaver</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Beaver</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>sandrabeaveremploymentagre.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1ec957f4d2144458b7877b7d18d928b5_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:36px;margin-bottom:5pt;vertical-align:text-bottom;width:145px"></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Employment Agreement is between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Evolus, Inc.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and Sandra Beaver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> an individual (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). This Agreement is entered into effective as of September 5, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">POSITION AND RESPONSIBILITIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;text-decoration:underline">Position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Employee shall be employed by the Company to render services to the Company in the position of Chief Financial Officer of the Company on the terms set forth in this Employment Agreement (the period of time Employee is employed with the Company on and after the Effective Date is referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Period of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). During the Period of Employment, Employee shall report directly to the Company&#8217;s President and Chief Executive Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Employee shall use Employee&#8217;s good faith efforts to perform Employee&#8217;s duties and responsibilities to the Company and such additional responsibilities (consistent with Employee&#8217;s position with the Company) as the CEO now or hereafter assigns to Employee. The principal place of Employee&#8217;s employment during the Period of Employment shall be the Company&#8217;s executive offices (currently located in Orange County, California) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company Offices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Other Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Period of Employment, Employee shall (i) devote substantially all of Employee&#8217;s business time and energy to the performance of Employee&#8217;s duties for the Company and (ii) hold no other employment.  Employee&#8217;s service on the boards of directors (or similar body) of other business entities is subject to the prior written approval of the CEO.  The Company shall have the right to require Employee to resign from any board or similar body (including, without limitation, any association, corporate, civic or charitable board or similar body) which Employee may then serve if the CEO reasonably determines that Employee&#8217;s service on such board or body interferes with the effective discharge of Employee&#8217;s duties and responsibilities to the Company or that any business related to such service is then in direct or indirect competition with any business of the Company or any of its affiliates, successors or assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;text-decoration:underline">No Breach of Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Employee hereby represents to the Company and agrees that&#58; (i) the execution and delivery of this Agreement by Employee and the Company and the performance by Employee of Employee&#8217;s duties and responsibilities to the Company do not and shall not constitute a breach of, conflict with, or otherwise contravene or cause a default under, the terms of any other agreement or policy to which Employee is a party or otherwise bound or any judgment, order or decree to which Employee is subject&#59; (ii) Employee is not bound by any employment, consulting, non-compete, non-solicitation, confidentiality, trade secret or similar agreement (other than this Employment Agreement) with any other person (other than ongoing, customary confidentiality obligations as to confidential information obtained from prior employers in the course of Employee&#8217;s prior employment with them)&#59; (iii) to the extent Employee has any confidential or similar information that Employee is not free to disclose to the Company, Employee will not disclose or bring on to the Company&#8217;s premises, computer networks, communications or systems, computers or any other devices or accounts, any such information to the extent such disclosure or transmission would violate applicable law or any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other agreement or policy to which Employee is a party or by which Employee is otherwise bound&#59; and (iv) Employee understands the Company will rely upon the accuracy and truth of the representations and warranties of Employee set forth herein and Employee consents to such reliance. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">COMPENSATION AND BENEFITS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company shall pay Employee a salary during the Period of Employment at the rate of Four Hundred and Twenty Thousand dollars ($420,000) per year (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Base Salary shall be paid in accordance with the Company&#8217;s regularly established payroll practices as in effect from time to time. Employee&#8217;s Base Salary shall be reviewed from time to time (not less frequently than annually commencing in 2023) in accordance with the established procedures of the Company for adjusting salaries for similarly situated employees and may be increased, but not decreased, in the sole discretion of the Company&#8217;s board of directors or a committee thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Sign-On Bonus. Employee will be eligible to receive a sign-on bonus of One Hundred Thousand Dollars ($100,000) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sign-On Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on the terms and conditions set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Sign-On Bonus will be paid within 60 days of Employee&#8217;s start date, provided Employee is employed with the Company at the time of such payment. If Employee satisfies the foregoing conditions and Employee remains employed by the Company for one year after Employee&#8217;s first day of employment by the Company, then 50% of the Sign-On Bonus will be considered earned and vested.  If Employee satisfies the foregoing conditions and Employee remains employed by the Company for two years after Employee&#8217;s first day of employment by the Company, then 100% of the Sign-On Bonus will be considered earned and vested.  If Employee ceases to be employed by the Company for any reason before the second anniversary of Employee&#8217;s first day of employment with the Company (other than a termination described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below), Employee agrees to pay to the Company (not later than sixty (60) days after the last day of Employment with the Company) any portion of the Sign-On Bonus that is not earned and vested (as set forth above) as of such last day of Employee&#8217;s employment with the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt;text-decoration:underline">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Period of Employment, Employee shall be eligible to participate in the Company&#8217;s annual discretionary incentive plan, under which Employee shall be eligible to receive an annual incentive bonus, as determined by the Board in its reasonable discretion (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), with a target annual bonus opportunity equal to forty percent (40)% of the Base Salary (with an agreed proration of 75% for the year 2022) based on and subject to 100% achievement of key performance indicators for Employee and the Company as determined by the Board. The terms of any written Annual Bonus plan developed by the Board shall govern any Annual Bonus that may be paid. Any Annual Bonus shall be paid in all events within two and one-half months after the end of the year in which such Annual Bonus becomes earned, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that no Annual Bonus shall be considered earned or payable unless, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Employee has remained continuously employed through the payment date of the Annual Bonus.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. From time to time the Board may grant long-term incentive awards (in the form of stock options, restricted stock units, performance stock units or other form of equity-based or other long-term incentive compensation) to Employee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In connection with Employee&#8217;s commencement of employment with the Company, the Company will grant Employee (i) an option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Restricted Stock Units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Option will be to purchase a number of shares of Company Common Stock equal to $1,125,000 divided by the Black-Scholes value of such an option (as determined by the Company using its regular stock option valuation methodology and assumptions, and subject to any value floor established by the Board for Company equity awards in that year generally) as of the first day of Employee&#8217;s employment with the Company.  The number of shares of Company Common Stock issued pursuant to your RSUs shall be equal to $375,000 divided by the 30-day average price of shares of the Company&#8217;s Common Stock (as determined by the Company using its regular restricted stock unit methodology and assumptions, and subject to any value floor established by the Board for Company equity awards in that year generally).  The number of shares subject to each of the Option and the RSUs will be subject to customary adjustments for stock splits, reverse splits, stock dividends and similar events after the date of grant.  The per share exercise price of the Option will equal the Nasdaq closing price (in regular trading) of a share of Company Common Stock on the date of grant of the Option (or as of the last Nasdaq trading day preceding the date of grant of the Option if such date of grant is not a Nasdaq trading day). The Option will have a maximum term of ten (10) years, subject to earlier termination as provided in the applicable option award agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Option and RSUs will each be granted on or promptly after Employee&#8217;s first day of employment with the Company in accordance with the Company&#8217;s standard practice, and such award will be scheduled to vest in equal annual installments over four years commencing with the date of grant of the award, subject in each case to Employee&#8217;s continuing employment with the Company through the applicable date of grant of the award (as to the grant of the award) or applicable vesting date (as to the vesting of the award). The Option and the RSUs will each be granted under an inducement equity incentive award and will be subject to such further terms and conditions as set forth in a written option award agreement and restricted stock unit agreement, to be entered into by the Company and Employee to evidence the awards.  The inducement equity incentive awards will be on terms consistent with the Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2017 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) except that the terms of the award will limit eligibility to new hire awards designed to qualify for the Nasdaq shareholder approval exception for inducement grants, and the form of option award agreement or restricted stock unit award used for option under the inducement grant will be consistent with the Company&#8217;s standard form of option award agreement and restricted stock unit award agreement used to grant employee such equity awards under the 2017 Plan.  Please note that future equity awards, if any, will be subject to Board approval, and Employee will not be considered for an additional equity award before January 2023.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Period of Employment, Employee shall be eligible to participate in the benefits made generally available by the Company to its other senior </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">executives, in accordance with and subject to the terms and conditions of the applicable benefit plans as they may be amended from time to time in the Company&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt;text-decoration:underline">Vacation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Employee&#8217;s vacation and other paid time off shall be governed by the Company&#8217;s usual policies applicable to senior management employees, as they may be amended from time to time in the Company&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company shall reimburse Employee for reasonable business expenses incurred, and for any other approved expenses incurred, in the performance of Employee&#8217;s duties hereunder in accordance with and subject to the Company&#8217;s customary expense reimbursement guidelines, as they may be amended from time to time in the Company&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Employment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As an employee of the Company, Employee shall be subject to and abide by the Company&#8217;s policies, procedures, practices, rules and regulations as adopted or as amended from time to time in the Company&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On or promptly after the date hereof and to the extent Employee is not already a party to such an agreement with the Company, the Company shall offer Employee the opportunity to enter into an Indemnification Agreement with the Company, on the form of Indemnification Agreement offered by the Company to its directors and other senior executives.  In addition, Employee shall be covered under a directors&#8217; and officers&#8217; liability insurance policy paid for by the Company both during and after (while there remains any potential liability to Employee) the termination of Employee&#8217;s employment to the extent that the Company maintains such a liability insurance policy at the applicable time for its active officers and directors and with the terms of such coverage to be consistent with the terms then in place as to the Company&#8217;s other senior executives or former senior executives, as the case may be.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">AT-WILL EMPLOYMENT&#59; TERMINATION BY COMPANY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.67pt;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Employee&#8217;s employment under this Agreement have no specific term. The Company may terminate Employee&#8217;s employment with the Company at will at any time upon written notice, with or without Cause or advance notice, for any reason or no reason at all, notwithstanding anything to the contrary contained in or arising from any statements, policies or practices of the Company relating to the employment, discipline or termination of its employees. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any of the following&#58; (a) the commission of any act of willful dishonesty by Employee in connection with the Company&#8217;s business or any act of fraud or embezzlement by Employee&#59; (b) a breach of the Company&#8217;s Employee Proprietary Information and Invention Agreement or a breach in any material respect by the Executive of any other contract the Employee is a party to with the Company&#59; (c) the refusal or omission by Employee to perform any lawful duties properly required Employee, provided that any such failure or refusal has been communicated to Employee in writing and Employee has been provided a reasonable opportunity to correct it, if correction is possible&#59; (d) any act or omission by Employee involving malfeasance or gross negligence in the performance of Employee&#8217;s duties to, or material deviation from any of the policies or directives of, the Company, provided, however, that in the case of deviations from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">policies or directives if a cure is not reasonably possible in the circumstances, (i) the Company must give Employee notice of such deviations within thirty (30) days of the Board becoming aware of such an occurrence, (ii) Employee must be given thirty (30) days to cure or correct the deviation, if curable, and (iii) Employee may only be terminated for Cause if the deviation remains uncured after thirty (30) days, if curable, following written notice and upon the approval of the Board&#59; (e) conduct on the part of Employee which constitutes the breach of any statutory or common law duty of loyalty to the Company&#59; or (f) any illegal act by Employee which the Board determines adversely affects the business of the Company, or any felony committed by Employee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">n.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination upon Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Employee&#8217;s employment under this Agreement shall terminate automatically upon Employee&#8217;s death or in the event that the Board determines in good faith that the Employee has a Disability. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a physical or mental impairment which, as reasonably determined by the Board, renders the Employee unable to perform the essential functions of his or her employment with the Company, even with reasonable accommodation that does not impose an undue hardship on the Company, for more than ninety (90) days in any 180-day period, unless a longer period is required by federal or state law, in which case that longer period would apply. The Employee agrees to reasonably cooperate with the Board in making any such determination as to the existence of a Disability.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">TERMINATION BY EMPLOYEE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee may terminate employment with the Company at any time upon written notice for any reason or no reason at all, with or without Good Reason. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any of the following which is not corrected by the Company within thirty (30) days after the Company has received written notice from Employee referring to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and specifying the circumstances purportedly constituting Good Reason and the correction sought (such notice to be given within thirty (30) days after the occurrence of such circumstance)&#58; (a) a material diminution in Employee&#8217;s title, duties, authorities, or responsibilities&#59;&#59; (b) a material reduction in Employee&#8217;s Base Salary or target level of Annual Bonus&#59; or (c) a material breach by the Company of any provision of this Agreement or any other agreement between the Company and Employee. Notwithstanding the foregoing, a termination of Employee&#8217;s employment with the Company shall not constitute a termination for Good Reason unless such termination occurs not more than ninety (90) days following the initial existence of the condition claimed to constitute good reason. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">TERMINATION OBLIGATIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">o.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Employee&#8217;s right to compensation and benefits under this Agreement, if any, upon termination of employment shall be determined in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">p.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">All Terminations of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon any termination of employment, Employee shall be entitled to prompt and full payment of all earned but unpaid Base Salary and accrued but unused vacation (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accrued Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Except as provided in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Employee&#8217;s rights following a termination of employment with respect to any benefits, incentives or awards provided to Employee pursuant to the terms of any plan, program or arrangement sponsored or maintained by the Company, whether tax-qualified or not (but excluding any severance plan, program or arrangement), which are not specifically addressed herein, shall be subject to the terms of such plan, program or arrangement, and this Agreement shall have no effect upon such terms except as specifically provided herein. Employee&#8217;s rights following a termination of employment with respect to any stock option, restricted stock unit, performance stock unit or other equity-based award that may be granted to Employee by the Company shall be governed by the applicable award agreement except as otherwise expressly provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Company acknowledges that any rights Employee may have to indemnification for actions taken as an officer or director under Company&#8217;s charter, other arrangements and its insurance policies shall not be forfeited or terminated upon a termination of Employee&#8217;s employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">q.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination of Employment by Company without Cause or by Employee for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the Company terminates Employee&#8217;s employment under this Agreement for any reason other than Cause (other than due to the Employee&#8217;s death or Disability), or Employee terminates Employee&#8217;s employment under this Agreement for Good Reason, and Employee satisfies the release requirements of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Qualified Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then in addition to the Accrued Benefits, Employee shall be entitled to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) a gross amount equal to (a) in the case of a Qualified Termination that occurs within three (3) months prior to, upon, or within twelve (12) months after a Change in Control (as such term is defined in the 2017 Plan), eighteen (18) months of Employee&#8217;s Base Salary (as in effect immediately prior to such termination of employment), or (b) in the case of any other Qualified Termination, twelve (12) months of Employee&#8217;s Base Salary (at the rate in effect immediately prior to the Severance Date), in each case payable in a lump sum on (or within ten (10) days after) the sixtieth (60th) day following the Employee&#8217;s last day of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Severance Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (provided that in the event of a Qualified Termination that occurs prior to a Change in Control and as to which the provisions of clause (a) above apply, the provisions of clause (a) above shall control but the payment to be made pursuant to clause (a) shall be made on the later of the date otherwise provided in clause (a) or the date of the Change in Control and such payment shall be reduced by any payments made, prior to the date of such payment pursuant to clause (a), pursuant to clause (b))&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) (a) in the case of a Qualified Termination that occurs within three (3) months prior to, upon, or within twelve (12) months after a Change in Control, one times Employee&#8217;s target Annual Bonus amount (at the rate in effect immediately prior to the Severance Date), payable in a lump sum on (or within ten (10) days after) the sixtieth (60th) day following the Severance Date, or (b) in the case of any other Qualified Termination, Employee shall be entitled to the Annual Bonus (if any) that Employee would have earned for the calendar year in which the Severance Date occurs (based on actual performance for such year), pro-rated based on the number of full months Employee was employed by the Company in that calendar year, payable at the time the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">normally pays Annual Bonuses after the close of the calendar year in which the Severance Date occurs (and in all events not later than two and one-half (2 &#189;) months after the end of such year) (provided that in the event of a Qualified Termination that occurs prior to a Change in Control and as to which the provisions of clause (a) above apply, the provisions of clause (a) above shall control but the payment to be made pursuant to clause (a) shall be made on the later of the date otherwise provided in clause (a) or the date of the Change in Control and such payment shall be reduced by any payments made, prior to the date of such payment pursuant to clause (a), pursuant to clause (b))&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) payment (at the time such Annual Bonus would otherwise be paid) of the Annual Bonus (if any) that Employee earned for the calendar year preceding the year in which the Severance Date occurs, to the extent not previously paid and disregarding the usual requirement to be employed on the bonus payment date&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) a lump sum payment of Fifteen Thousand Dollars ($15,000) as outplacement assistance, payable on (or within ten (10) days after) the sixtieth (60th) day following the Severance Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v) a lump sum payment, payable on (or within ten (10) days after) the sixtieth (60th) day following the Severance Date, of the amount Employee would be expected to pay in order to continue medical coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), at the same or reasonably equivalent medical coverage for Employee (and, if applicable, Employee&#8217;s eligible dependents) as in effect immediately prior to the Severance Date, for twelve (12) months following the Severance Date (or, if clause (i)(a) above applies, eighteen (18) months following the Severance Date) as calculated by the Company in good faith (provided that in the event of a Qualified Termination that occurs prior to a Change in Control, any additional amount due to Employee pursuant to this clause (iv) as a result of such Change in Control shall be paid on the date of the Change in Control)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi) in the case of a Qualified Termination that occurs within three (3) months prior to, upon or in connection with or within twelve (12) months after Change in Control, as to each stock option, restricted stock unit and other equity-based award granted by the Company to Employee that is outstanding immediately prior to the Severance Date, Employee shall fully vest in any time and service-based vesting conditions applicable to the award, with any performance-based vesting requirements to be treated as provided for in the applicable award agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, if Employee breaches his or her obligations under the Company&#8217;s Employee Proprietary Information and Invention Agreement at any time, from and after the date of such breach and not in any way in limitation of any right or remedy otherwise available to the Company, the Employee will no longer be entitled to, and the Company will no longer be obligated to pay, any remaining unpaid portion of the severance benefits provided herein or to any continued Company-paid or reimbursed coverage pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; provided that, if the Employee provides the release contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in no event shall the Employee be entitled to benefits pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of less than $5,000, which amount the parties agree is good and adequate consideration, in and of itself, for the Employee&#8217;s release contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">r.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt;text-decoration:underline">Other Terminations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon termination of Employee&#8217;s employment by Company for Cause, due to the Employee&#8217;s death or Disability, or by Employee for any reason other than Good Reason, Employee shall be entitled only to the compensation and benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and no severance compensation and benefits. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">s.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:28.34pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any and all amounts payable and benefits or additional rights provided pursuant to this Agreement upon a termination of employment (including the benefits provided for in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) beyond the Accrued Benefits shall only be payable if, and are subject to the condition precedent that, Employee delivers to the Company and does not revoke a general release of claims in favor of the Company in the form acceptable to the Company, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> such release does not purport to&#58; (i) revoke any of the rights provided pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement or rights to continued indemnification for actions taken as an officer or director prior to the termination of employment&#59; or (ii) impose upon Employee any new or additional restrictive covenants (such as new confidentiality, non-competition or non-solicitation obligations) that do not otherwise survive the termination of Employee&#8217;s employment. Such release must be executed by Employee on or after the Severance Date and delivered by Employee to the Company so that it is received by the Company no later than forty-five (45) days following the Severance Date (or such longer period to the extent required by law), and Employee must not revoke such release (or any portion thereof).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt;text-decoration:underline">Resignation and Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon any termination of employment, Employee agrees to resign, and hereby does resign, from all offices and directorships Employee then holds with the Company, including any such positions with its subsidiaries. Following a termination of employment, Employee shall cooperate reasonably in the orderly transfer of Employee&#8217;s duties to other employees. Employee shall also reasonably (after taking into account Employee&#8217;s post-termination responsibilities and obligations) cooperate with the Company in the defense of any action brought by any third party against the Company that relates to Employee&#8217;s employment by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">u.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Continuing Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Employee understands and agrees that Employee&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sections 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> herein (including the exhibits and schedules described therein) shall survive a termination of Employee&#8217;s employment and any termination of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Administrative Leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that the Company provides the Employee notice of termination without Cause pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or the Employee provides the Company notice of termination pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company will have the option to place the Employee on paid administrative leave during the notice period.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">INVENTIONS AND PROPRIETARY INFORMATION</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee agrees to sign and be bound by the terms of the Company&#8217;s standard employee proprietary information and invention assignment agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">ARBITRATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee agrees to sign and be bound by the terms of the Company&#8217;s standard employee Arbitration Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">ATTORNEYS&#8217; FEES AND COSTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In any dispute arising from or relating to this Agreement or Employee&#8217;s hiring, employment, compensation, benefits, or termination, the prevailing party shall be entitled to recover its reasonable attorneys&#8217; fees and costs.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">AMENDMENTS&#59; WAIVERS&#59; REMEDIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement may not be amended or waived except by a writing signed by Employee and by a duty authorized officer of the Company other than Employee. Failure to exercise any right under this Agreement shall not constitute a waiver of such right. Any waiver of any breach of this Agreement shall not operate as a waiver of any subsequent breaches. All rights or remedies specified for a party herein shall be cumulative and in addition to all other rights and remedies of the party hereunder or under applicable law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">ASSIGNMENT&#59; BINDING EFFECT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">w.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The performance of Employee is personal hereunder, and Employee agrees that Employee shall have no right to assign and shall not assign or purport to assign any rights or obligations under this Agreement. This Agreement may be assigned or transferred by the Company&#59; and nothing in this Agreement shall prevent the consolidation, merger or sale of the Company or a sale of any or all or substantially all of its assets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">x.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the foregoing restriction on assignment by Employee, this Agreement shall inure to the benefit of and be binding upon each of the parties&#59; the affiliates, officers, directors, agents, successors and assigns of the Company&#59; and the heirs, devisees, spouses, legal representatives and successors of Employee.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">NOTICES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All notices or other communications required or permitted hereunder shall be made in writing and shall be deemed to have been duly given if delivered&#58; (a) by hand&#59; (b) by a nationally recognized overnight courier service&#59; or (c) by United States first class registered or certified mail, return receipt requested, to the principal address of the other party, as set forth below. The date of notice shall be deemed to be the earlier of (i) actual receipt of notice by any permitted means, or (ii) five (5) business days following dispatch by overnight delivery service or the United States Mail. Employee shall be obligated to notify the Company in writing of any change in Employee&#8217;s address. Notice of change of address shall be effective only when done in accordance with this paragraph.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company&#8217;s Notice Address&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Evolus, Inc.<br>520 Newport Center Dr., Suite 1200<br>Newport Beach, California 92660</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Legal<br><br>Employee&#8217;s Notice&#58; to Employee at Employee&#8217;s address on file in the Company&#8217;s payroll records </font></div><div style="margin-bottom:12pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">SEVERABILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If any provision of this Agreement shall be held by a court or arbitrator to be invalid, unenforceable or void, such provision shall be enforced to the fullest extent permitted by law, and the remainder of this Agreement shall remain in full force and effect. In the event that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed the maximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall reduce the time period or scope to the maximum time period or scope permitted by law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">TAX MATTERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">y.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any and all amounts payable under this Agreement or otherwise shall be subject to, and the Company may withhold from such amounts, any federal, state, local or other taxes as may be required to be withheld pursuant to any applicable law or regulation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">z.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;text-decoration:underline">Section 409A Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">The intent of the parties hereto is that payments and benefits under this Agreement be exempt from (to the extent possible) Section 409A (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of the Internal Revenue Code of 1986 and the regulations and guidance promulgated thereunder, as amended (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith. To the extent that any provision hereof is modified in order to comply with Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to the parties hereto of the applicable provision without violating the provisions of Section 409A. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits that constitute &#8220;nonqualified deferred compensation&#8221; under Section 409A upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Section 409A and, for purposes of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">To the extent that reimbursements or other in-kind benefits under this Agreement constitute &#8220;nonqualified deferred compensation&#8221; for purposes of Section 409A, (A) all expenses or other reimbursements hereunder shall be made on or prior to the last day of the taxable year following the taxable year in which such expenses were incurred by Employee, (B) any right to reimbursement or in- kind benefits shall not be subject to liquidation or exchange for another benefit and (C) no such reimbursement, expenses eligible for reimbursement or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">For purposes of Section 409A, Employee&#8217;s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days, the actual date of payment within the specified period shall be at the sole discretion of the Board.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding any other provision of this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes &#8220;nonqualified deferred compensation&#8221; for purposes of Section 409A be subject to offset by any other amount unless otherwise permitted by Section 409A.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">Notwithstanding any other provision of this Agreement, to the extent required to avoid the imposition of tax, penalties or interest under Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided under this Agreement during the six- (6)-month period immediately following a termination of employment shall instead be paid on the first payroll date after the six (6)-month anniversary of the termination of employment (or Employee&#8217;s death, if earlier).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">aa.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.36pt;text-decoration:underline">Section 280G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Notwithstanding anything contained in this Agreement to the contrary, to the extent that the payments and benefits provided under this Agreement and benefits provided to, or for the benefit of, Employee under any other Company plan or agreement (such payments or benefits are collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) would be subject to the excise tax (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) imposed under Section 4999 of the Code, the Benefits shall be reduced (but not below zero) if and to the extent that a reduction in the Benefits would result in Employee retaining a larger amount, on an after-tax basis (taking into account federal, state and local income taxes and the Excise Tax), than if Employee received all of the Benefits (such reduced amount is referred to hereinafter as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Limited Benefit Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Unless Employee shall have given prior written notice specifying a different order to the Company to effectuate the Limited Benefit Amount, any such notice consistent with the requirements of Section 409A of the Code to avoid the imputation of any tax, penalty or interest thereunder, the Company shall reduce or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">eliminate the Benefits by first reducing or eliminating amounts which are payable from any cash severance, then from any payment in respect of an equity award that is not covered by Treas. Reg. Section 1.280G-1 Q&#47;A-24(b) or (c), then from any payment in respect of an equity award that is covered by Treas. Reg. Section 1.280G-1 Q&#47;A-24(c), in each case in reverse order beginning with payments or benefits which are to be paid the farthest in time from the Determination (as defined below). Any notice given by Employee pursuant to the preceding sentence shall take precedence over the provisions of any other plan, arrangement or agreement governing Employee&#8217;s rights and entitlements to any benefits or compensation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">A determination as to whether the Benefits shall be reduced to the Limited Benefit Amount pursuant to this Agreement and the amount of such Limited Benefit Amount shall be made by the Company&#8217;s independent public accountants or another certified public accounting firm or executive compensation consulting firm of national reputation designated by the Company and acceptable to Employee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) at the Company&#8217;s expense. The Firm shall provide its determination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), together with detailed supporting calculations and documentation to the Company and Employee within ten (10) business days of the date of termination of Employee&#8217;s employment, if applicable, or such other time as reasonably requested by the Company or Employee. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">GOVERNING LAW</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement shall be governed by and construed in accordance with the laws of the State of California.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">INTERPRETATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. Sections and section headings contained in this Agreement are for reference purposes only and shall not affect in any manner the meaning or interpretation of this Agreement. Whenever the context requires, references to the singular shall include the plural and the plural the singular.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">OBLIGATIONS SURVIVE TERMINATION OF EMPLOYMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each party agrees that any and all of such party&#8217;s obligations under this Agreement, including any agreement contemplated hereby, shall survive a termination of employment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">COUNTERPARTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement may be executed in any number of counterparts, and the signature pages may be transmitted by pdf or electronic means, each of which shall be deemed an original of this Agreement, but all of which together shall constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">AUTHORITY</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each party represents and warrants that such party has the right, power and authority to enter into and execute this Agreement and to perform and discharge all of the obligations hereunder&#59; and that this Agreement constitutes the valid and legally binding agreement and obligation of such party and is enforceable in accordance with its terms.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">ENTIRE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement is intended to be the final, complete and exclusive statement of the terms of Employee&#8217;s employment by the Company and may not be contradicted by evidence of any prior or contemporaneous statements or agreements, except for agreements specifically referenced herein (including the agreements referenced in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sections 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> above). To the extent that the practices, policies or procedures of the Company, now or in the future, apply to Employee and are inconsistent with the terms of this Agreement, the provisions of this Agreement shall control. Any subsequent change in Employee&#8217;s duties, position or compensation shall not affect the validity or scope of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">EMPLOYEE ACKNOWLEDGEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EMPLOYEE ACKNOWLEDGES THAT EMPLOYEE HAS HAD THE OPPORTUNITY TO CONSULT LEGAL COUNSEL CONCERNING THIS AGREEMENT, THAT EMPLOYEE HAS READ AND UNDERSTANDS THE AGREEMENT, THAT EMPLOYEE IS FULLY AWARE OF ITS LEGAL EFFECT AND THAT EMPLOYEE HAS ENTERED INTO IT FREELY BASED ON EMPLOYEE&#8217;S OWN JUDGMENT AND NOT ON ANY REPRESENTATIONS OR PROMISES OTHER THAN THOSE CONTAINED IN THIS AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;The remainder of this page has intentionally been left blank. The signature page follows on the next page.&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><div id="i1ec957f4d2144458b7877b7d18d928b5_4"></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:36px;margin-bottom:5pt;vertical-align:text-bottom;width:145px"></div></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By signing below, each of the parties hereto acknowledges and agrees to all of the terms of this Employment Agreement, effective as of the Effective Date.</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sandra Beaver (&#8220;Employee&#8221;)</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sign name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;Sandra Beaver&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EVOLUS, INC., a Delaware Corporation (the &#8220;Company&#8221;)</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sign name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;David Moatazedi&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> David Moatazedi&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> President and Chief Executive Officer&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311q32022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ieb186cf818664e0bbfd59199580b62df_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">I, David Moatazedi, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">I have reviewed this Quarterly Report on Form 10-Q of Evolus, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and&#160;15d-15(f))&#160;for the registrant and have&#58;</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:49.5pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">(b)&#160;&#160;&#160;&#160;Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:49.5pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:49.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 8, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Moatazedi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Moatazedi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312q32022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iada6b9165ce446309d4b7ecb35350b74_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">I, Sandra Beaver, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">I have reviewed this Quarterly Report on Form 10-Q of Evolus, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and&#160;15d-15(f))&#160;for the registrant and have&#58;</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:49.5pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">(b)&#160;&#160;&#160;&#160;Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:49.5pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:49.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:49.5pt;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:44.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 8, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sandra Beaver</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Beaver</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321q32022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i737ac4e5499f429fafa442739c4483c4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.&#160;&#167; 1350 AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the undersigned hereby certifies, in accordance with 18 U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, in his or her capacity as an officer of Evolus, Inc., that, to his or her knowledge&#58; </font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Quarterly Report on Form&#160;10-Q of Evolus, Inc. for the quarter ended September 30, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Evolus, Inc.</font></div><div style="margin-top:12pt;text-indent:27pt"><font><br></font></div><div style="padding-left:12.37pt;padding-right:12.37pt;text-align:center;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:43.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.513%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 8, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Moatazedi</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Moatazedi</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 8, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sandra Beaver</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Beaver</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>eols-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9907a7dd-9da5-4da3-a916-5b93970552d6,g:d423565a-304b-425b-af42-a6f72195e86c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:eols="http://www.evolus.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolus.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.evolus.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.evolus.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.evolus.com/role/DescriptionofBusiness">
        <link:definition>0000007 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestments" roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments">
        <link:definition>0000009 - Disclosure - Fair Value Measurements and Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000010 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.evolus.com/role/AccruedExpenses">
        <link:definition>0000011 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoans" roleURI="http://www.evolus.com/role/TermLoans">
        <link:definition>0000012 - Disclosure - Term Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DaewoongConvertibleNote" roleURI="http://www.evolus.com/role/DaewoongConvertibleNote">
        <link:definition>0000013 - Disclosure - Daewoong Convertible Note</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.evolus.com/role/OperatingLeases">
        <link:definition>0000014 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.evolus.com/role/CommitmentsandContingencies">
        <link:definition>0000015 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.evolus.com/role/StockholdersEquity">
        <link:definition>0000016 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedytoxAllerganSettlementAgreementsandDaewoongArrangement" roleURI="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement">
        <link:definition>0000017 - Disclosure - Medytox/Allergan Settlement Agreements and Daewoong Arrangement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000018 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsTables" roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables">
        <link:definition>0000019 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000020 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.evolus.com/role/AccruedExpensesTables">
        <link:definition>0000021 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoansTables" roleURI="http://www.evolus.com/role/TermLoansTables">
        <link:definition>0000022 - Disclosure - Term Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.evolus.com/role/OperatingLeasesTables">
        <link:definition>0000023 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.evolus.com/role/StockholdersEquityTables">
        <link:definition>0000024 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.evolus.com/role/DescriptionofBusinessDetails">
        <link:definition>0000025 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails">
        <link:definition>0000027 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails">
        <link:definition>0000028 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsContingentRoyaltyObligationDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsContingentRoyaltyObligationDetails">
        <link:definition>0000029 - Disclosure - Fair Value Measurements and Short-Term Investments - Contingent Royalty Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails">
        <link:definition>0000030 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1">
        <link:definition>0000030 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails">
        <link:definition>0000031 - Disclosure - Goodwill and Intangible Assets - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetNarrativeDetails" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails">
        <link:definition>0000032 - Disclosure - Goodwill and Intangible Asset - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" roleURI="http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails">
        <link:definition>0000033 - Disclosure - Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoansPharmakonTermLoansDetails" roleURI="http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails">
        <link:definition>0000034 - Disclosure - Term Loans - Pharmakon Term Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoansMaturitiesofDebtDetails" roleURI="http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails">
        <link:definition>0000035 - Disclosure - Term Loans - Maturities of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoansOxfordTermLoansDetails" roleURI="http://www.evolus.com/role/TermLoansOxfordTermLoansDetails">
        <link:definition>0000036 - Disclosure - Term Loans - Oxford Term Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DaewoongConvertibleNoteDetails" roleURI="http://www.evolus.com/role/DaewoongConvertibleNoteDetails">
        <link:definition>0000037 - Disclosure - Daewoong Convertible Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesNarrativeDetails" roleURI="http://www.evolus.com/role/OperatingLeasesNarrativeDetails">
        <link:definition>0000038 - Disclosure - Operating Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesLeaseCostDetails" roleURI="http://www.evolus.com/role/OperatingLeasesLeaseCostDetails">
        <link:definition>0000039 - Disclosure - Operating Leases - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" roleURI="http://www.evolus.com/role/OperatingLeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails">
        <link:definition>0000040 - Disclosure - Operating Leases - Schedule of Weighted-Average Remaining Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesOperatingLeaseMaturityDetails" roleURI="http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails">
        <link:definition>0000041 - Disclosure - Operating Leases - Operating Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesOperatingLeaseMaturityDetails_1" roleURI="http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails_1">
        <link:definition>0000041 - Disclosure - Operating Leases - Operating Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.evolus.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000042 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000043 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofValuationAssumptionsDetails" roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails">
        <link:definition>0000044 - Disclosure - Stockholders&#8217; Equity - Schedule of Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofStockOptionActivityDetails" roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails">
        <link:definition>0000045 - Disclosure - Stockholders&#8217; Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockUnitDetails" roleURI="http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails">
        <link:definition>0000046 - Disclosure - Stockholders&#8217; Equity - Restricted Stock Unit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockbasedCompensationExpenseAllocationDetails" roleURI="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails">
        <link:definition>0000047 - Disclosure - Stockholder's Equity - Stock-based Compensation Expense Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails" roleURI="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails">
        <link:definition>0000048 - Disclosure - Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eols_PaymentsOfContingentRoyaltyObligation" abstract="false" name="PaymentsOfContingentRoyaltyObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_ATMSalesAgreementMember" abstract="true" name="ATMSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_LineofCreditFacilityNumberofAdvances" abstract="false" name="LineofCreditFacilityNumberofAdvances" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_DebtInstrumentAmortizationPeriod" abstract="false" name="DebtInstrumentAmortizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_FollowOnOfferingMember" abstract="true" name="FollowOnOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_PharmakonTermLoansTwoMember" abstract="true" name="PharmakonTermLoansTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" abstract="false" name="DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="eols_PaymentsForInventory" abstract="false" name="PaymentsForInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" abstract="false" name="SaleOfStockCommissionPaymentUponGrossProceedsPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" abstract="false" name="AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DaewoongConvertibleNoteMember" abstract="true" name="DaewoongConvertibleNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" abstract="false" name="LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" abstract="false" name="ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DebtInstrumentNumberOfTranches" abstract="false" name="DebtInstrumentNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_DebtInstrumentFeeAmountWaived" abstract="false" name="DebtInstrumentFeeAmountWaived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_IntellectualPropertyDisputesJeuveauMember" abstract="true" name="IntellectualPropertyDisputesJeuveauMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_DebtInstrumentPeriodOfInterestOnlyPayments" abstract="false" name="DebtInstrumentPeriodOfInterestOnlyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_DebtInstrumentOfFinalPaymentAmountWaived" abstract="false" name="DebtInstrumentOfFinalPaymentAmountWaived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_SaleOfStockCommissionPaid" abstract="false" name="SaleOfStockCommissionPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentTermsAxis" abstract="true" name="DebtInstrumentPrepaymentTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="eols_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_StockIssuedForAccruedLitigationSettlementExpense" abstract="false" name="StockIssuedForAccruedLitigationSettlementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_OxfordTermLoanFacilityMember" abstract="true" name="OxfordTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_LesseeOperatingLeaseTerminationPeriod" abstract="false" name="LesseeOperatingLeaseTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" abstract="false" name="DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_AccountingPoliciesTable" abstract="true" name="AccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" abstract="false" name="DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_MilestonePaymentInConnectionWithAgreement" abstract="false" name="MilestonePaymentInConnectionWithAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentFeeAmountWaived" abstract="false" name="DebtInstrumentPrepaymentFeeAmountWaived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_RegistrationRightsAgreementSellingPeriod" abstract="false" name="RegistrationRightsAgreementSellingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_PharmakonTermLoansOneMember" abstract="true" name="PharmakonTermLoansOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_IncreaseDecreaseInAccruedLitigationSettlement" abstract="false" name="IncreaseDecreaseInAccruedLitigationSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_MilestonePaymentsForIntangibleAssets" abstract="false" name="MilestonePaymentsForIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_SaleOfStockMaximumConsiderationReceivable" abstract="false" name="SaleOfStockMaximumConsiderationReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_TermTwoMember" abstract="true" name="TermTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentFeePercentageThereafter" abstract="false" name="DebtInstrumentPrepaymentFeePercentageThereafter" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_TermThreeMember" abstract="true" name="TermThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" abstract="true" name="RestrictedStockUnitsRSUsPerformanceConditionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentFeePercentageYearTwo" abstract="false" name="DebtInstrumentPrepaymentFeePercentageYearTwo" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" abstract="false" name="DebtInstrumentNumberOfPeriodicPaymentsPrincipal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_StockIssuedDuringPeriodValuesLitigationSettlement" abstract="false" name="StockIssuedDuringPeriodValuesLitigationSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentAmountThreshold" abstract="false" name="DebtInstrumentPrepaymentAmountThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" abstract="false" name="LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentTermsDomain" abstract="true" name="DebtInstrumentPrepaymentTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_StockIssuedDuringPeriodSharesLitigationSettlement" abstract="false" name="StockIssuedDuringPeriodSharesLitigationSettlement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eols_LossContingencySettlementAgreementPaymentTerms" abstract="false" name="LossContingencySettlementAgreementPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" abstract="false" name="ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_IntangibleAssetsGrossIncludingGoodwill" abstract="false" name="IntangibleAssetsGrossIncludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_RestrictedStockUnitsRSUsMarketConditionsMember" abstract="true" name="RestrictedStockUnitsRSUsMarketConditionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_OxfordTermLoanFacilityTrancheTwoMember" abstract="true" name="OxfordTermLoanFacilityTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_ContingentRoyaltyObligationMember" abstract="true" name="ContingentRoyaltyObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_PharmakonTermLoansMember" abstract="true" name="PharmakonTermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" abstract="false" name="ShareIssuanceAgreementPercentageOfShareDisposePerYear" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_SCHAEONLLCMember" abstract="true" name="SCHAEONLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_DaewoongSettlementAgreementMember" abstract="true" name="DaewoongSettlementAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_EvolusIncMember" abstract="true" name="EvolusIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" abstract="false" name="DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_AccountingPoliciesLineItems" abstract="true" name="AccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eols_OxfordTermLoanFacilityTrancheOneMember" abstract="true" name="OxfordTermLoanFacilityTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_TermOneMember" abstract="true" name="TermOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>eols-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9907a7dd-9da5-4da3-a916-5b93970552d6,g:d423565a-304b-425b-af42-a6f72195e86c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="eols-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_39b3acb0-1143-461a-8efc-03ca0d8736e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_241abcf2-6797-4aba-8522-59175e465d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_39b3acb0-1143-461a-8efc-03ca0d8736e0" xlink:to="loc_us-gaap_StockholdersEquity_241abcf2-6797-4aba-8522-59175e465d97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2be80a88-2a6b-47b7-ae3f-8769791e3d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_39b3acb0-1143-461a-8efc-03ca0d8736e0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2be80a88-2a6b-47b7-ae3f-8769791e3d84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5a3ad13c-72bc-4852-ad95-7fad8011bb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_39b3acb0-1143-461a-8efc-03ca0d8736e0" xlink:to="loc_us-gaap_Liabilities_5a3ad13c-72bc-4852-ad95-7fad8011bb4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_874e3d8b-8a3e-4989-aacc-743a14e3106a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_baef94c0-934b-44e4-b127-7cd1d1fdfbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_874e3d8b-8a3e-4989-aacc-743a14e3106a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_baef94c0-934b-44e4-b127-7cd1d1fdfbd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ea00ab99-9eda-4f08-b656-0e3e4157a74c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_874e3d8b-8a3e-4989-aacc-743a14e3106a" xlink:to="loc_us-gaap_Goodwill_ea00ab99-9eda-4f08-b656-0e3e4157a74c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4f0ea791-3296-49f0-93e4-b9a9f29cc2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_874e3d8b-8a3e-4989-aacc-743a14e3106a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4f0ea791-3296-49f0-93e4-b9a9f29cc2c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_76526a39-8937-4df9-9843-b1ed882e1aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_874e3d8b-8a3e-4989-aacc-743a14e3106a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_76526a39-8937-4df9-9843-b1ed882e1aa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_557e7489-d609-43b2-9a8d-9735108f310c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_874e3d8b-8a3e-4989-aacc-743a14e3106a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_557e7489-d609-43b2-9a8d-9735108f310c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4012b7b1-70d2-425b-a7e9-5040ca195c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_874e3d8b-8a3e-4989-aacc-743a14e3106a" xlink:to="loc_us-gaap_AssetsCurrent_4012b7b1-70d2-425b-a7e9-5040ca195c56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_80dfc1b4-b110-4884-aa4e-d8d735486389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f9d86d1-12ab-4609-bf1e-056b215638dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80dfc1b4-b110-4884-aa4e-d8d735486389" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f9d86d1-12ab-4609-bf1e-056b215638dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_91b5bd74-460b-4110-8045-5e78de580d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80dfc1b4-b110-4884-aa4e-d8d735486389" xlink:to="loc_us-gaap_AdditionalPaidInCapital_91b5bd74-460b-4110-8045-5e78de580d01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c3e54326-441f-4bcb-b5ba-b461855dfb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80dfc1b4-b110-4884-aa4e-d8d735486389" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c3e54326-441f-4bcb-b5ba-b461855dfb1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7d97dfdf-e00b-4076-84ce-a7c28bea33e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80dfc1b4-b110-4884-aa4e-d8d735486389" xlink:to="loc_us-gaap_PreferredStockValue_7d97dfdf-e00b-4076-84ce-a7c28bea33e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cf0b9949-49aa-4cc6-852e-82e2237ec7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80dfc1b4-b110-4884-aa4e-d8d735486389" xlink:to="loc_us-gaap_CommonStockValue_cf0b9949-49aa-4cc6-852e-82e2237ec7bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_37cad2e8-32a5-4093-a97c-6b92bd366dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0d19994d-ac06-4b6c-b31a-319afc2d4c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37cad2e8-32a5-4093-a97c-6b92bd366dc1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0d19994d-ac06-4b6c-b31a-319afc2d4c71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_40d96053-27a9-47e5-90c8-eda2265b3709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37cad2e8-32a5-4093-a97c-6b92bd366dc1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_40d96053-27a9-47e5-90c8-eda2265b3709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_b37418ce-3778-467c-9b40-1e6b64e2ea1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37cad2e8-32a5-4093-a97c-6b92bd366dc1" xlink:to="loc_us-gaap_ContractualObligation_b37418ce-3778-467c-9b40-1e6b64e2ea1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_7a260f3a-26f6-4def-be5d-1be25f954222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37cad2e8-32a5-4093-a97c-6b92bd366dc1" xlink:to="loc_us-gaap_SecuredLongTermDebt_7a260f3a-26f6-4def-be5d-1be25f954222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_64ac2116-b9a3-4def-a99b-76c156762b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37cad2e8-32a5-4093-a97c-6b92bd366dc1" xlink:to="loc_us-gaap_LiabilitiesCurrent_64ac2116-b9a3-4def-a99b-76c156762b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_648a3bbb-64c9-4f40-96f8-9d8a6f971bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37cad2e8-32a5-4093-a97c-6b92bd366dc1" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_648a3bbb-64c9-4f40-96f8-9d8a6f971bea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_77c8c1f2-dee1-4c54-9877-3b88d6c8d193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_938d79ac-a3a0-4184-a26f-021821ae0155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_77c8c1f2-dee1-4c54-9877-3b88d6c8d193" xlink:to="loc_us-gaap_LitigationReserveCurrent_938d79ac-a3a0-4184-a26f-021821ae0155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f8cc1e24-bd00-42a5-8ede-9fc0436c8b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_77c8c1f2-dee1-4c54-9877-3b88d6c8d193" xlink:to="loc_us-gaap_AccountsPayableCurrent_f8cc1e24-bd00-42a5-8ede-9fc0436c8b19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_c190707f-612a-4ede-80f4-bc286cebbd78" xlink:href="eols-20220930.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_77c8c1f2-dee1-4c54-9877-3b88d6c8d193" xlink:to="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_c190707f-612a-4ede-80f4-bc286cebbd78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8dee850b-fe56-4b14-af71-471f4875295b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_77c8c1f2-dee1-4c54-9877-3b88d6c8d193" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8dee850b-fe56-4b14-af71-471f4875295b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_58d68cbe-7388-41d7-92cf-e354af1d10cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_77c8c1f2-dee1-4c54-9877-3b88d6c8d193" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_58d68cbe-7388-41d7-92cf-e354af1d10cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0f5d0485-f9b6-4f72-bca6-e0da77a8f31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b3516b2e-a897-4e0b-b2d3-b2bc8adf4ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0f5d0485-f9b6-4f72-bca6-e0da77a8f31a" xlink:to="loc_us-gaap_InventoryNet_b3516b2e-a897-4e0b-b2d3-b2bc8adf4ea5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_31c5d5fe-e74c-4922-9055-d7f5011f5152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0f5d0485-f9b6-4f72-bca6-e0da77a8f31a" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_31c5d5fe-e74c-4922-9055-d7f5011f5152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c478c36-3be8-492e-857c-b6d794e6da91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0f5d0485-f9b6-4f72-bca6-e0da77a8f31a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c478c36-3be8-492e-857c-b6d794e6da91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ccb8a22e-ad4f-4d19-ab51-a4083a1159b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0f5d0485-f9b6-4f72-bca6-e0da77a8f31a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ccb8a22e-ad4f-4d19-ab51-a4083a1159b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_51c02026-837c-49d0-a23a-89f85f5e6f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0f5d0485-f9b6-4f72-bca6-e0da77a8f31a" xlink:to="loc_us-gaap_OtherAssetsCurrent_51c02026-837c-49d0-a23a-89f85f5e6f59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="eols-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f84865d1-f901-4f09-ab55-0f9ac32e6866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2862a716-fc1f-4e1e-a20c-72be8772f1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f84865d1-f901-4f09-ab55-0f9ac32e6866" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2862a716-fc1f-4e1e-a20c-72be8772f1c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f9db9740-8505-4539-a8ad-0d674098c1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f84865d1-f901-4f09-ab55-0f9ac32e6866" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f9db9740-8505-4539-a8ad-0d674098c1ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_72eb4f1f-cbc2-4cb4-be01-10fdd2e3c6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f84865d1-f901-4f09-ab55-0f9ac32e6866" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_72eb4f1f-cbc2-4cb4-be01-10fdd2e3c6c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f523c402-f0e5-47c6-bd95-32a4e6a51abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f84865d1-f901-4f09-ab55-0f9ac32e6866" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f523c402-f0e5-47c6-bd95-32a4e6a51abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_81c2f9f4-0b1b-4733-8760-dc79e07ab2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f84865d1-f901-4f09-ab55-0f9ac32e6866" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_81c2f9f4-0b1b-4733-8760-dc79e07ab2c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6c9970ed-b169-4f06-ae87-0978ba49c0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f84865d1-f901-4f09-ab55-0f9ac32e6866" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6c9970ed-b169-4f06-ae87-0978ba49c0f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_1ef36187-c94d-4481-8bb1-aa408e613501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f84865d1-f901-4f09-ab55-0f9ac32e6866" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_1ef36187-c94d-4481-8bb1-aa408e613501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a9123ab1-1ea3-49b1-9980-a40a4239c659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3fbf7d9-caf3-4fd2-a3a1-751071d804d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a9123ab1-1ea3-49b1-9980-a40a4239c659" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3fbf7d9-caf3-4fd2-a3a1-751071d804d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c8c5f66c-50f6-4d75-8ece-371181e0498b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a9123ab1-1ea3-49b1-9980-a40a4239c659" xlink:to="loc_us-gaap_CostsAndExpenses_c8c5f66c-50f6-4d75-8ece-371181e0498b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ac285c1-be78-4224-b991-202e5fc9532e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1192e0ea-b1c9-4878-abc0-4724e70d69be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3ac285c1-be78-4224-b991-202e5fc9532e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1192e0ea-b1c9-4878-abc0-4724e70d69be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_786d8b90-0ee3-4a26-9de1-66c976aba0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3ac285c1-be78-4224-b991-202e5fc9532e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_786d8b90-0ee3-4a26-9de1-66c976aba0f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af7690b5-cbd6-4a37-b349-4959b70b723d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5fb04d7a-4ff4-4f19-995d-71d6f5f8a2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af7690b5-cbd6-4a37-b349-4959b70b723d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5fb04d7a-4ff4-4f19-995d-71d6f5f8a2fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5a5f528b-cfdd-4906-adf4-14c490a44c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af7690b5-cbd6-4a37-b349-4959b70b723d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5a5f528b-cfdd-4906-adf4-14c490a44c69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_7f4e5176-12e7-48f7-acfa-c3981edef72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af7690b5-cbd6-4a37-b349-4959b70b723d" xlink:to="loc_us-gaap_InvestmentIncomeNet_7f4e5176-12e7-48f7-acfa-c3981edef72d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7be872cb-3a26-49ba-894e-5672c56c20f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af7690b5-cbd6-4a37-b349-4959b70b723d" xlink:to="loc_us-gaap_InterestExpense_7be872cb-3a26-49ba-894e-5672c56c20f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_304b1f97-8555-4b2b-b12f-d04ba51781ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af7690b5-cbd6-4a37-b349-4959b70b723d" xlink:to="loc_us-gaap_OperatingIncomeLoss_304b1f97-8555-4b2b-b12f-d04ba51781ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d3d50c39-e688-42ed-be8d-ce290a037c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f297422-5027-4e46-895d-ae736c6de4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d3d50c39-e688-42ed-be8d-ce290a037c1a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f297422-5027-4e46-895d-ae736c6de4a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9113fd31-45c2-4dda-b66c-ad8f6a200c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d3d50c39-e688-42ed-be8d-ce290a037c1a" xlink:to="loc_us-gaap_NetIncomeLoss_9113fd31-45c2-4dda-b66c-ad8f6a200c67" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="eols-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5d6ab52b-f263-419e-937a-a3a2a5c4e962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40f52973-3afd-431e-96f2-762b8d86a4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5d6ab52b-f263-419e-937a-a3a2a5c4e962" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40f52973-3afd-431e-96f2-762b8d86a4be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2a5451fa-9030-46e7-9c5a-7e0f95ddf554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5d6ab52b-f263-419e-937a-a3a2a5c4e962" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2a5451fa-9030-46e7-9c5a-7e0f95ddf554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e843d4b-810a-4530-a37c-e85a845ae5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5d6ab52b-f263-419e-937a-a3a2a5c4e962" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e843d4b-810a-4530-a37c-e85a845ae5e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_445356b3-108c-4de7-9a00-f850ad31134b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5d6ab52b-f263-419e-937a-a3a2a5c4e962" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_445356b3-108c-4de7-9a00-f850ad31134b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dc63d4f2-fe03-4e95-b06c-d15a6cd60997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_NetIncomeLoss_dc63d4f2-fe03-4e95-b06c-d15a6cd60997" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_de648c64-2ca8-4db2-adcd-ea377b656d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_de648c64-2ca8-4db2-adcd-ea377b656d70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_0259c54b-fe05-4ba3-a9d3-504a8998663f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_0259c54b-fe05-4ba3-a9d3-504a8998663f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_98440c46-1e37-4f4f-8290-8c1776133940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_98440c46-1e37-4f4f-8290-8c1776133940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_568a2b1c-03cc-4a96-9b64-1d4184a6fb80" xlink:href="eols-20220930.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_568a2b1c-03cc-4a96-9b64-1d4184a6fb80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7d973238-0360-4a36-90da-18f5350f6e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7d973238-0360-4a36-90da-18f5350f6e81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6a3039e4-f5c8-423a-b07a-593663f059e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6a3039e4-f5c8-423a-b07a-593663f059e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_00c4e53e-fe99-4d69-8579-b5fb48487179" xlink:href="eols-20220930.xsd#eols_IncreaseDecreaseInAccruedLitigationSettlement"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_00c4e53e-fe99-4d69-8579-b5fb48487179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_9419dbdb-a361-4ca2-9884-210a6c044949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_9419dbdb-a361-4ca2-9884-210a6c044949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_289f4475-0f4e-4f47-b99a-8266e1ab261a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_289f4475-0f4e-4f47-b99a-8266e1ab261a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cd3fdefb-1eae-41d3-937c-4edda5024897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_ShareBasedCompensation_cd3fdefb-1eae-41d3-937c-4edda5024897" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cab537c1-eb67-4b29-a4c5-f9ca93eecf70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cab537c1-eb67-4b29-a4c5-f9ca93eecf70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a10d217d-39fa-4eb9-8387-1749295a912b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a10d217d-39fa-4eb9-8387-1749295a912b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_63988160-2675-47a5-b8b8-8288e848c5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_63988160-2675-47a5-b8b8-8288e848c5d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bfcb62a1-7bf6-4f08-9505-f395599bc3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bfcb62a1-7bf6-4f08-9505-f395599bc3d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8ede5c8c-e527-4268-8c11-a528f92e7eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8ede5c8c-e527-4268-8c11-a528f92e7eb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f155901a-25ea-47d6-b097-ae2b19ddc692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f155901a-25ea-47d6-b097-ae2b19ddc692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_cd729463-b047-4cd7-a21e-a2658d6df0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9f87b7a-e6ef-4426-b8f7-639cda8a8674" xlink:to="loc_us-gaap_PaidInKindInterest_cd729463-b047-4cd7-a21e-a2658d6df0d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bff7e14d-c12d-425c-b3c3-7f2e7a6ba112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6f2fa4ba-d599-4ca0-a590-3e31a6d047d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bff7e14d-c12d-425c-b3c3-7f2e7a6ba112" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6f2fa4ba-d599-4ca0-a590-3e31a6d047d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_dca12edb-53f3-4a8c-a3d3-69deab81b8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bff7e14d-c12d-425c-b3c3-7f2e7a6ba112" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_dca12edb-53f3-4a8c-a3d3-69deab81b8e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_28ced330-fa40-433f-9e47-081b1f56682c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bff7e14d-c12d-425c-b3c3-7f2e7a6ba112" xlink:to="loc_us-gaap_RepaymentsOfDebt_28ced330-fa40-433f-9e47-081b1f56682c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_03770c57-bef1-472c-b949-74830b8e6951" xlink:href="eols-20220930.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bff7e14d-c12d-425c-b3c3-7f2e7a6ba112" xlink:to="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_03770c57-bef1-472c-b949-74830b8e6951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_0448717d-4c24-4760-91b4-2ad85672d137" xlink:href="eols-20220930.xsd#eols_PaymentsOfContingentRoyaltyObligation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bff7e14d-c12d-425c-b3c3-7f2e7a6ba112" xlink:to="loc_eols_PaymentsOfContingentRoyaltyObligation_0448717d-4c24-4760-91b4-2ad85672d137" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23276306-82bc-4328-b0ab-ef29f9bb73fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_760f6a16-c4cb-4b94-bd43-b4e9ea2f700d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23276306-82bc-4328-b0ab-ef29f9bb73fe" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_760f6a16-c4cb-4b94-bd43-b4e9ea2f700d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_54e7e797-7119-4304-b21e-363f889d0df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23276306-82bc-4328-b0ab-ef29f9bb73fe" xlink:to="loc_us-gaap_PaymentsForSoftware_54e7e797-7119-4304-b21e-363f889d0df8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_2ed59828-c2bd-4d90-9827-b71b7823741b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23276306-82bc-4328-b0ab-ef29f9bb73fe" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_2ed59828-c2bd-4d90-9827-b71b7823741b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9adc42aa-d6f6-4953-a2db-6fb95d35c591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6f374fd8-7c36-44de-bc10-255184f86ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9adc42aa-d6f6-4953-a2db-6fb95d35c591" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6f374fd8-7c36-44de-bc10-255184f86ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12ef466a-ba93-407d-9a69-5942e04bcc20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9adc42aa-d6f6-4953-a2db-6fb95d35c591" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12ef466a-ba93-407d-9a69-5942e04bcc20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_fd5da78d-53ba-4e0f-853a-6ff27af3fcd7" xlink:href="eols-20220930.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b049d1f4-fa0b-4fe6-81f1-6a9073a7d46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_fd5da78d-53ba-4e0f-853a-6ff27af3fcd7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b049d1f4-fa0b-4fe6-81f1-6a9073a7d46d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_84eebec4-8449-4f76-b906-f096fe05df28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_fd5da78d-53ba-4e0f-853a-6ff27af3fcd7" xlink:to="loc_us-gaap_Goodwill_84eebec4-8449-4f76-b906-f096fe05df28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_29db3a90-b161-45ba-b20f-cf8ded949d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_9b68db1e-4744-4232-85c6-ada7e6ec0296" xlink:href="eols-20220930.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_29db3a90-b161-45ba-b20f-cf8ded949d03" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_9b68db1e-4744-4232-85c6-ada7e6ec0296" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_db45ff63-2b3d-4ed1-a413-269d216f980e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_29db3a90-b161-45ba-b20f-cf8ded949d03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_db45ff63-2b3d-4ed1-a413-269d216f980e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="eols-20220930.xsd#GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c2b97f27-cfa2-4d29-9816-18bb5c70d6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae82a714-5483-4dbf-936b-b5fcf3849ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c2b97f27-cfa2-4d29-9816-18bb5c70d6d7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae82a714-5483-4dbf-936b-b5fcf3849ed8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1b189ff6-2e5a-4f74-b24a-dbf92d472df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c2b97f27-cfa2-4d29-9816-18bb5c70d6d7" xlink:to="loc_us-gaap_Goodwill_1b189ff6-2e5a-4f74-b24a-dbf92d472df4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_753ceda7-0cdc-4068-a1d8-d112491567f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5aea8248-dd04-408b-adc4-448b62fdebe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_753ceda7-0cdc-4068-a1d8-d112491567f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5aea8248-dd04-408b-adc4-448b62fdebe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_799dbba4-77eb-4cbb-8394-65e76df4c616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_753ceda7-0cdc-4068-a1d8-d112491567f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_799dbba4-77eb-4cbb-8394-65e76df4c616" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a4a4dd44-32e3-41a2-b5fa-2349ae28a219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_753ceda7-0cdc-4068-a1d8-d112491567f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a4a4dd44-32e3-41a2-b5fa-2349ae28a219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_daa339e8-4e29-4036-b3c2-6d3c292b95a3" xlink:href="eols-20220930.xsd#eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_753ceda7-0cdc-4068-a1d8-d112491567f5" xlink:to="loc_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_daa339e8-4e29-4036-b3c2-6d3c292b95a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bea372d0-1cf3-4f21-9b4d-1dd5d8024d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_753ceda7-0cdc-4068-a1d8-d112491567f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bea372d0-1cf3-4f21-9b4d-1dd5d8024d4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_95d9fcfb-86ce-47d1-9987-1013c9c20693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_753ceda7-0cdc-4068-a1d8-d112491567f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_95d9fcfb-86ce-47d1-9987-1013c9c20693" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_02cfad67-694c-4e04-84cd-2bba154bd03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_69cd6bc6-3344-414f-9d7c-26c2f5638766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_02cfad67-694c-4e04-84cd-2bba154bd03a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_69cd6bc6-3344-414f-9d7c-26c2f5638766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6d9bb006-d92c-4ed4-a6f0-ea12e12e4e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_02cfad67-694c-4e04-84cd-2bba154bd03a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6d9bb006-d92c-4ed4-a6f0-ea12e12e4e43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_27392eb0-f09b-447d-89bb-185e583a14e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_02cfad67-694c-4e04-84cd-2bba154bd03a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_27392eb0-f09b-447d-89bb-185e583a14e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_e5b0a9d5-9b90-4fd8-a773-c3d0524dffbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_02cfad67-694c-4e04-84cd-2bba154bd03a" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_e5b0a9d5-9b90-4fd8-a773-c3d0524dffbd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#TermLoansMaturitiesofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_71fbc963-2a25-4cd9-a41c-d6b58e61137b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6e49afdc-0b35-4362-b038-6973e853af41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_71fbc963-2a25-4cd9-a41c-d6b58e61137b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6e49afdc-0b35-4362-b038-6973e853af41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_eb534b39-248a-4142-ad51-8d264ccc8e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_71fbc963-2a25-4cd9-a41c-d6b58e61137b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_eb534b39-248a-4142-ad51-8d264ccc8e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7c11e92c-eb57-4a7b-b3d9-34935d14f9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_00e6a5a6-f71d-4bf3-9966-4bcd7f5f781e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_7c11e92c-eb57-4a7b-b3d9-34935d14f9d3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_00e6a5a6-f71d-4bf3-9966-4bcd7f5f781e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LongTermDebtMaturityAfterYearFour_6bf48fe0-9059-41ae-b727-5c092cc18911" xlink:href="eols-20220930.xsd#eols_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_7c11e92c-eb57-4a7b-b3d9-34935d14f9d3" xlink:to="loc_eols_LongTermDebtMaturityAfterYearFour_6bf48fe0-9059-41ae-b727-5c092cc18911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_7bd1677a-ef37-4514-933d-e3b0a4f971b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_7c11e92c-eb57-4a7b-b3d9-34935d14f9d3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_7bd1677a-ef37-4514-933d-e3b0a4f971b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fa8c4122-8862-40a8-93dd-c06cf24b3440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_7c11e92c-eb57-4a7b-b3d9-34935d14f9d3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fa8c4122-8862-40a8-93dd-c06cf24b3440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_454d8a1f-fcdc-4c04-9284-d9bda91a653c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_7c11e92c-eb57-4a7b-b3d9-34935d14f9d3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_454d8a1f-fcdc-4c04-9284-d9bda91a653c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b6c16c0b-9b6b-41fe-8a2f-da0582377d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_7c11e92c-eb57-4a7b-b3d9-34935d14f9d3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b6c16c0b-9b6b-41fe-8a2f-da0582377d90" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesLeaseCostDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#OperatingLeasesLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/OperatingLeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_4d5a6e8b-45a8-4cc2-b7c0-dc9d7af12a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_aac39ad8-2de0-4bc3-add9-7f5097438f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4d5a6e8b-45a8-4cc2-b7c0-dc9d7af12a3b" xlink:to="loc_us-gaap_OperatingLeaseCost_aac39ad8-2de0-4bc3-add9-7f5097438f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_6f6a1c82-e0b6-4248-ad7a-78a12622e2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4d5a6e8b-45a8-4cc2-b7c0-dc9d7af12a3b" xlink:to="loc_us-gaap_VariableLeaseCost_6f6a1c82-e0b6-4248-ad7a-78a12622e2e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#OperatingLeasesOperatingLeaseMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d772ba1c-d667-4b80-b5d1-67428f5c30af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6c1e399f-299c-44a5-9f1f-6eea26a6fda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d772ba1c-d667-4b80-b5d1-67428f5c30af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6c1e399f-299c-44a5-9f1f-6eea26a6fda6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cfe12e06-e2f5-4fdb-bf89-06b6b8bc8ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d772ba1c-d667-4b80-b5d1-67428f5c30af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cfe12e06-e2f5-4fdb-bf89-06b6b8bc8ee6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a6bd0611-7164-495a-a7b7-f5474c56bdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d772ba1c-d667-4b80-b5d1-67428f5c30af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a6bd0611-7164-495a-a7b7-f5474c56bdfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_eaee6528-d9a2-4992-aaf7-e2ad453db329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d772ba1c-d667-4b80-b5d1-67428f5c30af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_eaee6528-d9a2-4992-aaf7-e2ad453db329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bd22318e-59f6-4e36-af15-214972e95810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d772ba1c-d667-4b80-b5d1-67428f5c30af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bd22318e-59f6-4e36-af15-214972e95810" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails_1" xlink:type="simple" xlink:href="eols-20220930.xsd#OperatingLeasesOperatingLeaseMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fec10402-a4ee-4973-9741-aa32b28bed0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5f34dde7-a56a-4b93-ac9e-cea58337cca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fec10402-a4ee-4973-9741-aa32b28bed0c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5f34dde7-a56a-4b93-ac9e-cea58337cca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e8a08b4a-3da6-4524-ad90-752f3b5c5901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fec10402-a4ee-4973-9741-aa32b28bed0c" xlink:to="loc_us-gaap_OperatingLeaseLiability_e8a08b4a-3da6-4524-ad90-752f3b5c5901" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>eols-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9907a7dd-9da5-4da3-a916-5b93970552d6,g:d423565a-304b-425b-af42-a6f72195e86c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="eols-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="iad95b87f3dfb413a8bb2ad5a459773f6_CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_144c1d34-b82c-42ba-9aee-a2cecf658239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_RevenuesAbstract_144c1d34-b82c-42ba-9aee-a2cecf658239" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_feefcfd4-8186-4bea-8877-bfacfc661b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_144c1d34-b82c-42ba-9aee-a2cecf658239" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_feefcfd4-8186-4bea-8877-bfacfc661b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_788f4baf-e4a0-4c78-8583-31d86f76449d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_788f4baf-e4a0-4c78-8583-31d86f76449d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_e8446b1b-4635-4067-b888-f20c9b053f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_e8446b1b-4635-4067-b888-f20c9b053f5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_83369f4c-2242-455f-a768-49f666194b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_83369f4c-2242-455f-a768-49f666194b7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_93db35e2-4dbb-4910-bf05-64368a05ad5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_93db35e2-4dbb-4910-bf05-64368a05ad5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_74db05a1-e8aa-4a66-9655-df3f6de3c526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_74db05a1-e8aa-4a66-9655-df3f6de3c526" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b23a5042-5f1d-4dfb-99ce-76260d73d1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b23a5042-5f1d-4dfb-99ce-76260d73d1c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_89ae5e6a-6849-40e4-a5a0-323ea495ae04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_89ae5e6a-6849-40e4-a5a0-323ea495ae04" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_674e522f-d0cc-4d5b-af59-629d1e15dfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_CostsAndExpenses_674e522f-d0cc-4d5b-af59-629d1e15dfd9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9960c6c0-6304-4757-b63a-f0082a7845f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_OperatingIncomeLoss_9960c6c0-6304-4757-b63a-f0082a7845f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_eeedc833-6ed2-4c26-9502-9d65d06a7c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_eeedc833-6ed2-4c26-9502-9d65d06a7c66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_1a6948b2-26f1-4eb3-bcfc-064e83d28da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_eeedc833-6ed2-4c26-9502-9d65d06a7c66" xlink:to="loc_us-gaap_InvestmentIncomeNet_1a6948b2-26f1-4eb3-bcfc-064e83d28da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7c28d171-cb7a-40fd-9444-a0fa37ecf21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_eeedc833-6ed2-4c26-9502-9d65d06a7c66" xlink:to="loc_us-gaap_InterestExpense_7c28d171-cb7a-40fd-9444-a0fa37ecf21f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_788737f2-c5c6-487e-a3bf-36cbf3ed437e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_eeedc833-6ed2-4c26-9502-9d65d06a7c66" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_788737f2-c5c6-487e-a3bf-36cbf3ed437e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b32d2431-2e2c-47ba-a5c9-b99c659ae261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_eeedc833-6ed2-4c26-9502-9d65d06a7c66" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b32d2431-2e2c-47ba-a5c9-b99c659ae261" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1556213b-3a9a-4ffe-bb48-93cd616112f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1556213b-3a9a-4ffe-bb48-93cd616112f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f4a0e99d-414b-44c4-bfb1-5a2153e97b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f4a0e99d-414b-44c4-bfb1-5a2153e97b90" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_898525f2-d3fd-40bf-88bb-a790dba20a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_NetIncomeLoss_898525f2-d3fd-40bf-88bb-a790dba20a59" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_59294772-6c3a-4d99-88c8-526aec2065fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_59294772-6c3a-4d99-88c8-526aec2065fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f0a4bba0-af2c-4ec7-9b35-67c5ea49e19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_59294772-6c3a-4d99-88c8-526aec2065fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f0a4bba0-af2c-4ec7-9b35-67c5ea49e19e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7cecb328-6763-4d73-b646-2792f949f810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7cecb328-6763-4d73-b646-2792f949f810" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_17626fb9-a514-4597-bd10-8f7b69535cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_EarningsPerShareBasic_17626fb9-a514-4597-bd10-8f7b69535cb3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_dbb1a463-918c-48c4-afb4-70653167eeee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_dbb1a463-918c-48c4-afb4-70653167eeee" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_25f11972-3f59-4a4d-a587-74289ad6ce43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_25f11972-3f59-4a4d-a587-74289ad6ce43" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_663b644e-5a96-41b7-937b-b2c679e7818a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_663b644e-5a96-41b7-937b-b2c679e7818a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_0f1cce03-bf90-4387-919b-3c21310b7a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_0f1cce03-bf90-4387-919b-3c21310b7a92" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2eba4b4f-a814-416e-bf4b-76c7c60f9d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_StatementTable_2eba4b4f-a814-416e-bf4b-76c7c60f9d11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c1db50a6-482a-4835-941b-fae3dc2946b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2eba4b4f-a814-416e-bf4b-76c7c60f9d11" xlink:to="loc_srt_ProductOrServiceAxis_c1db50a6-482a-4835-941b-fae3dc2946b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c1db50a6-482a-4835-941b-fae3dc2946b6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c1db50a6-482a-4835-941b-fae3dc2946b6" xlink:to="loc_srt_ProductsAndServicesDomain_c1db50a6-482a-4835-941b-fae3dc2946b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_03c6eb8a-3867-4210-b309-1f0b893051c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c1db50a6-482a-4835-941b-fae3dc2946b6" xlink:to="loc_srt_ProductsAndServicesDomain_03c6eb8a-3867-4210-b309-1f0b893051c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_388892e5-fce7-4234-b33a-9be09ce6bb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_03c6eb8a-3867-4210-b309-1f0b893051c3" xlink:to="loc_us-gaap_ProductMember_388892e5-fce7-4234-b33a-9be09ce6bb12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_d2b809bc-98f2-4753-9527-dbefa76d429c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_03c6eb8a-3867-4210-b309-1f0b893051c3" xlink:to="loc_us-gaap_ServiceMember_d2b809bc-98f2-4753-9527-dbefa76d429c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="eols-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i0a084b365df0438fb9f91331ceb6c7e7_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d57ffd00-829e-4ced-8be9-96fea55dc3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d57ffd00-829e-4ced-8be9-96fea55dc3fe" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_23bd06f5-ea1b-4a66-a6b8-8c7fa021c5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_23bd06f5-ea1b-4a66-a6b8-8c7fa021c5ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8746ef42-61db-4245-b60a-e50f212469f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_CommonStockSharesIssued_8746ef42-61db-4245-b60a-e50f212469f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c8763b21-2052-40b1-beb3-dfd5ff0346a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_StockholdersEquity_c8763b21-2052-40b1-beb3-dfd5ff0346a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_5652dd1f-c256-481e-93cd-6f9e17f17858" xlink:href="eols-20220930.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_5652dd1f-c256-481e-93cd-6f9e17f17858" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodValuesLitigationSettlement_77283366-b8a3-4126-9865-07301a8e6dca" xlink:href="eols-20220930.xsd#eols_StockIssuedDuringPeriodValuesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_eols_StockIssuedDuringPeriodValuesLitigationSettlement_77283366-b8a3-4126-9865-07301a8e6dca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e1a9b0d5-a119-44d7-be22-be6b19ad8056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e1a9b0d5-a119-44d7-be22-be6b19ad8056" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_654dfc1f-bf5f-4935-974b-e27596513a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_654dfc1f-bf5f-4935-974b-e27596513a94" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a816b150-da4f-4582-8c23-60d634b21821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a816b150-da4f-4582-8c23-60d634b21821" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e72bfcaa-8ce4-490b-a659-095adf83be0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e72bfcaa-8ce4-490b-a659-095adf83be0c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5d54be10-5391-4221-8eac-272bc56854bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5d54be10-5391-4221-8eac-272bc56854bc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_77abcce3-ad88-4f3d-9c17-d0499dbf5a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_NetIncomeLoss_77abcce3-ad88-4f3d-9c17-d0499dbf5a46" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_82dbfc3f-9f58-400d-a13a-ea9826901004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_82dbfc3f-9f58-400d-a13a-ea9826901004" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f23c8d3f-aae7-420e-8e91-cb7e6930603a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1dc328f1-d1bb-4c47-bcd1-8bcda73eca7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f6fe233e-11d4-43c1-af1b-bfe0fb3c50e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cc092b21-163c-4f9f-ae4c-7530e12d6829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d57ffd00-829e-4ced-8be9-96fea55dc3fe" xlink:to="loc_us-gaap_StatementTable_cc092b21-163c-4f9f-ae4c-7530e12d6829" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2178bfc8-2fb1-4440-aca4-42b59639eb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cc092b21-163c-4f9f-ae4c-7530e12d6829" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2178bfc8-2fb1-4440-aca4-42b59639eb5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2178bfc8-2fb1-4440-aca4-42b59639eb5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2178bfc8-2fb1-4440-aca4-42b59639eb5a" xlink:to="loc_us-gaap_EquityComponentDomain_2178bfc8-2fb1-4440-aca4-42b59639eb5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2178bfc8-2fb1-4440-aca4-42b59639eb5a" xlink:to="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_be3d7f80-be91-45ad-b418-c9774d8e72e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:to="loc_us-gaap_PreferredStockMember_be3d7f80-be91-45ad-b418-c9774d8e72e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a7b96820-b44d-4e96-a1ff-5334f1161542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:to="loc_us-gaap_CommonStockMember_a7b96820-b44d-4e96-a1ff-5334f1161542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_de818edb-6717-4c51-8565-8930b3276801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_de818edb-6717-4c51-8565-8930b3276801" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c187c213-380f-4a7c-9ba6-2be8cc660085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c187c213-380f-4a7c-9ba6-2be8cc660085" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d891092c-5a98-40d7-8798-4b4c5531e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:to="loc_us-gaap_RetainedEarningsMember_d891092c-5a98-40d7-8798-4b4c5531e54f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b2134e9b-68c6-46bc-be3a-faa22d69f895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cc092b21-163c-4f9f-ae4c-7530e12d6829" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b2134e9b-68c6-46bc-be3a-faa22d69f895" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b2134e9b-68c6-46bc-be3a-faa22d69f895_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b2134e9b-68c6-46bc-be3a-faa22d69f895" xlink:to="loc_us-gaap_ClassOfStockDomain_b2134e9b-68c6-46bc-be3a-faa22d69f895_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a508d9e6-3f8f-4b4a-8e5e-4ccd298b788b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b2134e9b-68c6-46bc-be3a-faa22d69f895" xlink:to="loc_us-gaap_ClassOfStockDomain_a508d9e6-3f8f-4b4a-8e5e-4ccd298b788b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_317ff28c-7e39-4be5-9a29-2bf1cf2be43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a508d9e6-3f8f-4b4a-8e5e-4ccd298b788b" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_317ff28c-7e39-4be5-9a29-2bf1cf2be43a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ba682e80-2449-4850-b0cd-dcf41c0c6150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cc092b21-163c-4f9f-ae4c-7530e12d6829" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ba682e80-2449-4850-b0cd-dcf41c0c6150" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ba682e80-2449-4850-b0cd-dcf41c0c6150_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba682e80-2449-4850-b0cd-dcf41c0c6150" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ba682e80-2449-4850-b0cd-dcf41c0c6150_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5cfd1d1d-98c3-4fa8-9b49-53db0ab07e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba682e80-2449-4850-b0cd-dcf41c0c6150" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5cfd1d1d-98c3-4fa8-9b49-53db0ab07e63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember_92de6eff-4822-43ef-9553-4d596cc5e0b4" xlink:href="eols-20220930.xsd#eols_FollowOnOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5cfd1d1d-98c3-4fa8-9b49-53db0ab07e63" xlink:to="loc_eols_FollowOnOfferingMember_92de6eff-4822-43ef-9553-4d596cc5e0b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_10c257e5-0264-4735-8c41-2537a510ef2d" xlink:href="eols-20220930.xsd#eols_ATMSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5cfd1d1d-98c3-4fa8-9b49-53db0ab07e63" xlink:to="loc_eols_ATMSalesAgreementMember_10c257e5-0264-4735-8c41-2537a510ef2d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="eols-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i45e551831006420ab938bedc4d809fb1_CondensedConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_293fbc3f-ede9-4336-86f6-de5267e94d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_293fbc3f-ede9-4336-86f6-de5267e94d3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_80f50c5b-be76-435d-a069-b8552d15d159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_293fbc3f-ede9-4336-86f6-de5267e94d3f" xlink:to="loc_us-gaap_NetIncomeLoss_80f50c5b-be76-435d-a069-b8552d15d159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_293fbc3f-ede9-4336-86f6-de5267e94d3f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0a767786-ead5-44cd-a2a6-49f4fc141a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0a767786-ead5-44cd-a2a6-49f4fc141a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_47519fcc-9a5f-42b3-b570-e06c94ef61b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_ShareBasedCompensation_47519fcc-9a5f-42b3-b570-e06c94ef61b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_09a320a9-efc5-4eb0-ac7b-0dd8b79a6fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_09a320a9-efc5-4eb0-ac7b-0dd8b79a6fa7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b44492c9-5881-44e3-a278-9285528da601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b44492c9-5881-44e3-a278-9285528da601" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_96e7ec3e-e6e3-4975-a8e8-f84bb1147b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_96e7ec3e-e6e3-4975-a8e8-f84bb1147b4f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_3ba88145-b3e0-46f5-9482-7aa9c4a98729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_PaidInKindInterest_3ba88145-b3e0-46f5-9482-7aa9c4a98729" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c0add504-255c-45b5-a0fa-a423646dbb48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c0add504-255c-45b5-a0fa-a423646dbb48" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a7cb27fc-c61b-45e0-8cb6-9c7b963ce1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a7cb27fc-c61b-45e0-8cb6-9c7b963ce1ec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9e4d1d17-c68f-434a-bc9d-4baf9885280f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9e4d1d17-c68f-434a-bc9d-4baf9885280f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_efbf9982-b26d-42f8-a6ca-36f7a301a736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_efbf9982-b26d-42f8-a6ca-36f7a301a736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0c4683ee-d56f-4cc7-8565-28d0cb53badc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0c4683ee-d56f-4cc7-8565-28d0cb53badc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_06ce841e-6aed-47ad-b0be-95f62a3ecf29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_06ce841e-6aed-47ad-b0be-95f62a3ecf29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cfb8f8d7-ff00-4b2b-a00e-d63a45a88bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cfb8f8d7-ff00-4b2b-a00e-d63a45a88bfd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a64a48d6-81ca-4956-b88b-2c423408be89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a64a48d6-81ca-4956-b88b-2c423408be89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1b5e55dd-f4e2-4ff0-94f7-8179a89f9ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1b5e55dd-f4e2-4ff0-94f7-8179a89f9ee6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_1bc2b338-f025-4af0-88c9-d2fd68b3a833" xlink:href="eols-20220930.xsd#eols_IncreaseDecreaseInAccruedLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_1bc2b338-f025-4af0-88c9-d2fd68b3a833" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_1e4a35b5-3779-4954-ade7-bd943ce77c21" xlink:href="eols-20220930.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_1e4a35b5-3779-4954-ade7-bd943ce77c21" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_87467f71-6f5f-452b-b3ad-37392048e38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_293fbc3f-ede9-4336-86f6-de5267e94d3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_87467f71-6f5f-452b-b3ad-37392048e38a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a913e522-0d4b-4e51-915e-4fb4066dec29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a913e522-0d4b-4e51-915e-4fb4066dec29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_efd14ebf-5b4c-47c9-a2cd-1f8329737642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a913e522-0d4b-4e51-915e-4fb4066dec29" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_efd14ebf-5b4c-47c9-a2cd-1f8329737642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_de2f43ff-5ef0-4ba5-a915-e2ae6999ec53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a913e522-0d4b-4e51-915e-4fb4066dec29" xlink:to="loc_us-gaap_PaymentsForSoftware_de2f43ff-5ef0-4ba5-a915-e2ae6999ec53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_dbb9813f-d5c5-424d-8af8-ba443b136809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a913e522-0d4b-4e51-915e-4fb4066dec29" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_dbb9813f-d5c5-424d-8af8-ba443b136809" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8487d76-933f-48f9-a82b-6cf0ffb18ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a913e522-0d4b-4e51-915e-4fb4066dec29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8487d76-933f-48f9-a82b-6cf0ffb18ca1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_aea48a9c-3cc2-4754-95d1-2dc87495abb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:to="loc_us-gaap_RepaymentsOfDebt_aea48a9c-3cc2-4754-95d1-2dc87495abb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_4cfe3a45-36f0-4662-bf9b-409a436b28b0" xlink:href="eols-20220930.xsd#eols_PaymentsOfContingentRoyaltyObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:to="loc_eols_PaymentsOfContingentRoyaltyObligation_4cfe3a45-36f0-4662-bf9b-409a436b28b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1cd20222-56bf-4b54-8a88-24b1226eaf72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1cd20222-56bf-4b54-8a88-24b1226eaf72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a921f7e6-04a3-4503-beb1-19443f5f726f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a921f7e6-04a3-4503-beb1-19443f5f726f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_c39c70e9-6bf6-4208-b29a-ead7f97a9b8e" xlink:href="eols-20220930.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:to="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_c39c70e9-6bf6-4208-b29a-ead7f97a9b8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53e66bf5-29b6-4309-a48a-6aa94fede8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53e66bf5-29b6-4309-a48a-6aa94fede8b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afc79b92-ee83-481b-9e0d-c255583ee249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afc79b92-ee83-481b-9e0d-c255583ee249" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1bf70477-e119-408f-8cbe-bc72146e88d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1bf70477-e119-408f-8cbe-bc72146e88d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee821504-b559-47c9-a816-82f034a02478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee821504-b559-47c9-a816-82f034a02478" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ccff4b2-a022-420d-96cb-176d6af31101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_880ec189-0330-4cf9-bd94-afef4020061c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_880ec189-0330-4cf9-bd94-afef4020061c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_42794ba2-a755-4fee-8ade-c633f529180a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_880ec189-0330-4cf9-bd94-afef4020061c" xlink:to="loc_us-gaap_InterestPaidNet_42794ba2-a755-4fee-8ade-c633f529180a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_1e482681-a2e1-41af-8665-2150f7695756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_880ec189-0330-4cf9-bd94-afef4020061c" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_1e482681-a2e1-41af-8665-2150f7695756" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5e3db957-c9f3-4426-a1d2-744181722ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_880ec189-0330-4cf9-bd94-afef4020061c" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5e3db957-c9f3-4426-a1d2-744181722ccf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_b4acb135-d1c7-4f7e-a266-445ab90bd310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5e3db957-c9f3-4426-a1d2-744181722ccf" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_b4acb135-d1c7-4f7e-a266-445ab90bd310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedForAccruedLitigationSettlementExpense_30685c1e-78ea-44e6-9ec7-e01b294cc4c4" xlink:href="eols-20220930.xsd#eols_StockIssuedForAccruedLitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5e3db957-c9f3-4426-a1d2-744181722ccf" xlink:to="loc_eols_StockIssuedForAccruedLitigationSettlementExpense_30685c1e-78ea-44e6-9ec7-e01b294cc4c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1e69e22b-e051-4279-8c11-db07b3712666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5e3db957-c9f3-4426-a1d2-744181722ccf" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1e69e22b-e051-4279-8c11-db07b3712666" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_35f1c456-520b-4b9c-87ee-c1e610cd0b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_StatementTable_35f1c456-520b-4b9c-87ee-c1e610cd0b63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3c256c64-fe05-4322-a30f-c0b8d30a473e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_35f1c456-520b-4b9c-87ee-c1e610cd0b63" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3c256c64-fe05-4322-a30f-c0b8d30a473e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c256c64-fe05-4322-a30f-c0b8d30a473e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3c256c64-fe05-4322-a30f-c0b8d30a473e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c256c64-fe05-4322-a30f-c0b8d30a473e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_667bb8ff-9da0-45a1-aed2-5f6197c8f1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3c256c64-fe05-4322-a30f-c0b8d30a473e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_667bb8ff-9da0-45a1-aed2-5f6197c8f1a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember_802c8ca2-f9bf-4403-a4db-54b8a8322572" xlink:href="eols-20220930.xsd#eols_FollowOnOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_667bb8ff-9da0-45a1-aed2-5f6197c8f1a1" xlink:to="loc_eols_FollowOnOfferingMember_802c8ca2-f9bf-4403-a4db-54b8a8322572" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_45183eb0-953a-4715-bf8c-9d512295c524" xlink:href="eols-20220930.xsd#eols_ATMSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_667bb8ff-9da0-45a1-aed2-5f6197c8f1a1" xlink:to="loc_eols_ATMSalesAgreementMember_45183eb0-953a-4715-bf8c-9d512295c524" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/DescriptionofBusinessDetails" xlink:type="extended" id="i0148dcc30f8f4dc4b09e6b00f6751001_DescriptionofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0dc7831b-fa36-4b7f-ae4c-040b7249d77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_NetIncomeLoss_0dc7831b-fa36-4b7f-ae4c-040b7249d77d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb24c5e6-4755-45ee-9b17-ed23f9aeab13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb24c5e6-4755-45ee-9b17-ed23f9aeab13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_ed709d3e-5231-403a-8db9-1c4f3ce73a48" xlink:href="eols-20220930.xsd#eols_IncreaseDecreaseInAccruedLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_ed709d3e-5231-403a-8db9-1c4f3ce73a48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5c43e446-1753-43f5-bb31-c3971111008d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5c43e446-1753-43f5-bb31-c3971111008d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_083af7c2-1aa3-492d-925f-dcbbbabaca3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_083af7c2-1aa3-492d-925f-dcbbbabaca3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c619e041-8542-4f8d-916e-18714308f4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c619e041-8542-4f8d-916e-18714308f4f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_10c3e430-8a63-4132-bb47-18ae60a0ccbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_10c3e430-8a63-4132-bb47-18ae60a0ccbd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aba63414-86d3-4640-9e1b-b48a3e5b714c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aba63414-86d3-4640-9e1b-b48a3e5b714c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a872565b-3699-44f7-8284-8758dac54939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aba63414-86d3-4640-9e1b-b48a3e5b714c" xlink:to="loc_us-gaap_DebtInstrumentAxis_a872565b-3699-44f7-8284-8758dac54939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a872565b-3699-44f7-8284-8758dac54939_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a872565b-3699-44f7-8284-8758dac54939" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a872565b-3699-44f7-8284-8758dac54939_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_93d7ba81-38b5-486a-9f9e-617aff3a47f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a872565b-3699-44f7-8284-8758dac54939" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_93d7ba81-38b5-486a-9f9e-617aff3a47f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_f0d36c8f-4cf3-4646-832a-d04781439f60" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93d7ba81-38b5-486a-9f9e-617aff3a47f4" xlink:to="loc_eols_PharmakonTermLoansMember_f0d36c8f-4cf3-4646-832a-d04781439f60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember_d41e39ec-ef41-4f07-bc17-8e77d09a7c3e" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93d7ba81-38b5-486a-9f9e-617aff3a47f4" xlink:to="loc_eols_PharmakonTermLoansOneMember_d41e39ec-ef41-4f07-bc17-8e77d09a7c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember_6c2be51a-9368-4568-87d5-84acc83490b9" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93d7ba81-38b5-486a-9f9e-617aff3a47f4" xlink:to="loc_eols_PharmakonTermLoansTwoMember_6c2be51a-9368-4568-87d5-84acc83490b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8ff58d6c-e99b-4099-b919-d62264131310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aba63414-86d3-4640-9e1b-b48a3e5b714c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8ff58d6c-e99b-4099-b919-d62264131310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8ff58d6c-e99b-4099-b919-d62264131310_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8ff58d6c-e99b-4099-b919-d62264131310" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8ff58d6c-e99b-4099-b919-d62264131310_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4844a5ef-9a59-4489-ae0e-32b41c439f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8ff58d6c-e99b-4099-b919-d62264131310" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4844a5ef-9a59-4489-ae0e-32b41c439f6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_2a2ccd46-209b-4814-8806-3bc7ec765d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4844a5ef-9a59-4489-ae0e-32b41c439f6c" xlink:to="loc_us-gaap_SecuredDebtMember_2a2ccd46-209b-4814-8806-3bc7ec765d8d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="id5a49abaed1a463aafb46de7bc5e0ffe_BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:href="eols-20220930.xsd#eols_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_6ef71c95-fdaf-41c4-abf5-3422918cca30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_6ef71c95-fdaf-41c4-abf5-3422918cca30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4bdb5b8e-6b07-436a-93be-e51c40ad6793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4bdb5b8e-6b07-436a-93be-e51c40ad6793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_4df5f20e-6e60-4307-9a40-33ebc1dc0345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_NumberOfReportingUnits_4df5f20e-6e60-4307-9a40-33ebc1dc0345" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1d96d3f2-8c0c-43b4-b987-3055bcf76b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1d96d3f2-8c0c-43b4-b987-3055bcf76b9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f17a1a2c-0504-439c-8fc0-6c91651bb1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f17a1a2c-0504-439c-8fc0-6c91651bb1cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_01c24fa1-c0a2-4e6a-91e8-32e99742eda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_01c24fa1-c0a2-4e6a-91e8-32e99742eda6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3894ff24-f0de-402a-b4b0-08fc19140ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3894ff24-f0de-402a-b4b0-08fc19140ab7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4853655f-586d-4c46-b461-eb4a138dc817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4853655f-586d-4c46-b461-eb4a138dc817" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_27867ab0-cc32-47e9-ae04-8be355de9138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_27867ab0-cc32-47e9-ae04-8be355de9138" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0c06371a-fb1d-4b67-9e86-c9fc112d724c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0c06371a-fb1d-4b67-9e86-c9fc112d724c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_f7746fcd-dbdb-4c8c-90ee-6937589bb358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_f7746fcd-dbdb-4c8c-90ee-6937589bb358" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_0f253aee-7bbf-407b-a687-350dca139685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_0f253aee-7bbf-407b-a687-350dca139685" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_6049e2c4-5fa7-43b0-9bd6-4b1b39b11ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_6049e2c4-5fa7-43b0-9bd6-4b1b39b11ce2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_56926c66-1d91-4b85-8ad7-9799aa411382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_56926c66-1d91-4b85-8ad7-9799aa411382" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms_557e075c-2b14-4c8c-bfde-910fee8f48bd" xlink:href="eols-20220930.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_eols_LossContingencySettlementAgreementPaymentTerms_557e075c-2b14-4c8c-bfde-910fee8f48bd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_aec2bea1-9e4e-4532-8ab7-f0e34dc1f249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_aec2bea1-9e4e-4532-8ab7-f0e34dc1f249" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_d355382a-3eb4-44f7-93e3-890b1b0814cc" xlink:href="eols-20220930.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_d355382a-3eb4-44f7-93e3-890b1b0814cc" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_fd58eb30-e8df-4f96-b4d3-909fa409339a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_LitigationSettlementExpense_fd58eb30-e8df-4f96-b4d3-909fa409339a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_238024c3-c45f-42e3-aef9-dd0ecb5245a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_238024c3-c45f-42e3-aef9-dd0ecb5245a8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_6ffefdaa-3356-4fb7-8f96-132f1828b678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_LitigationReserveCurrent_6ffefdaa-3356-4fb7-8f96-132f1828b678" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_9eae4fa7-8b7a-4ce5-848f-7f5316162256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_9eae4fa7-8b7a-4ce5-848f-7f5316162256" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_571ef65e-e59b-4efe-a680-2c84ab5fdd08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_571ef65e-e59b-4efe-a680-2c84ab5fdd08" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f05d1f5-7064-40dd-ab71-efc0c59d1c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f05d1f5-7064-40dd-ab71-efc0c59d1c0f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:href="eols-20220930.xsd#eols_AccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84d7f775-d339-4d9d-9f8d-210054dd9edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84d7f775-d339-4d9d-9f8d-210054dd9edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84d7f775-d339-4d9d-9f8d-210054dd9edb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84d7f775-d339-4d9d-9f8d-210054dd9edb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84d7f775-d339-4d9d-9f8d-210054dd9edb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ca64ccde-ab51-4ed8-813b-607d810ae1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84d7f775-d339-4d9d-9f8d-210054dd9edb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ca64ccde-ab51-4ed8-813b-607d810ae1a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_48d46045-d681-467d-9054-60eff1cdb5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ca64ccde-ab51-4ed8-813b-607d810ae1a4" xlink:to="loc_us-gaap_DistributionRightsMember_48d46045-d681-467d-9054-60eff1cdb5cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_1fd50d35-f62c-47fd-bc9f-f46629b3143c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ca64ccde-ab51-4ed8-813b-607d810ae1a4" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_1fd50d35-f62c-47fd-bc9f-f46629b3143c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_800aea3e-6422-4053-8759-3943503542e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:to="loc_srt_ProductOrServiceAxis_800aea3e-6422-4053-8759-3943503542e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_800aea3e-6422-4053-8759-3943503542e2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_800aea3e-6422-4053-8759-3943503542e2" xlink:to="loc_srt_ProductsAndServicesDomain_800aea3e-6422-4053-8759-3943503542e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4f710090-a908-4a2f-abdd-ad3c27ad38fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_800aea3e-6422-4053-8759-3943503542e2" xlink:to="loc_srt_ProductsAndServicesDomain_4f710090-a908-4a2f-abdd-ad3c27ad38fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_dd8a50ad-3dab-4f67-92dd-5cb47ed8552a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4f710090-a908-4a2f-abdd-ad3c27ad38fe" xlink:to="loc_us-gaap_ServiceMember_dd8a50ad-3dab-4f67-92dd-5cb47ed8552a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_436c0ef0-15fe-48b6-b411-312259ee30b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:to="loc_srt_LitigationCaseAxis_436c0ef0-15fe-48b6-b411-312259ee30b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_436c0ef0-15fe-48b6-b411-312259ee30b7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_436c0ef0-15fe-48b6-b411-312259ee30b7" xlink:to="loc_srt_LitigationCaseTypeDomain_436c0ef0-15fe-48b6-b411-312259ee30b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_83cb1e78-e9eb-41d1-adc4-3a664883a4ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_436c0ef0-15fe-48b6-b411-312259ee30b7" xlink:to="loc_srt_LitigationCaseTypeDomain_83cb1e78-e9eb-41d1-adc4-3a664883a4ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_35f1ebcf-39df-4e33-b782-3031606cfafc" xlink:href="eols-20220930.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_83cb1e78-e9eb-41d1-adc4-3a664883a4ac" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_35f1ebcf-39df-4e33-b782-3031606cfafc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_485e9bbd-5ae1-46ef-b802-76b1df323414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_485e9bbd-5ae1-46ef-b802-76b1df323414" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_485e9bbd-5ae1-46ef-b802-76b1df323414_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_485e9bbd-5ae1-46ef-b802-76b1df323414" xlink:to="loc_us-gaap_EquityComponentDomain_485e9bbd-5ae1-46ef-b802-76b1df323414_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6173dacb-3bed-464d-8cfe-5081180ce3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_485e9bbd-5ae1-46ef-b802-76b1df323414" xlink:to="loc_us-gaap_EquityComponentDomain_6173dacb-3bed-464d-8cfe-5081180ce3b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a555be0f-a093-4b80-b4a7-28a300333785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6173dacb-3bed-464d-8cfe-5081180ce3b4" xlink:to="loc_us-gaap_CommonStockMember_a555be0f-a093-4b80-b4a7-28a300333785" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55c4a599-e12f-48d1-9ccd-7c2136fda9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55c4a599-e12f-48d1-9ccd-7c2136fda9ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_55c4a599-e12f-48d1-9ccd-7c2136fda9ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55c4a599-e12f-48d1-9ccd-7c2136fda9ee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_55c4a599-e12f-48d1-9ccd-7c2136fda9ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5653f58a-f991-4a38-83e0-e1fbf2f73be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55c4a599-e12f-48d1-9ccd-7c2136fda9ee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5653f58a-f991-4a38-83e0-e1fbf2f73be3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_687981a9-b88c-4e0a-895e-0bab060578cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5653f58a-f991-4a38-83e0-e1fbf2f73be3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_687981a9-b88c-4e0a-895e-0bab060578cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cec6e105-2d81-4f5e-b49c-86508438a3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5653f58a-f991-4a38-83e0-e1fbf2f73be3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cec6e105-2d81-4f5e-b49c-86508438a3e9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails" xlink:type="extended" id="i9f5641fa21504e4e97f038fa05fa03f9_FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b792bf5f-2f54-4d37-b667-73d772efc1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_bea1e26b-060b-4f74-a6c1-93955943e092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b792bf5f-2f54-4d37-b667-73d772efc1e7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_bea1e26b-060b-4f74-a6c1-93955943e092" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fc0b81c-a438-49c8-8fd8-465b066fea9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b792bf5f-2f54-4d37-b667-73d772efc1e7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fc0b81c-a438-49c8-8fd8-465b066fea9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_78504e01-33de-43b4-ba92-8c6eef6d4638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fc0b81c-a438-49c8-8fd8-465b066fea9f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_78504e01-33de-43b4-ba92-8c6eef6d4638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78504e01-33de-43b4-ba92-8c6eef6d4638_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78504e01-33de-43b4-ba92-8c6eef6d4638" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78504e01-33de-43b4-ba92-8c6eef6d4638_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6038ce39-b6bf-483e-a4ce-b0010651ae87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78504e01-33de-43b4-ba92-8c6eef6d4638" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6038ce39-b6bf-483e-a4ce-b0010651ae87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_631ad8f2-58e2-401a-8a22-f9459be4ec74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6038ce39-b6bf-483e-a4ce-b0010651ae87" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_631ad8f2-58e2-401a-8a22-f9459be4ec74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a4c354e-af41-40b9-b10a-f1e72f0d5135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fc0b81c-a438-49c8-8fd8-465b066fea9f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a4c354e-af41-40b9-b10a-f1e72f0d5135" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a4c354e-af41-40b9-b10a-f1e72f0d5135_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a4c354e-af41-40b9-b10a-f1e72f0d5135" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a4c354e-af41-40b9-b10a-f1e72f0d5135_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_085bafe8-88bc-4c50-a44e-3112cb7e3dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a4c354e-af41-40b9-b10a-f1e72f0d5135" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_085bafe8-88bc-4c50-a44e-3112cb7e3dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_914bed75-dfe6-42ed-a950-ade49a066e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_085bafe8-88bc-4c50-a44e-3112cb7e3dd3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_914bed75-dfe6-42ed-a950-ade49a066e4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1c039b21-2e59-4aaf-a70c-90e91f076166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_085bafe8-88bc-4c50-a44e-3112cb7e3dd3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1c039b21-2e59-4aaf-a70c-90e91f076166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5aa024ca-545c-4bfd-bb93-36f0b31c6f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_085bafe8-88bc-4c50-a44e-3112cb7e3dd3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5aa024ca-545c-4bfd-bb93-36f0b31c6f31" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" xlink:type="extended" id="id01f2a082cf64b28900aa59965117443_FairValueMeasurementsandShortTermInvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f598c638-ae15-4542-9f58-01e7312ca873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_78f451d7-20ba-416f-be59-71184d7bcc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f598c638-ae15-4542-9f58-01e7312ca873" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_78f451d7-20ba-416f-be59-71184d7bcc8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7846cdc7-18b1-4e83-9519-919115f65d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f598c638-ae15-4542-9f58-01e7312ca873" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7846cdc7-18b1-4e83-9519-919115f65d0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f598c638-ae15-4542-9f58-01e7312ca873" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7561a57e-0594-45eb-bc53-aa5a764ca7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7561a57e-0594-45eb-bc53-aa5a764ca7b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7561a57e-0594-45eb-bc53-aa5a764ca7b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7561a57e-0594-45eb-bc53-aa5a764ca7b2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7561a57e-0594-45eb-bc53-aa5a764ca7b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a802de0-3af8-4ba6-a56d-0f6dcb66ebc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7561a57e-0594-45eb-bc53-aa5a764ca7b2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a802de0-3af8-4ba6-a56d-0f6dcb66ebc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationMember_4a37ce80-b5c2-46c7-913e-a5380640adf0" xlink:href="eols-20220930.xsd#eols_ContingentRoyaltyObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a802de0-3af8-4ba6-a56d-0f6dcb66ebc3" xlink:to="loc_eols_ContingentRoyaltyObligationMember_4a37ce80-b5c2-46c7-913e-a5380640adf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a1472f3f-d9a5-435e-b6a3-d3b259f8c663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a1472f3f-d9a5-435e-b6a3-d3b259f8c663" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a1472f3f-d9a5-435e-b6a3-d3b259f8c663_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a1472f3f-d9a5-435e-b6a3-d3b259f8c663" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a1472f3f-d9a5-435e-b6a3-d3b259f8c663_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5d2aa8f0-3b5f-4591-b883-aba1377b6c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a1472f3f-d9a5-435e-b6a3-d3b259f8c663" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5d2aa8f0-3b5f-4591-b883-aba1377b6c2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_ca2aa0e0-0089-4c21-a1d1-7ccd6c5869f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5d2aa8f0-3b5f-4591-b883-aba1377b6c2e" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_ca2aa0e0-0089-4c21-a1d1-7ccd6c5869f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_fc896f26-99be-46b3-98f6-c7afaba720e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_fc896f26-99be-46b3-98f6-c7afaba720e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fc896f26-99be-46b3-98f6-c7afaba720e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fc896f26-99be-46b3-98f6-c7afaba720e0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fc896f26-99be-46b3-98f6-c7afaba720e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cbccba63-238f-4ab9-9741-5df3c3424663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fc896f26-99be-46b3-98f6-c7afaba720e0" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cbccba63-238f-4ab9-9741-5df3c3424663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5251cba9-394b-4d25-a147-9d795256981b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cbccba63-238f-4ab9-9741-5df3c3424663" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5251cba9-394b-4d25-a147-9d795256981b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e77d05b1-0010-4f48-99ff-e9f59bf35eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5251cba9-394b-4d25-a147-9d795256981b" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e77d05b1-0010-4f48-99ff-e9f59bf35eb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d5f7700e-6450-49c3-b0dd-48f40d67bf37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:to="loc_us-gaap_DebtInstrumentAxis_d5f7700e-6450-49c3-b0dd-48f40d67bf37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d5f7700e-6450-49c3-b0dd-48f40d67bf37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d5f7700e-6450-49c3-b0dd-48f40d67bf37" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d5f7700e-6450-49c3-b0dd-48f40d67bf37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_513f549c-9f1d-4526-a8ac-6eb2352a9bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d5f7700e-6450-49c3-b0dd-48f40d67bf37" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_513f549c-9f1d-4526-a8ac-6eb2352a9bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_b3c08b38-488c-4de3-a624-439c89eea39b" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_513f549c-9f1d-4526-a8ac-6eb2352a9bc8" xlink:to="loc_eols_PharmakonTermLoansMember_b3c08b38-488c-4de3-a624-439c89eea39b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended" id="ic4b370bcc2464a2689036dd4ce0b0b39_GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8030833a-4a35-41f6-9de7-cbc2b9724565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b2c9ff9-432b-4b99-b3d3-88ff20fef77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8030833a-4a35-41f6-9de7-cbc2b9724565" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b2c9ff9-432b-4b99-b3d3-88ff20fef77c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_41b01d1c-b522-4a2d-bc4c-0ed00a2c178d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b2c9ff9-432b-4b99-b3d3-88ff20fef77c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_41b01d1c-b522-4a2d-bc4c-0ed00a2c178d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f737771b-01bb-457c-af1a-757a9c0e9ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b2c9ff9-432b-4b99-b3d3-88ff20fef77c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f737771b-01bb-457c-af1a-757a9c0e9ec1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_437fa5fb-4f3c-4a57-a6de-ba584d9b664d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b2c9ff9-432b-4b99-b3d3-88ff20fef77c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_437fa5fb-4f3c-4a57-a6de-ba584d9b664d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce0ed87e-8421-441b-a7ce-6e8e0b66b14f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b2c9ff9-432b-4b99-b3d3-88ff20fef77c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce0ed87e-8421-441b-a7ce-6e8e0b66b14f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_34383603-e949-49d7-9c42-6c0f46cc799a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8030833a-4a35-41f6-9de7-cbc2b9724565" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_34383603-e949-49d7-9c42-6c0f46cc799a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_cfd877f7-c63b-44a6-b3fd-383c912b1fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_34383603-e949-49d7-9c42-6c0f46cc799a" xlink:to="loc_us-gaap_Goodwill_cfd877f7-c63b-44a6-b3fd-383c912b1fb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_964f5b16-fcd0-4551-b7f2-fb4bc48f6434" xlink:href="eols-20220930.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8030833a-4a35-41f6-9de7-cbc2b9724565" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_964f5b16-fcd0-4551-b7f2-fb4bc48f6434" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_9473c9c1-3806-41d9-9e78-bd39e2f3d631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8030833a-4a35-41f6-9de7-cbc2b9724565" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_9473c9c1-3806-41d9-9e78-bd39e2f3d631" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_93d75a67-f34e-4a19-b22f-9e78bc88418e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8030833a-4a35-41f6-9de7-cbc2b9724565" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_93d75a67-f34e-4a19-b22f-9e78bc88418e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d041b4de-d045-4fad-821d-b53d941ea063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_93d75a67-f34e-4a19-b22f-9e78bc88418e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d041b4de-d045-4fad-821d-b53d941ea063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d041b4de-d045-4fad-821d-b53d941ea063_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d041b4de-d045-4fad-821d-b53d941ea063" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d041b4de-d045-4fad-821d-b53d941ea063_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_08641364-efe6-4073-821b-100ddd8b6196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d041b4de-d045-4fad-821d-b53d941ea063" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_08641364-efe6-4073-821b-100ddd8b6196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_a7d4a70c-393f-405d-89d8-2658659d5f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_08641364-efe6-4073-821b-100ddd8b6196" xlink:to="loc_us-gaap_DistributionRightsMember_a7d4a70c-393f-405d-89d8-2658659d5f98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_e8de7051-b611-4c0a-9f20-2ed2a5603640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_08641364-efe6-4073-821b-100ddd8b6196" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_e8de7051-b611-4c0a-9f20-2ed2a5603640" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#GoodwillandIntangibleAssetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails" xlink:type="extended" id="ia1794f76c84f459ab87e9c7560fdf60b_GoodwillandIntangibleAssetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ff7dbed9-3b44-426b-8445-4c3207ff7b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_e0c1273e-b3f5-407b-a82c-abed5e2cd0a1" xlink:href="eols-20220930.xsd#eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ff7dbed9-3b44-426b-8445-4c3207ff7b27" xlink:to="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_e0c1273e-b3f5-407b-a82c-abed5e2cd0a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_9b76bed5-4daa-4750-801f-bc130c09a6f1" xlink:href="eols-20220930.xsd#eols_MilestonePaymentsForIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ff7dbed9-3b44-426b-8445-4c3207ff7b27" xlink:to="loc_eols_MilestonePaymentsForIntangibleAssets_9b76bed5-4daa-4750-801f-bc130c09a6f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_222365ea-ecb5-42fd-99c6-e4de5c219529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ff7dbed9-3b44-426b-8445-4c3207ff7b27" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_222365ea-ecb5-42fd-99c6-e4de5c219529" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f2fd660f-3475-4c5c-bb25-2339fcdc24f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ff7dbed9-3b44-426b-8445-4c3207ff7b27" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f2fd660f-3475-4c5c-bb25-2339fcdc24f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_339ffc10-860c-4356-b340-ea27712517e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ff7dbed9-3b44-426b-8445-4c3207ff7b27" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_339ffc10-860c-4356-b340-ea27712517e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_43a776fb-7379-4d6a-ad1d-546bf21e5816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_339ffc10-860c-4356-b340-ea27712517e8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_43a776fb-7379-4d6a-ad1d-546bf21e5816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43a776fb-7379-4d6a-ad1d-546bf21e5816_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43a776fb-7379-4d6a-ad1d-546bf21e5816" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43a776fb-7379-4d6a-ad1d-546bf21e5816_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d71dcdc7-6a12-4bd7-81ca-389f281e1b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43a776fb-7379-4d6a-ad1d-546bf21e5816" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d71dcdc7-6a12-4bd7-81ca-389f281e1b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EvolusIncMember_8c422ac8-3df2-4db6-9d42-2c0310c946aa" xlink:href="eols-20220930.xsd#eols_EvolusIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d71dcdc7-6a12-4bd7-81ca-389f281e1b85" xlink:to="loc_eols_EvolusIncMember_8c422ac8-3df2-4db6-9d42-2c0310c946aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_72bcf51a-91a5-4728-a7cc-7fa5af2871d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_339ffc10-860c-4356-b340-ea27712517e8" xlink:to="loc_dei_LegalEntityAxis_72bcf51a-91a5-4728-a7cc-7fa5af2871d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_72bcf51a-91a5-4728-a7cc-7fa5af2871d1_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_72bcf51a-91a5-4728-a7cc-7fa5af2871d1" xlink:to="loc_dei_EntityDomain_72bcf51a-91a5-4728-a7cc-7fa5af2871d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ef7dd189-e768-47b3-af27-93f59ea4b461" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_72bcf51a-91a5-4728-a7cc-7fa5af2871d1" xlink:to="loc_dei_EntityDomain_ef7dd189-e768-47b3-af27-93f59ea4b461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SCHAEONLLCMember_fe862b4a-d7d4-4c5e-84e9-fd176f9521e2" xlink:href="eols-20220930.xsd#eols_SCHAEONLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ef7dd189-e768-47b3-af27-93f59ea4b461" xlink:to="loc_eols_SCHAEONLLCMember_fe862b4a-d7d4-4c5e-84e9-fd176f9521e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#TermLoansPharmakonTermLoansDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails" xlink:type="extended" id="i135cbdf3803d469ca65b54ad12f05b33_TermLoansPharmakonTermLoansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfTranches_7d32b062-3421-4b34-8b7b-bff84de279de" xlink:href="eols-20220930.xsd#eols_DebtInstrumentNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_eols_DebtInstrumentNumberOfTranches_7d32b062-3421-4b34-8b7b-bff84de279de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_66ad7032-00bf-4380-830c-43bdd3a34f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_66ad7032-00bf-4380-830c-43bdd3a34f31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_918cc369-e4ed-4f74-816e-9bbbca68eaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentTerm_918cc369-e4ed-4f74-816e-9bbbca68eaf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_638e5dca-cb25-4bde-8cc7-0404fd8ab6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_638e5dca-cb25-4bde-8cc7-0404fd8ab6aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_22071f6a-e7ad-4354-a464-e285ad7cbe9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_22071f6a-e7ad-4354-a464-e285ad7cbe9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_c411e776-61e6-4926-a3b2-421120b62979" xlink:href="eols-20220930.xsd#eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_c411e776-61e6-4926-a3b2-421120b62979" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_148f36b8-dd74-40c3-814a-1f548b791895" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_148f36b8-dd74-40c3-814a-1f548b791895" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentAmountThreshold_700abd2e-db98-4666-a6e1-f4fa303c34b3" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_eols_DebtInstrumentPrepaymentAmountThreshold_700abd2e-db98-4666-a6e1-f4fa303c34b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_d74cce3a-b999-4eef-9ee8-f12fad322ad7" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_d74cce3a-b999-4eef-9ee8-f12fad322ad7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6fe96342-0c00-4c73-aac5-0a644aab7bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6fe96342-0c00-4c73-aac5-0a644aab7bda" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_1fa3bf4a-2ed7-4e1f-b220-4aec314dd8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_1fa3bf4a-2ed7-4e1f-b220-4aec314dd8c3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_89e64bcb-bd51-45e7-955a-3b4fc02f2fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_89e64bcb-bd51-45e7-955a-3b4fc02f2fd0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9a6c0238-e197-4dde-9454-c1091e4d6b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:to="loc_us-gaap_DebtInstrumentAxis_9a6c0238-e197-4dde-9454-c1091e4d6b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9a6c0238-e197-4dde-9454-c1091e4d6b52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9a6c0238-e197-4dde-9454-c1091e4d6b52" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9a6c0238-e197-4dde-9454-c1091e4d6b52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_07aae266-2122-42a4-9bd3-0cf3b807432b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9a6c0238-e197-4dde-9454-c1091e4d6b52" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_07aae266-2122-42a4-9bd3-0cf3b807432b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_55d5c0aa-84b5-4937-8ee5-12bf75dcff33" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07aae266-2122-42a4-9bd3-0cf3b807432b" xlink:to="loc_eols_PharmakonTermLoansMember_55d5c0aa-84b5-4937-8ee5-12bf75dcff33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember_083e2b2e-684b-4b73-b609-a7ca84645090" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07aae266-2122-42a4-9bd3-0cf3b807432b" xlink:to="loc_eols_PharmakonTermLoansOneMember_083e2b2e-684b-4b73-b609-a7ca84645090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember_8e18519b-98cb-42bc-b470-ec100cad07fd" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07aae266-2122-42a4-9bd3-0cf3b807432b" xlink:to="loc_eols_PharmakonTermLoansTwoMember_8e18519b-98cb-42bc-b470-ec100cad07fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5fff515d-4ed5-483d-84cc-c8d2f14a243e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5fff515d-4ed5-483d-84cc-c8d2f14a243e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5fff515d-4ed5-483d-84cc-c8d2f14a243e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5fff515d-4ed5-483d-84cc-c8d2f14a243e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5fff515d-4ed5-483d-84cc-c8d2f14a243e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dd190949-6a7d-49f5-ba71-8394823882f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5fff515d-4ed5-483d-84cc-c8d2f14a243e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dd190949-6a7d-49f5-ba71-8394823882f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3b2db3e9-9866-4bc2-b54a-b25e760686e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dd190949-6a7d-49f5-ba71-8394823882f5" xlink:to="loc_us-gaap_SecuredDebtMember_3b2db3e9-9866-4bc2-b54a-b25e760686e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_a6334ff2-7e65-4459-9a1e-2a32787b68c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:to="loc_us-gaap_VariableRateAxis_a6334ff2-7e65-4459-9a1e-2a32787b68c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a6334ff2-7e65-4459-9a1e-2a32787b68c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_a6334ff2-7e65-4459-9a1e-2a32787b68c5" xlink:to="loc_us-gaap_VariableRateDomain_a6334ff2-7e65-4459-9a1e-2a32787b68c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_209bf528-8b57-4734-8072-7039e0a8e1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_a6334ff2-7e65-4459-9a1e-2a32787b68c5" xlink:to="loc_us-gaap_VariableRateDomain_209bf528-8b57-4734-8072-7039e0a8e1b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_b26a87dd-2312-4411-b56b-d502958687e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_209bf528-8b57-4734-8072-7039e0a8e1b6" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_b26a87dd-2312-4411-b56b-d502958687e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsAxis_73a9d4e4-3d41-4a45-9d4b-36a82521b8b2" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsAxis_73a9d4e4-3d41-4a45-9d4b-36a82521b8b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsDomain_73a9d4e4-3d41-4a45-9d4b-36a82521b8b2_default" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsAxis_73a9d4e4-3d41-4a45-9d4b-36a82521b8b2" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsDomain_73a9d4e4-3d41-4a45-9d4b-36a82521b8b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsDomain_c6261d3b-d29f-46f3-bde6-ee49d53ef41d" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsAxis_73a9d4e4-3d41-4a45-9d4b-36a82521b8b2" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsDomain_c6261d3b-d29f-46f3-bde6-ee49d53ef41d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermOneMember_2af0b4c7-a459-4bf9-ae51-31ac7d5f622a" xlink:href="eols-20220930.xsd#eols_TermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_c6261d3b-d29f-46f3-bde6-ee49d53ef41d" xlink:to="loc_eols_TermOneMember_2af0b4c7-a459-4bf9-ae51-31ac7d5f622a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermTwoMember_1fbf6c5c-10b6-4b97-86e8-24aacf73d23a" xlink:href="eols-20220930.xsd#eols_TermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_c6261d3b-d29f-46f3-bde6-ee49d53ef41d" xlink:to="loc_eols_TermTwoMember_1fbf6c5c-10b6-4b97-86e8-24aacf73d23a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermThreeMember_3d66a98e-e241-4469-a387-cbef8c12dc4f" xlink:href="eols-20220930.xsd#eols_TermThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_c6261d3b-d29f-46f3-bde6-ee49d53ef41d" xlink:to="loc_eols_TermThreeMember_3d66a98e-e241-4469-a387-cbef8c12dc4f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansOxfordTermLoansDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#TermLoansOxfordTermLoansDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/TermLoansOxfordTermLoansDetails" xlink:type="extended" id="i81279e4694434fcdbe5e5f22d6a8a439_TermLoansOxfordTermLoansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2c401b72-fa0a-4cfb-98bf-f06b620f7144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2c401b72-fa0a-4cfb-98bf-f06b620f7144" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LineofCreditFacilityNumberofAdvances_f2b45d4c-3c7c-4b60-8442-6a613cb44a5e" xlink:href="eols-20220930.xsd#eols_LineofCreditFacilityNumberofAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_LineofCreditFacilityNumberofAdvances_f2b45d4c-3c7c-4b60-8442-6a613cb44a5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dbcf82f3-0ce7-41de-9b21-18af231d59f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dbcf82f3-0ce7-41de-9b21-18af231d59f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d0819420-69e0-419d-8a41-6620a9672aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d0819420-69e0-419d-8a41-6620a9672aa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_1e9b9722-d390-4312-8b53-c4ec6ffdedbc" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_1e9b9722-d390-4312-8b53-c4ec6ffdedbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_13431239-2272-44d5-8b9b-c8c45b6eaa93" xlink:href="eols-20220930.xsd#eols_DebtInstrumentAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentAmortizationPeriod_13431239-2272-44d5-8b9b-c8c45b6eaa93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_dd2effa9-e6fe-4621-b611-fa65526c713b" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_dd2effa9-e6fe-4621-b611-fa65526c713b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_7d9086ba-1173-4d99-9495-75e5957a6b30" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_7d9086ba-1173-4d99-9495-75e5957a6b30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_10e65f9b-605d-4826-ac48-4acfe4ea59b0" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_10e65f9b-605d-4826-ac48-4acfe4ea59b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_038e8675-99f0-4f4a-8219-4bedde93a28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_038e8675-99f0-4f4a-8219-4bedde93a28d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentFeeAmountWaived_15b1cf14-8b4e-4d96-83ef-cc0bb6a62f1e" xlink:href="eols-20220930.xsd#eols_DebtInstrumentFeeAmountWaived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentFeeAmountWaived_15b1cf14-8b4e-4d96-83ef-cc0bb6a62f1e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentOfFinalPaymentAmountWaived_508bf169-aab5-4245-b0e8-3cc4af7125e8" xlink:href="eols-20220930.xsd#eols_DebtInstrumentOfFinalPaymentAmountWaived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentOfFinalPaymentAmountWaived_508bf169-aab5-4245-b0e8-3cc4af7125e8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeeAmountWaived_15ddbdf5-b4f5-4aba-9c5c-92e8161716c4" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentFeeAmountWaived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentPrepaymentFeeAmountWaived_15ddbdf5-b4f5-4aba-9c5c-92e8161716c4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8447b487-06e9-4a04-8af3-c153c5630907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8447b487-06e9-4a04-8af3-c153c5630907" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2319400e-8ab9-4694-b585-1e00cacf0b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_us-gaap_DebtInstrumentTable_2319400e-8ab9-4694-b585-1e00cacf0b4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1e054864-8fb8-46a4-908d-3a83f1035c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2319400e-8ab9-4694-b585-1e00cacf0b4c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1e054864-8fb8-46a4-908d-3a83f1035c13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1e054864-8fb8-46a4-908d-3a83f1035c13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1e054864-8fb8-46a4-908d-3a83f1035c13" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1e054864-8fb8-46a4-908d-3a83f1035c13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a8a9c2ce-2452-4eaa-adcc-6fc4ac0d3dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1e054864-8fb8-46a4-908d-3a83f1035c13" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a8a9c2ce-2452-4eaa-adcc-6fc4ac0d3dfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_9a2153fd-abca-428b-97c0-f0698e46a5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a8a9c2ce-2452-4eaa-adcc-6fc4ac0d3dfe" xlink:to="loc_us-gaap_SecuredDebtMember_9a2153fd-abca-428b-97c0-f0698e46a5cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6c82e792-5f0b-4b6f-a11b-70b6b2e86a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2319400e-8ab9-4694-b585-1e00cacf0b4c" xlink:to="loc_us-gaap_DebtInstrumentAxis_6c82e792-5f0b-4b6f-a11b-70b6b2e86a6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6c82e792-5f0b-4b6f-a11b-70b6b2e86a6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6c82e792-5f0b-4b6f-a11b-70b6b2e86a6e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6c82e792-5f0b-4b6f-a11b-70b6b2e86a6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a212fba9-1134-4f24-9ca4-ac058aeee946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6c82e792-5f0b-4b6f-a11b-70b6b2e86a6e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a212fba9-1134-4f24-9ca4-ac058aeee946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityTrancheOneMember_a0d5b384-22eb-43e5-ba2c-0fdc281f81bb" xlink:href="eols-20220930.xsd#eols_OxfordTermLoanFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a212fba9-1134-4f24-9ca4-ac058aeee946" xlink:to="loc_eols_OxfordTermLoanFacilityTrancheOneMember_a0d5b384-22eb-43e5-ba2c-0fdc281f81bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityTrancheTwoMember_45c1bb82-2e00-4852-8676-062cb170944d" xlink:href="eols-20220930.xsd#eols_OxfordTermLoanFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a212fba9-1134-4f24-9ca4-ac058aeee946" xlink:to="loc_eols_OxfordTermLoanFacilityTrancheTwoMember_45c1bb82-2e00-4852-8676-062cb170944d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermLoanFacilityMember_6e0da36a-3275-4bad-9d6c-791baafeb53f" xlink:href="eols-20220930.xsd#eols_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a212fba9-1134-4f24-9ca4-ac058aeee946" xlink:to="loc_eols_TermLoanFacilityMember_6e0da36a-3275-4bad-9d6c-791baafeb53f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityMember_13b52471-2b3a-489f-959a-c0f83989630e" xlink:href="eols-20220930.xsd#eols_OxfordTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a212fba9-1134-4f24-9ca4-ac058aeee946" xlink:to="loc_eols_OxfordTermLoanFacilityMember_13b52471-2b3a-489f-959a-c0f83989630e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_966bf7e9-2406-4bd0-a037-36c57d68e74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2319400e-8ab9-4694-b585-1e00cacf0b4c" xlink:to="loc_us-gaap_VariableRateAxis_966bf7e9-2406-4bd0-a037-36c57d68e74b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_966bf7e9-2406-4bd0-a037-36c57d68e74b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_966bf7e9-2406-4bd0-a037-36c57d68e74b" xlink:to="loc_us-gaap_VariableRateDomain_966bf7e9-2406-4bd0-a037-36c57d68e74b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b84fcff4-95fa-455d-b056-809f4c1a24a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_966bf7e9-2406-4bd0-a037-36c57d68e74b" xlink:to="loc_us-gaap_VariableRateDomain_b84fcff4-95fa-455d-b056-809f4c1a24a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9f81e176-c4db-4d70-b167-04ec6008013b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b84fcff4-95fa-455d-b056-809f4c1a24a1" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9f81e176-c4db-4d70-b167-04ec6008013b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DaewoongConvertibleNoteDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#DaewoongConvertibleNoteDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/DaewoongConvertibleNoteDetails" xlink:type="extended" id="i91adf5b46d74421f824375a68a64be58_DaewoongConvertibleNoteDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8b87c7b7-8f8d-4c21-869b-98f3f1d0377e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8b87c7b7-8f8d-4c21-869b-98f3f1d0377e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ceffc1f-59db-4b0c-a5c5-3106193d790d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ceffc1f-59db-4b0c-a5c5-3106193d790d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_a0c3daa9-8868-4620-8ffd-6e3d0df95039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_ConvertibleDebt_a0c3daa9-8868-4620-8ffd-6e3d0df95039" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4c6851fc-f625-4018-a896-36f698805de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4c6851fc-f625-4018-a896-36f698805de9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_a53ad1a6-54a7-40e5-8c3d-a259ec32571e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_a53ad1a6-54a7-40e5-8c3d-a259ec32571e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_343957a8-19e1-477b-abf4-5ba4ac2278c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_343957a8-19e1-477b-abf4-5ba4ac2278c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_f2fbad7f-52e8-491b-a013-5d23958c765d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_f2fbad7f-52e8-491b-a013-5d23958c765d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_664cddd9-20ec-4237-b3a6-250425ab35e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_f2fbad7f-52e8-491b-a013-5d23958c765d" xlink:to="loc_us-gaap_DebtInstrumentAxis_664cddd9-20ec-4237-b3a6-250425ab35e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_664cddd9-20ec-4237-b3a6-250425ab35e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_664cddd9-20ec-4237-b3a6-250425ab35e8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_664cddd9-20ec-4237-b3a6-250425ab35e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_434a4fbb-e1ed-4f67-b22d-c11d2a86b3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_664cddd9-20ec-4237-b3a6-250425ab35e8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_434a4fbb-e1ed-4f67-b22d-c11d2a86b3a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_5d415b1b-f993-40f0-9291-653c3d303308" xlink:href="eols-20220930.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_434a4fbb-e1ed-4f67-b22d-c11d2a86b3a4" xlink:to="loc_eols_DaewoongConvertibleNoteMember_5d415b1b-f993-40f0-9291-653c3d303308" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5b891567-9c52-4556-b805-7391fc52016f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_f2fbad7f-52e8-491b-a013-5d23958c765d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5b891567-9c52-4556-b805-7391fc52016f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5b891567-9c52-4556-b805-7391fc52016f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5b891567-9c52-4556-b805-7391fc52016f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5b891567-9c52-4556-b805-7391fc52016f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a02e8dfd-f514-4718-8baa-cbf3994247c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5b891567-9c52-4556-b805-7391fc52016f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a02e8dfd-f514-4718-8baa-cbf3994247c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_9e940c03-14b3-4c84-a692-1d5f64ae5d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a02e8dfd-f514-4718-8baa-cbf3994247c4" xlink:to="loc_us-gaap_ConvertibleDebtMember_9e940c03-14b3-4c84-a692-1d5f64ae5d4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_79d00c80-337b-4239-939f-5bd519ea77fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_f2fbad7f-52e8-491b-a013-5d23958c765d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_79d00c80-337b-4239-939f-5bd519ea77fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_79d00c80-337b-4239-939f-5bd519ea77fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_79d00c80-337b-4239-939f-5bd519ea77fc" xlink:to="loc_us-gaap_EquityComponentDomain_79d00c80-337b-4239-939f-5bd519ea77fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c5c817cf-b231-4421-8a63-469d161d1030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_79d00c80-337b-4239-939f-5bd519ea77fc" xlink:to="loc_us-gaap_EquityComponentDomain_c5c817cf-b231-4421-8a63-469d161d1030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b065a08f-b78c-40cc-9496-87ef76969bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c5c817cf-b231-4421-8a63-469d161d1030" xlink:to="loc_us-gaap_CommonStockMember_b065a08f-b78c-40cc-9496-87ef76969bf1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i8d9f9a6d356e4bcf958f0eb801b6997b_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e47b6a66-0847-484b-b960-b6ab178db0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e47b6a66-0847-484b-b960-b6ab178db0d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d60cac02-1d1c-4c39-9aee-88f6132f6c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d60cac02-1d1c-4c39-9aee-88f6132f6c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1af71d52-7458-4f78-af47-61e61a17a721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1af71d52-7458-4f78-af47-61e61a17a721" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_fef9ace8-73c8-4a51-a571-e52784d8de6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_fef9ace8-73c8-4a51-a571-e52784d8de6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2712bca7-9c41-4cdc-b387-db9105f195be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2712bca7-9c41-4cdc-b387-db9105f195be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a2e38174-229d-47aa-8481-743c2e05d8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a2e38174-229d-47aa-8481-743c2e05d8a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6f00e11a-0a77-4b70-97b9-e9ac764b725f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6f00e11a-0a77-4b70-97b9-e9ac764b725f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5e5f9b52-2939-4d3d-a017-7e9a45c701d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_CommonStockSharesIssued_5e5f9b52-2939-4d3d-a017-7e9a45c701d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_b4dea2a3-94f9-4b2b-8d39-d699d38c9315" xlink:href="eols-20220930.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_b4dea2a3-94f9-4b2b-8d39-d699d38c9315" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_b247d14f-9742-44f1-a36e-e4402af8d603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_b247d14f-9742-44f1-a36e-e4402af8d603" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockMaximumConsiderationReceivable_e6c843e5-8031-4f35-a9ca-59466cb3de10" xlink:href="eols-20220930.xsd#eols_SaleOfStockMaximumConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_eols_SaleOfStockMaximumConsiderationReceivable_e6c843e5-8031-4f35-a9ca-59466cb3de10" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_e6f88b22-3a5c-4f3f-8055-40ebf98ae97f" xlink:href="eols-20220930.xsd#eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_e6f88b22-3a5c-4f3f-8055-40ebf98ae97f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_22a49b3b-3c36-402e-83d0-16718ad3c119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_22a49b3b-3c36-402e-83d0-16718ad3c119" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e8fda76f-7a42-4449-a72d-fd4ed20a55cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e8fda76f-7a42-4449-a72d-fd4ed20a55cd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaid_a34b5efd-56f6-4dac-9d72-82aa7caee353" xlink:href="eols-20220930.xsd#eols_SaleOfStockCommissionPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_eols_SaleOfStockCommissionPaid_a34b5efd-56f6-4dac-9d72-82aa7caee353" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e86035fb-39ae-4074-a4e9-8e4490188c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e86035fb-39ae-4074-a4e9-8e4490188c85" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_ac4fd804-6150-4269-9981-b5ef9be68da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_ac4fd804-6150-4269-9981-b5ef9be68da3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_058067f1-cdd0-4bb9-973d-53eea009a9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_058067f1-cdd0-4bb9-973d-53eea009a9f1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bf7c2a2c-d7b5-46cb-b82b-796308610861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bf7c2a2c-d7b5-46cb-b82b-796308610861" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51578769-472d-4d90-bb88-6faefeac26a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51578769-472d-4d90-bb88-6faefeac26a0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bae946bf-8d27-4048-bc53-8ee36ee3bb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bae946bf-8d27-4048-bc53-8ee36ee3bb6a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f7cbc3a2-e5f4-43cb-8d96-904607fac270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f7cbc3a2-e5f4-43cb-8d96-904607fac270" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_97c043ed-a39a-456d-b43d-aef7c4d16680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_97c043ed-a39a-456d-b43d-aef7c4d16680" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_73c138fb-dd23-4992-9ada-489b0611a554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_73c138fb-dd23-4992-9ada-489b0611a554" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f650f66b-e11d-478d-b20b-3f2704102660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f650f66b-e11d-478d-b20b-3f2704102660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f650f66b-e11d-478d-b20b-3f2704102660_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f650f66b-e11d-478d-b20b-3f2704102660" xlink:to="loc_us-gaap_EquityComponentDomain_f650f66b-e11d-478d-b20b-3f2704102660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b294f025-edc4-4fde-a32c-204729742e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f650f66b-e11d-478d-b20b-3f2704102660" xlink:to="loc_us-gaap_EquityComponentDomain_b294f025-edc4-4fde-a32c-204729742e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_51b4e66e-c87e-4fbe-915f-56ba124f53d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b294f025-edc4-4fde-a32c-204729742e93" xlink:to="loc_us-gaap_CommonStockMember_51b4e66e-c87e-4fbe-915f-56ba124f53d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f4ef2f0d-8ce5-480b-9742-305238f49b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b294f025-edc4-4fde-a32c-204729742e93" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f4ef2f0d-8ce5-480b-9742-305238f49b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_893390ef-8da7-45fb-b2e7-d37aa36f40c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_us-gaap_DebtInstrumentAxis_893390ef-8da7-45fb-b2e7-d37aa36f40c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_893390ef-8da7-45fb-b2e7-d37aa36f40c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_893390ef-8da7-45fb-b2e7-d37aa36f40c1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_893390ef-8da7-45fb-b2e7-d37aa36f40c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_41404cb4-26f6-4075-a2e2-572aa94b5c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_893390ef-8da7-45fb-b2e7-d37aa36f40c1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_41404cb4-26f6-4075-a2e2-572aa94b5c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_470c4ebe-eb5c-43f7-9d6c-841c3b965bdc" xlink:href="eols-20220930.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_41404cb4-26f6-4075-a2e2-572aa94b5c80" xlink:to="loc_eols_DaewoongConvertibleNoteMember_470c4ebe-eb5c-43f7-9d6c-841c3b965bdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3269727b-715a-4826-9c02-18f9eb6d962f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3269727b-715a-4826-9c02-18f9eb6d962f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3269727b-715a-4826-9c02-18f9eb6d962f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3269727b-715a-4826-9c02-18f9eb6d962f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3269727b-715a-4826-9c02-18f9eb6d962f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3d8dd003-d437-47f8-88d2-ebaee5875725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3269727b-715a-4826-9c02-18f9eb6d962f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3d8dd003-d437-47f8-88d2-ebaee5875725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_469e93bd-c3db-47e8-86b3-2c08b47cbd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3d8dd003-d437-47f8-88d2-ebaee5875725" xlink:to="loc_us-gaap_ConvertibleDebtMember_469e93bd-c3db-47e8-86b3-2c08b47cbd17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_32c48bcc-c97a-4f6a-86d8-4b6d5fa3f89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_32c48bcc-c97a-4f6a-86d8-4b6d5fa3f89e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_32c48bcc-c97a-4f6a-86d8-4b6d5fa3f89e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_32c48bcc-c97a-4f6a-86d8-4b6d5fa3f89e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_32c48bcc-c97a-4f6a-86d8-4b6d5fa3f89e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6726f6d-d151-42cf-a424-f2483375fd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_32c48bcc-c97a-4f6a-86d8-4b6d5fa3f89e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6726f6d-d151-42cf-a424-f2483375fd7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_d1c956b9-0672-4a52-8fdd-11afd32149e7" xlink:href="eols-20220930.xsd#eols_ATMSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6726f6d-d151-42cf-a424-f2483375fd7e" xlink:to="loc_eols_ATMSalesAgreementMember_d1c956b9-0672-4a52-8fdd-11afd32149e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_47e55cfe-2614-4a01-8602-334c9c4efe4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_us-gaap_AwardTypeAxis_47e55cfe-2614-4a01-8602-334c9c4efe4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47e55cfe-2614-4a01-8602-334c9c4efe4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_47e55cfe-2614-4a01-8602-334c9c4efe4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47e55cfe-2614-4a01-8602-334c9c4efe4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_419909c7-6384-4a5b-a57f-c53e5d02e966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_47e55cfe-2614-4a01-8602-334c9c4efe4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_419909c7-6384-4a5b-a57f-c53e5d02e966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_20727d74-6f9f-48af-9316-f70ca66cfc57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_419909c7-6384-4a5b-a57f-c53e5d02e966" xlink:to="loc_us-gaap_EmployeeStockOptionMember_20727d74-6f9f-48af-9316-f70ca66cfc57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_211e8952-8193-4325-8a3e-8b4419b049d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_419909c7-6384-4a5b-a57f-c53e5d02e966" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_211e8952-8193-4325-8a3e-8b4419b049d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_71b66230-d319-42fd-ad0c-a3aae72446e1" xlink:href="eols-20220930.xsd#eols_RestrictedStockUnitsRSUsMarketConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_419909c7-6384-4a5b-a57f-c53e5d02e966" xlink:to="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_71b66230-d319-42fd-ad0c-a3aae72446e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_8093c0f0-cca8-4e60-a007-d3737a0f16e2" xlink:href="eols-20220930.xsd#eols_RestrictedStockUnitsRSUsPerformanceConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_419909c7-6384-4a5b-a57f-c53e5d02e966" xlink:to="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_8093c0f0-cca8-4e60-a007-d3737a0f16e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d9825905-49f0-4714-9134-2059978d9c95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_srt_RangeAxis_d9825905-49f0-4714-9134-2059978d9c95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9825905-49f0-4714-9134-2059978d9c95_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d9825905-49f0-4714-9134-2059978d9c95" xlink:to="loc_srt_RangeMember_d9825905-49f0-4714-9134-2059978d9c95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_580b2fee-35fb-44ea-8ede-1753a5212390" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d9825905-49f0-4714-9134-2059978d9c95" xlink:to="loc_srt_RangeMember_580b2fee-35fb-44ea-8ede-1753a5212390" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3d56a5ec-b70d-4ee2-b74c-209e7eff8d5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_580b2fee-35fb-44ea-8ede-1753a5212390" xlink:to="loc_srt_MinimumMember_3d56a5ec-b70d-4ee2-b74c-209e7eff8d5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_63c323f5-de38-4772-84cb-d2045c17155f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_580b2fee-35fb-44ea-8ede-1753a5212390" xlink:to="loc_srt_MaximumMember_63c323f5-de38-4772-84cb-d2045c17155f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#StockholdersEquityScheduleofValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails" xlink:type="extended" id="i52c5443e60cb4fc4ae3b1ead2be0fcc0_StockholdersEquityScheduleofValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_284941e0-5686-4d8a-87b7-75874a45117f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1f4b998d-9576-4a88-b8f6-a7ef4d9212bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_284941e0-5686-4d8a-87b7-75874a45117f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1f4b998d-9576-4a88-b8f6-a7ef4d9212bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c22e1ac0-10cb-4d58-9f56-19fa83d1ee4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_284941e0-5686-4d8a-87b7-75874a45117f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c22e1ac0-10cb-4d58-9f56-19fa83d1ee4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_603c70b4-65ea-43e3-bda7-3e03550046ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_284941e0-5686-4d8a-87b7-75874a45117f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_603c70b4-65ea-43e3-bda7-3e03550046ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_88db13a6-b462-4695-8e29-844da917332a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_284941e0-5686-4d8a-87b7-75874a45117f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_88db13a6-b462-4695-8e29-844da917332a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3c05c3e6-08b0-490f-864a-f725ecaab93d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_284941e0-5686-4d8a-87b7-75874a45117f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3c05c3e6-08b0-490f-864a-f725ecaab93d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_55b590b6-ed17-408f-af00-99122e1eff3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3c05c3e6-08b0-490f-864a-f725ecaab93d" xlink:to="loc_us-gaap_AwardTypeAxis_55b590b6-ed17-408f-af00-99122e1eff3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55b590b6-ed17-408f-af00-99122e1eff3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_55b590b6-ed17-408f-af00-99122e1eff3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55b590b6-ed17-408f-af00-99122e1eff3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d38eda95-e10d-41fd-8583-073a07f30bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_55b590b6-ed17-408f-af00-99122e1eff3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d38eda95-e10d-41fd-8583-073a07f30bd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3bdbc279-27c5-4966-965e-133aacafbc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d38eda95-e10d-41fd-8583-073a07f30bd2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3bdbc279-27c5-4966-965e-133aacafbc78" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#StockholdersEquityScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="extended" id="i530e157b06514d378c30393e08c403d7_StockholdersEquityScheduleofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_348ebb6b-badb-455c-8751-629aaaf0219a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_348ebb6b-badb-455c-8751-629aaaf0219a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7e6b0a34-d3cf-47b7-8e1e-46466032a8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7e6b0a34-d3cf-47b7-8e1e-46466032a8eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6138d7ce-f7f0-4f1d-9e2d-c2b351e148b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6138d7ce-f7f0-4f1d-9e2d-c2b351e148b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_80945e6f-f138-4c7b-8de8-2cec0c07c320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_80945e6f-f138-4c7b-8de8-2cec0c07c320" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13a52592-5e71-4243-970e-18318e871380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a37158fd-ea96-4613-ae6e-1fe682b36992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a37158fd-ea96-4613-ae6e-1fe682b36992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_595c4e7f-9168-4e20-9d9e-c8e4d872343d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_595c4e7f-9168-4e20-9d9e-c8e4d872343d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5c3826fe-db0d-42ae-95a9-8c5ab616a235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5c3826fe-db0d-42ae-95a9-8c5ab616a235" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8886abcf-4e4f-44b9-985a-785a043a3a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8886abcf-4e4f-44b9-985a-785a043a3a6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_03d71c96-f5b9-4de2-8ca0-7531eac86a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_03d71c96-f5b9-4de2-8ca0-7531eac86a8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9418058-069b-4b29-8b48-69a21107203b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a51032d3-050b-4621-baf0-f568cb2b3825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a51032d3-050b-4621-baf0-f568cb2b3825" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ce1d235a-5f89-49d7-9397-d4dfb0e772f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ce1d235a-5f89-49d7-9397-d4dfb0e772f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_aa9652a8-f56e-408b-82f1-9ff4bafdcf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ce1d235a-5f89-49d7-9397-d4dfb0e772f8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_aa9652a8-f56e-408b-82f1-9ff4bafdcf9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_198b681e-3054-4df7-9f17-8c013394be73" xlink:href="eols-20220930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_198b681e-3054-4df7-9f17-8c013394be73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_b7933bf3-fc90-467d-99ee-f409569c5afe" xlink:href="eols-20220930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_b7933bf3-fc90-467d-99ee-f409569c5afe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e8963fe-a141-428f-9b39-39adf90cc983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_b7933bf3-fc90-467d-99ee-f409569c5afe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e8963fe-a141-428f-9b39-39adf90cc983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c87b986c-33d6-4796-b7f1-c68358c0826e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c87b986c-33d6-4796-b7f1-c68358c0826e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa902a94-194e-4ed2-a53d-5f80131fbe39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa902a94-194e-4ed2-a53d-5f80131fbe39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f1c6bb45-6eb3-4df2-9314-9ad80ef06943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa902a94-194e-4ed2-a53d-5f80131fbe39" xlink:to="loc_us-gaap_AwardTypeAxis_f1c6bb45-6eb3-4df2-9314-9ad80ef06943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1c6bb45-6eb3-4df2-9314-9ad80ef06943_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f1c6bb45-6eb3-4df2-9314-9ad80ef06943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1c6bb45-6eb3-4df2-9314-9ad80ef06943_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3017e93-b5f4-4571-ab05-2f52c46f3df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f1c6bb45-6eb3-4df2-9314-9ad80ef06943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3017e93-b5f4-4571-ab05-2f52c46f3df7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0c8694f5-304a-4010-86db-ff6020dd6f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3017e93-b5f4-4571-ab05-2f52c46f3df7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0c8694f5-304a-4010-86db-ff6020dd6f2c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#StockholdersEquityRestrictedStockUnitDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails" xlink:type="extended" id="iac84db1559014745b01f5e2d51c61fda_StockholdersEquityRestrictedStockUnitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f1a5f21-de90-45bf-a26b-c6b374ea83b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f1a5f21-de90-45bf-a26b-c6b374ea83b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8975c11f-2d93-4b0c-9222-ef1705cf2bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8975c11f-2d93-4b0c-9222-ef1705cf2bb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_55cbdcd0-7572-4460-902d-f93b4b0d8a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_55cbdcd0-7572-4460-902d-f93b4b0d8a80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_569b6e59-504e-465d-a6c9-0d92f72a3c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_569b6e59-504e-465d-a6c9-0d92f72a3c06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b5907787-3fbe-46e5-b4ef-4c8dabdec980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b5907787-3fbe-46e5-b4ef-4c8dabdec980" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1f127b9-3e68-405f-8424-f9de5c3c5bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f1a5f21-de90-45bf-a26b-c6b374ea83b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bbde7183-da96-4bc6-b71d-96f466977893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bbde7183-da96-4bc6-b71d-96f466977893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc585a1b-e339-42bb-9925-2021d0dad3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc585a1b-e339-42bb-9925-2021d0dad3c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c7be7f60-da7c-4a5a-86b0-0ffa1a1f92d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c7be7f60-da7c-4a5a-86b0-0ffa1a1f92d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_30a4c669-ec38-4bd2-8b5c-e37ccf74d892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_30a4c669-ec38-4bd2-8b5c-e37ccf74d892" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ced040c0-87ae-45d0-9d55-71a153507027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4d98c91-d1ee-4136-9b79-978b3c46359e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f1a5f21-de90-45bf-a26b-c6b374ea83b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4d98c91-d1ee-4136-9b79-978b3c46359e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6f7fe66c-8f2a-4efb-badd-9371c7977177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4d98c91-d1ee-4136-9b79-978b3c46359e" xlink:to="loc_us-gaap_AwardTypeAxis_6f7fe66c-8f2a-4efb-badd-9371c7977177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f7fe66c-8f2a-4efb-badd-9371c7977177_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6f7fe66c-8f2a-4efb-badd-9371c7977177" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f7fe66c-8f2a-4efb-badd-9371c7977177_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_550224ac-3b30-49e4-894d-e4f7397f903e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6f7fe66c-8f2a-4efb-badd-9371c7977177" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_550224ac-3b30-49e4-894d-e4f7397f903e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_032850ce-a05d-4c60-a7bb-b2ce0d4f2074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_550224ac-3b30-49e4-894d-e4f7397f903e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_032850ce-a05d-4c60-a7bb-b2ce0d4f2074" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#StockholdersEquityStockbasedCompensationExpenseAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails" xlink:type="extended" id="i3ee46950c4e74cff8963d22aba89e09b_StockholdersEquityStockbasedCompensationExpenseAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db6a61f0-fee8-4afa-a1bf-58965f24c9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_77d7caca-d26e-49e7-816e-69404f6706d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db6a61f0-fee8-4afa-a1bf-58965f24c9e5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_77d7caca-d26e-49e7-816e-69404f6706d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eef7825-53ad-45b2-acc1-bb4a46029a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db6a61f0-fee8-4afa-a1bf-58965f24c9e5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eef7825-53ad-45b2-acc1-bb4a46029a1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0fcc90f6-9bbc-4fc5-9229-533abcd1ad2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eef7825-53ad-45b2-acc1-bb4a46029a1c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0fcc90f6-9bbc-4fc5-9229-533abcd1ad2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0fcc90f6-9bbc-4fc5-9229-533abcd1ad2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0fcc90f6-9bbc-4fc5-9229-533abcd1ad2b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0fcc90f6-9bbc-4fc5-9229-533abcd1ad2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3c92625e-dac7-479e-81db-6298b8e0230e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0fcc90f6-9bbc-4fc5-9229-533abcd1ad2b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3c92625e-dac7-479e-81db-6298b8e0230e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ee27f83-2279-44d6-bc87-7ec2e36ba2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3c92625e-dac7-479e-81db-6298b8e0230e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ee27f83-2279-44d6-bc87-7ec2e36ba2e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d6dcfa05-4afe-4011-87cd-f30bcfb311af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3c92625e-dac7-479e-81db-6298b8e0230e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d6dcfa05-4afe-4011-87cd-f30bcfb311af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails" xlink:type="extended" id="i0b2c1249c4c440ec8683b41dcfb598d5_MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_edefa169-ff89-4e29-bd01-5cda8e6c6e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_edefa169-ff89-4e29-bd01-5cda8e6c6e88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms_0ce5caac-f6b8-40d9-93ed-397e9f45b662" xlink:href="eols-20220930.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_LossContingencySettlementAgreementPaymentTerms_0ce5caac-f6b8-40d9-93ed-397e9f45b662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_52127096-ee8e-45d8-80f2-2b12401742d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_52127096-ee8e-45d8-80f2-2b12401742d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_0813f8c0-dffd-497f-9937-851e28f4454c" xlink:href="eols-20220930.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_0813f8c0-dffd-497f-9937-851e28f4454c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9c39e234-1142-4f26-96f9-be37c97fb452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9c39e234-1142-4f26-96f9-be37c97fb452" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_e29a5a35-5698-4d5f-958e-73342dab2bf4" xlink:href="eols-20220930.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_e29a5a35-5698-4d5f-958e-73342dab2bf4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RegistrationRightsAgreementSellingPeriod_a2ece729-d440-4281-931c-00f3af179740" xlink:href="eols-20220930.xsd#eols_RegistrationRightsAgreementSellingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_RegistrationRightsAgreementSellingPeriod_a2ece729-d440-4281-931c-00f3af179740" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_063d9add-c625-4c34-83ed-693562794924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_063d9add-c625-4c34-83ed-693562794924" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_602c035a-a916-42f6-8cc5-80546e90100e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_LitigationReserveCurrent_602c035a-a916-42f6-8cc5-80546e90100e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_8326da17-bb0b-4d9c-a031-005feb259fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_LitigationReserve_8326da17-bb0b-4d9c-a031-005feb259fe1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_cdb92063-0719-4b8f-9b93-24f90a09ee2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_cdb92063-0719-4b8f-9b93-24f90a09ee2d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentInConnectionWithAgreement_8ee8e7cc-0c21-4df2-80a9-9d8597d3e83e" xlink:href="eols-20220930.xsd#eols_MilestonePaymentInConnectionWithAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_MilestonePaymentInConnectionWithAgreement_8ee8e7cc-0c21-4df2-80a9-9d8597d3e83e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_29447986-17a7-4098-a568-9a96c03d90c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_ConvertibleDebt_29447986-17a7-4098-a568-9a96c03d90c6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b367ff91-d5e9-43dd-b111-d6d62603dc09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b367ff91-d5e9-43dd-b111-d6d62603dc09" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_161255c0-e92f-4d64-a4fc-f9426782d48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_161255c0-e92f-4d64-a4fc-f9426782d48b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_20d16a13-3f0f-46ae-9e3a-fd77770ff50d" xlink:href="eols-20220930.xsd#eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_20d16a13-3f0f-46ae-9e3a-fd77770ff50d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_90318dc1-2059-454c-8dbf-d147a6866d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_90318dc1-2059-454c-8dbf-d147a6866d79" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsForInventory_af891275-b746-4834-a142-b53f0e74ff32" xlink:href="eols-20220930.xsd#eols_PaymentsForInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_PaymentsForInventory_af891275-b746-4834-a142-b53f0e74ff32" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_02bf8763-9c06-4ff8-97ae-989176e71ae2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_srt_LitigationCaseAxis_02bf8763-9c06-4ff8-97ae-989176e71ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_02bf8763-9c06-4ff8-97ae-989176e71ae2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_02bf8763-9c06-4ff8-97ae-989176e71ae2" xlink:to="loc_srt_LitigationCaseTypeDomain_02bf8763-9c06-4ff8-97ae-989176e71ae2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_73dde369-d33c-4903-97a7-e2feb583f3c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_02bf8763-9c06-4ff8-97ae-989176e71ae2" xlink:to="loc_srt_LitigationCaseTypeDomain_73dde369-d33c-4903-97a7-e2feb583f3c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_ceccc051-ac1c-4ad6-b77f-c25e27eeaf17" xlink:href="eols-20220930.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_73dde369-d33c-4903-97a7-e2feb583f3c7" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_ceccc051-ac1c-4ad6-b77f-c25e27eeaf17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d261ebc5-76d9-471e-9003-b5975151c44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d261ebc5-76d9-471e-9003-b5975151c44e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d261ebc5-76d9-471e-9003-b5975151c44e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d261ebc5-76d9-471e-9003-b5975151c44e" xlink:to="loc_us-gaap_EquityComponentDomain_d261ebc5-76d9-471e-9003-b5975151c44e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4cf419b8-a117-450f-b9cd-9fe7317b577f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d261ebc5-76d9-471e-9003-b5975151c44e" xlink:to="loc_us-gaap_EquityComponentDomain_4cf419b8-a117-450f-b9cd-9fe7317b577f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_51e946ab-1cd0-4bb7-91c6-9bc108705990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4cf419b8-a117-450f-b9cd-9fe7317b577f" xlink:to="loc_us-gaap_CommonStockMember_51e946ab-1cd0-4bb7-91c6-9bc108705990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_17ff070c-bc50-4df0-8582-825d0f3a2aa9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_srt_StatementScenarioAxis_17ff070c-bc50-4df0-8582-825d0f3a2aa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_17ff070c-bc50-4df0-8582-825d0f3a2aa9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_17ff070c-bc50-4df0-8582-825d0f3a2aa9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_17ff070c-bc50-4df0-8582-825d0f3a2aa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_76464cde-512b-4db2-a416-c590ce792164" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_17ff070c-bc50-4df0-8582-825d0f3a2aa9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_76464cde-512b-4db2-a416-c590ce792164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d85753f8-661c-4cdb-9aa3-4846b83f2bc4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_76464cde-512b-4db2-a416-c590ce792164" xlink:to="loc_srt_ScenarioForecastMember_d85753f8-661c-4cdb-9aa3-4846b83f2bc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1a06569-48ff-4822-afd1-4c04610b9e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1a06569-48ff-4822-afd1-4c04610b9e08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1a06569-48ff-4822-afd1-4c04610b9e08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1a06569-48ff-4822-afd1-4c04610b9e08" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1a06569-48ff-4822-afd1-4c04610b9e08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0f9a3856-8b00-4fc1-93ca-97b67f9a58b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1a06569-48ff-4822-afd1-4c04610b9e08" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0f9a3856-8b00-4fc1-93ca-97b67f9a58b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongSettlementAgreementMember_87365cd7-a967-43e3-a220-42e63d9359db" xlink:href="eols-20220930.xsd#eols_DaewoongSettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0f9a3856-8b00-4fc1-93ca-97b67f9a58b4" xlink:to="loc_eols_DaewoongSettlementAgreementMember_87365cd7-a967-43e3-a220-42e63d9359db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_d3b50072-f611-4d2c-b456-51c93142f622" xlink:href="eols-20220930.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0f9a3856-8b00-4fc1-93ca-97b67f9a58b4" xlink:to="loc_eols_DaewoongConvertibleNoteMember_d3b50072-f611-4d2c-b456-51c93142f622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b378b81a-d6a7-4613-9180-b203b54ba973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b378b81a-d6a7-4613-9180-b203b54ba973" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b378b81a-d6a7-4613-9180-b203b54ba973_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b378b81a-d6a7-4613-9180-b203b54ba973" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b378b81a-d6a7-4613-9180-b203b54ba973_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_35a38c68-4ac6-47f3-85fb-f21385f1be04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b378b81a-d6a7-4613-9180-b203b54ba973" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_35a38c68-4ac6-47f3-85fb-f21385f1be04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1af8b62f-365c-4862-a58f-e1b5a7841b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_35a38c68-4ac6-47f3-85fb-f21385f1be04" xlink:to="loc_us-gaap_ConvertibleDebtMember_1af8b62f-365c-4862-a58f-e1b5a7841b34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3cbf259b-7070-469f-aff3-a9baa7172e61" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_srt_RangeAxis_3cbf259b-7070-469f-aff3-a9baa7172e61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3cbf259b-7070-469f-aff3-a9baa7172e61_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3cbf259b-7070-469f-aff3-a9baa7172e61" xlink:to="loc_srt_RangeMember_3cbf259b-7070-469f-aff3-a9baa7172e61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_620a9bd3-5b24-48c7-8a2d-f7ad206a6388" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3cbf259b-7070-469f-aff3-a9baa7172e61" xlink:to="loc_srt_RangeMember_620a9bd3-5b24-48c7-8a2d-f7ad206a6388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c6b1d053-b4e1-472c-b51e-0a04c2a77abe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_620a9bd3-5b24-48c7-8a2d-f7ad206a6388" xlink:to="loc_srt_MaximumMember_c6b1d053-b4e1-472c-b51e-0a04c2a77abe" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>eols-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9907a7dd-9da5-4da3-a916-5b93970552d6,g:d423565a-304b-425b-af42-a6f72195e86c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_be39dd87-af2b-47f6-a096-493c6485c295_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_2db78c4b-7926-4eeb-912e-e507314f75eb_terseLabel_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs Performance Conditions</link:label>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_label_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Performance Conditions [Member]</link:label>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_documentation_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Performance Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:href="eols-20220930.xsd#eols_RestrictedStockUnitsRSUsPerformanceConditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:to="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1a87dcf-f11f-434a-a4db-73c5ea14817b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_65e2d472-7e2e-499e-996e-d28f126d66a7_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_05321cec-a868-4b07-aa1e-2ffa88b6cab7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_28e8298f-366c-44cc-8651-61283c5c33c8_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_b0999ed6-f3a3-48ae-9526-040bd1b7260d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit loss expense (reversal)</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_17f7ed41-f098-49cb-80d9-1d9f3cf366ce_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total principal payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_64f4da1d-3ef7-4203-8e43-84a70c68afdc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e0e748b7-4082-4016-a849-f99a045fe9d8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5ce3edd2-17dd-4f58-8d4c-ed420334c4de_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fe0b6368-909e-4cc6-b6d4-0756aac180c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6e96b72f-63a4-4426-8b61-1e4c6e32c4fb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_RegistrationRightsAgreementSellingPeriod_c69ec682-1065-439d-a7b7-4965f3ba2af6_terseLabel_en-US" xlink:label="lab_eols_RegistrationRightsAgreementSellingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration rights agreement, selling period</link:label>
    <link:label id="lab_eols_RegistrationRightsAgreementSellingPeriod_label_en-US" xlink:label="lab_eols_RegistrationRightsAgreementSellingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Rights Agreement, Selling Period</link:label>
    <link:label id="lab_eols_RegistrationRightsAgreementSellingPeriod_documentation_en-US" xlink:label="lab_eols_RegistrationRightsAgreementSellingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Rights Agreement, Selling Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RegistrationRightsAgreementSellingPeriod" xlink:href="eols-20220930.xsd#eols_RegistrationRightsAgreementSellingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RegistrationRightsAgreementSellingPeriod" xlink:to="lab_eols_RegistrationRightsAgreementSellingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d88147b1-a7ac-4164-a9fd-4d24facfff40_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent promissory note payable</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_e29628f5-6da2-4d8c-bdad-94157856cb19_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DaewoongConvertibleNoteMember_876ca459-c03d-4834-b072-a01972d45304_terseLabel_en-US" xlink:label="lab_eols_DaewoongConvertibleNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Convertible Note</link:label>
    <link:label id="lab_eols_DaewoongConvertibleNoteMember_label_en-US" xlink:label="lab_eols_DaewoongConvertibleNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Convertible Note [Member]</link:label>
    <link:label id="lab_eols_DaewoongConvertibleNoteMember_documentation_en-US" xlink:label="lab_eols_DaewoongConvertibleNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Convertible Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember" xlink:href="eols-20220930.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DaewoongConvertibleNoteMember" xlink:to="lab_eols_DaewoongConvertibleNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_e9dd4538-bedb-404b-a917-c81739ec8a09_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_3778767e-890a-487c-b7c5-102d1fb1fcbb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e018796-a7b6-47ae-8a83-d2faf2062ab4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_5ce2c603-ca21-494a-92fc-2032a7ba368e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5c1c70e4-6d9c-462b-b154-afa46080358f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0d9f2989-0382-40df-9ed8-d32493aa4cd3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80b3e9db-69fa-4491-963b-885fe6770013_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4477357f-a1ed-400d-a2ca-d4e7ff8b5b1d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate (in percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_64e88282-e1e8-411e-81fa-38a39df00f1a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_98d9e6c3-3a7f-432d-a7d2-b07d17a8d49f_terseLabel_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs Market Conditions</link:label>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_label_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Market Conditions [Member]</link:label>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_documentation_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Market Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:href="eols-20220930.xsd#eols_RestrictedStockUnitsRSUsMarketConditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:to="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a2d099e2-03eb-4db6-832a-17e508b453de_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_979394c0-d21d-4529-bc68-286eb2061a73_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for conversion of convertible note</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_1f7755b8-18f1-462c-98fe-a5bc550e00a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_34ecf79b-c005-4aa0-a6dd-3918a5d8244d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_66851b96-0837-4a02-97f8-76a8d322e9c9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_346cf50c-ecb3-466f-8d63-88ab92889018_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e45d3ece-4c45-4707-8bac-330ce9d3caee_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_eaf563fe-09b3-4e04-916e-a41c34aa79fa_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6ed7e488-6a56-433a-b4c6-247ec8e09dde_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities excluded from the computation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a6e9bc14-dbf7-4495-ad38-44c9fb63c986_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c3c87500-b4f8-4b1c-aa3a-7517c41c66cc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_94b1b8cd-2e10-4189-b10f-2aa9ea0190a9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_11a74db1-ab8d-4f1f-92fb-66dbb79039d8_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_4bb623a6-33cd-4b8c-b5eb-0fe617c431bd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_20e943a3-fb57-406a-8e16-a3d8b171c84c_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_8c3e6344-c5d6-4731-bf66-0da5d63ec237_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PharmakonTermLoansOneMember_3a45dd2e-37af-4a42-8e0b-2a71c7844456_terseLabel_en-US" xlink:label="lab_eols_PharmakonTermLoansOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche A Loan</link:label>
    <link:label id="lab_eols_PharmakonTermLoansOneMember_label_en-US" xlink:label="lab_eols_PharmakonTermLoansOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans One [Member]</link:label>
    <link:label id="lab_eols_PharmakonTermLoansOneMember_documentation_en-US" xlink:label="lab_eols_PharmakonTermLoansOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PharmakonTermLoansOneMember" xlink:to="lab_eols_PharmakonTermLoansOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentAmountThreshold_551e6945-d502-4cc6-8edd-c0bbf59eb160_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment amount threshold</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentAmountThreshold_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Amount Threshold</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentAmountThreshold_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:to="lab_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_26446d9a-e2bd-45ad-99d4-b78ec94a3864_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_c037c2cb-32ee-4659-a9e3-50657c2a29f3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8adb8908-de83-4618-919b-3b5923d4708b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1d98add2-ec2d-47fc-a9b3-568ec697b6b8_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_OxfordTermLoanFacilityTrancheTwoMember_27688b45-0f75-4868-8322-f9d937c17706_terseLabel_en-US" xlink:label="lab_eols_OxfordTermLoanFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second tranche</link:label>
    <link:label id="lab_eols_OxfordTermLoanFacilityTrancheTwoMember_label_en-US" xlink:label="lab_eols_OxfordTermLoanFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan Facility, Tranche Two [Member]</link:label>
    <link:label id="lab_eols_OxfordTermLoanFacilityTrancheTwoMember_documentation_en-US" xlink:label="lab_eols_OxfordTermLoanFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan Facility, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityTrancheTwoMember" xlink:href="eols-20220930.xsd#eols_OxfordTermLoanFacilityTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OxfordTermLoanFacilityTrancheTwoMember" xlink:to="lab_eols_OxfordTermLoanFacilityTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_deadbabe-560a-49c2-9851-b9551448abc4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3dfc8cd0-a97a-4081-9c4c-47b139e97baa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_67830aba-e36c-4a75-b32e-adcac3854adf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_15009fca-5d6b-4d08-a063-bf1cce9ed07d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ed759ee5-e8a0-4100-82dc-24f1a278e66d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_68594890-7678-4bce-aec8-874d911f5429_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2a39bffd-5eea-4e66-8126-86280c833908_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_63b0feb4-d71d-439d-8a96-8f8d98bed6db_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a72518d1-b0f8-4c8a-854c-cebabe45da40_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9bad8fb2-7d80-4137-a2ec-d2be8a35b2c5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d6582868-79aa-4eb8-a6c7-069855fd3cb7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_18a4e13a-6ff4-48ac-a3bb-ee42eafd1d32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_57460547-40be-4732-9b24-45a091f169e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_31eb3926-cdf7-4635-ac47-6cc7605a1c3b_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d996672e-a7ae-4f9e-944b-82c18cfe7f09_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_798358b8-c1d5-4610-8f05-fb94ec4944c4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e15822d-24c6-4bf8-ac68-f9857782e9f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_389f72ba-f579-465b-88d9-1be5151bf45f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5a7e9beb-bc5e-4cdc-981b-6d5c6669ddf9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the incentive equity plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b74839a4-47c3-4dc3-a717-5c20fe437935_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0321c95d-d560-45b9-8737-dafabe70a633_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4aa08911-90ff-4052-9f59-91eca11021cf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8bab4008-0f1b-4b0e-98dd-c2945f95a2ca_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e54b2c94-3c19-4bee-855a-d0fb09a723e8_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6e9ddbab-019f-4048-9ca1-c8cb27743f9a_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_975db363-9156-4e70-ad9d-0b514803b2fb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_684180a5-46d3-4ad2-b11d-69ca49445a83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_43cfabff-2cdc-4b88-a7a8-e74c4dec9457_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f56b05fa-6b92-4f8c-bc83-187983de1fe0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_36dbcb42-b734-4cf6-b6bf-4f143b44c7f9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_d0970aec-1285-4b29-8b5a-28308f7283de_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares beneficially own percentage</link:label>
    <link:label id="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_label_en-US" xlink:label="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Percentage of Shares Beneficially Owned</link:label>
    <link:label id="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_documentation_en-US" xlink:label="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Percentage of Shares Beneficially Owned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" xlink:href="eols-20220930.xsd#eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" xlink:to="lab_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_789d82bb-72bd-4c57-9a4f-fd5308f1564e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5dbbdf9c-42c4-457b-b4be-b0873f259e95_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d0903598-0ab8-4b27-a590-9c5bfa44240d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6374b195-8ada-40da-8bf5-2f107175c497_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Convertible Note</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e84b9a9b-c63b-44a7-815b-8253ff47a97c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8272cdf4-b4d0-4b05-85a1-42530111c2a7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_190d0906-999f-4776-9977-b837750b41a3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_7d3017d9-d88c-472a-ae17-34a2b3128120_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_ee76719b-f297-499b-b211-7ed1ec07ec2e_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Obligation [Member]</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Obligation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationMember" xlink:href="eols-20220930.xsd#eols_ContingentRoyaltyObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligationMember" xlink:to="lab_eols_ContingentRoyaltyObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f2e307e1-e9b8-4296-be8d-9bfd6698ebe3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ea4fbda5-b430-4393-b9d6-90dcbbac0fde_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3986d6ef-b97a-4707-a128-54e4a0021448_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PharmakonTermLoansMember_4c10f26f-b4dc-47c1-8e05-9b025367816e_terseLabel_en-US" xlink:label="lab_eols_PharmakonTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans</link:label>
    <link:label id="lab_eols_PharmakonTermLoansMember_label_en-US" xlink:label="lab_eols_PharmakonTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans [Member]</link:label>
    <link:label id="lab_eols_PharmakonTermLoansMember_documentation_en-US" xlink:label="lab_eols_PharmakonTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PharmakonTermLoansMember" xlink:to="lab_eols_PharmakonTermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ea457591-fef1-4378-8886-f080265b4a5b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SaleOfStockMaximumConsiderationReceivable_e3854abc-b9f4-4cf1-8f12-8d2227f94dd1_terseLabel_en-US" xlink:label="lab_eols_SaleOfStockMaximumConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consideration receivable</link:label>
    <link:label id="lab_eols_SaleOfStockMaximumConsiderationReceivable_label_en-US" xlink:label="lab_eols_SaleOfStockMaximumConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Consideration Receivable</link:label>
    <link:label id="lab_eols_SaleOfStockMaximumConsiderationReceivable_documentation_en-US" xlink:label="lab_eols_SaleOfStockMaximumConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Consideration Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockMaximumConsiderationReceivable" xlink:href="eols-20220930.xsd#eols_SaleOfStockMaximumConsiderationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SaleOfStockMaximumConsiderationReceivable" xlink:to="lab_eols_SaleOfStockMaximumConsiderationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_ce61ff52-2413-406f-9031-ba5d39dd5230_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d258f72b-da30-4bfd-ad6f-3a9bc63feaf3_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_1c378646-4e6f-4b50-a2ce-b0f2e9cac0f8_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, writeoff</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_2e5d5601-1713-434e-9943-890b012a15a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PaymentsForInventory_baf84914-ae62-44db-ac97-9ea3fe3c2c58_terseLabel_en-US" xlink:label="lab_eols_PaymentsForInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory payments</link:label>
    <link:label id="lab_eols_PaymentsForInventory_label_en-US" xlink:label="lab_eols_PaymentsForInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Inventory</link:label>
    <link:label id="lab_eols_PaymentsForInventory_documentation_en-US" xlink:label="lab_eols_PaymentsForInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsForInventory" xlink:href="eols-20220930.xsd#eols_PaymentsForInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PaymentsForInventory" xlink:to="lab_eols_PaymentsForInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_77144e3d-fb25-45b4-a511-256e02637ebf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c05dffd-f623-4aeb-a20d-025bbed0d9f4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_3bdd15ad-b3c5-4f98-a28c-f0acaa70f875_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_617c6328-27d0-49cd-83ed-c85c17439e6b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ca619c90-e2fe-49e6-b5cc-c9cc84cacaa7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7bc10c61-29c8-4be3-ba38-788296781c1d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_c868277f-b0be-43c6-bcf5-971b13b913c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3946ecba-66c4-437d-a072-96ceea890816_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_b449e4fb-26a0-43ac-9783-4a0b4d322a75_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable operating lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_097d265d-51cb-4543-b361-c12e11192063_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a207f3b9-6984-43e3-ab84-a9066e0e2ca5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f55b8ca7-6f63-4bce-8734-5e73de78fce9_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_07f3546d-f6d9-4238-88a8-0a533b3a8f68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3faa97bd-6ad4-4dd3-b858-9d9954eabc08_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919ec27c-cd4a-4e9a-a9fe-328bf2bae50a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_StockIssuedForAccruedLitigationSettlementExpense_7bb0e7b0-ed54-4bc1-acf4-44851375ca76_terseLabel_en-US" xlink:label="lab_eols_StockIssuedForAccruedLitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in exchange for accrued litigation settlement expense</link:label>
    <link:label id="lab_eols_StockIssuedForAccruedLitigationSettlementExpense_label_en-US" xlink:label="lab_eols_StockIssuedForAccruedLitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Accrued Litigation Settlement Expense</link:label>
    <link:label id="lab_eols_StockIssuedForAccruedLitigationSettlementExpense_documentation_en-US" xlink:label="lab_eols_StockIssuedForAccruedLitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Accrued Litigation Settlement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedForAccruedLitigationSettlementExpense" xlink:href="eols-20220930.xsd#eols_StockIssuedForAccruedLitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedForAccruedLitigationSettlementExpense" xlink:to="lab_eols_StockIssuedForAccruedLitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1d9f7506-fe0a-4b5c-b051-8c5d4302b3d3_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from extinguishment of debts, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_30f81111-2b11-4e39-ab9b-4c5d81d536e5_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from extinguishment of debts</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_7b511a64-459d-4499-934f-f32b52d82669_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from extinguishment of debts, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_6d64034f-2d38-4fcb-9de5-a9115668ebd2_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1f031df7-392f-47a0-b762-db5ccd0f5785_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f9c36ab3-ca2e-4425-8e17-c598058e63bf_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dd0f920c-a44b-4c51-aec6-fffd90e3215d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the incentive equity plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0a79e25f-5a0c-4d65-8e0e-c0a409e56e96_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveNoncurrent_4886c06c-2bea-41be-ad38-43f6c2ca0788_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveNoncurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveNoncurrent" xlink:to="lab_us-gaap_LitigationReserveNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a7169041-48b5-4a50-9bf8-eee3a58faa22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_112d6308-6e54-47cc-b441-03872d69f126_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fde3e964-d026-453e-9648-6cbcbbdff9e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_8403bed4-a995-4ae8-8e2a-3c6fae105bcb_terseLabel_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issuance agreement, percentage of share dispose per year</link:label>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_label_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issuance Agreement, Percentage of Share Dispose Per Year</link:label>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_documentation_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issuance Agreement, Percentage of Share Dispose Per Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" xlink:href="eols-20220930.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" xlink:to="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_d2368fc3-28fd-4a05-a890-c6fb481cd5fb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_cc58d4a0-2bce-4858-934b-e28cedb204e0_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e9d5acfc-245e-4e39-8295-cec53e804547_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_d588073a-7dc2-4a29-b19c-300ccf224bd6_terseLabel_en-US" xlink:label="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension period</link:label>
    <link:label id="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_label_en-US" xlink:label="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements</link:label>
    <link:label id="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_documentation_en-US" xlink:label="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:href="eols-20220930.xsd#eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:to="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_055c067f-f1c6-47c7-8c0a-d39c4dc48f06_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_434b33bc-1939-4c47-b5dc-e0a69268fae1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_23a13c51-020e-45fa-85e1-21934ffc9de5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_eb38eea7-2164-4369-986c-b1ce63e884fb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of secured debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_220d4175-e918-498d-9c9b-330763fff484_terseLabel_en-US" xlink:label="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="eols-20220930.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermLoanFacilityMember_5e8cc03c-a78f-491d-99cf-3184d8669bc3_terseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_eols_TermLoanFacilityMember_label_en-US" xlink:label="lab_eols_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermLoanFacilityMember" xlink:href="eols-20220930.xsd#eols_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityMember" xlink:to="lab_eols_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_340ec388-6c2b-45b0-919d-7ad8f384a3f4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c6a798f9-21c9-4e52-a556-5400c932969d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_32f66d40-8b82-47e6-8466-ca67b4c9b7d7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_15f06ed7-a533-4c4c-810d-22f258a37a7f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_36a038de-3b4e-4ce5-a68b-a360903ce24d_terseLabel_en-US" xlink:label="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with incentive equity plan</link:label>
    <link:label id="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_label_en-US" xlink:label="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan</link:label>
    <link:label id="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_documentation_en-US" xlink:label="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:href="eols-20220930.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:to="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5058aa90-5654-41b9-836b-cc490fa0930b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fef343ed-4c64-4c7c-856e-aadb89394f66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eb629c8e-8e85-49cd-8734-ec25765a03dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_62eb96e8-ce7d-45f5-ae68-b801c55eccc0_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_50cb929a-2a8c-4e50-901f-ef95732773fe_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3b00987d-6d3c-4d9d-bd57-0c29f7eb9bea_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_cace769a-476f-4c56-ae08-2563b9219ba8_terseLabel_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, commission payment upon gross proceeds</link:label>
    <link:label id="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_label_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage</link:label>
    <link:label id="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_documentation_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:href="eols-20220930.xsd#eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:to="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_26e62fdb-04de-4518-94a0-bfd643261781_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_75368617-117f-4bd7-8021-f701c72ea1c6_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0da9cdb5-afd4-4c2f-af11-72d6d2498dea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5e0a4cff-e9c5-4cc4-a9e0-09f7aaf9e662_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_51e539c3-b377-4423-b948-6fa15f26d828_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermTwoMember_1d865c08-748b-429e-bc4f-cfc7a4d0e284_terseLabel_en-US" xlink:label="lab_eols_TermTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Two</link:label>
    <link:label id="lab_eols_TermTwoMember_label_en-US" xlink:label="lab_eols_TermTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Two [Member]</link:label>
    <link:label id="lab_eols_TermTwoMember_documentation_en-US" xlink:label="lab_eols_TermTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermTwoMember" xlink:href="eols-20220930.xsd#eols_TermTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermTwoMember" xlink:to="lab_eols_TermTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_79b0c439-e1b8-488d-93a6-725353a0194f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_f1416abb-6933-4e26-af50-7078d1b50ed6_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, net of discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-Term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_df62e671-4f88-4570-b4e2-de1a2f64fc9e_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of interest only payments</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_label_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period Of Interest Only Payments</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period Of Interest Only Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:to="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_76f5f395-bd10-4c10-8878-37c1af7ab977_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b9fab60d-be80-4b4e-81de-e0108a6d27a9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a025fe14-c04e-4a84-a764-f2c7642f3dc1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2ca42223-8389-48ea-8abc-bfaccac7d5b7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_2c38c8e3-947e-4e94-a575-a58922e6f25d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_462c0546-8a0c-47f4-8874-50bddedc989a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_173c88b0-b803-41c9-88c7-2d1f1de8ef4a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4c1a45f6-43b5-4d0d-919e-3b972e03306e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_d11ab49d-232b-4ca3-b77c-bc3a0a167573_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_364371f3-957a-4757-a46f-b92ce4974031_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_244722e2-fc78-418b-a15e-0c9d7b6975b1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsDomain_cdcb72b2-377c-4ded-8e1e-35ab1a1d0e26_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms [Domain]</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsDomain_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms [Domain]</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsDomain_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsDomain" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain" xlink:to="lab_eols_DebtInstrumentPrepaymentTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_OxfordTermLoanFacilityMember_d40a4d23-383a-43b1-9cd2-bd879ffbbb09_terseLabel_en-US" xlink:label="lab_eols_OxfordTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan Facility</link:label>
    <link:label id="lab_eols_OxfordTermLoanFacilityMember_label_en-US" xlink:label="lab_eols_OxfordTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan Facility [Member]</link:label>
    <link:label id="lab_eols_OxfordTermLoanFacilityMember_documentation_en-US" xlink:label="lab_eols_OxfordTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityMember" xlink:href="eols-20220930.xsd#eols_OxfordTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OxfordTermLoanFacilityMember" xlink:to="lab_eols_OxfordTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_83d61971-23b2-4191-868a-5e32e47a0ea7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_199a4a29-6a70-4f51-aa6e-4577aa59d7da_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_30358cfe-4e28-48ca-b9d9-8de9c0cf11f3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_5a28dd75-5997-459e-97bd-453323a02049_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Instruments Recorded at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_OxfordTermLoanFacilityTrancheOneMember_ce8d6fad-59fe-498b-b5fc-90e27be7fed5_terseLabel_en-US" xlink:label="lab_eols_OxfordTermLoanFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First tranche</link:label>
    <link:label id="lab_eols_OxfordTermLoanFacilityTrancheOneMember_label_en-US" xlink:label="lab_eols_OxfordTermLoanFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan Facility, Tranche One [Member]</link:label>
    <link:label id="lab_eols_OxfordTermLoanFacilityTrancheOneMember_documentation_en-US" xlink:label="lab_eols_OxfordTermLoanFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan Facility, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityTrancheOneMember" xlink:href="eols-20220930.xsd#eols_OxfordTermLoanFacilityTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OxfordTermLoanFacilityTrancheOneMember" xlink:to="lab_eols_OxfordTermLoanFacilityTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_4c8e37df-425f-4400-8f10-09e23ed562d4_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4371cce0-cfea-43ed-88b7-244deb55d1fb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_7a8aa13c-506d-44f9-8f59-59d51591322e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement payment from Daewoong</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_936e0a7c-a78a-4fd8-b89a-f9b5c150beaf_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement payment from Daewoong</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_774819f4-9c61-4b81-97be-c26188df329a_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ac51cc20-2698-4e29-bc90-96ce4b3a5f1f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5a2d9db9-232f-4e3b-9daa-37999534feb5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense Allocation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ab4d7bd6-f456-4bda-8b7b-1692960058c3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_AccountingPoliciesLineItems_d5859ad6-227c-4bd7-a924-c26b76204030_terseLabel_en-US" xlink:label="lab_eols_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:label id="lab_eols_AccountingPoliciesLineItems_label_en-US" xlink:label="lab_eols_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:label id="lab_eols_AccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_eols_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AccountingPoliciesLineItems" xlink:href="eols-20220930.xsd#eols_AccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AccountingPoliciesLineItems" xlink:to="lab_eols_AccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_6680b638-a5cd-4299-81c0-6c689d0e6698_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Composition of Lease Expense and Other Quantitative Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1a677e95-bbb4-4309-a6df-4cb74d8bcca5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentFeeAmountWaived_f3f6409b-a185-4b2c-9a8f-150e7f1d55fc_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentFeeAmountWaived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument fee amount comprised</link:label>
    <link:label id="lab_eols_DebtInstrumentFeeAmountWaived_label_en-US" xlink:label="lab_eols_DebtInstrumentFeeAmountWaived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Fee Amount Waived</link:label>
    <link:label id="lab_eols_DebtInstrumentFeeAmountWaived_documentation_en-US" xlink:label="lab_eols_DebtInstrumentFeeAmountWaived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Fee Amount Waived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentFeeAmountWaived" xlink:href="eols-20220930.xsd#eols_DebtInstrumentFeeAmountWaived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentFeeAmountWaived" xlink:to="lab_eols_DebtInstrumentFeeAmountWaived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_298db58d-985c-4884-a8ce-2bbaf5031515_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_25ae60ea-ff07-456e-bfd0-7d2289383bfc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ec0f220b-bb00-4d05-a1c5-fdfc9f16428f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_06011aa9-b48c-4f5d-9f00-5933263efd63_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_12cf8f2d-98fe-4b31-97d1-3f609298fe97_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d06e94ab-6bf0-4b44-89f3-b99298258f28_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a9684c4a-066f-4beb-8e3d-c927c1e5d8a0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8667c615-12d7-4703-839a-84eb1514a7aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_536cca5f-57ec-4dc0-8ce2-c874edc6ca71_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7c2fcba3-6bd2-45ac-a108-7255d69ba729_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4c619808-f1c0-446e-8c69-4ca10358e43f_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cd1c5a1a-3af9-4f75-8a01-6a6b4f26e8bf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65e47403-200b-4111-ae1d-61377385fc33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_001e34ae-18c9-4ce6-a2f0-f582bc4e3c2b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_35f8a7a4-660c-4177-8db0-61ba88690bd7_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_45447872-c614-4fdb-a67a-be577d439983_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9c5458bc-116e-46ad-9401-daad5530e2b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_04ce1209-2448-4f5a-a712-353cae710249_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_91289819-4613-429d-a63f-8c24ae51478b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9d42af83-8588-4378-ab78-89b30ef64f42_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f7681491-1e53-4f7f-9ebf-c74e113c71a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_37887aca-e1ba-4eb7-a15c-a565cc0dc087_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a692a67-ad94-4f1b-8018-472ab6f182da_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4c376535-8d25-4a9f-a148-baa11a226e57_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_885484e9-95cc-4027-aa3f-ecd3adf4cd29_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_e2a5518f-7bcc-4c6e-b24c-f1cfcb1c5b9d_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term , Exercisable (Years)</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:href="eols-20220930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_69ae1585-8df4-4b34-9d18-0365118d5f9f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_338df20a-b08a-499a-bb14-6fb713c16fc7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_8eb2fb1f-c305-4cea-bab4-721a982dcb20_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_f538d76d-4bb5-4dfc-ad0e-3668c1fe6b8d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f6417d65-d9ae-447d-a11c-abc66b910e5f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_79ad426b-885f-4280-b87c-ef16c0dbaeb4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties under the Medytox/Allergan Settlement Agreements</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_1b7eb91e-da03-4f86-9efb-110231b6bd9d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_90a26c84-0694-4e83-9b83-660a19815a2d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_ec520155-7c6d-4ed5-9ee1-7dff5f79ed51_terseLabel_en-US" xlink:label="lab_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_label_en-US" xlink:label="lab_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Amortization Expense After Year Four</link:label>
    <link:label id="lab_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_documentation_en-US" xlink:label="lab_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Amortization Expense After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:href="eols-20220930.xsd#eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:to="lab_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_695f6344-cd14-4c02-9989-75433d4c4942_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ce416c9e-93ad-44dd-8d07-8c00068cfb79_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_464cfaff-2216-4739-a46b-2e6d1bf17afa_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_dc75fa89-c16c-4a46-aa8d-4a619b06fbc2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_5f9117bb-73c7-4cc2-9322-8c9e139475a2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible note to equity</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_44d89dbe-4e93-4704-a210-2eeb848b9ee8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_22cac6fd-84a6-48e4-a3b1-82ad866d0261_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_97ccf527-08d6-4db9-a75e-e2e3a1f574d0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Issued But Not Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_EvolusIncMember_c5730a5e-55d5-4866-95c8-50db906b6cb5_terseLabel_en-US" xlink:label="lab_eols_EvolusIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolus, Inc.</link:label>
    <link:label id="lab_eols_EvolusIncMember_label_en-US" xlink:label="lab_eols_EvolusIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolus, Inc [Member]</link:label>
    <link:label id="lab_eols_EvolusIncMember_documentation_en-US" xlink:label="lab_eols_EvolusIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolus, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EvolusIncMember" xlink:href="eols-20220930.xsd#eols_EvolusIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EvolusIncMember" xlink:to="lab_eols_EvolusIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7b511626-2246-41d2-ab93-e7a825d854c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_e086bd2e-7a7b-4e42-8350-9df67ec4c178_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service revenue</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4a6fdd02-e0b9-46c8-9d58-85f814eb3da3_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_3c8a9f40-a88e-4436-af8e-8661f9e143fe_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_38aec01c-8a7c-4661-977f-c969661fd859_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of final payment of full principal amount</link:label>
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_label_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Percentage Of Principal Amount, Balloon Payment</link:label>
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Percentage Of Principal Amount, Balloon Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:to="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_c98df77f-5b35-4b94-87f6-e2a130385b9b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_5b91698c-b215-4176-bb63-af238f313e0e_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_26cb37a0-2491-47b3-ac6c-0ba9ebf6eb1f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5a79a9f8-c3b1-4b7f-be07-6ecf3f169f1a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_aac1f543-1068-43ef-94e4-fe71083deb0e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2ac63dc0-e214-45ab-a236-44d017a254cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d9ccf7ac-a4c8-4a61-8d7a-ed7ad21cc4a6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bcca7ab3-cf96-4068-b2d5-0e731efcee40_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_443c82b3-59ce-41d7-aa10-ee31f788684d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_b1320095-3391-433a-a2a4-4a564d5225b2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LongTermDebtMaturityAfterYearFour_e6ce9119-7a30-4648-be18-aeb9902dd435_terseLabel_en-US" xlink:label="lab_eols_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_eols_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_eols_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Four</link:label>
    <link:label id="lab_eols_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_eols_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LongTermDebtMaturityAfterYearFour" xlink:href="eols-20220930.xsd#eols_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LongTermDebtMaturityAfterYearFour" xlink:to="lab_eols_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_408e5ad0-acfe-4be2-97e1-ed9daaec978a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f5b69722-8fbd-4829-8316-0026d949eb0d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PharmakonTermLoansTwoMember_744ff9d9-1023-4306-83dd-fb095d99a1a8_terseLabel_en-US" xlink:label="lab_eols_PharmakonTermLoansTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche B Loan</link:label>
    <link:label id="lab_eols_PharmakonTermLoansTwoMember_label_en-US" xlink:label="lab_eols_PharmakonTermLoansTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans Two [Member]</link:label>
    <link:label id="lab_eols_PharmakonTermLoansTwoMember_documentation_en-US" xlink:label="lab_eols_PharmakonTermLoansTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Term Loans Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PharmakonTermLoansTwoMember" xlink:to="lab_eols_PharmakonTermLoansTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_98a218df-e0ad-4d7f-a62b-d0d7e41ac597_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f278ad4e-01d0-4df0-9842-c2694a659f68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8018c8f6-64a7-47e6-9069-8754ffc115c7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b61ef4eb-114a-423d-9493-15a24199ebeb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_218b7d2e-91df-4c5c-b3ea-ae4356026747_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_06ec8227-b78e-4045-82c5-583ba9c3dd44_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product cost of sales (excludes amortization of intangible assets)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d7b6beda-6461-490e-b6de-2c5fd061fd45_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding used to compute diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_a188eab2-0244-4fbc-9a8a-4b011df99ecb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_23ef8910-405c-4f08-8a7d-940e80aa5632_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_39995df3-da53-48a6-b0e8-c83a1bd5c6f0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_05d22290-2f44-4e6e-a830-258db897b03b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_54dfa778-489c-4039-98ed-13b7d6ad869c_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities, current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermThreeMember_96b26cf4-9d71-4ee8-a1b1-e756737917cf_terseLabel_en-US" xlink:label="lab_eols_TermThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Three</link:label>
    <link:label id="lab_eols_TermThreeMember_label_en-US" xlink:label="lab_eols_TermThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Three [Member]</link:label>
    <link:label id="lab_eols_TermThreeMember_documentation_en-US" xlink:label="lab_eols_TermThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermThreeMember" xlink:href="eols-20220930.xsd#eols_TermThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermThreeMember" xlink:to="lab_eols_TermThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_88f86bb0-1d5f-4247-b96a-bfc961ec8cb5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.00001 par value; 100,000,000 shares authorized; 56,183,414 and 55,576,988 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d4b4aff2-f910-4295-a600-ad3b1909b551_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_eac1504e-6ae9-458d-9a4c-1f2078f8c97a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_ae89cdd9-059a-41ad-aae7-c8ea0c161928_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ef7414e-1a37-4185-b892-8abfefafa7bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_ed68c15f-d4f1-4cb8-8ee3-5003eae8e1f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_a5c4250a-46c9-48ce-a6e7-3ae468e2e0b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_8f8a240d-7ba3-4151-b1df-5db927e0ae28_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Obligation Payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_365a2381-38b0-4946-9ee4-cf67e0d27975_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_cbe44cc7-9b57-4a1e-ad0d-031dba4573d1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_FollowOnOfferingMember_5754c6a5-55e1-4955-9b5f-651c29e1673b_terseLabel_en-US" xlink:label="lab_eols_FollowOnOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Offering</link:label>
    <link:label id="lab_eols_FollowOnOfferingMember_label_en-US" xlink:label="lab_eols_FollowOnOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Offering [Member]</link:label>
    <link:label id="lab_eols_FollowOnOfferingMember_documentation_en-US" xlink:label="lab_eols_FollowOnOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Offering Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember" xlink:href="eols-20220930.xsd#eols_FollowOnOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_FollowOnOfferingMember" xlink:to="lab_eols_FollowOnOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e64640d8-ac6c-4e1c-adb7-8fe5f59763c8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a92bcd8c-0634-4447-9e5e-a506479aae78_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ad3eda9-0983-4ff2-91ae-e989ff063f19_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_650ec1d2-91d9-4636-8f5f-17cb9e5cac7d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4b6c3b8b-2d46-48dc-bad6-cd75017da930_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7cd69473-da64-4d12-b2d6-4335e862e038_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3c9e492b-7579-447a-b412-6b99d6567084_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d21613b5-836b-4616-a48e-4c7d77936d76_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_469c06d2-6e1b-48cc-bbdc-db6be0b5a3f5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b91477b8-a473-4094-889b-bcf5917eac73_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7a4ff2f7-8496-4282-99c8-bfa364f22b7e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued revenue contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_708bbaf5-936d-4c00-b4f3-2ad4081aafbb_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software recorded in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_56b25460-4250-4aee-8762-f9e0603d9923_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ATMSalesAgreementMember_610c0dab-dd42-4f67-ae04-4f85c92ba088_terseLabel_en-US" xlink:label="lab_eols_ATMSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Sales Agreement</link:label>
    <link:label id="lab_eols_ATMSalesAgreementMember_label_en-US" xlink:label="lab_eols_ATMSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Sales Agreement [Member]</link:label>
    <link:label id="lab_eols_ATMSalesAgreementMember_documentation_en-US" xlink:label="lab_eols_ATMSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Sales Agreement Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember" xlink:href="eols-20220930.xsd#eols_ATMSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ATMSalesAgreementMember" xlink:to="lab_eols_ATMSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d388e34-3e8b-41c9-be87-ad5afc594bdf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_078e2dc2-e6f4-495e-bbd6-3b10597bfb08_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_019a2654-fd3a-40c2-960d-db7afb0ba289_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Life (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7be8586d-634d-49fa-a2b7-4486e481a08f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_8b211450-ea3f-4a0c-a90a-00f736e43ba1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_e27a1a08-59de-4d56-a0b5-aab13eecec2a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_4a490b89-d84f-4789-a9b4-54dc758cf08e_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_f7d7e708-5885-4fda-98b2-4d826c61e74f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, new claims filed, number</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_30dfc442-c610-4682-afd2-6b9102a041ab_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_a6a32778-96d8-4196-95d3-1267130d6677_terseLabel_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments for intangible assets</link:label>
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_label_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments For Intangible Assets</link:label>
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_documentation_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments For Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets" xlink:href="eols-20220930.xsd#eols_MilestonePaymentsForIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentsForIntangibleAssets" xlink:to="lab_eols_MilestonePaymentsForIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_650770fd-cdd3-4085-8a8a-467533e791db_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_fbc017b7-e9ff-49ba-add0-59ee7cdcf39d_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8de0376b-c14b-4917-93c1-5cd3fbcf526e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5f299cc4-68cf-4062-be07-155dfe514bff_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c349c624-a427-42ab-9e2a-c1a4dc2d3c06_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_1f2bf15d-9393-477c-a26d-555bae9a4724_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_774eaa52-3d9e-459f-8cc2-bd2728c0749e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Contractual Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4f617a4e-e6f4-4387-bf36-eab248523911_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_272dd575-e679-43a9-a353-7f6155b12cef_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_75e34e81-65b9-412b-a433-8b3ace20752b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_e0448de1-33e5-4bde-bcc4-094e35079bbf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived_26fb2ff8-a393-4f9d-bba1-b474802c5e87_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument prepayment fee amount</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Amount, Waived</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Amount, Waived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeeAmountWaived" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentFeeAmountWaived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeeAmountWaived" xlink:to="lab_eols_DebtInstrumentPrepaymentFeeAmountWaived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ce172d8f-69bd-4900-8290-28358a58aac4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70492bae-79fa-4f3e-b52d-b571958816ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d87e9326-1c1c-4279-8e26-206e7838358d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f79f68c0-33fe-46ad-af4c-6f57e69a8a38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_7cca030a-63a1-43c2-a8b6-0ae3f2617a82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_6982733e-0c71-471f-868f-c6d993e14c9c_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net book value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_922a893d-779b-494a-976f-6c4397ecd9a4_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_335c6879-da74-4bed-bcf5-62710e3c33d2_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement, current</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b8d914d2-fe33-4ecb-8272-f6a607183b0c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b970a4d4-f4fb-483a-a3f6-6f8885bdc923_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98a1acc1-67fc-489c-bc65-15a1a090c247_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1c39d05c-6267-452a-8384-ad9c9106de99_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_AccountingPoliciesTable_0eed7df3-7c76-4140-a3b2-38f2f37fbae7_terseLabel_en-US" xlink:label="lab_eols_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:label id="lab_eols_AccountingPoliciesTable_label_en-US" xlink:label="lab_eols_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:label id="lab_eols_AccountingPoliciesTable_documentation_en-US" xlink:label="lab_eols_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AccountingPoliciesTable" xlink:href="eols-20220930.xsd#eols_AccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AccountingPoliciesTable" xlink:to="lab_eols_AccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_cfefa187-7b9d-4c67-8524-7b5ecb580cf6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2a7fe995-ac9e-4a47-a5fd-b0f38865a9be_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_575f3e7a-8520-4e7a-bc77-d676cc382193_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value recorded in operating expenses</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1bf25099-c34e-40c5-bec6-21450253044b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_eb5fda7c-afe5-44c6-a328-c7dfbddf6907_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_2fee0e8c-dcd4-48d3-ba15-166201712a85_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_63d084bc-53bb-45e0-a876-8a116261fe6c_negatedTerseLabel_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent royalty obligation to Evolus Founders</link:label>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_label_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_documentation_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Contingent Royalty Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation" xlink:href="eols-20220930.xsd#eols_PaymentsOfContingentRoyaltyObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PaymentsOfContingentRoyaltyObligation" xlink:to="lab_eols_PaymentsOfContingentRoyaltyObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_74eedb10-8dbc-4f9a-8bbb-7b0bcabf6caf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_1a97dc1c-a72e-4d75-ac16-a7a84f76ce31_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt, net of discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_45ddbdae-c843-46c7-8096-c0c04775e46e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ab31fb64-cabf-4f4e-89db-dba86535f6a4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_48733c22-812b-4da4-af24-8a752828d4ae_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, percentage of principal amount, prepaid multiplied</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:to="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_34651ada-154f-4c13-bdf2-6a1f981a4f08_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_88760710-bea6-4592-9b74-dba53278df8f_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee percentage, thereafter</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Thereafter</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_42a9eab7-db80-4a90-958a-0f4c9ae07a59_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsAxis_c19b2cd9-1fec-40d7-8e56-f17cca14af85_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms [Axis]</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsAxis_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms [Axis]</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsAxis_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsAxis" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsAxis" xlink:to="lab_eols_DebtInstrumentPrepaymentTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0a7ac2f-7f1a-4ae7-802d-2281674b5b3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_615692cc-66c6-419f-bd32-92ce6b6754e0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_73177fe5-926f-4a01-93ee-3ad1497257bb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_864d32bc-c398-48c9-8983-b35722df99ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_0d7c1a2e-4d06-4fd7-9991-f0b99535d855_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithAgreement_317ba30f-55b0-442f-a19b-20c18d5ce1da_terseLabel_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent milestone payment</link:label>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithAgreement_label_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment In Connection With Agreement</link:label>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithAgreement_documentation_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment In Connection With Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentInConnectionWithAgreement" xlink:href="eols-20220930.xsd#eols_MilestonePaymentInConnectionWithAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentInConnectionWithAgreement" xlink:to="lab_eols_MilestonePaymentInConnectionWithAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9d2be3d1-652e-47d3-91be-d99c7a7834e6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer liability revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_638b5220-ff7f-4bd9-9de2-4f2eeccc8706_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ea0e67a1-9b7b-4c9c-bba0-ce88cf04a78a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_b4267847-9d4c-423e-8bbd-5387b97143db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_85a7fc0a-cc0c-4703-94c4-afa3432c731d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_13a09505-3be8-4860-a2a0-65fc638b692a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_552eabf3-2ea6-4786-96b2-a6db2003dd51_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_51ab5862-0231-452a-850f-a38603947088_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_bfd07065-812a-4b80-82cd-a54b1f78a51e_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of termination fee prior to lease termination date</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_label_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:href="eols-20220930.xsd#eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:to="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_34108ee7-e375-4bb3-97fc-d810dba742c2_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Book Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LineofCreditFacilityNumberofAdvances_be6892f3-d710-4dd5-a115-ade5ca9fee3d_terseLabel_en-US" xlink:label="lab_eols_LineofCreditFacilityNumberofAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of advances</link:label>
    <link:label id="lab_eols_LineofCreditFacilityNumberofAdvances_label_en-US" xlink:label="lab_eols_LineofCreditFacilityNumberofAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Advances</link:label>
    <link:label id="lab_eols_LineofCreditFacilityNumberofAdvances_documentation_en-US" xlink:label="lab_eols_LineofCreditFacilityNumberofAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LineofCreditFacilityNumberofAdvances" xlink:href="eols-20220930.xsd#eols_LineofCreditFacilityNumberofAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LineofCreditFacilityNumberofAdvances" xlink:to="lab_eols_LineofCreditFacilityNumberofAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_5e44171e-3032-49bf-afed-1d80fa331a3a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermOneMember_370ea191-ac36-476e-b4e9-ec3b65e9e8ab_terseLabel_en-US" xlink:label="lab_eols_TermOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term One</link:label>
    <link:label id="lab_eols_TermOneMember_label_en-US" xlink:label="lab_eols_TermOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term One [Member]</link:label>
    <link:label id="lab_eols_TermOneMember_documentation_en-US" xlink:label="lab_eols_TermOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermOneMember" xlink:href="eols-20220930.xsd#eols_TermOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermOneMember" xlink:to="lab_eols_TermOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_f136dca8-21b4-4279-aad5-5036e6d8ef77_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_859a5c0e-99f7-4e5f-a940-03e56c5f6c76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_61e5d992-8cad-4e7f-8d93-3592010db0d4_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-kind interest on convertible note</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1ca50431-02c3-4f32-a2ac-f5b808054cf5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DistributionRightsMember_f5b8d9d2-17d3-41d4-9ecf-d716abd6aab1_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution right</link:label>
    <link:label id="lab_us-gaap_DistributionRightsMember_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember" xlink:to="lab_us-gaap_DistributionRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4ff5ec3a-44e2-4a2d-bf6e-cead73d9ef11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_44ae8534-089c-49a6-a53b-a2c3c539596f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6ce98eb7-adf0-40a8-a0d4-bef77abbc0be_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_d851e83b-1e09-44ff-9c04-204bac0f2f6a_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_0a2c2f3b-dfa3-431f-80f9-afe931a2a809_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DaewoongSettlementAgreementMember_b4117e32-206b-4e79-93a2-70889fa64fd0_terseLabel_en-US" xlink:label="lab_eols_DaewoongSettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Settlement Agreement</link:label>
    <link:label id="lab_eols_DaewoongSettlementAgreementMember_label_en-US" xlink:label="lab_eols_DaewoongSettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Settlement Agreement [Member]</link:label>
    <link:label id="lab_eols_DaewoongSettlementAgreementMember_documentation_en-US" xlink:label="lab_eols_DaewoongSettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daewoong Settlement Agreement Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongSettlementAgreementMember" xlink:href="eols-20220930.xsd#eols_DaewoongSettlementAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DaewoongSettlementAgreementMember" xlink:to="lab_eols_DaewoongSettlementAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_231f2892-93d8-4f05-a4fc-3bdc03eb15fc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_fa1dfe3d-ecff-465d-b10f-3b96e3a4e427_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_906ab48c-fc77-4c8d-8cb8-67ccdf2e01cc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_bcbd07e8-05c6-4dff-9bd3-c9a9d2e1a13c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4ed9b7bc-c167-4957-9ee7-64ebf1936d5f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_ecb7737d-607b-4b83-a4a9-eff0b42295fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3ca60d36-007d-444b-9389-efe0070c5cbc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a845b29b-f0d8-4912-854f-af8446ba761d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_be56bcf3-a64e-412e-9ecf-d9f46c2e6250_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6622a738-4957-45ed-a6fb-36d1d23c5965_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1be4944-40d1-4405-8e37-7c37e75910dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_45f85b1d-439a-4bac-8962-7ebf49e5b1e3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_f34ce5ec-7e0b-493c-bfac-dd21f4aeebaf_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_9f46b912-71e2-40a7-b195-4a085f37ee26_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dc56e0e6-385b-46bd-beb5-bb0336ca67a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement_621f0b60-bdea-4ed6-80dc-3a3fe87d363e_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with litigation settlement</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Values, Litigation Settlement</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Values, Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodValuesLitigationSettlement" xlink:href="eols-20220930.xsd#eols_StockIssuedDuringPeriodValuesLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodValuesLitigationSettlement" xlink:to="lab_eols_StockIssuedDuringPeriodValuesLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_81447e50-135d-4376-9d77-81ec6ed0ca74_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8819dcd1-6d66-4685-aa08-aa92e0874f38_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9b4f933f-95bd-4d44-8d57-3328d51d646a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6f0b1214-2b2e-408d-9e9a-5dd978e30906_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1a080495-9df3-4d0d-9287-6d147b63ad16_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding used to compute basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_93976bbd-8a52-43b8-9068-4b0e25832209_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_512ea8a2-73d1-4cb1-af09-65e068be4fb2_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:href="eols-20220930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c32e343d-12cb-45a9-8f3c-70d5de5fc9a8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d076893e-1eca-47b2-8351-526e59e001dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_33893705-1c7d-419d-ad47-6c9681d1a495_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a12583bd-fcdd-49db-b737-49801b5783fa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2d80da3c-9acd-4f0b-9fb4-e379d0ace191_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_f70b8967-ca42-4cd6-b509-5c9620912a32_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible asset</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_1853fc4a-2ecc-4ba2-8612-108e12383cea_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1edc3c84-ac26-4e71-82f8-75d9ad873cd1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a2606c3a-0f12-42a1-884c-c8beaa43f506_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for conversion of convertible note (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_17366de0-aeed-4923-91af-4683d6c594cd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_6b27f5ca-6038-4fcc-9f15-a11e2f4ec6ff_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_68caaffe-74af-412f-bc4d-7ef874f9a9a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_a3286647-c493-4970-9d15-ba6fe0098b3b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b3b854c4-1e8c-47ad-a8e0-8060d72697d3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_bda05ce5-c811-4a38-aa59-87d791906a31_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_c2d5ab7f-c23d-48e7-94d3-3796c215c715_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase percentage of maximum shares outstanding (equal to)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_0fa5461a-16f2-46b0-bc39-791860f438fd_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_ba7568e5-1949-4c2e-8276-8e8b59d03cf7_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_9e360efb-3a30-4880-b37e-ed9315092037_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fe1a5a6c-f7c5-47b4-aa39-93da3b3d26b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6401a4f9-aad0-4d0e-81c3-1209f8e303ea_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_472eccbe-f1fb-4a0b-8c78-8f00d273f835_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_ffe161c5-f51c-4b12-b686-cdcf346c2781_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ecbd3f78-1f2b-4923-9984-7685785a8311_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_b4398ea9-5270-427d-9a78-52a1210f1336_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_ec92683d-e2b4-4560-aa94-a6bdc7fec113_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of written notice</link:label>
    <link:label id="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_label_en-US" xlink:label="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date</link:label>
    <link:label id="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:href="eols-20220930.xsd#eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:to="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_61988739-f1b4-4201-89f3-740a6359dc09_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement_dc48c893-eef2-44f2-beac-00f40c598b14_terseLabel_en-US" xlink:label="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement_label_en-US" xlink:label="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Litigation Settlement</link:label>
    <link:label id="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement_documentation_en-US" xlink:label="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement" xlink:href="eols-20220930.xsd#eols_IncreaseDecreaseInAccruedLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement" xlink:to="lab_eols_IncreaseDecreaseInAccruedLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SaleOfStockCommissionPaid_8649f87b-487c-437d-b987-2eb7892f4bdd_terseLabel_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total commission</link:label>
    <link:label id="lab_eols_SaleOfStockCommissionPaid_label_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Paid</link:label>
    <link:label id="lab_eols_SaleOfStockCommissionPaid_documentation_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaid" xlink:href="eols-20220930.xsd#eols_SaleOfStockCommissionPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SaleOfStockCommissionPaid" xlink:to="lab_eols_SaleOfStockCommissionPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aad1d263-b527-43a0-b0ba-eec8fe1e1238_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_0e1ab8bf-4b1b-408f-ab58-05c3b987f645_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of periodic payments</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_label_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Periodic Payments, Principal</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_documentation_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Periodic Payments, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" xlink:href="eols-20220930.xsd#eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" xlink:to="lab_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_fb6a8beb-34bf-47db-8c79-04f9b6c9df09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_52dc574c-7c3f-4d15-a9ab-e7870f53e949_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d16e7aeb-1305-4f46-bd08-c61048a56258_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_00ade48d-244d-4d31-9180-a0403762d78f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f5622367-13a4-4822-a95c-2355433d2050_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaae276-ed58-4520-ad5a-d95f7ba0015f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_22527c05-e837-411a-9e9b-45b0e4f34644_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_49893b3c-44d2-4f23-9e4a-401787f0af72_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4c2ef550-782f-4955-82d9-7f032b0c6465_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4a484a6d-9aae-4a6d-9a1b-d182f8d6b2d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_a88b09d6-9c41-4de8-8684-de5d542e2661_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_3f758e3d-5d2f-452f-98ff-68303ed986fb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a2d052cb-ffc8-43de-8d6a-37eff6a6a942_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3c9f2af5-a441-426e-8746-fa76f534a253_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_f945398f-491d-400b-9cb2-f9cf4f905893_totalLabel_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross (including goodwill)</link:label>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_label_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_documentation_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:href="eols-20220930.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:to="lab_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_44015c35-888a-49f7-95f8-923061a46188_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_dd9cff59-2e0d-442e-a9cb-1ee838c93bdc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived_b02b4ea3-7521-403c-87ab-ee50d68d1fa2_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument of principal amount payment</link:label>
    <link:label id="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived_label_en-US" xlink:label="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Of Final Payment Amount Waived</link:label>
    <link:label id="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived_documentation_en-US" xlink:label="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Of Final Payment Amount Waived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentOfFinalPaymentAmountWaived" xlink:href="eols-20220930.xsd#eols_DebtInstrumentOfFinalPaymentAmountWaived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentOfFinalPaymentAmountWaived" xlink:to="lab_eols_DebtInstrumentOfFinalPaymentAmountWaived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_1305beaf-4f6d-4bcf-a3a8-3d71336792ca_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_66c30c64-8f68-41f8-9300-5031b6743cfd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_996acb4f-d847-476f-8b0e-87a6e455bd18_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_af6c3e8e-f0dc-41aa-ad87-d532c5ba238b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration receivable from Daewoong</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationPeriod_8710fe05-bf21-4bc9-8008-068bc0ee266d_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationPeriod_label_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationPeriod_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeaseTerminationPeriod" xlink:href="eols-20220930.xsd#eols_LesseeOperatingLeaseTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeaseTerminationPeriod" xlink:to="lab_eols_LesseeOperatingLeaseTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_01711089-2337-4aab-92ec-80669c45f880_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4fa8af90-2b05-408a-96a6-8bf155246fef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_8f2ddb02-637e-4c21-934d-01bd27edb2fe_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_label_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amortization Period</link:label>
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_documentation_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod" xlink:href="eols-20220930.xsd#eols_DebtInstrumentAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentAmortizationPeriod" xlink:to="lab_eols_DebtInstrumentAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_fa584882-f636-4f7c-8aa4-3a3d91b3ee07_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_23f04ff1-b54f-4a7e-9348-44b2f5968d7e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_6c455d04-3c81-4428-b4e4-157569ac7e0a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_117f6260-551a-4c94-b5ec-ea5696ccea4c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_9093287c-c16b-464e-828f-dad0f95358f8_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c4f3b951-a43f-4d72-954d-643fc22a2737_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_b231a069-22be-4799-a115-abb14d31223c_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anniversary period</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_label_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Payment Commencement Period</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Payment Commencement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" xlink:to="lab_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d44329ec-90be-4571-af73-eec201cde757_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3c7da5b5-b920-46d2-b589-a0612201498d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6c564982-710f-4cab-8b0e-686441a4bc56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares authorized under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_a23be2b2-b0bb-4d3e-8a6c-afcf2e2e293b_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee percentage, year two</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Year Two</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LossContingencySettlementAgreementPaymentTerms_80229183-75c2-441c-86e9-f7dfc777a5e2_terseLabel_en-US" xlink:label="lab_eols_LossContingencySettlementAgreementPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreement, payment terms (in years)</link:label>
    <link:label id="lab_eols_LossContingencySettlementAgreementPaymentTerms_label_en-US" xlink:label="lab_eols_LossContingencySettlementAgreementPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreement, Payment Terms</link:label>
    <link:label id="lab_eols_LossContingencySettlementAgreementPaymentTerms_documentation_en-US" xlink:label="lab_eols_LossContingencySettlementAgreementPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreement, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms" xlink:href="eols-20220930.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LossContingencySettlementAgreementPaymentTerms" xlink:to="lab_eols_LossContingencySettlementAgreementPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_20a1b8b9-39a8-4dd3-920f-0d3418396350_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a972b796-14ad-4375-a936-da27340cd04c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining in 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SCHAEONLLCMember_7ccaef5a-e1d3-4942-9b5c-de027c3f1f5e_terseLabel_en-US" xlink:label="lab_eols_SCHAEONLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCH</link:label>
    <link:label id="lab_eols_SCHAEONLLCMember_label_en-US" xlink:label="lab_eols_SCHAEONLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCH-AEON, LLC [Member]</link:label>
    <link:label id="lab_eols_SCHAEONLLCMember_documentation_en-US" xlink:label="lab_eols_SCHAEONLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCH-AEON, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SCHAEONLLCMember" xlink:href="eols-20220930.xsd#eols_SCHAEONLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SCHAEONLLCMember" xlink:to="lab_eols_SCHAEONLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ba58010f-68c8-49b2-8889-68c8bed302c4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_74dd3da4-68a0-4cd0-9470-c0a3166fa5fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_949963e3-a579-4194-a55a-70183411b7c3_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_85c5fe4a-b697-4fb5-ac93-84e42539c3bb_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a12a2a67-a9df-4ff4-8e9c-cd34a1156a55_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity CIK</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b726d56b-28f7-467c-839e-c3ae70dc6e71_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0016fb36-5cc6-441f-bf54-c815295b00f1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c77a2615-a67b-43a5-9e25-3279c24daf4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_349fd94f-4096-4183-855a-dca4d5ae953e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bbfbc7b5-0de9-4a04-a0c9-93314663614f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_IntellectualPropertyDisputesJeuveauMember_83b76c28-643f-4523-990b-60bf0cf73e77_terseLabel_en-US" xlink:label="lab_eols_IntellectualPropertyDisputesJeuveauMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Disputes, Jeuveau</link:label>
    <link:label id="lab_eols_IntellectualPropertyDisputesJeuveauMember_label_en-US" xlink:label="lab_eols_IntellectualPropertyDisputesJeuveauMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Disputes, Jeuveau [Member]</link:label>
    <link:label id="lab_eols_IntellectualPropertyDisputesJeuveauMember_documentation_en-US" xlink:label="lab_eols_IntellectualPropertyDisputesJeuveauMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Disputes, Jeuveau</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember" xlink:href="eols-20220930.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IntellectualPropertyDisputesJeuveauMember" xlink:to="lab_eols_IntellectualPropertyDisputesJeuveauMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_0015b0e7-455d-42d2-bac6-77fa054c59f1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_5412486c-2fcb-4f5f-8d9e-7a8e0a1f9def_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement_44988390-5644-40a3-b5af-68afeedd93f1_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with litigation settlement (in shares)</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Litigation Settlement</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:href="eols-20220930.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:to="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_cf7d2f85-18dc-4cfb-8dec-05c9a536f79b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_9d4e3673-d3bc-43ba-bdc3-fd60316b514f_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_b353c824-e11a-46a0-9d2c-35153fb12c29_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3a1df864-7303-4e73-a10b-8df72a202b88_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0e191894-a6ea-4818-b5f8-5a489ee47175_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6df834ac-6cec-45a4-92fa-e82857150ccf_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_8106121b-7bdd-43c7-89fa-e210ba78149c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_79163730-e911-4430-955d-08db4607b335_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment, amount</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForSoftware_e9504893-2f18-43c8-9168-a891207c9168_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to capitalized software</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware" xlink:to="lab_us-gaap_PaymentsForSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4961575a-922c-494e-90e0-d3fb56c5afda_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8e66d9c0-0057-4dc3-8304-0fa6c69a94c5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentNumberOfTranches_7722d9bf-73c2-42fd-bf3e-e4525c8ecd79_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfTranches_label_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfTranches_documentation_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfTranches" xlink:href="eols-20220930.xsd#eols_DebtInstrumentNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentNumberOfTranches" xlink:to="lab_eols_DebtInstrumentNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_a3409da8-cfba-42f1-ba0e-b228c3f5cfbd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_5bd768a3-665b-4506-b840-2bad2e48a47a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_50b110a1-82d3-45d9-b698-af6e5360c668_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b49aacd8-78af-4762-bdcd-0b2c35db1a22_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing information</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_aef8bdb7-1f48-4932-b825-16eda3f71605_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_ebfbba97-d58d-4fd6-ad38-9cc62e827621_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_464822b8-c6ac-4fc1-87a7-83cb24286665_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual, payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dc4ec613-1661-4891-a9c6-3653c9737682_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8426a1cc-452d-46dd-951a-ec77a1e174a2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_135e705c-3a50-4faf-8dc5-4c9edf178fb6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term purchase commitment, amount</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ed3847a7-64b7-467f-bdec-641bcda550bd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_22adc134-8393-4f32-b81e-c9a560efc6c7_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Obligation Payable to Related Party, Current</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Obligation Payable to Related Party, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:href="eols-20220930.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:to="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>eols-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9907a7dd-9da5-4da3-a916-5b93970552d6,g:d423565a-304b-425b-af42-a6f72195e86c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolus.com/role/Cover" xlink:type="simple" xlink:href="eols-20220930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_73b083c7-c670-41c6-b567-4373672fd724" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_DocumentType_73b083c7-c670-41c6-b567-4373672fd724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_df562fe3-7e40-4357-a4a1-64f610dc339f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_DocumentQuarterlyReport_df562fe3-7e40-4357-a4a1-64f610dc339f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_127d41ee-7ff1-4ace-95cd-7bb9594dd33b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_DocumentPeriodEndDate_127d41ee-7ff1-4ace-95cd-7bb9594dd33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4e70eea0-c4c8-45f5-880a-36f09c0a7a3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_DocumentTransitionReport_4e70eea0-c4c8-45f5-880a-36f09c0a7a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fcdfea12-1c20-49ee-ae88-a0eb267aba48" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityFileNumber_fcdfea12-1c20-49ee-ae88-a0eb267aba48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9267bb39-cf4f-4548-bec7-fac75773494d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityRegistrantName_9267bb39-cf4f-4548-bec7-fac75773494d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_477a9de8-f76f-4efd-bf15-7d6c35a734e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_477a9de8-f76f-4efd-bf15-7d6c35a734e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fffa5f8a-232c-4292-bb90-55e4df8e5a7d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityTaxIdentificationNumber_fffa5f8a-232c-4292-bb90-55e4df8e5a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cb028b91-97c3-4e6c-b1a2-36ff8554bf1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityAddressAddressLine1_cb028b91-97c3-4e6c-b1a2-36ff8554bf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9e381364-71af-4634-888f-81a7974c120c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityAddressCityOrTown_9e381364-71af-4634-888f-81a7974c120c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_41dc51b2-7981-4c06-9db9-437714d4f9ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityAddressStateOrProvince_41dc51b2-7981-4c06-9db9-437714d4f9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_92e1d868-767a-4033-8479-e360ed9564cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityAddressPostalZipCode_92e1d868-767a-4033-8479-e360ed9564cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3a1fda68-19a2-4db9-8836-672dda738014" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_CityAreaCode_3a1fda68-19a2-4db9-8836-672dda738014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9356f6bc-d825-41ad-b585-66bebf79f148" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_LocalPhoneNumber_9356f6bc-d825-41ad-b585-66bebf79f148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_af3d38ee-dfcd-4fdd-b912-722d821a3716" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_Security12bTitle_af3d38ee-dfcd-4fdd-b912-722d821a3716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3b94f104-1593-494f-9bbe-aea3d226ab07" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_TradingSymbol_3b94f104-1593-494f-9bbe-aea3d226ab07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f697d858-f42e-4bf7-b028-6fc4583ff74e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_SecurityExchangeName_f697d858-f42e-4bf7-b028-6fc4583ff74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7053a94f-8c1f-407b-bf18-021ce16f4618" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityCurrentReportingStatus_7053a94f-8c1f-407b-bf18-021ce16f4618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ae50e4f9-062a-4704-ad27-80ac6e304f9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityInteractiveDataCurrent_ae50e4f9-062a-4704-ad27-80ac6e304f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3810f6c4-c408-4ed6-ba44-049c280c79a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityFilerCategory_3810f6c4-c408-4ed6-ba44-049c280c79a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_249b21c2-dae1-45d7-90b7-3beb88c99aa6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntitySmallBusiness_249b21c2-dae1-45d7-90b7-3beb88c99aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4add4e29-c2c7-46b1-875c-e2f327c24f9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityEmergingGrowthCompany_4add4e29-c2c7-46b1-875c-e2f327c24f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_f80cda8e-9992-41ba-9aa3-e2e84fb42611" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityExTransitionPeriod_f80cda8e-9992-41ba-9aa3-e2e84fb42611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_85ea8ffb-568a-40df-8225-489caf1e9b7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityShellCompany_85ea8ffb-568a-40df-8225-489caf1e9b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_62ea367d-2518-4a35-b13f-0b094b438a1a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_62ea367d-2518-4a35-b13f-0b094b438a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_aaf92729-ec4c-42ae-bb98-1a7127cc8665" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_AmendmentFlag_aaf92729-ec4c-42ae-bb98-1a7127cc8665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e2a9972d-3cab-47da-8ef4-adc20388c6ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_DocumentFiscalYearFocus_e2a9972d-3cab-47da-8ef4-adc20388c6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f816aea6-904f-47d2-9f64-9b1d1bf7a064" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f816aea6-904f-47d2-9f64-9b1d1bf7a064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c462a04b-6194-4323-9e0d-e79eea0a44dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_EntityCentralIndexKey_c462a04b-6194-4323-9e0d-e79eea0a44dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5474ba46-b042-4f5b-94bc-9b0c33a227a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e770fb55-3089-4923-bfd2-a2bc27d55d6a" xlink:to="loc_dei_CurrentFiscalYearEndDate_5474ba46-b042-4f5b-94bc-9b0c33a227a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="eols-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b3851781-7f01-4b96-9c12-86b48360f34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e3f05652-532f-4d0c-82b0-b600f404fffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b3851781-7f01-4b96-9c12-86b48360f34e" xlink:to="loc_us-gaap_AssetsAbstract_e3f05652-532f-4d0c-82b0-b600f404fffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d44761a6-e5eb-4442-8dd6-2cac8cfa7cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3f05652-532f-4d0c-82b0-b600f404fffc" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d44761a6-e5eb-4442-8dd6-2cac8cfa7cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f69818a8-0c2f-45dc-85a1-4f5af2369055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d44761a6-e5eb-4442-8dd6-2cac8cfa7cb0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f69818a8-0c2f-45dc-85a1-4f5af2369055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2cd01a9d-4a17-435c-a62d-8dd7aa840207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d44761a6-e5eb-4442-8dd6-2cac8cfa7cb0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2cd01a9d-4a17-435c-a62d-8dd7aa840207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5f196afb-c1ff-4bf8-9217-ff0ac1ca534f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d44761a6-e5eb-4442-8dd6-2cac8cfa7cb0" xlink:to="loc_us-gaap_InventoryNet_5f196afb-c1ff-4bf8-9217-ff0ac1ca534f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d963fe2f-4310-4e3d-b21b-0e44d1b4c06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d44761a6-e5eb-4442-8dd6-2cac8cfa7cb0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d963fe2f-4310-4e3d-b21b-0e44d1b4c06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_81858e13-609b-4fd6-bda8-a7c0419e94bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d44761a6-e5eb-4442-8dd6-2cac8cfa7cb0" xlink:to="loc_us-gaap_OtherAssetsCurrent_81858e13-609b-4fd6-bda8-a7c0419e94bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ae627666-fcdd-415d-a341-d13a7b5d19f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d44761a6-e5eb-4442-8dd6-2cac8cfa7cb0" xlink:to="loc_us-gaap_AssetsCurrent_ae627666-fcdd-415d-a341-d13a7b5d19f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c6732840-b5fd-485a-9027-5f352c4ac1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3f05652-532f-4d0c-82b0-b600f404fffc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c6732840-b5fd-485a-9027-5f352c4ac1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_522665bf-b2f6-419b-8d5e-813dd492b486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3f05652-532f-4d0c-82b0-b600f404fffc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_522665bf-b2f6-419b-8d5e-813dd492b486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_81f2bb21-8231-4dfd-8520-4da15421897e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3f05652-532f-4d0c-82b0-b600f404fffc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_81f2bb21-8231-4dfd-8520-4da15421897e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_93055c41-16fe-4969-a644-c91ae0cce90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3f05652-532f-4d0c-82b0-b600f404fffc" xlink:to="loc_us-gaap_Goodwill_93055c41-16fe-4969-a644-c91ae0cce90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8990df9f-41c2-4e8a-adc8-fe8221a9e42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3f05652-532f-4d0c-82b0-b600f404fffc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8990df9f-41c2-4e8a-adc8-fe8221a9e42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1938a937-23dc-4a43-a737-80e9bae3cdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3f05652-532f-4d0c-82b0-b600f404fffc" xlink:to="loc_us-gaap_Assets_1938a937-23dc-4a43-a737-80e9bae3cdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411c6bb7-a2a6-4d08-8a05-ea1ba69502f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b3851781-7f01-4b96-9c12-86b48360f34e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411c6bb7-a2a6-4d08-8a05-ea1ba69502f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5abb240b-36f0-4b5b-b8e7-2fc74f674a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411c6bb7-a2a6-4d08-8a05-ea1ba69502f6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5abb240b-36f0-4b5b-b8e7-2fc74f674a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9cbd195d-270b-4979-86d3-356d1f81f470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5abb240b-36f0-4b5b-b8e7-2fc74f674a79" xlink:to="loc_us-gaap_AccountsPayableCurrent_9cbd195d-270b-4979-86d3-356d1f81f470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_df9f70ec-1091-4d83-9d93-890a0d0e4083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5abb240b-36f0-4b5b-b8e7-2fc74f674a79" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_df9f70ec-1091-4d83-9d93-890a0d0e4083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_4cef1720-4dec-4adb-8aa2-58451d1a2a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5abb240b-36f0-4b5b-b8e7-2fc74f674a79" xlink:to="loc_us-gaap_LitigationReserveCurrent_4cef1720-4dec-4adb-8aa2-58451d1a2a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f23e779-ef9f-4a49-90b1-570bd75b6d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5abb240b-36f0-4b5b-b8e7-2fc74f674a79" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f23e779-ef9f-4a49-90b1-570bd75b6d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_a97ee7f5-b8f8-4fe9-a8d9-b094bb747260" xlink:href="eols-20220930.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5abb240b-36f0-4b5b-b8e7-2fc74f674a79" xlink:to="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_a97ee7f5-b8f8-4fe9-a8d9-b094bb747260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ec1790af-7f59-4254-b768-1dbc7e161160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5abb240b-36f0-4b5b-b8e7-2fc74f674a79" xlink:to="loc_us-gaap_LiabilitiesCurrent_ec1790af-7f59-4254-b768-1dbc7e161160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_dc4a4bb7-8d1c-4d6b-bdfe-74355a223623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411c6bb7-a2a6-4d08-8a05-ea1ba69502f6" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_dc4a4bb7-8d1c-4d6b-bdfe-74355a223623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3433baa8-52fe-47d0-8276-f4fd05c90fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411c6bb7-a2a6-4d08-8a05-ea1ba69502f6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3433baa8-52fe-47d0-8276-f4fd05c90fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_d77ff5f0-fd2a-4fe5-9c4c-e9788a9ce9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411c6bb7-a2a6-4d08-8a05-ea1ba69502f6" xlink:to="loc_us-gaap_ContractualObligation_d77ff5f0-fd2a-4fe5-9c4c-e9788a9ce9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_6e3eec4c-394a-4807-803d-58113145ae11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411c6bb7-a2a6-4d08-8a05-ea1ba69502f6" xlink:to="loc_us-gaap_SecuredLongTermDebt_6e3eec4c-394a-4807-803d-58113145ae11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4d955d38-e546-41dd-b504-d7dc69bd840e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411c6bb7-a2a6-4d08-8a05-ea1ba69502f6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4d955d38-e546-41dd-b504-d7dc69bd840e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f0fbabb8-775b-475f-8bb9-8067c678ca7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411c6bb7-a2a6-4d08-8a05-ea1ba69502f6" xlink:to="loc_us-gaap_Liabilities_f0fbabb8-775b-475f-8bb9-8067c678ca7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cd33ca13-21ec-4240-a676-969bc6559006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411c6bb7-a2a6-4d08-8a05-ea1ba69502f6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cd33ca13-21ec-4240-a676-969bc6559006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_db42cc08-f7a5-4054-af93-8c7fef00ca12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411c6bb7-a2a6-4d08-8a05-ea1ba69502f6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_db42cc08-f7a5-4054-af93-8c7fef00ca12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4ec44979-c7cb-4e8f-a3ba-dcc295901981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db42cc08-f7a5-4054-af93-8c7fef00ca12" xlink:to="loc_us-gaap_PreferredStockValue_4ec44979-c7cb-4e8f-a3ba-dcc295901981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cd176a2e-8973-446d-93f0-75a4e07eb97a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db42cc08-f7a5-4054-af93-8c7fef00ca12" xlink:to="loc_us-gaap_CommonStockValue_cd176a2e-8973-446d-93f0-75a4e07eb97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_00ea9da3-924f-4850-b8df-88ebe64cc316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db42cc08-f7a5-4054-af93-8c7fef00ca12" xlink:to="loc_us-gaap_AdditionalPaidInCapital_00ea9da3-924f-4850-b8df-88ebe64cc316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dccf02c2-259c-4446-bfba-752b9ba0746a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db42cc08-f7a5-4054-af93-8c7fef00ca12" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dccf02c2-259c-4446-bfba-752b9ba0746a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2df20d81-1962-445a-a835-c4d7c39b227c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db42cc08-f7a5-4054-af93-8c7fef00ca12" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2df20d81-1962-445a-a835-c4d7c39b227c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5add68b6-fc25-46af-a7bc-b267e5c24dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db42cc08-f7a5-4054-af93-8c7fef00ca12" xlink:to="loc_us-gaap_StockholdersEquity_5add68b6-fc25-46af-a7bc-b267e5c24dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe82f5b2-91b5-4277-983a-24db57861222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_411c6bb7-a2a6-4d08-8a05-ea1ba69502f6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe82f5b2-91b5-4277-983a-24db57861222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="eols-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bbc3e26e-a537-4e36-8fbd-dd13385fe4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7124f292-ea97-4eaf-b5b5-b91048b8ff31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bbc3e26e-a537-4e36-8fbd-dd13385fe4c9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7124f292-ea97-4eaf-b5b5-b91048b8ff31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_34339e72-9265-4161-9f68-8754feefe65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bbc3e26e-a537-4e36-8fbd-dd13385fe4c9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_34339e72-9265-4161-9f68-8754feefe65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5377acf6-fdd6-416a-bfae-cd9aec702b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bbc3e26e-a537-4e36-8fbd-dd13385fe4c9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5377acf6-fdd6-416a-bfae-cd9aec702b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e531a5b4-c7c8-49aa-a177-b927bd330b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bbc3e26e-a537-4e36-8fbd-dd13385fe4c9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e531a5b4-c7c8-49aa-a177-b927bd330b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fa311a68-f932-465f-a4ff-b36cbb15a476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bbc3e26e-a537-4e36-8fbd-dd13385fe4c9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fa311a68-f932-465f-a4ff-b36cbb15a476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_66d29e7d-9a5e-4606-b23a-f1bacedb5c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bbc3e26e-a537-4e36-8fbd-dd13385fe4c9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_66d29e7d-9a5e-4606-b23a-f1bacedb5c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_638074e6-c41e-4a33-bf29-dba5ea38b956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bbc3e26e-a537-4e36-8fbd-dd13385fe4c9" xlink:to="loc_us-gaap_CommonStockSharesIssued_638074e6-c41e-4a33-bf29-dba5ea38b956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3784633b-1190-41b0-84dc-90f5d6c93608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bbc3e26e-a537-4e36-8fbd-dd13385fe4c9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3784633b-1190-41b0-84dc-90f5d6c93608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="eols-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_962be948-5599-4711-8a2e-c2c3254e3f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2eba4b4f-a814-416e-bf4b-76c7c60f9d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_962be948-5599-4711-8a2e-c2c3254e3f37" xlink:to="loc_us-gaap_StatementTable_2eba4b4f-a814-416e-bf4b-76c7c60f9d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c1db50a6-482a-4835-941b-fae3dc2946b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2eba4b4f-a814-416e-bf4b-76c7c60f9d11" xlink:to="loc_srt_ProductOrServiceAxis_c1db50a6-482a-4835-941b-fae3dc2946b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_03c6eb8a-3867-4210-b309-1f0b893051c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c1db50a6-482a-4835-941b-fae3dc2946b6" xlink:to="loc_srt_ProductsAndServicesDomain_03c6eb8a-3867-4210-b309-1f0b893051c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_388892e5-fce7-4234-b33a-9be09ce6bb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_03c6eb8a-3867-4210-b309-1f0b893051c3" xlink:to="loc_us-gaap_ProductMember_388892e5-fce7-4234-b33a-9be09ce6bb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_d2b809bc-98f2-4753-9527-dbefa76d429c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_03c6eb8a-3867-4210-b309-1f0b893051c3" xlink:to="loc_us-gaap_ServiceMember_d2b809bc-98f2-4753-9527-dbefa76d429c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2eba4b4f-a814-416e-bf4b-76c7c60f9d11" xlink:to="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_144c1d34-b82c-42ba-9aee-a2cecf658239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_RevenuesAbstract_144c1d34-b82c-42ba-9aee-a2cecf658239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_feefcfd4-8186-4bea-8877-bfacfc661b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_144c1d34-b82c-42ba-9aee-a2cecf658239" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_feefcfd4-8186-4bea-8877-bfacfc661b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_788f4baf-e4a0-4c78-8583-31d86f76449d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_788f4baf-e4a0-4c78-8583-31d86f76449d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_e8446b1b-4635-4067-b888-f20c9b053f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_e8446b1b-4635-4067-b888-f20c9b053f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_83369f4c-2242-455f-a768-49f666194b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_83369f4c-2242-455f-a768-49f666194b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_93db35e2-4dbb-4910-bf05-64368a05ad5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_93db35e2-4dbb-4910-bf05-64368a05ad5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_74db05a1-e8aa-4a66-9655-df3f6de3c526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_74db05a1-e8aa-4a66-9655-df3f6de3c526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b23a5042-5f1d-4dfb-99ce-76260d73d1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b23a5042-5f1d-4dfb-99ce-76260d73d1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_89ae5e6a-6849-40e4-a5a0-323ea495ae04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_89ae5e6a-6849-40e4-a5a0-323ea495ae04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_674e522f-d0cc-4d5b-af59-629d1e15dfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_20af153c-da44-4a84-a5fd-45a6e60574f6" xlink:to="loc_us-gaap_CostsAndExpenses_674e522f-d0cc-4d5b-af59-629d1e15dfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9960c6c0-6304-4757-b63a-f0082a7845f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_OperatingIncomeLoss_9960c6c0-6304-4757-b63a-f0082a7845f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_eeedc833-6ed2-4c26-9502-9d65d06a7c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_eeedc833-6ed2-4c26-9502-9d65d06a7c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_1a6948b2-26f1-4eb3-bcfc-064e83d28da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_eeedc833-6ed2-4c26-9502-9d65d06a7c66" xlink:to="loc_us-gaap_InvestmentIncomeNet_1a6948b2-26f1-4eb3-bcfc-064e83d28da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7c28d171-cb7a-40fd-9444-a0fa37ecf21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_eeedc833-6ed2-4c26-9502-9d65d06a7c66" xlink:to="loc_us-gaap_InterestExpense_7c28d171-cb7a-40fd-9444-a0fa37ecf21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_788737f2-c5c6-487e-a3bf-36cbf3ed437e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_eeedc833-6ed2-4c26-9502-9d65d06a7c66" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_788737f2-c5c6-487e-a3bf-36cbf3ed437e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b32d2431-2e2c-47ba-a5c9-b99c659ae261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_eeedc833-6ed2-4c26-9502-9d65d06a7c66" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b32d2431-2e2c-47ba-a5c9-b99c659ae261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1556213b-3a9a-4ffe-bb48-93cd616112f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1556213b-3a9a-4ffe-bb48-93cd616112f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f4a0e99d-414b-44c4-bfb1-5a2153e97b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f4a0e99d-414b-44c4-bfb1-5a2153e97b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_898525f2-d3fd-40bf-88bb-a790dba20a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_NetIncomeLoss_898525f2-d3fd-40bf-88bb-a790dba20a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_59294772-6c3a-4d99-88c8-526aec2065fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_59294772-6c3a-4d99-88c8-526aec2065fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f0a4bba0-af2c-4ec7-9b35-67c5ea49e19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_59294772-6c3a-4d99-88c8-526aec2065fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f0a4bba0-af2c-4ec7-9b35-67c5ea49e19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7cecb328-6763-4d73-b646-2792f949f810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7cecb328-6763-4d73-b646-2792f949f810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_17626fb9-a514-4597-bd10-8f7b69535cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_EarningsPerShareBasic_17626fb9-a514-4597-bd10-8f7b69535cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_dbb1a463-918c-48c4-afb4-70653167eeee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_dbb1a463-918c-48c4-afb4-70653167eeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_25f11972-3f59-4a4d-a587-74289ad6ce43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_25f11972-3f59-4a4d-a587-74289ad6ce43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_663b644e-5a96-41b7-937b-b2c679e7818a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_663b644e-5a96-41b7-937b-b2c679e7818a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_0f1cce03-bf90-4387-919b-3c21310b7a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224bdb59-3ace-48ea-9352-8568d999ed4a" xlink:to="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_0f1cce03-bf90-4387-919b-3c21310b7a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="eols-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d25821e1-ef34-4964-a637-5c3657643df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cc092b21-163c-4f9f-ae4c-7530e12d6829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d25821e1-ef34-4964-a637-5c3657643df6" xlink:to="loc_us-gaap_StatementTable_cc092b21-163c-4f9f-ae4c-7530e12d6829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2178bfc8-2fb1-4440-aca4-42b59639eb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc092b21-163c-4f9f-ae4c-7530e12d6829" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2178bfc8-2fb1-4440-aca4-42b59639eb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2178bfc8-2fb1-4440-aca4-42b59639eb5a" xlink:to="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_be3d7f80-be91-45ad-b418-c9774d8e72e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:to="loc_us-gaap_PreferredStockMember_be3d7f80-be91-45ad-b418-c9774d8e72e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a7b96820-b44d-4e96-a1ff-5334f1161542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:to="loc_us-gaap_CommonStockMember_a7b96820-b44d-4e96-a1ff-5334f1161542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_de818edb-6717-4c51-8565-8930b3276801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_de818edb-6717-4c51-8565-8930b3276801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c187c213-380f-4a7c-9ba6-2be8cc660085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c187c213-380f-4a7c-9ba6-2be8cc660085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d891092c-5a98-40d7-8798-4b4c5531e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_13714c4e-2182-4b90-9b66-aae22c655147" xlink:to="loc_us-gaap_RetainedEarningsMember_d891092c-5a98-40d7-8798-4b4c5531e54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b2134e9b-68c6-46bc-be3a-faa22d69f895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc092b21-163c-4f9f-ae4c-7530e12d6829" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b2134e9b-68c6-46bc-be3a-faa22d69f895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a508d9e6-3f8f-4b4a-8e5e-4ccd298b788b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b2134e9b-68c6-46bc-be3a-faa22d69f895" xlink:to="loc_us-gaap_ClassOfStockDomain_a508d9e6-3f8f-4b4a-8e5e-4ccd298b788b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_317ff28c-7e39-4be5-9a29-2bf1cf2be43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a508d9e6-3f8f-4b4a-8e5e-4ccd298b788b" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_317ff28c-7e39-4be5-9a29-2bf1cf2be43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ba682e80-2449-4850-b0cd-dcf41c0c6150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc092b21-163c-4f9f-ae4c-7530e12d6829" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ba682e80-2449-4850-b0cd-dcf41c0c6150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5cfd1d1d-98c3-4fa8-9b49-53db0ab07e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba682e80-2449-4850-b0cd-dcf41c0c6150" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5cfd1d1d-98c3-4fa8-9b49-53db0ab07e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember_92de6eff-4822-43ef-9553-4d596cc5e0b4" xlink:href="eols-20220930.xsd#eols_FollowOnOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5cfd1d1d-98c3-4fa8-9b49-53db0ab07e63" xlink:to="loc_eols_FollowOnOfferingMember_92de6eff-4822-43ef-9553-4d596cc5e0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_10c257e5-0264-4735-8c41-2537a510ef2d" xlink:href="eols-20220930.xsd#eols_ATMSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5cfd1d1d-98c3-4fa8-9b49-53db0ab07e63" xlink:to="loc_eols_ATMSalesAgreementMember_10c257e5-0264-4735-8c41-2537a510ef2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d57ffd00-829e-4ced-8be9-96fea55dc3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc092b21-163c-4f9f-ae4c-7530e12d6829" xlink:to="loc_us-gaap_StatementLineItems_d57ffd00-829e-4ced-8be9-96fea55dc3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d57ffd00-829e-4ced-8be9-96fea55dc3fe" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_23bd06f5-ea1b-4a66-a6b8-8c7fa021c5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_23bd06f5-ea1b-4a66-a6b8-8c7fa021c5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8746ef42-61db-4245-b60a-e50f212469f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_CommonStockSharesIssued_8746ef42-61db-4245-b60a-e50f212469f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c8763b21-2052-40b1-beb3-dfd5ff0346a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_StockholdersEquity_c8763b21-2052-40b1-beb3-dfd5ff0346a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_5652dd1f-c256-481e-93cd-6f9e17f17858" xlink:href="eols-20220930.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_5652dd1f-c256-481e-93cd-6f9e17f17858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodValuesLitigationSettlement_77283366-b8a3-4126-9865-07301a8e6dca" xlink:href="eols-20220930.xsd#eols_StockIssuedDuringPeriodValuesLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_eols_StockIssuedDuringPeriodValuesLitigationSettlement_77283366-b8a3-4126-9865-07301a8e6dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e1a9b0d5-a119-44d7-be22-be6b19ad8056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e1a9b0d5-a119-44d7-be22-be6b19ad8056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_654dfc1f-bf5f-4935-974b-e27596513a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_654dfc1f-bf5f-4935-974b-e27596513a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a816b150-da4f-4582-8c23-60d634b21821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a816b150-da4f-4582-8c23-60d634b21821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e72bfcaa-8ce4-490b-a659-095adf83be0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e72bfcaa-8ce4-490b-a659-095adf83be0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5d54be10-5391-4221-8eac-272bc56854bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5d54be10-5391-4221-8eac-272bc56854bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_77abcce3-ad88-4f3d-9c17-d0499dbf5a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_NetIncomeLoss_77abcce3-ad88-4f3d-9c17-d0499dbf5a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_82dbfc3f-9f58-400d-a13a-ea9826901004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_82dbfc3f-9f58-400d-a13a-ea9826901004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f23c8d3f-aae7-420e-8e91-cb7e6930603a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f23c8d3f-aae7-420e-8e91-cb7e6930603a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1dc328f1-d1bb-4c47-bcd1-8bcda73eca7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_CommonStockSharesIssued_1dc328f1-d1bb-4c47-bcd1-8bcda73eca7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f6fe233e-11d4-43c1-af1b-bfe0fb3c50e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35eda5ba-833f-4296-be53-1e8737009cbb" xlink:to="loc_us-gaap_StockholdersEquity_f6fe233e-11d4-43c1-af1b-bfe0fb3c50e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="eols-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5c843a44-2f8f-4381-8b73-4f8cc2fa1884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_35f1c456-520b-4b9c-87ee-c1e610cd0b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c843a44-2f8f-4381-8b73-4f8cc2fa1884" xlink:to="loc_us-gaap_StatementTable_35f1c456-520b-4b9c-87ee-c1e610cd0b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3c256c64-fe05-4322-a30f-c0b8d30a473e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_35f1c456-520b-4b9c-87ee-c1e610cd0b63" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3c256c64-fe05-4322-a30f-c0b8d30a473e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_667bb8ff-9da0-45a1-aed2-5f6197c8f1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3c256c64-fe05-4322-a30f-c0b8d30a473e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_667bb8ff-9da0-45a1-aed2-5f6197c8f1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember_802c8ca2-f9bf-4403-a4db-54b8a8322572" xlink:href="eols-20220930.xsd#eols_FollowOnOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_667bb8ff-9da0-45a1-aed2-5f6197c8f1a1" xlink:to="loc_eols_FollowOnOfferingMember_802c8ca2-f9bf-4403-a4db-54b8a8322572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_45183eb0-953a-4715-bf8c-9d512295c524" xlink:href="eols-20220930.xsd#eols_ATMSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_667bb8ff-9da0-45a1-aed2-5f6197c8f1a1" xlink:to="loc_eols_ATMSalesAgreementMember_45183eb0-953a-4715-bf8c-9d512295c524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_35f1c456-520b-4b9c-87ee-c1e610cd0b63" xlink:to="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_293fbc3f-ede9-4336-86f6-de5267e94d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_293fbc3f-ede9-4336-86f6-de5267e94d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_80f50c5b-be76-435d-a069-b8552d15d159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_293fbc3f-ede9-4336-86f6-de5267e94d3f" xlink:to="loc_us-gaap_NetIncomeLoss_80f50c5b-be76-435d-a069-b8552d15d159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_293fbc3f-ede9-4336-86f6-de5267e94d3f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0a767786-ead5-44cd-a2a6-49f4fc141a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0a767786-ead5-44cd-a2a6-49f4fc141a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_47519fcc-9a5f-42b3-b570-e06c94ef61b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_ShareBasedCompensation_47519fcc-9a5f-42b3-b570-e06c94ef61b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_09a320a9-efc5-4eb0-ac7b-0dd8b79a6fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_09a320a9-efc5-4eb0-ac7b-0dd8b79a6fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b44492c9-5881-44e3-a278-9285528da601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b44492c9-5881-44e3-a278-9285528da601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_96e7ec3e-e6e3-4975-a8e8-f84bb1147b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_96e7ec3e-e6e3-4975-a8e8-f84bb1147b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_3ba88145-b3e0-46f5-9482-7aa9c4a98729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_PaidInKindInterest_3ba88145-b3e0-46f5-9482-7aa9c4a98729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c0add504-255c-45b5-a0fa-a423646dbb48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c0add504-255c-45b5-a0fa-a423646dbb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a7cb27fc-c61b-45e0-8cb6-9c7b963ce1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a7cb27fc-c61b-45e0-8cb6-9c7b963ce1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9e4d1d17-c68f-434a-bc9d-4baf9885280f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9e4d1d17-c68f-434a-bc9d-4baf9885280f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_901384ea-8ab9-497a-8685-e642817407c2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_efbf9982-b26d-42f8-a6ca-36f7a301a736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_efbf9982-b26d-42f8-a6ca-36f7a301a736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0c4683ee-d56f-4cc7-8565-28d0cb53badc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0c4683ee-d56f-4cc7-8565-28d0cb53badc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_06ce841e-6aed-47ad-b0be-95f62a3ecf29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_06ce841e-6aed-47ad-b0be-95f62a3ecf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cfb8f8d7-ff00-4b2b-a00e-d63a45a88bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cfb8f8d7-ff00-4b2b-a00e-d63a45a88bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a64a48d6-81ca-4956-b88b-2c423408be89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a64a48d6-81ca-4956-b88b-2c423408be89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1b5e55dd-f4e2-4ff0-94f7-8179a89f9ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1b5e55dd-f4e2-4ff0-94f7-8179a89f9ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_1bc2b338-f025-4af0-88c9-d2fd68b3a833" xlink:href="eols-20220930.xsd#eols_IncreaseDecreaseInAccruedLitigationSettlement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_1bc2b338-f025-4af0-88c9-d2fd68b3a833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_1e4a35b5-3779-4954-ade7-bd943ce77c21" xlink:href="eols-20220930.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c75ac9d-5f47-41e8-94ee-65833a3afbf3" xlink:to="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_1e4a35b5-3779-4954-ade7-bd943ce77c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_87467f71-6f5f-452b-b3ad-37392048e38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_293fbc3f-ede9-4336-86f6-de5267e94d3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_87467f71-6f5f-452b-b3ad-37392048e38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a913e522-0d4b-4e51-915e-4fb4066dec29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a913e522-0d4b-4e51-915e-4fb4066dec29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_efd14ebf-5b4c-47c9-a2cd-1f8329737642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a913e522-0d4b-4e51-915e-4fb4066dec29" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_efd14ebf-5b4c-47c9-a2cd-1f8329737642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_de2f43ff-5ef0-4ba5-a915-e2ae6999ec53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a913e522-0d4b-4e51-915e-4fb4066dec29" xlink:to="loc_us-gaap_PaymentsForSoftware_de2f43ff-5ef0-4ba5-a915-e2ae6999ec53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_dbb9813f-d5c5-424d-8af8-ba443b136809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a913e522-0d4b-4e51-915e-4fb4066dec29" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_dbb9813f-d5c5-424d-8af8-ba443b136809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8487d76-933f-48f9-a82b-6cf0ffb18ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a913e522-0d4b-4e51-915e-4fb4066dec29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8487d76-933f-48f9-a82b-6cf0ffb18ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_aea48a9c-3cc2-4754-95d1-2dc87495abb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:to="loc_us-gaap_RepaymentsOfDebt_aea48a9c-3cc2-4754-95d1-2dc87495abb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_4cfe3a45-36f0-4662-bf9b-409a436b28b0" xlink:href="eols-20220930.xsd#eols_PaymentsOfContingentRoyaltyObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:to="loc_eols_PaymentsOfContingentRoyaltyObligation_4cfe3a45-36f0-4662-bf9b-409a436b28b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1cd20222-56bf-4b54-8a88-24b1226eaf72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1cd20222-56bf-4b54-8a88-24b1226eaf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a921f7e6-04a3-4503-beb1-19443f5f726f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a921f7e6-04a3-4503-beb1-19443f5f726f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_c39c70e9-6bf6-4208-b29a-ead7f97a9b8e" xlink:href="eols-20220930.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:to="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_c39c70e9-6bf6-4208-b29a-ead7f97a9b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53e66bf5-29b6-4309-a48a-6aa94fede8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7b83d6b2-8080-4f78-80c5-852662ef78a3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53e66bf5-29b6-4309-a48a-6aa94fede8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afc79b92-ee83-481b-9e0d-c255583ee249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afc79b92-ee83-481b-9e0d-c255583ee249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1bf70477-e119-408f-8cbe-bc72146e88d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1bf70477-e119-408f-8cbe-bc72146e88d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee821504-b559-47c9-a816-82f034a02478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee821504-b559-47c9-a816-82f034a02478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ccff4b2-a022-420d-96cb-176d6af31101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ccff4b2-a022-420d-96cb-176d6af31101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_880ec189-0330-4cf9-bd94-afef4020061c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8327cbb-f64c-4630-9756-7613b91d9b94" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_880ec189-0330-4cf9-bd94-afef4020061c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_42794ba2-a755-4fee-8ade-c633f529180a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_880ec189-0330-4cf9-bd94-afef4020061c" xlink:to="loc_us-gaap_InterestPaidNet_42794ba2-a755-4fee-8ade-c633f529180a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_1e482681-a2e1-41af-8665-2150f7695756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_880ec189-0330-4cf9-bd94-afef4020061c" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_1e482681-a2e1-41af-8665-2150f7695756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5e3db957-c9f3-4426-a1d2-744181722ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_880ec189-0330-4cf9-bd94-afef4020061c" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5e3db957-c9f3-4426-a1d2-744181722ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_b4acb135-d1c7-4f7e-a266-445ab90bd310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5e3db957-c9f3-4426-a1d2-744181722ccf" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_b4acb135-d1c7-4f7e-a266-445ab90bd310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedForAccruedLitigationSettlementExpense_30685c1e-78ea-44e6-9ec7-e01b294cc4c4" xlink:href="eols-20220930.xsd#eols_StockIssuedForAccruedLitigationSettlementExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5e3db957-c9f3-4426-a1d2-744181722ccf" xlink:to="loc_eols_StockIssuedForAccruedLitigationSettlementExpense_30685c1e-78ea-44e6-9ec7-e01b294cc4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1e69e22b-e051-4279-8c11-db07b3712666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5e3db957-c9f3-4426-a1d2-744181722ccf" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1e69e22b-e051-4279-8c11-db07b3712666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="eols-20220930.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab6ab99c-bcc3-439f-9a37-f597d0b277a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d53e83e5-f44b-4263-9bb8-a4d8d5b64c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab6ab99c-bcc3-439f-9a37-f597d0b277a3" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d53e83e5-f44b-4263-9bb8-a4d8d5b64c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="eols-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7b092f53-7abd-479f-8b3b-46c702102e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3084c01e-0d8e-43e1-8437-49db316bb787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7b092f53-7abd-479f-8b3b-46c702102e4f" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3084c01e-0d8e-43e1-8437-49db316bb787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments" xlink:type="simple" xlink:href="eols-20220930.xsd#FairValueMeasurementsandShortTermInvestments"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5915bd09-d717-4a0b-88d2-8a090095d8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2d21c241-fca0-4f1e-8dfc-6307e45b918c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5915bd09-d717-4a0b-88d2-8a090095d8e0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2d21c241-fca0-4f1e-8dfc-6307e45b918c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="eols-20220930.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a12f4474-5e56-4d79-9853-d13a77e9ad1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_34d797bd-d7f8-4ad5-9c42-a9f5f15b94c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a12f4474-5e56-4d79-9853-d13a77e9ad1e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_34d797bd-d7f8-4ad5-9c42-a9f5f15b94c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpenses" xlink:type="simple" xlink:href="eols-20220930.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c262dfbd-2393-4da3-b85b-2f3c502f830c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_aea26e0f-58ab-463e-982e-84aae5d50950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c262dfbd-2393-4da3-b85b-2f3c502f830c" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_aea26e0f-58ab-463e-982e-84aae5d50950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoans" xlink:type="simple" xlink:href="eols-20220930.xsd#TermLoans"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_831db843-67da-4ad6-85b6-d4323880d854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_9fc04022-92ac-43ce-aaa7-327d8d67d689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_831db843-67da-4ad6-85b6-d4323880d854" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_9fc04022-92ac-43ce-aaa7-327d8d67d689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DaewoongConvertibleNote" xlink:type="simple" xlink:href="eols-20220930.xsd#DaewoongConvertibleNote"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DaewoongConvertibleNote" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5a39b985-cd5a-4501-b263-bf8da52281e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4bc33de1-35f4-4798-9abd-1a0cf669b683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5a39b985-cd5a-4501-b263-bf8da52281e3" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4bc33de1-35f4-4798-9abd-1a0cf669b683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeases" xlink:type="simple" xlink:href="eols-20220930.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a26ba79f-39a0-44f2-a8fd-fc98c4852843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_35228e9c-d229-4b28-a2d5-8737f79377d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a26ba79f-39a0-44f2-a8fd-fc98c4852843" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_35228e9c-d229-4b28-a2d5-8737f79377d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="eols-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_35b66606-cd4a-475f-ab9b-203dece06753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ae36ce38-2785-408f-b6bd-fdce1722ac34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_35b66606-cd4a-475f-ab9b-203dece06753" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ae36ce38-2785-408f-b6bd-fdce1722ac34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquity" xlink:type="simple" xlink:href="eols-20220930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82563387-baaf-4e62-8af4-0b63e2eaaf42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1bf6cc88-b335-4487-b3c8-f772aedf1543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82563387-baaf-4e62-8af4-0b63e2eaaf42" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1bf6cc88-b335-4487-b3c8-f772aedf1543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement" xlink:type="simple" xlink:href="eols-20220930.xsd#MedytoxAllerganSettlementAgreementsandDaewoongArrangement"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c7f342c5-72d8-4f5e-8f9a-51b54eb6031f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4973afaf-9ecb-4a68-9b9a-9b5bfd65412f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c7f342c5-72d8-4f5e-8f9a-51b54eb6031f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4973afaf-9ecb-4a68-9b9a-9b5bfd65412f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="eols-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_77f05190-4852-48ca-8080-4e79c3e279b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_77f05190-4852-48ca-8080-4e79c3e279b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e433c4d7-9971-4805-b571-6f6f82aae202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e433c4d7-9971-4805-b571-6f6f82aae202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_291ee910-b58c-4fad-bf2e-a2e683436f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_UseOfEstimates_291ee910-b58c-4fad-bf2e-a2e683436f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_5586ccff-2d65-429d-a8d3-f06e06c3a434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_5586ccff-2d65-429d-a8d3-f06e06c3a434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ce712b8b-4a9b-4637-8f65-0a04d9018e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ce712b8b-4a9b-4637-8f65-0a04d9018e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ddf781de-7db3-454e-b49d-ece9debe1489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ddf781de-7db3-454e-b49d-ece9debe1489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_217b3bac-b4fd-4a4d-8283-81608ea2b17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_217b3bac-b4fd-4a4d-8283-81608ea2b17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_c764ad75-6b0f-4406-9257-2070302890d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_c764ad75-6b0f-4406-9257-2070302890d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_f72c12e8-4df4-4da8-938a-c50d0e87ad72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_f72c12e8-4df4-4da8-938a-c50d0e87ad72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0511ce64-83d6-4cc3-a43d-6ce7026c2aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0511ce64-83d6-4cc3-a43d-6ce7026c2aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_ca90de26-ee52-438c-a578-4bdff06e45b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_ca90de26-ee52-438c-a578-4bdff06e45b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_86c3f005-cc6c-41d7-a11a-ab5adf43fbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_86c3f005-cc6c-41d7-a11a-ab5adf43fbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_4b997fc1-6954-42f2-86a8-150da89df19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_4b997fc1-6954-42f2-86a8-150da89df19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7ecb8f37-c0b4-4932-b407-d17ee206b041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7ecb8f37-c0b4-4932-b407-d17ee206b041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_a685d52a-a69a-440f-9ecc-358526d25d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_DebtPolicyTextBlock_a685d52a-a69a-440f-9ecc-358526d25d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9e9d0827-7a49-4bde-8bfd-6e479725b4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9e9d0827-7a49-4bde-8bfd-6e479725b4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_cc9eb21a-f38d-462c-be73-f3f648f042a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_cc9eb21a-f38d-462c-be73-f3f648f042a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_bff8c478-41b4-49fd-9ace-11812ee835a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_bff8c478-41b4-49fd-9ace-11812ee835a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_8431e11e-7717-4e60-85d6-bbc8fa6c1796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_8431e11e-7717-4e60-85d6-bbc8fa6c1796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4e838ba2-88f8-4970-a753-0302e112fa2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4e838ba2-88f8-4970-a753-0302e112fa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_aba5fb70-0f4b-42d9-8baf-35cb33b27c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_aba5fb70-0f4b-42d9-8baf-35cb33b27c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9d962290-85b8-49de-92ca-2fcb8bce3d85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9d962290-85b8-49de-92ca-2fcb8bce3d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f7e7e213-efb4-4d2f-a21a-9d7e57428e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c3df364-bf56-479e-b67c-37164ee1789d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f7e7e213-efb4-4d2f-a21a-9d7e57428e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables" xlink:type="simple" xlink:href="eols-20220930.xsd#FairValueMeasurementsandShortTermInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_55c54317-3aed-43ce-8162-7cb9e207002d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a347fc7b-ce37-4904-befa-59a3951fc001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_55c54317-3aed-43ce-8162-7cb9e207002d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a347fc7b-ce37-4904-befa-59a3951fc001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6b68f58f-2a0b-44c1-9f63-821896530a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_55c54317-3aed-43ce-8162-7cb9e207002d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6b68f58f-2a0b-44c1-9f63-821896530a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="eols-20220930.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9a7a1c28-1485-4cc4-bc42-0efd93778e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_9694607f-6a01-4b19-ab65-06459bef7dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9a7a1c28-1485-4cc4-bc42-0efd93778e92" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_9694607f-6a01-4b19-ab65-06459bef7dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c0fca674-aae2-4877-99b6-818c858c6c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9a7a1c28-1485-4cc4-bc42-0efd93778e92" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c0fca674-aae2-4877-99b6-818c858c6c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="eols-20220930.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6cb0d94d-e072-42f4-8b77-31efb15d08e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_961a51fd-2a49-4235-ba4c-7a66ce408b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6cb0d94d-e072-42f4-8b77-31efb15d08e6" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_961a51fd-2a49-4235-ba4c-7a66ce408b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansTables" xlink:type="simple" xlink:href="eols-20220930.xsd#TermLoansTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fe945010-4295-4f64-a61f-af175d5794ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f2ece080-e6ed-472d-b74e-b4acfed9b846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fe945010-4295-4f64-a61f-af175d5794ea" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f2ece080-e6ed-472d-b74e-b4acfed9b846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="eols-20220930.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_685c4cb1-4909-47b2-9298-44148d99698b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_19024571-8e8c-4240-a27f-21377d33e6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_685c4cb1-4909-47b2-9298-44148d99698b" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_19024571-8e8c-4240-a27f-21377d33e6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4f014d42-93bf-44d7-b498-3a1926c61e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_685c4cb1-4909-47b2-9298-44148d99698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4f014d42-93bf-44d7-b498-3a1926c61e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="eols-20220930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5e5f8b0-d53c-4ecc-8a90-582cc266c50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fb9bba28-0776-46fb-aa10-6900ad5d94a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5e5f8b0-d53c-4ecc-8a90-582cc266c50b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fb9bba28-0776-46fb-aa10-6900ad5d94a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e037f4af-97f0-4e1b-a191-8fd790fe691c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5e5f8b0-d53c-4ecc-8a90-582cc266c50b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e037f4af-97f0-4e1b-a191-8fd790fe691c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_b54e318b-96ff-4491-b156-19753dfbf273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5e5f8b0-d53c-4ecc-8a90-582cc266c50b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_b54e318b-96ff-4491-b156-19753dfbf273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8d2a7620-631c-4729-a8c4-493d8e8c3ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5e5f8b0-d53c-4ecc-8a90-582cc266c50b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8d2a7620-631c-4729-a8c4-493d8e8c3ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b03dfb7f-3289-41b0-a4f8-46aa24112230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aba63414-86d3-4640-9e1b-b48a3e5b714c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b03dfb7f-3289-41b0-a4f8-46aa24112230" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aba63414-86d3-4640-9e1b-b48a3e5b714c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a872565b-3699-44f7-8284-8758dac54939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aba63414-86d3-4640-9e1b-b48a3e5b714c" xlink:to="loc_us-gaap_DebtInstrumentAxis_a872565b-3699-44f7-8284-8758dac54939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_93d7ba81-38b5-486a-9f9e-617aff3a47f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a872565b-3699-44f7-8284-8758dac54939" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_93d7ba81-38b5-486a-9f9e-617aff3a47f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_f0d36c8f-4cf3-4646-832a-d04781439f60" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93d7ba81-38b5-486a-9f9e-617aff3a47f4" xlink:to="loc_eols_PharmakonTermLoansMember_f0d36c8f-4cf3-4646-832a-d04781439f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember_d41e39ec-ef41-4f07-bc17-8e77d09a7c3e" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93d7ba81-38b5-486a-9f9e-617aff3a47f4" xlink:to="loc_eols_PharmakonTermLoansOneMember_d41e39ec-ef41-4f07-bc17-8e77d09a7c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember_6c2be51a-9368-4568-87d5-84acc83490b9" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93d7ba81-38b5-486a-9f9e-617aff3a47f4" xlink:to="loc_eols_PharmakonTermLoansTwoMember_6c2be51a-9368-4568-87d5-84acc83490b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8ff58d6c-e99b-4099-b919-d62264131310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aba63414-86d3-4640-9e1b-b48a3e5b714c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8ff58d6c-e99b-4099-b919-d62264131310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4844a5ef-9a59-4489-ae0e-32b41c439f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8ff58d6c-e99b-4099-b919-d62264131310" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4844a5ef-9a59-4489-ae0e-32b41c439f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_2a2ccd46-209b-4814-8806-3bc7ec765d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4844a5ef-9a59-4489-ae0e-32b41c439f6c" xlink:to="loc_us-gaap_SecuredDebtMember_2a2ccd46-209b-4814-8806-3bc7ec765d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aba63414-86d3-4640-9e1b-b48a3e5b714c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0dc7831b-fa36-4b7f-ae4c-040b7249d77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_NetIncomeLoss_0dc7831b-fa36-4b7f-ae4c-040b7249d77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb24c5e6-4755-45ee-9b17-ed23f9aeab13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb24c5e6-4755-45ee-9b17-ed23f9aeab13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_ed709d3e-5231-403a-8db9-1c4f3ce73a48" xlink:href="eols-20220930.xsd#eols_IncreaseDecreaseInAccruedLitigationSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_eols_IncreaseDecreaseInAccruedLitigationSettlement_ed709d3e-5231-403a-8db9-1c4f3ce73a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5c43e446-1753-43f5-bb31-c3971111008d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5c43e446-1753-43f5-bb31-c3971111008d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_083af7c2-1aa3-492d-925f-dcbbbabaca3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_083af7c2-1aa3-492d-925f-dcbbbabaca3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c619e041-8542-4f8d-916e-18714308f4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c619e041-8542-4f8d-916e-18714308f4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_10c3e430-8a63-4132-bb47-18ae60a0ccbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46024539-ee9d-4ba9-a3ee-2e25e8370da2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_10c3e430-8a63-4132-bb47-18ae60a0ccbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a3b112fa-db72-4976-b303-8bbb8f61dc02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:href="eols-20220930.xsd#eols_AccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3b112fa-db72-4976-b303-8bbb8f61dc02" xlink:to="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84d7f775-d339-4d9d-9f8d-210054dd9edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84d7f775-d339-4d9d-9f8d-210054dd9edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ca64ccde-ab51-4ed8-813b-607d810ae1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_84d7f775-d339-4d9d-9f8d-210054dd9edb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ca64ccde-ab51-4ed8-813b-607d810ae1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_48d46045-d681-467d-9054-60eff1cdb5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ca64ccde-ab51-4ed8-813b-607d810ae1a4" xlink:to="loc_us-gaap_DistributionRightsMember_48d46045-d681-467d-9054-60eff1cdb5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_1fd50d35-f62c-47fd-bc9f-f46629b3143c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ca64ccde-ab51-4ed8-813b-607d810ae1a4" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_1fd50d35-f62c-47fd-bc9f-f46629b3143c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_800aea3e-6422-4053-8759-3943503542e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:to="loc_srt_ProductOrServiceAxis_800aea3e-6422-4053-8759-3943503542e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4f710090-a908-4a2f-abdd-ad3c27ad38fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_800aea3e-6422-4053-8759-3943503542e2" xlink:to="loc_srt_ProductsAndServicesDomain_4f710090-a908-4a2f-abdd-ad3c27ad38fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_dd8a50ad-3dab-4f67-92dd-5cb47ed8552a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4f710090-a908-4a2f-abdd-ad3c27ad38fe" xlink:to="loc_us-gaap_ServiceMember_dd8a50ad-3dab-4f67-92dd-5cb47ed8552a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_436c0ef0-15fe-48b6-b411-312259ee30b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:to="loc_srt_LitigationCaseAxis_436c0ef0-15fe-48b6-b411-312259ee30b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_83cb1e78-e9eb-41d1-adc4-3a664883a4ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_436c0ef0-15fe-48b6-b411-312259ee30b7" xlink:to="loc_srt_LitigationCaseTypeDomain_83cb1e78-e9eb-41d1-adc4-3a664883a4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_35f1ebcf-39df-4e33-b782-3031606cfafc" xlink:href="eols-20220930.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_83cb1e78-e9eb-41d1-adc4-3a664883a4ac" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_35f1ebcf-39df-4e33-b782-3031606cfafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_485e9bbd-5ae1-46ef-b802-76b1df323414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_485e9bbd-5ae1-46ef-b802-76b1df323414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6173dacb-3bed-464d-8cfe-5081180ce3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_485e9bbd-5ae1-46ef-b802-76b1df323414" xlink:to="loc_us-gaap_EquityComponentDomain_6173dacb-3bed-464d-8cfe-5081180ce3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a555be0f-a093-4b80-b4a7-28a300333785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6173dacb-3bed-464d-8cfe-5081180ce3b4" xlink:to="loc_us-gaap_CommonStockMember_a555be0f-a093-4b80-b4a7-28a300333785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55c4a599-e12f-48d1-9ccd-7c2136fda9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55c4a599-e12f-48d1-9ccd-7c2136fda9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5653f58a-f991-4a38-83e0-e1fbf2f73be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_55c4a599-e12f-48d1-9ccd-7c2136fda9ee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5653f58a-f991-4a38-83e0-e1fbf2f73be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_687981a9-b88c-4e0a-895e-0bab060578cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5653f58a-f991-4a38-83e0-e1fbf2f73be3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_687981a9-b88c-4e0a-895e-0bab060578cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cec6e105-2d81-4f5e-b49c-86508438a3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5653f58a-f991-4a38-83e0-e1fbf2f73be3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cec6e105-2d81-4f5e-b49c-86508438a3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:href="eols-20220930.xsd#eols_AccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesTable_717256ff-6ed9-41bb-90ce-2728d3ab752c" xlink:to="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_6ef71c95-fdaf-41c4-abf5-3422918cca30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_6ef71c95-fdaf-41c4-abf5-3422918cca30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4bdb5b8e-6b07-436a-93be-e51c40ad6793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4bdb5b8e-6b07-436a-93be-e51c40ad6793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_4df5f20e-6e60-4307-9a40-33ebc1dc0345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_NumberOfReportingUnits_4df5f20e-6e60-4307-9a40-33ebc1dc0345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1d96d3f2-8c0c-43b4-b987-3055bcf76b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1d96d3f2-8c0c-43b4-b987-3055bcf76b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f17a1a2c-0504-439c-8fc0-6c91651bb1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f17a1a2c-0504-439c-8fc0-6c91651bb1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_01c24fa1-c0a2-4e6a-91e8-32e99742eda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_01c24fa1-c0a2-4e6a-91e8-32e99742eda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3894ff24-f0de-402a-b4b0-08fc19140ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3894ff24-f0de-402a-b4b0-08fc19140ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4853655f-586d-4c46-b461-eb4a138dc817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4853655f-586d-4c46-b461-eb4a138dc817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_27867ab0-cc32-47e9-ae04-8be355de9138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_27867ab0-cc32-47e9-ae04-8be355de9138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0c06371a-fb1d-4b67-9e86-c9fc112d724c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0c06371a-fb1d-4b67-9e86-c9fc112d724c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_f7746fcd-dbdb-4c8c-90ee-6937589bb358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_f7746fcd-dbdb-4c8c-90ee-6937589bb358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_0f253aee-7bbf-407b-a687-350dca139685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_0f253aee-7bbf-407b-a687-350dca139685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_6049e2c4-5fa7-43b0-9bd6-4b1b39b11ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_6049e2c4-5fa7-43b0-9bd6-4b1b39b11ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_56926c66-1d91-4b85-8ad7-9799aa411382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_56926c66-1d91-4b85-8ad7-9799aa411382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms_557e075c-2b14-4c8c-bfde-910fee8f48bd" xlink:href="eols-20220930.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_eols_LossContingencySettlementAgreementPaymentTerms_557e075c-2b14-4c8c-bfde-910fee8f48bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_aec2bea1-9e4e-4532-8ab7-f0e34dc1f249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_aec2bea1-9e4e-4532-8ab7-f0e34dc1f249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_d355382a-3eb4-44f7-93e3-890b1b0814cc" xlink:href="eols-20220930.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_d355382a-3eb4-44f7-93e3-890b1b0814cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_fd58eb30-e8df-4f96-b4d3-909fa409339a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_LitigationSettlementExpense_fd58eb30-e8df-4f96-b4d3-909fa409339a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_238024c3-c45f-42e3-aef9-dd0ecb5245a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_238024c3-c45f-42e3-aef9-dd0ecb5245a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_6ffefdaa-3356-4fb7-8f96-132f1828b678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_LitigationReserveCurrent_6ffefdaa-3356-4fb7-8f96-132f1828b678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_9eae4fa7-8b7a-4ce5-848f-7f5316162256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_9eae4fa7-8b7a-4ce5-848f-7f5316162256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_571ef65e-e59b-4efe-a680-2c84ab5fdd08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_571ef65e-e59b-4efe-a680-2c84ab5fdd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f05d1f5-7064-40dd-ab71-efc0c59d1c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_43779833-5f43-438f-ad0d-3fd01962fd5a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f05d1f5-7064-40dd-ab71-efc0c59d1c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_28cdbb4f-4957-44e6-a2bf-bdddb1f5c090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fc0b81c-a438-49c8-8fd8-465b066fea9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_28cdbb4f-4957-44e6-a2bf-bdddb1f5c090" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fc0b81c-a438-49c8-8fd8-465b066fea9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_78504e01-33de-43b4-ba92-8c6eef6d4638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fc0b81c-a438-49c8-8fd8-465b066fea9f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_78504e01-33de-43b4-ba92-8c6eef6d4638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6038ce39-b6bf-483e-a4ce-b0010651ae87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78504e01-33de-43b4-ba92-8c6eef6d4638" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6038ce39-b6bf-483e-a4ce-b0010651ae87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_631ad8f2-58e2-401a-8a22-f9459be4ec74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6038ce39-b6bf-483e-a4ce-b0010651ae87" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_631ad8f2-58e2-401a-8a22-f9459be4ec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a4c354e-af41-40b9-b10a-f1e72f0d5135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fc0b81c-a438-49c8-8fd8-465b066fea9f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a4c354e-af41-40b9-b10a-f1e72f0d5135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_085bafe8-88bc-4c50-a44e-3112cb7e3dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a4c354e-af41-40b9-b10a-f1e72f0d5135" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_085bafe8-88bc-4c50-a44e-3112cb7e3dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_914bed75-dfe6-42ed-a950-ade49a066e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_085bafe8-88bc-4c50-a44e-3112cb7e3dd3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_914bed75-dfe6-42ed-a950-ade49a066e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1c039b21-2e59-4aaf-a70c-90e91f076166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_085bafe8-88bc-4c50-a44e-3112cb7e3dd3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1c039b21-2e59-4aaf-a70c-90e91f076166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5aa024ca-545c-4bfd-bb93-36f0b31c6f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_085bafe8-88bc-4c50-a44e-3112cb7e3dd3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5aa024ca-545c-4bfd-bb93-36f0b31c6f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b792bf5f-2f54-4d37-b667-73d772efc1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fc0b81c-a438-49c8-8fd8-465b066fea9f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b792bf5f-2f54-4d37-b667-73d772efc1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_bea1e26b-060b-4f74-a6c1-93955943e092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b792bf5f-2f54-4d37-b667-73d772efc1e7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_bea1e26b-060b-4f74-a6c1-93955943e092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bc113033-1863-485b-b9a7-9b150bb73c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bc113033-1863-485b-b9a7-9b150bb73c52" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7561a57e-0594-45eb-bc53-aa5a764ca7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7561a57e-0594-45eb-bc53-aa5a764ca7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a802de0-3af8-4ba6-a56d-0f6dcb66ebc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7561a57e-0594-45eb-bc53-aa5a764ca7b2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a802de0-3af8-4ba6-a56d-0f6dcb66ebc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationMember_4a37ce80-b5c2-46c7-913e-a5380640adf0" xlink:href="eols-20220930.xsd#eols_ContingentRoyaltyObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a802de0-3af8-4ba6-a56d-0f6dcb66ebc3" xlink:to="loc_eols_ContingentRoyaltyObligationMember_4a37ce80-b5c2-46c7-913e-a5380640adf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a1472f3f-d9a5-435e-b6a3-d3b259f8c663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a1472f3f-d9a5-435e-b6a3-d3b259f8c663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5d2aa8f0-3b5f-4591-b883-aba1377b6c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a1472f3f-d9a5-435e-b6a3-d3b259f8c663" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5d2aa8f0-3b5f-4591-b883-aba1377b6c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_ca2aa0e0-0089-4c21-a1d1-7ccd6c5869f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5d2aa8f0-3b5f-4591-b883-aba1377b6c2e" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_ca2aa0e0-0089-4c21-a1d1-7ccd6c5869f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_fc896f26-99be-46b3-98f6-c7afaba720e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_fc896f26-99be-46b3-98f6-c7afaba720e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cbccba63-238f-4ab9-9741-5df3c3424663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fc896f26-99be-46b3-98f6-c7afaba720e0" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cbccba63-238f-4ab9-9741-5df3c3424663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5251cba9-394b-4d25-a147-9d795256981b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cbccba63-238f-4ab9-9741-5df3c3424663" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5251cba9-394b-4d25-a147-9d795256981b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e77d05b1-0010-4f48-99ff-e9f59bf35eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5251cba9-394b-4d25-a147-9d795256981b" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e77d05b1-0010-4f48-99ff-e9f59bf35eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d5f7700e-6450-49c3-b0dd-48f40d67bf37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:to="loc_us-gaap_DebtInstrumentAxis_d5f7700e-6450-49c3-b0dd-48f40d67bf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_513f549c-9f1d-4526-a8ac-6eb2352a9bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d5f7700e-6450-49c3-b0dd-48f40d67bf37" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_513f549c-9f1d-4526-a8ac-6eb2352a9bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_b3c08b38-488c-4de3-a624-439c89eea39b" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_513f549c-9f1d-4526-a8ac-6eb2352a9bc8" xlink:to="loc_eols_PharmakonTermLoansMember_b3c08b38-488c-4de3-a624-439c89eea39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f598c638-ae15-4542-9f58-01e7312ca873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ccc5d53f-7643-4b29-a480-9262943d441f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f598c638-ae15-4542-9f58-01e7312ca873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_78f451d7-20ba-416f-be59-71184d7bcc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f598c638-ae15-4542-9f58-01e7312ca873" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_78f451d7-20ba-416f-be59-71184d7bcc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7846cdc7-18b1-4e83-9519-919115f65d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f598c638-ae15-4542-9f58-01e7312ca873" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7846cdc7-18b1-4e83-9519-919115f65d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsContingentRoyaltyObligationDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#FairValueMeasurementsandShortTermInvestmentsContingentRoyaltyObligationDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsContingentRoyaltyObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_01c014ef-2001-4500-b76a-a8544d6f2277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5ad1eb57-36b0-4f32-84fb-98ac1e887af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_01c014ef-2001-4500-b76a-a8544d6f2277" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5ad1eb57-36b0-4f32-84fb-98ac1e887af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e65a69a3-80b0-46ac-a87e-c0f7930eb5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5ad1eb57-36b0-4f32-84fb-98ac1e887af2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e65a69a3-80b0-46ac-a87e-c0f7930eb5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_fc93ae9d-5c9f-4c66-94d5-85ca1d0de53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5ad1eb57-36b0-4f32-84fb-98ac1e887af2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_fc93ae9d-5c9f-4c66-94d5-85ca1d0de53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b45cb72e-4963-44eb-a433-5948da69c7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5ad1eb57-36b0-4f32-84fb-98ac1e887af2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b45cb72e-4963-44eb-a433-5948da69c7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_056a2e5c-9587-4e54-8480-0f103dbe605d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5ad1eb57-36b0-4f32-84fb-98ac1e887af2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_056a2e5c-9587-4e54-8480-0f103dbe605d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8faeb15-d447-4660-bd72-72846c7b7a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_93d75a67-f34e-4a19-b22f-9e78bc88418e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8faeb15-d447-4660-bd72-72846c7b7a26" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_93d75a67-f34e-4a19-b22f-9e78bc88418e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d041b4de-d045-4fad-821d-b53d941ea063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_93d75a67-f34e-4a19-b22f-9e78bc88418e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d041b4de-d045-4fad-821d-b53d941ea063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_08641364-efe6-4073-821b-100ddd8b6196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d041b4de-d045-4fad-821d-b53d941ea063" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_08641364-efe6-4073-821b-100ddd8b6196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_a7d4a70c-393f-405d-89d8-2658659d5f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_08641364-efe6-4073-821b-100ddd8b6196" xlink:to="loc_us-gaap_DistributionRightsMember_a7d4a70c-393f-405d-89d8-2658659d5f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_e8de7051-b611-4c0a-9f20-2ed2a5603640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_08641364-efe6-4073-821b-100ddd8b6196" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_e8de7051-b611-4c0a-9f20-2ed2a5603640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8030833a-4a35-41f6-9de7-cbc2b9724565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_93d75a67-f34e-4a19-b22f-9e78bc88418e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8030833a-4a35-41f6-9de7-cbc2b9724565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b2c9ff9-432b-4b99-b3d3-88ff20fef77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8030833a-4a35-41f6-9de7-cbc2b9724565" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b2c9ff9-432b-4b99-b3d3-88ff20fef77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_41b01d1c-b522-4a2d-bc4c-0ed00a2c178d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b2c9ff9-432b-4b99-b3d3-88ff20fef77c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_41b01d1c-b522-4a2d-bc4c-0ed00a2c178d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f737771b-01bb-457c-af1a-757a9c0e9ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b2c9ff9-432b-4b99-b3d3-88ff20fef77c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f737771b-01bb-457c-af1a-757a9c0e9ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_437fa5fb-4f3c-4a57-a6de-ba584d9b664d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b2c9ff9-432b-4b99-b3d3-88ff20fef77c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_437fa5fb-4f3c-4a57-a6de-ba584d9b664d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce0ed87e-8421-441b-a7ce-6e8e0b66b14f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1b2c9ff9-432b-4b99-b3d3-88ff20fef77c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce0ed87e-8421-441b-a7ce-6e8e0b66b14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_34383603-e949-49d7-9c42-6c0f46cc799a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8030833a-4a35-41f6-9de7-cbc2b9724565" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_34383603-e949-49d7-9c42-6c0f46cc799a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_cfd877f7-c63b-44a6-b3fd-383c912b1fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_34383603-e949-49d7-9c42-6c0f46cc799a" xlink:to="loc_us-gaap_Goodwill_cfd877f7-c63b-44a6-b3fd-383c912b1fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_964f5b16-fcd0-4551-b7f2-fb4bc48f6434" xlink:href="eols-20220930.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8030833a-4a35-41f6-9de7-cbc2b9724565" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_964f5b16-fcd0-4551-b7f2-fb4bc48f6434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_9473c9c1-3806-41d9-9e78-bd39e2f3d631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8030833a-4a35-41f6-9de7-cbc2b9724565" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_9473c9c1-3806-41d9-9e78-bd39e2f3d631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="eols-20220930.xsd#GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c123260-539f-49cc-ac0d-5eb45eacaa94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_521c5f5a-fc38-42cf-95d6-7b7969be1052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c123260-539f-49cc-ac0d-5eb45eacaa94" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_521c5f5a-fc38-42cf-95d6-7b7969be1052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cef12383-2b65-4081-adf5-9006097b518e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c123260-539f-49cc-ac0d-5eb45eacaa94" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cef12383-2b65-4081-adf5-9006097b518e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ce4672c9-64b5-4a59-ada2-37999cee10f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c123260-539f-49cc-ac0d-5eb45eacaa94" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ce4672c9-64b5-4a59-ada2-37999cee10f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b311a0a6-f119-49c2-aa8a-2c91edcd9a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c123260-539f-49cc-ac0d-5eb45eacaa94" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b311a0a6-f119-49c2-aa8a-2c91edcd9a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0423202e-95ce-4655-82e7-352337bc0f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c123260-539f-49cc-ac0d-5eb45eacaa94" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0423202e-95ce-4655-82e7-352337bc0f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_da661ad9-8869-4d4c-9653-3798b36b45f0" xlink:href="eols-20220930.xsd#eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c123260-539f-49cc-ac0d-5eb45eacaa94" xlink:to="loc_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_da661ad9-8869-4d4c-9653-3798b36b45f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e9841309-a7cb-4756-88d5-53284fba3b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c123260-539f-49cc-ac0d-5eb45eacaa94" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e9841309-a7cb-4756-88d5-53284fba3b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#GoodwillandIntangibleAssetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdd9451a-7ec5-4418-a2fc-1907c1bb2499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_339ffc10-860c-4356-b340-ea27712517e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdd9451a-7ec5-4418-a2fc-1907c1bb2499" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_339ffc10-860c-4356-b340-ea27712517e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_43a776fb-7379-4d6a-ad1d-546bf21e5816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_339ffc10-860c-4356-b340-ea27712517e8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_43a776fb-7379-4d6a-ad1d-546bf21e5816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d71dcdc7-6a12-4bd7-81ca-389f281e1b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43a776fb-7379-4d6a-ad1d-546bf21e5816" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d71dcdc7-6a12-4bd7-81ca-389f281e1b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EvolusIncMember_8c422ac8-3df2-4db6-9d42-2c0310c946aa" xlink:href="eols-20220930.xsd#eols_EvolusIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d71dcdc7-6a12-4bd7-81ca-389f281e1b85" xlink:to="loc_eols_EvolusIncMember_8c422ac8-3df2-4db6-9d42-2c0310c946aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_72bcf51a-91a5-4728-a7cc-7fa5af2871d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_339ffc10-860c-4356-b340-ea27712517e8" xlink:to="loc_dei_LegalEntityAxis_72bcf51a-91a5-4728-a7cc-7fa5af2871d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ef7dd189-e768-47b3-af27-93f59ea4b461" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_72bcf51a-91a5-4728-a7cc-7fa5af2871d1" xlink:to="loc_dei_EntityDomain_ef7dd189-e768-47b3-af27-93f59ea4b461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SCHAEONLLCMember_fe862b4a-d7d4-4c5e-84e9-fd176f9521e2" xlink:href="eols-20220930.xsd#eols_SCHAEONLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ef7dd189-e768-47b3-af27-93f59ea4b461" xlink:to="loc_eols_SCHAEONLLCMember_fe862b4a-d7d4-4c5e-84e9-fd176f9521e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ff7dbed9-3b44-426b-8445-4c3207ff7b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_339ffc10-860c-4356-b340-ea27712517e8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ff7dbed9-3b44-426b-8445-4c3207ff7b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_e0c1273e-b3f5-407b-a82c-abed5e2cd0a1" xlink:href="eols-20220930.xsd#eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ff7dbed9-3b44-426b-8445-4c3207ff7b27" xlink:to="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_e0c1273e-b3f5-407b-a82c-abed5e2cd0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_9b76bed5-4daa-4750-801f-bc130c09a6f1" xlink:href="eols-20220930.xsd#eols_MilestonePaymentsForIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ff7dbed9-3b44-426b-8445-4c3207ff7b27" xlink:to="loc_eols_MilestonePaymentsForIntangibleAssets_9b76bed5-4daa-4750-801f-bc130c09a6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_222365ea-ecb5-42fd-99c6-e4de5c219529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ff7dbed9-3b44-426b-8445-4c3207ff7b27" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_222365ea-ecb5-42fd-99c6-e4de5c219529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f2fd660f-3475-4c5c-bb25-2339fcdc24f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ff7dbed9-3b44-426b-8445-4c3207ff7b27" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f2fd660f-3475-4c5c-bb25-2339fcdc24f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6a74a662-0e35-4b82-93b5-3e2b38eaed45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_9271e84a-ca3f-41d7-8911-d8a8185a2b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6a74a662-0e35-4b82-93b5-3e2b38eaed45" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_9271e84a-ca3f-41d7-8911-d8a8185a2b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b31e5e1c-75b9-43f2-af44-f1f0468648dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6a74a662-0e35-4b82-93b5-3e2b38eaed45" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b31e5e1c-75b9-43f2-af44-f1f0468648dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4e59c258-c7d6-4d02-92bc-f3535dd5929c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6a74a662-0e35-4b82-93b5-3e2b38eaed45" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4e59c258-c7d6-4d02-92bc-f3535dd5929c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f280ad9c-0438-497f-9ec9-5ed7102d31c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6a74a662-0e35-4b82-93b5-3e2b38eaed45" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f280ad9c-0438-497f-9ec9-5ed7102d31c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_85bdb561-8355-4ad0-81ec-036a749779fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6a74a662-0e35-4b82-93b5-3e2b38eaed45" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_85bdb561-8355-4ad0-81ec-036a749779fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#TermLoansPharmakonTermLoansDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_207d3b08-b993-4b52-bee3-024d29278088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_207d3b08-b993-4b52-bee3-024d29278088" xlink:to="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9a6c0238-e197-4dde-9454-c1091e4d6b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:to="loc_us-gaap_DebtInstrumentAxis_9a6c0238-e197-4dde-9454-c1091e4d6b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_07aae266-2122-42a4-9bd3-0cf3b807432b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9a6c0238-e197-4dde-9454-c1091e4d6b52" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_07aae266-2122-42a4-9bd3-0cf3b807432b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_55d5c0aa-84b5-4937-8ee5-12bf75dcff33" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07aae266-2122-42a4-9bd3-0cf3b807432b" xlink:to="loc_eols_PharmakonTermLoansMember_55d5c0aa-84b5-4937-8ee5-12bf75dcff33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember_083e2b2e-684b-4b73-b609-a7ca84645090" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07aae266-2122-42a4-9bd3-0cf3b807432b" xlink:to="loc_eols_PharmakonTermLoansOneMember_083e2b2e-684b-4b73-b609-a7ca84645090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember_8e18519b-98cb-42bc-b470-ec100cad07fd" xlink:href="eols-20220930.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07aae266-2122-42a4-9bd3-0cf3b807432b" xlink:to="loc_eols_PharmakonTermLoansTwoMember_8e18519b-98cb-42bc-b470-ec100cad07fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5fff515d-4ed5-483d-84cc-c8d2f14a243e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5fff515d-4ed5-483d-84cc-c8d2f14a243e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dd190949-6a7d-49f5-ba71-8394823882f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5fff515d-4ed5-483d-84cc-c8d2f14a243e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dd190949-6a7d-49f5-ba71-8394823882f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3b2db3e9-9866-4bc2-b54a-b25e760686e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dd190949-6a7d-49f5-ba71-8394823882f5" xlink:to="loc_us-gaap_SecuredDebtMember_3b2db3e9-9866-4bc2-b54a-b25e760686e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_a6334ff2-7e65-4459-9a1e-2a32787b68c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:to="loc_us-gaap_VariableRateAxis_a6334ff2-7e65-4459-9a1e-2a32787b68c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_209bf528-8b57-4734-8072-7039e0a8e1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_a6334ff2-7e65-4459-9a1e-2a32787b68c5" xlink:to="loc_us-gaap_VariableRateDomain_209bf528-8b57-4734-8072-7039e0a8e1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_b26a87dd-2312-4411-b56b-d502958687e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_209bf528-8b57-4734-8072-7039e0a8e1b6" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_b26a87dd-2312-4411-b56b-d502958687e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsAxis_73a9d4e4-3d41-4a45-9d4b-36a82521b8b2" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentTermsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsAxis_73a9d4e4-3d41-4a45-9d4b-36a82521b8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsDomain_c6261d3b-d29f-46f3-bde6-ee49d53ef41d" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsAxis_73a9d4e4-3d41-4a45-9d4b-36a82521b8b2" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsDomain_c6261d3b-d29f-46f3-bde6-ee49d53ef41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermOneMember_2af0b4c7-a459-4bf9-ae51-31ac7d5f622a" xlink:href="eols-20220930.xsd#eols_TermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_c6261d3b-d29f-46f3-bde6-ee49d53ef41d" xlink:to="loc_eols_TermOneMember_2af0b4c7-a459-4bf9-ae51-31ac7d5f622a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermTwoMember_1fbf6c5c-10b6-4b97-86e8-24aacf73d23a" xlink:href="eols-20220930.xsd#eols_TermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_c6261d3b-d29f-46f3-bde6-ee49d53ef41d" xlink:to="loc_eols_TermTwoMember_1fbf6c5c-10b6-4b97-86e8-24aacf73d23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermThreeMember_3d66a98e-e241-4469-a387-cbef8c12dc4f" xlink:href="eols-20220930.xsd#eols_TermThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_c6261d3b-d29f-46f3-bde6-ee49d53ef41d" xlink:to="loc_eols_TermThreeMember_3d66a98e-e241-4469-a387-cbef8c12dc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_405fb321-65c1-4606-815b-b5ed3f867940" xlink:to="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfTranches_7d32b062-3421-4b34-8b7b-bff84de279de" xlink:href="eols-20220930.xsd#eols_DebtInstrumentNumberOfTranches"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_eols_DebtInstrumentNumberOfTranches_7d32b062-3421-4b34-8b7b-bff84de279de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_66ad7032-00bf-4380-830c-43bdd3a34f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_66ad7032-00bf-4380-830c-43bdd3a34f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_918cc369-e4ed-4f74-816e-9bbbca68eaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentTerm_918cc369-e4ed-4f74-816e-9bbbca68eaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_638e5dca-cb25-4bde-8cc7-0404fd8ab6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_638e5dca-cb25-4bde-8cc7-0404fd8ab6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_22071f6a-e7ad-4354-a464-e285ad7cbe9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_22071f6a-e7ad-4354-a464-e285ad7cbe9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_c411e776-61e6-4926-a3b2-421120b62979" xlink:href="eols-20220930.xsd#eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal_c411e776-61e6-4926-a3b2-421120b62979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_148f36b8-dd74-40c3-814a-1f548b791895" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod_148f36b8-dd74-40c3-814a-1f548b791895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentAmountThreshold_700abd2e-db98-4666-a6e1-f4fa303c34b3" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentAmountThreshold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_eols_DebtInstrumentPrepaymentAmountThreshold_700abd2e-db98-4666-a6e1-f4fa303c34b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_d74cce3a-b999-4eef-9ee8-f12fad322ad7" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_d74cce3a-b999-4eef-9ee8-f12fad322ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6fe96342-0c00-4c73-aac5-0a644aab7bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6fe96342-0c00-4c73-aac5-0a644aab7bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_1fa3bf4a-2ed7-4e1f-b220-4aec314dd8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_1fa3bf4a-2ed7-4e1f-b220-4aec314dd8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_89e64bcb-bd51-45e7-955a-3b4fc02f2fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08be0972-cdfb-4c1f-a6d5-c8960ca2d8ca" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_89e64bcb-bd51-45e7-955a-3b4fc02f2fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#TermLoansMaturitiesofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_59dd6dd7-fbff-4f97-becc-74fcbdfa1a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_57c4a033-533c-4ccf-b5c7-83dd2ad1cec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59dd6dd7-fbff-4f97-becc-74fcbdfa1a2e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_57c4a033-533c-4ccf-b5c7-83dd2ad1cec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9bfb39c3-853a-48d4-8f58-13b2d8e45721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59dd6dd7-fbff-4f97-becc-74fcbdfa1a2e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9bfb39c3-853a-48d4-8f58-13b2d8e45721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b9db4b1c-b4f1-48a7-a85e-440d655d3105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59dd6dd7-fbff-4f97-becc-74fcbdfa1a2e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b9db4b1c-b4f1-48a7-a85e-440d655d3105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0346d713-2cd6-45ff-a502-9cb3527db860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59dd6dd7-fbff-4f97-becc-74fcbdfa1a2e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0346d713-2cd6-45ff-a502-9cb3527db860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3db8a336-f5cb-4cfb-8433-6cc467389e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59dd6dd7-fbff-4f97-becc-74fcbdfa1a2e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3db8a336-f5cb-4cfb-8433-6cc467389e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LongTermDebtMaturityAfterYearFour_46fe95e8-bd50-4b18-ab10-6f43ab09bc53" xlink:href="eols-20220930.xsd#eols_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59dd6dd7-fbff-4f97-becc-74fcbdfa1a2e" xlink:to="loc_eols_LongTermDebtMaturityAfterYearFour_46fe95e8-bd50-4b18-ab10-6f43ab09bc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ca11ae71-542d-4677-8d35-a030d1f3d724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59dd6dd7-fbff-4f97-becc-74fcbdfa1a2e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ca11ae71-542d-4677-8d35-a030d1f3d724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_af2b7b57-ce65-429f-9aa0-ffb8fcefaa38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59dd6dd7-fbff-4f97-becc-74fcbdfa1a2e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_af2b7b57-ce65-429f-9aa0-ffb8fcefaa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9327e15a-dc5a-4521-8a25-1b9f04d31e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59dd6dd7-fbff-4f97-becc-74fcbdfa1a2e" xlink:to="loc_us-gaap_LongTermDebt_9327e15a-dc5a-4521-8a25-1b9f04d31e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansOxfordTermLoansDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#TermLoansOxfordTermLoansDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoansOxfordTermLoansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_755b373d-121a-4812-890a-d0b98defb0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2319400e-8ab9-4694-b585-1e00cacf0b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_755b373d-121a-4812-890a-d0b98defb0fc" xlink:to="loc_us-gaap_DebtInstrumentTable_2319400e-8ab9-4694-b585-1e00cacf0b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1e054864-8fb8-46a4-908d-3a83f1035c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2319400e-8ab9-4694-b585-1e00cacf0b4c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1e054864-8fb8-46a4-908d-3a83f1035c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a8a9c2ce-2452-4eaa-adcc-6fc4ac0d3dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1e054864-8fb8-46a4-908d-3a83f1035c13" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a8a9c2ce-2452-4eaa-adcc-6fc4ac0d3dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_9a2153fd-abca-428b-97c0-f0698e46a5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a8a9c2ce-2452-4eaa-adcc-6fc4ac0d3dfe" xlink:to="loc_us-gaap_SecuredDebtMember_9a2153fd-abca-428b-97c0-f0698e46a5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6c82e792-5f0b-4b6f-a11b-70b6b2e86a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2319400e-8ab9-4694-b585-1e00cacf0b4c" xlink:to="loc_us-gaap_DebtInstrumentAxis_6c82e792-5f0b-4b6f-a11b-70b6b2e86a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a212fba9-1134-4f24-9ca4-ac058aeee946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6c82e792-5f0b-4b6f-a11b-70b6b2e86a6e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a212fba9-1134-4f24-9ca4-ac058aeee946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityTrancheOneMember_a0d5b384-22eb-43e5-ba2c-0fdc281f81bb" xlink:href="eols-20220930.xsd#eols_OxfordTermLoanFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a212fba9-1134-4f24-9ca4-ac058aeee946" xlink:to="loc_eols_OxfordTermLoanFacilityTrancheOneMember_a0d5b384-22eb-43e5-ba2c-0fdc281f81bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityTrancheTwoMember_45c1bb82-2e00-4852-8676-062cb170944d" xlink:href="eols-20220930.xsd#eols_OxfordTermLoanFacilityTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a212fba9-1134-4f24-9ca4-ac058aeee946" xlink:to="loc_eols_OxfordTermLoanFacilityTrancheTwoMember_45c1bb82-2e00-4852-8676-062cb170944d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermLoanFacilityMember_6e0da36a-3275-4bad-9d6c-791baafeb53f" xlink:href="eols-20220930.xsd#eols_TermLoanFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a212fba9-1134-4f24-9ca4-ac058aeee946" xlink:to="loc_eols_TermLoanFacilityMember_6e0da36a-3275-4bad-9d6c-791baafeb53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_OxfordTermLoanFacilityMember_13b52471-2b3a-489f-959a-c0f83989630e" xlink:href="eols-20220930.xsd#eols_OxfordTermLoanFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a212fba9-1134-4f24-9ca4-ac058aeee946" xlink:to="loc_eols_OxfordTermLoanFacilityMember_13b52471-2b3a-489f-959a-c0f83989630e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_966bf7e9-2406-4bd0-a037-36c57d68e74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2319400e-8ab9-4694-b585-1e00cacf0b4c" xlink:to="loc_us-gaap_VariableRateAxis_966bf7e9-2406-4bd0-a037-36c57d68e74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b84fcff4-95fa-455d-b056-809f4c1a24a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_966bf7e9-2406-4bd0-a037-36c57d68e74b" xlink:to="loc_us-gaap_VariableRateDomain_b84fcff4-95fa-455d-b056-809f4c1a24a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9f81e176-c4db-4d70-b167-04ec6008013b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b84fcff4-95fa-455d-b056-809f4c1a24a1" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9f81e176-c4db-4d70-b167-04ec6008013b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2319400e-8ab9-4694-b585-1e00cacf0b4c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2c401b72-fa0a-4cfb-98bf-f06b620f7144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2c401b72-fa0a-4cfb-98bf-f06b620f7144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LineofCreditFacilityNumberofAdvances_f2b45d4c-3c7c-4b60-8442-6a613cb44a5e" xlink:href="eols-20220930.xsd#eols_LineofCreditFacilityNumberofAdvances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_LineofCreditFacilityNumberofAdvances_f2b45d4c-3c7c-4b60-8442-6a613cb44a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dbcf82f3-0ce7-41de-9b21-18af231d59f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dbcf82f3-0ce7-41de-9b21-18af231d59f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d0819420-69e0-419d-8a41-6620a9672aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d0819420-69e0-419d-8a41-6620a9672aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_1e9b9722-d390-4312-8b53-c4ec6ffdedbc" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_1e9b9722-d390-4312-8b53-c4ec6ffdedbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_13431239-2272-44d5-8b9b-c8c45b6eaa93" xlink:href="eols-20220930.xsd#eols_DebtInstrumentAmortizationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentAmortizationPeriod_13431239-2272-44d5-8b9b-c8c45b6eaa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_dd2effa9-e6fe-4621-b611-fa65526c713b" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_dd2effa9-e6fe-4621-b611-fa65526c713b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_7d9086ba-1173-4d99-9495-75e5957a6b30" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_7d9086ba-1173-4d99-9495-75e5957a6b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_10e65f9b-605d-4826-ac48-4acfe4ea59b0" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_10e65f9b-605d-4826-ac48-4acfe4ea59b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_038e8675-99f0-4f4a-8219-4bedde93a28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_038e8675-99f0-4f4a-8219-4bedde93a28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentFeeAmountWaived_15b1cf14-8b4e-4d96-83ef-cc0bb6a62f1e" xlink:href="eols-20220930.xsd#eols_DebtInstrumentFeeAmountWaived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentFeeAmountWaived_15b1cf14-8b4e-4d96-83ef-cc0bb6a62f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentOfFinalPaymentAmountWaived_508bf169-aab5-4245-b0e8-3cc4af7125e8" xlink:href="eols-20220930.xsd#eols_DebtInstrumentOfFinalPaymentAmountWaived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentOfFinalPaymentAmountWaived_508bf169-aab5-4245-b0e8-3cc4af7125e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentFeeAmountWaived_15ddbdf5-b4f5-4aba-9c5c-92e8161716c4" xlink:href="eols-20220930.xsd#eols_DebtInstrumentPrepaymentFeeAmountWaived"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_eols_DebtInstrumentPrepaymentFeeAmountWaived_15ddbdf5-b4f5-4aba-9c5c-92e8161716c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8447b487-06e9-4a04-8af3-c153c5630907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75ec2759-7da1-4510-a171-58bf6ec0d44c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8447b487-06e9-4a04-8af3-c153c5630907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DaewoongConvertibleNoteDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#DaewoongConvertibleNoteDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DaewoongConvertibleNoteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9bd75e80-c436-4a7a-832f-fdb52be1a186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_f2fbad7f-52e8-491b-a013-5d23958c765d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9bd75e80-c436-4a7a-832f-fdb52be1a186" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_f2fbad7f-52e8-491b-a013-5d23958c765d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_664cddd9-20ec-4237-b3a6-250425ab35e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_f2fbad7f-52e8-491b-a013-5d23958c765d" xlink:to="loc_us-gaap_DebtInstrumentAxis_664cddd9-20ec-4237-b3a6-250425ab35e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_434a4fbb-e1ed-4f67-b22d-c11d2a86b3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_664cddd9-20ec-4237-b3a6-250425ab35e8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_434a4fbb-e1ed-4f67-b22d-c11d2a86b3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_5d415b1b-f993-40f0-9291-653c3d303308" xlink:href="eols-20220930.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_434a4fbb-e1ed-4f67-b22d-c11d2a86b3a4" xlink:to="loc_eols_DaewoongConvertibleNoteMember_5d415b1b-f993-40f0-9291-653c3d303308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5b891567-9c52-4556-b805-7391fc52016f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_f2fbad7f-52e8-491b-a013-5d23958c765d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5b891567-9c52-4556-b805-7391fc52016f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a02e8dfd-f514-4718-8baa-cbf3994247c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5b891567-9c52-4556-b805-7391fc52016f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a02e8dfd-f514-4718-8baa-cbf3994247c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_9e940c03-14b3-4c84-a692-1d5f64ae5d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a02e8dfd-f514-4718-8baa-cbf3994247c4" xlink:to="loc_us-gaap_ConvertibleDebtMember_9e940c03-14b3-4c84-a692-1d5f64ae5d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_79d00c80-337b-4239-939f-5bd519ea77fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_f2fbad7f-52e8-491b-a013-5d23958c765d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_79d00c80-337b-4239-939f-5bd519ea77fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c5c817cf-b231-4421-8a63-469d161d1030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_79d00c80-337b-4239-939f-5bd519ea77fc" xlink:to="loc_us-gaap_EquityComponentDomain_c5c817cf-b231-4421-8a63-469d161d1030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b065a08f-b78c-40cc-9496-87ef76969bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c5c817cf-b231-4421-8a63-469d161d1030" xlink:to="loc_us-gaap_CommonStockMember_b065a08f-b78c-40cc-9496-87ef76969bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_f2fbad7f-52e8-491b-a013-5d23958c765d" xlink:to="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8b87c7b7-8f8d-4c21-869b-98f3f1d0377e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8b87c7b7-8f8d-4c21-869b-98f3f1d0377e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ceffc1f-59db-4b0c-a5c5-3106193d790d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ceffc1f-59db-4b0c-a5c5-3106193d790d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_a0c3daa9-8868-4620-8ffd-6e3d0df95039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_ConvertibleDebt_a0c3daa9-8868-4620-8ffd-6e3d0df95039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4c6851fc-f625-4018-a896-36f698805de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4c6851fc-f625-4018-a896-36f698805de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_a53ad1a6-54a7-40e5-8c3d-a259ec32571e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_a53ad1a6-54a7-40e5-8c3d-a259ec32571e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_343957a8-19e1-477b-abf4-5ba4ac2278c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_cf626fdf-8a36-45e3-adb0-dc555c4d6fe1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_343957a8-19e1-477b-abf4-5ba4ac2278c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#OperatingLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cffe000c-a8b8-4d2a-9917-69610864fa42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dd811944-1ab9-492e-abec-abb88c1187f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cffe000c-a8b8-4d2a-9917-69610864fa42" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dd811944-1ab9-492e-abec-abb88c1187f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeaseTerminationPeriod_a6948b6f-7729-43e2-a7b8-cb2ddc5bec6b" xlink:href="eols-20220930.xsd#eols_LesseeOperatingLeaseTerminationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cffe000c-a8b8-4d2a-9917-69610864fa42" xlink:to="loc_eols_LesseeOperatingLeaseTerminationPeriod_a6948b6f-7729-43e2-a7b8-cb2ddc5bec6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_fe04405c-cc1e-4b90-8808-2cdb16ce2a33" xlink:href="eols-20220930.xsd#eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cffe000c-a8b8-4d2a-9917-69610864fa42" xlink:to="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_fe04405c-cc1e-4b90-8808-2cdb16ce2a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_78e0b939-55c6-4d3c-b933-29a14cdb0fcb" xlink:href="eols-20220930.xsd#eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cffe000c-a8b8-4d2a-9917-69610864fa42" xlink:to="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_78e0b939-55c6-4d3c-b933-29a14cdb0fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_e872a185-b899-4399-b72e-4bbe69477c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cffe000c-a8b8-4d2a-9917-69610864fa42" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_e872a185-b899-4399-b72e-4bbe69477c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesLeaseCostDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#OperatingLeasesLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5643ffd5-96dd-447b-93aa-98bc0997733e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1c81a01a-c469-49d6-a767-b3d2e6b89a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5643ffd5-96dd-447b-93aa-98bc0997733e" xlink:to="loc_us-gaap_OperatingLeaseCost_1c81a01a-c469-49d6-a767-b3d2e6b89a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_7484a828-fe9e-4204-8593-75f3fa0de389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5643ffd5-96dd-447b-93aa-98bc0997733e" xlink:to="loc_us-gaap_VariableLeaseCost_7484a828-fe9e-4204-8593-75f3fa0de389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_614b9b4d-1ed8-40f2-92d0-ef6e210e6b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5643ffd5-96dd-447b-93aa-98bc0997733e" xlink:to="loc_us-gaap_LeaseCost_614b9b4d-1ed8-40f2-92d0-ef6e210e6b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#OperatingLeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce5473b9-b41c-455d-a025-1d3551836bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_aada6839-7e5c-4588-9a55-2bf595ea6102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce5473b9-b41c-455d-a025-1d3551836bc4" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_aada6839-7e5c-4588-9a55-2bf595ea6102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e1cf7563-2c27-43f6-9fbf-2a91f273a1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce5473b9-b41c-455d-a025-1d3551836bc4" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e1cf7563-2c27-43f6-9fbf-2a91f273a1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#OperatingLeasesOperatingLeaseMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_840412d3-2016-4a35-abcd-2f5deaa56131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_19aa7999-8f51-45a4-8f44-af3f5d56b7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_840412d3-2016-4a35-abcd-2f5deaa56131" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_19aa7999-8f51-45a4-8f44-af3f5d56b7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a33644ac-5195-4bf3-b777-68dd87b85ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_19aa7999-8f51-45a4-8f44-af3f5d56b7b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a33644ac-5195-4bf3-b777-68dd87b85ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6f66ca53-5240-45bc-9da9-612a71051c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_19aa7999-8f51-45a4-8f44-af3f5d56b7b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6f66ca53-5240-45bc-9da9-612a71051c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a963bf33-833e-4f7b-a215-1437d16757b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_19aa7999-8f51-45a4-8f44-af3f5d56b7b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a963bf33-833e-4f7b-a215-1437d16757b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7dbe96ec-bc9f-4970-b9af-d61c94867b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_19aa7999-8f51-45a4-8f44-af3f5d56b7b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7dbe96ec-bc9f-4970-b9af-d61c94867b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a54673e8-b18c-48ab-82b8-529f74413e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_19aa7999-8f51-45a4-8f44-af3f5d56b7b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a54673e8-b18c-48ab-82b8-529f74413e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d2eb153-8b64-488e-a517-0c2f6913b7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_19aa7999-8f51-45a4-8f44-af3f5d56b7b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d2eb153-8b64-488e-a517-0c2f6913b7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_617bee90-3e98-451a-9e02-5b9867e0dd94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_19aa7999-8f51-45a4-8f44-af3f5d56b7b7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_617bee90-3e98-451a-9e02-5b9867e0dd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0e4c6e53-db59-4b94-be17-19477f6c0d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_19aa7999-8f51-45a4-8f44-af3f5d56b7b7" xlink:to="loc_us-gaap_OperatingLeaseLiability_0e4c6e53-db59-4b94-be17-19477f6c0d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails_1" xlink:type="simple" xlink:href="eols-20220930.xsd#OperatingLeasesOperatingLeaseMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1740cabe-2c9f-4c78-911c-cbce6df1de8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_8fd40c79-f7b6-4304-9e5e-758130bafbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1740cabe-2c9f-4c78-911c-cbce6df1de8a" xlink:to="loc_us-gaap_PurchaseObligation_8fd40c79-f7b6-4304-9e5e-758130bafbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c8ea1652-40e4-4d62-aacf-afa4083897ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1740cabe-2c9f-4c78-911c-cbce6df1de8a" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c8ea1652-40e4-4d62-aacf-afa4083897ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_bdb3ac38-e1ea-4b78-aee4-27f4cba27887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1740cabe-2c9f-4c78-911c-cbce6df1de8a" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_bdb3ac38-e1ea-4b78-aee4-27f4cba27887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3e590513-957c-4e30-b694-7a2fb377df60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1740cabe-2c9f-4c78-911c-cbce6df1de8a" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3e590513-957c-4e30-b694-7a2fb377df60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7265fc4b-d656-4793-b879-65c8b97971c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7265fc4b-d656-4793-b879-65c8b97971c1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f650f66b-e11d-478d-b20b-3f2704102660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f650f66b-e11d-478d-b20b-3f2704102660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b294f025-edc4-4fde-a32c-204729742e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f650f66b-e11d-478d-b20b-3f2704102660" xlink:to="loc_us-gaap_EquityComponentDomain_b294f025-edc4-4fde-a32c-204729742e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_51b4e66e-c87e-4fbe-915f-56ba124f53d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b294f025-edc4-4fde-a32c-204729742e93" xlink:to="loc_us-gaap_CommonStockMember_51b4e66e-c87e-4fbe-915f-56ba124f53d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f4ef2f0d-8ce5-480b-9742-305238f49b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b294f025-edc4-4fde-a32c-204729742e93" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f4ef2f0d-8ce5-480b-9742-305238f49b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_893390ef-8da7-45fb-b2e7-d37aa36f40c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_us-gaap_DebtInstrumentAxis_893390ef-8da7-45fb-b2e7-d37aa36f40c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_41404cb4-26f6-4075-a2e2-572aa94b5c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_893390ef-8da7-45fb-b2e7-d37aa36f40c1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_41404cb4-26f6-4075-a2e2-572aa94b5c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_470c4ebe-eb5c-43f7-9d6c-841c3b965bdc" xlink:href="eols-20220930.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_41404cb4-26f6-4075-a2e2-572aa94b5c80" xlink:to="loc_eols_DaewoongConvertibleNoteMember_470c4ebe-eb5c-43f7-9d6c-841c3b965bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3269727b-715a-4826-9c02-18f9eb6d962f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3269727b-715a-4826-9c02-18f9eb6d962f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3d8dd003-d437-47f8-88d2-ebaee5875725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3269727b-715a-4826-9c02-18f9eb6d962f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3d8dd003-d437-47f8-88d2-ebaee5875725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_469e93bd-c3db-47e8-86b3-2c08b47cbd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3d8dd003-d437-47f8-88d2-ebaee5875725" xlink:to="loc_us-gaap_ConvertibleDebtMember_469e93bd-c3db-47e8-86b3-2c08b47cbd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_32c48bcc-c97a-4f6a-86d8-4b6d5fa3f89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_32c48bcc-c97a-4f6a-86d8-4b6d5fa3f89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6726f6d-d151-42cf-a424-f2483375fd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_32c48bcc-c97a-4f6a-86d8-4b6d5fa3f89e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6726f6d-d151-42cf-a424-f2483375fd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_d1c956b9-0672-4a52-8fdd-11afd32149e7" xlink:href="eols-20220930.xsd#eols_ATMSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6726f6d-d151-42cf-a424-f2483375fd7e" xlink:to="loc_eols_ATMSalesAgreementMember_d1c956b9-0672-4a52-8fdd-11afd32149e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_47e55cfe-2614-4a01-8602-334c9c4efe4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_us-gaap_AwardTypeAxis_47e55cfe-2614-4a01-8602-334c9c4efe4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_419909c7-6384-4a5b-a57f-c53e5d02e966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_47e55cfe-2614-4a01-8602-334c9c4efe4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_419909c7-6384-4a5b-a57f-c53e5d02e966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_20727d74-6f9f-48af-9316-f70ca66cfc57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_419909c7-6384-4a5b-a57f-c53e5d02e966" xlink:to="loc_us-gaap_EmployeeStockOptionMember_20727d74-6f9f-48af-9316-f70ca66cfc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_211e8952-8193-4325-8a3e-8b4419b049d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_419909c7-6384-4a5b-a57f-c53e5d02e966" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_211e8952-8193-4325-8a3e-8b4419b049d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_71b66230-d319-42fd-ad0c-a3aae72446e1" xlink:href="eols-20220930.xsd#eols_RestrictedStockUnitsRSUsMarketConditionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_419909c7-6384-4a5b-a57f-c53e5d02e966" xlink:to="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_71b66230-d319-42fd-ad0c-a3aae72446e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_8093c0f0-cca8-4e60-a007-d3737a0f16e2" xlink:href="eols-20220930.xsd#eols_RestrictedStockUnitsRSUsPerformanceConditionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_419909c7-6384-4a5b-a57f-c53e5d02e966" xlink:to="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_8093c0f0-cca8-4e60-a007-d3737a0f16e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d9825905-49f0-4714-9134-2059978d9c95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_srt_RangeAxis_d9825905-49f0-4714-9134-2059978d9c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_580b2fee-35fb-44ea-8ede-1753a5212390" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d9825905-49f0-4714-9134-2059978d9c95" xlink:to="loc_srt_RangeMember_580b2fee-35fb-44ea-8ede-1753a5212390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3d56a5ec-b70d-4ee2-b74c-209e7eff8d5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_580b2fee-35fb-44ea-8ede-1753a5212390" xlink:to="loc_srt_MinimumMember_3d56a5ec-b70d-4ee2-b74c-209e7eff8d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_63c323f5-de38-4772-84cb-d2045c17155f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_580b2fee-35fb-44ea-8ede-1753a5212390" xlink:to="loc_srt_MaximumMember_63c323f5-de38-4772-84cb-d2045c17155f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e93830f4-ecac-478a-b2c2-e6b9909620d4" xlink:to="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e47b6a66-0847-484b-b960-b6ab178db0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e47b6a66-0847-484b-b960-b6ab178db0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d60cac02-1d1c-4c39-9aee-88f6132f6c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d60cac02-1d1c-4c39-9aee-88f6132f6c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1af71d52-7458-4f78-af47-61e61a17a721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1af71d52-7458-4f78-af47-61e61a17a721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_fef9ace8-73c8-4a51-a571-e52784d8de6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_fef9ace8-73c8-4a51-a571-e52784d8de6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2712bca7-9c41-4cdc-b387-db9105f195be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2712bca7-9c41-4cdc-b387-db9105f195be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a2e38174-229d-47aa-8481-743c2e05d8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a2e38174-229d-47aa-8481-743c2e05d8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6f00e11a-0a77-4b70-97b9-e9ac764b725f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6f00e11a-0a77-4b70-97b9-e9ac764b725f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5e5f9b52-2939-4d3d-a017-7e9a45c701d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_CommonStockSharesIssued_5e5f9b52-2939-4d3d-a017-7e9a45c701d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_b4dea2a3-94f9-4b2b-8d39-d699d38c9315" xlink:href="eols-20220930.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_b4dea2a3-94f9-4b2b-8d39-d699d38c9315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_b247d14f-9742-44f1-a36e-e4402af8d603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_b247d14f-9742-44f1-a36e-e4402af8d603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockMaximumConsiderationReceivable_e6c843e5-8031-4f35-a9ca-59466cb3de10" xlink:href="eols-20220930.xsd#eols_SaleOfStockMaximumConsiderationReceivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_eols_SaleOfStockMaximumConsiderationReceivable_e6c843e5-8031-4f35-a9ca-59466cb3de10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_e6f88b22-3a5c-4f3f-8055-40ebf98ae97f" xlink:href="eols-20220930.xsd#eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_e6f88b22-3a5c-4f3f-8055-40ebf98ae97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_22a49b3b-3c36-402e-83d0-16718ad3c119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_22a49b3b-3c36-402e-83d0-16718ad3c119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e8fda76f-7a42-4449-a72d-fd4ed20a55cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e8fda76f-7a42-4449-a72d-fd4ed20a55cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaid_a34b5efd-56f6-4dac-9d72-82aa7caee353" xlink:href="eols-20220930.xsd#eols_SaleOfStockCommissionPaid"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_eols_SaleOfStockCommissionPaid_a34b5efd-56f6-4dac-9d72-82aa7caee353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e86035fb-39ae-4074-a4e9-8e4490188c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e86035fb-39ae-4074-a4e9-8e4490188c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_ac4fd804-6150-4269-9981-b5ef9be68da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_ac4fd804-6150-4269-9981-b5ef9be68da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_058067f1-cdd0-4bb9-973d-53eea009a9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_058067f1-cdd0-4bb9-973d-53eea009a9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bf7c2a2c-d7b5-46cb-b82b-796308610861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bf7c2a2c-d7b5-46cb-b82b-796308610861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51578769-472d-4d90-bb88-6faefeac26a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51578769-472d-4d90-bb88-6faefeac26a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bae946bf-8d27-4048-bc53-8ee36ee3bb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bae946bf-8d27-4048-bc53-8ee36ee3bb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f7cbc3a2-e5f4-43cb-8d96-904607fac270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f7cbc3a2-e5f4-43cb-8d96-904607fac270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_97c043ed-a39a-456d-b43d-aef7c4d16680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_97c043ed-a39a-456d-b43d-aef7c4d16680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_73c138fb-dd23-4992-9ada-489b0611a554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8581608b-368e-4112-843b-43fad4e9466c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_73c138fb-dd23-4992-9ada-489b0611a554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#StockholdersEquityScheduleofValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a6e0b45-37db-48f7-aae0-eaf859d4562c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3c05c3e6-08b0-490f-864a-f725ecaab93d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a6e0b45-37db-48f7-aae0-eaf859d4562c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3c05c3e6-08b0-490f-864a-f725ecaab93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_55b590b6-ed17-408f-af00-99122e1eff3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3c05c3e6-08b0-490f-864a-f725ecaab93d" xlink:to="loc_us-gaap_AwardTypeAxis_55b590b6-ed17-408f-af00-99122e1eff3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d38eda95-e10d-41fd-8583-073a07f30bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_55b590b6-ed17-408f-af00-99122e1eff3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d38eda95-e10d-41fd-8583-073a07f30bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3bdbc279-27c5-4966-965e-133aacafbc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d38eda95-e10d-41fd-8583-073a07f30bd2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3bdbc279-27c5-4966-965e-133aacafbc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_284941e0-5686-4d8a-87b7-75874a45117f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3c05c3e6-08b0-490f-864a-f725ecaab93d" xlink:to="loc_us-gaap_ClassOfStockLineItems_284941e0-5686-4d8a-87b7-75874a45117f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1f4b998d-9576-4a88-b8f6-a7ef4d9212bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_284941e0-5686-4d8a-87b7-75874a45117f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1f4b998d-9576-4a88-b8f6-a7ef4d9212bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c22e1ac0-10cb-4d58-9f56-19fa83d1ee4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_284941e0-5686-4d8a-87b7-75874a45117f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c22e1ac0-10cb-4d58-9f56-19fa83d1ee4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_603c70b4-65ea-43e3-bda7-3e03550046ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_284941e0-5686-4d8a-87b7-75874a45117f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_603c70b4-65ea-43e3-bda7-3e03550046ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_88db13a6-b462-4695-8e29-844da917332a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_284941e0-5686-4d8a-87b7-75874a45117f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_88db13a6-b462-4695-8e29-844da917332a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#StockholdersEquityScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_def4b96b-f407-4408-bc37-574effe29eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa902a94-194e-4ed2-a53d-5f80131fbe39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_def4b96b-f407-4408-bc37-574effe29eb7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa902a94-194e-4ed2-a53d-5f80131fbe39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f1c6bb45-6eb3-4df2-9314-9ad80ef06943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa902a94-194e-4ed2-a53d-5f80131fbe39" xlink:to="loc_us-gaap_AwardTypeAxis_f1c6bb45-6eb3-4df2-9314-9ad80ef06943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3017e93-b5f4-4571-ab05-2f52c46f3df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f1c6bb45-6eb3-4df2-9314-9ad80ef06943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3017e93-b5f4-4571-ab05-2f52c46f3df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0c8694f5-304a-4010-86db-ff6020dd6f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3017e93-b5f4-4571-ab05-2f52c46f3df7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0c8694f5-304a-4010-86db-ff6020dd6f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa902a94-194e-4ed2-a53d-5f80131fbe39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_348ebb6b-badb-455c-8751-629aaaf0219a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_348ebb6b-badb-455c-8751-629aaaf0219a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7e6b0a34-d3cf-47b7-8e1e-46466032a8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7e6b0a34-d3cf-47b7-8e1e-46466032a8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6138d7ce-f7f0-4f1d-9e2d-c2b351e148b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6138d7ce-f7f0-4f1d-9e2d-c2b351e148b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_80945e6f-f138-4c7b-8de8-2cec0c07c320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_80945e6f-f138-4c7b-8de8-2cec0c07c320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13a52592-5e71-4243-970e-18318e871380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47ff218f-8ef6-4ed7-9fd2-c4e74f0e8e95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13a52592-5e71-4243-970e-18318e871380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a37158fd-ea96-4613-ae6e-1fe682b36992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a37158fd-ea96-4613-ae6e-1fe682b36992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_595c4e7f-9168-4e20-9d9e-c8e4d872343d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_595c4e7f-9168-4e20-9d9e-c8e4d872343d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5c3826fe-db0d-42ae-95a9-8c5ab616a235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5c3826fe-db0d-42ae-95a9-8c5ab616a235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8886abcf-4e4f-44b9-985a-785a043a3a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8886abcf-4e4f-44b9-985a-785a043a3a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_03d71c96-f5b9-4de2-8ca0-7531eac86a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_03d71c96-f5b9-4de2-8ca0-7531eac86a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9418058-069b-4b29-8b48-69a21107203b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_abade7a8-ace7-48d8-ab4a-5584d5f8afaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9418058-069b-4b29-8b48-69a21107203b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a51032d3-050b-4621-baf0-f568cb2b3825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a51032d3-050b-4621-baf0-f568cb2b3825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ce1d235a-5f89-49d7-9397-d4dfb0e772f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ce1d235a-5f89-49d7-9397-d4dfb0e772f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_aa9652a8-f56e-408b-82f1-9ff4bafdcf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ce1d235a-5f89-49d7-9397-d4dfb0e772f8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_aa9652a8-f56e-408b-82f1-9ff4bafdcf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_198b681e-3054-4df7-9f17-8c013394be73" xlink:href="eols-20220930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_198b681e-3054-4df7-9f17-8c013394be73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_b7933bf3-fc90-467d-99ee-f409569c5afe" xlink:href="eols-20220930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_b7933bf3-fc90-467d-99ee-f409569c5afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e8963fe-a141-428f-9b39-39adf90cc983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_b7933bf3-fc90-467d-99ee-f409569c5afe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e8963fe-a141-428f-9b39-39adf90cc983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c87b986c-33d6-4796-b7f1-c68358c0826e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a907a282-ea52-460b-ab33-a72538a455ed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c87b986c-33d6-4796-b7f1-c68358c0826e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#StockholdersEquityRestrictedStockUnitDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91e79dd2-31ea-4b34-b540-bbf5099a08c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4d98c91-d1ee-4136-9b79-978b3c46359e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91e79dd2-31ea-4b34-b540-bbf5099a08c1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4d98c91-d1ee-4136-9b79-978b3c46359e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6f7fe66c-8f2a-4efb-badd-9371c7977177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4d98c91-d1ee-4136-9b79-978b3c46359e" xlink:to="loc_us-gaap_AwardTypeAxis_6f7fe66c-8f2a-4efb-badd-9371c7977177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_550224ac-3b30-49e4-894d-e4f7397f903e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6f7fe66c-8f2a-4efb-badd-9371c7977177" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_550224ac-3b30-49e4-894d-e4f7397f903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_032850ce-a05d-4c60-a7bb-b2ce0d4f2074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_550224ac-3b30-49e4-894d-e4f7397f903e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_032850ce-a05d-4c60-a7bb-b2ce0d4f2074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f1a5f21-de90-45bf-a26b-c6b374ea83b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4d98c91-d1ee-4136-9b79-978b3c46359e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f1a5f21-de90-45bf-a26b-c6b374ea83b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f1a5f21-de90-45bf-a26b-c6b374ea83b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8975c11f-2d93-4b0c-9222-ef1705cf2bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8975c11f-2d93-4b0c-9222-ef1705cf2bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_55cbdcd0-7572-4460-902d-f93b4b0d8a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_55cbdcd0-7572-4460-902d-f93b4b0d8a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_569b6e59-504e-465d-a6c9-0d92f72a3c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_569b6e59-504e-465d-a6c9-0d92f72a3c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b5907787-3fbe-46e5-b4ef-4c8dabdec980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b5907787-3fbe-46e5-b4ef-4c8dabdec980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1f127b9-3e68-405f-8424-f9de5c3c5bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cc8a070-1562-413c-82f2-5b59fb4f50b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1f127b9-3e68-405f-8424-f9de5c3c5bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f1a5f21-de90-45bf-a26b-c6b374ea83b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bbde7183-da96-4bc6-b71d-96f466977893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bbde7183-da96-4bc6-b71d-96f466977893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc585a1b-e339-42bb-9925-2021d0dad3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc585a1b-e339-42bb-9925-2021d0dad3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c7be7f60-da7c-4a5a-86b0-0ffa1a1f92d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c7be7f60-da7c-4a5a-86b0-0ffa1a1f92d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_30a4c669-ec38-4bd2-8b5c-e37ccf74d892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_30a4c669-ec38-4bd2-8b5c-e37ccf74d892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ced040c0-87ae-45d0-9d55-71a153507027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5f818538-7efc-4aab-a88a-8482b93fd6ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ced040c0-87ae-45d0-9d55-71a153507027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#StockholdersEquityStockbasedCompensationExpenseAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df596e7e-62be-43b8-b236-3d6909ec1971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eef7825-53ad-45b2-acc1-bb4a46029a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df596e7e-62be-43b8-b236-3d6909ec1971" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eef7825-53ad-45b2-acc1-bb4a46029a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0fcc90f6-9bbc-4fc5-9229-533abcd1ad2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eef7825-53ad-45b2-acc1-bb4a46029a1c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0fcc90f6-9bbc-4fc5-9229-533abcd1ad2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3c92625e-dac7-479e-81db-6298b8e0230e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0fcc90f6-9bbc-4fc5-9229-533abcd1ad2b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3c92625e-dac7-479e-81db-6298b8e0230e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ee27f83-2279-44d6-bc87-7ec2e36ba2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3c92625e-dac7-479e-81db-6298b8e0230e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ee27f83-2279-44d6-bc87-7ec2e36ba2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d6dcfa05-4afe-4011-87cd-f30bcfb311af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3c92625e-dac7-479e-81db-6298b8e0230e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d6dcfa05-4afe-4011-87cd-f30bcfb311af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db6a61f0-fee8-4afa-a1bf-58965f24c9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eef7825-53ad-45b2-acc1-bb4a46029a1c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db6a61f0-fee8-4afa-a1bf-58965f24c9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_77d7caca-d26e-49e7-816e-69404f6706d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db6a61f0-fee8-4afa-a1bf-58965f24c9e5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_77d7caca-d26e-49e7-816e-69404f6706d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails" xlink:type="simple" xlink:href="eols-20220930.xsd#MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a205194-ad92-4522-9c9c-35bb5f35a188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a205194-ad92-4522-9c9c-35bb5f35a188" xlink:to="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_02bf8763-9c06-4ff8-97ae-989176e71ae2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_srt_LitigationCaseAxis_02bf8763-9c06-4ff8-97ae-989176e71ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_73dde369-d33c-4903-97a7-e2feb583f3c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_02bf8763-9c06-4ff8-97ae-989176e71ae2" xlink:to="loc_srt_LitigationCaseTypeDomain_73dde369-d33c-4903-97a7-e2feb583f3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_ceccc051-ac1c-4ad6-b77f-c25e27eeaf17" xlink:href="eols-20220930.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_73dde369-d33c-4903-97a7-e2feb583f3c7" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_ceccc051-ac1c-4ad6-b77f-c25e27eeaf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d261ebc5-76d9-471e-9003-b5975151c44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d261ebc5-76d9-471e-9003-b5975151c44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4cf419b8-a117-450f-b9cd-9fe7317b577f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d261ebc5-76d9-471e-9003-b5975151c44e" xlink:to="loc_us-gaap_EquityComponentDomain_4cf419b8-a117-450f-b9cd-9fe7317b577f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_51e946ab-1cd0-4bb7-91c6-9bc108705990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4cf419b8-a117-450f-b9cd-9fe7317b577f" xlink:to="loc_us-gaap_CommonStockMember_51e946ab-1cd0-4bb7-91c6-9bc108705990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_17ff070c-bc50-4df0-8582-825d0f3a2aa9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_srt_StatementScenarioAxis_17ff070c-bc50-4df0-8582-825d0f3a2aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_76464cde-512b-4db2-a416-c590ce792164" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_17ff070c-bc50-4df0-8582-825d0f3a2aa9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_76464cde-512b-4db2-a416-c590ce792164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d85753f8-661c-4cdb-9aa3-4846b83f2bc4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_76464cde-512b-4db2-a416-c590ce792164" xlink:to="loc_srt_ScenarioForecastMember_d85753f8-661c-4cdb-9aa3-4846b83f2bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1a06569-48ff-4822-afd1-4c04610b9e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1a06569-48ff-4822-afd1-4c04610b9e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0f9a3856-8b00-4fc1-93ca-97b67f9a58b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1a06569-48ff-4822-afd1-4c04610b9e08" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0f9a3856-8b00-4fc1-93ca-97b67f9a58b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongSettlementAgreementMember_87365cd7-a967-43e3-a220-42e63d9359db" xlink:href="eols-20220930.xsd#eols_DaewoongSettlementAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0f9a3856-8b00-4fc1-93ca-97b67f9a58b4" xlink:to="loc_eols_DaewoongSettlementAgreementMember_87365cd7-a967-43e3-a220-42e63d9359db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DaewoongConvertibleNoteMember_d3b50072-f611-4d2c-b456-51c93142f622" xlink:href="eols-20220930.xsd#eols_DaewoongConvertibleNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0f9a3856-8b00-4fc1-93ca-97b67f9a58b4" xlink:to="loc_eols_DaewoongConvertibleNoteMember_d3b50072-f611-4d2c-b456-51c93142f622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b378b81a-d6a7-4613-9180-b203b54ba973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b378b81a-d6a7-4613-9180-b203b54ba973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_35a38c68-4ac6-47f3-85fb-f21385f1be04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b378b81a-d6a7-4613-9180-b203b54ba973" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_35a38c68-4ac6-47f3-85fb-f21385f1be04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1af8b62f-365c-4862-a58f-e1b5a7841b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_35a38c68-4ac6-47f3-85fb-f21385f1be04" xlink:to="loc_us-gaap_ConvertibleDebtMember_1af8b62f-365c-4862-a58f-e1b5a7841b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3cbf259b-7070-469f-aff3-a9baa7172e61" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_srt_RangeAxis_3cbf259b-7070-469f-aff3-a9baa7172e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_620a9bd3-5b24-48c7-8a2d-f7ad206a6388" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3cbf259b-7070-469f-aff3-a9baa7172e61" xlink:to="loc_srt_RangeMember_620a9bd3-5b24-48c7-8a2d-f7ad206a6388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c6b1d053-b4e1-472c-b51e-0a04c2a77abe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_620a9bd3-5b24-48c7-8a2d-f7ad206a6388" xlink:to="loc_srt_MaximumMember_c6b1d053-b4e1-472c-b51e-0a04c2a77abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cbdf4052-5d96-4001-ac34-fc23ea465df6" xlink:to="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_edefa169-ff89-4e29-bd01-5cda8e6c6e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_edefa169-ff89-4e29-bd01-5cda8e6c6e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms_0ce5caac-f6b8-40d9-93ed-397e9f45b662" xlink:href="eols-20220930.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_LossContingencySettlementAgreementPaymentTerms_0ce5caac-f6b8-40d9-93ed-397e9f45b662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_52127096-ee8e-45d8-80f2-2b12401742d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_52127096-ee8e-45d8-80f2-2b12401742d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_0813f8c0-dffd-497f-9937-851e28f4454c" xlink:href="eols-20220930.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_0813f8c0-dffd-497f-9937-851e28f4454c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9c39e234-1142-4f26-96f9-be37c97fb452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9c39e234-1142-4f26-96f9-be37c97fb452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_e29a5a35-5698-4d5f-958e-73342dab2bf4" xlink:href="eols-20220930.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear_e29a5a35-5698-4d5f-958e-73342dab2bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RegistrationRightsAgreementSellingPeriod_a2ece729-d440-4281-931c-00f3af179740" xlink:href="eols-20220930.xsd#eols_RegistrationRightsAgreementSellingPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_RegistrationRightsAgreementSellingPeriod_a2ece729-d440-4281-931c-00f3af179740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_063d9add-c625-4c34-83ed-693562794924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_063d9add-c625-4c34-83ed-693562794924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_602c035a-a916-42f6-8cc5-80546e90100e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_LitigationReserveCurrent_602c035a-a916-42f6-8cc5-80546e90100e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_8326da17-bb0b-4d9c-a031-005feb259fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_LitigationReserve_8326da17-bb0b-4d9c-a031-005feb259fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_cdb92063-0719-4b8f-9b93-24f90a09ee2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_cdb92063-0719-4b8f-9b93-24f90a09ee2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestonePaymentInConnectionWithAgreement_8ee8e7cc-0c21-4df2-80a9-9d8597d3e83e" xlink:href="eols-20220930.xsd#eols_MilestonePaymentInConnectionWithAgreement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_MilestonePaymentInConnectionWithAgreement_8ee8e7cc-0c21-4df2-80a9-9d8597d3e83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_29447986-17a7-4098-a568-9a96c03d90c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_ConvertibleDebt_29447986-17a7-4098-a568-9a96c03d90c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b367ff91-d5e9-43dd-b111-d6d62603dc09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b367ff91-d5e9-43dd-b111-d6d62603dc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_161255c0-e92f-4d64-a4fc-f9426782d48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_161255c0-e92f-4d64-a4fc-f9426782d48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_20d16a13-3f0f-46ae-9e3a-fd77770ff50d" xlink:href="eols-20220930.xsd#eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned_20d16a13-3f0f-46ae-9e3a-fd77770ff50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_90318dc1-2059-454c-8dbf-d147a6866d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_90318dc1-2059-454c-8dbf-d147a6866d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsForInventory_af891275-b746-4834-a142-b53f0e74ff32" xlink:href="eols-20220930.xsd#eols_PaymentsForInventory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f23ef334-3164-4b6d-8096-c5cf7633732b" xlink:to="loc_eols_PaymentsForInventory_af891275-b746-4834-a142-b53f0e74ff32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  !]    'Y" (   !6*3+J  "  $E$051X7NS=
MNT_KS/K__?N_VPU=BG04E!1T%)1(E$BT2)1+JT74B!910PT]U$E-]CAFA62<
M@YW,7(>9]TN?XOE]GWVO!-NQ9ZXY^+\9           XV'_Q_P$
M  Q'P1T         @ 0HN ,         D  %=P          $J#@#@
M  !  A3< 0        !(@(([           )4' '         " !"NX
M     "1 P1T         @ 0HN ,         D  %=P          $J#@#@
M      !  A3< 0        !(@(([           )4' '         " !"NX
M         "1 P3V=Z63V]MKDX?[[[Y\F=[??%^=QCOZWDO$H_A^T"?]M^X_\
M_3-[>?[YE\-' $ ?[4UC^8X4<G49WVI"SD[C^]+)<?R_"?]A=$?Z>(\_$0
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MTV:W&5ZR"@      7"F]X#Z=-*6N"O=G3YYVPQD /7V\5_IRB.2YN6;!#0
M    \*+<@OO'>S.EO5N[(8>$.>_ =E^?S&?/DI/C9LR/">\      ,"V$@ON
M3X_?%^=QL8:DS7C$&PZ!7^U[F+GSY$Y[YV&'=P      8%59!?>G1S9PD,[9
M*=-.4;5V,0WOAQ#.S35E=P      8% 1!??IY/OO'TKMFFFWFF'".^K13FEG
MZQC=L+T[       PQG_!_>&>N:6&<G'.NU51N*_/YFVHW';LY.J2V>X
M , (SP5W-I QFW!>_OYAGQF4YNWU^^HROMJ)D;#)#       ,,!GP?WME9T<
M'*3=9X82& K [C%>PE ?      !0Y:W@_O7)#%-_H>P.OUA)XR[C$1M; 0
M    +7X*[NV;4;NU%>(EE-WA"Z5VUSD[Y7VJ      ! GI."^]LKE:]"0MD=
M]E%J+R9WM^PP P      ))DON$\G["%38"B[PR9*[>5E/)J]/,<G&@
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M),K9*?<9      "0D'[!G9<6DFWY^R>^8H"A/MZ_ST[C2XN0-N,16[H#
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M/^3FVF*1?8NOSV8*?/'33M>&+=T+5N>F[?/%-+.'>V>#26WQO:!;4',*
M    MLI3<)].2MA;^>2XF4;JJ\*U23OYO8"3TCN4Q@KT]5G1-3P>->-\3X_2
M6\3D,)TTV\X4,5+2G!$      (#-LA3<FXW%.W4*-RFISMXUG30SW\,)*F_#
MAV[8 J(D16Y1U<W9J;^9[/T54'D?CXH].P      ((4,!?>'^[A"X257EW5M
M1?+QWNPY4\S./VMS<>YI(R!L4OPK4L/-Y^FQHFOUZ[-9<^/TYG-R7-&9 @
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MRIM"7)S'7PAEFTY,O*%W4WB70!\6]L[>E/%H]O8:?V&4[>TUO@QDPR(M
M  #JL:O@_O79K1W(A4T\:F5Z-Y*_?^*OBV73B=VM@7A%:JV4;RDWU_$7 @
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M??;R''\9      !0E@T%=ZTWRS&]'3N9K+E76T>S>"ZHMF,7M4GNO%0
M (#2;2BX/]S'90*9U#Q3&/T9G%4]'H5O%7_/TJEM/+4E+)%!'UJ#RB?'\3<!
M      !E65]P_[ZZC,L$(JFP9(D]?;R;J[E?G,=?LFQOK_$14 _3A]&;UIM^
M><TR      !EVU!P5REE7EW&WP/8PE[-??9P'W_)4NGM@KTQ5-LQ2+B!=*^B
M_*GH+@$     0)76%=RURA"U[H*-_1FLN=<Q?55K$<S&4&W'<#IO(&!H&0
M  " HJTKN*MLX,[.MMB/M8U-SD[C;UB>E^?XK]9-;9OY(!65A]UX%'\-
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M     (!2=0KN\F],O;J,O@-PD(]W0S7W,DK#IH8QV/\::84[1O<RRQR6:
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MR=MRLK\UJ&?8NAUBY)=T4' '   P0&PCS?B# 0#E6BJXO[UV'PEY<W'^^^E
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MK[5(_ T    @3JP1&'\P *!<%-R!?]3?GBHYR5U]>OO59?R5 %5B?:U%XF\
M    <6*-P/B# 0#E4BVXOSPO?1- G_PFSE'$)KGK3V__^HR_$Z!*?HU+_ T
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MX#Z;/_@];+4Q.!?GM"FQ0F,)\[!02\*RDC9J7PTWYW+(U@[8=$N>W)XJ9I^
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M?;T3WJFYKZ+@G@(3W@DA%88I[5 E6B"($EJ3'^_Q%P),47F)J,KO0K)VW*:
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M =96ED-[L8;Y<:W0>0LWBIZC=.$0W=W6\ZQ%7E(]P"8U3<I R21_-6U"X_D
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MZXJ"NU>ZU?8C6NT83'(L<1%F#6 8\?TZXM#LQDZ2_< V3,\4%IY<_]:'-3W
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M$@    92:+4NA67] &"*>,%=?N"7!5:04<_T]GF8!0PA+\_=RR]OF"($  "
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MM@-$TGGAWOTTWJ-?X1' #\7<4/Z__&AY>ZVCCW'?9#PJUJOPL. G(EQ]"G<
M %K5]O9@Y1<QNVH!Q!.C<.]\DY!BN0@/ G:7P#"9'R]OKR6PR-U@&0Y4GD+A
M2=5RC+D$ *!UY=?,EKJ1Z<1^6@!QQ2C<.U]U:ZX%AX@_3&:OY>VU[B^W[;@
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MJZ13N9UP<FR8._]0?M/8/G/:SG02'@8  '3O[;7Z<GIU697OY?_>W;;T#1&
M-D0JW*,T*>-1>!CPIV06@&]NKL-C:TIYZ?WS$<5NTL82?OHDRMTO]V4!  "
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MUP   $"'<BC<B[0'RWSD[M:$F7WD7+5O!MZVU[+NW(_4[ON:SS)XWPV3 0
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M-A?G8;>2108X(7JYV-Q<9S,(:.=HV_^A9YU[G8OSP37OY0_[<)_I]6MT.P
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M#C$WUQ:VYZJ\9D^.PS=4>A]#VP$  ( \#:QP+]Z7S9Z=AN6.]#7323&?A><
M>2FO68^G#"?C4?'T&)X#     )D87N%>>[BWU+WG&8_*=SE\W\G7VZM;9?W/
MV6GY1H=O/0   $ ^AEJXEY:+S702UCW2CYA'T5<OSR;,]#9WM^';#0   )";
M 1?N[XRJZ%O.3FVTV'O59>L)E3[%_J@   ! 7PR]<*\85=&/&-<^* :[]R-&
M/P$   #]HG#_S].C-;.YYN38+HL#]?:ZN;H,SP?))1?G)K8#    /:-P_\-Z
MM;FY#BLA23FJ=@JU>X8IKUS/HP    !]I'#?LER8,)-!5.T$U.Y9Q P9
MH-<4[E^8SS8GQV%5)"E$U<XWU.XIY^:Z6*_"MPP   "@1Q3NWWIZ5+LGE+-3
M8RC8R=MKM:6J71G2R=6E<>T   # $"C<=Z!VCYZKRV*Y"-\7^-YZY>*-'U4[
M    ,"0*]YUI[KI/^8+?W9I!P:'FL\W%>7AV2=M1M0,   ##HW#_H9=G6ZIV
MD8OS\J4.7WPX1#UGQFVSMC,>5??)5.T   # ("G<][)<V)BQE9P<%P_WJCK:
M]?+L^FTE]8;&'DD!    !DSA?H#URH+99E*^AC?7IK33J7K"NU$SC>3JTH;&
M     (7"O1GSF06S^V0\JGHZHV.(Z^VU>+C?3"?A^2G_3/U(BB7M     /]1
MN#?'@MD=8ST[:7I[=0GO%)<P    P!<4[BVH%\S:6S7(V6FU&%9)1_K6J]]S
MW@V,^C-US^Z1%    ("O*=S;]+'F?3P*JZN!9#KYW= 9.D&FEHOJ_IFKV*TR
M    @!THW+LRGVUNK@<Q)UK)3E\-IWRO]U=X>JR>UP$   !@9PKWSM73*FZN
M^S-SYN1X<W%>C8N9S\(?%OJJ'OC>RPO98G8   " ?2G<8YO/JC6S5Y<Y+7X_
M.ZU6O]8-NV7L4+PO?G]YWMS=5E='+I/?QZ/J:.]NJ^=1K&0'    :(+"/3'+
M1;5L]NZV&EN10@5_=EH=R=VM>AU^YJ."KU?!1V_AZWJ]/)CR<G8M P   +1#
MX9Z\]:IJQ^KFKB[BSTX;FV(QG?S^TZXNZS^_FMI<_G5F2D ;ZLMY/OM].=<K
MXNLT,A?^Y/CWGU87Z_5],I<S    0%<4[KVP7-0MWK]C62MDP44-    D"&%
M.P      -$#A#@      #5"X P    !  Q3N      #0 (4[       T0.$.
M       -4+@#     $ #%.X      -  A3L      #1 X0X       U0N ,
M    0#+4/U\    [241!5 ,4[@      T "%.P      -$#A#@      #5"X
M P    !  Q3N      #0 (4[       TX'^S: 7)2( 5!     !)14Y$KD)@
!@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641879046848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EVOLUS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1385614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">520 Newport Center Drive Suite 1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newport Beach<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">284-4555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EOLS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,246,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity CIK</a></td>
<td class="text">0001570562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641876741264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 65,572<span></span>
</td>
<td class="nump">$ 146,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">20,920<span></span>
</td>
<td class="nump">14,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">21,565<span></span>
</td>
<td class="nump">1,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">3,656<span></span>
</td>
<td class="nump">5,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">4,233<span></span>
</td>
<td class="nump">11,042<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">115,946<span></span>
</td>
<td class="nump">178,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,882<span></span>
</td>
<td class="nump">1,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,149<span></span>
</td>
<td class="nump">2,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">49,108<span></span>
</td>
<td class="nump">50,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,426<span></span>
</td>
<td class="nump">2,758<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">192,719<span></span>
</td>
<td class="nump">257,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,564<span></span>
</td>
<td class="nump">6,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">29,883<span></span>
</td>
<td class="nump">29,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">6,517<span></span>
</td>
<td class="nump">5,314<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">51,271<span></span>
</td>
<td class="nump">57,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveNoncurrent', window );">Accrued litigation settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">2,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">39,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Term loan, net of discounts and issuance costs</a></td>
<td class="nump">71,712<span></span>
</td>
<td class="nump">71,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">163,499<span></span>
</td>
<td class="nump">175,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00001 par value; 100,000,000 shares authorized; 56,183,414 and 55,576,988 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">513,717<span></span>
</td>
<td class="nump">504,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(368)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(484,130)<span></span>
</td>
<td class="num">(422,882)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">29,220<span></span>
</td>
<td class="nump">81,876<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 192,719<span></span>
</td>
<td class="nump">$ 257,483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Obligation Payable to Related Party, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641879014368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">56,183,414<span></span>
</td>
<td class="nump">55,576,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">56,183,414<span></span>
</td>
<td class="nump">55,576,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641877670432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 33,899<span></span>
</td>
<td class="nump">$ 26,677<span></span>
</td>
<td class="nump">$ 104,970<span></span>
</td>
<td class="nump">$ 65,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Product cost of sales (excludes amortization of intangible assets)</a></td>
<td class="nump">13,490<span></span>
</td>
<td class="nump">11,490<span></span>
</td>
<td class="nump">42,517<span></span>
</td>
<td class="nump">27,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Settlement payment from Daewoong</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">34,794<span></span>
</td>
<td class="nump">31,673<span></span>
</td>
<td class="nump">105,111<span></span>
</td>
<td class="nump">78,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Revaluation of contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">3,946<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">920<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="nump">2,695<span></span>
</td>
<td class="nump">4,702<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">51,796<span></span>
</td>
<td class="nump">45,787<span></span>
</td>
<td class="nump">159,663<span></span>
</td>
<td class="nump">91,393<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(17,897)<span></span>
</td>
<td class="num">(19,110)<span></span>
</td>
<td class="num">(54,693)<span></span>
</td>
<td class="num">(26,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,343)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
<td class="num">(6,466)<span></span>
</td>
<td class="num">(1,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debts, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(968)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(62)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes:</a></td>
<td class="num">(20,264)<span></span>
</td>
<td class="num">(19,421)<span></span>
</td>
<td class="num">(61,210)<span></span>
</td>
<td class="num">(28,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,276)<span></span>
</td>
<td class="num">(19,433)<span></span>
</td>
<td class="num">(61,248)<span></span>
</td>
<td class="num">(28,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss, net of tax</a></td>
<td class="num">(203)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(368)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (20,479)<span></span>
</td>
<td class="num">$ (19,433)<span></span>
</td>
<td class="num">$ (61,616)<span></span>
</td>
<td class="num">$ (28,633)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding used to compute basic net loss per share (in shares)</a></td>
<td class="nump">56,176,949<span></span>
</td>
<td class="nump">55,007,132<span></span>
</td>
<td class="nump">55,997,545<span></span>
</td>
<td class="nump">47,818,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding used to compute diluted net loss per share (in shares)</a></td>
<td class="nump">56,176,949<span></span>
</td>
<td class="nump">55,007,132<span></span>
</td>
<td class="nump">55,997,545<span></span>
</td>
<td class="nump">47,818,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Cost, Product and Service [Extensible List]</a></td>
<td class="text">Product revenue, net<span></span>
</td>
<td class="text">Product revenue, net<span></span>
</td>
<td class="text">Product revenue, net<span></span>
</td>
<td class="text">Product revenue, net<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 33,215<span></span>
</td>
<td class="nump">$ 26,677<span></span>
</td>
<td class="nump">$ 103,604<span></span>
</td>
<td class="nump">$ 64,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 684<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,366<span></span>
</td>
<td class="nump">$ 702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641801290368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Follow-On Offering</div></th>
<th class="th"><div>ATM Sales Agreement</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Follow-On Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>ATM Sales Agreement</div>
</th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th">
<div>Additional Paid In Capital </div>
<div>Follow-On Offering</div>
</th>
<th class="th">
<div>Additional Paid In Capital </div>
<div>ATM Sales Agreement</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,749,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">$ (72,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (376,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement', window );">Issuance of common stock in connection with litigation settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValuesLitigationSettlement', window );">Issuance of common stock in connection with litigation settlement</a></td>
<td class="nump">48,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for conversion of convertible note (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for conversion of convertible note</a></td>
<td class="nump">39,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">6,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,401<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,736,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">23,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(369,671)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,749,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">(72,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(376,072)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(28,633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,553,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">97,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(404,705)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,736,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">23,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(369,671)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,289<span></span>
</td>
<td class="nump">10,350,000<span></span>
</td>
<td class="nump">209,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="nump">644<span></span>
</td>
<td class="nump">$ 92,212<span></span>
</td>
<td class="nump">$ 2,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="nump">$ 92,212<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(15,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,601)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,372,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">106,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(385,272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(19,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,433)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,553,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 97,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(404,705)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">55,576,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,576,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 81,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(422,882)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(17,501)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,041,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 67,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="num">(440,383)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">55,576,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,576,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 81,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(422,882)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (61,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">56,183,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,183,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 29,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(368)<span></span>
</td>
<td class="num">(484,130)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,041,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">67,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="num">(440,383)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(23,471)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,063,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">46,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="num">(463,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(20,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">$ (203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">56,183,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,183,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 29,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 513,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (368)<span></span>
</td>
<td class="num">$ (484,130)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodValuesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Values, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodValuesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641872908352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (61,248)<span></span>
</td>
<td class="num">$ (28,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,695<span></span>
</td>
<td class="nump">4,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">8,421<span></span>
</td>
<td class="nump">6,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">573<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-kind interest on convertible note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Revaluation of contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">3,946<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,626)<span></span>
</td>
<td class="num">(4,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(15,283)<span></span>
</td>
<td class="num">(7,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,338<span></span>
</td>
<td class="num">(2,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(110)<span></span>
</td>
<td class="nump">14,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_IncreaseDecreaseInAccruedLitigationSettlement', window );">Accrued litigation settlement</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(723)<span></span>
</td>
<td class="num">(619)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(76,138)<span></span>
</td>
<td class="num">(24,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(752)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Additions to capitalized software</a></td>
<td class="num">(796)<span></span>
</td>
<td class="num">(580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(1,548)<span></span>
</td>
<td class="nump">4,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of long term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(76,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_PaymentsOfContingentRoyaltyObligation', window );">Payment of contingent royalty obligation to Evolus Founders</a></td>
<td class="num">(3,169)<span></span>
</td>
<td class="num">(2,295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan', window );">Issuance of common stock in connection with incentive equity plan</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(2,630)<span></span>
</td>
<td class="nump">25,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash</a></td>
<td class="num">(368)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents</a></td>
<td class="num">(80,684)<span></span>
</td>
<td class="nump">5,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">146,256<span></span>
</td>
<td class="nump">102,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">65,572<span></span>
</td>
<td class="nump">107,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">5,651<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible note to equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedForAccruedLitigationSettlementExpense', window );">Issuance of common stock in exchange for accrued litigation settlement expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capitalized software recorded in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember', window );">Follow-On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">92,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember', window );">ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IncreaseDecreaseInAccruedLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IncreaseDecreaseInAccruedLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_PaymentsOfContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Of Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_PaymentsOfContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedForAccruedLitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Accrued Litigation Settlement Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedForAccruedLitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641877451776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolus, Inc., (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in February 2019. The product was also approved by Health Canada in August 2018 and the European Commission (&#8220;EC&#8221;) in September 2019. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019, in Canada through a distribution partner in October 2019, and in Great Britain in September 2022. The Company currently generates all of its net revenues from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is headquartered in Newport Beach, California.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements&#160;have been prepared&#160;on a basis that&#160;assumes that&#160;the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company&#8217;s assets and the satisfaction of the Company&#8217;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has incurred recurring net operating losses and negative cash flows from operating activities and management expects operating losses and negative cash flows to continue for at least the next 12 months. The Company recorded net loss of $20,276 and $61,248 for the three and nine months ended September 30, 2022, respectively. The Company used cash of $76,138 from operations during the nine months ended September 30, 2022, which includes a settlement payment of $15,000. As of September 30, 2022, the Company had $65,572 in cash and cash equivalents and an accumulated deficit of $484,130. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a $125,000 Term Loan agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC (collectively, &#8220;Pharmakon&#8221;). The first tranche of $75,000 was funded on December 29, 2021. The second tranche of $50,000 may be drawn at the Company&#8217;s election no later than December 31, 2022, subject to the terms and conditions of the loan agreement. As of September 30, 2022, the Company has not drawn the second tranche. The Company received net proceeds of $68,695 from Pharmakon, after issuance costs and debt discounts in December 2021. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its current capital resources, which consist of cash and cash equivalents, will be sufficient to fund operations through at least the next 12 months from the date the accompanying condensed consolidated financial statements are issued based on its expected cash needs. The Company may need to raise additional capital to fund future operations through entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its scope of operations to reduce the current rate of spending through actions such as reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641880256192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the annual financial statements and in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. Pursuant to these SEC rules and regulations, the Company has condensed or omitted certain financial information and disclosures normally included in annual financial statements prepared in accordance with GAAP. In the opinion of management, the interim </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, considered necessary for a fair statement of the interim periods. The interim results presented herein are not necessarily indicative of the results of operations to be expected for the full year ending December&#160;31, 2022 or for any other interim period.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements and related disclosures should be read in conjunction with the financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on March 3, 2022. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly-owned subsidiaries, Evolus Pharma Limited, Evolus International Ltd. and Evolus Pharma BV, and have been prepared in conformity with GAAP. All intercompany transactions have been eliminated.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements, inventory valuations and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#8217;s actual results could differ materially from those estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full impact of&#160;current global events, including rising inflation, volatility in the financial and credit markets, the COVID-19&#160;pandemic and the Ukrainian-Russian war, is unknown and cannot be reasonably estimated. However, where possible, management has considered the potential impact of rising inflation, volatility in the financial and credit markets, the COVID-19 pandemic, and the Ukrainian-Russian war, and their respective market impacts, on its estimates and assumptions, and there was not a material impact to the Company&#8217;s condensed consolidated financial statements as of and for the nine months ended September 30, 2022. The Company&#8217;s future assessment of the impact of these events, as well as other factors, could result in material impacts to the Company&#8217;s financial statements in future reporting periods.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (&#8220;Daewoong&#8221;) entered into an agreement (the &#8220;Daewoong Agreement&#8221;), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the United States in May 2019, in Canada through its distribution partner in October 2019, and in Great Britain in September 2022 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#8217;s business and its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve, and the severity and magnitude of future outbreaks, or other similar public health crises, could result in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets caused by these or other events, such as increased inflation and rising interest rates and the military conflict between Russia and Ukraine, may increase the Company&#8217;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it operates in a single operating and reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#8217;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#8217; ability to pay.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed consolidated statements of operations and comprehensive loss using the specific-identification method.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of finished goods h</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eld for sale and distribution. Cost is determined based on the estimated amount payable to the Company&#8217;s supplier after accounting for any reimbursement receivable pursuant to the Daewoong Settlement Agreement (as such term is defined, and such agreement is discussed, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), using the first-in, first-out method with prioritization of the items with the earliest expiration dates. Inventory valuation reser</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product cost of sales, excluding amortization of intangible assets, consisted of the inventory cost, and, for periods on or after December 16, 2020, included certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox and Allergan pursuant to the Medytox/Allergan Settlement Agreements (as such term is defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Settlement Agreement with respect to such royalties. In the nine months ended September 30, 2021, the Company recorded a one-time settlement payment of $25,500 from Daewoong in connection with the Daewoong Settlement Agreement as part of cost of sales.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</span></div><div style="margin-bottom:9pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately five years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease. </span></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has one reporting unit. There was no impairment of goodwill for any of the periods presented.</span></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution right intangible asset related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of 20 years. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying condensed consolidated balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of two years upon being placed in service. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was no material impairment of long-lived assets for any periods presented.</span></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying condensed consolidated balance sheets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the condensed consolidated balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of September 30, 2022.</span></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Royalty Obligation Payable to Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are determined at each reporting period end and recorded in operating expenses in the accompanying condensed consolidated statements of operations and comprehensive loss and as a liability in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt represents the debt balance with Pharmakon (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), net of discount and issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated into U.S. dollars at current exchange rates as of balance sheet date, and income and expense items are translated into U.S. dollars using the average rates of exchange prevailing during the period. Gains and losses arising from translation are recorded in other comprehensive gain (loss) as a separate component of shareholders&#8217; equity. Foreign currency gains or losses on transactions denominated in a currency other than the Company&#8217;s functional currency are recorded in other expenses, net in the accompanying condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates product revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Great Britain and service revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received. The Company recognized $684 and $1,366 of service revenues for the three and nine months ended September 30, 2022, respectively, and $0 and $702, respectively, of service revenues for the three and nine months ended September 30, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Revenue Adjustments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume-based rebates, consumer loyalty programs and co-branded marketing programs. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Volume-based Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Consumer Loyalty Program &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company launched a consumer loyalty program, which allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and redeem the rewards for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#8220;Reward&#8221;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on historical sales data, estimated average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of redemption, expected customer and consumer participation rates in the loyalty program, and estimated number of qualifying treatments to be performed by customers. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-Branded Marketing Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company offers eligible customers with a certain level of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#8217;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of September 30, 2022 and December&#160;31, 2021, all amounts included in accounts receivable, net on the accompanying condensed consolidated balance sheets are related to contracts with customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract assets nor unbilled receivables as of September 30, 2022 or December&#160;31, 2021. Sales commissions are included in selling, general and administrative expenses when incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and deferred revenue associated with Rewards under the consumer loyalty program and co-branded marketing programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December&#160;31, 2021, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program and co-branded marketing programs, were $10,188 and $7,934, respectively, which were recorded in accrued expenses in the accompanying condensed consolidated balance sheets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, the Company recognized $7,566 and $2,802, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collectability</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of September 30, 2022 and December&#160;31, 2021, allowance for doubtful accounts was $3,271 and $2,385, respectively. For the three and nine months ended September 30, 2022, reversal of and provision for bad debts were $623 and $1,363, respectively, and the write-off amount was $392 and $477, respectively. For the three and nine months ended September 30, 2021, provision for bad debts were $188 and $501, respectively, and the write-off amount was $23 and $214, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical Expedients</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.</span></div><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.</span></div><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a License and Research Collaboration Agreement (the &#8220;Collaboration Agreement&#8221;) with a 3D printing company with biomaterial capabilities (the &#8220;Licensor&#8221;). Under the terms of the Collaboration Agreement, the Company was granted a license to the Licensor&#8217;s technology to develop and commercialize any aesthetic product or non-therapeutic product that is created through the use or practice of the Licensor&#8217;s patents. The Company paid $2,000 upon the signing of the Collaboration Agreement and has research funding, ongoing milestone and royalty payment obligations depending on the development plans, the success of such development and approval and commercialization of products. The upfront payment of $2,000 was recorded as in-process research and development expense.</span></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Settlement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, upon entering into certain agreements to settle intellectual property disputes relating to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company agreed to pay to Allergan and Medytox $35,000 in multiple payments over two years, of which $15,000 was paid in the third quarter of 2021 and $15,000 was paid in the first quarter of 2022, and issued 6,762,652 shares of its common stock to Medytox. In addition, for the period from December 16, 2020 to September 16, 2022 (the &#8220;Restricted Period&#8221;), the Company agreed to pay to Allergan and Medytox a royalty on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a certain dollar amount per vial sold in the United States and a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold in other Evolus territories. Royalties for sales during the Restricted Period ended in the third quarter of 2022. For the period from September 17, 2022 to September 16, 2032, the Company agreed to pay to Medytox a mid-single digit royalty percentage on all net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The royalty payments are made quarterly and recorded as product cost of sales on the accompanying condensed consolidated statements of operations and comprehensive loss in the periods the royalties are incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement agreements resulted in an $83,421 charge for the fourth quarter of 2020, which consisted of $35,000 in deferred cash payments and $48,421 from the issuance of 6,762,652 shares of the Company&#8217;s common stock in February </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021. In the first quarter of 2022, the Company made the second cash payment of $15,000 to Medytox and Allergan with the $5,000 balance due in 2023. As of September 30, 2022 and December&#160;31, 2021, a current liability of $5,000 and $15,000, respectively, and non-current liability of $0 and $5,000, respectively, were recorded in the accompanying condensed consolidated balance sheets. </span></div><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in March 2021, Daewoong and the Company entered into certain agreements, pursuant to which</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Daewoong agreed to pay the Company an amount equal to $25,500, which was recorded as a settlement payment from Daewoong and included as part of cost of sales on the accompanying condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2021. For the period from December 16, 2020 to September 16, 2022, Daewoong also agreed to reimburse the Company certain amounts with respect to the royalties payable to Medytox and Allergan. This reimbursement is received quarterly and recorded as an offset to the related royalties to Medytox and Allergan in the product cost of sales on the accompanying condensed consolidated statements of operations and comprehensive loss. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the details of all litigation settlement agreements.</span></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value on the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the condensed consolidated balance sheets and in the selling, general and administrative or research and development expenses in the condensed consolidated statements of operations and comprehensive loss. </span></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies an estimated annual effective tax rate (&#8220;ETR&#8221;) approach for calculating a tax provision or benefit for interim periods, as required under GAAP.&#160;The Company recorded an income tax expense of $12 and $12 for the three months ended September 30, 2022 and 2021, respectively, and an income tax expense of $38 and $33 for the nine months ended September 30, 2022 and 2021, respectively.&#160;The Company&#8217;s ETR differs from the U.S. federal statutory tax rate of 21% for the three and nine months ended September 30, 2022 and 2021, primarily as a result of the impact of the change of the valuation allowance to offset its deferred tax assets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect that changes to state tax laws through September 30, 2022 to materially impact its condensed consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. Excluded from the dilutive net loss per share computation for the three and nine months ended September 30, 2022 and 2021 were stock options of 4,932,632 and 3,873,352, respectively, and non-vested RSUs of 2,638,803 and 1,771,938, respectively, because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update will increase transparency of government assistance received by most business entities by requiring the disclosure of: (1) the types of transactions; (2) the accounting for the transactions; and, (3) the effect of the transactions on a business entity&#8217;s financial statements. ASU No. 2021-10 is effective for financial statements issued for annual periods beginning after December 15, 2021, with early application permitted. The Company has adopted this guidance on the effective date of January 1, 2022. There are no material impacts to the condensed consolidated financial statements as a result of this adoption.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Issued But Not Adopted</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU No. 2016-13, the FASB issued ASU No. 2018-19,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU does not change the core principle of the guidance in ASU No. 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04 which did not change the core principle of the guidance in ASU No. 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January 1, 2023. The Company is in the process of determining the effects the adoption will have on its consolidated financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the consolidated financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in January 2021, the FASB issued ASU No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope (&#8220;ASU 2021-01&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Both ASU No. 2020-04 and ASU No. 2021-01 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued because of reference rate reform. ASU No. 2020-04 and ASU No. 2021-01 are effective upon issuance for contract modifications and hedging relationships, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company does not expect adoption of this guidance will have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641892283104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Short-Term Investments</a></td>
<td class="text">Fair Value Measurements and Short-Term Investments<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:47.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:47.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the nine months ended September 30, 2022 and 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable to Evolus Founders based on Level 3 inputs using a discounted cash flows method. The significant unobservable input assumptions that can significantly change the fair value include (i) projected amount and timing of net revenues during the payment period, which terminates at the end of the second quarter of 2029, (ii) the discount rate, and (iii) the timing of payments. During the three and nine months ended September 30, 2022 and 2021, the Company utilized a discount rate of 13.0%, reflecting the Company&#8217;s risk profile. Net revenue projections are also updated to reflect changes in the timing of expected sales.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.452%"><tr><td style="width:1.0%"/><td style="width:44.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recorded in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Assets and Liabilities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. </span></div>The Company estimates the fair value of the long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of September 30, 2022 and December&#160;31, 2021, the fair value of long-term debt was $70,360 and $75,448, respectively. The fair value of operating lease liabilities&#160;as of September 30, 2022 and December&#160;31, 2021 approximated their carrying value.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641892283104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:40.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.891%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,220)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,108&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,536&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,220)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:40.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.891%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,390&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*  Intangible assets with indefinite lives have an indeterminable average life.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;September 30, 2022 that are subject to amortization:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:71.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.173%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining in 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution right represents the license and associated distribution right to develop Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the initial term of which expires in September 2023 and is automatically extended for unlimited additional three-year terms provided that the Company meets certain performance requirements. The Company paid Daewoong $3,000 in milestone payments in 2019, pursuant to the Daewoong Agreement, which increased the cost basis of the distribution. Under the Daewoong Settlement Agreement (as defined in Note 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), there is no additional cash consideration due to Daewoong. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $531 and $0 for the three months ended September 30, 2022 and 2021, respectively, and $938 and $633 for the nine months ended September 30, 2022 and 2021, respectively, related to costs of computer software developed for internal use. The Company recorded total intangible assets amortization expense of $838 and $843 for the three months ended September 30, 2022 and 2021, respectively, and $2,454 and $4,463 for the nine months ended September 30, 2022 and 2021, respectively, within depreciation and amortization on the accompanying condensed consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641881132240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"/><td style="width:57.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties under the Medytox/Allergan Settlement Agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued revenue contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641880983088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loans</a></td>
<td class="text">Term Loans<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmakon Term Loans</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, the Company entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to the Company in two tranches (&#8220;Pharmakon Term Loans&#8221;). The first tranche of $75,000 was funded on December 29, 2021. The second tranche of $50,000 may be drawn at the Company&#8217;s election no later than December 31, 2022, subject to the terms and conditions of the Pharmakon Term Loans. As of September 30, 2022, the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has not drawn the second tranche. The Pharmakon Term Loans will mature on the six-year anniversary of the closing date of the first tranche (&#8220;Maturity Date&#8221;). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans accrue interest at a per annum rate equal to the greater of 1.0% or 3-month U.S. Dollar LIBOR rate plus 8.5% per annum. In the event U.S. Dollar LIBOR rate is discontinued, the interest rate for the Pharmakon Term Loans will be based on an alternate benchmark rate established in the manner provided under the loan agreement for the Pharmakon Term Loans. The Company agreed to make 12 equal quarterly payments of principal on the outstanding Pharmakon Term Loans commencing on or immediately following the 39th-month anniversary of the funding date of the first tranche continuing through the Maturity Date.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect to prepay all amounts, not less than $20,000, owed prior to the Maturity Date. Prepayments of the first tranche prior to the second anniversary of the closing date of the first tranche and prepayments of the second tranche prior to the second anniversary of the date on which the second tranche is drawn by the Company will be accompanied by a make whole amount equal to the sum of all interest that would have accrued through such second anniversary. Prepayments of the Pharmakon Term Loans will also be accompanied by a prepayment premium equal to the principal amount so prepaid multiplied by 3.0% if made prior to the third anniversary of the closing date of the first tranche, 2.0% if made on or after the third anniversary of the closing date of the first tranche but prior to the fourth anniversary of the closing date of the first tranche, and 1.0% if made on or after the fourth anniversary of the closing date of the first tranche but prior to the Maturity Date. If the Pharmakon Term Loans are accelerated following the occurrence of an event of default, including a material adverse change, the Company is required to immediately pay Pharmakon an amount equal to the sum of all outstanding principal, unpaid interest, and applicable make whole and prepayment premiums.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans are secured by substantially all of the Company&#8217;s assets. The Pharmakon Term Loans contain customary affirmative and restrictive covenants and representations and warranties. The affirmative covenants include, among others, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. The restrictive covenants include, among others, incurring certain additional indebtedness, consummating certain change in control transactions, or incurring any non- permitted lien or other encumbrance on the Company&#8217;s assets, without Pharmakon&#8217;s prior written consent. The Pharmakon Term Loans do not contain covenants requiring the Company to maintain a minimum cash threshold or minimum revenues or earnings. As of September 30, 2022, the Company was in compliance with its debt covenants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing date of the first tranche, the Company incurred $3,042 and $3,263 in debt discounts and issuance costs related to the Pharmakon Term Loans, respectively. Debt discounts and issuance costs related to the entire Pharmakon Term Loans have been allocated pro rata between the funded and unfunded portions. Debt discounts and issuance costs allocated to the first tranche of $75,000 have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. As of September 30, 2022, the borrowings outstanding under the Pharmakon Term Loans were classified as long-term debt in the accompanying condensed consolidated balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately 12.22% as of September 30, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.299%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net of discounts and issuance costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,712&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oxford Term Loan</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2019, the Company entered into a Loan and Security Agreement with Oxford (the &#8220;Loan Agreement&#8221;), providing for a credit facility of up to $100,000. Pursuant to the terms of the credit facility, the lender extended term loans (the &#8220;Oxford Term Loan&#8221;), available in two advances, to the Company. The first tranche of $75,000 was funded on the closing date. The second tranche of $25,000 was not drawn. The credit facility bore an annual interest rate equal to the greater of 9.5%, or the 30-day U.S. Dollar LIBOR rate plus 7.0%. The Company agreed to pay interest-only for the first 36 months until May 2022, followed by a 23-month amortization period. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the earliest to occur of the maturity date, the acceleration of the Oxford Term Loan, or the prepayment of the Oxford Term Loan, the Company was required to pay to Oxford a final payment of 5.5% of the full principal amount of the Oxford Term Loan funded (&#8220;Final Payment&#8221;). The Company could elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee was also paid, which would be equal to 2.0% of the amount prepaid if the prepayment occurred after March 15, 2020 and on or prior to March 15, 2021, or 1.0% of the amount prepaid if the prepayment occurred thereafter (&#8220;Prepayment Fee&#8221;).</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, the Company and Oxford entered into an agreement (&#8220;Payoff Letter&#8221;), pursuant to which (i) the Company paid Oxford $76,447 to discharge in full all outstanding obligations, including accrued interest, by and between Oxford, in its capacity as collateral agent and lender, and the Company, and (ii) effective upon such repayment, the Loan Agreement, and all unfunded commitments thereunder, guarantees and other security interests granted to Oxford in connection with the Loan Agreement and all other obligations of and restrictions on the Company under the Loan Agreement, terminated. As a condition to entering into the Payoff Letter, Oxford agreed to waive a total of $4,300 of fees comprised of (i) $2,800 of the Final Payment and (ii) the Prepayment Fee of $1,500. As a result, the Company recorded a loss of $1,939 in extinguishment of debts, net on the accompanying condensed consolidated statements of operations and comprehensive loss in the nine months ended September 30, 2021.</span></div>Daewoong Convertible Note<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2020, the Company entered into a Convertible Promissory Note Purchase Agreement with Daewoong for the principal amount of $40,000 (the &#8220;Daewoong Convertible Note&#8221;), which was funded on July 30, 2020. Additionally, on July 6, 2020, the Company, Daewoong and Oxford entered into a Subordination Agreement pursuant to which the Daewoong Convertible Note was subordinated to the Company&#8217;s obligations under the Loan Agreement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Convertible Note bore interest at a rate of 3.0% payable semi-annually in arrears on June 30th and December 31st of each year and was to mature on July 30, 2025, subject to earlier conversion as provided below. Interest was initially paid in kind by adding the accrued amount thereof to the outstanding principal amount on a semi-annual basis on June 30th and December 31st of each calendar year for so long as any principal amount under the Oxford Term Loan remained outstanding and the Subordination Agreement was not terminated. Interest became payable in cash after the Oxford Term Loan was repaid in full, and the Subordination Agreement was terminated on January 4, 2021. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the outstanding principal balance including all accrued and unpaid interest thereon, of $40,779 was converted, at the conversion price of $13.00 per share, into 3,136,869 shares of the Company&#8217;s common stock under the Conversion Agreement (as defined in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 11.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The conversion was accounted for as an extinguishment of debt resulting in a gain of $971, which is recorded in loss from extinguishment of debts, net on the accompanying condensed consolidated statements of operations and comprehensive loss. The Daewoong Convertible Note was not registered, and the shares of the Company&#8217;s common stock issued upon conversion of the Daewoong Convertible Note have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the details of the Conversion Agreement.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641878981280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Daewoong Convertible Note<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Daewoong Convertible Note</a></td>
<td class="text">Term Loans<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmakon Term Loans</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, the Company entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to the Company in two tranches (&#8220;Pharmakon Term Loans&#8221;). The first tranche of $75,000 was funded on December 29, 2021. The second tranche of $50,000 may be drawn at the Company&#8217;s election no later than December 31, 2022, subject to the terms and conditions of the Pharmakon Term Loans. As of September 30, 2022, the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has not drawn the second tranche. The Pharmakon Term Loans will mature on the six-year anniversary of the closing date of the first tranche (&#8220;Maturity Date&#8221;). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans accrue interest at a per annum rate equal to the greater of 1.0% or 3-month U.S. Dollar LIBOR rate plus 8.5% per annum. In the event U.S. Dollar LIBOR rate is discontinued, the interest rate for the Pharmakon Term Loans will be based on an alternate benchmark rate established in the manner provided under the loan agreement for the Pharmakon Term Loans. The Company agreed to make 12 equal quarterly payments of principal on the outstanding Pharmakon Term Loans commencing on or immediately following the 39th-month anniversary of the funding date of the first tranche continuing through the Maturity Date.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect to prepay all amounts, not less than $20,000, owed prior to the Maturity Date. Prepayments of the first tranche prior to the second anniversary of the closing date of the first tranche and prepayments of the second tranche prior to the second anniversary of the date on which the second tranche is drawn by the Company will be accompanied by a make whole amount equal to the sum of all interest that would have accrued through such second anniversary. Prepayments of the Pharmakon Term Loans will also be accompanied by a prepayment premium equal to the principal amount so prepaid multiplied by 3.0% if made prior to the third anniversary of the closing date of the first tranche, 2.0% if made on or after the third anniversary of the closing date of the first tranche but prior to the fourth anniversary of the closing date of the first tranche, and 1.0% if made on or after the fourth anniversary of the closing date of the first tranche but prior to the Maturity Date. If the Pharmakon Term Loans are accelerated following the occurrence of an event of default, including a material adverse change, the Company is required to immediately pay Pharmakon an amount equal to the sum of all outstanding principal, unpaid interest, and applicable make whole and prepayment premiums.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans are secured by substantially all of the Company&#8217;s assets. The Pharmakon Term Loans contain customary affirmative and restrictive covenants and representations and warranties. The affirmative covenants include, among others, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. The restrictive covenants include, among others, incurring certain additional indebtedness, consummating certain change in control transactions, or incurring any non- permitted lien or other encumbrance on the Company&#8217;s assets, without Pharmakon&#8217;s prior written consent. The Pharmakon Term Loans do not contain covenants requiring the Company to maintain a minimum cash threshold or minimum revenues or earnings. As of September 30, 2022, the Company was in compliance with its debt covenants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing date of the first tranche, the Company incurred $3,042 and $3,263 in debt discounts and issuance costs related to the Pharmakon Term Loans, respectively. Debt discounts and issuance costs related to the entire Pharmakon Term Loans have been allocated pro rata between the funded and unfunded portions. Debt discounts and issuance costs allocated to the first tranche of $75,000 have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. As of September 30, 2022, the borrowings outstanding under the Pharmakon Term Loans were classified as long-term debt in the accompanying condensed consolidated balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately 12.22% as of September 30, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.299%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net of discounts and issuance costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,712&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oxford Term Loan</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2019, the Company entered into a Loan and Security Agreement with Oxford (the &#8220;Loan Agreement&#8221;), providing for a credit facility of up to $100,000. Pursuant to the terms of the credit facility, the lender extended term loans (the &#8220;Oxford Term Loan&#8221;), available in two advances, to the Company. The first tranche of $75,000 was funded on the closing date. The second tranche of $25,000 was not drawn. The credit facility bore an annual interest rate equal to the greater of 9.5%, or the 30-day U.S. Dollar LIBOR rate plus 7.0%. The Company agreed to pay interest-only for the first 36 months until May 2022, followed by a 23-month amortization period. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the earliest to occur of the maturity date, the acceleration of the Oxford Term Loan, or the prepayment of the Oxford Term Loan, the Company was required to pay to Oxford a final payment of 5.5% of the full principal amount of the Oxford Term Loan funded (&#8220;Final Payment&#8221;). The Company could elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee was also paid, which would be equal to 2.0% of the amount prepaid if the prepayment occurred after March 15, 2020 and on or prior to March 15, 2021, or 1.0% of the amount prepaid if the prepayment occurred thereafter (&#8220;Prepayment Fee&#8221;).</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, the Company and Oxford entered into an agreement (&#8220;Payoff Letter&#8221;), pursuant to which (i) the Company paid Oxford $76,447 to discharge in full all outstanding obligations, including accrued interest, by and between Oxford, in its capacity as collateral agent and lender, and the Company, and (ii) effective upon such repayment, the Loan Agreement, and all unfunded commitments thereunder, guarantees and other security interests granted to Oxford in connection with the Loan Agreement and all other obligations of and restrictions on the Company under the Loan Agreement, terminated. As a condition to entering into the Payoff Letter, Oxford agreed to waive a total of $4,300 of fees comprised of (i) $2,800 of the Final Payment and (ii) the Prepayment Fee of $1,500. As a result, the Company recorded a loss of $1,939 in extinguishment of debts, net on the accompanying condensed consolidated statements of operations and comprehensive loss in the nine months ended September 30, 2021.</span></div>Daewoong Convertible Note<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2020, the Company entered into a Convertible Promissory Note Purchase Agreement with Daewoong for the principal amount of $40,000 (the &#8220;Daewoong Convertible Note&#8221;), which was funded on July 30, 2020. Additionally, on July 6, 2020, the Company, Daewoong and Oxford entered into a Subordination Agreement pursuant to which the Daewoong Convertible Note was subordinated to the Company&#8217;s obligations under the Loan Agreement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Convertible Note bore interest at a rate of 3.0% payable semi-annually in arrears on June 30th and December 31st of each year and was to mature on July 30, 2025, subject to earlier conversion as provided below. Interest was initially paid in kind by adding the accrued amount thereof to the outstanding principal amount on a semi-annual basis on June 30th and December 31st of each calendar year for so long as any principal amount under the Oxford Term Loan remained outstanding and the Subordination Agreement was not terminated. Interest became payable in cash after the Oxford Term Loan was repaid in full, and the Subordination Agreement was terminated on January 4, 2021. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the outstanding principal balance including all accrued and unpaid interest thereon, of $40,779 was converted, at the conversion price of $13.00 per share, into 3,136,869 shares of the Company&#8217;s common stock under the Conversion Agreement (as defined in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 11.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The conversion was accounted for as an extinguishment of debt resulting in a gain of $971, which is recorded in loss from extinguishment of debts, net on the accompanying condensed consolidated statements of operations and comprehensive loss. The Daewoong Convertible Note was not registered, and the shares of the Company&#8217;s common stock issued upon conversion of the Daewoong Convertible Note have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the details of the Conversion Agreement.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641878190144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating Leases<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s corporate headquarters in Newport Beach, California is leased under a five-year non-cancelable operating lease, which expires on January 31, 2025. Lease payments increase each year on February 1 based on an annual rent escalation clause. The Company may, under certain circumstances, terminate the lease on the 36-month anniversary of the lease commencement date by providing a written notice 12 months prior to such anniversary and paying a termination fee&#160;equal to six months basic rent plus certain other expenses. The Company has an option to extend the term of the lease for an additional 60 months, which is not recognized as part of its ROU assets and lease liabilities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreement does not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.690%"><tr><td style="width:1.0%"/><td style="width:41.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.940%"><tr><td style="width:1.0%"/><td style="width:72.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.897%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.440%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease&#160;expenses were included in the selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. Operating lease right-of-use assets and related current and noncurrent operating lease liabilities are presented in the accompanying condensed consolidated balance sheets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of September 30, 2022:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:68.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,798&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641877440256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:10pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately $1,074. Certain minimum purchase commitments related to the purchase of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are described below.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Supply Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Agreement includes certain minimum annual purchases that the Company is required to make in order to maintain the exclusivity of the license. The Company may, however, meet these minimum purchase obligations by achieving certain market share in the licensed territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions. </span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16 and 28, 2020, two putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#8217;s acquisition of the right to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, three of its officers, and Alphaeon Corporation, the Company&#8217;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint. On February 10, 2022, Alphaeon Corporation served its motion to dismiss the amended complaint. Both motions were fully briefed on June 16, 2022. The outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2020 and December 2, 2020, two putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#8217;s officers </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-09986-PPG, and adjourned defendants&#8217; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#8217; stipulated stay of the consolidated derivative suit pending the court&#8217;s decision on the defendants&#8217; motion to dismiss the Securities Class Action.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Books and Records Demand</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#8217;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to the demand in December 2021. The outcome of this matter is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legal Matters</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, from time to time, involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. No amounts were accrued as of September 30, 2022 and December&#160;31, 2021.</span></div>Medytox/Allergan Settlement Agreements and Daewoong Arrangement<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medytox/Allergan Settlement Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Settlement Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company, Allergan and Medytox entered into a Settlement and License Agreement (the &#8220;U.S. Settlement Agreement&#8221;), pursuant to which, among other things: (i) Allergan and Medytox agreed to file a petition requesting the remedial orders related to the ITC Action be rescinded with respect to the Company; (ii) Medytox agreed to dismiss substantially similar litigation in California against the Company; (iii) the Company, on the one hand, and Medytox and Allergan, on the other hand, agreed to mutually release certain claims they may have against one another and their respective affiliates; (iv) Allergan and Medytox granted to the Company and its agents a license to manufacture and commercialize certain products identified in the U.S. Settlement Agreement, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Licensed Products&#8221;), in the United States during the 21 month period that, pursuant to the ITC Action, the Company was restricted from, among other things, selling, marketing, or promoting such imported Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States (the &#8220;Restricted Period&#8221;); (v) the Company agreed to pay to Allergan and Medytox $35,000 in multiple payments over two years, of which the Company paid the first cash payment of $15,000 in the third quarter of 2021 and the second cash payment of $15,000 in the first quarter of 2022; and (vi) during the Restricted Period, the Company agreed to pay to Allergan and Medytox certain confidential royalties on the sale of Licensed Products, calculated on dollar amount per vial sold of Licensed Products by or on behalf of the Company in the United States. Royalties for sales during the Restricted Period ended on September 16, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ROW Settlement Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#8220;ROW Settlement Agreement&#8221; and, together with the U.S. Settlement Agreement, the &#8220;Medytox/Allergan Settlement Agreements&#8221;), pursuant to which, among other things: (i) the Company and Medytox agreed to mutually release certain claims they may have against one another and their respective affiliates; (ii) Medytox granted to the Company and its agents a license to manufacture and commercialize the Licensed Products, in Canada, the European Union, Switzerland, member countries and cooperating countries of the European Economic Area, Russia, certain members of the Commonwealth of Independent States, South Africa, Australia and Japan (the &#8220;ROW Territories&#8221;) during the Restricted Period; (iii) Medytox granted to the Company and its agents a fully paid up license to manufacture and commercialize the Licensed Products in the ROW Territories and the United States from the end of the Restricted Period (the &#8220;Medytox License Period&#8221;); (iv) the Company and Medytox agreed to enter into the Share Issuance Agreement (as defined below) pursuant to which the Company issued 6,762,652 shares (the &#8220;Settlement Shares&#8221;) of the Company&#8217;s common stock, par value $0.00001 per share, to Medytox; (v) the Company and Medytox agreed to enter into the Registration Rights Agreement (as defined below), pursuant to which the Company granted certain registration rights to Medytox with respect to the Settlement Shares; (vi) during the Restricted Period that ended September 16, 2022, the Company agreed to pay Medytox a confidential low-double digit royalty on net sales of the Licensed Products sold by or on behalf of the Company in the ROW Territories; and (vii) during the Medytox License Period from September 17, 2022 to September 16, 2032, the Company agreed to pay Medytox a confidential mid-single digit royalty percentage on net sales of the Licensed Products sold by or on behalf of the Company in the United States and the ROW Territories.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share Issuance Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox entered into a Share Issuance Agreement effective February 18, 2021 (the &#8220;Share Issuance Agreement&#8221;). Pursuant to the Share Issuance Agreement and subject to the terms and conditions set forth therein, among other things, the Company issued to Medytox the Settlement Shares to enter into the ROW Settlement Agreement and in consideration for Medytox&#8217;s representations, warranties, and other agreements set forth in the Share Issuance Agreement. The Settlement Shares are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates, prevented Medytox from transferring any shares of common stock prior to February 16, 2022 and, thereafter, prohibit Medytox from transferring more than 25% of the shares it holds prior to September 16, 2023, more than 50% of the shares it holds prior to September 16, 2024 and more than 75% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Rights Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox also entered into a Registration Rights Agreement effective February 18, 2021 (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the Registration Rights Agreement, among other things, the Company agreed, after March 31, 2022, (i) to comply with certain requests by Medytox to register for sale, under the Securities Act, the Settlement Shares, and (ii) to include the Settlement Shares in certain registrations by the Company of its securities for sale under the Securities Act, to the extent requested by Medytox, in each case subject to certain customary conditions, exceptions and limitations as set forth in the Registration Rights Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Medytox&#8217;s registration rights under the Registration Rights Agreement will terminate at such time that Medytox is able to sell all of the Settlement Shares over a three-month period, or less, pursuant to an exemption to registration under the Securities Act.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company accrued $7,936 for royalties under the Medytox/Allergan Settlement Agreements and $5,000 of accrued litigation settlement expense. As of December&#160;31, 2021, the Company accrued $12,447 for royalties under the Medytox/Allergan Settlement Agreements and $20,000 of accrued litigation settlement expense. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daewoong Arrangement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Daewoong Settlement Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the Company and Daewoong entered into a Confidential Settlement and Release Agreement (the &#8220;Daewoong Settlement Agreement&#8221;), pursuant to which, among other things: (i) Daewoong agreed to (a) pay to the Company an amount equal to $25,500, which the Company received in April 2021, (b) pay certain legal fees incurred by the Company&#8217;s litigation counsel in connection with its defense of the ITC Action (including any appeal of the resulting remedial orders), (c) cancel all remaining milestone payments totaling $10,500 in aggregate, and (d) reimburse the Company certain amounts (calculated on a dollar amount per vials sold basis in the United States) for sales of certain products with respect to which the Company is required to pay Medytox and Allergan royalties pursuant to the U.S. Settlement Agreement; and (ii) the Company agreed to (a) release, on behalf of itself and certain of its affiliates and representatives, certain claims they may have against Daewoong related to the allegations made in or the subject matter of the Medytox/Allergan Actions, or any orders, remedies and losses resulting from the Medytox/Allergan Actions, and (b) coordinate with Daewoong on certain matters related to the Medytox/Allergan Actions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conversion Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Daewoong Settlement Agreement, the Company and Daewoong also entered into a Convertible Promissory Note Conversion Agreement (the &#8220;Conversion Agreement&#8221;), pursuant to which, among other things, (i) the principal balance under the Daewoong Convertible Note, together with all accrued and unpaid interest thereon, in the amount of $40,779 was converted, at the conversion price of $13.00 per share, into 3,136,869 shares of Common Stock; and (ii) the Daewoong Convertible Note was deemed cancelled and satisfied in full in connection with such conversion.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the conversion, shares owned by Daewoong, together with its affiliates and attribution parties, did not exceed 9.99% of the Company&#8217;s then outstanding common shares immediately following such issuance, as required under the terms of the Daewoong Convertible Note.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Daewoong Agreement Amendment</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Daewoong Settlement Agreement, on March 23, 2021, the Company and Daewoong also entered into the Third Amendment to the Supply Agreement (the &#8220;Daewoong Agreement Amendment&#8221;). Pursuant to the Daewoong Agreement Amendment, the parties amended the Daewoong Agreement to (i) expand the territory within which the Company may distribute Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to certain countries in Europe, (ii) reduce the period of time with respect to which the Company is required to deliver binding forecasts to Daewoong, (iii) introduce certain limitations on Daewoong&#8217;s ability to convert the Company&#8217;s exclusive license for certain territories to a non-exclusive license in the event the Company fails to meet certain minimum purchase requirements for such territory, (iv) adjust the minimum purchase requirements and reduce the transfer price per vial of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> applicable to various territories, (v) require that any Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> supplied by Daewoong match certain shelf-life thresholds, and (vi) prohibit the Company from sharing certain confidential information of Daewoong with Medytox or its affiliates or representatives.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December&#160;31, 2021, the Company had $3,257 and $5,657, respectively, in reimbursement receivable from Daewoong, respectively, in other current assets in the accompanying condensed consolidated balance sheets. Total inventory payments to Daewoong were $14,238 and $40,509 for the three and nine months ended September 30, 2022, respectively. Total inventory payments to Daewoong were $10,916 and $24,576 for the three and nine months ended September 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641879937488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has 10,000,000 authorized shares of preferred stock with a par value of $0.00001 per share. As of September 30, 2022, no shares of its preferred stock were issued and outstanding. </span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has 100,000,000 authorized shares of common stock with a par value of $0.00001 per share. As of September 30, 2022, 56,183,414 shares of its common stock were issued and outstanding. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2021, the Company issued 6,762,652 shares of its common stock to Medytox pursuant to the Share Issuance Agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company issued 3,136,869 shares of its common stock to Daewoong in connection with the conversion of Daewoong Convertible Note. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Daewoong Convertible Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;At-the-market&#8221; Offerings of Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2021, the Company entered into an &#8220;at-the-market&#8221; sales agreement with SVB Leerink LLC (the &#8220;Sales Agent&#8221;) pursuant to which shares of the Company&#8217;s common stock could be sold from time to time for aggregate gross proceeds of up to $75,000 (the &#8220;ATM Program&#8221;). The Sales Agent was entitled to compensation, at a commission rate equal to 3.0% of the gross proceeds from sales of the Company&#8217;s common shares under the ATM Program. Since August 2021, the Company has not sold any shares under the ATM Program and the Company terminated the ATM Program in May 2022. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, the Company sold a total of 724,835 shares of its common stock pursuant to the ATM Program at the prevailing market prices for total net proceeds of $8,203 and paid total commissions of $254 to the Sales Agent. For the nine months ended September 30, 2021, the Company sold a total of 934,367 shares of its common stock pursuant to the ATM Program at the prevailing market prices for a total net proceeds of $10,910 and paid total commissions of $337 to the Sales Agent.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Omnibus Incentive Plan and Stock-based Compensation Allocation</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;) provides for the grant of incentive options to employees of the Company, and for the grant of non-statutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#8217;s officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is 4,361,291 shares, plus an annual increase on each anniversary of November 21, 2017 equal to 4.0% of the total issued and outstanding shares of the Company&#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#8217;s Board of Directors). As of September 30, 2022, the Company had an aggregate of 1,447,855 shares of its common stock available for future issuance under the Plan.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Grants</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company&#8217;s Plan. Such grants were made pursuant to a stand-alone nonstatutory stock option agreement and a stand-alone RSU agreement, which were approved by the Compensation Committee of the Board of Directors. Any shares underlying the inducement grants are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance. </span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company granted options to purchase 171,103 shares of common stock and 39,012 RSUs as a material inducement for the employment of the Senior Vice President of Corporate Development. In September 2022, the Company granted options to purchase 169,158 shares of common stock and 36,443 RSUs as a material inducement for the employment of the Chief Financial Officer. As of September 30, 2022, stock options to purchase 340,261 shares of common stock and 75,455 RSUs remained outstanding outside of the Plan. </span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Award Activity and Balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options are granted at exercise prices based on the Company&#8217;s common stock price on the date of grant. The options and RSU grants generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzU1MQ_69856644-a55a-4627-8d51-4a7ed13cffd0">one</span>- to four-year period. There have been no awards granted with performance conditions or market conditions for the periods presented. The options have a contractual term of ten years. The fair value of options is estimated using the Black-Scholes option pricing model, which has various inputs, including the grant date common share price, exercise price, risk-free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#8217;s options as well as significantly impact its results of operations. The fair value of RSU grants is determined at the grant date based on the common share price. The Company records stock-based compensation expense net of actual forfeitures when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in determining the fair value of stock options granted were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:47.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.024%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the nine months ended September 30, 2022, is presented below:</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:47.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terms (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,922,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,098)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(602,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,932,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,860,912&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of outstanding and exercisable options represents the excess of the fair market value of the Company&#8217;s common stock over the exercise price of underlying options as of September 30, 2022 and December&#160;31, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the nine months ended September 30, 2022, is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"/><td style="width:57.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(553,328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401,656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.46&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense:</span></div><div style="margin-bottom:9pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,421&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641881031648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medytox/Allergan Settlement Agreements and Daewoong Arrangement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:10pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately $1,074. Certain minimum purchase commitments related to the purchase of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are described below.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Supply Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Agreement includes certain minimum annual purchases that the Company is required to make in order to maintain the exclusivity of the license. The Company may, however, meet these minimum purchase obligations by achieving certain market share in the licensed territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions. </span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16 and 28, 2020, two putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#8217;s acquisition of the right to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, three of its officers, and Alphaeon Corporation, the Company&#8217;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint. On February 10, 2022, Alphaeon Corporation served its motion to dismiss the amended complaint. Both motions were fully briefed on June 16, 2022. The outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2020 and December 2, 2020, two putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#8217;s officers </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-09986-PPG, and adjourned defendants&#8217; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#8217; stipulated stay of the consolidated derivative suit pending the court&#8217;s decision on the defendants&#8217; motion to dismiss the Securities Class Action.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Books and Records Demand</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#8217;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to the demand in December 2021. The outcome of this matter is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legal Matters</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, from time to time, involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. No amounts were accrued as of September 30, 2022 and December&#160;31, 2021.</span></div>Medytox/Allergan Settlement Agreements and Daewoong Arrangement<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medytox/Allergan Settlement Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Settlement Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company, Allergan and Medytox entered into a Settlement and License Agreement (the &#8220;U.S. Settlement Agreement&#8221;), pursuant to which, among other things: (i) Allergan and Medytox agreed to file a petition requesting the remedial orders related to the ITC Action be rescinded with respect to the Company; (ii) Medytox agreed to dismiss substantially similar litigation in California against the Company; (iii) the Company, on the one hand, and Medytox and Allergan, on the other hand, agreed to mutually release certain claims they may have against one another and their respective affiliates; (iv) Allergan and Medytox granted to the Company and its agents a license to manufacture and commercialize certain products identified in the U.S. Settlement Agreement, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Licensed Products&#8221;), in the United States during the 21 month period that, pursuant to the ITC Action, the Company was restricted from, among other things, selling, marketing, or promoting such imported Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States (the &#8220;Restricted Period&#8221;); (v) the Company agreed to pay to Allergan and Medytox $35,000 in multiple payments over two years, of which the Company paid the first cash payment of $15,000 in the third quarter of 2021 and the second cash payment of $15,000 in the first quarter of 2022; and (vi) during the Restricted Period, the Company agreed to pay to Allergan and Medytox certain confidential royalties on the sale of Licensed Products, calculated on dollar amount per vial sold of Licensed Products by or on behalf of the Company in the United States. Royalties for sales during the Restricted Period ended on September 16, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ROW Settlement Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#8220;ROW Settlement Agreement&#8221; and, together with the U.S. Settlement Agreement, the &#8220;Medytox/Allergan Settlement Agreements&#8221;), pursuant to which, among other things: (i) the Company and Medytox agreed to mutually release certain claims they may have against one another and their respective affiliates; (ii) Medytox granted to the Company and its agents a license to manufacture and commercialize the Licensed Products, in Canada, the European Union, Switzerland, member countries and cooperating countries of the European Economic Area, Russia, certain members of the Commonwealth of Independent States, South Africa, Australia and Japan (the &#8220;ROW Territories&#8221;) during the Restricted Period; (iii) Medytox granted to the Company and its agents a fully paid up license to manufacture and commercialize the Licensed Products in the ROW Territories and the United States from the end of the Restricted Period (the &#8220;Medytox License Period&#8221;); (iv) the Company and Medytox agreed to enter into the Share Issuance Agreement (as defined below) pursuant to which the Company issued 6,762,652 shares (the &#8220;Settlement Shares&#8221;) of the Company&#8217;s common stock, par value $0.00001 per share, to Medytox; (v) the Company and Medytox agreed to enter into the Registration Rights Agreement (as defined below), pursuant to which the Company granted certain registration rights to Medytox with respect to the Settlement Shares; (vi) during the Restricted Period that ended September 16, 2022, the Company agreed to pay Medytox a confidential low-double digit royalty on net sales of the Licensed Products sold by or on behalf of the Company in the ROW Territories; and (vii) during the Medytox License Period from September 17, 2022 to September 16, 2032, the Company agreed to pay Medytox a confidential mid-single digit royalty percentage on net sales of the Licensed Products sold by or on behalf of the Company in the United States and the ROW Territories.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share Issuance Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox entered into a Share Issuance Agreement effective February 18, 2021 (the &#8220;Share Issuance Agreement&#8221;). Pursuant to the Share Issuance Agreement and subject to the terms and conditions set forth therein, among other things, the Company issued to Medytox the Settlement Shares to enter into the ROW Settlement Agreement and in consideration for Medytox&#8217;s representations, warranties, and other agreements set forth in the Share Issuance Agreement. The Settlement Shares are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates, prevented Medytox from transferring any shares of common stock prior to February 16, 2022 and, thereafter, prohibit Medytox from transferring more than 25% of the shares it holds prior to September 16, 2023, more than 50% of the shares it holds prior to September 16, 2024 and more than 75% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Rights Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox also entered into a Registration Rights Agreement effective February 18, 2021 (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the Registration Rights Agreement, among other things, the Company agreed, after March 31, 2022, (i) to comply with certain requests by Medytox to register for sale, under the Securities Act, the Settlement Shares, and (ii) to include the Settlement Shares in certain registrations by the Company of its securities for sale under the Securities Act, to the extent requested by Medytox, in each case subject to certain customary conditions, exceptions and limitations as set forth in the Registration Rights Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Medytox&#8217;s registration rights under the Registration Rights Agreement will terminate at such time that Medytox is able to sell all of the Settlement Shares over a three-month period, or less, pursuant to an exemption to registration under the Securities Act.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company accrued $7,936 for royalties under the Medytox/Allergan Settlement Agreements and $5,000 of accrued litigation settlement expense. As of December&#160;31, 2021, the Company accrued $12,447 for royalties under the Medytox/Allergan Settlement Agreements and $20,000 of accrued litigation settlement expense. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daewoong Arrangement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Daewoong Settlement Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, the Company and Daewoong entered into a Confidential Settlement and Release Agreement (the &#8220;Daewoong Settlement Agreement&#8221;), pursuant to which, among other things: (i) Daewoong agreed to (a) pay to the Company an amount equal to $25,500, which the Company received in April 2021, (b) pay certain legal fees incurred by the Company&#8217;s litigation counsel in connection with its defense of the ITC Action (including any appeal of the resulting remedial orders), (c) cancel all remaining milestone payments totaling $10,500 in aggregate, and (d) reimburse the Company certain amounts (calculated on a dollar amount per vials sold basis in the United States) for sales of certain products with respect to which the Company is required to pay Medytox and Allergan royalties pursuant to the U.S. Settlement Agreement; and (ii) the Company agreed to (a) release, on behalf of itself and certain of its affiliates and representatives, certain claims they may have against Daewoong related to the allegations made in or the subject matter of the Medytox/Allergan Actions, or any orders, remedies and losses resulting from the Medytox/Allergan Actions, and (b) coordinate with Daewoong on certain matters related to the Medytox/Allergan Actions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conversion Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Daewoong Settlement Agreement, the Company and Daewoong also entered into a Convertible Promissory Note Conversion Agreement (the &#8220;Conversion Agreement&#8221;), pursuant to which, among other things, (i) the principal balance under the Daewoong Convertible Note, together with all accrued and unpaid interest thereon, in the amount of $40,779 was converted, at the conversion price of $13.00 per share, into 3,136,869 shares of Common Stock; and (ii) the Daewoong Convertible Note was deemed cancelled and satisfied in full in connection with such conversion.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the conversion, shares owned by Daewoong, together with its affiliates and attribution parties, did not exceed 9.99% of the Company&#8217;s then outstanding common shares immediately following such issuance, as required under the terms of the Daewoong Convertible Note.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Daewoong Agreement Amendment</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Daewoong Settlement Agreement, on March 23, 2021, the Company and Daewoong also entered into the Third Amendment to the Supply Agreement (the &#8220;Daewoong Agreement Amendment&#8221;). Pursuant to the Daewoong Agreement Amendment, the parties amended the Daewoong Agreement to (i) expand the territory within which the Company may distribute Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to certain countries in Europe, (ii) reduce the period of time with respect to which the Company is required to deliver binding forecasts to Daewoong, (iii) introduce certain limitations on Daewoong&#8217;s ability to convert the Company&#8217;s exclusive license for certain territories to a non-exclusive license in the event the Company fails to meet certain minimum purchase requirements for such territory, (iv) adjust the minimum purchase requirements and reduce the transfer price per vial of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> applicable to various territories, (v) require that any Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> supplied by Daewoong match certain shelf-life thresholds, and (vi) prohibit the Company from sharing certain confidential information of Daewoong with Medytox or its affiliates or representatives.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December&#160;31, 2021, the Company had $3,257 and $5,657, respectively, in reimbursement receivable from Daewoong, respectively, in other current assets in the accompanying condensed consolidated balance sheets. Total inventory payments to Daewoong were $14,238 and $40,509 for the three and nine months ended September 30, 2022, respectively. Total inventory payments to Daewoong were $10,916 and $24,576 for the three and nine months ended September 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641801245888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the annual financial statements and in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. Pursuant to these SEC rules and regulations, the Company has condensed or omitted certain financial information and disclosures normally included in annual financial statements prepared in accordance with GAAP. In the opinion of management, the interim </span></div>consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, considered necessary for a fair statement of the interim periods. The interim results presented herein are not necessarily indicative of the results of operations to be expected for the full year ending December&#160;31, 2022 or for any other interim period.The accompanying unaudited condensed consolidated financial statements and related disclosures should be read in conjunction with the financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on March 3, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly-owned subsidiaries, Evolus Pharma Limited, Evolus International Ltd. and Evolus Pharma BV, and have been prepared in conformity with GAAP. All intercompany transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements, inventory valuations and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#8217;s actual results could differ materially from those estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full impact of&#160;current global events, including rising inflation, volatility in the financial and credit markets, the COVID-19&#160;pandemic and the Ukrainian-Russian war, is unknown and cannot be reasonably estimated. However, where possible, management has considered the potential impact of rising inflation, volatility in the financial and credit markets, the COVID-19 pandemic, and the Ukrainian-Russian war, and their respective market impacts, on its estimates and assumptions, and there was not a material impact to the Company&#8217;s condensed consolidated financial statements as of and for the nine months ended September 30, 2022. The Company&#8217;s future assessment of the impact of these events, as well as other factors, could result in material impacts to the Company&#8217;s financial statements in future reporting periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties and Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (&#8220;Daewoong&#8221;) entered into an agreement (the &#8220;Daewoong Agreement&#8221;), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the United States in May 2019, in Canada through its distribution partner in October 2019, and in Great Britain in September 2022 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#8217;s business and its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve, and the severity and magnitude of future outbreaks, or other similar public health crises, could result in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets caused by these or other events, such as increased inflation and rising interest rates and the military conflict between Russia and Ukraine, may increase the Company&#8217;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#8217;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#8217; ability to pay.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it operates in a single operating and reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed consolidated statements of operations and comprehensive loss using the specific-identification method.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of finished goods h</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eld for sale and distribution. Cost is determined based on the estimated amount payable to the Company&#8217;s supplier after accounting for any reimbursement receivable pursuant to the Daewoong Settlement Agreement (as such term is defined, and such agreement is discussed, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), using the first-in, first-out method with prioritization of the items with the earliest expiration dates. Inventory valuation reser</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product cost of sales, excluding amortization of intangible assets, consisted of the inventory cost, and, for periods on or after December 16, 2020, included certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox and Allergan pursuant to the Medytox/Allergan Settlement Agreements (as such term is defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Settlement Agreement with respect to such royalties. In the nine months ended September 30, 2021, the Company recorded a one-time settlement payment of $25,500 from Daewoong in connection with the Daewoong Settlement Agreement as part of cost of sales.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</span></div><div style="margin-bottom:9pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately five years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it </span></div>would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has one reporting unit.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution right intangible asset related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of 20 years. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying condensed consolidated balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of two years upon being placed in service. </span></div>The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying condensed consolidated balance sheets. </span></div>Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the condensed consolidated balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingent Royalty Obligation Payable to Evolus Founders</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Royalty Obligation Payable to Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable </span></div>are determined at each reporting period end and recorded in operating expenses in the accompanying condensed consolidated statements of operations and comprehensive loss and as a liability in the condensed consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt represents the debt balance with Pharmakon (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), net of discount and issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated into U.S. dollars at current exchange rates as of balance sheet date, and income and expense items are translated into U.S. dollars using the average rates of exchange prevailing during the period. Gains and losses arising from translation are recorded in other comprehensive gain (loss) as a separate component of shareholders&#8217; equity. Foreign currency gains or losses on transactions denominated in a currency other than the Company&#8217;s functional currency are recorded in other expenses, net in the accompanying condensed consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates product revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Great Britain and service revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received. The Company recognized $684 and $1,366 of service revenues for the three and nine months ended September 30, 2022, respectively, and $0 and $702, respectively, of service revenues for the three and nine months ended September 30, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Revenue Adjustments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume-based rebates, consumer loyalty programs and co-branded marketing programs. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Volume-based Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Consumer Loyalty Program &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company launched a consumer loyalty program, which allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and redeem the rewards for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#8220;Reward&#8221;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on historical sales data, estimated average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of redemption, expected customer and consumer participation rates in the loyalty program, and estimated number of qualifying treatments to be performed by customers. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-Branded Marketing Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company offers eligible customers with a certain level of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#8217;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of September 30, 2022 and December&#160;31, 2021, all amounts included in accounts receivable, net on the accompanying condensed consolidated balance sheets are related to contracts with customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract assets nor unbilled receivables as of September 30, 2022 or December&#160;31, 2021. Sales commissions are included in selling, general and administrative expenses when incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and deferred revenue associated with Rewards under the consumer loyalty program and co-branded marketing programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December&#160;31, 2021, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program and co-branded marketing programs, were $10,188 and $7,934, respectively, which were recorded in accrued expenses in the accompanying condensed consolidated balance sheets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, the Company recognized $7,566 and $2,802, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collectability</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of September 30, 2022 and December&#160;31, 2021, allowance for doubtful accounts was $3,271 and $2,385, respectively. For the three and nine months ended September 30, 2022, reversal of and provision for bad debts were $623 and $1,363, respectively, and the write-off amount was $392 and $477, respectively. For the three and nine months ended September 30, 2021, provision for bad debts were $188 and $501, respectively, and the write-off amount was $23 and $214, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical Expedients</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-process Research and Development</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a License and Research Collaboration Agreement (the &#8220;Collaboration Agreement&#8221;) with a 3D printing company with biomaterial capabilities (the &#8220;Licensor&#8221;). Under the terms of the Collaboration Agreement, the Company was granted a license to the Licensor&#8217;s technology to develop and commercialize any aesthetic product or non-therapeutic product that is created through the use or practice of the Licensor&#8217;s patents. The Company paid $2,000 upon the signing of the Collaboration Agreement and has research funding, ongoing milestone and royalty payment obligations depending on the development plans, the success of such development and approval and commercialization of products. The upfront payment of $2,000 was recorded as in-process research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value on the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</span></div>The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the condensed consolidated balance sheets and in the selling, general and administrative or research and development expenses in the condensed consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies an estimated annual effective tax rate (&#8220;ETR&#8221;) approach for calculating a tax provision or benefit for interim periods, as required under GAAP.&#160;The Company recorded an income tax expense of $12 and $12 for the three months ended September 30, 2022 and 2021, respectively, and an income tax expense of $38 and $33 for the nine months ended September 30, 2022 and 2021, respectively.&#160;The Company&#8217;s ETR differs from the U.S. federal statutory tax rate of 21% for the three and nine months ended September 30, 2022 and 2021, primarily as a result of the impact of the change of the valuation allowance to offset its deferred tax assets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions.</span></div>The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect that changes to state tax laws through September 30, 2022 to materially impact its condensed consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. Excluded from the dilutive net loss per share computation for the three and nine months ended September 30, 2022 and 2021 were stock options of 4,932,632 and 3,873,352, respectively, and non-vested RSUs of 2,638,803 and 1,771,938, respectively, because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Issued But Not Adopted</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update will increase transparency of government assistance received by most business entities by requiring the disclosure of: (1) the types of transactions; (2) the accounting for the transactions; and, (3) the effect of the transactions on a business entity&#8217;s financial statements. ASU No. 2021-10 is effective for financial statements issued for annual periods beginning after December 15, 2021, with early application permitted. The Company has adopted this guidance on the effective date of January 1, 2022. There are no material impacts to the condensed consolidated financial statements as a result of this adoption.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Issued But Not Adopted</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU No. 2016-13, the FASB issued ASU No. 2018-19,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU does not change the core principle of the guidance in ASU No. 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04 which did not change the core principle of the guidance in ASU No. 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January 1, 2023. The Company is in the process of determining the effects the adoption will have on its consolidated financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the consolidated financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in January 2021, the FASB issued ASU No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope (&#8220;ASU 2021-01&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Both ASU No. 2020-04 and ASU No. 2021-01 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued because of reference rate reform. ASU No. 2020-04 and ASU No. 2021-01 are effective upon issuance for contract modifications and hedging relationships, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company does not expect adoption of this guidance will have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641877444784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text">The fair value of these instruments was as follows:<div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:47.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:47.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Financial Instruments Recorded at Fair Value on a Recurring Basis</a></td>
<td class="text">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.452%"><tr><td style="width:1.0%"/><td style="width:44.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recorded in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641881105408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:40.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.891%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,220)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,108&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,536&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,220)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:40.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.891%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,390&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*  Intangible assets with indefinite lives have an indeterminable average life.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;September 30, 2022 that are subject to amortization:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:71.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.173%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining in 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641881005088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"/><td style="width:57.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties under the Medytox/Allergan Settlement Agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued revenue contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641880940416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text">As of September 30, 2022, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.299%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net of discounts and issuance costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,712&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641873371632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Composition of Lease Expense and Other Quantitative Information</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.690%"><tr><td style="width:1.0%"/><td style="width:41.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.940%"><tr><td style="width:1.0%"/><td style="width:72.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.897%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.440%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of September 30, 2022:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:68.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,798&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641877456192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in determining the fair value of stock options granted were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:47.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.024%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the nine months ended September 30, 2022, is presented below:</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:47.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terms (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,922,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,098)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(602,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,932,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,860,912&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the nine months ended September 30, 2022, is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"/><td style="width:57.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(553,328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401,656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.46&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense Allocation</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense:</span></div><div style="margin-bottom:9pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,421&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641872935376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 14, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20,276,000)<span></span>
</td>
<td class="num">$ (23,471,000)<span></span>
</td>
<td class="num">$ (17,501,000)<span></span>
</td>
<td class="num">$ (19,433,000)<span></span>
</td>
<td class="num">$ (15,601,000)<span></span>
</td>
<td class="nump">$ 6,401,000<span></span>
</td>
<td class="num">$ (61,248,000)<span></span>
</td>
<td class="num">$ (28,633,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,138,000<span></span>
</td>
<td class="nump">24,344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_IncreaseDecreaseInAccruedLitigationSettlement', window );">Accrued litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000,000)<span></span>
</td>
<td class="num">$ (15,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 146,256,000<span></span>
</td>
<td class="nump">65,572,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,572,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">422,882,000<span></span>
</td>
<td class="nump">$ 484,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 484,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember', window );">Pharmakon Term Loans | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of secured debt</a></td>
<td class="nump">68,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember', window );">Tranche B Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IncreaseDecreaseInAccruedLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IncreaseDecreaseInAccruedLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641802355168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 18, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Settlement payment from Daewoong</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,899,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,677,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,970,000<span></span>
</td>
<td class="nump">65,016,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Accrued revenue contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,934,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer liability revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,566,000<span></span>
</td>
<td class="nump">2,802,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,385,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit loss expense (reversal)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(623,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363,000<span></span>
</td>
<td class="nump">501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Accounts receivable, writeoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveNoncurrent', window );">Accrued litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,932,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,873,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,932,632<span></span>
</td>
<td class="nump">3,873,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,638,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,771,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,638,803<span></span>
</td>
<td class="nump">1,771,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement', window );">Issuance of common stock in connection with litigation settlement (in shares) | shares</a></td>
<td class="nump">6,762,652<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember', window );">Intellectual Property Disputes, Jeuveau</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LossContingencySettlementAgreementPaymentTerms', window );">Settlement agreement, payment terms (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss contingency accrual, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,366,000<span></span>
</td>
<td class="nump">$ 702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Accounting Policies [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LossContingencySettlementAgreementPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreement, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LossContingencySettlementAgreementPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641879062320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Assets and Liabilities on a Recurring Basis (Details) - Contingent royalty obligation payable to Evolus Founders - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 45,517<span></span>
</td>
<td class="nump">$ 44,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 45,517<span></span>
</td>
<td class="nump">$ 44,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641876862752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 45,517<span></span>
</td>
<td class="nump">$ 45,415<span></span>
</td>
<td class="nump">$ 44,740<span></span>
</td>
<td class="nump">$ 43,300<span></span>
</td>
<td class="nump">$ 42,683<span></span>
</td>
<td class="nump">$ 41,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Pharmakon Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 70,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641872997824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Contingent Royalty Obligation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="nump">$ 45,415<span></span>
</td>
<td class="nump">$ 42,683<span></span>
</td>
<td class="nump">$ 44,740<span></span>
</td>
<td class="nump">$ 41,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(1,114)<span></span>
</td>
<td class="num">(783)<span></span>
</td>
<td class="num">(3,169)<span></span>
</td>
<td class="num">(2,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recorded in operating expenses</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">3,946<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of period</a></td>
<td class="nump">$ 45,517<span></span>
</td>
<td class="nump">$ 43,300<span></span>
</td>
<td class="nump">$ 45,517<span></span>
</td>
<td class="nump">$ 43,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641798763536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="nump">$ 67,328<span></span>
</td>
<td class="nump">$ 66,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(18,220)<span></span>
</td>
<td class="num">(15,765)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">49,108<span></span>
</td>
<td class="nump">50,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_IntangibleAssetsGrossIncludingGoodwill', window );">Intangible assets, gross (including goodwill)</a></td>
<td class="nump">88,536<span></span>
</td>
<td class="nump">87,598<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Net book value</a></td>
<td class="nump">$ 70,316<span></span>
</td>
<td class="nump">$ 71,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Life (Years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="nump">$ 59,076<span></span>
</td>
<td class="nump">$ 59,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(10,806)<span></span>
</td>
<td class="num">(8,589)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 48,270<span></span>
</td>
<td class="nump">$ 50,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Life (Years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="nump">$ 8,252<span></span>
</td>
<td class="nump">$ 7,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(7,414)<span></span>
</td>
<td class="num">(7,176)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IntangibleAssetsGrossIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Gross (Including Goodwill)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IntangibleAssetsGrossIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641877555408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Future Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remaining in 2022</a></td>
<td class="nump">$ 859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">3,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">3,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">2,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">2,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour', window );">Thereafter</a></td>
<td class="nump">35,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 49,108<span></span>
</td>
<td class="nump">$ 50,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets Amortization Expense After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641876870576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Asset - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">Capitalized computer software</a></td>
<td class="nump">$ 531<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">$ 2,454<span></span>
</td>
<td class="nump">$ 4,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember', window );">Evolus, Inc. | SCH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements', window );">Extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_MilestonePaymentsForIntangibleAssets', window );">Milestone payments for intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentsForIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments For Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentsForIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641878827664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties under the Medytox/Allergan Settlement Agreements</a></td>
<td class="nump">$ 7,936<span></span>
</td>
<td class="nump">$ 12,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related benefits</a></td>
<td class="nump">7,094<span></span>
</td>
<td class="nump">6,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Accrued revenue contract liabilities</a></td>
<td class="nump">10,188<span></span>
</td>
<td class="nump">7,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">4,665<span></span>
</td>
<td class="nump">2,756<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities, current</a></td>
<td class="nump">$ 29,883<span></span>
</td>
<td class="nump">$ 29,993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641800238768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loans - Pharmakon Term Loans (Details) - Secured Debt<br></strong></div></th>
<th class="th">
<div>Dec. 14, 2021 </div>
<div>USD ($) </div>
<div>payment </div>
<div>tranche</div>
</th>
<th class="th"><div>Mar. 15, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentAmountThreshold', window );">Prepayment amount threshold</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember', window );">Pharmakon Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal', window );">Number of periodic payments | payment</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="nump">$ 3,042,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember', window );">Pharmakon Term Loans | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod', window );">Anniversary period</a></td>
<td class="text">39 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Term One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount', window );">Debt instrument, percentage of principal amount, prepaid multiplied</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Term Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount', window );">Debt instrument, percentage of principal amount, prepaid multiplied</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Term Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount', window );">Debt instrument, percentage of principal amount, prepaid multiplied</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember', window );">Tranche B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Periodic Payments, Principal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Payment Commencement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentTermsAxis=eols_TermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentTermsAxis=eols_TermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentTermsAxis=eols_TermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentTermsAxis=eols_TermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentTermsAxis=eols_TermThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentTermsAxis=eols_TermThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641877869456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loans - Maturities of Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LongTermDebtMaturityAfterYearFour', window );">Thereafter</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal payments</a></td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discounts and issuance costs</a></td>
<td class="num">(3,288)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt, net of discounts and issuance costs</a></td>
<td class="nump">$ 71,712<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641798865600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loans - Oxford Term Loans (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 15, 2019 </div>
<div>USD ($) </div>
<div>advance</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 968,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember', window );">Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment', window );">Percentage of final payment of full principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageYearTwo', window );">Prepayment fee percentage, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageThereafter', window );">Prepayment fee percentage, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityMember', window );">Oxford Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of long-term lines of credit</a></td>
<td class="nump">$ 76,447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentFeeAmountWaived', window );">Debt instrument fee amount comprised</a></td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentOfFinalPaymentAmountWaived', window );">Debt instrument of principal amount payment</a></td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeeAmountWaived', window );">Debt instrument prepayment fee amount</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,939,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Contingent promissory note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LineofCreditFacilityNumberofAdvances', window );">Number of advances | advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPeriodOfInterestOnlyPayments', window );">Period of interest only payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | First tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Contingent promissory note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Contingent promissory note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amortization Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentFeeAmountWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Fee Amount Waived</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentFeeAmountWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentOfFinalPaymentAmountWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Of Final Payment Amount Waived</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentOfFinalPaymentAmountWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Percentage Of Principal Amount, Balloon Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPeriodOfInterestOnlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Period Of Interest Only Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPeriodOfInterestOnlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeeAmountWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Prepayment Fee Amount, Waived</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeeAmountWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LineofCreditFacilityNumberofAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Number of Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LineofCreditFacilityNumberofAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_OxfordTermLoanFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641877628192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Daewoong Convertible Note (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 23, 2021 </div>
<div>USD ($) </div>
<div>position </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 06, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) from extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (968,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) from extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 971,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Conversion of common shares (in shares)</a></td>
<td class="nump">3,136,869<span></span>
</td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641880233856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LesseeOperatingLeaseTerminationPeriod', window );">Termination period</a></td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate', window );">Period of written notice</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent', window );">Period of termination fee prior to lease termination date</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">60 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641879902144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed operating lease expense</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable operating lease expense</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost</a></td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">$ 876<span></span>
</td>
<td class="nump">$ 837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641879799008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of Weighted-Average Remaining Lease Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate (in percent)</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641880220480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Operating Lease Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">3,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 2,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641879023712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 02, 2020 </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Oct. 28, 2020 </div>
<div>complaint</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,074,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, new claims filed, number | complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss contingency, number of plaintiffs | plaintiff</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641798160032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 23, 2021 </div>
<div>position</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 18, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,183,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,183,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,183,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,576,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,183,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,183,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,183,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,576,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the incentive equity plan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 644<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,361,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase percentage of maximum shares outstanding (equal to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,447,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,447,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,447,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,932,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,932,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,932,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,638,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,638,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,638,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,158<span></span>
</td>
<td class="nump">171,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,665,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,922,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 2 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,443<span></span>
</td>
<td class="nump">39,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,926,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsMarketConditionsMember', window );">RSUs Market Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsPerformanceConditionsMember', window );">RSUs Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember', window );">ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_SaleOfStockMaximumConsiderationReceivable', window );">Maximum consideration receivable | $</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage', window );">Sale of stock, commission payment upon gross proceeds</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the incentive equity plan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,203<span></span>
</td>
<td class="nump">$ 2,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_SaleOfStockCommissionPaid', window );">Total commission | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,183,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,183,414<span></span>
</td>
<td class="nump">56,063,413<span></span>
</td>
<td class="nump">56,041,364<span></span>
</td>
<td class="nump">55,553,792<span></span>
</td>
<td class="nump">54,372,792<span></span>
</td>
<td class="nump">43,736,971<span></span>
</td>
<td class="nump">56,183,414<span></span>
</td>
<td class="nump">55,553,792<span></span>
</td>
<td class="nump">55,576,988<span></span>
</td>
<td class="nump">33,749,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement', window );">Issuance of common stock in connection with litigation settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,001<span></span>
</td>
<td class="nump">22,049<span></span>
</td>
<td class="nump">464,376<span></span>
</td>
<td class="nump">456,165<span></span>
</td>
<td class="nump">76,289<span></span>
</td>
<td class="nump">88,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724,835<span></span>
</td>
<td class="nump">209,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Daewoong Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Conversion of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,136,869<span></span>
</td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the incentive equity plan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 644<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid In Capital | ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with the incentive equity plan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,203<span></span>
</td>
<td class="nump">$ 2,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SaleOfStockCommissionPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SaleOfStockCommissionPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SaleOfStockMaximumConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SaleOfStockMaximumConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsMarketConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsMarketConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsPerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsPerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641877937264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Valuation Assumptions (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">83.80%<span></span>
</td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">78.60%<span></span>
</td>
<td class="nump">78.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="nump">1.12%<span></span>
</td>
<td class="nump">1.92%<span></span>
</td>
<td class="nump">1.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 2 months 8 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641877974400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">4,932,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,932,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,922,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">169,158<span></span>
</td>
<td class="nump">171,103<span></span>
</td>
<td class="nump">1,665,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(602,342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">340,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,261<span></span>
</td>
<td class="nump">3,922,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable (in shares)</a></td>
<td class="nump">2,860,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,860,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 9.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.37<span></span>
</td>
<td class="nump">$ 11.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">$ 10.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 2 months 23 days<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable', window );">Weighted Average Remaining Contractual Term , Exercisable (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 4,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,245<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 1,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641798865600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Restricted Stock Unit (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,638,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,638,803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,926,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">36,443<span></span>
</td>
<td class="nump">39,012<span></span>
</td>
<td class="nump">1,667,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(553,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(401,656)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">75,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 7.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641880001184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity - Stock-based Compensation Expense Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="nump">$ 2,483<span></span>
</td>
<td class="nump">$ 2,476<span></span>
</td>
<td class="nump">$ 8,421<span></span>
</td>
<td class="nump">$ 6,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="nump">2,398<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">8,236<span></span>
</td>
<td class="nump">6,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140641875643040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 23, 2021 </div>
<div>USD ($) </div>
<div>position </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 18, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 15, 2025</div></th>
<th class="th"><div>Sep. 15, 2024</div></th>
<th class="th"><div>Sep. 15, 2023</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_RegistrationRightsAgreementSellingPeriod', window );">Registration rights agreement, selling period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties under the Medytox/Allergan Settlement Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Accrued litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Consideration receivable from Daewoong</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_PaymentsForInventory', window );">Inventory payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,916,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,509,000<span></span>
</td>
<td class="nump">$ 24,576,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongSettlementAgreementMember', window );">Daewoong Settlement Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term purchase commitment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_MilestonePaymentInConnectionWithAgreement', window );">Contingent milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember', window );">Daewoong Convertible Note | Convertible Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned', window );">Common stock shares beneficially own percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear', window );">Share issuance agreement, percentage of share dispose per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement', window );">Issuance of common stock in connection with litigation settlement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Daewoong Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Conversion of common shares (in shares)</a></td>
<td class="nump">3,136,869<span></span>
</td>
<td class="nump">3,136,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember', window );">Intellectual Property Disputes, Jeuveau</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LossContingencySettlementAgreementPaymentTerms', window );">Settlement agreement, payment terms (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Percentage of Shares Beneficially Owned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LossContingencySettlementAgreementPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreement, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LossContingencySettlementAgreementPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentInConnectionWithAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment In Connection With Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentInConnectionWithAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_PaymentsForInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_PaymentsForInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RegistrationRightsAgreementSellingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registration Rights Agreement, Selling Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RegistrationRightsAgreementSellingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Issuance Agreement, Percentage of Share Dispose Per Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_DaewoongSettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_DaewoongSettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_DaewoongConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>eols-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:eols="http://www.evolus.com/20220930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="eols-20220930.xsd" xlink:type="simple"/>
    <context id="i5d4379a4158c443fab6596315f543818_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i39ff6d4019914c7fb0f58a9c69af0da7_I20221104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if255f3612ce24011914ed9f9fc5283c0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i67b0a77f15c444c19f759b3deaef409d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibd30dda6fae047ba8fc0f4931c1cf694_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie045c20cf6bc4a46bc1cd1a0cb076bd5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i22f3e32c1ab94b0382fce87da10b1f25_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i519de1da8eb84a708ab6875c547d1cb9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib7a96d1a07754c188b0a005f18255480_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i57cb5111d30d40a68b4e495a42bac87d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i325d14c124e140b2af640417dd708743_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i19b70069ec2b4bc88563acac780cb0fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie933be957e064dbf9e19c7a328a5a3a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icec2119209b14768b574684aa088fd0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbfa32b8bceb4d85b8d585d6362e9ead_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d107be2e3b249e3a47304c93fca1cf8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b2a587e790f4e898dff40a08b249f56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9ad3bd07da14e6e91626d72417cbd26_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i14697910a2c7431d8e843fa9e6047c3f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i089a8fa6f6594b3f9738d50bda403e59_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2d310130bd084da3ac0de405205ba752_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if2006f8ecb5641f4ace06a537399080a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i322856dfc9674ae588e828493d27d95e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia31b6cb915184194bff3d93618626fd2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i111481324b7843119d6ff1bdabd0d80a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1769ef3b028f40ceb603ef14511541b8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7727dfd31c3944fab9afd583ea30a2d7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i29999457232e44aeb12a5ace34004e44_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i29512e75fcde470fa4dc860e639a878e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5492be0135c14a0aa71f49ae2531d9a3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i173b74f14d1d431b99aed7270421b1ec_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib97a0827a3aa4c1e87cc2994ec2eedf5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic5af4588f76d4ab8bd0886c2f0f3080f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i65e3e596ba3f464aad3607fcd5ad2218_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i490de831fccb414783dc72487430e05b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4e4cc38409b74c9b8c6c73ff0a0b3ddc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if314cfb6f75348ed94b97148ad316c5d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i96c5b48b38fc4cd6814bfde2d6a09765_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iddd953d7c6a94c3a9fbeca055456caca_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i15763c0703af45cbaf1faa81f158530e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic940384570964e689ab795df4e66ccb7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i13db4b6383624d5097720364e94a31b5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8c628e554673429f919660de503a710e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide79544f24324f7b8502d4f715dcf188_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia80760aeda834165a0bd09ccfcabfa32_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i48b21d372773402dbf5d667fe310b72b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ideffba28e2bf412cb0e77892da2aa722_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2512c22190594595845dd6dc9d382f8b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7b5a39a32eeb4cab9368027d10b64144_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9e42c0d2b5a8488e921290035592036a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic5cb60ec41f240cdbd130979758bbe33_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8398583e0d2541f0ad8db5defad16243_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifbb65d439c414edbb7040d29388dad05_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i458f436d90584702b2e171f24fc2ffd9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i54b5f0ef22bf4fa9839716763e9e8209_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2d7f6a0cb1b497cbfc385cc704bccf2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1fddad6db8d4551816b8c9aecd79504_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b12284fc5ce4b21a29b45a18ae68685_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff586361777d462b9327912ebb0fdc8c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41a3e5c8a1c94c8488ef9e164b01e0cf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0566f63895a44386a854828b2eacdf90_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic3a862462206439c8bc023adde6f54e2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib29835257f2c4dd18c50418dd8adfee9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5c84c79944be420fb608efbdf8406369_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id470dada4c0e4d9f9665fcb85a0e6d32_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic2398dc3c9da43c4ac481b18ad745499_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i47b462307ce144bc832c08ae7d8df5c1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4b7351c853c140558b8a86c3ba8db24b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaf8b55b81fd54639927f832aefd0c105_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i85c698504400444cad7bd76a594cae6a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i38daf97bf6b54a5d9f36afcbc66faad1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibe0af0b6fdac41d79d91b5cfebd2f064_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie7690b2a3bee42b0adbdb700c288530e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i483c0c81c82a4127a108474382234dae_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia70412995ddc4b699370638e386fbd7d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0a4f256b4cc8459bacffb1ecf8154425_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i986ed2aacf8249efa66cfd1e39a120f5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i711c0ec8101d43c2bf551aec2015fe93_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i517b67724cfa4e4a9a9d6760c1b208ba_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie47683c6c9bd447d932d1f3f3b371104_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i41fd4a2cf7cb49e6a38c2fc9b0df76fd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i696aed9396534e69a8f395b92916dbb8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i86e69b86a1f34f1f860a8d0303c3f93a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icb5cba7d4b31433baac45503a471e4ed_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2d9bfad2231c4ef9be095f3e3afb8838_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibaff2091727e4bbda42ae97fb2c0ca83_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0eda81fe6f4443b3840b17e1ed17844d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i67e38e0bc0df4e4d88a289133b9464f5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i81ca472192774250bc53a843ace80459_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i68b52e5c01fb45b685329d95b6300084_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i19e324736d7a4b58bee7bebe0815ab9a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0788351e9e084ee681884fb575fce218_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a3343570b8b4e2da7fe85c347c87365_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id4b79303cf634cad95d0ba5d12c163ef_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i87e2257ed337439eaac012b86d0a396b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ee94ea6704b4637b072dc991661fa7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf185154c94a4f079a63adb078d887d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafb5504b024a49c98e5b98f03ed55642_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74d2705a944e47df928e202fbe73806f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icd37f700914349598839f80a5c3ac5fc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i39e0aaab2daf4a1f9ae49292e3fa113f_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7982c1b9a3ab4239b877aa1d02a5459e_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i1f6eead0dce949398cd5a205a8b761a2_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="id23cfd7dc1564cd6aaa76f53b45ccf4f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0997749416bc4e028361e395d1f8bf92_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic6fd11493b9d4a18967f5147f5eb25fc_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ie6f902c0f3cf4c5f86905379573f1883_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i84371b8801da47da9efba13175f076d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if066a834ef404c0da380ab9066a249ab_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ifd893c426cf344bfb3e70e80a9717b85_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaa3b589eceb84e1c94c3c2c4af20ab72_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib29f2936ca6c4e15a73ecfb1e92029f6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8813e5b8a70741dc843401ec024d4735_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib956a75826f1489e9a25f9ab19425726_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i107ea59f6dc34340846131488239195e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic4b9df72617243df82a84ee6f7a17e88_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i33badbda974443e1a5a538c1d41eb1f2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6de66ce7e4cd487684e1ec075b96e8c2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib955eea1a8f64090909d07cf0f04a443_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibc3b4cc897fe4b31821dca208a7264a5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iead433642b5a445d83074f84bb63c628_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i03eb03f09bcf4e01b9c6fba2243bb8aa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i46b9d9f3ec3d401cab72265246433b66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11377a43f27c4faba7aad6793f724743_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8509a6d0797e4a1b8fd1d32a15d74377_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84d7dc8ca08a4da6a6c642d9a973ff92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7373271b2dde4aba839209bce8d0292e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib746515f688d46d7934e1ac056024bba_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i74ba879b9f0b49eeb45d7c48810743cf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iefccff05ba3b424ea7695cd478bcf8c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d5a4bd9076b49e990faeaca86303ea1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7b7b2f262aa04bfebf9a790343dc73ff_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d84afa1250640b198c1fb1a6169c85a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieab10e4bb85e456c8270ad88c92f573a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a097741d79a4319ba97c97d46d0a539_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1eae918cd3a1458f8f5c7ea81225a697_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i492a93cfde634638aead055c0ca3b153_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8be82e572d441889a4d6f6934c06888_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic324d34859d240ffa67a43c66f937f95_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i87008557f7394da183cb13535fff98b5_I20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="i9f70375f5d4e414ba6839f26fe0ddc44_I20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="i681b2a7d205d410ca672bf2a337a55b0_I20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="ie655358ab82b4cf3933d54db2925cf4b_D20211214-20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-14</startDate>
            <endDate>2021-12-14</endDate>
        </period>
    </context>
    <context id="i0931e5250f9643efa1a3ac8af4f22859_D20211214-20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-14</startDate>
            <endDate>2021-12-14</endDate>
        </period>
    </context>
    <context id="id0259e20c7b64238ace67075cd4ebde3_D20211214-20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-14</startDate>
            <endDate>2021-12-14</endDate>
        </period>
    </context>
    <context id="ibb4a33cd285f450c9199ba56c40498b4_I20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="id39eaeea68ce4b2b873c2e7097ffad4f_I20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="idb4fee43c2d44ee2b2e15ef341def13b_I20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="i3bfea5e3671f467c9abe90444ff80e16_I20211214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="i12401c3106e141e3932d964c36466a9c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i32423b3783a74a82a50b52069242757e_I20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-15</instant>
        </period>
    </context>
    <context id="iba0b2ad793844b26a191ac3cd34f31f2_I20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-15</instant>
        </period>
    </context>
    <context id="ie6b945adff8f46008df2b4591b66e2fe_I20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoanFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-15</instant>
        </period>
    </context>
    <context id="i9de13a38f24141ecadd52a63c397047d_D20190315-20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-15</startDate>
            <endDate>2019-03-15</endDate>
        </period>
    </context>
    <context id="ia0f2553d528c41c3ab5ae3858f5fda13_D20190315-20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-15</startDate>
            <endDate>2019-03-15</endDate>
        </period>
    </context>
    <context id="i4d21558b1b844fea9ffd52152f5a0b6d_I20190315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-15</instant>
        </period>
    </context>
    <context id="i2ea01d8678a148839f20dd947155b9a2_D20210104-20210104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="i9984dc72d84a433bbbf2c8e4297d8ab3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifcabd9d8120a4b52ad4211b9b2779160_I20200706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-06</instant>
        </period>
    </context>
    <context id="ibfb737bacd0248fc910875d3a4549e77_I20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-23</instant>
        </period>
    </context>
    <context id="i4504c78963354d1badb28c7c64e116ec_D20210323-20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="i671a3057546c42ba9908a766f27874d3_D20210323-20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="i2b2b0c3bea3a4f22ae04d9279885dafc_D20201016-20201028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2020-10-16</startDate>
            <endDate>2020-10-28</endDate>
        </period>
    </context>
    <context id="id4a4bebb895c49d0bbdd0bf38322e752_D20201127-20201202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2020-11-27</startDate>
            <endDate>2020-12-02</endDate>
        </period>
    </context>
    <context id="i32d51cd4bd6f4489a4adb7b2aa247e44_D20210228-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-28</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ic8fb36cf68884af1a7d8744f3d77a5ba_D20210325-20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="ia933b0ab944743ada651aa08e01c3fa0_D20210326-20210326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="ib05b2ea5b15449b3949c409f13302aba_I20210326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="i39845926fd4c4a7185d0ad1aec0a9125_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id8d569b52d5c4b558d7fce708c55c3d1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic5451817e64c44dda2476fee6acbac53_I20171121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2017-11-21</instant>
        </period>
    </context>
    <context id="ie5823e0351234f7f9b1f20c5fe18cbe0_D20171121-20171121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2017-11-21</startDate>
            <endDate>2017-11-21</endDate>
        </period>
    </context>
    <context id="i47a9787376af49c4af38a5bd745283ea_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i848b50e6e7d3430995e3db062f15f819_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="iaa10e78f3b4c4e968e52a77f68b4440f_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i239833aec97149198fa33cf47989aa8d_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0bc7da1566164597b0db01be97552e79_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5f7d73b878d64950a8425ead93d94a97_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iee5500851309496fb43072fa4dccbd43_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i01ed1c49defa42e594f5fe2cb8f08e35_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib0fe33cc353c4425a6f61687288e7219_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsMarketConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i39b3ec4c69b340288a1cd5b5320c3f95_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie3807d087dad4368af0d30e4e6ea552b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8fd6507cc4bd4d85bca970b83ba305bb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib6a44426e14f4cf68658b6c28359fe8f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i61c0058713f24095b11a013badcef8e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b27e8a6feca4241b642ac4baf127f19_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8faa1fb37e374acb85de383e56577e09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0ba6f3c5b4314563a0f6c2b8e9485876_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0df63e74062b463990c0a0996e88bf4d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7000885be6d948baa6c2a16a20a9b3d0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if5753737be3a4d78816715ef5956b5f1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide927851f3d44d388940de49dc572cbc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibab36228520640d2af7899d4d89c4119_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i16951a5be9bf4007b7826543c19fc57c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie70ba7a39fbf47b5ba3502a70a32b3cf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1894854da2af42638a40edaec631c6a8_I20210218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-18</instant>
        </period>
    </context>
    <context id="i748d6131bd954dc9aa10faa24cb00d27_D20210218-20210218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-18</startDate>
            <endDate>2021-02-18</endDate>
        </period>
    </context>
    <context id="i5d8448ecaa3a48df85d5889b9d36144b_D20210218-20210218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-18</startDate>
            <endDate>2021-02-18</endDate>
        </period>
    </context>
    <context id="ia1bd190fdbab49dabebbb80e51c1f276_I20230915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-15</instant>
        </period>
    </context>
    <context id="i97e475107c9e4c7997018cc44ab1d86f_I20240915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-15</instant>
        </period>
    </context>
    <context id="ia06093115e034c0794719bee09423007_I20250915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-15</instant>
        </period>
    </context>
    <context id="ib6c9bed41b124f498f1b2cccdadacc84_D20210218-20210218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2021-02-18</startDate>
            <endDate>2021-02-18</endDate>
        </period>
    </context>
    <context id="ie66d630b4d65447f8c7f52dd587c90cc_D20210323-20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="i3389f3c7fed74caf844e5cc2688cd6f0_D20210323-20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:DaewoongConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="reporting_unit">
        <measure>eols:reporting_unit</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tranche">
        <measure>eols:tranche</measure>
    </unit>
    <unit id="payment">
        <measure>eols:payment</measure>
    </unit>
    <unit id="advance">
        <measure>eols:advance</measure>
    </unit>
    <unit id="position">
        <measure>eols:position</measure>
    </unit>
    <unit id="complaint">
        <measure>eols:complaint</measure>
    </unit>
    <unit id="plaintiff">
        <measure>eols:plaintiff</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80L2ZyYWc6YWE0ZmM3OWI5NTZjNGY0NDkyMTY5MzAzNmUyZWY5NmEvdGFibGU6YjQ2NDQyZGYxOWRkNDRjM2FkYmM1MDFkNTYzN2FmNDcvdGFibGVyYW5nZTpiNDY0NDJkZjE5ZGQ0NGMzYWRiYzUwMWQ1NjM3YWY0N18xLTEtMS0xLTY2MzUx_e1d73f59-b7c5-4d27-b0cc-9730a4aa9eb4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80L2ZyYWc6YWE0ZmM3OWI5NTZjNGY0NDkyMTY5MzAzNmUyZWY5NmEvdGFibGU6YjQ2NDQyZGYxOWRkNDRjM2FkYmM1MDFkNTYzN2FmNDcvdGFibGVyYW5nZTpiNDY0NDJkZjE5ZGQ0NGMzYWRiYzUwMWQ1NjM3YWY0N180LTEtMS0xLTY2MzUx_a378f7ab-421e-44e9-8aef-1f880b97d0e4">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80L2ZyYWc6YWE0ZmM3OWI5NTZjNGY0NDkyMTY5MzAzNmUyZWY5NmEvdGFibGU6YjQ2NDQyZGYxOWRkNDRjM2FkYmM1MDFkNTYzN2FmNDcvdGFibGVyYW5nZTpiNDY0NDJkZjE5ZGQ0NGMzYWRiYzUwMWQ1NjM3YWY0N181LTEtMS0xLTY2MzUx_51ddc4a4-406d-4555-856c-9a3921b2dd44">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80L2ZyYWc6YWE0ZmM3OWI5NTZjNGY0NDkyMTY5MzAzNmUyZWY5NmEvdGFibGU6YjQ2NDQyZGYxOWRkNDRjM2FkYmM1MDFkNTYzN2FmNDcvdGFibGVyYW5nZTpiNDY0NDJkZjE5ZGQ0NGMzYWRiYzUwMWQ1NjM3YWY0N182LTEtMS0xLTY2MzUx_3cdb1727-e765-4202-a440-bc34670feb2b">0001570562</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80L2ZyYWc6YWE0ZmM3OWI5NTZjNGY0NDkyMTY5MzAzNmUyZWY5NmEvdGV4dHJlZ2lvbjphYTRmYzc5Yjk1NmM0ZjQ0OTIxNjkzMDM2ZTJlZjk2YV8zNA_0fef1358-277b-440c-b76a-b15049c3c961">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0wLTEtMS02NjM1MQ_10a43e2f-3e60-477c-96dd-c813c9ca153a">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0wLTEtMS02NjM1MQ_41cadcf3-4b1a-47e7-9c8e-6ea6514114cf">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0wLTEtMS02NjM1MQ_42d06fef-136c-4320-8d1b-5576fedb6eb4">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0wLTEtMS02NjM1MQ_d46a4bb0-fbe7-47e2-be47-adc7a74bafa6">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iee5500851309496fb43072fa4dccbd43_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzU1MQ_69856644-a55a-4627-8d51-4a7ed13cffd0">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzIy_25453bf5-8126-4906-a1b6-c1a5b3790fc0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzIw_40a4a3e8-3a82-4489-8b92-05977454fbb8">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8zNTY_d2380ef6-695b-456a-afcf-bd9799555b91">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzI0_2b3ed0e4-011b-4b7c-930d-d499348ceae3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzE4_43d58ba5-9313-4031-a255-e5ea7a8627cd">001-38381</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzI1_6461d4e2-7a13-4034-98e8-45015344c2db">EVOLUS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV8wLTEtMS0xLTY2MzUx_57ff5b9c-bd95-4ad2-973a-d1ffe9787be8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV8wLTUtMS0xLTY2MzUx_474a1b89-2c4f-4a84-81d8-af78fafcc041">46-1385614</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV8zLTEtMS0xLTY2MzUxL3RleHRyZWdpb246OWJlOTY1MDc5ZjMxNDczNmIyZDNhYzI5YzFmNzgxMTlfNA_b57e4c30-5d86-4276-8ec7-e8707fbf2cf8">520 Newport Center Drive Suite 1200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV8zLTEtMS0xLTY2MzUxL3RleHRyZWdpb246OWJlOTY1MDc5ZjMxNDczNmIyZDNhYzI5YzFmNzgxMTlfNw_10cf0663-dcaf-49f9-b241-7c67fd0609b8">Newport Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV8zLTEtMS0xLTY2MzUxL3RleHRyZWdpb246OWJlOTY1MDc5ZjMxNDczNmIyZDNhYzI5YzFmNzgxMTlfMTE_bc27c196-c73c-4c3c-832a-2b80e94ba571">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV8zLTUtMS0xLTY2MzUx_26abc399-f609-4882-b13b-9f2de3b178fe">92660</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV81LTMtMS0xLTY2MzUxL3RleHRyZWdpb246NTgwNGEzOTY1NjA5NDM0NDgxMTE3M2ZhNDMzNTFmYjNfNA_2d4466ac-1b43-491d-985e-678a1e457e17">(949)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6NWViMzA1YzMxYjIyNDU0MWFkY2UwN2FiNzY2N2YxZTkvdGFibGVyYW5nZTo1ZWIzMDVjMzFiMjI0NTQxYWRjZTA3YWI3NjY3ZjFlOV81LTMtMS0xLTY2MzUxL3RleHRyZWdpb246NTgwNGEzOTY1NjA5NDM0NDgxMTE3M2ZhNDMzNTFmYjNfNw_aad767e5-aa3d-4d2f-8f88-0dd549d65ba9">284-4555</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6YmQ1YTM5MzAzMDg0NDBhMzkxZGE0MmU0MDNmZGVkYzIvdGFibGVyYW5nZTpiZDVhMzkzMDMwODQ0MGEzOTFkYTQyZTQwM2ZkZWRjMl8xLTEtMS0xLTY2MzUx_0ac10feb-9bae-490d-aeb7-e36273447393">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6YmQ1YTM5MzAzMDg0NDBhMzkxZGE0MmU0MDNmZGVkYzIvdGFibGVyYW5nZTpiZDVhMzkzMDMwODQ0MGEzOTFkYTQyZTQwM2ZkZWRjMl8xLTMtMS0xLTY2MzUx_d67f5e80-5a35-48cb-95ee-609fbfb9cde5">EOLS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6YmQ1YTM5MzAzMDg0NDBhMzkxZGE0MmU0MDNmZGVkYzIvdGFibGVyYW5nZTpiZDVhMzkzMDMwODQ0MGEzOTFkYTQyZTQwM2ZkZWRjMl8xLTUtMS0xLTY2MzUxL3RleHRyZWdpb246NzBhMGRlNmZmM2U2NGJlNDg3MmZhM2Y5MGM5M2E1MWJfNA_3238ae08-7a58-4b55-9f8e-62e75ac5f6d4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzE0_c35a5879-0304-4fc4-9920-7546e5e75765">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzE1_0660c01c-1a54-4474-9326-13b99958e7b0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6ZmNhMDA0NThmYzU5NGM3MWFiZjNiYTc2NGRjZjA4MDUvdGFibGVyYW5nZTpmY2EwMDQ1OGZjNTk0YzcxYWJmM2JhNzY0ZGNmMDgwNV8xLTAtMS0xLTY2MzUx_315b7ac8-7ed3-4ca4-9f65-cec6d405041f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6ZmNhMDA0NThmYzU5NGM3MWFiZjNiYTc2NGRjZjA4MDUvdGFibGVyYW5nZTpmY2EwMDQ1OGZjNTk0YzcxYWJmM2JhNzY0ZGNmMDgwNV8xLTMtMS0xLTY2MzUx_e0eb4206-727f-4b4d-8d1f-447c7eca12f6">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGFibGU6ZmNhMDA0NThmYzU5NGM3MWFiZjNiYTc2NGRjZjA4MDUvdGFibGVyYW5nZTpmY2EwMDQ1OGZjNTk0YzcxYWJmM2JhNzY0ZGNmMDgwNV8yLTMtMS0xLTY2MzUx_fda46882-243b-4b4f-b983-066aa15c008b">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzE5_c8578240-b09c-44e8-b572-103f2df33704">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMzIx_55cc75c4-84cd-4014-8fea-24863b7349fd">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i39ff6d4019914c7fb0f58a9c69af0da7_I20221104"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xL2ZyYWc6NjNmYjRkMGM4ZDMwNDQ0ZTlhZDcyYWMyZGFlZjJhOWYvdGV4dHJlZ2lvbjo2M2ZiNGQwYzhkMzA0NDRlOWFkNzJhYzJkYWVmMmE5Zl8yMjMy_5297f55d-74d8-4799-911f-199a51f13ce9"
      unitRef="shares">56246570</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNC0xLTEtMS02NjM1MQ_76ea5e77-d7fb-486f-9b74-bd153c26a05d"
      unitRef="usd">65572000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNC0zLTEtMS02NjM1MQ_de4d85f3-eb93-49ce-b26b-44b7e78bec10"
      unitRef="usd">146256000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNi0xLTEtMS02NjM1MQ_2b234b90-e9d2-4835-8403-19932656b1b9"
      unitRef="usd">20920000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNi0zLTEtMS02NjM1MQ_e8fb5805-b46c-40ac-9598-4e33dccafead"
      unitRef="usd">14657000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNy0xLTEtMS02NjM1MQ_b5a057a2-55f1-4b61-9847-506d79ddc0dd"
      unitRef="usd">21565000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNy0zLTEtMS02NjM1MQ_f88db08e-e518-4abf-aca3-ce78050cff04"
      unitRef="usd">1762000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTAtMS0xLTEtNjYzNTE_fa262c52-2ab4-444e-8fbd-9168148b85cf"
      unitRef="usd">3656000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTAtMy0xLTEtNjYzNTE_0b3e8e0a-74b5-447e-8d84-59218048b412"
      unitRef="usd">5082000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTEtMS0xLTEtNjYzNTE_ea1dfeee-9e1f-4309-b7fc-c69437a5c91a"
      unitRef="usd">4233000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTEtMy0xLTEtNjYzNTE_41dc589f-1d41-4278-9f9b-54366e7c4e99"
      unitRef="usd">11042000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTItMS0xLTEtNjYzNTE_ab5ac0ea-82d9-4a73-8662-bbc408cad314"
      unitRef="usd">115946000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTItMy0xLTEtNjYzNTE_96c5ad57-87b4-4877-869b-537cdad17eba"
      unitRef="usd">178799000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTMtMS0xLTEtNjYzNTE_ff9d0064-4371-4d6a-b8ba-530f738d9b27"
      unitRef="usd">1882000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTMtMy0xLTEtNjYzNTE_b90a571a-e734-406b-8b0e-d86e384b098a"
      unitRef="usd">1371000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTQtMS0xLTEtNjYzNTE_19f99e29-1a2a-478c-b203-f630e584e110"
      unitRef="usd">2149000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTQtMy0xLTEtNjYzNTE_78a51504-9c36-47be-9c30-3ce3d2b8f7af"
      unitRef="usd">2722000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTUtMS0xLTEtNjYzNTE_90a3b6a0-984a-47d6-b84e-1340b966f822"
      unitRef="usd">49108000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTUtMy0xLTEtNjYzNTE_1b3109e3-e525-4e45-88c2-b0e4113b77b7"
      unitRef="usd">50625000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTYtMS0xLTEtNjYzNTE_ae9aa570-4ead-4249-b9cd-49f126e4fc15"
      unitRef="usd">21208000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTYtMy0xLTEtNjYzNTE_c220b412-a84a-4301-a37b-facc19edfb74"
      unitRef="usd">21208000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTctMS0xLTEtNjYzNTE_7da24dda-1329-4e7b-beae-952861d83e44"
      unitRef="usd">2426000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTctMy0xLTEtNjYzNTE_f56d88f4-ce31-4d13-a914-7cf9fd7ee0a4"
      unitRef="usd">2758000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTgtMS0xLTEtNjYzNTE_232cd75f-6524-4bc3-88a0-ab1a08a349a6"
      unitRef="usd">192719000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMTgtMy0xLTEtNjYzNTE_6de172c9-71ec-4db0-b0f2-095aa3c08702"
      unitRef="usd">257483000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjEtMS0xLTEtNjYzNTE_fa087a16-2a35-46e3-ad9b-b4836bc7a701"
      unitRef="usd">8564000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjEtMy0xLTEtNjYzNTE_a7a02fcf-f90f-4c34-9a07-fe6aa71897d5"
      unitRef="usd">6091000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjItMS0xLTEtNjYzNTE_ba3d4c51-d1ef-44cb-a888-1895560712c0"
      unitRef="usd">29883000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjItMy0xLTEtNjYzNTE_9dcfc841-0526-49c9-b401-0c06f9458edf"
      unitRef="usd">29993000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjMtMS0xLTEtNjYzNTE_8a51efe4-8990-40c1-aaae-6b31a2f5b213"
      unitRef="usd">5000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjMtMy0xLTEtNjYzNTE_760badac-66fc-4251-9a40-68b2014dd54a"
      unitRef="usd">15000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjUtMS0xLTEtNjYzNTE_9ee154ab-c75d-4112-a6c8-f9bf24e7a19b"
      unitRef="usd">1307000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjUtMy0xLTEtNjYzNTE_5da8845a-7f25-47c2-bf6e-c5b457955821"
      unitRef="usd">1265000</us-gaap:OperatingLeaseLiabilityCurrent>
    <eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjYtMS0xLTEtNjYzNTE_e5d18847-e2ab-40a4-9a3c-22740222b103"
      unitRef="usd">6517000</eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent>
    <eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjYtMy0xLTEtNjYzNTE_df416392-dfce-4180-bfde-273cac2ff765"
      unitRef="usd">5314000</eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjktMS0xLTEtNjYzNTE_2f5574ea-2c71-4256-a06c-8938554d7814"
      unitRef="usd">51271000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMjktMy0xLTEtNjYzNTE_4f935fef-6aed-440d-858f-1632b848fb09"
      unitRef="usd">57663000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzAtMS0xLTEtNjYzNTE_09c6f2ca-5084-4664-af15-4ab5f72b1d4e"
      unitRef="usd">0</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzAtMy0xLTEtNjYzNTE_647995fd-ee4d-4e49-928f-c40963e4ea9a"
      unitRef="usd">5000000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzEtMS0xLTEtNjYzNTE_7ba03427-ed83-4827-a10f-757e90de110f"
      unitRef="usd">1491000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzEtMy0xLTEtNjYzNTE_27b8b970-ca12-4b0b-ac78-8e8acf394b21"
      unitRef="usd">2256000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractualObligation
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzItMS0xLTEtNjYzNTE_7494df01-6659-4caa-b1cb-a6def63a4b40"
      unitRef="usd">39000000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzItMy0xLTEtNjYzNTE_2ec32947-8b1a-4762-b097-1d67fd9ccb64"
      unitRef="usd">39426000</us-gaap:ContractualObligation>
    <us-gaap:SecuredLongTermDebt
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzMtMS0xLTEtNjYzNTE_f99c362a-d05b-4626-aaba-798d390e63bc"
      unitRef="usd">71712000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzMtMy0xLTEtNjYzNTE_6e5b8de1-5f5d-4f85-b284-325bce78cc50"
      unitRef="usd">71222000</us-gaap:SecuredLongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzUtMS0xLTEtNjYzNTE_6fe866a6-1069-4918-9708-9f6414d51f41"
      unitRef="usd">25000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzUtMy0xLTEtNjYzNTE_b3c76c1d-29b4-4a1a-97fd-4e46c8ecf87d"
      unitRef="usd">40000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzYtMS0xLTEtNjYzNTE_f918c59c-084b-4bb8-a789-c51e13bedb61"
      unitRef="usd">163499000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzYtMy0xLTEtNjYzNTE_476dea63-c92c-48bc-9fd8-63e600a0df39"
      unitRef="usd">175607000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzctMS0xLTEtNjYzNTE_90f11ec5-5b45-48d9-92dd-5532ae4bf522"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzctMy0xLTEtNjYzNTE_dfd06d3a-8787-47ad-b4b4-cef1ab6e274a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV8yMQ_6cd615b8-aaed-4705-99af-6d0f33e846b3"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV8yMQ_c7701fac-70e1-4b40-9c72-e668a3e8d193"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV8zNQ_3fe21a35-8323-4d6c-9ad1-a3e316c21323"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV8zNQ_71c2f5eb-acfc-422e-a58e-5c60d562540a"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV81Nw_02989ebd-76af-4a22-a5a1-e247127827c1"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV81Nw_160a6188-705f-4dca-be51-539d86b39df3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV81Nw_7b36b307-cf22-44bf-a3ff-7bd3b05f7dfc"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjoyZDZlN2JiZWM5YTc0ZGYxYjc0OWVmZmI5ODJlNmU1NV81Nw_9507ef07-c963-4846-aef7-f5156afc5d5c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMS0xLTEtNjYzNTE_87d0c319-2e99-4212-9557-c7a9d9375342"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfMzktMy0xLTEtNjYzNTE_167ff144-b8ea-4866-bed6-a3e79695ab86"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N18xOA_74b3bd52-a95c-416a-a237-7b373d9e5ac8"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N18xOA_d75c741c-e679-4683-b306-21980b74cd33"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N18zMg_074b64d4-9a44-4355-a670-b3cf35d82712"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N18zMg_e900bac0-cca7-47d3-9871-2d6799396b0f"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N181NA_13ac0631-5f36-4754-ba26-7e3f6d3c17c5"
      unitRef="shares">56183414</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N181NA_69e8a0ea-e11c-4d21-b167-3ea3660791b7"
      unitRef="shares">56183414</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N182MQ_ba5d130b-8e6e-4556-b9e7-357afdd2fb05"
      unitRef="shares">55576988</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMC0xLTEtNjYzNTEvdGV4dHJlZ2lvbjo4YWE3N2E4MmE5MzY0MzFkOTkwZTYyZjg4NjVjYjE4N182MQ_efdb60d1-ab2e-4e3e-ae01-aa05734b5057"
      unitRef="shares">55576988</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMS0xLTEtNjYzNTE_8c76e9ca-d7b9-4032-8fd9-2a07958f85d8"
      unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDAtMy0xLTEtNjYzNTE_1ac617c4-81fb-4421-94e5-393c91ee03a7"
      unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDEtMS0xLTEtNjYzNTE_8624ae3f-da81-4dcb-87b5-7b5c1903005e"
      unitRef="usd">513717000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDEtMy0xLTEtNjYzNTE_bfa68098-7354-4b91-bb4c-b138311570e0"
      unitRef="usd">504757000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDItMS0xLTEtNjYzNTE_cac83027-3b81-4110-8146-da3ced575f36"
      unitRef="usd">-368000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDItMy0xLTEtNjYzNTE_9ec47e65-4de9-4cc3-b1ed-61f5a3d10128"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDMtMS0xLTEtNjYzNTE_f9a28612-78d1-4688-8ee2-9c8bb107128b"
      unitRef="usd">-484130000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDMtMy0xLTEtNjYzNTE_fc314f53-b77d-48a1-b74f-86a40fb86cf7"
      unitRef="usd">-422882000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDQtMS0xLTEtNjYzNTE_814628b2-5034-49d2-b9bd-abcc8adaa2b5"
      unitRef="usd">29220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDQtMy0xLTEtNjYzNTE_68d230ad-3eea-436d-a3ad-0c6d592b1264"
      unitRef="usd">81876000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDUtMS0xLTEtNjYzNTE_fbdb878d-1e4b-4639-9165-13a5e85dff25"
      unitRef="usd">192719000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8xNi9mcmFnOmNmYmJkYWJhN2M3NDQxY2RhOTkyYjQwMjk2NTIwMzc3L3RhYmxlOmQzNzgzY2Q2NjZhZTRiODU4OWM3NWQ5YmQ2MWVhNjk5L3RhYmxlcmFuZ2U6ZDM3ODNjZDY2NmFlNGI4NTg5Yzc1ZDliZDYxZWE2OTlfNDUtMy0xLTEtNjYzNTE_e1192aa0-02d9-40e1-aa8c-e44393180c62"
      unitRef="usd">257483000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if255f3612ce24011914ed9f9fc5283c0_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMy0xLTEtMS02NjM1MQ_6ed0d91e-3e97-4cb6-899b-9f2ec3aa8d71"
      unitRef="usd">33215000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67b0a77f15c444c19f759b3deaef409d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMy0zLTEtMS02NjM1MQ_0ce19be5-0e2c-40bd-8c55-d1828c286f49"
      unitRef="usd">26677000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd30dda6fae047ba8fc0f4931c1cf694_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMy01LTEtMS02NjM1MQ_e0cbab37-9a8e-43fe-bbef-2cf864833b32"
      unitRef="usd">103604000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie045c20cf6bc4a46bc1cd1a0cb076bd5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMy03LTEtMS02NjM1MQ_f5d1fade-b5cf-4e17-a636-7f17e8e4798d"
      unitRef="usd">64314000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22f3e32c1ab94b0382fce87da10b1f25_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNC0xLTEtMS02NjM1MQ_3de11afd-f590-4c5f-b215-b1bbdec3cecc"
      unitRef="usd">684000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i519de1da8eb84a708ab6875c547d1cb9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNC0zLTEtMS02NjM1MQ_b945b761-6172-47c1-a4b5-8578b202ba58"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7a96d1a07754c188b0a005f18255480_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNC01LTEtMS02NjM1MQ_2db130cf-020e-4dd9-a2c7-c882095918ec"
      unitRef="usd">1366000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57cb5111d30d40a68b4e495a42bac87d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNC03LTEtMS02NjM1MQ_894a9f85-7eb7-4c25-953c-746a43094a9e"
      unitRef="usd">702000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNS0xLTEtMS02NjM1MQ_fc8a0309-f646-44ed-961d-45a48bbca9c3"
      unitRef="usd">33899000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNS0zLTEtMS02NjM1MQ_568efe0f-a54a-4549-b3bf-f5452699a7f6"
      unitRef="usd">26677000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNS01LTEtMS02NjM1MQ_c652f3a3-6466-4e40-aadc-46bb8eac0b92"
      unitRef="usd">104970000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfNS03LTEtMS02NjM1MQ_d8e5d5c0-3d42-4e62-980a-97773a107e0f"
      unitRef="usd">65016000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0xLTEtMS02NjM1MQ_cb51bd9c-4150-4406-b850-e0fa67eb3463"
      unitRef="usd">13490000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC0zLTEtMS02NjM1MQ_3639d9d5-a78a-41f1-bae0-b29ebc677c26"
      unitRef="usd">11490000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC01LTEtMS02NjM1MQ_49bad24d-b976-4399-aadc-065689c7e609"
      unitRef="usd">42517000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOC03LTEtMS02NjM1MQ_51d2c9f0-5814-4d57-b6fb-34d929a59648"
      unitRef="usd">27700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOS0xLTEtMS02NjM1MQ_e88347f6-00f1-43a7-8bae-dfae7d0d4d4a"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOS0zLTEtMS02NjM1MQ_e15c2dee-56ec-4df9-956a-d894ced41b96"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOS01LTEtMS02NjM1MQ_dae46367-6011-4c5b-bfce-059186fcb7db"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfOS03LTEtMS02NjM1MQ_6eba1fa7-2333-4104-a3ec-9fe31c44a9bd"
      unitRef="usd">25500000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTAtMS0xLTEtNjYzNTE_9b0971b2-fc43-4f1f-8985-63bef25c320e"
      unitRef="usd">34794000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTAtMy0xLTEtNjYzNTE_9b2e99f3-77e0-4db8-b6b0-9e3bfad0429e"
      unitRef="usd">31673000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTAtNS0xLTEtNjYzNTE_c8b7508d-a8be-4d95-b598-67dc073f1859"
      unitRef="usd">105111000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTAtNy0xLTEtNjYzNTE_a0d35876-2910-425d-bb9a-ec006c4b55fc"
      unitRef="usd">78801000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTEtMS0xLTEtNjYzNTE_5201ee8e-d285-4e51-958b-7e4b984c82f4"
      unitRef="usd">1376000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTEtMy0xLTEtNjYzNTE_4b56782f-4617-4669-8538-a9302e3ec6ec"
      unitRef="usd">301000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTEtNS0xLTEtNjYzNTE_4259c3e3-6765-47c8-97db-0a391adb623a"
      unitRef="usd">3394000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTEtNy0xLTEtNjYzNTE_c1412e31-660b-4bfd-8c54-1a3f8d9d826f"
      unitRef="usd">1641000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTItMS0xLTEtNjYzNTE_287164dc-ea2c-4f2d-801a-2b4ce6a4ad85"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTItMy0xLTEtNjYzNTE_b83ce1d7-94f8-4cfb-a787-c6c6d052e44a"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTItNS0xLTEtNjYzNTE_52ed679d-070f-4c09-a8d9-6d410fd88fda"
      unitRef="usd">2000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTItNy0xLTEtNjYzNTE_0e568363-1c86-4fa7-9b42-9775261ab25a"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTMtMS0xLTEtNjYzNTE_58c8c8b9-7176-4fe7-bffb-a078ca548d73"
      unitRef="usd">-1216000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTMtMy0xLTEtNjYzNTE_39b34c4a-aa40-4eb5-9aaa-ffddfbdc69f8"
      unitRef="usd">-1400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTMtNS0xLTEtNjYzNTE_984a5e7a-8528-4636-a6e0-f049249b7ebe"
      unitRef="usd">-3946000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTMtNy0xLTEtNjYzNTE_d4888a99-d3cf-4800-b86e-09480ebb9b42"
      unitRef="usd">-4049000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTQtMS0xLTEtNjYzNTE_91dbae26-8acf-430d-bb58-dc4eff35cf63"
      unitRef="usd">920000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTQtMy0xLTEtNjYzNTE_38f192c6-4e3c-4c74-941b-05d80ed65d4f"
      unitRef="usd">923000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTQtNS0xLTEtNjYzNTE_80652e59-fadd-4488-b4d5-3b300c41d777"
      unitRef="usd">2695000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTQtNy0xLTEtNjYzNTE_9fee5bec-f130-4941-8290-f48d0c4a3a84"
      unitRef="usd">4702000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTYtMS0xLTEtNjYzNTE_92306da1-0d0e-47d1-9785-437e93744d3e"
      unitRef="usd">51796000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTYtMy0xLTEtNjYzNTE_0ed7797b-6b3b-4c61-85d9-45308b3fd9e4"
      unitRef="usd">45787000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTYtNS0xLTEtNjYzNTE_eeb7b189-df1f-4295-96f3-58f240452e7a"
      unitRef="usd">159663000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTYtNy0xLTEtNjYzNTE_43c8d8d0-a0de-4224-b001-39fdd2be8e19"
      unitRef="usd">91393000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTctMS0xLTEtNjYzNTE_7aa92dc0-1b02-454d-a3a6-347e96e1440b"
      unitRef="usd">-17897000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTctMy0xLTEtNjYzNTE_9bef3a2b-5e26-44c1-840e-4a271561f8cb"
      unitRef="usd">-19110000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTctNS0xLTEtNjYzNTE_fb6ffe3c-de84-42c0-9194-d567b0b7e737"
      unitRef="usd">-54693000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTctNy0xLTEtNjYzNTE_b3dd322a-ca5a-42ad-8cf7-91e5ff67d943"
      unitRef="usd">-26377000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTktMS0xLTEtNjYzNTE_ada4e28d-bcfb-4e15-84a4-ac12b37b7146"
      unitRef="usd">38000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTktMy0xLTEtNjYzNTE_e70fa8f7-8005-4fe5-b2c0-92bdf396b2a8"
      unitRef="usd">0</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTktNS0xLTEtNjYzNTE_5c715133-88d9-493b-8078-f57617464d37"
      unitRef="usd">42000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMTktNy0xLTEtNjYzNTE_21620ac6-a80e-41bf-84d2-5900e72f1123"
      unitRef="usd">1000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjAtMS0xLTEtNjYzNTE_904c781a-4f47-48b6-922d-671f616c2622"
      unitRef="usd">2343000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjAtMy0xLTEtNjYzNTE_a6b82d2f-ae45-41d3-ab82-52579ca14d6b"
      unitRef="usd">311000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjAtNS0xLTEtNjYzNTE_d3a54bd5-e92a-4379-8e66-2e4a24e4944d"
      unitRef="usd">6466000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjAtNy0xLTEtNjYzNTE_54eda735-a042-497f-8f45-dd254e23c84b"
      unitRef="usd">1256000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjEtMS0xLTEtNjYzNTE_2bd3c039-0a46-48e2-8864-0c7f68c93fc2"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjEtMy0xLTEtNjYzNTE_0c6ddad0-731f-4693-bb36-550be18875c6"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjEtNS0xLTEtNjYzNTE_e727ea6b-9779-4afb-b513-ab8a9cb888dd"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjEtNy0xLTEtNjYzNTE_89b09a80-20ac-442d-81cc-6f149e979d63"
      unitRef="usd">-968000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjItMS0xLTEtNjYzNTE_263dcde0-840c-4f26-9c40-7f7384532780"
      unitRef="usd">-62000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjItMy0xLTEtNjYzNTE_dc9dc950-b97a-42f7-bcc6-29dd09c10587"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjItNS0xLTEtNjYzNTE_f6575941-96b6-4d06-acbb-7880de917ee6"
      unitRef="usd">-93000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjItNy0xLTEtNjYzNTE_20881cf3-28e2-4106-b6b1-db4e4b1d483d"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjMtMS0xLTEtNjYzNTE_35129cb3-450b-4706-b673-512980ac1876"
      unitRef="usd">-20264000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjMtMy0xLTEtNjYzNTE_685d930b-07d3-4c25-9964-f2c46e8f6f7b"
      unitRef="usd">-19421000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjMtNS0xLTEtNjYzNTE_2accf076-9236-4fe5-9821-879e110edad9"
      unitRef="usd">-61210000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjMtNy0xLTEtNjYzNTE_eb59a0db-37e1-4090-a82d-b52aaf708eab"
      unitRef="usd">-28600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjQtMS0xLTEtNjYzNTE_42d1d2b4-173a-4c71-aaeb-67a58abb30b0"
      unitRef="usd">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjQtMy0xLTEtNjYzNTE_dc656361-ab1b-4dfb-81ed-637eaffbd142"
      unitRef="usd">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjQtNS0xLTEtNjYzNTE_63b0a84e-1f29-4b75-a65d-68314a8d3995"
      unitRef="usd">38000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjQtNy0xLTEtNjYzNTE_c22b8092-1f62-4528-9609-b07c14b8bba2"
      unitRef="usd">33000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjUtMS0xLTEtNjYzNTE_a3c44d69-8fd5-4dce-837f-65f5f2e3b575"
      unitRef="usd">-20276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjUtMy0xLTEtNjYzNTE_e1420182-edf5-49b0-8d5e-c2dec88e826d"
      unitRef="usd">-19433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjUtNS0xLTEtNjYzNTE_ecf55072-a682-491c-97c0-ed1ffe6a5c40"
      unitRef="usd">-61248000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjUtNy0xLTEtNjYzNTE_2f2969d5-a763-4bfa-87b6-172b10a052d4"
      unitRef="usd">-28633000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjctMS0xLTEtNjYzNTE_fc4286a3-99e0-4414-8dba-4d326ac8a764"
      unitRef="usd">-203000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjctMy0xLTEtNjYzNTE_09e23684-030d-4fda-a15a-c9b8e5286228"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjctNS0xLTEtNjYzNTE_6de18dc7-6285-40bf-b0b2-8b70d7694fac"
      unitRef="usd">-368000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjctNy0xLTEtNjYzNTE_35f76a8a-8310-4e06-86b8-8dd255746855"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjktMS0xLTEtNjYzNTE_d380eb06-ff71-40a0-bebe-c6b85acae301"
      unitRef="usd">-20479000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjktMy0xLTEtNjYzNTE_30c6669b-28b2-4a93-b3c8-fcff39ee7a52"
      unitRef="usd">-19433000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjktNS0xLTEtNjYzNTE_949964e1-4886-48f2-98b4-d92662353d62"
      unitRef="usd">-61616000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMjktNy0xLTEtNjYzNTE_de3cdce2-9e08-4c2a-8c67-ce88d5c6fbb6"
      unitRef="usd">-28633000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtMS0xLTEtNjYzNTE_26ff5649-b9b4-46fc-9cf0-37ec02df7bfc"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtMS0xLTEtNjYzNTE_bf6da31c-fbd8-4b5f-9ff9-235316131136"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtMy0xLTEtNjYzNTE_12da1125-3d8c-4ba3-ba4e-7dfb518509d7"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtMy0xLTEtNjYzNTE_92a2ace7-35b0-4f07-a8cc-c0f9146c8cb2"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtNS0xLTEtNjYzNTE_78192884-7b53-4926-9bf9-01b06f8a4d35"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtNS0xLTEtNjYzNTE_fb92fe43-8288-4d74-8ce0-39479212f455"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtNy0xLTEtNjYzNTE_a43b3158-209b-432c-b8e8-021f5e7d3272"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzAtNy0xLTEtNjYzNTE_bc8f977e-92d4-4a49-831a-fbcc6010480c"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtMS0xLTEtNjYzNTE_805e04f6-3693-4b56-9758-80ea5762a86c"
      unitRef="shares">56176949</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtMS0xLTEtNjYzNTE_9f1fbc71-8f41-45b1-9cfc-032348816f52"
      unitRef="shares">56176949</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtMy0xLTEtNjYzNTE_652bc86d-8fa2-4f3d-b5ff-9b9586adb6dd"
      unitRef="shares">55007132</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtMy0xLTEtNjYzNTE_c7566884-8b54-457d-9e72-bfcf6ffbc4d4"
      unitRef="shares">55007132</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtNS0xLTEtNjYzNTE_3c30d1d7-1331-4b17-9d64-ac45cdce38bf"
      unitRef="shares">55997545</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtNS0xLTEtNjYzNTE_4517f56c-4022-43f5-a381-d1d644ae94af"
      unitRef="shares">55997545</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtNy0xLTEtNjYzNTE_33fb4d54-c1d0-4524-9b52-ca4e89a929d1"
      unitRef="shares">47818288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yMi9mcmFnOmU4YTdkOTFjN2IxYzQwOTI4YWJhZWVhMzZlZTA3ZTRiL3RhYmxlOmEwOWM1NjlhNGYzODQwZTE4YzdmNWE1ZTk5YjEyNGEzL3RhYmxlcmFuZ2U6YTA5YzU2OWE0ZjM4NDBlMThjN2Y1YTVlOTliMTI0YTNfMzEtNy0xLTEtNjYzNTE_a6d1fbb3-2fd0-46d0-b5c5-2d0a343cba95"
      unitRef="shares">47818288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i19b70069ec2b4bc88563acac780cb0fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi0xLTEtMS02NjM1MQ_08125a68-2028-4e0c-9a22-a8c9c0a52b07"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i19b70069ec2b4bc88563acac780cb0fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi0zLTEtMS02NjM1MQ_450957b3-2d0e-4b0c-815c-dce90e786c32"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie933be957e064dbf9e19c7a328a5a3a0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi01LTEtMS02NjM1MQ_f1515d16-8f54-4814-a1c7-0fd24d415085"
      unitRef="shares">33749228</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ie933be957e064dbf9e19c7a328a5a3a0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi03LTEtMS02NjM1MQ_21116319-af39-4de8-9009-2e651d0d3857"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icec2119209b14768b574684aa088fd0a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi05LTEtMS02NjM1MQ_4d5c9a4c-8a30-4b0b-9ef1-60a0cd43182e"
      unitRef="usd">303113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idbfa32b8bceb4d85b8d585d6362e9ead_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi0xMS0xLTEtNjYzNTE_e08684a8-c36f-416d-ac0c-4ea896a45aa3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d107be2e3b249e3a47304c93fca1cf8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi0xMy0xLTEtNjYzNTE_abc3d5e9-45ba-4175-ac41-23810c0fe759"
      unitRef="usd">-376072000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b2a587e790f4e898dff40a08b249f56_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMi0xNS0xLTEtNjYzNTE_a9a49596-a8af-4828-b821-d843f3d1139f"
      unitRef="usd">-72958000</us-gaap:StockholdersEquity>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="ia9ad3bd07da14e6e91626d72417cbd26_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMy01LTEtMS02NjM1MQ_085ad566-889b-4157-8637-c77d49d61d08"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <eols:StockIssuedDuringPeriodValuesLitigationSettlement
      contextRef="i14697910a2c7431d8e843fa9e6047c3f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMy05LTEtMS02NjM1MQ_f388b65a-b94c-4d44-933e-0e2fca9f47d5"
      unitRef="usd">48421000</eols:StockIssuedDuringPeriodValuesLitigationSettlement>
    <eols:StockIssuedDuringPeriodValuesLitigationSettlement
      contextRef="i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMy0xNS0xLTEtNjYzNTE_38e4c322-4fbb-421d-bf7c-4966fac0fae0"
      unitRef="usd">48421000</eols:StockIssuedDuringPeriodValuesLitigationSettlement>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ia9ad3bd07da14e6e91626d72417cbd26_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNC01LTEtMS02NjM1MQ_9d18c9a4-d18c-4082-8532-9bb1cb6502e9"
      unitRef="shares">3136869</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i14697910a2c7431d8e843fa9e6047c3f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNC05LTEtMS02NjM1MQ_df17d8ce-d784-4ba1-b4f9-6e9b1356f037"
      unitRef="usd">39808000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNC0xNS0xLTEtNjYzNTE_a72bf501-077c-430a-8d49-c9559a05eb0b"
      unitRef="usd">39808000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia9ad3bd07da14e6e91626d72417cbd26_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNS01LTEtMS02NjM1MQ_85adf86a-be5b-41cd-bed3-ac8df39be294"
      unitRef="shares">88222</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i14697910a2c7431d8e843fa9e6047c3f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNS05LTEtMS02NjM1MQ_7737e360-3d62-4fd5-b23d-72df77c0fb96"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNS0xNS0xLTEtNjYzNTE_4b698e22-33b6-48d4-ab72-62cbfc200a41"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i14697910a2c7431d8e843fa9e6047c3f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNi05LTEtMS02NjM1MQ_c957e89a-0b93-41a9-8f7e-f8725b0df7be"
      unitRef="usd">1606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNi0xNS0xLTEtNjYzNTE_63a1882f-7175-4c94-b3f4-8e3bc22c8e5c"
      unitRef="usd">1606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i089a8fa6f6594b3f9738d50bda403e59_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNy0xMy0xLTEtNjYzNTE_18959e5f-67b6-4d0c-a4e5-94c15c9185e5"
      unitRef="usd">6401000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfNy0xNS0xLTEtNjYzNTE_2eba76c1-5c42-4b9e-b288-d631c5051ae7"
      unitRef="usd">6401000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2d310130bd084da3ac0de405205ba752_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS0xLTEtMS02NjM1MQ_f3fefa62-38f7-45e2-b3a2-815c0e38d764"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i2d310130bd084da3ac0de405205ba752_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS0zLTEtMS02NjM1MQ_4dd7bf88-0ab1-4bd0-b27b-c2b04bfadcc7"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="if2006f8ecb5641f4ace06a537399080a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS01LTEtMS02NjM1MQ_73358981-c048-4735-9dd1-9b497a442cb0"
      unitRef="shares">43736971</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="if2006f8ecb5641f4ace06a537399080a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS03LTEtMS02NjM1MQ_56c21433-9f9e-47a9-acc3-acca4cd58b80"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i322856dfc9674ae588e828493d27d95e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS05LTEtMS02NjM1MQ_b139dc0c-0ce6-4f66-a204-186997dfa34a"
      unitRef="usd">392959000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia31b6cb915184194bff3d93618626fd2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS0xMS0xLTEtNjYzNTE_3160ec08-d85c-4020-9f5b-2a9a85e35c05"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i111481324b7843119d6ff1bdabd0d80a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS0xMy0xLTEtNjYzNTE_9cdb97c8-84ef-485d-a6bc-d351dcb1795e"
      unitRef="usd">-369671000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1769ef3b028f40ceb603ef14511541b8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfOS0xNS0xLTEtNjYzNTE_2b8f130e-89f9-4824-af9a-0361788bdb2d"
      unitRef="usd">23289000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7727dfd31c3944fab9afd583ea30a2d7_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTAtNS0xLTEtNjYzNTE_85b381b5-6f47-4ee3-9b54-86aa12eaecfa"
      unitRef="shares">10350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i29999457232e44aeb12a5ace34004e44_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTAtOS0xLTEtNjYzNTE_aa2da3a7-0a65-4df9-9e67-3843746a2b90"
      unitRef="usd">92212000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i29512e75fcde470fa4dc860e639a878e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTAtMTUtMS0xLTY2MzUx_35fe8f42-23dc-4730-a9ed-1a9087819dbf"
      unitRef="usd">92212000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5492be0135c14a0aa71f49ae2531d9a3_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTEtNS0xLTEtNjYzNTE_22edddbc-8d06-417e-85fb-7d07333bbf44"
      unitRef="shares">209532</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i173b74f14d1d431b99aed7270421b1ec_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTEtOS0xLTEtNjYzNTE_468394bc-3df1-474a-9394-2d4b6ce22641"
      unitRef="usd">2707000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib97a0827a3aa4c1e87cc2994ec2eedf5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTEtMTUtMS0xLTY2MzUx_f10940e6-c871-403a-9dc3-a0bcabb35f2c"
      unitRef="usd">2707000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic5af4588f76d4ab8bd0886c2f0f3080f_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTItNS0xLTEtNjYzNTE_c86c41b1-c935-4e3b-ab35-7dc233bbf281"
      unitRef="shares">76289</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i65e3e596ba3f464aad3607fcd5ad2218_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTItOS0xLTEtNjYzNTE_7e4082e2-d0d7-4b78-a73d-5f936b08deba"
      unitRef="usd">644000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i490de831fccb414783dc72487430e05b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTItMTUtMS0xLTY2MzUx_23d50256-c9f2-4363-946d-a96210a94538"
      unitRef="usd">644000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i65e3e596ba3f464aad3607fcd5ad2218_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTMtOS0xLTEtNjYzNTE_3256cb8d-8466-4910-8a86-c81c4fdb897d"
      unitRef="usd">2887000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i490de831fccb414783dc72487430e05b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTMtMTUtMS0xLTY2MzUx_d9a80a86-0cfa-44c8-a294-36a2481049ed"
      unitRef="usd">2887000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i4e4cc38409b74c9b8c6c73ff0a0b3ddc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTQtMTMtMS0xLTY2MzUx_aea46bc2-b068-478d-b2ed-47db452b813d"
      unitRef="usd">-15601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i490de831fccb414783dc72487430e05b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTQtMTUtMS0xLTY2MzUx_7325ad3f-931d-4472-9707-df1fdb4c9f53"
      unitRef="usd">-15601000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if314cfb6f75348ed94b97148ad316c5d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtMS0xLTEtNjYzNTE_89320255-d709-40e9-9fa4-0e53df40d5c0"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="if314cfb6f75348ed94b97148ad316c5d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtMy0xLTEtNjYzNTE_1af6797a-d814-4b50-a657-92c08c583d1e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i96c5b48b38fc4cd6814bfde2d6a09765_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtNS0xLTEtNjYzNTE_afe88fb2-6b4d-4ce4-9606-d2ae9570da48"
      unitRef="shares">54372792</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i96c5b48b38fc4cd6814bfde2d6a09765_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtNy0xLTEtNjYzNTE_c33b357f-2d43-4229-80c9-18db07a35742"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iddd953d7c6a94c3a9fbeca055456caca_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtOS0xLTEtNjYzNTE_be55ac08-3659-416a-a7c1-4451f3b5e011"
      unitRef="usd">491409000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15763c0703af45cbaf1faa81f158530e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtMTEtMS0xLTY2MzUx_2ac410f4-b434-45b6-a4e0-efbac44acfa2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic940384570964e689ab795df4e66ccb7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtMTMtMS0xLTY2MzUx_32c21aa2-19f5-4dc1-9a49-f93dbf302852"
      unitRef="usd">-385272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i13db4b6383624d5097720364e94a31b5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTYtMTUtMS0xLTY2MzUx_5746ae37-4f39-4ae8-aa95-0ac7c8914fc8"
      unitRef="usd">106138000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8c628e554673429f919660de503a710e_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTctNS0xLTEtNjY3MTA_b411572e-342e-4262-aebd-8822eee670ed"
      unitRef="shares">724835</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ide79544f24324f7b8502d4f715dcf188_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTctOS0xLTEtNjY3MTA_c6f89404-e740-44d3-97fa-16b2a2559f66"
      unitRef="usd">8203000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia80760aeda834165a0bd09ccfcabfa32_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTctMTUtMS0xLTY2NzEw_eee35e72-e2a6-42fc-8b75-b11c47448715"
      unitRef="usd">8203000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i48b21d372773402dbf5d667fe310b72b_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTgtNS0xLTEtNjY3MTA_e759365f-a97e-426f-9129-655f316dfded"
      unitRef="shares">456165</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTgtMTUtMS0xLTY2NzEw_403b48b9-bc03-4a9e-9867-770acd01d9c5"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ideffba28e2bf412cb0e77892da2aa722_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTktOS0xLTEtNjY3MTA_7d270400-da2f-4c48-87d4-4c6281c1c7ca"
      unitRef="usd">2496000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMTktMTUtMS0xLTY2NzEw_e38f786e-4c8d-4c9c-b168-05e1c07129e6"
      unitRef="usd">2496000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i2512c22190594595845dd6dc9d382f8b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjAtMTMtMS0xLTY2NzEw_fe01a0cc-c8c7-4aea-85f3-36a522935737"
      unitRef="usd">-19433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjAtMTUtMS0xLTY2NzEw_d5674c1a-8b0d-41f1-a78a-6ef70dec7c20"
      unitRef="usd">-19433000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7b5a39a32eeb4cab9368027d10b64144_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtMS0xLTEtNjY3MTk_6151b793-fcb2-4e13-8fbc-bd734e17465a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i7b5a39a32eeb4cab9368027d10b64144_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtMy0xLTEtNjY3MTk_091651f2-66d5-4829-8f8d-ace611d972c6"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9e42c0d2b5a8488e921290035592036a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtNS0xLTEtNjY3MTk_d90ff9c6-55d4-4df8-a756-1237489c5bde"
      unitRef="shares">55553792</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i9e42c0d2b5a8488e921290035592036a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtNy0xLTEtNjY3MTk_145320cd-d556-4cf6-928d-10f4da3da96c"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5cb60ec41f240cdbd130979758bbe33_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtOS0xLTEtNjY3MTk_a5a566ab-9a63-49c1-9e67-5f9677ae946f"
      unitRef="usd">502108000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8398583e0d2541f0ad8db5defad16243_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtMTEtMS0xLTY2NzE5_e94470e5-c4aa-487b-b7bd-bc57f4b4d5a3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifbb65d439c414edbb7040d29388dad05_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtMTMtMS0xLTY2NzE5_0cf7d923-309d-470a-bb5f-4dea45b9df8c"
      unitRef="usd">-404705000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i458f436d90584702b2e171f24fc2ffd9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOmE1NTlmMDlmMGVjZTQ1NmFiOThmZTIzMWY1MjgxYzZkL3RhYmxlcmFuZ2U6YTU1OWYwOWYwZWNlNDU2YWI5OGZlMjMxZjUyODFjNmRfMjEtMTUtMS0xLTY2NzE5_e34110b9-8b14-46ed-9ddf-2770863524df"
      unitRef="usd">97404000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i54b5f0ef22bf4fa9839716763e9e8209_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi0xLTEtMS02NjM1MQ_095d5824-ed35-4c68-bebc-4f84269a623a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i54b5f0ef22bf4fa9839716763e9e8209_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi0zLTEtMS02NjM1MQ_ce876ff0-3b19-4b67-951d-985e3baafd2d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="id2d7f6a0cb1b497cbfc385cc704bccf2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi01LTEtMS02NjM1MQ_fbdc17bc-b473-42a7-aa9d-45e2393487b4"
      unitRef="shares">55576988</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="id2d7f6a0cb1b497cbfc385cc704bccf2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi03LTEtMS02NjM1MQ_90977ab0-bd07-4cde-b210-e9ff68071ac5"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib1fddad6db8d4551816b8c9aecd79504_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi05LTEtMS02NjM1MQ_f59a1595-741b-4b3d-96fb-93cb0da06c94"
      unitRef="usd">504757000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0b12284fc5ce4b21a29b45a18ae68685_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi0xMS0xLTEtNjYzNTE_f293a026-98bd-42cf-9435-447b08f8af99"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff586361777d462b9327912ebb0fdc8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi0xMy0xLTEtNjYzNTE_9e0b4c59-372c-40df-a631-652f140330e1"
      unitRef="usd">-422882000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMi0xNS0xLTEtNjYzNTE_34690262-82aa-493f-a4a9-a0cbc8d34b39"
      unitRef="usd">81876000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i41a3e5c8a1c94c8488ef9e164b01e0cf_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMy01LTEtMS02NjM1MQ_412d588f-1a6b-4bde-89e2-ec4fcf80f52c"
      unitRef="shares">464376</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0566f63895a44386a854828b2eacdf90_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMy05LTEtMS02NjM1MQ_c723f862-4114-4feb-be15-e9101dd8b170"
      unitRef="usd">17000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic3a862462206439c8bc023adde6f54e2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMy0xNS0xLTEtNjYzNTE_4388e3da-f0a4-4042-a9a6-a05a786045a4"
      unitRef="usd">17000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0566f63895a44386a854828b2eacdf90_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNC05LTEtMS02NjM1MQ_86395702-6d5b-430d-916f-62dafc773ce1"
      unitRef="usd">2959000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic3a862462206439c8bc023adde6f54e2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNC0xNS0xLTEtNjYzNTE_a3bd5a09-fbfe-4763-a74f-771534ba24ba"
      unitRef="usd">2959000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ib29835257f2c4dd18c50418dd8adfee9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNS0xMy0xLTEtNjYzNTE_d083d8c7-f498-4c81-a0e9-d8da2d17f3f1"
      unitRef="usd">-17501000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic3a862462206439c8bc023adde6f54e2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNS0xNS0xLTEtNjYzNTE_9fabc88f-f5f9-4579-85b7-6334f24550ea"
      unitRef="usd">-17501000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5c84c79944be420fb608efbdf8406369_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNi0xMS0xLTEtNjYzNTE_88e04dde-8461-421a-aba4-085b9289cda8"
      unitRef="usd">-103000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic3a862462206439c8bc023adde6f54e2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNi0xNS0xLTEtNjYzNTE_ff477909-0469-43ff-8a80-d8d2d9924eec"
      unitRef="usd">-103000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id470dada4c0e4d9f9665fcb85a0e6d32_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy0xLTEtMS02NjM1MQ_6007f45a-f18c-464f-8f1b-c4dd70b4771d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="id470dada4c0e4d9f9665fcb85a0e6d32_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy0zLTEtMS02NjM1MQ_8c055e44-e316-4210-b6f7-e0506f22ea27"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic2398dc3c9da43c4ac481b18ad745499_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy01LTEtMS02NjM1MQ_6cc6e78a-15ef-4418-a31d-4434e5ab01ea"
      unitRef="shares">56041364</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic2398dc3c9da43c4ac481b18ad745499_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy03LTEtMS02NjM1MQ_c812c48f-42ae-4100-be74-9ca402c264f2"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47b462307ce144bc832c08ae7d8df5c1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy05LTEtMS02NjM1MQ_67c36263-dd24-4ef5-bad2-d85f483b8f55"
      unitRef="usd">507733000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b7351c853c140558b8a86c3ba8db24b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy0xMS0xLTEtNjYzNTE_697a01d3-b0f3-477f-825a-d3d2328c2d19"
      unitRef="usd">-103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaf8b55b81fd54639927f832aefd0c105_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy0xMy0xLTEtNjYzNTE_1bd46d59-cea2-4092-b5a6-5bd6c20d72eb"
      unitRef="usd">-440383000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i85c698504400444cad7bd76a594cae6a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfNy0xNS0xLTEtNjYzNTE_16a52fe4-a5d2-46f1-9778-1b78a6c4a09c"
      unitRef="usd">67248000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i38daf97bf6b54a5d9f36afcbc66faad1_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfOC01LTEtMS02NjM1MQ_80103f69-806f-4d93-9448-028d3d77eab4"
      unitRef="shares">22049</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibe0af0b6fdac41d79d91b5cfebd2f064_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfOC05LTEtMS02NjM1MQ_beb2466f-9774-442a-81dc-391349a4b688"
      unitRef="usd">167000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie7690b2a3bee42b0adbdb700c288530e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfOC0xNS0xLTEtNjYzNTE_ba552e0c-722a-4d5b-8137-3cfa34e49b75"
      unitRef="usd">167000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibe0af0b6fdac41d79d91b5cfebd2f064_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfOS05LTEtMS02NjM1MQ_9ba19a41-6ee4-4a81-ae9f-ff4cf7ccef1c"
      unitRef="usd">2979000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie7690b2a3bee42b0adbdb700c288530e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfOS0xNS0xLTEtNjYzNTE_559c260b-4291-43a1-89ee-692aa8149b7a"
      unitRef="usd">2979000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i483c0c81c82a4127a108474382234dae_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTAtMTMtMS0xLTY2MzUx_4c27be0d-2be2-431e-aa45-d89825be7f0e"
      unitRef="usd">-23471000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7690b2a3bee42b0adbdb700c288530e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTAtMTUtMS0xLTY2MzUx_7b7da86d-525c-4cec-bd93-5cc327c0c0fe"
      unitRef="usd">-23471000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia70412995ddc4b699370638e386fbd7d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTEtMTEtMS0xLTY2MzUx_b5663288-127f-4782-a375-1ff97494eb1e"
      unitRef="usd">-62000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie7690b2a3bee42b0adbdb700c288530e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTEtMTUtMS0xLTY2MzUx_1ab23e92-b327-4c3b-8137-cd0f2496e9a4"
      unitRef="usd">-62000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0a4f256b4cc8459bacffb1ecf8154425_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItMS0xLTEtNjYzNTE_eabc175b-0a90-41d5-bb44-5763450135a6"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0a4f256b4cc8459bacffb1ecf8154425_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItMy0xLTEtNjYzNTE_984350c1-fcc6-4ec1-8763-b92497e50b95"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i986ed2aacf8249efa66cfd1e39a120f5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItNS0xLTEtNjYzNTE_ce1027ef-46d1-43dd-9023-e8d24cd9100d"
      unitRef="shares">56063413</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i986ed2aacf8249efa66cfd1e39a120f5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItNy0xLTEtNjYzNTE_5c54ca46-5629-49bc-bfbc-5b07d4e408a7"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i711c0ec8101d43c2bf551aec2015fe93_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItOS0xLTEtNjYzNTE_6acdc531-efc6-4fc1-a04d-aeff244f838f"
      unitRef="usd">510879000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i517b67724cfa4e4a9a9d6760c1b208ba_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItMTEtMS0xLTY2MzUx_64cf2c63-1919-4b49-9fa0-e063dcc98b22"
      unitRef="usd">-165000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie47683c6c9bd447d932d1f3f3b371104_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItMTMtMS0xLTY2MzUx_1672cde1-6256-481a-80bc-8845dcc8432f"
      unitRef="usd">-463854000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i41fd4a2cf7cb49e6a38c2fc9b0df76fd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTItMTUtMS0xLTY2MzUx_344293e7-e23c-4f58-bbbe-85ac774d543e"
      unitRef="usd">46861000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i696aed9396534e69a8f395b92916dbb8_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTMtNS0xLTEtNjY3Mzg_f70c4e4d-f5b7-4881-b5af-a5d074df2a5c"
      unitRef="shares">120001</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i86e69b86a1f34f1f860a8d0303c3f93a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTMtOS0xLTEtNjY3Mzg_75cf91f9-0cee-49b3-a5d4-07d63e84167f"
      unitRef="usd">355000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTMtMTUtMS0xLTY2NzM4_3f655750-1986-4392-a5ed-6f4a90c7b48c"
      unitRef="usd">355000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i86e69b86a1f34f1f860a8d0303c3f93a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTQtOS0xLTEtNjY3Mzg_22f0af7e-7523-406e-94dd-02489b6ea37b"
      unitRef="usd">2483000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTQtMTUtMS0xLTY2NzM4_c19c45e0-e0b9-4149-87d2-521ffa8c6170"
      unitRef="usd">2483000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="icb5cba7d4b31433baac45503a471e4ed_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTUtMTMtMS0xLTY2NzM4_12b3b4fb-0344-4319-94e9-1671def71482"
      unitRef="usd">-20276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTUtMTUtMS0xLTY2NzM4_9e02a6d4-2692-4d1c-9c78-aa1cb5cd8451"
      unitRef="usd">-20276000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2d9bfad2231c4ef9be095f3e3afb8838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTYtMTEtMS0xLTY2NzM4_7cd6dd16-c6d8-47eb-aca9-d4dd4cfbb810"
      unitRef="usd">-203000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTYtMTUtMS0xLTY2NzM4_ad60e529-f2ff-4ae0-b291-da171967ebc2"
      unitRef="usd">-203000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibaff2091727e4bbda42ae97fb2c0ca83_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctMS0xLTEtNjY3NDU_3e5aeeae-a8b5-4b37-aa94-84f439eaed35"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ibaff2091727e4bbda42ae97fb2c0ca83_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctMy0xLTEtNjY3NDU_0e5a9e32-4005-48f2-8ff5-39b541c265b5"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0eda81fe6f4443b3840b17e1ed17844d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctNS0xLTEtNjY3NDU_d2303433-3b7e-43c3-bc5d-dc8abf3d57bc"
      unitRef="shares">56183414</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0eda81fe6f4443b3840b17e1ed17844d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctNy0xLTEtNjY3NDU_fd3675e0-473a-42dc-bcab-634f98eff784"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67e38e0bc0df4e4d88a289133b9464f5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctOS0xLTEtNjY3NDU_f4013969-e2ac-4bbb-a066-79e003013d0c"
      unitRef="usd">513717000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81ca472192774250bc53a843ace80459_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctMTEtMS0xLTY2NzQ1_5d972e77-1a0e-4dc9-9206-6f00ed6ea64f"
      unitRef="usd">-368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i68b52e5c01fb45b685329d95b6300084_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctMTMtMS0xLTY2NzQ1_4b84a4f9-2373-4ed3-88b0-95a0e37a339d"
      unitRef="usd">-484130000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yNS9mcmFnOmFhOGI2MWY4ZjJhNjRhZTViZTAwODM0MTE4OWQ5Zjg0L3RhYmxlOjVlODcxODZiNjBiNzQ5Zjc5NzEyYWI0MzExYjY1MjkyL3RhYmxlcmFuZ2U6NWU4NzE4NmI2MGI3NDlmNzk3MTJhYjQzMTFiNjUyOTJfMTctMTUtMS0xLTY2NzQ1_7ad057b4-d6cc-4059-8e5b-8c5ee4785602"
      unitRef="usd">29220000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMy0xLTEtMS02NjM1MQ_934a6df5-11b5-47f3-9435-e636e75332bd"
      unitRef="usd">-61248000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMy0zLTEtMS02NjM1MQ_ffb17dbd-bfb7-4d49-a502-8e63d9824c66"
      unitRef="usd">-28633000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNS0xLTEtMS02NjM1MQ_864cdabd-a733-47e2-b0de-b5db72d94c15"
      unitRef="usd">2695000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNS0zLTEtMS02NjM1MQ_52b5dac6-8ab9-414c-8f6c-bfbb1c9f3766"
      unitRef="usd">4702000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNi0xLTEtMS02NjM1MQ_dc8dfd8c-53cb-485e-a554-85b0910edce0"
      unitRef="usd">8421000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNi0zLTEtMS02NjM1MQ_106fcd72-0333-43ec-b7f2-28c36eff6d76"
      unitRef="usd">6927000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNy0xLTEtMS02NjM1MQ_4a47994a-2d3c-479b-abd2-58ebd45a4d70"
      unitRef="usd">1363000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNy0zLTEtMS02NjM1MQ_31ec0de6-99f2-415b-864c-8164f8d975d5"
      unitRef="usd">501000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfOS0xLTEtMS02NjM1MQ_32ec4a44-4c3b-4f17-98a6-476f66947e43"
      unitRef="usd">573000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfOS0zLTEtMS02NjM1MQ_f88d8835-09a3-40e4-9d5c-4d5d03e9ed71"
      unitRef="usd">512000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTAtMS0xLTEtNjYzNTE_864ea6bd-fd34-4088-9c5f-00aa881e6b65"
      unitRef="usd">805000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTAtMy0xLTEtNjYzNTE_021bf288-ef72-46ef-8112-cacdf1c5bd1d"
      unitRef="usd">882000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTEtMS0xLTEtNjYzNTE_eae6c54b-b81e-4cf0-943f-98e77190720e"
      unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTEtMy0xLTEtNjYzNTE_d8e230c8-0bee-4c50-b137-c525449613ef"
      unitRef="usd">272000</us-gaap:PaidInKindInterest>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTItMS0xLTEtNjYzNTE_605df42c-0f55-4876-92ed-32089c844e11"
      unitRef="usd">-15000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTItMy0xLTEtNjYzNTE_c966ad6c-01d6-4b89-93d1-a64543bf06e7"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTMtMS0xLTEtNjYzNTE_34c13c2f-9240-4409-9c87-75100d1b4d8b"
      unitRef="usd">3946000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTMtMy0xLTEtNjYzNTE_e5342d35-7b53-42e1-9f03-cabd499ac14d"
      unitRef="usd">4049000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTQtMS0xLTEtNjYzNTE_300a3af2-08bc-4e2a-9231-535d0976107c"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTQtMy0xLTEtNjYzNTE_47ff34f1-039b-46f3-86de-3524b0508746"
      unitRef="usd">-968000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTYtMS0xLTEtNjYzNTE_d6dbb23e-ff91-40fd-9695-9393df5dfb65"
      unitRef="usd">7626000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTYtMy0xLTEtNjYzNTE_7a4c0746-1a87-469f-bffe-51b0a2bfb28b"
      unitRef="usd">4110000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTctMS0xLTEtNjYzNTE_c7cd378c-435b-4565-9518-2675295a6ff3"
      unitRef="usd">15283000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTctMy0xLTEtNjYzNTE_9b192fdb-f45d-433c-9ccb-5698d9f0de51"
      unitRef="usd">7161000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTktMS0xLTEtNjYzNTE_bd92450a-415e-413a-b28e-3d140a66f5f6"
      unitRef="usd">-1426000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMTktMy0xLTEtNjYzNTE_a1bfb3cb-730c-4b4d-9ba2-6fdf7eb5fe6f"
      unitRef="usd">-344000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjAtMS0xLTEtNjYzNTE_1e7e32ee-d83a-4cfe-9b40-d6d95e4ca3cb"
      unitRef="usd">-2300000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjAtMy0xLTEtNjYzNTE_daa87dba-69f6-46b6-919f-1fab112199ac"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjEtMS0xLTEtNjYzNTE_2769f07b-9b90-434e-b777-a21c1eb0c14d"
      unitRef="usd">2338000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjEtMy0xLTEtNjYzNTE_c0d7458a-ea88-496d-a1d3-760b0bad7ac3"
      unitRef="usd">-2312000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjItMS0xLTEtNjYzNTE_5acacf7e-24db-41ba-bd43-9ca582e682b5"
      unitRef="usd">-110000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjItMy0xLTEtNjYzNTE_6d00dc07-3bf6-44e5-b719-d765a6e563db"
      unitRef="usd">14334000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <eols:IncreaseDecreaseInAccruedLitigationSettlement
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjMtMS0xLTEtNjYzNTE_d3e82aba-9191-4d16-912f-157f0c7208e7"
      unitRef="usd">-15000000</eols:IncreaseDecreaseInAccruedLitigationSettlement>
    <eols:IncreaseDecreaseInAccruedLitigationSettlement
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjMtMy0xLTEtNjYzNTE_36919ffc-2604-471f-9103-8faf6d83fca9"
      unitRef="usd">-15000000</eols:IncreaseDecreaseInAccruedLitigationSettlement>
    <eols:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjQtMS0xLTEtNjYzNTE_a30e1401-c6aa-4b69-997f-61d4fb76c56a"
      unitRef="usd">-723000</eols:IncreaseDecreaseInOperatingLeaseLiabilities>
    <eols:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjQtMy0xLTEtNjYzNTE_11c26016-d0e5-4d01-bd82-d13541bc0f1f"
      unitRef="usd">-619000</eols:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjUtMS0xLTEtNjYzNTE_4cfa5486-326b-4ec1-bcab-6e7bbc1c5d76"
      unitRef="usd">-76138000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjUtMy0xLTEtNjYzNTE_a8f1dbe0-23ab-457b-ac49-f58e9109e1fe"
      unitRef="usd">-24344000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjctMS0xLTEtNjYzNTE_2a9ec1c0-73c8-4c60-aa8f-d663525c0bef"
      unitRef="usd">752000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjctMy0xLTEtNjYzNTE_dc1f5457-e7cd-47bb-823b-339234fa9da4"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForSoftware
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjgtMS0xLTEtNjYzNTE_bf81ae22-4d5d-4e80-b228-34a0c34e7a35"
      unitRef="usd">796000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMjgtMy0xLTEtNjYzNTE_7a7b457c-c420-4c64-90b0-546ab6958fb8"
      unitRef="usd">580000</us-gaap:PaymentsForSoftware>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzAtMS0xLTEtNjYzNTE_13b3e66c-f958-431c-951a-803f303cf15e"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzAtMy0xLTEtNjYzNTE_f0d5e392-0d1a-4e52-a03b-20a4c4119e57"
      unitRef="usd">5000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzEtMS0xLTEtNjYzNTE_d6f788fd-9e9a-4fc2-8db8-553fc1fa51dc"
      unitRef="usd">-1548000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzEtMy0xLTEtNjYzNTE_b5293345-5eb9-4d4e-800e-9ce4b5c6ba2c"
      unitRef="usd">4420000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfDebt
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzMtMS0xLTEtNjYzNTE_8e5ae5a6-24f4-4b19-a94c-72afdc0b4c12"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzMtMy0xLTEtNjYzNTE_6736dd26-fb37-42fa-8075-9901b4e08ef8"
      unitRef="usd">76323000</us-gaap:RepaymentsOfDebt>
    <eols:PaymentsOfContingentRoyaltyObligation
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzQtMS0xLTEtNjYzNTE_ef845d57-8572-4b26-a145-b094e96dc7a0"
      unitRef="usd">3169000</eols:PaymentsOfContingentRoyaltyObligation>
    <eols:PaymentsOfContingentRoyaltyObligation
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzQtMy0xLTEtNjYzNTE_20a75d4b-ef3f-456f-8c59-4ccbc3a6f0fa"
      unitRef="usd">2295000</eols:PaymentsOfContingentRoyaltyObligation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i19e324736d7a4b58bee7bebe0815ab9a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzctMS0xLTEtNjYzNTE_3d7b825c-9a43-47cd-ae07-db37f9daca52"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0788351e9e084ee681884fb575fce218_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzctMy0xLTEtNjYzNTE_996e39a9-da4c-4a6e-aac6-db24d7b786b2"
      unitRef="usd">92426000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzgtMS0xLTEtNjYzNTE_91291540-e016-4d51-a481-34c904378351"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzgtMy0xLTEtNjYzNTE_4227686d-bcf0-4f1c-a873-71787c821e60"
      unitRef="usd">214000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9a3343570b8b4e2da7fe85c347c87365_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzktMS0xLTEtNjYzNTE_7dd547ee-850e-42fc-9f38-dd4931ffc740"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id4b79303cf634cad95d0ba5d12c163ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfMzktMy0xLTEtNjYzNTE_c487cda8-6c7a-414f-b67a-3d24bbd80f6f"
      unitRef="usd">10910000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDAtMS0xLTEtNjYzNTE_fead8275-ebf7-46bf-a752-d88d3b07b204"
      unitRef="usd">539000</eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan>
    <eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDAtMy0xLTEtNjYzNTE_01968a51-4fa7-4e27-930c-246f4ba6ed32"
      unitRef="usd">654000</eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDQtMS0xLTEtNjYzNTE_cfa86c92-41c1-4a0e-9412-0fe37f0e3af9"
      unitRef="usd">-2630000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDQtMy0xLTEtNjYzNTE_91bd2f1a-557d-4d80-8b91-e721dec0f14a"
      unitRef="usd">25158000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDUtMS0xLTEtNjYzNTE_929ae8af-e081-40a2-9c05-c9671dc4ec07"
      unitRef="usd">-368000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDUtMy0xLTEtNjYzNTE_25ef85be-99f2-4063-9d2a-d6db04384f80"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDYtMS0xLTEtNjYzNTE_6238060d-4a6d-4e7d-910d-45c13bd39588"
      unitRef="usd">-80684000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDYtMy0xLTEtNjYzNTE_630371ce-0dc5-42eb-83f5-2f8583b2353b"
      unitRef="usd">5234000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDctMS0xLTEtNjYzNTE_6f47d72e-3e05-432d-a912-e7f1ad88eea3"
      unitRef="usd">146256000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5b2a587e790f4e898dff40a08b249f56_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDctMy0xLTEtNjYzNTE_0372e676-f0b0-47ac-afde-f89b46320257"
      unitRef="usd">102562000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDgtMS0xLTEtNjYzNTE_f00fabae-6be4-494a-af00-3cb184341766"
      unitRef="usd">65572000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i458f436d90584702b2e171f24fc2ffd9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOmMyNDI1NzIzYjUyYTRkZDE4YmI5NzUxMzIwMzY2MzM1L3RhYmxlcmFuZ2U6YzI0MjU3MjNiNTJhNGRkMThiYjk3NTEzMjAzNjYzMzVfNDgtMy0xLTEtNjYzNTE_73e00a9c-158a-424e-a5ee-7af3b70b8789"
      unitRef="usd">107796000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfMy0xLTEtMS02NjM1MQ_ed012286-8607-491b-8240-4ee3a42917de"
      unitRef="usd">5651000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfMy0zLTEtMS02NjM1MQ_17d8d3e5-8430-4fa0-a259-7dc1c4fe2b7c"
      unitRef="usd">79000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfNC0xLTEtMS02NjM1MQ_e6d124ad-a85c-4ac2-87a4-36a042b65427"
      unitRef="usd">70000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfNC0zLTEtMS02NjM1MQ_78255216-aea2-4c14-90a9-2f7a5126b1eb"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfNi0xLTEtMS02NjM1MQ_6b931691-1872-4a8b-85d7-2d43b09c08f9"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfNi0zLTEtMS02NjM1MQ_35044c54-759e-4098-ba4e-1a7759233f6b"
      unitRef="usd">39808000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <eols:StockIssuedForAccruedLitigationSettlementExpense
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfNy0xLTEtMS02NjM1MQ_eb3f5cd6-e994-4f33-82ff-05079c4ff27a"
      unitRef="usd">0</eols:StockIssuedForAccruedLitigationSettlementExpense>
    <eols:StockIssuedForAccruedLitigationSettlementExpense
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfNy0zLTEtMS02NjM1MQ_3da86d96-1a7d-47ea-9780-a627f9c46d17"
      unitRef="usd">48421000</eols:StockIssuedForAccruedLitigationSettlementExpense>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfMTAtMS0xLTEtNjYzNTE_06e872a0-0073-47f1-82d5-1ece29bde053"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8yOC9mcmFnOjYxYTNhYjg5NGIyODRiNDhhNWNlNTE2MzM1YzdhNzViL3RhYmxlOjA5ZTlkOWI3ZmU3MDRmMjI5ZTM4YjE4MzI2ODJkYjgxL3RhYmxlcmFuZ2U6MDllOWQ5YjdmZTcwNGYyMjllMzhiMTgzMjY4MmRiODFfMTAtMy0xLTEtNjYzNTE_78b363b0-f85c-44fb-9686-cdb40d24c941"
      unitRef="usd">10000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMzc0MQ_42ecfb10-a203-419e-aebe-2febb589a342">Description of Business&lt;div style="margin-bottom:10pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolus, Inc., (&#x201c;Evolus&#x201d; or the &#x201c;Company&#x201d;) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) in February 2019. The product was also approved by Health Canada in August 2018 and the European Commission (&#x201c;EC&#x201d;) in September 2019. Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#x201c;frown lines,&#x201d; in adults. The Company commercially launched Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States in May 2019, in Canada through a distribution partner in October 2019, and in Great Britain in September 2022. The Company currently generates all of its net revenues from Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is headquartered in Newport Beach, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Financial Condition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements&#160;have been prepared&#160;on a basis that&#160;assumes that&#160;the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company&#x2019;s assets and the satisfaction of the Company&#x2019;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company has incurred recurring net operating losses and negative cash flows from operating activities and management expects operating losses and negative cash flows to continue for at least the next 12 months. The Company recorded net loss of $20,276 and $61,248 for the three and nine months ended September 30, 2022, respectively. The Company used cash of $76,138 from operations during the nine months ended September 30, 2022, which includes a settlement payment of $15,000. As of September 30, 2022, the Company had $65,572 in cash and cash equivalents and an accumulated deficit of $484,130. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company entered into a $125,000 Term Loan agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC (collectively, &#x201c;Pharmakon&#x201d;). The first tranche of $75,000 was funded on December 29, 2021. The second tranche of $50,000 may be drawn at the Company&#x2019;s election no later than December 31, 2022, subject to the terms and conditions of the loan agreement. As of September 30, 2022, the Company has not drawn the second tranche. The Company received net proceeds of $68,695 from Pharmakon, after issuance costs and debt discounts in December 2021. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term Loans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its current capital resources, which consist of cash and cash equivalents, will be sufficient to fund operations through at least the next 12 months from the date the accompanying condensed consolidated financial statements are issued based on its expected cash needs. The Company may need to raise additional capital to fund future operations through entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its scope of operations to reduce the current rate of spending through actions such as reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMTg3NQ_a3c44d69-8fd5-4dce-837f-65f5f2e3b575"
      unitRef="usd">-20276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMTg4Mg_ecf55072-a682-491c-97c0-ed1ffe6a5c40"
      unitRef="usd">-61248000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMTkzNg_1a29897d-f780-464a-bc1c-8c5d7845eae6"
      unitRef="usd">-76138000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <eols:IncreaseDecreaseInAccruedLitigationSettlement
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjAwOQ_d3e82aba-9191-4d16-912f-157f0c7208e7"
      unitRef="usd">-15000000</eols:IncreaseDecreaseInAccruedLitigationSettlement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjAzOQ_18f8ab4b-2f14-472e-adea-da5a233c46c1"
      unitRef="usd">65572000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjEwMQ_c7917478-89d5-43e2-84ab-404f10fb6952"
      unitRef="usd">-484130000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i87e2257ed337439eaac012b86d0a396b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjE1MQ_857da5b3-4a1a-4383-a6b3-1aded71c195f"
      unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1ee94ea6704b4637b072dc991661fa7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjMyNA_6ee20c45-8483-4360-9c23-9104fc1378e5"
      unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibf185154c94a4f079a63adb078d887d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjM4Mg_75db7f88-993e-44a5-8581-25045c543a11"
      unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="iafb5504b024a49c98e5b98f03ed55642_D20211201-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNC9mcmFnOjIwOWQwNWQ2NDgyNjQ5MmM4NjA1NTA5OTYyN2ZiN2MyL3RleHRyZWdpb246MjA5ZDA1ZDY0ODI2NDkyYzg2MDU1MDk5NjI3ZmI3YzJfMjYwOQ_3d6cc1f1-7a07-4f7a-bed7-26f15aa0c604"
      unitRef="usd">68695000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5NDc_5316931f-eb80-4c9d-a931-a135ba872a86">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the annual financial statements and in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. Pursuant to these SEC rules and regulations, the Company has condensed or omitted certain financial information and disclosures normally included in annual financial statements prepared in accordance with GAAP. In the opinion of management, the interim &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, considered necessary for a fair statement of the interim periods. The interim results presented herein are not necessarily indicative of the results of operations to be expected for the full year ending December&#160;31, 2022 or for any other interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements and related disclosures should be read in conjunction with the financial statements and notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on March 3, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly-owned subsidiaries, Evolus Pharma Limited, Evolus International Ltd. and Evolus Pharma BV, and have been prepared in conformity with GAAP. All intercompany transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements, inventory valuations and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#x2019;s actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The full impact of&#160;current global events, including rising inflation, volatility in the financial and credit markets, the COVID-19&#160;pandemic and the Ukrainian-Russian war, is unknown and cannot be reasonably estimated. However, where possible, management has considered the potential impact of rising inflation, volatility in the financial and credit markets, the COVID-19 pandemic, and the Ukrainian-Russian war, and their respective market impacts, on its estimates and assumptions, and there was not a material impact to the Company&#x2019;s condensed consolidated financial statements as of and for the nine months ended September 30, 2022. The Company&#x2019;s future assessment of the impact of these events, as well as other factors, could result in material impacts to the Company&#x2019;s financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (&#x201c;Daewoong&#x201d;) entered into an agreement (the &#x201c;Daewoong Agreement&#x201d;), pursuant to which the Company received an exclusive distribution license to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#x2019;s commercialization of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company commercially launched Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in the United States in May 2019, in Canada through its distribution partner in October 2019, and in Great Britain in September 2022 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#x2019;s business and its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company&#x2019;s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic continues to evolve, and the severity and magnitude of future outbreaks, or other similar public health crises, could result in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets caused by these or other events, such as increased inflation and rising interest rates and the military conflict between Russia and Ukraine, may increase the Company&#x2019;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it operates in a single operating and reportable segment. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#x2019;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#x2019;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#x2019; ability to pay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed consolidated statements of operations and comprehensive loss using the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of finished goods h&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;eld for sale and distribution. Cost is determined based on the estimated amount payable to the Company&#x2019;s supplier after accounting for any reimbursement receivable pursuant to the Daewoong Settlement Agreement (as such term is defined, and such agreement is discussed, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), using the first-in, first-out method with prioritization of the items with the earliest expiration dates. Inventory valuation reser&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#x2019;s inventory reserve calculations could result in an increase to its inventory valuation reserves. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product cost of sales, excluding amortization of intangible assets, consisted of the inventory cost, and, for periods on or after December 16, 2020, included certain royalties on the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; payable to Medytox and Allergan pursuant to the Medytox/Allergan Settlement Agreements (as such term is defined in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medytox/Allergan Settlement Agreements and Daewoong Arrangement)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Settlement Agreement with respect to such royalties. In the nine months ended September 30, 2021, the Company recorded a one-time settlement payment of $25,500 from Daewoong in connection with the Daewoong Settlement Agreement as part of cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately five years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#x2019;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has one reporting unit. There was no impairment of goodwill for any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The distribution right intangible asset related to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#x2019;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of 20 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying condensed consolidated balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of two years upon being placed in service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was no material impairment of long-lived assets for any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#x2019;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#x201c;ROU&#x201d;) asset which represents the Company&#x2019;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#x2019;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#x2019;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the condensed consolidated balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Royalty Obligation Payable to Evolus Founders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are determined at each reporting period end and recorded in operating expenses in the accompanying condensed consolidated statements of operations and comprehensive loss and as a liability in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt represents the debt balance with Pharmakon (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6. Term Loans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), net of discount and issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements of foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated into U.S. dollars at current exchange rates as of balance sheet date, and income and expense items are translated into U.S. dollars using the average rates of exchange prevailing during the period. Gains and losses arising from translation are recorded in other comprehensive gain (loss) as a separate component of shareholders&#x2019; equity. Foreign currency gains or losses on transactions denominated in a currency other than the Company&#x2019;s functional currency are recorded in other expenses, net in the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates product revenue from the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States and Great Britain and service revenue from the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through a distribution partner in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#x2019; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received. The Company recognized $684 and $1,366 of service revenues for the three and nine months ended September 30, 2022, respectively, and $0 and $702, respectively, of service revenues for the three and nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s disaggregation of revenue is consistent with its operating segment as disclosed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gross-to-Net Revenue Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume-based rebates, consumer loyalty programs and co-branded marketing programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Volume-based Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Consumer Loyalty Program &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company launched a consumer loyalty program, which allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and redeem the rewards for Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#x201c;Reward&#x201d;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on historical sales data, estimated average selling price of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at the time of redemption, expected customer and consumer participation rates in the loyalty program, and estimated number of qualifying treatments to be performed by customers. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Co-Branded Marketing Programs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company offers eligible customers with a certain level of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#x2019;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of September 30, 2022 and December&#160;31, 2021, all amounts included in accounts receivable, net on the accompanying condensed consolidated balance sheets are related to contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any contract assets nor unbilled receivables as of September 30, 2022 or December&#160;31, 2021. Sales commissions are included in selling, general and administrative expenses when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and deferred revenue associated with Rewards under the consumer loyalty program and co-branded marketing programs. The Company&#x2019;s contract liabilities are included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022 and December&#160;31, 2021, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program and co-branded marketing programs, were $10,188 and $7,934, respectively, which were recorded in accrued expenses in the accompanying condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2022 and 2021, the Company recognized $7,566 and $2,802, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collectability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#x2019;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#x2019;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of September 30, 2022 and December&#160;31, 2021, allowance for doubtful accounts was $3,271 and $2,385, respectively. For the three and nine months ended September 30, 2022, reversal of and provision for bad debts were $623 and $1,363, respectively, and the write-off amount was $392 and $477, respectively. For the three and nine months ended September 30, 2021, provision for bad debts were $188 and $501, respectively, and the write-off amount was $23 and $214, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Practical Expedients&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#x2019;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company entered into a License and Research Collaboration Agreement (the &#x201c;Collaboration Agreement&#x201d;) with a 3D printing company with biomaterial capabilities (the &#x201c;Licensor&#x201d;). Under the terms of the Collaboration Agreement, the Company was granted a license to the Licensor&#x2019;s technology to develop and commercialize any aesthetic product or non-therapeutic product that is created through the use or practice of the Licensor&#x2019;s patents. The Company paid $2,000 upon the signing of the Collaboration Agreement and has research funding, ongoing milestone and royalty payment obligations depending on the development plans, the success of such development and approval and commercialization of products. The upfront payment of $2,000 was recorded as in-process research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation Settlement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, upon entering into certain agreements to settle intellectual property disputes relating to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company agreed to pay to Allergan and Medytox $35,000 in multiple payments over two years, of which $15,000 was paid in the third quarter of 2021 and $15,000 was paid in the first quarter of 2022, and issued 6,762,652 shares of its common stock to Medytox. In addition, for the period from December 16, 2020 to September 16, 2022 (the &#x201c;Restricted Period&#x201d;), the Company agreed to pay to Allergan and Medytox a royalty on the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, based on a certain dollar amount per vial sold in the United States and a low-double digit royalty on net sales of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sold in other Evolus territories. Royalties for sales during the Restricted Period ended in the third quarter of 2022. For the period from September 17, 2022 to September 16, 2032, the Company agreed to pay to Medytox a mid-single digit royalty percentage on all net sales of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The royalty payments are made quarterly and recorded as product cost of sales on the accompanying condensed consolidated statements of operations and comprehensive loss in the periods the royalties are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The settlement agreements resulted in an $83,421 charge for the fourth quarter of 2020, which consisted of $35,000 in deferred cash payments and $48,421 from the issuance of 6,762,652 shares of the Company&#x2019;s common stock in February &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021. In the first quarter of 2022, the Company made the second cash payment of $15,000 to Medytox and Allergan with the $5,000 balance due in 2023. As of September 30, 2022 and December&#160;31, 2021, a current liability of $5,000 and $15,000, respectively, and non-current liability of $0 and $5,000, respectively, were recorded in the accompanying condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separately, in March 2021, Daewoong and the Company entered into certain agreements, pursuant to which&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Daewoong agreed to pay the Company an amount equal to $25,500, which was recorded as a settlement payment from Daewoong and included as part of cost of sales on the accompanying condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2021. For the period from December 16, 2020 to September 16, 2022, Daewoong also agreed to reimburse the Company certain amounts with respect to the royalties payable to Medytox and Allergan. This reimbursement is received quarterly and recorded as an offset to the related royalties to Medytox and Allergan in the product cost of sales on the accompanying condensed consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medytox/Allergan Settlement Agreements and Daewoong Arrangement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the details of all litigation settlement agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#x2019;s common stock, expected risk-free interest rate, and the option&#x2019;s expected life. The fair value of the Company&#x2019;s restricted stock units (&#x201c;RSUs&#x201d;) is based on the fair value on the grant date of the Company&#x2019;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the condensed consolidated balance sheets and in the selling, general and administrative or research and development expenses in the condensed consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies an estimated annual effective tax rate (&#x201c;ETR&#x201d;) approach for calculating a tax provision or benefit for interim periods, as required under GAAP.&#160;The Company recorded an income tax expense of $12 and $12 for the three months ended September 30, 2022 and 2021, respectively, and an income tax expense of $38 and $33 for the nine months ended September 30, 2022 and 2021, respectively.&#160;The Company&#x2019;s ETR differs from the U.S. federal statutory tax rate of 21% for the three and nine months ended September 30, 2022 and 2021, primarily as a result of the impact of the change of the valuation allowance to offset its deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect that changes to state tax laws through September 30, 2022 to materially impact its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. Excluded from the dilutive net loss per share computation for the three and nine months ended September 30, 2022 and 2021 were stock options of 4,932,632 and 3,873,352, respectively, and non-vested RSUs of 2,638,803 and 1,771,938, respectively, because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This update will increase transparency of government assistance received by most business entities by requiring the disclosure of: (1) the types of transactions; (2) the accounting for the transactions; and, (3) the effect of the transactions on a business entity&#x2019;s financial statements. ASU No. 2021-10 is effective for financial statements issued for annual periods beginning after December 15, 2021, with early application permitted. The Company has adopted this guidance on the effective date of January 1, 2022. There are no material impacts to the condensed consolidated financial statements as a result of this adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Issued But Not Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#x2019;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU No. 2016-13, the FASB issued ASU No. 2018-19,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 326, Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU does not change the core principle of the guidance in ASU No. 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04 which did not change the core principle of the guidance in ASU No. 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January 1, 2023. The Company is in the process of determining the effects the adoption will have on its consolidated financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the consolidated financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and in January 2021, the FASB issued ASU No. 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Scope (&#x201c;ASU 2021-01&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Both ASU No. 2020-04 and ASU No. 2021-01 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or another reference rate expected to be discontinued because of reference rate reform. ASU No. 2020-04 and ASU No. 2021-01 are effective upon issuance for contract modifications and hedging relationships, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company does not expect adoption of this guidance will have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#x2019;s present or future financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5NDg_69386e05-5b9e-4eda-9bc7-38148e8f5cb4">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the annual financial statements and in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. Pursuant to these SEC rules and regulations, the Company has condensed or omitted certain financial information and disclosures normally included in annual financial statements prepared in accordance with GAAP. In the opinion of management, the interim &lt;/span&gt;&lt;/div&gt;consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, considered necessary for a fair statement of the interim periods. The interim results presented herein are not necessarily indicative of the results of operations to be expected for the full year ending December&#160;31, 2022 or for any other interim period.The accompanying unaudited condensed consolidated financial statements and related disclosures should be read in conjunction with the financial statements and notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on March 3, 2022.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MDE_b15575ab-5929-4194-bbd9-673f6e410eda">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly-owned subsidiaries, Evolus Pharma Limited, Evolus International Ltd. and Evolus Pharma BV, and have been prepared in conformity with GAAP. All intercompany transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5NTA_1e7a45df-971d-4ed0-bf1a-d0a2768d3d02">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements, inventory valuations and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#x2019;s actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The full impact of&#160;current global events, including rising inflation, volatility in the financial and credit markets, the COVID-19&#160;pandemic and the Ukrainian-Russian war, is unknown and cannot be reasonably estimated. However, where possible, management has considered the potential impact of rising inflation, volatility in the financial and credit markets, the COVID-19 pandemic, and the Ukrainian-Russian war, and their respective market impacts, on its estimates and assumptions, and there was not a material impact to the Company&#x2019;s condensed consolidated financial statements as of and for the nine months ended September 30, 2022. The Company&#x2019;s future assessment of the impact of these events, as well as other factors, could result in material impacts to the Company&#x2019;s financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI4OTc_7f5923f8-875b-4e2e-bcea-1b2d51fd3d26">&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (&#x201c;Daewoong&#x201d;) entered into an agreement (the &#x201c;Daewoong Agreement&#x201d;), pursuant to which the Company received an exclusive distribution license to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#x2019;s commercialization of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company commercially launched Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in the United States in May 2019, in Canada through its distribution partner in October 2019, and in Great Britain in September 2022 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#x2019;s business and its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company&#x2019;s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic continues to evolve, and the severity and magnitude of future outbreaks, or other similar public health crises, could result in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets caused by these or other events, such as increased inflation and rising interest rates and the military conflict between Russia and Ukraine, may increase the Company&#x2019;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#x2019;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#x2019;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#x2019; ability to pay.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI4OTU_57523f9e-e1e0-456d-b1a5-692b900d5e65">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it operates in a single operating and reportable segment. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MTU_42622644-b0fd-4dfa-9994-ba8c3735e19e">Cash and Cash EquivalentsCash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MDI_1e76037a-6c44-419f-bed8-bcd57d83e2b8">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed consolidated statements of operations and comprehensive loss using the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5NTQ_9e00831a-4701-4a34-b94b-e0ef8443f946">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of finished goods h&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;eld for sale and distribution. Cost is determined based on the estimated amount payable to the Company&#x2019;s supplier after accounting for any reimbursement receivable pursuant to the Daewoong Settlement Agreement (as such term is defined, and such agreement is discussed, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), using the first-in, first-out method with prioritization of the items with the earliest expiration dates. Inventory valuation reser&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#x2019;s inventory reserve calculations could result in an increase to its inventory valuation reserves. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product cost of sales, excluding amortization of intangible assets, consisted of the inventory cost, and, for periods on or after December 16, 2020, included certain royalties on the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; payable to Medytox and Allergan pursuant to the Medytox/Allergan Settlement Agreements (as such term is defined in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medytox/Allergan Settlement Agreements and Daewoong Arrangement)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Settlement Agreement with respect to such royalties. In the nine months ended September 30, 2021, the Company recorded a one-time settlement payment of $25,500 from Daewoong in connection with the Daewoong Settlement Agreement as part of cost of sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTE0ODY_6eba1fa7-2333-4104-a3ec-9fe31c44a9bd"
      unitRef="usd">25500000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MDQ_3f19560e-d16a-43cf-ae07-e53df129548a">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MzA_d5ab6a94-dc95-46b0-9667-97a4d1d5ab47">Property and EquipmentProperty and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately five years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTMxMzU_edafe925-e952-4969-8170-4bc6a8b2e9be">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MDk_87307185-da32-45ff-904b-b7603fc7f2e1">&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it &lt;/span&gt;&lt;/div&gt;would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#x2019;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has one reporting unit.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTQ3OTk_01a1ab5b-3b28-4aa1-8e66-f564e255aa67"
      unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTQ4Mjg_07ae2e05-8cfa-4fef-8380-9946c60989fc"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTQ4Mjg_c274b429-bd58-43a8-b761-e0b8932fc97a"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTQ4Mjg_cd5bb5ab-3c95-462d-8e8f-b44af0040eab"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTQ4Mjg_e3598c40-71a5-4ef3-b798-3f2a5631a257"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5Mzk_0a395f88-ada2-4201-a259-cf755cb755ac">&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The distribution right intangible asset related to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#x2019;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of 20 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying condensed consolidated balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of two years upon being placed in service. &lt;/span&gt;&lt;/div&gt;The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i74d2705a944e47df928e202fbe73806f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTUzNDc_0bb45564-b6c3-4bcd-8e19-3a3e6caef17b">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icd37f700914349598839f80a5c3ac5fc_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTU4Mjk_48689d4c-e6cf-4a85-86d1-7adaa1af6351">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTY3Nzk_6c412bfe-7982-4c39-acb7-9b6d7150a78c"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTY3Nzk_b2a2ecfe-483c-47da-b318-94525cb77a2e"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTY3Nzk_b6132a1f-d829-4dfb-b12e-6a6ff2615ed9"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMTY3Nzk_ff97063b-f86d-4c78-ab05-c4be59708bf1"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5NDE_8e600dd3-0aa2-4a8d-b9a4-ecc330c1a99c">&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#x2019;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#x201c;ROU&#x201d;) asset which represents the Company&#x2019;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#x2019;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancelable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#x2019;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the condensed consolidated balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5Mjg_efbc3464-cad9-47b9-b183-c747c9d6d1b1">&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Royalty Obligation Payable to Evolus Founders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable &lt;/span&gt;&lt;/div&gt;are determined at each reporting period end and recorded in operating expenses in the accompanying condensed consolidated statements of operations and comprehensive loss and as a liability in the condensed consolidated balance sheets.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MjQ_d9b65dca-c9b0-4f8a-a154-9d81cb3ef509">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt represents the debt balance with Pharmakon (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6. Term Loans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), net of discount and issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MTY_6eb360ba-f145-443e-a8fa-b37b804fb9a6">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements of foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated into U.S. dollars at current exchange rates as of balance sheet date, and income and expense items are translated into U.S. dollars using the average rates of exchange prevailing during the period. Gains and losses arising from translation are recorded in other comprehensive gain (loss) as a separate component of shareholders&#x2019; equity. Foreign currency gains or losses on transactions denominated in a currency other than the Company&#x2019;s functional currency are recorded in other expenses, net in the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MjA_843febbb-91ae-4c9b-9f34-ab6ffe86b409">&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates product revenue from the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States and Great Britain and service revenue from the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through a distribution partner in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#x2019; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received. The Company recognized $684 and $1,366 of service revenues for the three and nine months ended September 30, 2022, respectively, and $0 and $702, respectively, of service revenues for the three and nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s disaggregation of revenue is consistent with its operating segment as disclosed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gross-to-Net Revenue Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume-based rebates, consumer loyalty programs and co-branded marketing programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Volume-based Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Consumer Loyalty Program &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company launched a consumer loyalty program, which allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and redeem the rewards for Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#x201c;Reward&#x201d;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on historical sales data, estimated average selling price of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at the time of redemption, expected customer and consumer participation rates in the loyalty program, and estimated number of qualifying treatments to be performed by customers. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Co-Branded Marketing Programs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company offers eligible customers with a certain level of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#x2019;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of September 30, 2022 and December&#160;31, 2021, all amounts included in accounts receivable, net on the accompanying condensed consolidated balance sheets are related to contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any contract assets nor unbilled receivables as of September 30, 2022 or December&#160;31, 2021. Sales commissions are included in selling, general and administrative expenses when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and deferred revenue associated with Rewards under the consumer loyalty program and co-branded marketing programs. The Company&#x2019;s contract liabilities are included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022 and December&#160;31, 2021, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program and co-branded marketing programs, were $10,188 and $7,934, respectively, which were recorded in accrued expenses in the accompanying condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2022 and 2021, the Company recognized $7,566 and $2,802, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collectability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#x2019;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#x2019;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of September 30, 2022 and December&#160;31, 2021, allowance for doubtful accounts was $3,271 and $2,385, respectively. For the three and nine months ended September 30, 2022, reversal of and provision for bad debts were $623 and $1,363, respectively, and the write-off amount was $392 and $477, respectively. For the three and nine months ended September 30, 2021, provision for bad debts were $188 and $501, respectively, and the write-off amount was $23 and $214, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Practical Expedients&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22f3e32c1ab94b0382fce87da10b1f25_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjMwMzY_96e24696-e3df-49cb-bab8-44ea4722beda"
      unitRef="usd">684000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7a96d1a07754c188b0a005f18255480_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjMwNDM_fe6544e7-635c-455e-84c2-ebca88e54f23"
      unitRef="usd">1366000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i519de1da8eb84a708ab6875c547d1cb9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjMxMTk_4dbc8683-4f59-44b4-9b07-62e652e80e37"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57cb5111d30d40a68b4e495a42bac87d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNTQ5NzU1ODU2ODUx_894a9f85-7eb7-4c25-953c-746a43094a9e"
      unitRef="usd">702000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjcxOTM_5bbbe947-ca23-4f7e-a6ad-a15eb74987de"
      unitRef="usd">10188000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjcyMDA_f929764a-9342-4d2d-8949-fef9cf735529"
      unitRef="usd">7934000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjczNjM_adcf7eac-dda1-462b-936e-bd0b91564a5a"
      unitRef="usd">7566000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjczNzA_7d4092d8-2650-4563-9562-6a8fcca2c1db"
      unitRef="usd">2802000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjgzOTM_d4055cf2-a2d0-484b-b1ed-0762a96ff36e"
      unitRef="usd">3271000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg0MDA_a9af2ced-7d2b-408f-80e3-bc1c34cfbdff"
      unitRef="usd">2385000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg0NzU_cec92107-15fc-4979-bc10-9ceb24aaa3f3"
      unitRef="usd">-623000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg0ODI_e1e320e4-3502-4489-b6f2-cc99eace2bee"
      unitRef="usd">1363000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg1Mjk_6e027b85-bd43-46e4-8d32-b55f3b32b5ee"
      unitRef="usd">392000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg1MzY_78ddbbb4-1be5-4789-9f61-db6c6b3987dd"
      unitRef="usd">477000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg2MTE_106e1643-ff59-4726-9e1b-6f8d8f6e57b9"
      unitRef="usd">188000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg2MTg_3c67007d-4bcd-49e3-8a3a-2dc594767514"
      unitRef="usd">501000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg2NjU_b9a6be23-1e7b-4710-b06a-94104f68ccab"
      unitRef="usd">23000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMjg2NzI_a3ea5b71-7058-4892-9119-e006aef06528"
      unitRef="usd">214000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5NDU_d4f40e75-4063-42d8-9972-1848cdb70e7d">&lt;div style="margin-bottom:10pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#x2019;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MjE_ab8652b4-560c-4f24-a6ba-3ed28f5d8433">&lt;div style="margin-bottom:10pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company entered into a License and Research Collaboration Agreement (the &#x201c;Collaboration Agreement&#x201d;) with a 3D printing company with biomaterial capabilities (the &#x201c;Licensor&#x201d;). Under the terms of the Collaboration Agreement, the Company was granted a license to the Licensor&#x2019;s technology to develop and commercialize any aesthetic product or non-therapeutic product that is created through the use or practice of the Licensor&#x2019;s patents. The Company paid $2,000 upon the signing of the Collaboration Agreement and has research funding, ongoing milestone and royalty payment obligations depending on the development plans, the success of such development and approval and commercialization of products. The upfront payment of $2,000 was recorded as in-process research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i39e0aaab2daf4a1f9ae49292e3fa113f_D20220601-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzA1OTI_d93a1175-a638-44bb-a7bc-7ec58d901f85"
      unitRef="usd">2000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i39e0aaab2daf4a1f9ae49292e3fa113f_D20220601-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzA4NTg_22d057ff-d357-4156-817a-1f8289e3e540"
      unitRef="usd">2000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i7982c1b9a3ab4239b877aa1d02a5459e_I20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzExMTM_a008a69f-c114-4e1c-88eb-2d9746a2fde1"
      unitRef="usd">35000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <eols:LossContingencySettlementAgreementPaymentTerms
      contextRef="i1f6eead0dce949398cd5a205a8b761a2_D20210201-20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzExNDI_e255329f-7126-47b8-9132-9e646924cbcf">P2Y</eols:LossContingencySettlementAgreementPaymentTerms>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="id23cfd7dc1564cd6aaa76f53b45ccf4f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzExNTU_66c66259-461a-4351-8763-8e157c4dfdfe"
      unitRef="usd">15000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i0997749416bc4e028361e395d1f8bf92_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzEyMDA_0f73203c-4279-4219-a051-4881a354a15c"
      unitRef="usd">15000</us-gaap:LossContingencyAccrualPayments>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="ic6fd11493b9d4a18967f5147f5eb25fc_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzEyNTM_dd73c8b9-acea-4e3f-8e3f-e4ed9ea400dd"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <us-gaap:LitigationSettlementExpense
      contextRef="ie6f902c0f3cf4c5f86905379573f1883_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIwMzI_2a6a1904-758b-4772-b9f6-5c2e77e9f797"
      unitRef="usd">83421000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i84371b8801da47da9efba13175f076d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIwOTM_5234eac6-eb18-411e-be71-3a9e661242d6"
      unitRef="usd">35000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="if066a834ef404c0da380ab9066a249ab_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIxMjY_6c77ce6c-435e-44a1-91ba-63095034bb8f"
      unitRef="usd">48421000</us-gaap:PaymentsForLegalSettlements>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="ic6fd11493b9d4a18967f5147f5eb25fc_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIxNTA_c3b0dad6-dcc0-4429-8157-445bf864c365"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i0997749416bc4e028361e395d1f8bf92_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIyODI_0f73203c-4279-4219-a051-4881a354a15c"
      unitRef="usd">15000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LitigationReserveCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIzMTg_8a51efe4-8990-40c1-aaae-6b31a2f5b213"
      unitRef="usd">5000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIzODI_8a51efe4-8990-40c1-aaae-6b31a2f5b213"
      unitRef="usd">5000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzIzODk_760badac-66fc-4251-9a40-68b2014dd54a"
      unitRef="usd">15000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzI0MzY_09c6f2ca-5084-4664-af15-4ab5f72b1d4e"
      unitRef="usd">0</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzI0NDM_647995fd-ee4d-4e49-928f-c40963e4ea9a"
      unitRef="usd">5000000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ifd893c426cf344bfb3e70e80a9717b85_D20210301-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzI2OTI_c5c08d22-d59e-436c-bf25-38eb80982e45"
      unitRef="usd">-25500000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MjI_fb521103-5bbc-40e6-abe2-d4a6141c048f">&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#x2019;s common stock, expected risk-free interest rate, and the option&#x2019;s expected life. The fair value of the Company&#x2019;s restricted stock units (&#x201c;RSUs&#x201d;) is based on the fair value on the grant date of the Company&#x2019;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.&lt;/span&gt;&lt;/div&gt;The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the condensed consolidated balance sheets and in the selling, general and administrative or research and development expenses in the condensed consolidated statements of operations and comprehensive loss.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MTE_6e0807ea-c228-4334-aa64-25e70e53e042">&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies an estimated annual effective tax rate (&#x201c;ETR&#x201d;) approach for calculating a tax provision or benefit for interim periods, as required under GAAP.&#160;The Company recorded an income tax expense of $12 and $12 for the three months ended September 30, 2022 and 2021, respectively, and an income tax expense of $38 and $33 for the nine months ended September 30, 2022 and 2021, respectively.&#160;The Company&#x2019;s ETR differs from the U.S. federal statutory tax rate of 21% for the three and nine months ended September 30, 2022 and 2021, primarily as a result of the impact of the change of the valuation allowance to offset its deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions.&lt;/span&gt;&lt;/div&gt;The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect that changes to state tax laws through September 30, 2022 to materially impact its condensed consolidated financial statements.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzQ4MzU_42d1d2b4-173a-4c71-aaeb-67a58abb30b0"
      unitRef="usd">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzQ4NDI_dc656361-ab1b-4dfb-81ed-637eaffbd142"
      unitRef="usd">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzQ5MDc_63b0a84e-1f29-4b75-a65d-68314a8d3995"
      unitRef="usd">38000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzQ5MTQ_c22b8092-1f62-4528-9609-b07c14b8bba2"
      unitRef="usd">33000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5MzM_9cc6cf31-dbac-4ca2-9e39-f8802a15e969">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. Excluded from the dilutive net loss per share computation for the three and nine months ended September 30, 2022 and 2021 were stock options of 4,932,632 and 3,873,352, respectively, and non-vested RSUs of 2,638,803 and 1,771,938, respectively, because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaa3b589eceb84e1c94c3c2c4af20ab72_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc0NTc_7bb65e99-b602-442b-bc88-11726fbeaac6"
      unitRef="shares">4932632</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib29f2936ca6c4e15a73ecfb1e92029f6_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc0NTc_840f4933-6573-4c90-afe6-2a0e484d900d"
      unitRef="shares">4932632</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8813e5b8a70741dc843401ec024d4735_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc0NjQ_3d76e1ef-915d-44cd-bba9-1b82af9e8320"
      unitRef="shares">3873352</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib956a75826f1489e9a25f9ab19425726_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc0NjQ_71473a18-dcb6-4df9-babb-27faec502e45"
      unitRef="shares">3873352</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i107ea59f6dc34340846131488239195e_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc1MDU_5f92939d-7c3c-4186-8e52-987e2f4bb135"
      unitRef="shares">2638803</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic4b9df72617243df82a84ee6f7a17e88_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc1MDU_88428e63-bb38-4e42-b9ca-b7400c690df5"
      unitRef="shares">2638803</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i33badbda974443e1a5a538c1d41eb1f2_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc1MTI_26e9a0b4-5e8b-4ca3-be60-d658dbce3c16"
      unitRef="shares">1771938</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6de66ce7e4cd487684e1ec075b96e8c2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfMzc1MTI_8976a696-154e-46df-ac9b-d93df1b64682"
      unitRef="shares">1771938</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV8zNy9mcmFnOjUxMjEzMzE4MWMwMzQwOWY5Mjc0ODNhNTAyMzA3MzhkL3RleHRyZWdpb246NTEyMTMzMTgxYzAzNDA5ZjkyNzQ4M2E1MDIzMDczOGRfNDI5Mjk_0d4db9df-5bb8-4004-8a70-c40467c18a05">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This update will increase transparency of government assistance received by most business entities by requiring the disclosure of: (1) the types of transactions; (2) the accounting for the transactions; and, (3) the effect of the transactions on a business entity&#x2019;s financial statements. ASU No. 2021-10 is effective for financial statements issued for annual periods beginning after December 15, 2021, with early application permitted. The Company has adopted this guidance on the effective date of January 1, 2022. There are no material impacts to the condensed consolidated financial statements as a result of this adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Issued But Not Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#x2019;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU No. 2016-13, the FASB issued ASU No. 2018-19,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 326, Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU does not change the core principle of the guidance in ASU No. 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04 which did not change the core principle of the guidance in ASU No. 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. As amended by ASU No. 2019-10, the updated guidance is effective for the Company as a smaller reporting company beginning January 1, 2023. The Company is in the process of determining the effects the adoption will have on its consolidated financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the consolidated financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and in January 2021, the FASB issued ASU No. 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Scope (&#x201c;ASU 2021-01&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Both ASU No. 2020-04 and ASU No. 2021-01 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or another reference rate expected to be discontinued because of reference rate reform. ASU No. 2020-04 and ASU No. 2021-01 are effective upon issuance for contract modifications and hedging relationships, and the Company is allowed to elect to apply the amendments prospectively through December 31, 2022. The Company does not expect adoption of this guidance will have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#x2019;s present or future financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfMjA0NQ_91cb3871-3bb7-4885-91ab-28557437092d">Fair Value Measurements and Short-Term Investments&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the nine months ended September 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of the contingent royalty obligation payable to Evolus Founders based on Level 3 inputs using a discounted cash flows method. The significant unobservable input assumptions that can significantly change the fair value include (i) projected amount and timing of net revenues during the payment period, which terminates at the end of the second quarter of 2029, (ii) the discount rate, and (iii) the timing of payments. During the three and nine months ended September 30, 2022 and 2021, the Company utilized a discount rate of 13.0%, reflecting the Company&#x2019;s risk profile. Net revenue projections are also updated to reflect changes in the timing of expected sales.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.452%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recorded in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Financial Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. &lt;/span&gt;&lt;/div&gt;The Company estimates the fair value of the long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of September 30, 2022 and December&#160;31, 2021, the fair value of long-term debt was $70,360 and $75,448, respectively. The fair value of operating lease liabilities&#160;as of September 30, 2022 and December&#160;31, 2021 approximated their carrying value.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfMjA1MA_d23952f6-0581-4906-88ca-8a2d94c0e1af">The fair value of these instruments was as follows:&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib955eea1a8f64090909d07cf0f04a443_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmFhNmI5ODhiYTk4YjQ4OThiNzY0MjI1ZjMxZDI2ZjE1L3RhYmxlcmFuZ2U6YWE2Yjk4OGJhOThiNDg5OGI3NjQyMjVmMzFkMjZmMTVfMy0xLTEtMS02NjM1MQ_956f85d5-ca9b-49a8-845c-0bb1b425dd2e"
      unitRef="usd">45517000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibc3b4cc897fe4b31821dca208a7264a5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmFhNmI5ODhiYTk4YjQ4OThiNzY0MjI1ZjMxZDI2ZjE1L3RhYmxlcmFuZ2U6YWE2Yjk4OGJhOThiNDg5OGI3NjQyMjVmMzFkMjZmMTVfMy0zLTEtMS02NjM1MQ_63af9be5-c26d-4b68-8565-7ae0b81cad46"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iead433642b5a445d83074f84bb63c628_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmFhNmI5ODhiYTk4YjQ4OThiNzY0MjI1ZjMxZDI2ZjE1L3RhYmxlcmFuZ2U6YWE2Yjk4OGJhOThiNDg5OGI3NjQyMjVmMzFkMjZmMTVfMy01LTEtMS02NjM1MQ_c462640b-5bae-44d5-8ab4-b3c646d0c1e2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i03eb03f09bcf4e01b9c6fba2243bb8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmFhNmI5ODhiYTk4YjQ4OThiNzY0MjI1ZjMxZDI2ZjE1L3RhYmxlcmFuZ2U6YWE2Yjk4OGJhOThiNDg5OGI3NjQyMjVmMzFkMjZmMTVfMy03LTEtMS02NjM1MQ_b2291dd2-805e-48cc-aef0-12a625f3319a"
      unitRef="usd">45517000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i46b9d9f3ec3d401cab72265246433b66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOjRhZDIzOTIwMWU2MTRmMmZhZWM1NTQxNmMwZWQ4YmZiL3RhYmxlcmFuZ2U6NGFkMjM5MjAxZTYxNGYyZmFlYzU1NDE2YzBlZDhiZmJfMy0xLTEtMS02NjM1MQ_c9604c8c-69dd-4224-bcfe-461351701987"
      unitRef="usd">44740000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i11377a43f27c4faba7aad6793f724743_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOjRhZDIzOTIwMWU2MTRmMmZhZWM1NTQxNmMwZWQ4YmZiL3RhYmxlcmFuZ2U6NGFkMjM5MjAxZTYxNGYyZmFlYzU1NDE2YzBlZDhiZmJfMy0zLTEtMS02NjM1MQ_b7642a7f-91ab-4378-bc5e-d7d32ec86f46"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8509a6d0797e4a1b8fd1d32a15d74377_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOjRhZDIzOTIwMWU2MTRmMmZhZWM1NTQxNmMwZWQ4YmZiL3RhYmxlcmFuZ2U6NGFkMjM5MjAxZTYxNGYyZmFlYzU1NDE2YzBlZDhiZmJfMy01LTEtMS02NjM1MQ_a47ba7da-0f3b-4ae4-a495-ad9d4af68086"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i84d7dc8ca08a4da6a6c642d9a973ff92_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOjRhZDIzOTIwMWU2MTRmMmZhZWM1NTQxNmMwZWQ4YmZiL3RhYmxlcmFuZ2U6NGFkMjM5MjAxZTYxNGYyZmFlYzU1NDE2YzBlZDhiZmJfMy03LTEtMS02NjM1MQ_a91f188c-eba4-4e0d-9e37-916768f787e6"
      unitRef="usd">44740000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i7373271b2dde4aba839209bce8d0292e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfOTY2_a112823c-0989-48cb-904d-8a87ad95dd52"
      unitRef="number">0.130</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="ib746515f688d46d7934e1ac056024bba_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfOTY2_e194ecad-1cdd-4641-b4e2-7bd73164ed34"
      unitRef="number">0.130</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfMjA0Nw_99065f11-7716-45d1-beb5-0f85a7c80a76">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.452%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recorded in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i41fd4a2cf7cb49e6a38c2fc9b0df76fd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMi0xLTEtMS02NjM1MQ_0e108687-cac7-4929-8ddb-9341df499bc7"
      unitRef="usd">45415000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i13db4b6383624d5097720364e94a31b5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMi0zLTEtMS02NjM1MQ_043cef8c-f23f-4814-8ad7-5fb81a9223a8"
      unitRef="usd">42683000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMi01LTEtMS02NjM1MQ_0a956e60-baab-499a-8d1f-d1c680193a35"
      unitRef="usd">44740000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5b2a587e790f4e898dff40a08b249f56_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMi03LTEtMS02NjM1MQ_32dac41b-8fad-4bbb-acd5-518b84187bfe"
      unitRef="usd">41546000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMy0xLTEtMS02NjM1MQ_3512cedd-1570-45c0-baa4-0931573e8d3a"
      unitRef="usd">1114000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMy0zLTEtMS02NjM1MQ_073aa864-0a3c-40bf-94ca-26f2cc0fafd1"
      unitRef="usd">783000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMy01LTEtMS02NjM1MQ_9e3f5c7a-3ccc-43c8-a262-d1025dfe0065"
      unitRef="usd">3169000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfMy03LTEtMS02NjM1MQ_aca7b9de-d228-4d23-865c-2255f56434c8"
      unitRef="usd">2295000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNC0xLTEtMS02NjM1MQ_d10be86d-9d3a-4d74-9d86-7a0b9968cea2"
      unitRef="usd">-1216000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNC0zLTEtMS02NjM1MQ_3347cc1b-f8ed-4356-bc01-09e7eb067773"
      unitRef="usd">-1400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNC01LTEtMS02NjM1MQ_984a5e7a-8528-4636-a6e0-f049249b7ebe"
      unitRef="usd">-3946000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNC03LTEtMS02NjM1MQ_d4888a99-d3cf-4800-b86e-09480ebb9b42"
      unitRef="usd">-4049000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNS0xLTEtMS02NjM1MQ_90f59a19-31a9-4ef1-85a0-bb66bfc6899f"
      unitRef="usd">45517000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i458f436d90584702b2e171f24fc2ffd9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNS0zLTEtMS02NjM1MQ_013749e0-0e2c-415d-b533-af26bdfe2482"
      unitRef="usd">43300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNS01LTEtMS02NjM1MQ_5c7c94bb-e1f8-4860-a684-5d62daf4e969"
      unitRef="usd">45517000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i458f436d90584702b2e171f24fc2ffd9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RhYmxlOmY0NGVhNGNhZGUwZjRhY2E5MTMxNGViOGVkNDU5MzY4L3RhYmxlcmFuZ2U6ZjQ0ZWE0Y2FkZTBmNGFjYTkxMzE0ZWI4ZWQ0NTkzNjhfNS03LTEtMS02NjM1MQ_90e58054-eaf7-4345-8f00-37f2c4cb729e"
      unitRef="usd">43300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i74ba879b9f0b49eeb45d7c48810743cf_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfMTkxOQ_22cd16ba-680a-4766-8f82-a1a11d98793b"
      unitRef="usd">70360000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iefccff05ba3b424ea7695cd478bcf8c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80My9mcmFnOjhiZGI3ODc2ZjRkNzQzZmY5MWQwNGY4OGYxNTQ4YTE4L3RleHRyZWdpb246OGJkYjc4NzZmNGQ3NDNmZjkxZDA0Zjg4ZjE1NDhhMThfMTkyNg_dd5bab8b-f28b-4683-8d1c-08ec6e2c9045"
      unitRef="usd">75448000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTQ5Mg_04e9f554-50a9-44c2-b44a-800dee5f02fd">Goodwill and Intangible Assets&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Original Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Original Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*  Intangible assets with indefinite lives have an indeterminable average life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;September 30, 2022 that are subject to amortization:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining in 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distribution right represents the license and associated distribution right to develop Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the initial term of which expires in September 2023 and is automatically extended for unlimited additional three-year terms provided that the Company meets certain performance requirements. The Company paid Daewoong $3,000 in milestone payments in 2019, pursuant to the Daewoong Agreement, which increased the cost basis of the distribution. Under the Daewoong Settlement Agreement (as defined in Note 11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), there is no additional cash consideration due to Daewoong. See&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalized $531 and $0 for the three months ended September 30, 2022 and 2021, respectively, and $938 and $633 for the nine months ended September 30, 2022 and 2021, respectively, related to costs of computer software developed for internal use. The Company recorded total intangible assets amortization expense of $838 and $843 for the three months ended September 30, 2022 and 2021, respectively, and $2,454 and $4,463 for the nine months ended September 30, 2022 and 2021, respectively, within depreciation and amortization on the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTQ4Ng_a94fce32-d144-4fb6-bf17-1ec8c62c5192">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Original Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Original Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*  Intangible assets with indefinite lives have an indeterminable average life.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i74d2705a944e47df928e202fbe73806f_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMi0xLTEtMS02NjM1MQ_c9546f90-d43d-47dc-8d65-13cd20121bea">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4d5a4bd9076b49e990faeaca86303ea1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMi0zLTEtMS02NjM1MQ_5bbf2587-3f27-450f-86c3-13a819a68e39"
      unitRef="usd">59076000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4d5a4bd9076b49e990faeaca86303ea1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMi01LTEtMS02NjM1MQ_e0d4e97f-f523-4bf6-bd76-7836f28fb76d"
      unitRef="usd">10806000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4d5a4bd9076b49e990faeaca86303ea1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMi03LTEtMS02NjM1MQ_9e882eaa-0ad4-4a0e-8a00-35d13fd399e5"
      unitRef="usd">48270000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7b7b2f262aa04bfebf9a790343dc73ff_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMy0xLTEtMS02NjM1MQ_150a9533-d211-4b33-89d0-868b71d9a5b5">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3d84afa1250640b198c1fb1a6169c85a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMy0zLTEtMS02NjM1MQ_d48df789-028c-4587-b616-b65f890d8d2e"
      unitRef="usd">8252000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3d84afa1250640b198c1fb1a6169c85a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMy01LTEtMS02NjM1MQ_460f9f6d-55f3-40b5-98e9-03112fcc019d"
      unitRef="usd">7414000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3d84afa1250640b198c1fb1a6169c85a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfMy03LTEtMS02NjM1MQ_9bd1ebaa-6ee0-448c-8ceb-ab3b3bfd34c9"
      unitRef="usd">838000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNC0zLTEtMS02NjM1MQ_a76f9ed1-bfd2-4a1d-83bd-ccf3f71895f3"
      unitRef="usd">67328000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNC01LTEtMS02NjM1MQ_760aaab0-ad6a-42a3-975d-343342fa6018"
      unitRef="usd">18220000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNC03LTEtMS02NjM1MQ_996422e2-657f-4314-8cbd-3d6342c60c2c"
      unitRef="usd">49108000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNi0zLTEtMS02NjM1MQ_66d82b49-0bc1-41cf-9fa2-979cbe153a76"
      unitRef="usd">21208000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNi03LTEtMS02NjM1MQ_ee5af62f-9318-4e2e-8c75-c98d70fd6136"
      unitRef="usd">21208000</us-gaap:Goodwill>
    <eols:IntangibleAssetsGrossIncludingGoodwill
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNy0zLTEtMS02NjM1MQ_3a1d7159-8851-4749-96ae-c7f9e082265d"
      unitRef="usd">88536000</eols:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNy01LTEtMS02NjM1MQ_6beef29a-5e35-4bc4-b95a-4cb169a1f19b"
      unitRef="usd">18220000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjQ4ZDU3MmNhNzU5OTRhMTE5ZWRmNTYxOGU4ZTQzODFiL3RhYmxlcmFuZ2U6NDhkNTcyY2E3NTk5NGExMTllZGY1NjE4ZThlNDM4MWJfNy03LTEtMS02NjM1MQ_fe94bef8-3b2e-4c45-b6fb-f2f13c0e0441"
      unitRef="usd">70316000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ieab10e4bb85e456c8270ad88c92f573a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMi0xLTEtMS02NjM1MQ_6ea2e678-6952-4cd1-aecc-680307d9ea00">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2a097741d79a4319ba97c97d46d0a539_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMi0zLTEtMS02NjM1MQ_ec26b0d0-5252-4f46-a0f1-866bb39ed03d"
      unitRef="usd">59076000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2a097741d79a4319ba97c97d46d0a539_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMi01LTEtMS02NjM1MQ_ad8f315a-8d61-452f-af5c-11bab4f04919"
      unitRef="usd">8589000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2a097741d79a4319ba97c97d46d0a539_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMi03LTEtMS02NjM1MQ_4bb3e56a-2b82-49e7-8c4b-7fe37bfa7706"
      unitRef="usd">50487000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1eae918cd3a1458f8f5c7ea81225a697_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMy0xLTEtMS02NjM1MQ_fb09a6da-73c6-4ff5-acb7-ba5beb908b40">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i492a93cfde634638aead055c0ca3b153_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMy0zLTEtMS02NjM1MQ_62c45f67-906b-40aa-8434-42dc631fb312"
      unitRef="usd">7314000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i492a93cfde634638aead055c0ca3b153_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMy01LTEtMS02NjM1MQ_dec08cc0-3d90-4ebe-9075-c94bbb15f5be"
      unitRef="usd">7176000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i492a93cfde634638aead055c0ca3b153_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfMy03LTEtMS02NjM1MQ_3a76ed2a-2718-4b8e-a26f-72eb873db803"
      unitRef="usd">138000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNC0zLTEtMS02NjM1MQ_d725d837-3efe-4000-a513-aabba61abbb8"
      unitRef="usd">66390000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNC01LTEtMS02NjM1MQ_75f6a447-a8d0-4a31-9e8b-749dfad508ba"
      unitRef="usd">15765000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNC03LTEtMS02NjM1MQ_f25e54ff-8808-4f54-b0f5-9d92862a68eb"
      unitRef="usd">50625000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNi0zLTEtMS02NjM1MQ_1fbe6a88-10fb-41b1-be37-f70f04ee3198"
      unitRef="usd">21208000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNi03LTEtMS02NjM1MQ_c8e601da-372d-4987-8d23-49eb0e3745c3"
      unitRef="usd">21208000</us-gaap:Goodwill>
    <eols:IntangibleAssetsGrossIncludingGoodwill
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNy0zLTEtMS02NjM1MQ_fdc17a08-7983-4e4a-b359-0fa0178b4049"
      unitRef="usd">87598000</eols:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNy01LTEtMS02NjM1MQ_9007a003-afb3-404d-9cda-d29ffdfce59c"
      unitRef="usd">15765000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOmY4ZjVhYTY5YWNlMDRjNGNiMTUxYmY5NzM4ZDFiNzQ3L3RhYmxlcmFuZ2U6ZjhmNWFhNjlhY2UwNGM0Y2IxNTFiZjk3MzhkMWI3NDdfNy03LTEtMS02NjM1MQ_e87fdbd6-35ab-47df-a500-4ec82afb5b5b"
      unitRef="usd">71833000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTQ5Ng_b25120d7-37d5-4ca8-a78d-ff12bbd5450e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;September 30, 2022 that are subject to amortization:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining in 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfMS0xLTEtMS02NjM1MQ_ba079011-2a80-4efb-b52d-951aaec68182"
      unitRef="usd">859000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfMi0xLTEtMS02NjM1MQ_8e537559-9d74-4f4b-91a3-09c212f65f3c"
      unitRef="usd">3434000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfMy0xLTEtMS02NjM1MQ_2aee7d3e-bc79-4274-ad7f-c79ebadc7a20"
      unitRef="usd">3195000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfNC0xLTEtMS02NjM1MQ_14964109-d6d6-487a-af26-5853539194b6"
      unitRef="usd">2955000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfNS0xLTEtMS02NjM1MQ_5fc80d27-0444-4cf1-9dd4-b4a690928eb3"
      unitRef="usd">2955000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <eols:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfNi0xLTEtMS02NjM1MQ_8f5ada91-e296-4100-920f-e124db5253da"
      unitRef="usd">35710000</eols:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RhYmxlOjA5ZmIwMjNkZmU1MjRjZmE4YjUxZTFkY2Y0OWM1YmMzL3RhYmxlcmFuZ2U6MDlmYjAyM2RmZTUyNGNmYThiNTFlMWRjZjQ5YzViYzNfNy0xLTEtMS02NjM1MQ_be626f34-6a0b-4500-a845-65f33f8da879"
      unitRef="usd">49108000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <eols:AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements
      contextRef="ia8be82e572d441889a4d6f6934c06888_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTQ4OQ_ab4d0973-3347-4582-822a-133746c4b9ce">P3Y</eols:AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements>
    <eols:MilestonePaymentsForIntangibleAssets
      contextRef="ic324d34859d240ffa67a43c66f937f95_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfNzM4_2c92019d-7a0f-4156-a102-031af532e0ae"
      unitRef="usd">3000</eols:MilestonePaymentsForIntangibleAssets>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTA0Mw_2f011860-1e73-4d4a-9fab-b5e80b7499ed"
      unitRef="usd">531000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTA1MA_7c455d74-cf87-4478-905f-37be823766ad"
      unitRef="usd">0</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTA5MA_92a1277d-0e32-4683-a62a-0f9734c67ec2"
      unitRef="usd">938000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTA5Nw_8f3fbee5-bbe0-4ab4-b6e0-455f74608434"
      unitRef="usd">633000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTI2OA_6542e857-0e9f-432a-a66b-582c0774ca16"
      unitRef="usd">838000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTI3NQ_671f3e62-b70d-40a5-bc7a-9838cb7cd9cb"
      unitRef="usd">843000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTMxNQ_aca933db-e978-43e9-b2bc-c08a424c285c"
      unitRef="usd">2454000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80Ni9mcmFnOmMwMmViOTk0ZDEyMTRlN2ZhMzkxNWJjYjFlZGEzMTIyL3RleHRyZWdpb246YzAyZWI5OTRkMTIxNGU3ZmEzOTE1YmNiMWVkYTMxMjJfMTMyMg_044099e7-541a-4eaa-96ed-155798c13b75"
      unitRef="usd">4463000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RleHRyZWdpb246ZDY3ZjIwMDRkZTE3NDVjNTk1ZWMwODgyZDczODE3MmJfNjI_6f1a6ce3-9cca-4526-9723-32d4ae8170cc">Accrued Expenses&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties under the Medytox/Allergan Settlement Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued revenue contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RleHRyZWdpb246ZDY3ZjIwMDRkZTE3NDVjNTk1ZWMwODgyZDczODE3MmJfNjU_0088945c-5612-4fb2-b5af-56206283af1e">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties under the Medytox/Allergan Settlement Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued revenue contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfMi0xLTEtMS02NjM1MQ_f44191e6-2c58-4875-94bb-2c6351f48722"
      unitRef="usd">7936000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfMi0zLTEtMS02NjM1MQ_e9fff7bd-4ffe-4b93-b14a-66e435a56dd8"
      unitRef="usd">12447000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfMy0xLTEtMS02NjM1MQ_89b4e252-ac1f-48c0-b33a-16be62a12f60"
      unitRef="usd">7094000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfMy0zLTEtMS02NjM1MQ_728fdde1-e56a-413b-a584-15b09d10e4ac"
      unitRef="usd">6856000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfNC0xLTEtMS02NjM1MQ_5bbbe947-ca23-4f7e-a6ad-a15eb74987de"
      unitRef="usd">10188000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfNC0zLTEtMS02NjM1MQ_f929764a-9342-4d2d-8949-fef9cf735529"
      unitRef="usd">7934000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfNS0xLTEtMS02NjM1MQ_0a4fa0a5-3599-49ef-ba91-31ee48c8a609"
      unitRef="usd">4665000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfNS0zLTEtMS02NjM1MQ_10d4548b-d2bd-466b-85fd-20970f1cc5f9"
      unitRef="usd">2756000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfNi0xLTEtMS02NjM1MQ_3f35284b-866d-4816-a466-b4de6a8736b7"
      unitRef="usd">29883000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV80OS9mcmFnOmQ2N2YyMDA0ZGUxNzQ1YzU5NWVjMDg4MmQ3MzgxNzJiL3RhYmxlOjE3MzY5MzYwODEyYzRlMDNhMjJhYjkzMjIyMWRmODE0L3RhYmxlcmFuZ2U6MTczNjkzNjA4MTJjNGUwM2EyMmFiOTMyMjIxZGY4MTRfNi0zLTEtMS02NjM1MQ_aa6aebca-81e8-4004-8a74-52ade90cc0fb"
      unitRef="usd">29993000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjcyNA_e9099cbe-0328-44e9-85c8-153ae3c816a9">Term Loans&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmakon Term Loans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 14, 2021, the Company entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to the Company in two tranches (&#x201c;Pharmakon Term Loans&#x201d;). The first tranche of $75,000 was funded on December 29, 2021. The second tranche of $50,000 may be drawn at the Company&#x2019;s election no later than December 31, 2022, subject to the terms and conditions of the Pharmakon Term Loans. As of September 30, 2022, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company has not drawn the second tranche. The Pharmakon Term Loans will mature on the six-year anniversary of the closing date of the first tranche (&#x201c;Maturity Date&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmakon Term Loans accrue interest at a per annum rate equal to the greater of 1.0% or 3-month U.S. Dollar LIBOR rate plus 8.5% per annum. In the event U.S. Dollar LIBOR rate is discontinued, the interest rate for the Pharmakon Term Loans will be based on an alternate benchmark rate established in the manner provided under the loan agreement for the Pharmakon Term Loans. The Company agreed to make 12 equal quarterly payments of principal on the outstanding Pharmakon Term Loans commencing on or immediately following the 39th-month anniversary of the funding date of the first tranche continuing through the Maturity Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may elect to prepay all amounts, not less than $20,000, owed prior to the Maturity Date. Prepayments of the first tranche prior to the second anniversary of the closing date of the first tranche and prepayments of the second tranche prior to the second anniversary of the date on which the second tranche is drawn by the Company will be accompanied by a make whole amount equal to the sum of all interest that would have accrued through such second anniversary. Prepayments of the Pharmakon Term Loans will also be accompanied by a prepayment premium equal to the principal amount so prepaid multiplied by 3.0% if made prior to the third anniversary of the closing date of the first tranche, 2.0% if made on or after the third anniversary of the closing date of the first tranche but prior to the fourth anniversary of the closing date of the first tranche, and 1.0% if made on or after the fourth anniversary of the closing date of the first tranche but prior to the Maturity Date. If the Pharmakon Term Loans are accelerated following the occurrence of an event of default, including a material adverse change, the Company is required to immediately pay Pharmakon an amount equal to the sum of all outstanding principal, unpaid interest, and applicable make whole and prepayment premiums.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmakon Term Loans are secured by substantially all of the Company&#x2019;s assets. The Pharmakon Term Loans contain customary affirmative and restrictive covenants and representations and warranties. The affirmative covenants include, among others, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. The restrictive covenants include, among others, incurring certain additional indebtedness, consummating certain change in control transactions, or incurring any non- permitted lien or other encumbrance on the Company&#x2019;s assets, without Pharmakon&#x2019;s prior written consent. The Pharmakon Term Loans do not contain covenants requiring the Company to maintain a minimum cash threshold or minimum revenues or earnings. As of September 30, 2022, the Company was in compliance with its debt covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing date of the first tranche, the Company incurred $3,042 and $3,263 in debt discounts and issuance costs related to the Pharmakon Term Loans, respectively. Debt discounts and issuance costs related to the entire Pharmakon Term Loans have been allocated pro rata between the funded and unfunded portions. Debt discounts and issuance costs allocated to the first tranche of $75,000 have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. As of September 30, 2022, the borrowings outstanding under the Pharmakon Term Loans were classified as long-term debt in the accompanying condensed consolidated balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately 12.22% as of September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term debt, net of discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Oxford Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 15, 2019, the Company entered into a Loan and Security Agreement with Oxford (the &#x201c;Loan Agreement&#x201d;), providing for a credit facility of up to $100,000. Pursuant to the terms of the credit facility, the lender extended term loans (the &#x201c;Oxford Term Loan&#x201d;), available in two advances, to the Company. The first tranche of $75,000 was funded on the closing date. The second tranche of $25,000 was not drawn. The credit facility bore an annual interest rate equal to the greater of 9.5%, or the 30-day U.S. Dollar LIBOR rate plus 7.0%. The Company agreed to pay interest-only for the first 36 months until May 2022, followed by a 23-month amortization period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the earliest to occur of the maturity date, the acceleration of the Oxford Term Loan, or the prepayment of the Oxford Term Loan, the Company was required to pay to Oxford a final payment of 5.5% of the full principal amount of the Oxford Term Loan funded (&#x201c;Final Payment&#x201d;). The Company could elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee was also paid, which would be equal to 2.0% of the amount prepaid if the prepayment occurred after March 15, 2020 and on or prior to March 15, 2021, or 1.0% of the amount prepaid if the prepayment occurred thereafter (&#x201c;Prepayment Fee&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 4, 2021, the Company and Oxford entered into an agreement (&#x201c;Payoff Letter&#x201d;), pursuant to which (i) the Company paid Oxford $76,447 to discharge in full all outstanding obligations, including accrued interest, by and between Oxford, in its capacity as collateral agent and lender, and the Company, and (ii) effective upon such repayment, the Loan Agreement, and all unfunded commitments thereunder, guarantees and other security interests granted to Oxford in connection with the Loan Agreement and all other obligations of and restrictions on the Company under the Loan Agreement, terminated. As a condition to entering into the Payoff Letter, Oxford agreed to waive a total of $4,300 of fees comprised of (i) $2,800 of the Final Payment and (ii) the Prepayment Fee of $1,500. As a result, the Company recorded a loss of $1,939 in extinguishment of debts, net on the accompanying condensed consolidated statements of operations and comprehensive loss in the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;Daewoong Convertible Note&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 6, 2020, the Company entered into a Convertible Promissory Note Purchase Agreement with Daewoong for the principal amount of $40,000 (the &#x201c;Daewoong Convertible Note&#x201d;), which was funded on July 30, 2020. Additionally, on July 6, 2020, the Company, Daewoong and Oxford entered into a Subordination Agreement pursuant to which the Daewoong Convertible Note was subordinated to the Company&#x2019;s obligations under the Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Daewoong Convertible Note bore interest at a rate of 3.0% payable semi-annually in arrears on June 30th and December 31st of each year and was to mature on July 30, 2025, subject to earlier conversion as provided below. Interest was initially paid in kind by adding the accrued amount thereof to the outstanding principal amount on a semi-annual basis on June 30th and December 31st of each calendar year for so long as any principal amount under the Oxford Term Loan remained outstanding and the Subordination Agreement was not terminated. Interest became payable in cash after the Oxford Term Loan was repaid in full, and the Subordination Agreement was terminated on January 4, 2021. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2021, the outstanding principal balance including all accrued and unpaid interest thereon, of $40,779 was converted, at the conversion price of $13.00 per share, into 3,136,869 shares of the Company&#x2019;s common stock under the Conversion Agreement (as defined in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 11.)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The conversion was accounted for as an extinguishment of debt resulting in a gain of $971, which is recorded in loss from extinguishment of debts, net on the accompanying condensed consolidated statements of operations and comprehensive loss. The Daewoong Convertible Note was not registered, and the shares of the Company&#x2019;s common stock issued upon conversion of the Daewoong Convertible Note have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the details of the Conversion Agreement.&lt;/span&gt;</us-gaap:DebtDisclosureTextBlock>
    <eols:DebtInstrumentNumberOfTranches
      contextRef="i87008557f7394da183cb13535fff98b5_I20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjcyNQ_088ef551-4821-46a0-86f6-663e9af13685"
      unitRef="tranche">2</eols:DebtInstrumentNumberOfTranches>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9f70375f5d4e414ba6839f26fe0ddc44_I20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMjY0_7a7342f8-d719-4e44-aefd-228293f68528"
      unitRef="usd">75000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i681b2a7d205d410ca672bf2a337a55b0_I20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMzIy_f9b17967-5a33-4621-ab0e-0db41e25c4ca"
      unitRef="usd">50000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="ie655358ab82b4cf3933d54db2925cf4b_D20211214-20211214"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjcyNg_a8cd08f7-a3e0-4f84-85fd-815059f97b41">P6Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i87008557f7394da183cb13535fff98b5_I20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNzI5_b9df53d1-d57f-451f-bb90-8c41f9f275f2"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i0931e5250f9643efa1a3ac8af4f22859_D20211214-20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNzcx_268eb433-9fa6-41bb-bd3f-eb2ad0be535e"
      unitRef="number">0.085</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <eols:DebtInstrumentNumberOfPeriodicPaymentsPrincipal
      contextRef="ie655358ab82b4cf3933d54db2925cf4b_D20211214-20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMTA0Nw_221d8ff0-e165-4ef3-9cc0-56ec7ce64599"
      unitRef="payment">12</eols:DebtInstrumentNumberOfPeriodicPaymentsPrincipal>
    <eols:DebtInstrumentPeriodicPaymentPaymentCommencementPeriod
      contextRef="id0259e20c7b64238ace67075cd4ebde3_D20211214-20211214"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMTE3MQ_10a5b3e9-9d5a-4903-a7f0-974fefa1adfb">P39M</eols:DebtInstrumentPeriodicPaymentPaymentCommencementPeriod>
    <eols:DebtInstrumentPrepaymentAmountThreshold
      contextRef="ibb4a33cd285f450c9199ba56c40498b4_I20211214"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMTMzMg_4b2a3d27-a69f-4729-bda5-10c58f79f265"
      unitRef="usd">20000</eols:DebtInstrumentPrepaymentAmountThreshold>
    <eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount
      contextRef="id39eaeea68ce4b2b873c2e7097ffad4f_I20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMTg4Ng_4d6d3fa4-36c3-4aa2-9bdf-6655fc1b3e68"
      unitRef="number">0.030</eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount>
    <eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount
      contextRef="idb4fee43c2d44ee2b2e15ef341def13b_I20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMTk3MA_8e7df458-a656-4f90-8502-1d1375bbc6e4"
      unitRef="number">0.020</eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount>
    <eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount
      contextRef="i3bfea5e3671f467c9abe90444ff80e16_I20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMjEzOA_4c01321a-a5a7-4e34-b5c3-87a1c57664c2"
      unitRef="number">0.010</eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i87008557f7394da183cb13535fff98b5_I20211214"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMzQ3NA_be8ae292-a65f-4f61-b591-ccb35175babe"
      unitRef="usd">3042000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i87008557f7394da183cb13535fff98b5_I20211214"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMzQ4MQ_72b52083-37ae-41d4-a0ce-7840cde5ccab"
      unitRef="usd">3263000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9f70375f5d4e414ba6839f26fe0ddc44_I20211214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfMzc4OA_3171ee88-e73b-408b-8635-5e94d1244070"
      unitRef="usd">75000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i12401c3106e141e3932d964c36466a9c_I20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNDM1Nw_da96da10-a005-47bf-9dfa-ca2ebda5bdb5"
      unitRef="number">0.1222</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjcyOA_ba14765e-ce2d-44c3-8c3c-c22a797aa3dc">As of September 30, 2022, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term debt, net of discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfMS0xLTEtMS02NjM1MQ_87cf0bc8-3c76-4113-8afb-92239de53e5d"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfMi0xLTEtMS02NjM1MQ_733212b5-88bc-4e69-a671-14f54fdb2da2"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfMy0xLTEtMS02NjM1MQ_c1c87aec-c8f4-42ce-93a6-992a93ebce11"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfNC0xLTEtMS02NjM1MQ_eda9669d-bc3d-4f48-b37a-35dd4f50a833"
      unitRef="usd">25000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfNS0xLTEtMS02NjM1MQ_043e4ac5-6233-450a-b6fb-03298bcf7e83"
      unitRef="usd">25000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <eols:LongTermDebtMaturityAfterYearFour
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfNi0xLTEtMS02NjM1MQ_14cf9d81-6da0-45ce-878e-90663e4ee624"
      unitRef="usd">25000000</eols:LongTermDebtMaturityAfterYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfNy0xLTEtMS02NjM1MQ_e9f2c799-56b9-4d17-8ec5-bbd4505e0389"
      unitRef="usd">75000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfOC0xLTEtMS02NjM1MQ_df7de65e-0b93-4159-9445-4b85a7a597ff"
      unitRef="usd">3288000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RhYmxlOjNhNjlmNDQxYWJmOTQ3YzBiYWUxMTA0YjBhNWNiMTI3L3RhYmxlcmFuZ2U6M2E2OWY0NDFhYmY5NDdjMGJhZTExMDRiMGE1Y2IxMjdfOS0xLTEtMS02NjM1MQ_14e7d7a6-0944-4f0b-9412-881af8fcb6b8"
      unitRef="usd">71712000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i32423b3783a74a82a50b52069242757e_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNDY1Ng_eb1cb27f-08dd-468e-8c1c-e5e2a07f4da3"
      unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <eols:LineofCreditFacilityNumberofAdvances
      contextRef="i32423b3783a74a82a50b52069242757e_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNDc3Ng_6ea1b0b2-0933-4373-8edd-71f7ba8b597f"
      unitRef="advance">2</eols:LineofCreditFacilityNumberofAdvances>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iba0b2ad793844b26a191ac3cd34f31f2_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNDgyNg_fcae83a0-26f8-484b-80cd-d4d573c89e71"
      unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie6b945adff8f46008df2b4591b66e2fe_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNDg4Mw_ede08a16-02c2-43ca-aa30-5bef743cfe5a"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i32423b3783a74a82a50b52069242757e_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNDk3NA_9f8affb2-9283-454f-b6b3-7b7e063c5e4f"
      unitRef="number">0.095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9de13a38f24141ecadd52a63c397047d_D20190315-20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTAyMA_d9139873-770f-4bd9-bdca-147f9fa587c1"
      unitRef="number">0.070</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <eols:DebtInstrumentPeriodOfInterestOnlyPayments
      contextRef="ia0f2553d528c41c3ab5ae3858f5fda13_D20190315-20190315"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTA3OA_f17efaf2-05ed-425b-ab9b-846507c64c3a">P36M</eols:DebtInstrumentPeriodOfInterestOnlyPayments>
    <eols:DebtInstrumentAmortizationPeriod
      contextRef="ia0f2553d528c41c3ab5ae3858f5fda13_D20190315-20190315"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTExOA_3873e736-a5ab-4929-8308-d07507100859">P23M</eols:DebtInstrumentAmortizationPeriod>
    <eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment
      contextRef="i4d21558b1b844fea9ffd52152f5a0b6d_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTM0NA_702a3fc7-1752-4521-9a3f-5ff5f5b277be"
      unitRef="number">0.055</eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment>
    <eols:DebtInstrumentPrepaymentFeePercentageYearTwo
      contextRef="i4d21558b1b844fea9ffd52152f5a0b6d_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTU3NQ_6c9e9527-3dd1-4e87-b033-959cf91791fc"
      unitRef="number">0.020</eols:DebtInstrumentPrepaymentFeePercentageYearTwo>
    <eols:DebtInstrumentPrepaymentFeePercentageThereafter
      contextRef="i4d21558b1b844fea9ffd52152f5a0b6d_I20190315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTY4Ng_97d46e86-e4e3-45e7-9a87-85e456bdb7ad"
      unitRef="number">0.010</eols:DebtInstrumentPrepaymentFeePercentageThereafter>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i2ea01d8678a148839f20dd947155b9a2_D20210104-20210104"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNTkwMw_f3f30a33-e56d-483b-a23a-86f63b4d1b7d"
      unitRef="usd">76447000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <eols:DebtInstrumentFeeAmountWaived
      contextRef="i2ea01d8678a148839f20dd947155b9a2_D20210104-20210104"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjQ1Mw_beba1991-1c79-4f42-aef5-9100a3c9204c"
      unitRef="usd">4300000</eols:DebtInstrumentFeeAmountWaived>
    <eols:DebtInstrumentOfFinalPaymentAmountWaived
      contextRef="i2ea01d8678a148839f20dd947155b9a2_D20210104-20210104"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjQ4MQ_38be68be-43d3-41e2-970c-fb77ea4af63e"
      unitRef="usd">2800000</eols:DebtInstrumentOfFinalPaymentAmountWaived>
    <eols:DebtInstrumentPrepaymentFeeAmountWaived
      contextRef="i2ea01d8678a148839f20dd947155b9a2_D20210104-20210104"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjUzNg_b1d9cffb-00bc-4ff6-b6e1-f56918c31ad5"
      unitRef="usd">1500000</eols:DebtInstrumentPrepaymentFeeAmountWaived>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9984dc72d84a433bbbf2c8e4297d8ab3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81Mi9mcmFnOmRjNWRlMjBhZDk5NTQ2NGU5YjgyOWU0N2RmZWY2ZDdmL3RleHRyZWdpb246ZGM1ZGUyMGFkOTk1NDY0ZTliODI5ZTQ3ZGZlZjZkN2ZfNjU4NA_7d15c773-0f15-4289-a8fc-4385127bdd01"
      unitRef="usd">-1939000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifcabd9d8120a4b52ad4211b9b2779160_I20200706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81NS9mcmFnOjhhNDBlYTZhMTcxNDQ2MzJhN2VlZGZkNGIzYjkzZmMyL3RleHRyZWdpb246OGE0MGVhNmExNzE0NDYzMmE3ZWVkZmQ0YjNiOTNmYzJfMTcy_5126dc3f-6c6b-4146-8ded-de6728551b12"
      unitRef="usd">40000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifcabd9d8120a4b52ad4211b9b2779160_I20200706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81NS9mcmFnOjhhNDBlYTZhMTcxNDQ2MzJhN2VlZGZkNGIzYjkzZmMyL3RleHRyZWdpb246OGE0MGVhNmExNzE0NDYzMmE3ZWVkZmQ0YjNiOTNmYzJfNTI1_e88469cd-41d4-4ef2-b31b-8b45b2d47761"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebt
      contextRef="ibfb737bacd0248fc910875d3a4549e77_I20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81NS9mcmFnOjhhNDBlYTZhMTcxNDQ2MzJhN2VlZGZkNGIzYjkzZmMyL3RleHRyZWdpb246OGE0MGVhNmExNzE0NDYzMmE3ZWVkZmQ0YjNiOTNmYzJfMTI2NQ_299034d1-33a0-4671-a876-17119648a167"
      unitRef="usd">40779000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ibfb737bacd0248fc910875d3a4549e77_I20210323"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81NS9mcmFnOjhhNDBlYTZhMTcxNDQ2MzJhN2VlZGZkNGIzYjkzZmMyL3RleHRyZWdpb246OGE0MGVhNmExNzE0NDYzMmE3ZWVkZmQ0YjNiOTNmYzJfMTMxMA_b0b1b307-680a-45f7-a5eb-2120661f46ae"
      unitRef="usdPerShare">13.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i4504c78963354d1badb28c7c64e116ec_D20210323-20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81NS9mcmFnOjhhNDBlYTZhMTcxNDQ2MzJhN2VlZGZkNGIzYjkzZmMyL3RleHRyZWdpb246OGE0MGVhNmExNzE0NDYzMmE3ZWVkZmQ0YjNiOTNmYzJfMTMyOQ_8f9bf57b-f8c8-4b55-9595-521ea8a2b1c1"
      unitRef="position">3136869</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i671a3057546c42ba9908a766f27874d3_D20210323-20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81NS9mcmFnOjhhNDBlYTZhMTcxNDQ2MzJhN2VlZGZkNGIzYjkzZmMyL3RleHRyZWdpb246OGE0MGVhNmExNzE0NDYzMmE3ZWVkZmQ0YjNiOTNmYzJfMTUwNg_d3f7b53e-fa5f-4de0-ada0-db5e60e9c865"
      unitRef="usd">971000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfMTg3NQ_5fc5bf2c-abf0-4c36-818a-7adffaf7d8d3">Operating Leases&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s corporate headquarters in Newport Beach, California is leased under a five-year non-cancelable operating lease, which expires on January 31, 2025. Lease payments increase each year on February 1 based on an annual rent escalation clause. The Company may, under certain circumstances, terminate the lease on the 36-month anniversary of the lease commencement date by providing a written notice 12 months prior to such anniversary and paying a termination fee&#160;equal to six months basic rent plus certain other expenses. The Company has an option to extend the term of the lease for an additional 60 months, which is not recognized as part of its ROU assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease agreement does not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease term and discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.940%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease&#160;expenses were included in the selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. Operating lease right-of-use assets and related current and noncurrent operating lease liabilities are presented in the accompanying condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of September 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfMTg3Ng_9cc953ef-bbf4-4825-8f80-c04403569888">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <eols:LesseeOperatingLeaseTerminationPeriod
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfMzUz_dc3d6866-ae78-4668-aeab-39925b08c404">P36M</eols:LesseeOperatingLeaseTerminationPeriod>
    <eols:LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfNDM1_266c8277-c695-4f25-bb1d-76b31a95d27b">P12M</eols:LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate>
    <eols:LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfNTAy_2e7ffc13-c025-47f6-8095-77eb598a17ff">P6M</eols:LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfNjIx_04a90fe3-787a-4fef-8501-df5fc02259ac">P60M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfMTg3Nw_7b4190af-6c09-45c4-8191-1d7e86d64cf2">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease term and discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.940%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMi0xLTEtMS02NjM1MQ_ba77c289-54a1-40bd-80d5-9caf638ad8c2"
      unitRef="usd">273000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMi0zLTEtMS02NjM1MQ_cbbca913-33eb-4882-b78c-66c3ff86368e"
      unitRef="usd">268000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMi01LTEtMS02NjM1MQ_d4757ece-8151-40ae-98bf-f51d56e57d76"
      unitRef="usd">811000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMi03LTEtMS02NjM1MQ_c6e99c3a-6451-4ad3-8773-df0c1a39c0ac"
      unitRef="usd">797000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMy0xLTEtMS02NjM1MQ_93ff34e9-7eec-4064-8408-31a10bcad799"
      unitRef="usd">18000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMy0zLTEtMS02NjM1MQ_ba11ca54-8444-48b6-a777-5dbccb529c70"
      unitRef="usd">20000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMy01LTEtMS02NjM1MQ_441c37bc-5dc9-47d0-8b30-0569f5e6752d"
      unitRef="usd">65000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfMy03LTEtMS02NjM1MQ_31646578-3128-4f13-acd3-406f9fdaa7d8"
      unitRef="usd">40000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfNS0xLTEtMS02NjM1MQ_e5936e70-c830-4776-88a4-ed4fae14e5cf"
      unitRef="usd">291000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfNS0zLTEtMS02NjM1MQ_b914acc0-8ebf-4174-b084-3e1adecf6f0b"
      unitRef="usd">288000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfNS01LTEtMS02NjM1MQ_cf753066-bdaf-46d3-af9e-44e53d3f28c7"
      unitRef="usd">876000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNlZDRhZDIwM2Y2NDQxZjI4ZWIxYzNhMjk5NWU0MzE2L3RhYmxlcmFuZ2U6Y2VkNGFkMjAzZjY0NDFmMjhlYjFjM2EyOTk1ZTQzMTZfNS03LTEtMS02NjM1MQ_f4bb075d-2798-43da-a399-11e0f72b9368"
      unitRef="usd">837000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOjMyNjY5MjhmYWM1MDRiNTRhNjc1YTc1YWZjY2QyMGQ3L3RhYmxlcmFuZ2U6MzI2NjkyOGZhYzUwNGI1NGE2NzVhNzVhZmNjZDIwZDdfMi0xLTEtMS02NjM1MQ_0c3b65e7-230b-4ed7-8cde-47858a42e0d6">P2Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i458f436d90584702b2e171f24fc2ffd9_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOjMyNjY5MjhmYWM1MDRiNTRhNjc1YTc1YWZjY2QyMGQ3L3RhYmxlcmFuZ2U6MzI2NjkyOGZhYzUwNGI1NGE2NzVhNzVhZmNjZDIwZDdfMi0zLTEtMS02NjM1MQ_4bba5b37-d197-4cb9-9a97-79767e5f7e5f">P3Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOjMyNjY5MjhmYWM1MDRiNTRhNjc1YTc1YWZjY2QyMGQ3L3RhYmxlcmFuZ2U6MzI2NjkyOGZhYzUwNGI1NGE2NzVhNzVhZmNjZDIwZDdfMy0xLTEtMS02NjM1MQ_98917b19-199e-4d97-869a-01d5d46ece02"
      unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i458f436d90584702b2e171f24fc2ffd9_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOjMyNjY5MjhmYWM1MDRiNTRhNjc1YTc1YWZjY2QyMGQ3L3RhYmxlcmFuZ2U6MzI2NjkyOGZhYzUwNGI1NGE2NzVhNzVhZmNjZDIwZDdfMy0zLTEtMS02NjM1MQ_987fa586-bcf2-489d-a46e-6e966d3db54a"
      unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RleHRyZWdpb246MTIxZGZhMDVkOTZhNGQwZjg0MmYxYzhjNTUwODQ2MWFfMTg3OQ_a19505ad-7f5b-4db1-b9a4-77c0732a9e4f">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of September 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfMS0xLTEtMS02NjM1MQ_c2366bd3-4b6b-423d-9923-facf012e7db4"
      unitRef="usd">318000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfMi0xLTEtMS02NjM1MQ_be45e881-066b-4aa5-b19e-aeaba6efe86b"
      unitRef="usd">1320000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfMy0xLTEtMS02NjM1MQ_6b4cb663-5d9c-400d-9e4c-1b070e6ed428"
      unitRef="usd">1377000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfNC0xLTEtMS02NjM1MQ_64c86a7c-def9-4a21-b5df-6919a61df814"
      unitRef="usd">115000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfNS0xLTEtMS02NjM1MQ_b85a1a8c-e0bb-4f02-bce9-16cf10794a43"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfNi0xLTEtMS02NjM1MQ_b797975a-d2d9-48c6-83ba-f0eccccb07a0"
      unitRef="usd">3130000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfNy0xLTEtMS02NjM1MQ_774fe63f-68e4-4744-92ca-e4e5c46533b8"
      unitRef="usd">332000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV81OC9mcmFnOjEyMWRmYTA1ZDk2YTRkMGY4NDJmMWM4YzU1MDg0NjFhL3RhYmxlOmNhNzEzNGUzMzUzYzQ0NzRiNzVkZWYxNmU4NzFiZGE4L3RhYmxlcmFuZ2U6Y2E3MTM0ZTMzNTNjNDQ3NGI3NWRlZjE2ZTg3MWJkYThfOC0xLTEtMS02NjM1MQ_7411674e-d8d4-467d-a8e6-ec3f76918c32"
      unitRef="usd">2798000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82MS9mcmFnOjExZDM1ZmQ3ZDYxMzRhZDg4NGZmYTY3OWNkNGFiN2M5L3RleHRyZWdpb246MTFkMzVmZDdkNjEzNGFkODg0ZmZhNjc5Y2Q0YWI3YzlfNjc5MQ_f5683296-b38a-4263-8d3a-1c02fad4074c">Commitments and Contingencies&lt;div style="margin-bottom:10pt;padding-right:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately $1,074. Certain minimum purchase commitments related to the purchase of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Daewoong Agreement includes certain minimum annual purchases that the Company is required to make in order to maintain the exclusivity of the license. The Company may, however, meet these minimum purchase obligations by achieving certain market share in the licensed territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#x2019;s future market share in various jurisdictions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Class Action Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 16 and 28, 2020, two putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#x2019;s acquisition of the right to sell Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;ITC Action&#x201d;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Evolus Inc. Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, three of its officers, and Alphaeon Corporation, the Company&#x2019;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint. On February 10, 2022, Alphaeon Corporation served its motion to dismiss the amended complaint. Both motions were fully briefed on June 16, 2022. The outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholder Derivative Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2020 and December 2, 2020, two putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#x2019;s officers &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Evolus, Inc. Derivative Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 1:20-cv-09986-PPG, and adjourned defendants&#x2019; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#x2019; stipulated stay of the consolidated derivative suit pending the court&#x2019;s decision on the defendants&#x2019; motion to dismiss the Securities Class Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Books and Records Demand&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#x2019;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#x2019;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#x2019;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to the demand in December 2021. The outcome of this matter is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is, from time to time, involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#x2019;s financial results for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#x2019;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. No amounts were accrued as of September 30, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;Medytox/Allergan Settlement Agreements and Daewoong Arrangement&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medytox/Allergan Settlement Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;U.S. Settlement Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 18, 2021, the Company, Allergan and Medytox entered into a Settlement and License Agreement (the &#x201c;U.S. Settlement Agreement&#x201d;), pursuant to which, among other things: (i) Allergan and Medytox agreed to file a petition requesting the remedial orders related to the ITC Action be rescinded with respect to the Company; (ii) Medytox agreed to dismiss substantially similar litigation in California against the Company; (iii) the Company, on the one hand, and Medytox and Allergan, on the other hand, agreed to mutually release certain claims they may have against one another and their respective affiliates; (iv) Allergan and Medytox granted to the Company and its agents a license to manufacture and commercialize certain products identified in the U.S. Settlement Agreement, including Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;Licensed Products&#x201d;), in the United States during the 21 month period that, pursuant to the ITC Action, the Company was restricted from, among other things, selling, marketing, or promoting such imported Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States (the &#x201c;Restricted Period&#x201d;); (v) the Company agreed to pay to Allergan and Medytox $35,000 in multiple payments over two years, of which the Company paid the first cash payment of $15,000 in the third quarter of 2021 and the second cash payment of $15,000 in the first quarter of 2022; and (vi) during the Restricted Period, the Company agreed to pay to Allergan and Medytox certain confidential royalties on the sale of Licensed Products, calculated on dollar amount per vial sold of Licensed Products by or on behalf of the Company in the United States. Royalties for sales during the Restricted Period ended on September 16, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ROW Settlement Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#x201c;ROW Settlement Agreement&#x201d; and, together with the U.S. Settlement Agreement, the &#x201c;Medytox/Allergan Settlement Agreements&#x201d;), pursuant to which, among other things: (i) the Company and Medytox agreed to mutually release certain claims they may have against one another and their respective affiliates; (ii) Medytox granted to the Company and its agents a license to manufacture and commercialize the Licensed Products, in Canada, the European Union, Switzerland, member countries and cooperating countries of the European Economic Area, Russia, certain members of the Commonwealth of Independent States, South Africa, Australia and Japan (the &#x201c;ROW Territories&#x201d;) during the Restricted Period; (iii) Medytox granted to the Company and its agents a fully paid up license to manufacture and commercialize the Licensed Products in the ROW Territories and the United States from the end of the Restricted Period (the &#x201c;Medytox License Period&#x201d;); (iv) the Company and Medytox agreed to enter into the Share Issuance Agreement (as defined below) pursuant to which the Company issued 6,762,652 shares (the &#x201c;Settlement Shares&#x201d;) of the Company&#x2019;s common stock, par value $0.00001 per share, to Medytox; (v) the Company and Medytox agreed to enter into the Registration Rights Agreement (as defined below), pursuant to which the Company granted certain registration rights to Medytox with respect to the Settlement Shares; (vi) during the Restricted Period that ended September 16, 2022, the Company agreed to pay Medytox a confidential low-double digit royalty on net sales of the Licensed Products sold by or on behalf of the Company in the ROW Territories; and (vii) during the Medytox License Period from September 17, 2022 to September 16, 2032, the Company agreed to pay Medytox a confidential mid-single digit royalty percentage on net sales of the Licensed Products sold by or on behalf of the Company in the United States and the ROW Territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Share Issuance Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the ROW Settlement Agreement, the Company and Medytox entered into a Share Issuance Agreement effective February 18, 2021 (the &#x201c;Share Issuance Agreement&#x201d;). Pursuant to the Share Issuance Agreement and subject to the terms and conditions set forth therein, among other things, the Company issued to Medytox the Settlement Shares to enter into the ROW Settlement Agreement and in consideration for Medytox&#x2019;s representations, warranties, and other agreements set forth in the Share Issuance Agreement. The Settlement Shares are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates, prevented Medytox from transferring any shares of common stock prior to February 16, 2022 and, thereafter, prohibit Medytox from transferring more than 25% of the shares it holds prior to September 16, 2023, more than 50% of the shares it holds prior to September 16, 2024 and more than 75% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Registration Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the ROW Settlement Agreement, the Company and Medytox also entered into a Registration Rights Agreement effective February 18, 2021 (the &#x201c;Registration Rights Agreement&#x201d;). Pursuant to the Registration Rights Agreement, among other things, the Company agreed, after March 31, 2022, (i) to comply with certain requests by Medytox to register for sale, under the Securities Act, the Settlement Shares, and (ii) to include the Settlement Shares in certain registrations by the Company of its securities for sale under the Securities Act, to the extent requested by Medytox, in each case subject to certain customary conditions, exceptions and limitations as set forth in the Registration Rights Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Medytox&#x2019;s registration rights under the Registration Rights Agreement will terminate at such time that Medytox is able to sell all of the Settlement Shares over a three-month period, or less, pursuant to an exemption to registration under the Securities Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the Company accrued $7,936 for royalties under the Medytox/Allergan Settlement Agreements and $5,000 of accrued litigation settlement expense. As of December&#160;31, 2021, the Company accrued $12,447 for royalties under the Medytox/Allergan Settlement Agreements and $20,000 of accrued litigation settlement expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Daewoong Arrangement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Daewoong Settlement Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2021, the Company and Daewoong entered into a Confidential Settlement and Release Agreement (the &#x201c;Daewoong Settlement Agreement&#x201d;), pursuant to which, among other things: (i) Daewoong agreed to (a) pay to the Company an amount equal to $25,500, which the Company received in April 2021, (b) pay certain legal fees incurred by the Company&#x2019;s litigation counsel in connection with its defense of the ITC Action (including any appeal of the resulting remedial orders), (c) cancel all remaining milestone payments totaling $10,500 in aggregate, and (d) reimburse the Company certain amounts (calculated on a dollar amount per vials sold basis in the United States) for sales of certain products with respect to which the Company is required to pay Medytox and Allergan royalties pursuant to the U.S. Settlement Agreement; and (ii) the Company agreed to (a) release, on behalf of itself and certain of its affiliates and representatives, certain claims they may have against Daewoong related to the allegations made in or the subject matter of the Medytox/Allergan Actions, or any orders, remedies and losses resulting from the Medytox/Allergan Actions, and (b) coordinate with Daewoong on certain matters related to the Medytox/Allergan Actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Conversion Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the Daewoong Settlement Agreement, the Company and Daewoong also entered into a Convertible Promissory Note Conversion Agreement (the &#x201c;Conversion Agreement&#x201d;), pursuant to which, among other things, (i) the principal balance under the Daewoong Convertible Note, together with all accrued and unpaid interest thereon, in the amount of $40,779 was converted, at the conversion price of $13.00 per share, into 3,136,869 shares of Common Stock; and (ii) the Daewoong Convertible Note was deemed cancelled and satisfied in full in connection with such conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the conversion, shares owned by Daewoong, together with its affiliates and attribution parties, did not exceed 9.99% of the Company&#x2019;s then outstanding common shares immediately following such issuance, as required under the terms of the Daewoong Convertible Note.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Daewoong Agreement Amendment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the Daewoong Settlement Agreement, on March 23, 2021, the Company and Daewoong also entered into the Third Amendment to the Supply Agreement (the &#x201c;Daewoong Agreement Amendment&#x201d;). Pursuant to the Daewoong Agreement Amendment, the parties amended the Daewoong Agreement to (i) expand the territory within which the Company may distribute Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to certain countries in Europe, (ii) reduce the period of time with respect to which the Company is required to deliver binding forecasts to Daewoong, (iii) introduce certain limitations on Daewoong&#x2019;s ability to convert the Company&#x2019;s exclusive license for certain territories to a non-exclusive license in the event the Company fails to meet certain minimum purchase requirements for such territory, (iv) adjust the minimum purchase requirements and reduce the transfer price per vial of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; applicable to various territories, (v) require that any Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; supplied by Daewoong match certain shelf-life thresholds, and (vi) prohibit the Company from sharing certain confidential information of Daewoong with Medytox or its affiliates or representatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022 and December&#160;31, 2021, the Company had $3,257 and $5,657, respectively, in reimbursement receivable from Daewoong, respectively, in other current assets in the accompanying condensed consolidated balance sheets. Total inventory payments to Daewoong were $14,238 and $40,509 for the three and nine months ended September 30, 2022, respectively. Total inventory payments to Daewoong were $10,916 and $24,576 for the three and nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82MS9mcmFnOjExZDM1ZmQ3ZDYxMzRhZDg4NGZmYTY3OWNkNGFiN2M5L3RleHRyZWdpb246MTFkMzVmZDdkNjEzNGFkODg0ZmZhNjc5Y2Q0YWI3YzlfMTkw_0e330c4a-a6b4-40fa-9a15-2da94ce0a7d4"
      unitRef="usd">1074000</us-gaap:PurchaseObligation>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i2b2b0c3bea3a4f22ae04d9279885dafc_D20201016-20201028"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82MS9mcmFnOjExZDM1ZmQ3ZDYxMzRhZDg4NGZmYTY3OWNkNGFiN2M5L3RleHRyZWdpb246MTFkMzVmZDdkNjEzNGFkODg0ZmZhNjc5Y2Q0YWI3YzlfODg2_5e14fffc-8541-4f95-b7b8-c356ae46bff8"
      unitRef="complaint">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="id4a4bebb895c49d0bbdd0bf38322e752_D20201127-20201202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82MS9mcmFnOjExZDM1ZmQ3ZDYxMzRhZDg4NGZmYTY3OWNkNGFiN2M5L3RleHRyZWdpb246MTFkMzVmZDdkNjEzNGFkODg0ZmZhNjc5Y2Q0YWI3YzlfMjY4OQ_20ed0b69-44b7-4639-9c06-cebc0926aba7"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82MS9mcmFnOjExZDM1ZmQ3ZDYxMzRhZDg4NGZmYTY3OWNkNGFiN2M5L3RleHRyZWdpb246MTFkMzVmZDdkNjEzNGFkODg0ZmZhNjc5Y2Q0YWI3YzlfNjc0Ng_a2a2800f-91fd-4fa0-a39f-5cb5473f9bf7"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82MS9mcmFnOjExZDM1ZmQ3ZDYxMzRhZDg4NGZmYTY3OWNkNGFiN2M5L3RleHRyZWdpb246MTFkMzVmZDdkNjEzNGFkODg0ZmZhNjc5Y2Q0YWI3YzlfNjc0Ng_f50db8d1-161b-4264-8b98-b9613d70f98d"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDg2NQ_6193a1de-7439-420a-a281-508ed49b10bf">Stockholders&#x2019; Equity&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has 10,000,000 authorized shares of preferred stock with a par value of $0.00001 per share. As of September 30, 2022, no shares of its preferred stock were issued and outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has 100,000,000 authorized shares of common stock with a par value of $0.00001 per share. As of September 30, 2022, 56,183,414 shares of its common stock were issued and outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 28, 2021, the Company issued 6,762,652 shares of its common stock to Medytox pursuant to the Share Issuance Agreement. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2021, the Company issued 3,136,869 shares of its common stock to Daewoong in connection with the conversion of Daewoong Convertible Note. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Daewoong Convertible Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x201c;At-the-market&#x201d; Offerings of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 26, 2021, the Company entered into an &#x201c;at-the-market&#x201d; sales agreement with SVB Leerink LLC (the &#x201c;Sales Agent&#x201d;) pursuant to which shares of the Company&#x2019;s common stock could be sold from time to time for aggregate gross proceeds of up to $75,000 (the &#x201c;ATM Program&#x201d;). The Sales Agent was entitled to compensation, at a commission rate equal to 3.0% of the gross proceeds from sales of the Company&#x2019;s common shares under the ATM Program. Since August 2021, the Company has not sold any shares under the ATM Program and the Company terminated the ATM Program in May 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September 30, 2021, the Company sold a total of 724,835 shares of its common stock pursuant to the ATM Program at the prevailing market prices for total net proceeds of $8,203 and paid total commissions of $254 to the Sales Agent. For the nine months ended September 30, 2021, the Company sold a total of 934,367 shares of its common stock pursuant to the ATM Program at the prevailing market prices for a total net proceeds of $10,910 and paid total commissions of $337 to the Sales Agent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Omnibus Incentive Plan and Stock-based Compensation Allocation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2017 Omnibus Incentive Plan (the &#x201c;Plan&#x201d;) provides for the grant of incentive options to employees of the Company, and for the grant of non-statutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#x2019;s officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is 4,361,291 shares, plus an annual increase on each anniversary of November 21, 2017 equal to 4.0% of the total issued and outstanding shares of the Company&#x2019;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#x2019;s Board of Directors). As of September 30, 2022, the Company had an aggregate of 1,447,855 shares of its common stock available for future issuance under the Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company&#x2019;s Plan. Such grants were made pursuant to a stand-alone nonstatutory stock option agreement and a stand-alone RSU agreement, which were approved by the Compensation Committee of the Board of Directors. Any shares underlying the inducement grants are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, the Company granted options to purchase 171,103 shares of common stock and 39,012 RSUs as a material inducement for the employment of the Senior Vice President of Corporate Development. In September 2022, the Company granted options to purchase 169,158 shares of common stock and 36,443 RSUs as a material inducement for the employment of the Chief Financial Officer. As of September 30, 2022, stock options to purchase 340,261 shares of common stock and 75,455 RSUs remained outstanding outside of the Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Award Activity and Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options are granted at exercise prices based on the Company&#x2019;s common stock price on the date of grant. The options and RSU grants generally vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzU1MQ_69856644-a55a-4627-8d51-4a7ed13cffd0"&gt;one&lt;/span&gt;- to four-year period. There have been no awards granted with performance conditions or market conditions for the periods presented. The options have a contractual term of ten years. The fair value of options is estimated using the Black-Scholes option pricing model, which has various inputs, including the grant date common share price, exercise price, risk-free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#x2019;s options as well as significantly impact its results of operations. The fair value of RSU grants is determined at the grant date based on the common share price. The Company records stock-based compensation expense net of actual forfeitures when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in determining the fair value of stock options granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity for the nine months ended September 30, 2022, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Terms (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,922,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(602,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,932,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,860,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of outstanding and exercisable options represents the excess of the fair market value of the Company&#x2019;s common stock over the exercise price of underlying options as of September 30, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity for the nine months ended September 30, 2022, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,926,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(553,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,638,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNjc_792ea7a7-da7d-40aa-a7b8-191f1cfaf78e"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMTI3_ca66e6b9-ef81-41fd-9b28-f941aab9b288"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMTUx_33249baf-d337-4266-8225-356685b91ace"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMTUx_40c6839a-9256-463f-abf4-7b21771331ac"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMjQz_c9a36e55-9f35-4f9e-a4c4-4ba90ec65569"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzAw_ff577121-6e29-4ed6-b0b3-88ba9e09beac"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzI0_13ac0631-5f36-4754-ba26-7e3f6d3c17c5"
      unitRef="shares">56183414</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzI0_69e8a0ea-e11c-4d21-b167-3ea3660791b7"
      unitRef="shares">56183414</us-gaap:CommonStockSharesIssued>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="i32d51cd4bd6f4489a4adb7b2aa247e44_D20210228-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDI1_5fa8f839-d5b6-4a08-87ef-ed2a6a84a655"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="ic8fb36cf68884af1a7d8744f3d77a5ba_D20210325-20210325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTg1_34426680-a92a-411b-a955-dc38e191775b"
      unitRef="shares">3136869</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <eols:SaleOfStockMaximumConsiderationReceivable
      contextRef="ia933b0ab944743ada651aa08e01c3fa0_D20210326-20210326"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMTAxNg_14f3d443-72a7-4f89-a491-686c1f5e0d59"
      unitRef="usd">75000000</eols:SaleOfStockMaximumConsiderationReceivable>
    <eols:SaleOfStockCommissionPaymentUponGrossProceedsPercentage
      contextRef="ib05b2ea5b15449b3949c409f13302aba_I20210326"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMTExNg_1351acb1-2c69-4d57-8450-32a78382b793"
      unitRef="number">0.030</eols:SaleOfStockCommissionPaymentUponGrossProceedsPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8c628e554673429f919660de503a710e_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxODg2_b411572e-342e-4262-aebd-8822eee670ed"
      unitRef="shares">724835</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ide79544f24324f7b8502d4f715dcf188_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxOTQx_c6f89404-e740-44d3-97fa-16b2a2559f66"
      unitRef="usd">8203000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <eols:SaleOfStockCommissionPaid
      contextRef="ia80760aeda834165a0bd09ccfcabfa32_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxOTU2_dc5d08ae-9274-4411-9d23-225c84bcdf87"
      unitRef="usd">254000</eols:SaleOfStockCommissionPaid>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i39845926fd4c4a7185d0ad1aec0a9125_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxODk4_eb722adb-8b90-49f7-8d07-f08048cfd53e"
      unitRef="shares">934367</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id8d569b52d5c4b558d7fce708c55c3d1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxOTYy_1b0cead1-fd3c-47ca-b668-b8893207737b"
      unitRef="usd">10910000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <eols:SaleOfStockCommissionPaid
      contextRef="id4b79303cf634cad95d0ba5d12c163ef_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxOTc1_ff275737-74c4-4ac7-bcee-0e2eae506074"
      unitRef="usd">337000</eols:SaleOfStockCommissionPaid>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic5451817e64c44dda2476fee6acbac53_I20171121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMjA4NA_9be71c63-b2c9-49fd-90fc-062b6105eb5e"
      unitRef="shares">4361291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="ie5823e0351234f7f9b1f20c5fe18cbe0_D20171121-20171121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMjE2OQ_a7444ab0-33a8-41e9-9296-d34f6898e3d9"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMjQwMg_4ba06385-9c9c-4e37-b06b-8a2818ffe97c"
      unitRef="shares">1447855</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i47a9787376af49c4af38a5bd745283ea_D20220201-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIwNzQ3_94e378fd-a9d9-4f40-ae15-9fc3eb0ea8f6"
      unitRef="shares">171103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i848b50e6e7d3430995e3db062f15f819_D20220201-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIwNzc4_13a59494-dadd-4575-9f68-5a00412b8cf9"
      unitRef="shares">39012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iaa10e78f3b4c4e968e52a77f68b4440f_D20220901-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxMDI2_a29f948d-a415-410e-b451-76186b20db5e"
      unitRef="shares">169158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i239833aec97149198fa33cf47989aa8d_D20220901-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxMDI5_e5000cc6-c947-4c74-a45a-2fae72b47373"
      unitRef="shares">36443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0bc7da1566164597b0db01be97552e79_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxMDQ3_7723b9db-85a7-4d80-8061-f2f373b8a822"
      unitRef="shares">340261</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5f7d73b878d64950a8425ead93d94a97_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNTQ5NzU1ODIxMDU3_0fd58ca8-575c-447d-b07f-d0e025501e88"
      unitRef="shares">75455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i01ed1c49defa42e594f5fe2cb8f08e35_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDg1Nw_d9745e91-7dba-4183-92dd-8300141f31a1">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib0fe33cc353c4425a6f61687288e7219_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzU5MA_c414c58f-7fbc-4fc3-870d-3fdd0ec4f1e2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i39b3ec4c69b340288a1cd5b5320c3f95_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzU5MA_e63ae0cc-a16d-4d1b-b152-0ca09f6fa2df"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfMzcyMw_47a91850-c3d3-4a88-a711-ae4099fba015">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDg3MA_7ae286c7-a73c-40e2-9571-e9a3b4a4a14e">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in determining the fair value of stock options granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie3807d087dad4368af0d30e4e6ea552b_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMi0xLTEtMS02NjM1MQ_dbc7e081-19c6-49d6-ae93-eb12dc6a6ab5"
      unitRef="number">0.838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8fd6507cc4bd4d85bca970b83ba305bb_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMi0zLTEtMS02NjM1MQ_048289e5-e08d-40da-80db-820b880566e7"
      unitRef="number">0.796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMi01LTEtMS02NjM1MQ_7985be25-118a-428d-98c1-70733fa491b9"
      unitRef="number">0.786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib6a44426e14f4cf68658b6c28359fe8f_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMi03LTEtMS02NjM1MQ_b701bfd9-a8df-4a13-bcbb-295d903d9327"
      unitRef="number">0.789</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie3807d087dad4368af0d30e4e6ea552b_D20220701-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMy0xLTEtMS02NjM1MQ_c60ad13a-f5cd-4b2b-8afa-e001b8de3971"
      unitRef="number">0.0325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8fd6507cc4bd4d85bca970b83ba305bb_D20210701-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMy0zLTEtMS02NjM1MQ_e1af62d7-2be4-4c53-9d6c-f453d64bcfb0"
      unitRef="number">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMy01LTEtMS02NjM1MQ_57c2b555-00de-4189-9bcf-5a21fd9c7b3b"
      unitRef="number">0.0192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib6a44426e14f4cf68658b6c28359fe8f_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfMy03LTEtMS02NjM1MQ_a22647e8-1f25-4d57-befc-848de36e5cf3"
      unitRef="number">0.0116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie3807d087dad4368af0d30e4e6ea552b_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNC0xLTEtMS02NjM1MQ_d3ab8d0c-29cd-432c-94fa-2b089a83e2fa">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8fd6507cc4bd4d85bca970b83ba305bb_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNC0zLTEtMS02NjM1MQ_a09b8ec8-f861-48e9-8e42-f4275c38aa25">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNC01LTEtMS02NjM1MQ_06058f61-43dc-4e77-af75-a4e6c9610408">P6Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib6a44426e14f4cf68658b6c28359fe8f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNC03LTEtMS02NjM1MQ_31ea3955-d460-480a-b070-466cb90fa14d">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie3807d087dad4368af0d30e4e6ea552b_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNS0xLTEtMS02NjM1MQ_979be8e3-9383-4d12-9e0c-ec93d34f59ef"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8fd6507cc4bd4d85bca970b83ba305bb_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNS0zLTEtMS02NjM1MQ_a0ef608e-dc9b-4531-8fdc-93ab0f2c66e1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNS01LTEtMS02NjM1MQ_d8656e0d-b3d3-4910-a928-335c43dcf704"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib6a44426e14f4cf68658b6c28359fe8f_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjkxYmZhZTA5YmNjNTRjNGJiM2Q0ZWRmYzFjZTNkM2RmL3RhYmxlcmFuZ2U6OTFiZmFlMDliY2M1NGM0YmIzZDRlZGZjMWNlM2QzZGZfNS03LTEtMS02NjM1MQ_83b2d68e-4b71-492e-b079-a460ff694818"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDg1OQ_f40997bd-422b-4fca-afa9-0bfb0d6b9c2a">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity for the nine months ended September 30, 2022, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Terms (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,922,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(602,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,932,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,860,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i61c0058713f24095b11a013badcef8e3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNS0xLTEtMS02NjM1MQ_1c763ca7-d913-44b1-abb4-b1718554364d"
      unitRef="shares">3922286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i61c0058713f24095b11a013badcef8e3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNS0zLTEtMS02NjM1MQ_d2b2768d-1f9f-4e23-89ae-0e9e70a0000b"
      unitRef="usdPerShare">11.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3b27e8a6feca4241b642ac4baf127f19_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNS01LTEtMS02NjM1MQ_cf2517db-d8cf-4140-8f6f-40b99cac7718">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i61c0058713f24095b11a013badcef8e3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNS03LTEtMS02NjM1MQ_dbe911fd-337d-4a6f-85c7-b9e95a82df7d"
      unitRef="usd">455000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNi0xLTEtMS02NjM1MQ_54092561-3f28-46a2-a6d8-5efda8cc3d5d"
      unitRef="shares">1665786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNi0zLTEtMS02NjM1MQ_6631c434-fa97-46fd-bfdc-5ef5758da1ec"
      unitRef="usdPerShare">6.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNy0xLTEtMS02NjM1MQ_60b322a3-d658-41c4-bcb4-53d0bad26dfe"
      unitRef="shares">53098</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfNy0zLTEtMS02NjM1MQ_28f73f38-bae5-437a-b6fa-9bff65881110"
      unitRef="usdPerShare">10.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfOC0xLTEtMS02NjM1MQ_75d2ef39-2756-4a5b-a365-b04cfb2e331b"
      unitRef="shares">602342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfOC0zLTEtMS02NjM1MQ_4fc3838e-3d23-47a2-87b0-da24c25028f4"
      unitRef="usdPerShare">14.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfOS0xLTEtMS02NjM1MQ_c77fa7ef-97bd-4f03-9029-8dd7927f7eef"
      unitRef="shares">4932632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0bc7da1566164597b0db01be97552e79_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfOS0zLTEtMS02NjM1MQ_4190fc6b-9fd0-45b5-b801-c68dcb5bc572"
      unitRef="usdPerShare">9.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfOS01LTEtMS02NjM1MQ_19ec2c59-5930-4c9f-a580-b705567e964e">P7Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i0bc7da1566164597b0db01be97552e79_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfOS03LTEtMS02NjM1MQ_a45214d0-9285-4199-87c6-8a3459254461"
      unitRef="usd">4245000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i0bc7da1566164597b0db01be97552e79_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfMTAtMS0xLTEtNjYzNTE_3e937130-08ad-48d8-8f70-f09347190672"
      unitRef="shares">2860912</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i0bc7da1566164597b0db01be97552e79_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfMTAtMy0xLTEtNjYzNTE_8187e57f-bc4e-460d-813b-f3c4b0b00dbb"
      unitRef="usdPerShare">10.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable
      contextRef="i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfMTAtNS0xLTEtNjYzNTE_9a777e9e-2ea3-48fe-a030-79ac865f557f">P6Y3D</eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i0bc7da1566164597b0db01be97552e79_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmM1NDYxZTEzYzUxOTRlODFhNjY2YjU3ZjMyZmFmNzk0L3RhYmxlcmFuZ2U6YzU0NjFlMTNjNTE5NGU4MWE2NjZiNTdmMzJmYWY3OTRfMTAtNy0xLTEtNjYzNTE_e5df229a-1404-4813-9186-1ea0cd5c7dea"
      unitRef="usd">1338000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDg3MQ_b8ab8a75-5e04-44a7-9e40-3a0eaacd9dce">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity for the nine months ended September 30, 2022, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,926,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(553,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,638,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8faa1fb37e374acb85de383e56577e09_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNC0xLTEtMS02NjM1MQ_395b6866-b0ac-4ada-9e77-771be8838af4"
      unitRef="shares">1926467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i8faa1fb37e374acb85de383e56577e09_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNC0zLTEtMS02NjM1MQ_62a1d9c4-bc01-4b2f-be42-c4d06b6bbfc4"
      unitRef="usdPerShare">8.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNS0xLTEtMS02NjM1MQ_a2d5f52f-4c4c-4062-9ad3-f761afd7b39e"
      unitRef="shares">1667320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNS0zLTEtMS02NjM1MQ_0e4b50fe-abec-4b90-bc1f-343b9627e5a0"
      unitRef="usdPerShare">6.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNi0xLTEtMS02NjM1MQ_2680a5ed-92e7-459e-880e-22034b2f1905"
      unitRef="shares">553328</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNi0zLTEtMS02NjM1MQ_fe907b10-cd45-4ceb-9d26-68655fe9b993"
      unitRef="usdPerShare">8.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNy0xLTEtMS02NjM1MQ_a2b35f1c-24bb-4950-bbee-308ea4b4bcd2"
      unitRef="shares">401656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfNy0zLTEtMS02NjM1MQ_59235589-f07e-462b-8b63-b0210172d30d"
      unitRef="usdPerShare">6.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfOC0xLTEtMS02NjM1MQ_81f11446-7926-4fc5-a30c-1fb00cfc4101"
      unitRef="shares">2638803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5f7d73b878d64950a8425ead93d94a97_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOmZkZjQ5ZmM1ZjlkYTQ1Y2JiMzM1YTZkN2FiN2MwOTMxL3RhYmxlcmFuZ2U6ZmRmNDlmYzVmOWRhNDVjYmIzMzVhNmQ3YWI3YzA5MzFfOC0zLTEtMS02NjM1MQ_8170041e-4a63-4adb-b016-05588f2bfe15"
      unitRef="usdPerShare">7.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RleHRyZWdpb246MmY4ZWZlMDllYjQxNGY2MGFiOTc4ZmZiNDE1MTk5MGVfNDg2MQ_b4854981-2ba8-4f17-b035-e00b54e7612f">&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0ba6f3c5b4314563a0f6c2b8e9485876_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMi0xLTEtMS02NjM1MQ_8237d17b-aa04-4980-bec1-164e883a0e1a"
      unitRef="usd">2398000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0df63e74062b463990c0a0996e88bf4d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMi0zLTEtMS02NjM1MQ_8af92bdb-b692-4aeb-a974-7cf8f76af5f7"
      unitRef="usd">2399000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7000885be6d948baa6c2a16a20a9b3d0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMi01LTEtMS02NjM1MQ_93f14eed-05d7-4739-99d0-1cb8ffd20acb"
      unitRef="usd">8236000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if5753737be3a4d78816715ef5956b5f1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMi03LTEtMS02NjM1MQ_d3732870-c5a6-4bf5-b46c-3049d9b67cc8"
      unitRef="usd">6784000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide927851f3d44d388940de49dc572cbc_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMy0xLTEtMS02NjM1MQ_5ca3e5fb-3db9-4375-9e63-d2dbf4bc252a"
      unitRef="usd">85000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibab36228520640d2af7899d4d89c4119_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMy0zLTEtMS02NjM1MQ_775d5bbb-c1fa-460f-a0ba-99a6a85ce6c0"
      unitRef="usd">77000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16951a5be9bf4007b7826543c19fc57c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMy01LTEtMS02NjM1MQ_13583b1a-95e8-4a1f-b110-7742a95c5c0b"
      unitRef="usd">185000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie70ba7a39fbf47b5ba3502a70a32b3cf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfMy03LTEtMS02NjM1MQ_dfc9b652-246e-4a63-8b08-63f546f6b571"
      unitRef="usd">143000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfNC0xLTEtMS02NjM1MQ_b0090b78-1069-4bbb-9df6-e94e12adde78"
      unitRef="usd">2483000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfNC0zLTEtMS02NjM1MQ_81ebe973-2817-4101-bcd4-38932b53ec11"
      unitRef="usd">2476000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfNC01LTEtMS02NjM1MQ_2000c062-cc7e-4bfc-8565-5c8fcbd81add"
      unitRef="usd">8421000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82NC9mcmFnOjJmOGVmZTA5ZWI0MTRmNjBhYjk3OGZmYjQxNTE5OTBlL3RhYmxlOjI3Njk1OGIwZWIyYTRlNThiZDVkYWZkNjY5MjU1MGVmL3RhYmxlcmFuZ2U6Mjc2OTU4YjBlYjJhNGU1OGJkNWRhZmQ2NjkyNTUwZWZfNC03LTEtMS02NjM1MQ_32683716-af00-4379-9cc1-1f2a99ff7f26"
      unitRef="usd">6927000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i1894854da2af42638a40edaec631c6a8_I20210218"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfMTI3NQ_882ea194-f1d8-4f3b-840b-3f345a05d3d7"
      unitRef="usd">35000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <eols:LossContingencySettlementAgreementPaymentTerms
      contextRef="i748d6131bd954dc9aa10faa24cb00d27_D20210218-20210218"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfMTMwNA_a4d519d9-1952-44f8-b289-50307293874b">P2Y</eols:LossContingencySettlementAgreementPaymentTerms>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="id23cfd7dc1564cd6aaa76f53b45ccf4f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfMTM2MA_a9c489a5-d12e-4d82-b320-ba345918ad72"
      unitRef="usd">15000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i0997749416bc4e028361e395d1f8bf92_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfMTQyMw_87888c29-429a-4d8c-a7f4-ebef1c5804ed"
      unitRef="usd">15000000</us-gaap:PaymentsForLegalSettlements>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="i5d8448ecaa3a48df85d5889b9d36144b_D20210218-20210218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfMzAwNA_9a3dfab2-a20e-45b6-b06e-57490b0d5427"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1894854da2af42638a40edaec631c6a8_I20210218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfMzA4MQ_42b413e0-1596-4011-a689-b79038b1e25b"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear
      contextRef="ia1bd190fdbab49dabebbb80e51c1f276_I20230915"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNDcxOA_8d9cd107-1895-4614-80f0-ca02bfc857d7"
      unitRef="number">0.25</eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear>
    <eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear
      contextRef="i97e475107c9e4c7997018cc44ab1d86f_I20240915"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNDc4Mw_5fa6aad3-067a-4212-b458-0cedaee99eb1"
      unitRef="number">0.50</eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear>
    <eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear
      contextRef="ia06093115e034c0794719bee09423007_I20250915"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNDg1MQ_ef03823a-1cb6-4e3c-8668-61a8164d0655"
      unitRef="number">0.75</eols:ShareIssuanceAgreementPercentageOfShareDisposePerYear>
    <eols:RegistrationRightsAgreementSellingPeriod
      contextRef="ib6c9bed41b124f498f1b2cccdadacc84_D20210218-20210218"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfOTk2OQ_08a65bac-a39c-4926-ae55-a98fb3efe7b4">P3M</eols:RegistrationRightsAgreementSellingPeriod>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNjA0Mg_f44191e6-2c58-4875-94bb-2c6351f48722"
      unitRef="usd">7936000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNjExMg_8a51efe4-8990-40c1-aaae-6b31a2f5b213"
      unitRef="usd">5000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNjE4Nw_e9fff7bd-4ffe-4b93-b14a-66e435a56dd8"
      unitRef="usd">12447000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:LitigationReserve
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNjI1Nw_b12cab4a-35be-4c41-a2e8-95ab95cec266"
      unitRef="usd">20000000</us-gaap:LitigationReserve>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="ie66d630b4d65447f8c7f52dd587c90cc_D20210323-20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNjYwMg_b623200e-39b1-4d83-9e3e-36d0f2257111"
      unitRef="usd">25500000</us-gaap:LongTermPurchaseCommitmentAmount>
    <eols:MilestonePaymentInConnectionWithAgreement
      contextRef="ie66d630b4d65447f8c7f52dd587c90cc_D20210323-20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNjg3OQ_a2c03f27-9663-43c7-a884-a64d471845c6"
      unitRef="usd">10500000</eols:MilestonePaymentInConnectionWithAgreement>
    <us-gaap:ConvertibleDebt
      contextRef="ibfb737bacd0248fc910875d3a4549e77_I20210323"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNzk4Nw_299034d1-33a0-4671-a876-17119648a167"
      unitRef="usd">40779000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ibfb737bacd0248fc910875d3a4549e77_I20210323"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfODAzMg_b0b1b307-680a-45f7-a5eb-2120661f46ae"
      unitRef="usdPerShare">13.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="ic8fb36cf68884af1a7d8744f3d77a5ba_D20210325-20210325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfODA1MQ_34426680-a92a-411b-a955-dc38e191775b"
      unitRef="shares">3136869</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <eols:DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned
      contextRef="i3389f3c7fed74caf844e5cc2688cd6f0_D20210323-20210323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfODMxMw_6bb2a50d-4789-4615-8187-34ceb77e2137"
      unitRef="number">0.0999</eols:DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="ia95f293a31d148f8a32dd28e1c5a5d71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfOTY2NQ_4a7cdc67-c2ea-49cf-a53a-3c53ff77ceff"
      unitRef="usd">3257000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i0d8271bdba63484f9f7c027ec1a48aa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfOTY3Mg_94d05df1-6122-48fe-aeb5-e596aa41b9b2"
      unitRef="usd">5657000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <eols:PaymentsForInventory
      contextRef="ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfOTg3Mg_4afca97a-2ee9-4c45-9eec-9a1417030baa"
      unitRef="usd">14238000</eols:PaymentsForInventory>
    <eols:PaymentsForInventory
      contextRef="i5d4379a4158c443fab6596315f543818_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfOTg3OQ_16ca1cee-4fc7-4cb2-b5bf-5a7e12c915e2"
      unitRef="usd">40509000</eols:PaymentsForInventory>
    <eols:PaymentsForInventory
      contextRef="i325d14c124e140b2af640417dd708743_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfOTk1MA_c4ef4de5-76a4-4217-9013-a297f99883cf"
      unitRef="usd">10916000</eols:PaymentsForInventory>
    <eols:PaymentsForInventory
      contextRef="i7e674bf346734dc5988b8d0e23837a00_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmZTRjYzMzMzdiMjRiYzM4MGQwOWE0OTc5NGNkMzI5L3NlYzpkZmU0Y2MzMzM3YjI0YmMzODBkMDlhNDk3OTRjZDMyOV82Ny9mcmFnOjlmZWVlODE3MzMzMDQ4MzE5ZWVkODhlMGYyMzFjNzE1L3RleHRyZWdpb246OWZlZWU4MTczMzMwNDgzMTllZWQ4OGUwZjIzMWM3MTVfNTQ5NzU1ODI0NDcx_38a82eea-00d1-43db-b804-81a395c6070f"
      unitRef="usd">24576000</eols:PaymentsForInventory>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MO?L(M[M18M-^Q[H52HFRO5PS"N"U /R^$L#PW8W^--9_"EW^"U!+ P04
M" !(B&A5Q=J:@/X"  !C"@  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;*U676_:,!3]*U8V3:W4-A^0 !U$:JFF[6$2*MKV,.W!32[$JF-GMH%NOW[7
M29H!#5_=> #;N>?XG.MK<H<KJ1YU!F#(4\Z%'CF9,<6UZ^HD@YSJ*UF P"<S
MJ7)J<*KFKBX4T+0$Y=P-/"]R<\J$$P_+M8F*AW)A.!,P440O\IRJ7[? Y6KD
M^,[SPCV;9\8NN/&PH'.8@OE23!3.W(8E93D(S:0@"F8CY\:_'ON>!9017QFL
M]-J86"L/4C[:R:=TY'A6$7!(C*6@^+.$,7!NF5#'SYK4:?:TP/7Q,_N'TCR:
M>: :QI)_8ZG)1D[?(2G,Z(*;>[GZ"+6AT/(EDNORFZRJV*CGD&2AC<QK,"K(
MF:A^Z5.=B#6 W]T!"&I <"R@4P,ZI=%*66GKCAH:#Y5<$66CD<T.RMR4:'3#
MA#W&J5'XE"'.Q&,I4CP42 F.M.0LI08GMY13D0"96F)-SB94@3 9&)90?DXN
MR5OB$IWAJAZZ!G58-C>I][RM]@QV[#F%XHITO L2>$'0 A_OA]]!@G"_A/N;
M<!?=-RD(FA0$)5]GEQR#EK$R#9$S\H$)-,XH)Q.I65EIWV\>M%%8;S_:K%;<
MW79N>PFO=4$3&#EXRS2H)3CQNS=^Y+UO,_Z?R#;2T&G2T-G''D_P_H!2>/A8
M=,GC!2FH(DO*%T#.F""IY)PJ30I0U<&?MV6CVJ)7;F'_09:Q#Y=>.'27ZS8/
M16WH[S;ZNZ?IK\J3T(7)I&*_\8'U4:VVBJ_XPW597O79TG]$X(:%L+$0OLH"
MTWIQ6'[X0M6V[GT1&X*C1G#T*L'XOM"&BI2)^2'5T4'5^R(V5/<:U;V]JL<R
MS_%>_T.9]XXJ\T-1&^+[C?C^">)/KO'^SM+=3OLQD1L.!HV#P<D.+HZL\<$+
M46'D]SM=O[NEOB4P#'O1H-]O%^][?U^8WBODGU#Q-?\1)MHBVUVX:QV ;;\^
M4S5G0A,.,X1Z5SWD4%5'4TV,+,JFX$$:;#'*889=("@;@,]G4IKGB>TSFKXR
M_@-02P,$%     @ 2(AH59-;@2TI"   '2P  !@   !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6RM6EUOXS86_2N$6Q0SP"0627U8:6*@B51T@'9W,.EL'Q;[
MP%B,+50679%.,OWU2\H?LL@K.IGJ)9'DPRN>>R\O#RE>/XOF3[GB7*&7=57+
MF\E*J<W5="H7*[YF\E)L>*U_>13-FBE]VRRG<M-P5K2-UM64!$$\7;.RGLRO
MVV>?FOFUV*JJK/FG!LGM>LV:K[>\$L\W$SPY//A<+E?*/)C.KS=LR>^Y^K+Y
MU.B[Z=%*4:YY+4M1HX8_WDQ^PE<YC4V#%O&?DC_+DVMDJ#P(\:>Y^5C<3 +3
M(U[QA3(FF/[WQ.]X51E+NA]_[8U.CN\T#4^O#]9_;LEK,@],\CM1_5$6:G4S
MF4U0P1_9ME*?Q?,O?$\H,O86HI+M7_2\QP83M-A*)=;[QKH'Z[+>_6<O>T><
M-"!XH '9-R"O;4#W#>AK&X3[!N%K&T3[!BWUZ8Y[Z[B,*3:_;L0S:@Q:6S,7
MK??;UMI?96T2Y5XU^M=2MU/S.U$7.NR\0/I*BJHLF-(W]TK_T_F@)!*/Z-\;
MWC 35XE8;9!KG90KDRU/'/TJI$07Z,M]AMY]_QY]C\H:_;X26ZFA\GJJ="?-
MJZ:+?8=N=QTB QVBZ#=1JY5$N>Y8 ;3/_.U33_NI=L[10^3@H5OB-7C/-Y>(
M!A\0"0@!^G/W^N88HO//WIY_\]M[SJ#'=*&M/3I@[S-_XO667T%QW;4,X9:F
MX%W)#5OPFXE.'LF;)SZ9__ =CH,?(:>.:2P;TU@^DK&>^\.C^T.?]8/[(>_O
M&L9M0S,[/,TIG:7I]?3IU*TNBL1QDO11F8O"09@F01^6N[ X"G!\1/4H1D>*
MD3?#]K6F7B+^LC&528+)%HV9;&,:R\8TEH]DK!>)^!B)V)MLGQI1;!<*+814
M9A:0K.(2O>,OBVI;Z"NV%HTJ_VXG!O-[62M6+\N'BB,F)5?R/12XW3NCT]RB
M86JEUAV P@XJ<U$AB;"5S;F+(DD2!'":)D?G)%[G: 6EJG:&1!OVM?W_V(@U
MRAA_%J)>0M03IR,V[;.(["PB=Q$7)(J&^,Z.?&=G^%;ZT?(#6O):#]"J%0*L
MT(JDE,H,V">P*LV<SM P24.+-H#"<4(MZBX*!Q'&V.+OPI+9+, P_?1(/SU3
M>"5GS6+5TBYT%:[$Q@0=XIP"&9[$%F471 .+209@J.V[''A;' ZPQ4&G"@,O
MWX_UQ:81"ZZE7?,&ZGNKOA0_#\D B%[WV'GN-=2G?2*&\;GYE57;8T5;:"6I
MD]X,[D9\997ZBL1#52YW #WNF2EV2J#\251;B7X66RTZ&UCU8C=0!-MI :%"
MFWH&H'1BQ+:#7%2HI_$!'Y'.1\3KHXSKN691[GS05H&3>0!D3IQ^I,1)"PAD
M5P  1.(TLGF[J# )R #O3OEBK[*;_RZ4+GO"D2<@9>IT0<]+J1-M%Q9&R<R6
M8P ,1VD<4YNXBTLQ3>D \TYT8K_J;%=X[>PFC@M!D'7H3CTXF:6)31O"I1@[
M:0[@HC!.'=X CL3T1-;VB7=2%)_1HFK%&ZUK%F+-C?!I _X>U*-X5$$ZJK5L
M5&OY6-;Z,>E$*?:KTH^UXMJNVH<%C(6K^.C,SD$7XZ0?)"_MU .$ZD#6=<H2
M^Z7ED>$^X4"*D,JC(;59 C!J*Z8,0L5A[,PG  R3:&"]ASMEB?W2LBLO_,54
MUFTI5ZV@UC-PP1^4_(!J#LL-5^LY\\I92'8>D@.0BS2>#3#O1"7VJ\I=?=F'
M>9BE*_$N8F+S=$$.3\".6TM]=OK[9YV8)'XQV0;X@3^*AA^*J6(O PM[XLJZ
M"Q*0V%XS0#B<AL1.;@@7:^5EAQA\[RP>6C>13E,2OZ;\>&3L&] $DH<VY?.8
M#,#8M2^', ,B@72RD/AEX;^X0I4.-$C.560FILZB",+IF%);!T(X'=/0(0J]
M=Q8/DNVT(/%O@^X&[J*W#[YD98W>&1? "H&,NC\ZJK5L5&OY6-;ZP>GD*O'+
MU2]UPUE5_LV+-B';NFKF$CT"P;A ZC&P9U( 9==7R!"-G9ST&>HS[G0J\6JN
M>?^#S. HC)S]6DTT3.P]8@@'CD( %^/87M/FX'L]H["3@L0O!0\E!^E5"9(K
MUN@Y](')<H'>Z:%8B*IBS<F/X';D_A6ST\X%E]2I3# LLET"P/!ED-H> :T-
M""G2"4?B%XZ0/XJRVIH/>F_P2/(ZC\ PQR, #/((:&W((YVT)'YI^4?[G9@7
M%^Q)+UR7?$=;(K%54K&Z,.OXK?GXJ41;S;6K]AE4.[YL7;AK#_O-U8A1C),X
M#9T!!B"C($@P=69S")FF213:FQX ,DQF>$9F RJ5="J5^%7JMSCQD';?X$97
M@ ZY$4 .N!%"PFYTD7XWTDX%4[\*OA-2?4"'CRIFX^Q>3WWE@J/_YB_*U&ZS
MF?AK*=7_P*^K?NL'N\WN"^'08N)N'#/9.&;R?VRF'XM.DU._)G]E_V[]9M[\
M37M,:]FHUO*QK/4#TJT>*/$*:N^Y N_"X\U!&--:-JJU?"QK_2"<G.WP[W![
M3A?L6_:/%Q!LE<\[  :=+P!@.*!Q8'_; G!Q2'$X4(J[%0+UKQ .A;?Q$/9:
M>'/2C6DM&]5:/I:U?BRZM0OU[[%[1_ZHF^JC6LM&M9:/9:T?A&XE1?TK*=_(
MC]TQ.+,WXP"0O3H&()@Z>\P ROUT-STY[KCFS;(]9RJU]MS6:G>4[?CT>);U
MI_8$I_7\%E_=8>!YAJ_RW4G5SOSNX.QOK%F6M405?]2O"BX3';=F=Q9U=Z/$
MICUL^2"4$NOV<L59P1L#T+\_"J$.-^8%QQ/!\_\#4$L#!!0    ( $B(:%7@
MU6S'!Q4  .A' 0 8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULS=U=<]M&
MFH;AO\+23,TF5:N(^ 8SMJL2$A^-;FQ2<6;W8&L/& FR6*%(#4G9,_]^09H6
M!'2S05AW-).#6+*!ZVT0? $0?-A\\VF]^7U[5U6[T3_NEZOMVXN[W>[A^ZNK
M[?5==3_??K=^J%;UO]RN-_?S7?WKYL/5]F%3S6\.*]TOK]SQ.+RZGR]6%^_>
M'/[NY\V[-^O'W7*QJG[>C+:/]_?SS3]_K);K3V\OG(LO?_'+XL/=;O\75^_>
M/,P_5.^KW=\>?M[4OUT]*3>+^VJU7:Q7HTUU^_;B!^?[,@[W*QR6^.]%]6G[
M[.?1?E-^6Z]_W_\B;MY>C/<CJI;5]6Y/S.L_/E;3:KG<2_4X_GY$+YYJ[E=\
M_O,7/3UL?+TQO\VWU72]_)_%S>[N[45\,;JI;N>/R]TOZT]Y==R@8.]=KY?;
MP_]'GX[+CB]&UX_;W?K^N'(]@OO%ZO.?\W\<'XAG*SC>B17<XPIN=X7)B16\
MXPI>9P7WU)#\XPI^9P7?.;%"<%PA.'<;PN,*86<%SSVQ0G1<(>JN<*I"?%PA
M[FYT=&*%R7&%27>CPU,[;OQESXV[JYRJX3SM[.[>]OU3JWS9W4YW?Y_<?<Z7
M'>X<]OC5Y^?BX8D\F^_F[]YLUI]&F_WRM;?_X= -A_7KY^]BM6_<][M-_:^+
M>KW=N^EZ=5.W874SJG_:KI>+F_FN_N7]KOZC[L_==K2^K7];7_]^MU[>5)OM
M7_X4NT[TUU'R]\?%[I^CR]'?WL]&W_SYV]&?1XO5Z->[]>-VOKK9OKG:U:/;
MU[BZ/H[DQ\\C<4^,Y-?U;KXTK#:UKY:NE_7!Y_*GU>BGV]MJLUA],!@SN_'#
MK^7H_7Q9;4<_?-A4A^TV((D=^;D^XE2;S>'!JQ^NT?MZ,'MQU/D'@YS:Y>GZ
M_KX^QIU:.SM_[=%9CU8^ #SOH1,]C__-S6)_&)\O1S_/%S<CL1I-YP\+\_.A
M^%KKO(V77\V?]U"H'O_Z^O'^<7EHPI]V=]6F[LO[^I1\MS]7?JQ&67TN'GVC
MUMOMMP:\/!^?5;>+ZT5GA%?UT>/I$.(^'4+<@^J?4'^L/BQ6J_K1K,^@R_GJ
MNAI]4X]Q>S??5-MO1_-=7>KZNY'G_.?(';MCTX'!ZN\O7;[?/LROJ[<7]0.Q
MK38?JXMW?_F3$X[_:CI<D-B,Q)+/6'# ]A=4']_5C\;'Y\<!LEQ&8CF)"1(K
M2$R2F"*Q$L):'>X]=;CW!W>XU1_:X20V([&$Q%)/.UQX7N1/7#=N'S4RLFI.
M8H+$"A*3)*9(K(2P5J/[3XWN#VST<YK[LQD^>Z)>1NXDZ#Q-I];20]N6Q!)]
M [HG9GT)I].$Y(!R$A/ZV+VQYSA>>P,*LJ8D,=6[>TK#,]"+PG'D/BW7:H?@
MJ1V"PXK>B780J^M--=_6I[NZ!PX_?;M_D?O\Y?!_?'DA_+^_U*\NZI<8FT_S
MS<W_F=HD(,^!)#8CL83$4A++2"PG,4%B!8E)$E,D5D)8Z\ 0/AT80NMY4FRW
MCX?3X_IV=/WY=LCV<#ND/CI<KU>KXUWI3XO=W6BYV"T^S ^_;ZO=;GFX,?#\
M MITK+"6'WJL(+$9B24DEH;:]7(8A6X8N)TS-5DT)S%!8@6)21)3)%9"6.LP
M$#T=!J(_]C!@:OU(>QK[L>]V+C>GUH$-[6D22T@L);&,Q'(2$V?M\X(L*4E,
MD5@)8:V.CI\Z.OZZCKY=;_8M_;&^Y-^W\.&?][_M%K\MJ]%JO:OZ3NG6PD-/
MZ20V([&$Q-)8OP7F>&$<3CJG=+)H3F*"Q H2DR2F2*R$L-8!8/)T )C\40<
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M\,G=V@'['KM= ^OX?@Y$;H'L#)#\ZQM7][YXMRZ!,8JW=H,@AJ_?((DTM"F
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ML#8^?&R!IFW9'+_OP9 H07*6[0SIOV\^-L#A/"=H9]>)K&4$[</.@)7^X78
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MQVP\=" '"!&G,*""QAX\CHRSLF4&TW)6F*L*(DPS#?PZNMH"VU [SW @2S#
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MA>"3+ O:,5Z8^BQ,Z;FH8AX8"TL7(@5LY% =&9)!+^T,DH=K-O)]%Q)SH^&
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M\6@8Z&!?BQY.LY=?$Y7?Q]SQ72(U!.QTIP"-$CV=/7[RA#=U/GLV&;V)"9Z
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M4[EQ\>QQ+C?B+;PO#RWC75MN8R]13[E7@,#,2V[OZ$4F/SF_B#'NBZG -,)
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M/C[B!(C^T;DM3HE7FL'8IH]HZ9@6'X#?E\YU^@<NL'/M1P+OY?\"4$L#!!0
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M0\,;:'VAM=N\L('^@CC_!U!+ P04    " !(B&A50D)I$O4%  #H#@  &0
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M//*(ZGM*OS"R=76<2X-=P4UK;,.@[ '<KZ0TIX6]8&CLR[]02P,$%     @
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MY$191:0<E1G:PRJ^W6CP6Y^3AI% N-L6\^RDT[_SO5Y_V$&OF_)1F=(T$ _
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M&0TM(_G4YEE&VNT-D'I0Y8I?L;UZB_LW$G=*-4XE/JO\T9N'TYL"'>0").\
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M[>7D'3O3":G-D#A^ Q+^J\F_M,W2/>U1O"7XF"%2SO$HB/S4EL H,=.IF"D
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M3AAX$.@D87>P)<$2<!D&@,O$!;]<;M 8>;!B%!_9Z6^!$8&8.(F' !R[44P
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MIH.7.WHOGK90]54< &_5E]Z[\LIP?>D@2=]5^0DK=M$Z76IT%<<^1[XJ"+P
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MZ*HCEB,(B7*$2(AT ?!X<IY.SYX(7^>4-UR'MWOR;)6^0<JAY:I0O=.,ZNH
M,5O?1L,XO79/_8^GY^G%U>7WT3 9#?UMD=/HC\>L$%?RG\BI!13E[\B$3\-?
MX;F1/S[3#9<_X0/'M$!\CO1QCJGCT=7%D=2 _"^-7?.?HIG9IK$K_G&I$:=7
M- #?SRW\J/N%-@A_F^C%OP!02P,$%     @ 2(AH54,D2*^!+P  N:,  !D
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M"VMI8=(=#+NO&US[2?*^:VR'U-C6.+J%\=]<)$U7RO"-V70E'8^=T?07?#P
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M=7CBJT/T4HKTZ/@EK^:_:H! 1/X@R6U-3)F5=EH'B?M-#2RY12[;V+:W)GC
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MWYUUDM@:ORFU.Y G(F\$4D4SE'1=L1+99ZJF(RK"H+HT_NB1<' -*8E\>*M
MY#/M+3JF6.]C!9V,0S)<#VZ>(W+1L@4ONQ@5J#T43IE-"&.#I8*Y7*F/ C4
MT7="'IT;"YAN64OHF6)RH,>8K^%%?('YS@)&BR:HG*2Z.&!*?]KB#+#;9%W6
MM_9DTE!*?@D\T<"?.A;FM$-G^0.L'/<.=HW PM7$@XNECSQ>HPI\!+ @MS)T
MVP$U"\ILP7"<(VC)_V0#M<2Y7-FP89_/=;<"8:,K@W^.N6%I*I _6U,2RJZC
MO0*IWL'9!$-O0:?3;?T)?!001?Q^('!JB_@#F ATU1(C@1V!SH?\9VURB7C
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MEE='H<54G"$F<OS,GPGQ%EQBCEY5):' 4P[  %"30X0VLD;7CD^D^GN@&$
ME5FT#^:J&' ,2, 0BV-V4SA-E 4<6F<CI!(0Q]KI6+T='H'1"E-<9;?69:O!
M^M$5HS8WQB@H\XLS-XHF U1H2?734)8SBY!'-0WEU*7$2T790064=3T75J=
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MU.<91X9SD3M-2 3H,ZDVF)W%4HC" IR@G3LB<5/BL#,.2I)=*/#A(#5SG=?
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M&V?/'L=\@R,HW^9:QDH2;K\L7L\;[ON&BUFEW(7+"D]^LCSS/NZS,<<TKH%
M/2=(\_'R#IXS!'YX]/3IW[+ZQ>P+JW7BX_'IXNO6JMM<+A[UE_H>V0AY6]Z
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M,DQ=6D"1/#T]];T0R$?H3<9C1\N(&* 4-FPEO:.N-C6U\"Q 86E1 %(<4AT
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M/2X4UC] )<,AL=EZ6^_H(V;>F@8?@-_7==WJ'SC!;=U\HN6]_!]02P,$%
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M#2^OB%VJZ<7-Q,BMZW\K::B;.K&@WQ=4]@#MKZ4TAXEUT/T0S?\!4$L#!!0
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M%??E'?J5\YU\63&-%U)\XKDIYX-T #D6K!'F1FY_P<X?1S"30KM?V+9W)^$
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M:7FY!RQ_;B@#^7Y+J7B\46=XS;'S_%]02P,$%     @ 2(AH5:S(QDF, P
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M7AJHYVO&Y-.B?$%S5!?]!U!+ P04    " !(B&A51@<8K=H"  "C"0  &0
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MYT?VJ(I=QG*'.:QH^C=)Q&YNC V4P :7J?A(#^^AB6>H^&*:\NH7'6K;T<A
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MKO E!V4-<'\AI7F<V,>B_6\P^0-02P,$%     @ 2(AH52M'+X&1!@  I3D
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M=J@/GJX*E:=UL#Z#-,XV?_GW6HB=@.!8 *T#Z%Z /S@2$-0!P5L#!G7 8"^
MTB,!81U077I_<^V5<!%7?#R2^9K(\FA-*S<J]:MHK5><E3?*HY+ZVUC'J?%7
M(5-RF_.L(#^3^P77VC_K_.U\_"$2BL=)\5$?\"BF*REF)!(3->HKW7Y)Z4_K
MMJXV;=$C;45B>D+\P2="/>J3;X\1^?#C1[+DK_K&4T1)GNG'P(*]=F._<*FQ
M88GUSRWAD3O\42Q/2.!59T4MX>P-%Q7XYD69F+[.29,8VB2&5MS@*'>BR$U6
M*+FJY/GK5A] ;I1(B[]MTF]H SNM+#>?BR6?BHN>KB>%D"^B-_[I!W_H_6(3
M' F+D# &@ADI"9J4!"[Z^"930E,5D5P)HI^2V9''P(GIFHL-S/<J6EGW7\;>
MB7<>COHONRHCVV0@F*'RH%%YX%3Y7HIM2>!IOBHKPT*WLLB3F4WK#6RXHX[N
M(SW/5.?:V637&QH)8R"8(7782!TZI;[-LYF^C:O[>L*S9W(WGXNROC^4-_B'
MVYNKNX>/-M&=V*XW.!(6(6$,!#-R,VQR,X36_R$R)4A8A(0Q$,Q(R6F3DE/G
MXW+%B[@@FP%Y6?Y?N(SY)!%5?V#+B1/7-2<;F.^;_<"I9_SS]WH%Y!DP$,S0
M_JS1_LS=*UB&IC;)G92NDB-A$1+&0# C%>=-*LZAE>D<F1(D+$+"& AFI,3W
M6AOG.9^/WU?I1$B2S[<^JB#_.BS558T+=\=->V,F=XM=M8;2&(IFJKUCFGVG
MVM4C$#>/P"<RUVW5PU6KVDY<UV< 2HN@-%;3=L?C/@TWG5-S?YFJMX[8=[J[
M0]7UL#6URNWF#,FKX-+6?5R[(SM+"[6^*)JI?FM^?9#[K3G[(Q5_O[P@'6L$
MI3$4S92Z=<"^VP*WQ7PI9)S/XNEVEJRLZO6F5?K!057W#\HZU M#:0Q%,W5O
M[;#O]L-5@9G%Q?1H'0\/JEO@#>CA?(.[H<XB0UTMBF:*W/I:W^G1ZBI>%"L]
M-A%DFA?*.I"O*8;4=!A8I(::52B-H6BFU*U?]=V&E<WGHEJ(*>O(5-<,_F0?
M#$*-*I06U;2]^4^?TKVZQE#-FEJW_M3O;E!UL?[?4VSNYCKG!&IEH32&HIF)
M:]VLC[6S/M3/0FD1E,90-'/]J[6TU&UI.T^WU;S]I9*ST#5%=NT^B\Z+75";
MBZ*9&6AM+G7;W*^;^0-R694SJ^108PNE15 :0]',5.RL!H.7@['KP=@%8>R*
M\'O88MK:8NJVQ5VG@FK<[KCV-#P<U;I;[:PXU!W7M'#_$HY.\=#6^5*W\[W,
M,CU<E067K[7WM6KHA@3G),TSM;#.\+AC.PL+M;\HFBE^:W^IV_Z:Y5X/7JN1
M[%UF[VRA:\!06@2E,13-S$KKEREV(9A"5X*AM A*8RB:F9C675.WNSZH_*W)
MKJ;N9)Q-XR5/ZLY ?U_^LB6>D725J'B9Q,)>W.P+O<%^!P%UV5 :0]',Q+16
MG+JMN+V.?5WG5KFA/AM*BZ TAJ*966E]-L7Z; KUV5!:!*4Q%,W\46/KLP.W
MSWZG.E:WNE_']I<CW"?7-3%0&D/1S,2T]COH8K^;.K:0PCHB<],Z_^P4ZL6A
M-(:BF7EIO7B ]>(!U(M#:1&4QE T,S$[O\_NZ,5!E>QM"]KND^N<&.P/NM]C
M03MH;7W@=N3;2G9U="+1#>C\C$!-/I3&4#0S%:W)#T)L\8+Z?"@M@M(8BF8F
MIO7YP5O6Q=\^D1@<+I"'EC<?W*UV5AQJX(]=PN%$8G_G#;?R!<8O7#YIK4@B
MYCK4.SG5N9.;=P(W.RI?5B^]37*E\K3:7 @^$[(\0'\_SW.UW2G?HVO>S!S_
M!U!+ P04    " !(B&A5E3K:D<D"  #V!P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6R5E6]/VS 0QK^*E:$))"!_VB2%M9& :F(22(C"]F+:"S>Y
M-A:)G=E."_OT.SLAZT;:CC>-G?B>WW-)[VZ\%O))Y0":/)<%5Q,GU[HZ=UV5
MYE!2=2HJX/AD(61)-6[ETE65!)K9H+)P \^+W)(R[B1C>^].)F-1ZX)QN)-$
MU65)Y<LE%&(]<7SG]<8]6^;:W'"3<467, /]6-U)W+F=2L9*X(H)3B0L)LZ%
M?W[IVP![XBN#M=I8$Y/*7(@GL_F231S/.(("4FTD*%Y6< 5%8930Q\]6U.F8
M)G!S_:K^V2:/R<RI@BM1?&.9SB?.R"$9+&A=Z'NQOH8VH=#HI:)0]I>LF[-A
M[)"T5EJ4;3 Z*!EOKO2Y?1$; 4&P)2!H P+KNP%9EU.J:3*68DVD.8UJ9F%3
MM=%HCG'S569:XE.&<3IY %F2&T&Y(B?DENI:,LU $;$@4YAK<C@%35FACL@!
M89P\Y*)6E&=J[&JD&PTW;4F7#2G80II!=4H&WC$)O" @C[,I.3PX^EO&1?-=
M!D&706!U!UMTK<TI4VDA5"V!?+^8*RWQ:__H\]AH#?NU3 F<JXJF,''P/ZY
MKL!)/G[P(^_3#J>#SNE@EWIR#Z9,,I#F[9JWT&>PD8BLA"FI5>*-W54/==A1
MASNI"!KT@9JH<#\H[$#A/M"P#Q3^+RCJ0-$^4-@'BMZ @M#SML#B#A;O@T5]
ML/@]L%$'&^V$/>2 K76A0?8A1^]!GG7(L]U(H6E!*LEXRBJSHB_8='5O@9^]
M,1!O-^![?UJ0M]/"(Z>ED)K]@@P;*E9SAM4L:C1!L-40IE1->0HD%:K?5ZN_
M:>QD$(Q&6XQM]$9_I[$;P9=$FPYI;!T3CE,22_?=]OPW-1W[L1_\8\_=Z.)F
M(MY2N638EPM88)QW&F-^LADRS4:+RC;VN= X)NPRQ\$,TAS YPLA].O&S(IN
MU">_ 5!+ P04    " !(B&A5W,L*N%X'  #G10  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6RUG%MSVS8"1O\*1KO3R<ZD%B^Z6%Y;,Y%)H.XX&X^]
MW7WH](&6((L3DE!!R(X[_?$%2$H49!JQDJ]^B$6*."#%$UP^P3Q_$O)SN>)<
MD2]Y5I07O952Z[-^OYRO>)Z4)V+-"_W.4L@\47I3/O3+M>3)HBJ49_W \T;]
M/$F+WO2\VG<CI^=BH[*TX#>2E)L\3^3SC&?BZ:+G][8[;M.'E3([^M/S=?+
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M[6A#UN#M(:ONGV@J]1!723WC777+ 0U=H;0(2HNA- JE,13-EJ8-70-LZ!I
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M+!Z_B])#J_IKPG3'59/&51.MJVYSN981+A##,IK*WUS'MDE:S+EV@H3YD+
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MDVLT.J5BTVW';2>H:M?EM@JI9[IA08\4:&M ^[E2>)C8 _IG+_D'4$L#!!0
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MRJ2Z+$TS40\FX!J@OL\9D]N.#E ]P:+?4$L#!!0    ( $B(:%74P*-P@0(
M & &   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;*U5VV[30!#]E9&1
M4)%H[-AI*<6QU*9"5 )1)4 ?$ \;>Q*ONA>SNTG:OV=V[5BIY)8B\6+O9<[9
MF>.SXWRGS9VM$1W<2Z'L-*J=:\[CV)8U2F9'ND%%.RMM)',T->O8-@99%4!2
MQ&F2G,:2<145>5B[,46N-TYPA3<&[$9*9AXN4>C=-!I'^X4Y7]?.+\1%WK U
M+M!];VX,S>*>I>(2E>5:@<'5-+H8G\\F/CX$_."XLP=C\)4LM;[SD^MJ&B4^
M(118.L_ Z+7%&0KAB2B-WQUGU!_I@8?C/?O'4#O5LF069UK<\LK5T^@L@@I7
M;"/<7.\^85?/B><KM;#A";LN-HF@W%BG90>F#"17[9O==SH< -*3)P!I!TA?
M"L@Z0!8*;3,+95TQQXK<Z!T8'TUL?A"T"6BJABO_%1?.T"XGG"N^-FB8XVH-
MGY'4L' ,"W)*M1$(>@6W00:LCB^V%+=&F*.W1A\/W]!(8*J"*VY+O5$.YLPA
M'%VA8US8-WGL*$M_5EQV&5VV&:5/9+3 9@19\A;2)$T'X+.7P\>/X3%ITPN4
M]@*E@2][@F^FI>2.?.MLJ'.FE9<+5<E)+5^UT'9C$'Y>+*TS9,M?0S6WATR&
M#_%7]=PVK,1I1'?1HMEB5+Q^-3Y-/@PI\)_('NF1]7IDS[$7O2-8YPC3.T($
M1SCOB".NX &9&3; \R>D+1(RD*1U;6%\!A5[L$-*/,^4O8CID0R37H;)O\E0
M[?UO@O^I?KI9)=EF4(&6?)P$=M]IMT4R2MY/\GA[6-Y?P]K<XX/[[WOO%V;6
M7%GZ("O"):-WU$M,V\_:B=--: E+[:C!A&%-OP T/H#V5UJ[_<1WF?ZG4OP!
M4$L#!!0    ( $B(:%7085!BP0(  )0'   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;(65:V_:,!2&_XJ555,KT>8&X3*(U!9-G=1JJ+3;AVD?##F
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M)WPEL)=';61.LN+\WG0^KB>.9S8$%!)E"%C_[6 &E!J0WL;/BNG42QKA<?M
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MG[I5S#TGSJ.2+L\%?T B&ZW0LHN<_=Q:\14FV4*YE4+]&BH[N;R5?/5KRZ.
MB?3-JSG!LX_(_[T/Y1/Z@&[5L@SV$4-\C?*!Z)]=GM[+++W9F+<>DS2,TG=J
M]/=;#[U]_0Z]1A9*MU2P%(4)^IZ$,GVO'JKK;UN^3VD2I.>65+%G$5BK,LZK
M(DYR)$Z,OO!$;E/D)P$+.NP]L_WBE+U_PC\Q %B*](IY\LS\%3$BWK+=&#GV
M>T1L0CH"NC:;?V)W8T3F1\V]/_/NF\T]ME+F.#?'!C*<:ADZ.9YC6H;EZNI<
M'87YI-L\JZ9GZ8ZNV,5(E<N4B7LV6KYYA5W[8Q>SD& >))@/!*;E8%+E8&)"
M7ZJ%'28;578CFJP8>JM>V.(U?M>5D )KFF-EN]']<K)PB.NHQ73?Y-KH<RC7
M/9WZ0$XU&J<5C5/C4OZ9[TTL0)?W3*B]%EVKNB'4AKBG$?K&1-S%YA1R>4."
M>9!@/A"8EA>WRHMK7-[--,@C:3 B#$T#))AGGANVT1.CHJMR^D!A:)S/*LYG
MQKB*LLZ/EW6C^5#"(<$\2# ?"$S+P;S*P?S/MM8Y9 X@P3Q(,!\(3,O!HLK!
MPO@>7+%-F"0#=E<CW-"<0()YBX,MV%D00N9N:PL&<JK1C>U:U=A&PO\2-,GV
MX!,TERC-V6!W@:?S5A/3-6Z&L>WHX[Q./'<Z.V#''/[_I:<A^K"YU7MD8A6F
M/0@RX@Q=B*!H7HG6)/O#U+$7\S;70%YUKDG--3'W'=G['D4LL-9<K%G89UD:
M$0>S#HGFE6@:ZZY-G$F[!X=RJ]->"TILU$H#U4P)II6UB4U<W"X$H-*QIU>_
M:URKZ.HLU9(/FS6?UAR\1V5=H'?1:<8.M9B*QU[@M@ T1S"8LIYN?2BW.K&U
M",0#5>!SR44W(ERQ3D9!12 HF@>*YD.AZ;FIA2 VJZ7N;BS@4:0D%-HQ4:S[
M[F4/*A%!T;P2;=[L/O"8..TWXR44(:XE(39KPF9KUI-S4)4(BN:5:)@T2'?'
MLTF;\Y=0@+B6@-BH;EK]7D_6074A*)I7HFFL8WML'[1^+R'Z<*WZL%GV'6O]
M>B8 5 2"HGDEFIZ R1C/V@EX"1E(:AE(S#*PHPGLQWV)VRREB['C+IK_6GV.
M.92A!)=H&L$G(O [@M;KO\YBK1:)62V>Z&4.V\:>'./#<.VQ,VWS"BH:^SGU
MH9SJC->:D1#X;P@$5#6"HGF@:#X4FIZ=6EH2L[3L\R7!##$X&:"R\\3T9L6W
M!$107'SQ)@X*Z%/GQX6>4+B 0FX'D)Z$6KD2LW(]>$6^LNQ<3%;NVR\+:E6H
M?[.8NDL2I%:]!D7S3O#AEE0;<O42BIC4BIB8%?'E9B/8ADJ&/JOTA$D:KM /
M&NT[M3 !U<*@:!XHF@^%IF>EUL+$K(6'9:7 <IO?W\GD8,,&%;6]?/I=HZ;3
M(XU/+56)6:H>)4<K*)U,S0[BP8[3_JQ@=C^8J3X^?2B?!:56X^19S,0F/_*7
MHA7?)[(X"E4]K8X57N:'Z5K/K_#9=7$XL(8ISBI^H6*CJ$<16RM(>SQ3+XPH
MCO\5-Y+O\O-M=UQ*'N>76T8#)K(!ZO<UY_+Y)G-0'<)<_@=02P,$%     @
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M10?Y?$FI>&\4#IK3VLE?4$L#!!0    ( $B(:%7NIWE.IP,  .H0   9
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;,586X^;.!3^*Q9;=5MI.EQ#DFF"
ME FLMM)6&DVVNP]5'SQP$JP!3&TGF=E?O[8A%!@FFNY2]26QS?F^<^7 87&D
M[)ZG  (]Y%G!ET8J1'EEFCQ.(<?\DI90R"M;RG(LY);M3%XRP(D&Y9GI6)9O
MYI@41K#09S<L6-"]R$@!-PSQ?9YC]G@-&3TN#=LX'=R272K4@1DL2KR##8A/
MY0V3.[-A24@.!2>T0 RV2V-E7T6VI0!:XB\"1]Y:(^7*':7W:O,A61J6L@@R
MB(6BP/+O &O(,L4D[?A:DQJ-3@5LKT_LOVGGI3-WF,.:9G^31*1+8V:@!+9X
MGXE;>OP=:H<FBB^F&=>_Z%C+6@:*]US0O 9+"W)25/_XH0Y$"R!YA@%.#7#Z
M .\9@%L#W)=J\&J ]U(-DQJ@73<KWW7@0BQPL&#TB)B2EFQJH:.OT3)>I%"%
MLA%,7B42)X*-H/%]2K,$V*\<15_W1#RB=T@?OU,92-":YK(L.=:)C1[4&M J
MRVA<';T)06"2\;<2]VD3HC>OWJ)7B!3HSY3N.2X2OC"%-%4I-./:K.O*+.<9
MLUSTD18BE185"20#^/ \?GX&;\H0-7%R3G&Z=LX2;J"\1*YU@1S+<0;L6;\<
M;@^Y\_^T1_]9>R<8;E,TKN9SG^-+,8.Z.F[PH^P; JT8P\4.U/KB5"4)DME'
M:UP2@3/R#R07:)73O93^_(>D1!\$Y/S+4'54^KUA_:IY7O$2Q[ T9'?DP Y@
M!*]_L7WK_5!JQB0+QR2+1B+K)-%KDNB=8P_J.U@FB;=N]KA]LT.5QJ$$5=R^
MYE8/HT/@>#-W81[:@1\2FOI=H?"IT,Q35=H6BIX*^7-GV@AU C!I C Y&X"-
M?#J18G>!=E  PYDN5IS()DNX8%@]P(8\/TOZO:4Y)EDX)EDT$EDG,WZ3&?\G
M]Q=_S"2.21:.21:-1-9)XK1)XO0']I>*>])N'>Y\UNLO@T+S7G]Y*C1SW%X3
MBIX*^=.9-]Q?9DT 9F<#<"M#BEF<ZB)-X"!?RDM5OD/NGF7ZWGH<DRP<DRP:
MB:R3CGF3COE/;BKS,9,X)EDX)EDT$EDGB;;U;5ZQ?F!;J<D[;QN37E<9D)E.
M>TUE0,;N$T5#0I[;:RIF:W;+@>WTT,RE0[+BJC?RYK09S%=Z'.V=7]M7:WO@
M/%2#O)X5O]%77P$^8K8C!4<9;*4JZW(J^Q^K!NMJ(VBI)\<[*N0<JI<I8#DJ
M*@%Y?4NI.&V4@N;S1O O4$L#!!0    ( $B(:%6V)$UG=0T  $7#   9
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M"U4P:9%,Z9P:V]7SL"PTHVD)I%R$O4XG#G/*)1D/Y3*_R4T9S-12FA'I-Z'
MW;ZD(]*-+TG@Y"8J92/R</;^YU*9ZW>!NY]\.#GI/)Q?[\?/*N"<A%[1JU>(
M7G3@0J4=C"6(7Y?@)75,NK\KW9BQ6JTSC#SPDT^WR:<8.?&06R9&ZW<0P[N.
MG>6P+HKQ,%.RK8V(N(#5ISD+'JD8D0D5?*HYL#*:<[%VX1X$9DHH'1A;E#9A
M%R+EDX.[K@?U6NOD7"I=Y789W/>T?GP/V/3 (!>B,=@C+C >%M08IN6-[50/
M5\%G4%"W[]>%=3C7=-WM79&64-ULDJG2*=--FB[9A,9#P3*PH_E\ 7>CBA!
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M)U!+ 0(4 Q0    ( $B(:%4'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 2(AH52N?[VWM    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ 2(AH59E<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " !(B&A50; DW.0%  "L'P  &
M        @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ 2(AH5=6]5:*T!@  %AT  !@              ("!)@X  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( $B(:%7%VIJ _@(  &,*   8
M              " @1 5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " !(B&A5DUN!+2D(   =+   &               @(%$&   >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 2(AH5>#5;,<'%0
MZ$<! !@              ("!HR   'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( $B(:%58:*[\TP@  +XJ   8              " @> U
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !(B&A5NKPQ
M_\$(  "<%   &               @('I/@  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ 2(AH50CGO/Z^*   !(<  !@
M ("!X$<  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $B(
M:%5BPN=6@ 4  "P.   8              " @=1P  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " !(B&A50D)I$O4%  #H#@  &0
M        @(&*=@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( $B(:%4.7:P<IP(  .0%   9              " @;9\  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 2(AH5<118BBX#0  2BD
M !D              ("!E'\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " !(B&A5W"6OP< -  !H*0  &0              @(&#C0
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $B(:%60FOZL
M^P4   (.   9              " @7J;  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ 2(AH5>6U+.$!%@  8T@  !D
M ("!K*$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !(
MB&A5\HL03GD*  ")'   &0              @('DMP  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( $B(:%6872;\ Q8  *=(   9
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M970R,2YX;6Q02P$"% ,4    " !(B&A5)!")S]$"   [!@  &0
M    @('-$P$ >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M $B(:%7V#A5PFP,  )$(   9              " @=46 0!X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ 2(AH57AH3@<1!0  V@P  !D
M             ("!IQH! 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " !(B&A5L>>*)64&  "!.P  &0              @('O'P$ >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( $B(:%77Z)QJ-0X
M &JY   9              " @8LF 0!X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ 2(AH50)$:8LO P  E X  !D              ("!
M]S0! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !(B&A5
MY(J>\.L#  ""%@  &0              @(%=. $ >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( $B(:%6LR,9)C ,  $$+   9
M      " @7\\ 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ 2(AH53 2)\=O!   MA,  !D              ("!0D ! 'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !(B&A51@<8K=H"  "C"0
M&0              @('H1 $ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( $B(:%4TKU 7N ,  )@1   9              " @?E' 0!X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 2(AH57PAID7_
M @  )P@  !D              ("!Z$L! 'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " !(B&A5*T<O@9$&  "E.0  &0
M@($>3P$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $B(
M:%65.MJ1R0(  /8'   9              " @>95 0!X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ 2(AH5=S+"KA>!P  YT4  !D
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M=#0P+GAM;%!+ 0(4 Q0    ( $B(:%7085!BP0(  )0'   9
M  " @?IM 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M2(AH56A/X"SM @  J L  !D              ("!\G ! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " !(B&A52_6 NJ85  !/<0$ &0
M            @($6= $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( $B(:%6U]1WR, ,  !\+   9              " @?.) 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 2(AH506ZM>7]!0
MD"D  !D              ("!6HT! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " !(B&A5?N<7*!H$  "Y%0  &0              @(&.
MDP$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $B(:%7N
MIWE.IP,  .H0   9              " @=^7 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ 2(AH5;8D36=U#0  1<,  !D
M     ("!O9L! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
M" !(B&A5.1M\X$(#  "X%   #0              @ %IJ0$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( $B(:%67BKL<P    !,"   +              "
M =:L 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $B(:%4GGQ&-&00  %(@   /
M              "  ;^M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !(
MB&A5DBR@EK@!  #G'   &@              @ $%L@$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !(B&A5C$_JC[H!  #N'   $P
M            @ 'ULP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .  X
+ #\/  #@M0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>212</ContextCount>
  <ElementCount>317</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Fair Value Measurements and Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Term Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoans</Role>
      <ShortName>Term Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Daewoong Convertible Note</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DaewoongConvertibleNote</Role>
      <ShortName>Daewoong Convertible Note</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Medytox/Allergan Settlement Agreements and Daewoong Arrangement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement</Role>
      <ShortName>Medytox/Allergan Settlement Agreements and Daewoong Arrangement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/AccruedExpenses</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Term Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoansTables</Role>
      <ShortName>Term Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/TermLoans</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/OperatingLeases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/DescriptionofBusiness</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Assets and Liabilities on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Fair Value Measurements and Short-Term Investments - Contingent Royalty Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsContingentRoyaltyObligationDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Contingent Royalty Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Goodwill and Intangible Assets - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Goodwill and Intangible Asset - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Asset - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Term Loans - Pharmakon Term Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails</Role>
      <ShortName>Term Loans - Pharmakon Term Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Term Loans - Maturities of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails</Role>
      <ShortName>Term Loans - Maturities of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Term Loans - Oxford Term Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoansOxfordTermLoansDetails</Role>
      <ShortName>Term Loans - Oxford Term Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Daewoong Convertible Note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DaewoongConvertibleNoteDetails</Role>
      <ShortName>Daewoong Convertible Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/DaewoongConvertibleNote</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Operating Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>Operating Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Operating Leases - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesLeaseCostDetails</Role>
      <ShortName>Operating Leases - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Operating Leases - Schedule of Weighted-Average Remaining Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails</Role>
      <ShortName>Operating Leases - Schedule of Weighted-Average Remaining Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Operating Leases - Operating Lease Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails</Role>
      <ShortName>Operating Leases - Operating Lease Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/CommitmentsandContingencies</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Stockholders??? Equity - Schedule of Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails</Role>
      <ShortName>Stockholders??? Equity - Schedule of Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Stockholders??? Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stockholders??? Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Stockholders??? Equity - Restricted Stock Unit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails</Role>
      <ShortName>Stockholders??? Equity - Restricted Stock Unit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Stockholder's Equity - Stock-based Compensation Expense Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails</Role>
      <ShortName>Stockholder's Equity - Stock-based Compensation Expense Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="eols-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails</Role>
      <ShortName>Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  eols-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="eols-20220930.htm">eols-20220930.htm</File>
    <File>eols-20220930.xsd</File>
    <File>eols-20220930_cal.xml</File>
    <File>eols-20220930_def.xml</File>
    <File>eols-20220930_lab.xml</File>
    <File>eols-20220930_pre.xml</File>
    <File>exhibit311q32022.htm</File>
    <File>exhibit312q32022.htm</File>
    <File>exhibit321q32022.htm</File>
    <File>sandrabeaveremploymentagre.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="723">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "eols-20220930.htm": {
   "axisCustom": 1,
   "axisStandard": 20,
   "contextCount": 212,
   "dts": {
    "calculationLink": {
     "local": [
      "eols-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "eols-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "eols-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eols-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eols-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "eols-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 472,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 5,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 10
   },
   "keyCustom": 40,
   "keyStandard": 277,
   "memberCustom": 20,
   "memberStandard": 27,
   "nsprefix": "eols",
   "nsuri": "http://www.evolus.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://www.evolus.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Accrued Expenses",
     "role": "http://www.evolus.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Term Loans",
     "role": "http://www.evolus.com/role/TermLoans",
     "shortName": "Term Loans",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Daewoong Convertible Note",
     "role": "http://www.evolus.com/role/DaewoongConvertibleNote",
     "shortName": "Daewoong Convertible Note",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Operating Leases",
     "role": "http://www.evolus.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Commitments and Contingencies",
     "role": "http://www.evolus.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://www.evolus.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Medytox/Allergan Settlement Agreements and Daewoong Arrangement",
     "role": "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement",
     "shortName": "Medytox/Allergan Settlement Agreements and Daewoong Arrangement",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)",
     "role": "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables",
     "shortName": "Fair Value Measurements and Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.evolus.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Term Loans (Tables)",
     "role": "http://www.evolus.com/role/TermLoansTables",
     "shortName": "Term Loans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Operating Leases (Tables)",
     "role": "http://www.evolus.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.evolus.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Description of Business (Details)",
     "role": "http://www.evolus.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "iafb5504b024a49c98e5b98f03ed55642_D20211201-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfSecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifd893c426cf344bfb3e70e80a9717b85_D20210301-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifd893c426cf344bfb3e70e80a9717b85_D20210301-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ib955eea1a8f64090909d07cf0f04a443_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities on a Recurring Basis (Details)",
     "role": "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements and Short-Term Investments - Assets and Liabilities on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ib955eea1a8f64090909d07cf0f04a443_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)",
     "role": "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
     "shortName": "Fair Value Measurements and Short-Term Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i74ba879b9f0b49eeb45d7c48810743cf_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i41fd4a2cf7cb49e6a38c2fc9b0df76fd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Fair Value Measurements and Short-Term Investments - Contingent Royalty Obligation (Details)",
     "role": "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsContingentRoyaltyObligationDetails",
     "shortName": "Fair Value Measurements and Short-Term Investments - Contingent Royalty Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)",
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Goodwill and Intangible Assets - Future Amortization Expense (Details)",
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedComputerSoftwareAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Goodwill and Intangible Asset - Narrative (Details)",
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails",
     "shortName": "Goodwill and Intangible Asset - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedComputerSoftwareAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "role": "http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i32423b3783a74a82a50b52069242757e_I20190315",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Term Loans - Pharmakon Term Loans (Details)",
     "role": "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails",
     "shortName": "Term Loans - Pharmakon Term Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ibb4a33cd285f450c9199ba56c40498b4_I20211214",
      "decimals": "-3",
      "lang": "en-US",
      "name": "eols:DebtInstrumentPrepaymentAmountThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Term Loans - Maturities of Debt (Details)",
     "role": "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails",
     "shortName": "Term Loans - Maturities of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Term Loans - Oxford Term Loans (Details)",
     "role": "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
     "shortName": "Term Loans - Oxford Term Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i4d21558b1b844fea9ffd52152f5a0b6d_I20190315",
      "decimals": "INF",
      "lang": "en-US",
      "name": "eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Daewoong Convertible Note (Details)",
     "role": "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
     "shortName": "Daewoong Convertible Note (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifcabd9d8120a4b52ad4211b9b2779160_I20200706",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Operating Leases - Narrative (Details)",
     "role": "http://www.evolus.com/role/OperatingLeasesNarrativeDetails",
     "shortName": "Operating Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Operating Leases - Lease Cost (Details)",
     "role": "http://www.evolus.com/role/OperatingLeasesLeaseCostDetails",
     "shortName": "Operating Leases - Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Operating Leases - Schedule of Weighted-Average Remaining Lease Term and Discount Rate (Details)",
     "role": "http://www.evolus.com/role/OperatingLeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails",
     "shortName": "Operating Leases - Schedule of Weighted-Average Remaining Lease Term and Discount Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Operating Leases - Operating Lease Maturity (Details)",
     "role": "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails",
     "shortName": "Operating Leases - Operating Lease Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.evolus.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ic5451817e64c44dda2476fee6acbac53_I20171121",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ie3807d087dad4368af0d30e4e6ea552b_D20220701-20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Stockholders\u2019 Equity - Schedule of Valuation Assumptions (Details)",
     "role": "http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails",
     "shortName": "Stockholders\u2019 Equity - Schedule of Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ie3807d087dad4368af0d30e4e6ea552b_D20220701-20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Stockholders\u2019 Equity - Schedule of Stock Option Activity (Details)",
     "role": "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
     "shortName": "Stockholders\u2019 Equity - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i6b5c16e739394eb49b608a8ed5093f5c_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Stockholders\u2019 Equity - Restricted Stock Unit (Details)",
     "role": "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails",
     "shortName": "Stockholders\u2019 Equity - Restricted Stock Unit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i1503801e937f4ba5b76e4a22fe86b177_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Stockholder's Equity - Stock-based Compensation Expense Allocation (Details)",
     "role": "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails",
     "shortName": "Stockholder's Equity - Stock-based Compensation Expense Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ifa3c19df1ed84a8fbd0413c8e5a6a09e_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ia95f293a31d148f8a32dd28e1c5a5d71_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)",
     "role": "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
     "shortName": "Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "ib6c9bed41b124f498f1b2cccdadacc84_D20210218-20210218",
      "decimals": null,
      "lang": "en-US",
      "name": "eols:RegistrationRightsAgreementSellingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i19b70069ec2b4bc88563acac780cb0fb_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i480181a8005d4beaaa9460f56ee7984d_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "eols:StockIssuedDuringPeriodValuesLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Description of Business",
     "role": "http://www.evolus.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Fair Value Measurements and Short-Term Investments",
     "role": "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments",
     "shortName": "Fair Value Measurements and Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eols-20220930.htm",
      "contextRef": "i5d4379a4158c443fab6596315f543818_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity CIK"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "eols_ATMSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Sales Agreement Member",
        "label": "ATM Sales Agreement [Member]",
        "terseLabel": "ATM Sales Agreement"
       }
      }
     },
     "localname": "ATMSalesAgreementMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_AccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Accounting Policies [Table]",
        "label": "Accounting Policies [Line Items]",
        "terseLabel": "Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesLineItems",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "eols_AccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Policies [Table]",
        "label": "Accounting Policies [Table]",
        "terseLabel": "Accounting Policies [Table]"
       }
      }
     },
     "localname": "AccountingPoliciesTable",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements",
        "label": "Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements",
        "terseLabel": "Extension period"
       }
      }
     },
     "localname": "AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_ContingentRoyaltyObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Royalty Obligation [Member]",
        "label": "Contingent Royalty Obligation [Member]",
        "terseLabel": "Contingent Royalty Obligation"
       }
      }
     },
     "localname": "ContingentRoyaltyObligationMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Royalty Obligation Payable to Related Party, Current",
        "label": "Contingent Royalty Obligation Payable to Related Party, Current",
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders"
       }
      }
     },
     "localname": "ContingentRoyaltyObligationPayabletoRelatedPartyCurrent",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_DaewoongConvertibleNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Daewoong Convertible Note",
        "label": "Daewoong Convertible Note [Member]",
        "terseLabel": "Daewoong Convertible Note"
       }
      }
     },
     "localname": "DaewoongConvertibleNoteMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_DaewoongSettlementAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Daewoong Settlement Agreement Member",
        "label": "Daewoong Settlement Agreement [Member]",
        "terseLabel": "Daewoong Settlement Agreement"
       }
      }
     },
     "localname": "DaewoongSettlementAgreementMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_DebtInstrumentAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Amortization Period",
        "label": "Debt Instrument, Amortization Period",
        "terseLabel": "Amortization period"
       }
      }
     },
     "localname": "DebtInstrumentAmortizationPeriod",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Percentage of Shares Beneficially Owned",
        "label": "Debt Instrument, Convertible, Percentage of Shares Beneficially Owned",
        "terseLabel": "Common stock shares beneficially own percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertiblePercentageOfSharesBeneficiallyOwned",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "eols_DebtInstrumentFeeAmountWaived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Fee Amount Waived",
        "label": "Debt Instrument Fee Amount Waived",
        "terseLabel": "Debt instrument fee amount comprised"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmountWaived",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_DebtInstrumentNumberOfPeriodicPaymentsPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number of Periodic Payments, Principal",
        "label": "Debt Instrument, Number of Periodic Payments, Principal",
        "terseLabel": "Number of periodic payments"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfPeriodicPaymentsPrincipal",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "eols_DebtInstrumentNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number of Tranches",
        "label": "Debt Instrument, Number of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfTranches",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "eols_DebtInstrumentOfFinalPaymentAmountWaived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Of Final Payment Amount Waived",
        "label": "Debt Instrument Of Final Payment Amount Waived",
        "terseLabel": "Debt instrument of principal amount payment"
       }
      }
     },
     "localname": "DebtInstrumentOfFinalPaymentAmountWaived",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Percentage Of Principal Amount, Balloon Payment",
        "label": "Debt Instrument, Percentage Of Principal Amount, Balloon Payment",
        "terseLabel": "Percentage of final payment of full principal amount"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfPrincipalAmountBalloonPayment",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eols_DebtInstrumentPeriodOfInterestOnlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Period Of Interest Only Payments",
        "label": "Debt Instrument, Period Of Interest Only Payments",
        "terseLabel": "Period of interest only payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodOfInterestOnlyPayments",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_DebtInstrumentPeriodicPaymentPaymentCommencementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Payment Commencement Period",
        "label": "Debt Instrument, Periodic Payment, Payment Commencement Period",
        "terseLabel": "Anniversary period"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPaymentCommencementPeriod",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_DebtInstrumentPrepaymentAmountThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Amount Threshold",
        "label": "Debt Instrument, Prepayment Amount Threshold",
        "terseLabel": "Prepayment amount threshold"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentAmountThreshold",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_DebtInstrumentPrepaymentFeeAmountWaived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Prepayment Fee Amount, Waived",
        "label": "Debt Instrument Prepayment Fee Amount, Waived",
        "terseLabel": "Debt instrument prepayment fee amount"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeeAmountWaived",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_DebtInstrumentPrepaymentFeePercentageThereafter": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Fee Percentage, Thereafter",
        "label": "Debt Instrument, Prepayment Fee Percentage, Thereafter",
        "terseLabel": "Prepayment fee percentage, thereafter"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageThereafter",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eols_DebtInstrumentPrepaymentFeePercentageYearTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Fee Percentage, Year Two",
        "label": "Debt Instrument, Prepayment Fee Percentage, Year Two",
        "terseLabel": "Prepayment fee percentage, year two"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageYearTwo",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eols_DebtInstrumentPrepaymentTermsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Terms",
        "label": "Debt Instrument, Prepayment Terms [Axis]",
        "terseLabel": "Debt Instrument, Prepayment Terms [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentTermsAxis",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "eols_DebtInstrumentPrepaymentTermsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Terms [Domain]",
        "label": "Debt Instrument, Prepayment Terms [Domain]",
        "terseLabel": "Debt Instrument, Prepayment Terms [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentTermsDomain",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount",
        "label": "Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount",
        "terseLabel": "Debt instrument, percentage of principal amount, prepaid multiplied"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eols_EvolusIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolus, Inc [Member]",
        "label": "Evolus, Inc [Member]",
        "terseLabel": "Evolus, Inc."
       }
      }
     },
     "localname": "EvolusIncMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets Amortization Expense After Year Four",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_FollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-On Offering Member",
        "label": "Follow-On Offering [Member]",
        "terseLabel": "Follow-On Offering"
       }
      }
     },
     "localname": "FollowOnOfferingMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_IncreaseDecreaseInAccruedLitigationSettlement": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Litigation Settlement",
        "label": "Increase (Decrease) In Accrued Litigation Settlement",
        "terseLabel": "Accrued litigation settlement"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLitigationSettlement",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_IntangibleAssetsGrossIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets, Gross (Including Goodwill)",
        "label": "Intangible Assets, Gross (Including Goodwill)",
        "totalLabel": "Intangible assets, gross (including goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsGrossIncludingGoodwill",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_IntellectualPropertyDisputesJeuveauMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intellectual Property Disputes, Jeuveau",
        "label": "Intellectual Property Disputes, Jeuveau [Member]",
        "terseLabel": "Intellectual Property Disputes, Jeuveau"
       }
      }
     },
     "localname": "IntellectualPropertyDisputesJeuveauMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date",
        "label": "Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date",
        "terseLabel": "Period of written notice"
       }
      }
     },
     "localname": "LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent",
        "label": "Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent",
        "terseLabel": "Period of termination fee prior to lease termination date"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_LesseeOperatingLeaseTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period",
        "label": "Lessee, Operating Lease, Termination Period",
        "terseLabel": "Termination period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_LineofCreditFacilityNumberofAdvances": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Number of Advances",
        "label": "Line of Credit Facility, Number of Advances",
        "terseLabel": "Number of advances"
       }
      }
     },
     "localname": "LineofCreditFacilityNumberofAdvances",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "eols_LongTermDebtMaturityAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, after Year Four",
        "label": "Long-Term Debt, Maturity, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturityAfterYearFour",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_LossContingencySettlementAgreementPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Settlement Agreement, Payment Terms",
        "label": "Loss Contingency, Settlement Agreement, Payment Terms",
        "terseLabel": "Settlement agreement, payment terms (in years)"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementPaymentTerms",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_MilestonePaymentInConnectionWithAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment In Connection With Agreement",
        "label": "Milestone Payment In Connection With Agreement",
        "terseLabel": "Contingent milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentInConnectionWithAgreement",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_MilestonePaymentsForIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments For Intangible Assets",
        "label": "Milestone Payments For Intangible Assets",
        "terseLabel": "Milestone payments for intangible assets"
       }
      }
     },
     "localname": "MilestonePaymentsForIntangibleAssets",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_OxfordTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term Loan Facility [Member]",
        "label": "Oxford Term Loan Facility [Member]",
        "terseLabel": "Oxford Term Loan Facility"
       }
      }
     },
     "localname": "OxfordTermLoanFacilityMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_OxfordTermLoanFacilityTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term Loan Facility, Tranche One [Member]",
        "label": "Oxford Term Loan Facility, Tranche One [Member]",
        "terseLabel": "First tranche"
       }
      }
     },
     "localname": "OxfordTermLoanFacilityTrancheOneMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_OxfordTermLoanFacilityTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term Loan Facility, Tranche Two [Member]",
        "label": "Oxford Term Loan Facility, Tranche Two [Member]",
        "terseLabel": "Second tranche"
       }
      }
     },
     "localname": "OxfordTermLoanFacilityTrancheTwoMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_PaymentsForInventory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Inventory",
        "label": "Payments For Inventory",
        "terseLabel": "Inventory payments"
       }
      }
     },
     "localname": "PaymentsForInventory",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_PaymentsOfContingentRoyaltyObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Contingent Royalty Obligation",
        "label": "Payments Of Contingent Royalty Obligation",
        "negatedTerseLabel": "Payment of contingent royalty obligation to Evolus Founders"
       }
      }
     },
     "localname": "PaymentsOfContingentRoyaltyObligation",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_PharmakonTermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmakon Term Loans",
        "label": "Pharmakon Term Loans [Member]",
        "terseLabel": "Pharmakon Term Loans"
       }
      }
     },
     "localname": "PharmakonTermLoansMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_PharmakonTermLoansOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmakon Term Loans One",
        "label": "Pharmakon Term Loans One [Member]",
        "terseLabel": "Tranche A Loan"
       }
      }
     },
     "localname": "PharmakonTermLoansOneMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_PharmakonTermLoansTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmakon Term Loans Two",
        "label": "Pharmakon Term Loans Two [Member]",
        "terseLabel": "Tranche B Loan"
       }
      }
     },
     "localname": "PharmakonTermLoansTwoMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan",
        "label": "Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan",
        "terseLabel": "Issuance of common stock in connection with incentive equity plan"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_RegistrationRightsAgreementSellingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registration Rights Agreement, Selling Period",
        "label": "Registration Rights Agreement, Selling Period",
        "terseLabel": "Registration rights agreement, selling period"
       }
      }
     },
     "localname": "RegistrationRightsAgreementSellingPeriod",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_RestrictedStockUnitsRSUsMarketConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units (RSUs), Market Conditions",
        "label": "Restricted Stock Units (RSUs), Market Conditions [Member]",
        "terseLabel": "RSUs Market Conditions"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsMarketConditionsMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_RestrictedStockUnitsRSUsPerformanceConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units (RSUs), Performance Conditions",
        "label": "Restricted Stock Units (RSUs), Performance Conditions [Member]",
        "terseLabel": "RSUs Performance Conditions"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsPerformanceConditionsMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_SCHAEONLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SCH-AEON, LLC [Member]",
        "label": "SCH-AEON, LLC [Member]",
        "terseLabel": "SCH"
       }
      }
     },
     "localname": "SCHAEONLLCMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_SaleOfStockCommissionPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Commission Paid",
        "label": "Sale Of Stock, Commission Paid",
        "terseLabel": "Total commission"
       }
      }
     },
     "localname": "SaleOfStockCommissionPaid",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage",
        "label": "Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage",
        "terseLabel": "Sale of stock, commission payment upon gross proceeds"
       }
      }
     },
     "localname": "SaleOfStockCommissionPaymentUponGrossProceedsPercentage",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eols_SaleOfStockMaximumConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Consideration Receivable",
        "label": "Sale Of Stock, Maximum Consideration Receivable",
        "terseLabel": "Maximum consideration receivable"
       }
      }
     },
     "localname": "SaleOfStockMaximumConsiderationReceivable",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_ShareIssuanceAgreementPercentageOfShareDisposePerYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Issuance Agreement, Percentage of Share Dispose Per Year",
        "label": "Share Issuance Agreement, Percentage of Share Dispose Per Year",
        "terseLabel": "Share issuance agreement, percentage of share dispose per year"
       }
      }
     },
     "localname": "ShareIssuanceAgreementPercentageOfShareDisposePerYear",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable",
        "terseLabel": "Weighted Average Remaining Contractual Term , Exercisable (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eols_StockIssuedDuringPeriodSharesLitigationSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Litigation Settlement",
        "label": "Stock Issued During Period, Shares, Litigation Settlement",
        "terseLabel": "Issuance of common stock in connection with litigation settlement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesLitigationSettlement",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eols_StockIssuedDuringPeriodValuesLitigationSettlement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Values, Litigation Settlement",
        "label": "Stock Issued During Period, Values, Litigation Settlement",
        "terseLabel": "Issuance of common stock in connection with litigation settlement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuesLitigationSettlement",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_StockIssuedForAccruedLitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued For Accrued Litigation Settlement Expense",
        "label": "Stock Issued For Accrued Litigation Settlement Expense",
        "terseLabel": "Issuance of common stock in exchange for accrued litigation settlement expense"
       }
      }
     },
     "localname": "StockIssuedForAccruedLitigationSettlementExpense",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eols_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility [Member]",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_TermOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term One",
        "label": "Term One [Member]",
        "terseLabel": "Term One"
       }
      }
     },
     "localname": "TermOneMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_TermThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Three",
        "label": "Term Three [Member]",
        "terseLabel": "Term Three"
       }
      }
     },
     "localname": "TermThreeMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eols_TermTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Two",
        "label": "Term Two [Member]",
        "terseLabel": "Term Two"
       }
      }
     },
     "localname": "TermTwoMember",
     "nsuri": "http://www.evolus.com/20220930",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r238",
      "r240",
      "r241",
      "r242",
      "r264",
      "r306",
      "r356",
      "r359",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r521",
      "r557",
      "r559",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r238",
      "r240",
      "r241",
      "r242",
      "r264",
      "r306",
      "r356",
      "r359",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r521",
      "r557",
      "r559",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r172",
      "r240",
      "r241",
      "r341",
      "r344",
      "r523",
      "r556",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r172",
      "r240",
      "r241",
      "r341",
      "r344",
      "r523",
      "r556",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r230",
      "r238",
      "r240",
      "r241",
      "r242",
      "r264",
      "r306",
      "r346",
      "r356",
      "r359",
      "r391",
      "r392",
      "r393",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r521",
      "r557",
      "r559",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r230",
      "r238",
      "r240",
      "r241",
      "r242",
      "r264",
      "r306",
      "r346",
      "r356",
      "r359",
      "r391",
      "r392",
      "r393",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r521",
      "r557",
      "r559",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r118",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r118",
      "r123",
      "r236",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r118",
      "r123",
      "r236",
      "r357",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Consideration receivable from Daewoong"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accounts payable and accrued liabilities, current"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r33",
      "r489"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r8",
      "r39"
     ],
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties under the Medytox/Allergan Settlement Agreements"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r50",
      "r51",
      "r52",
      "r545",
      "r564",
      "r565"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r52",
      "r60",
      "r61",
      "r62",
      "r110",
      "r111",
      "r112",
      "r436",
      "r486",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r489"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r398",
      "r399",
      "r400",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r361",
      "r403",
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Allocated stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r27",
      "r177",
      "r187",
      "r189",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Accounts receivable, writeoff"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r88",
      "r284",
      "r296",
      "r297",
      "r471"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r88",
      "r216",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Securities excluded from the computation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r14",
      "r105",
      "r155",
      "r164",
      "r170",
      "r185",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r432",
      "r437",
      "r459",
      "r487",
      "r489",
      "r528",
      "r543"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r32",
      "r105",
      "r185",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r432",
      "r437",
      "r459",
      "r487",
      "r489"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r386",
      "r387",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r355",
      "r358",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r355",
      "r358",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r87",
      "r429"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "verboseLabel": "Revaluation of contingent royalty obligation payable to Evolus Founders"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capitalized software recorded in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAdditions": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions made to capitalized computer software costs during the period.",
        "label": "Capitalized Computer Software, Additions",
        "terseLabel": "Capitalized computer software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r10",
      "r90"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r83",
      "r90",
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r83",
      "r460"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing information"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r102",
      "r105",
      "r126",
      "r127",
      "r128",
      "r130",
      "r132",
      "r139",
      "r140",
      "r141",
      "r185",
      "r249",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r304",
      "r305",
      "r309",
      "r313",
      "r320",
      "r459",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r532",
      "r549"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r243",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "verboseLabel": "Medytox/Allergan Settlement Agreements and Daewoong Arrangement"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CommitmentsandContingencies",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r246",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingent Royalty Obligation Payable to Evolus Founders"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Capital shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r489"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.00001 par value; 100,000,000 shares authorized; 56,183,414 and 55,576,988 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r55",
      "r57",
      "r58",
      "r66",
      "r535",
      "r551"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r217",
      "r221",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Capitalized software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r144",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties and Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r330",
      "r331",
      "r342"
     ],
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Accrued revenue contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract with customer liability revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r17",
      "r530",
      "r544"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r264",
      "r274",
      "r275",
      "r276",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r294",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r304",
      "r305",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r70",
      "r523"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Product cost of sales (excludes amortization of intangible assets)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r93",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of convertible note to equity"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r278",
      "r285",
      "r286",
      "r288",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loans",
        "verboseLabel": "Daewoong Convertible Note"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNote",
      "http://www.evolus.com/role/TermLoans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r104",
      "r108",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r294",
      "r295",
      "r296",
      "r297",
      "r472",
      "r529",
      "r530",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r17",
      "r289",
      "r530",
      "r542"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "totalLabel": "Total principal payments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r263",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r42",
      "r263",
      "r321",
      "r324",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Conversion of common shares (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r261",
      "r294",
      "r295",
      "r470",
      "r472",
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount",
        "verboseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r41",
      "r293",
      "r470",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate on debt"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r104",
      "r108",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r294",
      "r295",
      "r296",
      "r297",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r104",
      "r108",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r287",
      "r294",
      "r295",
      "r296",
      "r297",
      "r321",
      "r325",
      "r326",
      "r327",
      "r469",
      "r470",
      "r472",
      "r473",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r274",
      "r469",
      "r473"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r274",
      "r290",
      "r294",
      "r295",
      "r471"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt discounts and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r106",
      "r416",
      "r421",
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r88",
      "r153"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DistributionRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels.",
        "label": "Distribution Rights [Member]",
        "terseLabel": "Distribution right"
       }
      }
     },
     "localname": "DistributionRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r67",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r124",
      "r126",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r443",
      "r444",
      "r536",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r67",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r126",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r443",
      "r444",
      "r536",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r60",
      "r61",
      "r62",
      "r110",
      "r111",
      "r112",
      "r114",
      "r120",
      "r122",
      "r138",
      "r186",
      "r320",
      "r328",
      "r398",
      "r399",
      "r400",
      "r418",
      "r419",
      "r442",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r486",
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r276",
      "r294",
      "r295",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r445",
      "r446",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r276",
      "r294",
      "r295",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r446",
      "r494",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r276",
      "r294",
      "r295",
      "r445",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r276",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Short-Term Investments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r276",
      "r347",
      "r348",
      "r353",
      "r354",
      "r446",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r276",
      "r294",
      "r295",
      "r347",
      "r348",
      "r353",
      "r354",
      "r446",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r276",
      "r294",
      "r295",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r446",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsContingentRoyaltyObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r449",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Financial Instruments Recorded at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Revaluation of contingent royalty obligation payable to Evolus Founders",
        "negatedTerseLabel": "Change in fair value recorded in operating expenses"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsContingentRoyaltyObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsContingentRoyaltyObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsContingentRoyaltyObligationDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r276",
      "r294",
      "r295",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r494",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r455",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r188",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r287",
      "r318",
      "r440",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Weighted-Average Life (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r12",
      "r222"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remaining in 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r217",
      "r218",
      "r222",
      "r225",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r222",
      "r525"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "eols_IntangibleAssetsGrossIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Original Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r217",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r222",
      "r524"
     ],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Book Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Definite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Settlement payment from Daewoong",
        "terseLabel": "Settlement payment from Daewoong"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r88",
      "r298",
      "r299"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss from extinguishment of debts",
        "negatedTerseLabel": "Loss from extinguishment of debts, net",
        "terseLabel": "Loss from extinguishment of debts, net",
        "verboseLabel": "Gain (loss) from extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r11",
      "r206",
      "r208",
      "r210",
      "r213",
      "r489",
      "r527"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "eols_IntangibleAssetsGrossIncludingGoodwill",
       "weight": 1.0
      },
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r212",
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r88",
      "r207",
      "r209",
      "r212",
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r88",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "In-process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r64",
      "r155",
      "r163",
      "r166",
      "r169",
      "r171",
      "r526",
      "r533",
      "r538",
      "r554"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes:"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r229",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r121",
      "r122",
      "r154",
      "r412",
      "r420",
      "r424",
      "r555"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r408",
      "r409",
      "r413",
      "r414",
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived intangible asset"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r215",
      "r220"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "totalLabel": "Net book value"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r63",
      "r152",
      "r468",
      "r471",
      "r537"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r82",
      "r84",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r29",
      "r489"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r28",
      "r99",
      "r137",
      "r201",
      "r202",
      "r203",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r72",
      "r73"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r184",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r482",
      "r484"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Lease, cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Composition of Lease Expense and Other Quantitative Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r105",
      "r165",
      "r185",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r433",
      "r437",
      "r438",
      "r459",
      "r487",
      "r488"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r105",
      "r185",
      "r459",
      "r489",
      "r531",
      "r547"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r40",
      "r105",
      "r185",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r433",
      "r437",
      "r438",
      "r459",
      "r487",
      "r488",
      "r489"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Contingent promissory note payable"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r44",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Accrued litigation settlement"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r44",
      "r235"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Accrued litigation settlement",
        "verboseLabel": "Accrued litigation settlement, current"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveNoncurrent": {
     "auth_ref": [
      "r44",
      "r235"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.",
        "label": "Estimated Litigation Liability, Noncurrent",
        "terseLabel": "Accrued litigation settlement"
       }
      }
     },
     "localname": "LitigationReserveNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement, expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r17",
      "r275",
      "r291",
      "r294",
      "r295",
      "r530",
      "r544"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Long term debt, net of discounts and issuance costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r108",
      "r247",
      "r280"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r108",
      "r247",
      "r280"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r108",
      "r247",
      "r280"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r108",
      "r247",
      "r280"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-Term Purchase Commitment, Amount",
        "terseLabel": "Long-term purchase commitment, amount"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentsandContingenciesDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Loss contingency accrual, payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r237",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss contingency, new claims filed, number"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r237",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss contingency, number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r83",
      "r86",
      "r89"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r53",
      "r56",
      "r62",
      "r65",
      "r89",
      "r105",
      "r113",
      "r115",
      "r116",
      "r117",
      "r118",
      "r121",
      "r122",
      "r129",
      "r155",
      "r163",
      "r166",
      "r169",
      "r171",
      "r185",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r444",
      "r459",
      "r534",
      "r550"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net loss",
        "terseLabel": "Net income (loss) attributable to parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Issued But Not Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r155",
      "r163",
      "r166",
      "r169",
      "r171"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r478",
      "r484"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Fixed operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r481",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate (in percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r480",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r31",
      "r489"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive gain (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r54",
      "r57",
      "r430",
      "r431",
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r48",
      "r50"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Paid-in-kind interest on convertible note"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForSoftware": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments for Software",
        "negatedTerseLabel": "Additions to capitalized software"
       }
      }
     },
     "localname": "PaymentsForSoftware",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments for offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r489"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r204",
      "r205"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from issuance of secured debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r228",
      "r489",
      "r539",
      "r548"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r228",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r68",
      "r190"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debts",
        "verboseLabel": "Credit loss expense (reversal)"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase commitment, amount"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Repayment of long term debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-Term Lines of Credit",
        "terseLabel": "Repayments of long-term lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r328",
      "r489",
      "r546",
      "r563",
      "r565"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r110",
      "r111",
      "r112",
      "r114",
      "r120",
      "r122",
      "r186",
      "r398",
      "r399",
      "r400",
      "r418",
      "r419",
      "r442",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r150",
      "r151",
      "r162",
      "r167",
      "r168",
      "r172",
      "r173",
      "r174",
      "r340",
      "r341",
      "r523"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r395",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense Allocation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r217",
      "r221",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r386",
      "r387",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r367",
      "r382",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share-based Compensation, Stock Options, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r102",
      "r139",
      "r140",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r313",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long-Term Debt, Noncurrent",
        "terseLabel": "Term loan, net of discounts and issuance costs"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service revenue"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Nonvested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Unit"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum number of shares authorized under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Outstanding stock options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Annual increase percentage of maximum shares outstanding (equal to)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r386",
      "r387",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r366",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r401",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r97",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Internal-use software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r102",
      "r105",
      "r126",
      "r127",
      "r128",
      "r130",
      "r132",
      "r139",
      "r140",
      "r141",
      "r185",
      "r249",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r304",
      "r305",
      "r309",
      "r313",
      "r320",
      "r459",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r47",
      "r60",
      "r61",
      "r62",
      "r110",
      "r111",
      "r112",
      "r114",
      "r120",
      "r122",
      "r138",
      "r186",
      "r320",
      "r328",
      "r398",
      "r399",
      "r400",
      "r418",
      "r419",
      "r442",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r486",
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/DaewoongConvertibleNoteDetails",
      "http://www.evolus.com/role/MedytoxAllerganSettlementAgreementsandDaewoongArrangementDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r138",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r46",
      "r279",
      "r320",
      "r321",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for conversion of convertible note (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r320",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in connection with the incentive equity plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r320",
      "r328",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r47",
      "r320",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for conversion of convertible note"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r320",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in connection with the incentive equity plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r24",
      "r25",
      "r105",
      "r178",
      "r185",
      "r459",
      "r489"
     ],
     "calculation": {
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r328",
      "r329",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r287",
      "r318",
      "r440",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of cost from product sold and service rendered.",
        "label": "Cost, Product and Service [Extensible Enumeration]",
        "terseLabel": "Cost, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r479",
      "r484"
     ],
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable operating lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/TermLoansOxfordTermLoansDetails",
      "http://www.evolus.com/role/TermLoansPharmakonTermLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r125",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted-average shares outstanding used to compute diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r124",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding used to compute basic net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolus.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r572": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r573": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r574": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r575": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r576": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r577": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r578": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r579": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r580": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r581": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r582": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r583": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r584": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r585": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001570562-22-000143-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001570562-22-000143-xbrl.zip
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MC(\T3%H +!1)%S!+QTA0XA!X[-(K'[G#"T.::<16QD@F*RG'3G'J,$.<*ZL
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MCR.-U%(0NBHG;A%(-NGHTICHPW#TS! 7I;-@E(2ARI$(U$(^2G#0)T>?:<V
MT,($X$LM.&5!I-/ J.96$XV%MU9-X1SY>;;/=Y'XY ^X!Y@EM%7"@)YA$4<E
MD%$>440=C9J:Q2/HU*)+DR>NLZDNEO3,4LPHM0"G&4^E;)C$@06_>,2=?)1D
M\E0E7MN82N92[%B(V@:D>:2!FFB5H@NH@V<B2C)Y0EL3(Y /2R(#L^F036*"
MEM$2AYQ10T=K_NG[ZT5)QK0##J5"0#@&$1ECX"4HABR6 0>/I6+,+PR'3#!*
M,B;2"!FH"L@ZE.H;,J^4(4ICL,*:"78=P)I_TDPI2C*NC>G8 1HB6!,I&>%
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M;2E, [?*2"09]@[@!$,X.$289Y+R.?!Z%YPMIN(U6\V%D5P1$3$#8Z(-.%4
M5K!FA$LBYB@7:''98O(I1: (@N%@+;RC25$H)L#58$H1JK'F88DM[N9=IP4]
MUZ_V GWJ9/W>SNZG1<07CEGM(Z@&+ FC/BIBBB3?* V60<W37L+%9HW)8XRT
M7]A;#XY;VEL6L.&&4^6P9SA8'.?I).L%9HVIX SA@Q NR,"<9TJ*Y+$"^)3<
M:A&4(TN<,2.L,7FL 1"4AV"P45$PI--?CZ2+*"*63L>9_<U9[[*.Z;C,M.XF
MC0UO:';[H?>/N32V%8JM=-7G>=F?91TM"N]I&4.J#*$(>)"&(/ FB6!F#G:F
MOAB)'M\#D^6?36L "N#ZX[]A3"9W1Y<?4HK0:(>N;]KJ@#+I%7?@.>&78#RC
M5+!T_#ECW"N*)(N*62NH$T0M^64R_$+FA%\0#1;1B+1UD06$K78B6D/ P;!6
M&;/DE\GP"YT3?F$"?% =:7#4,X1=6NX@@A,F4LTB(69_D\.,0H8Q[D?"5$K#
M:"32L6BLD<9X(36-DJ2RV[\PB18(,HR/7Q1'V@@ _AI\1(.MBAY[2@SF'KA%
MRB6_+ )D&"._L)3"J9P!)X1Y(XQP@#>]-EK2F-+]EORR )!A?/PBJ:1$8DN\
M!_UBC:*:)+P9E$=ILT*5;3_#$+-1[JY*3Q7S_^U6N+MW;&0]UQUT^CNF_Z-=
M:C_/M44VUSI,>=8YA!]WNI>FU;_<MJTJ[^NED_Z?#RVO=[YU!JDOW^QXJ]J
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M4_<<Q#@#&T8*"[JW]M>'S722Y/IV<V^SN;<[EFK@,Q/AS]-0)Q/]?ER9EW_
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M#.N$]21:T"P80*LX:"D9..>1:&\#IR4^347?8%M!BZOA8X/"&0\6\*UEM53
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MX<M5)L%])2V>Y1'&)R6IY[M3]NY@3MP-KO)!39$;#JP;# >S[[52KJ/D-BJ
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MUT)@4+H,M!/9AUU]NL2U,+)!D:H'"_KVCO8JZ-<*^L5)N\EPD6(":6, 1!)
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M+%;3+ELAK]VE: /3BLJLGR#:,D4\L4Q>A%I@#GV4%FW0HALSI>KQR#V(-U1
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M26V5!^XC#ZROV*;RP)IY8#&ZD9Q,J22CA:@Q.S?9,C#4( 0AE2-.1<75UK;
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MS!Z*45P'05RP2'@4YMIN:[:K=QNS^M?QM)9QM>=C?EP>7$*U$2:*!%*5S(E
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MADYIY)2:(%.B+E@72/BNJSG-MYD?5=OMEEEN(6/.^.",\AHTQ@2H10 KG8?
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MX3Z146<3[LDF;( @)ZAAC LDHC.(!Q[!Z\$1&1^Y$UXZ2WUNW<3IOJ@ZVY<
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M53SF\QC^_O F^[?!J#<['<_A$6%Z^?C;,MIW(SL/@]DUECH?S_J)6CD=O^'
M+&?P\OPHYSY,=6C/I_&GYH>?F^JXP:B,N'SHYW6)YR_8.//+]U4OUP97BR>2
MT6QSZZA=_<6U.7Y2S/$&C*E>4^R)D/S2E_$3<NEK7WLL(4\(U]_TV*^_)MFW
M/?6JP8K+7UY][!61T2LO/<S66W>XG-4F:E.SQ&/X2^\(WG8Z[;T &Q?^PTW^
M 0CM'.R:BY,>P_TUL'S;95H)%]P ,K=[#7,0[SH-):\SX<>V<.1;=E>K@CF[
MI_9F?GX^+-  _!<X#/QP/)U/*N:;IC]I;S"J @6 $;_C_MGW5KN[_J.T]17@
M!?*=6UB53,\\R H6IUO=1V^=]=>V:=\X5/E#!AOW3C/]LMX_KV%#'<?'D'#X
MX5#\S]OAQU?_?LG@.]G1\S_.CCZ\A+\=\3\_O. P)OKJ^7]]A&?^M1E'A+$,
M7_W[=_'GAP#S\Y^/__GGQ=&'X?#HR^G@Z.W)EZ,/?_*CLS\&KY[_FIH8XM$;
M3(\_')&CW]_'@ FE6B(ML4+<$(<TY1CQ&)GEU! 58LXWE(*T*-_P.]V\= :I
M/5.[SP3K+8/4V9R;V)PO&S8';(H.+ JD.<O4V!8C2X5!*GCB>8K4*7_P5-V:
MQJU]"<X/%<_Y\5GLS>Q?V\0]M\YP;-O4KV]"=\WP1S&A=X#I\AYZF[=09T5O
M;D6/GVTC-QD(Y38@JT5N6N0ITLIRQ*3%G(*\.%5@16]-\MN^#.O.YOR0-N<.
M8-NVS?F1:_J_GRW:1'1*4R$HD<A&2Q'WA".#K4$T*2L(E8Y$UY7TW\_-QGB$
M2JAU,/H$+DRA81R%%5+&&T9?O[GL]SZ?\3W@>_E]D._'9S^AZMZT17;XV1C$
M/YD.2B_?;'?+V/(5;LXZRDE'%;]\A^\?Q5F[=WS_/+K9<H]5/\TR;>!T-IGG
M^Y_#,UC;&>E.X'V<P(,M;T ZPX@T!!&MX 2VVB$M@D(4!.VP\5AGZM#VG<"=
M2]"9J>_H$GR;F>KNG&YEJS:]!28PYUYPI(2)B&.CD;,\(F(5_(4REB1X"\ST
M-;XUL6G[G(4'#"*_UKAHP7>:(\;6^\D\AMYP,!N<%->B-XVS694) F\]STFD
M77K H[B-VV]/ID6GVAA^'4\.JWWVVV*;O5GLLA?5)NOPYCYL^(Z\ <>2\$&B
M: Q'/#&&-$T)88&5\3PEJNP/W#ZRLU4_I*W:;W>IV]FJ#G3>RF!M@<Y@M0Q&
M9I09$%?1(J,T1E92E<!BR4#4P5.N^YRV*=/I1^M]]. &_!ABP_9\,(-A? '$
M/AVGV6<[B;U)KML+I9U3J5*=Y^JN<WM1RG[R#4*#\6LTWV6&/(Z0S-XCQ_7N
M*V=@&,SFDSA].?+SR22&7^:SX_'LSU@2[SHDOX]LO+?;;56QC%I1BQ'&BL')
MF A ^2 0B3Y2XT+$@G6AX\Y.M6!J]\NR?%T[U=FCF]FC3683[9AD#J-4$MMX
M<LA(+9$/CN- N3><5"0/K3%%#Q/T7LJCLE(GOEH2WM&J/&Y:%;*^/)O4&Y6Q
MNXK0@Y&#/7"Q&'QM+A;64;%\3RJ6^V7VV%J-A\7"<LWA'S<6[1(^EE\7MFW)
MS/( I[E&P-+/-XPQ5U^?YO!$CD"<QTG]&TS;7I=AQK1IAI>1MBSF4(WK::&C
MV)[@-4TN/[AR5;[.6'7GN[E'GE3H;?O?&O,?S\_@\7X/P8AU6/]J<F)'@R_%
M+"Z5"'XY'(77@/$S=4'^]55::-52J9XO& W>PIA^&8[]Q_L%_5^.%Z#_)3SO
M]\_'__Z='C\_N3C^\+LX.COBQQ\.R?';0_'J[9\7Q_1_!L?TZ ( _##^YQ\7
M__/O< Y;2!YE\/_\D/S/\S_QJ^<OX?,?+_[\<D*/GK\C1\\_BN,/V2EXR?[\
M\E_IZ(O'1[^_YS3ZY$@NY,,,<6(BLM%%1%-T3FAC&:>5@U;8H YS%(<;QJUA
MSN$@>"#1"BIIQ)(E*8AWYJ 7P9,Z!UG-)G,X-)_#KY/!^:S.8?UE/H6M-)TV
M;D"]03:T!%ZKO[5*0RC"N?*;KX)D.^#OW2E/>>)/)4+KKZ%.ER[3=:WC/<'+
MU3.YW_M;CC=1_'/UU_(+^;DWGL"!$'OU:\\JC%^_^/?>8-JS^5 H<<*<IN*B
MG<\N>K4OT$MC/\]G)2Q,B$, [I/L'IQ/QF'N9]->.6UB;QJ'"9W;BYZ-4_@=
MG+X>+-''.'O2>PLOUU^:X^,1'A'*9^PY/.43G+>PX -X5!I,IK/FR;W_BO-/
M,))& GM=7%E<KROQW[;/DIT[Q'9>15A8@@)3P0 K_O.=C/N:FZ+WM_.)A:TY
MAY?F9[/Q7X/1(?KK4YK^O9<FX[.R^.^>O'G2^W4\#@44/)_,3WJ' 7R%P716
MH=W>WU8VS:_/#Y<;9M3[-;K)W$XN>G!*F$K"C=@^6]A/P^FXEBZ(VEWT_C/:
MX>RT]\R.;+#Y 8?SDSG(&CZNR_?GKWHQGXS/(ZP6;):SP;1DW2\V]+/5KU\R
M3%7?WVV5;]\JE?K#RD\&<99%:C#N?7P.?YO# P=9?LU&ZI6=U)M=G,?>8;E7
MF _K\V$48'XE0% ;&Y#/.;A-\+S!6=D')8>M-A:P-:*=-#EQ9V/PJFQ53C&-
ML%:Q=S*T+@Z'=M++(P;S5G;4Q]'X\Z@'^ZO>%+"7X??J'8VMR_=N83Z<3=?M
M3LZ[BY,,0X87O:&=C_PI#+;;-[?8-Y4HWXT&"R[+<A@<V<HJ]/,OM<+/3B?C
M^<DI;+20S<O S<NN.;>3V2CF2OG>*S\;-_K<+Q8!_OC/2;2SWB\3.,0'HTV]
MIW1#PCFF/)J!>$_B*%;MXT':S=DRBC,X?#Y%P%'3R@AVPO]FX3]Y>(O6N\_U
M6MVG8&]/HPW_"\=GID<I&QV^!HPE;/5H_6D?M&8X #LZ&MCKAEGNU@^](93^
M;?"_\P&XYQ=%CY=1E1QV&:P53+855&=YK07#YTW (3MC=>SHRKAXY8B?VD\9
M4D<P=Y,(%B^&ZN]@_VP/]B?LA]FIG55_M-/I/,]C^9?9RM;Y/ ![UGB#^1RT
MO9-Q'A[\S<?)*!M$>%SU4+![=0)*_8Y\(@^+6<S/S(DJH"P7^7TKWU'NJ]7/
M\.CI-(+9;+#9%#1MFNK[PTL^,AQ8-\BYZ['Z7#YS![.*X+@^+4;9Q\ASF$^F
MY>QWM9]5/A#&\,G1.,.$W$<UAZM@#X4/@!2KIP! F,0TC  S\]/ $DQ+,6::
MYXO%7BR=5J?-^.HI5H.J-J,?PKP U7C;3&21L%,FW+-G5<I.SL:O?]S]N=7)
M9FGUSO+^ 4'#2>-A0AGY3$_'\V%87:O\.NRE/.;J9N5R4;9>2=X,,G[+_Q2O
MN;\VSU.;95[=\^8UAA_*I1(L,6#\[&# ;T.07[U71O&DV/(EOV5]2B_?G3??
MI^7N@O';DV5E1)'[=9^\NO:E\&+6&T8[K7;5*/XUZQ$*L#3SVFZYK]5NR1/)
M7Y*WPO^]P?UZLLP3$Q*)07.KDPN8$^9U%%9:;&(=>E,W[W9^'&<5<\-O,*P'
MD1/[_:-N;T_8\>_O002<!VF03D$@'GQ$FJF$I$@BT<B<4"+3R_:IVFX!4O;4
M321^=_WM.XE?1^+\Z.1]]$D(K"BR4M-,U^B141ZC& @<&=(*S_'!4TGZE&^7
MSBU=VM-)K*Y01IGWNK(/N2U@]G]6.:^+=]('8S'-=@ELS_!BW8R4>%JQ1S<T
M'W>ZF3)]V6MPU0<PH5\NWDUS@>>KQJ0>+JQOM]-V[[2/7XY/WA-+C38JH)2S
MY+GD%CD/VTU[$93F(MHH#YXJV2=LUTY;.?$ 7?;"O)R:Y52ZUI;[?#KPIPU\
MRJ!BI7[PW%Z4_][[EBM5'F"YP+N?QN>Q^N_+T5<J/;HMMW/+?3C\_.KW]X%%
M3:VSR!!#X#@C$GZB"1&A$O:*8AUS-UG1!SBXM>6>] X+AMFUF=;QW,U.O7TV
MKSP<;?9(.P1;-9EDS^Q?=CA_&!5 ][$]OL#V('GU'7>()L(1SQW&;8@6!2LL
M90"%I">7]IC,?IN_K"5N5<]0ZASF)1(,1BE$<)(&-S8RW[Y=+CG._H@Y9AC#
M"SL!RWDR/5R.\7DUQ&[3[-XT+SX?_?[>*T,45QIIDR$RBQ2!N^(0QSP1G)PT
M@N:R+P[GV"ZCTGKG]>6H!R?/(I9,UJU=26XIH3GP%.V-=K)6D5*A8F!,<6:B
MM1X3ZK0,V#(C7=5#\NKV[9ER8\FO\:OUL>+8Z+;M)=LV5RMJH<"L.8:X)1:V
MK6: ^.%7 A8/K AXWB+!44AWGX6]MW%RUOMMG$W:"4#]@I8^#V:GO5]>/_NC
M]]O@K$0 7U>W%M/3P7F_]\M@_/K4@D!ZSV##@.%[6?CBJG#5OWI_.[)3V$I_
M[_WVNKK5@/>?K[W_]6_/>G^#73]L/(5^<[M5/??C>-3<?%8^1'5)/LNW9Z?Q
MIG:6Q&AXM%)AGCO-*P=.4?#&$"E)LLIWN_-N=N?1Q?'A>QDCQ9YG F_8F)Q)
MC(RG#- :6%5/F-)1@&]PR>;,]^II7I#_>-5XF0+72+4YIC''I[]U=[A$M" B
MEPI8GC"@?LEL@#VB@]8JD&YWW-'NR#$*)8)326MD#(N(<PO[1&APJ@3FPH.O
M90G@-(%W[XXS6V++86+S#?EL9WP^%AL#6V T[F4DE*,:=F4K,=(@_^G<?2A!
M]G%]ES\Y:T+Z]17.(L@^7#.7UW<GJD!_-=[9ULZ])&DH1UW/)V,?8[AQY-4F
M)V I'::PN8TWH&S.Z(19#$)(3JO*)D '5673U;O\=3V07\%I;RA^7J4W.=:=
M0:;KMOLEV_W/[+6R(+TGB2!E<P>5I"QR,3/OR42$M=A+S,$MT7V FI<$2A8'
M)!RMN?RA-VB(EOQX6KLG >10.FA5=SF##=CWI)?K7N[X:OC2Z]/=T+0D]LJ[
MN6+_YCO=EJW1 JE-[S4'IMP=A<HBVN$J)W [+NZOG93@XG 0/S57F3E?IDZG
M :>_U&_F8/9X/O$Y%ZL*,N;K[\%TMNA)MRM"T*^NK.%@FLY3]KKS$^%0R3AF
M-<ZYR ^Z_!YNF;@82JK8Y@W]#>[E>[GV85 (9O)=>06H\IRK>\0F-#_*QGW]
M(,JG;/YSN8BV@VE<E7ZS4LW\ZDOI'=,L[F5%(@UOAAT/ \^_PF[*GH!U=;W1
M\ER=5GY(G3 %ZWH"YV1U33V&I9CT:N%D:2PXJL&X+5<]#VE:36!<KJGM)SL8
M-C?1JV<S"*'D34WRLMC9K!C=3PT*^'P:1V4-\N)FD50$R/GMQ=8NOAV6[N5:
MGD#.?%G>?8]=2>I:6;\\PKP*C:!S@L#F]%:^O5_2FJNAPT[)<VQ> +>JQD/+
MN_B<6S@X&94[_)(E!H?T/-]?PRK"Z7!>P/*JK,;-._(7--I0TA3AC=-2S5Q"
M\_7.]=7'IG-0#0 WY;/5GP99LVU*]7DTM'F_]LOQGY^0*VS+7*;SQ5-]G)35
MR844=N)/ZX^">S@^S]L!/@T*UMR#YRSK.B4;MD6-U*IU6TP(UO=D#$!FPR[]
M8R/1?W_%,ZK]Q3/TOHIGWBPWXN$B1><UV"Q0U6EK2F(N&ESX[J^C#R_@,R_X
MT;^//A]]R<__4QQ]\(#UCD\!&UX<?3ED1U]./V[BPN.W+RZ.WL*WO3WYZ\\O
MAU^.GP-._/#QXOC+[_R(O@!L^/++T7/_Y=4__TC'SU^*X^?^O<B$S(PD%%V^
M0?,F( N_(TN8<#93;FBY61.C I>4):6TE)FUP E,O-6,6MB0$8O-FIA?F@RI
MU5*EHC9OYF=GMLJ*6I%2;RFF7B.G;RB@N7J8Z]-RA%.O71 D8,ZU<\K[%,%W
ML9Q)I=R"V>&N-FI9IU=I8Y->5/\^[HUZ\AYVJ98@-01^)#CL,5ADG%<(UI;K
MJ)/PCF]*% L9L(HI$1*X5]%ZX2T+2<I(F6=A<Z,^D(S/G?K4^CN _61Y]K83
M/ MP:@!RA@U51F:!< 6XCL L#"_!IJ,%=]@D%&>V?&PEE?,<H*,?G.?SO\IT
MSR4-\'H.N83=:?D@F<-B(>RBH.:?AX>O%R4U39;G)(.Y23V2.L!3 AK+M+L7
M#6'QCB*=-RM5.HN.QH,S>&S.;BZ(]/5\DGWT)K0$& \^U)O,&S0SB2=U3<ET
M.V*TE$H&AF>#61%5C966J[GBAE7 :5%N.JT34&'!ZAR):K&_(H^%3'<():\A
MH-QJQ<?G@U&=&[I,3:SFT*S#-O9:.S]V8;$-)@W!'S.3!KV<2:,CQ6C!6#I2
MC(<W_(X4XW&08NQT2*YT,#;AJPXD%_SC9"./D6K)O",>U)HI[Y+]FNV\/YRW
M>^Y70_'UN1-O4HR$VOQ^A;DU%'PI+B()'O["#YY>#16;XI4<7UNI:]G(VP3X
M.+QH2F66M1-K'RC@,I0DE66,JX2C>\D.)LLO;6!<@T%@HP_&35QS"="FN60V
M@YT,W^&AI_#HC'@FI=/9XCL&!3F56M\<$EP4VE0?WXJ@N;B,J399U&D.D[^(
M=M*K@UW-A4P5>FDN(3/$*_,![%?%LM9G\&0'7FJ[P[%[(UZ]L?;DJ%3XNL[3
M6\'$=9F2RX*T!>C"LS[,1]65ZL)KN?29%5/<*J#>=?M\6('L/XHOD#VD7V&#
M]PA&_[W8&LVN@(?LW!3P;TZ"& SA#8MA9?]AG,N.<YR459MGQ^;H;<5G[C!N
MLL:(TT5+CIZ_>.^($$I8AX2A)E/=<.1<,$@JEF3D!,=@'VCTX_72(:_@[%+V
M#^H6<*&JWV9>FM-K9S5I0X5>11K&TWA9$>GGTS&XYVC\>91IU><.3KD!G#OY
MWK%"VO6U?Y..M_CSRWP\C)K+CM]FX4D5KUC[T"__JM+P=L1L*K.7(P?Y.FO%
MOS\<#JNSIR'$R3DJT^;"9_FD.(01C?+Z[+AD677T[];VO)O&5^G%=#8XRZ&?
M1VAMX%GO2526BY"0423DV"Q&+A&+ K9421U8P/2!6IMWE>XL)-QZU'.T+-0=
M3)L08[E"/[,?XR)^%YL)564%N1#^?'&!FHMNRVUOK:[7,D>7Z/.;?$5[^;?9
M4D1>X]J,5:YC_ J<!L$L'UM;PW[/S6<+&#VL4XAA(JM\))G>9CC^7 *+&0N%
M\=S- "<OS&:_ O6?<K%+[RS:C-MJ1R#WIQ[-QH#^\ZLU],YS*BWF4)7?D"T7
MF'%;U6G;LW%.-LB@&@:^(I[\YNG*' !6G0[@.3EP/"Q('@QQ'F2Y8!ZM+5M5
M [_RK":CI.J*8:?C<O6_ED^Q<CS,YE6.2?$C?,&C80"2F/3R4"85;T^=&3!>
M7>CKQESN]YJA.#T#F+3/#ED%:IN<@I/AV.7E_=0(-&^<C/(G@VG=:7Q82P[.
M,OBIL!G4*'NY&4O^39537J4$- 'T5_]Z^1P14WTIS#_$,SAVFI#_NX\3T+Z!
M':$_YM,I_+?WV4[Z5:Y&S;=4$GM&==K(0I07"QG 2?N?X\^9N"D[LIF^J2%F
MZ*_NB#J"W[BM%8%#COR5F'VS-GN>=:^9</^J&=<O@YHMZW;K9]:C@T<WB4*7
M68_%8V 1/M<YKG:QA9M9KB?<++3@1KY<1? Q6OK5URD0W:U]=:)2)L"83M=B
M!@NA5%<US1:%+_\<<PAC6KOFF1AD/"EAB:RYE1YG86W,?'K9U"^SX/70%A=(
MB_#%?2*L9YFB8U2SY/TQF'ZL2CGR3X\/;G$8\WN5<@/:I)%6P@'<HA$Y'RTB
MC@9!$L MNI6S$5/P2H=(**<<,VJ8"0#.7%+2.$W4S>#9!K?HG5K[&P*VO"\J
M0_%N5(.=V>#:N.T>7<.7HTS'QA8>5N&)M/'S.,.'RJ'R<5[HMD"AGU0^5W,7
MW+QQ<2&\7E.W6F*URC.Y>/YA\W+S@'XF)%S<'5<!T]4+XD61@"U==6' V8"O
M\<U5F98E_; C?[M%UG.&80M!E2#M@O.U"0[7N'TK%:&_9/E\-RJG>_WR?X/R
MAO$9((9R9"W2#Q9O?P'F8YR1RR% D'[O#2#Z+W$RA$W9KVD&^[W#>28O'0[@
MQ^IL[R_<BXW'/BM]F#]7M*3PMY=P8N;LR[P?FY&6?+#Q'-YPF#($7COX_!A=
MLLN*!:JS/1:K!"/X+PO"ZKA*;['S*@@[R&G,HWG&'+G2)M/+KBYSO@#Q"[18
MR>^_Q[!GUE.Y"Z%HAJ15[D:17''+3L8 2&=-G>6Z% M!J2]@:;=E:6XL&C+<
MXA4M/A[ \?4Y][CDQBQ^JQ-[IU7^=\-3"NO2I.-/%_QCA:<L6[C!*!=HE2OT
M37K6OU68K-1V=9OMFS?;WZO-!(?69%#\ZT(F5^VWO&>V3ZK-HK7AH/*AFW?V
MZR*#QFH4+WT\S,41Y^?P9G!"2E!DL;<[\=V"HK1WF$.U<5)BLB4Q:[)@;%NI
M!*C-]:K?W4@(3$B_5[);+A%X[W-Q=U8B%,4=#+ LL! 7JZ&D;5]OJ><+3L%.
MW+<0=TL+^<R3*E-RMKPO?5;\H),X\BMNP'VDC-PK)VY>B1;*BY"N\O*KT?P8
M+@!G_.-P.(RY!TQOR=*U-(P;ON+A9))3AO,KCW:[W[Y4]'XCV!V1_MTZ-=_
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MIZAMX6FP&PI?N1[+%=AJ4;<+8V7$DI.72IOZ-5!5GP'9ZF7;!/9S07TYR^Z
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M$SU=\[B\#$8]6I#TB"#1W^]S0Q<ZDEP:7V6SCE/*MPON*_[!.CGIS;R%S13
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M4,$TTMA9E!6<*,F]IQQ43+I#"KP]+M]^XW]HX[/@]%52>0)W%BHLT8AEPJ-
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M-+\B+:$7FSL6FX]_'U%;<(>=1Q+G%M##6*2UD@AK09273E"2;8P>,N>JR 7
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M'=,4"X*M4203JB"<J?PVD,F77YU%W]QDW(/29J#T;0F4.%5>:@>@1+A%3',
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MYY0BY0G7UCO"1-#>Z0[]<6?@0\7J'HI[*.[5YAZ*;QB*E_VMN2F,9%HCA[U
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M\-$RL'C"0&+CL"I<=(.JA/52D_@3FUY=A=LQO>67U!Z._+H+1SV,]()V9<]
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MB$-9WRY43V-N'AT:Y7RFHB2&8>'NJ'@9KJ&HR(2.6@)C?/%RV+E<WH/*]'I
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M4H&QF&%S 1Y"D?.&:*T[5O7/37<JTK#>^K^'?%W;::K!M%O1LMD@\5=F,,!
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M7C!CK+SIV.#I<G7VEE*'P5D_G6D?!^/_.S(#V/13*!G<%-XY;_V!IW@;K5<
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MG+V8RJV.2[3.XE2L7"#CD- ?R*A >,*%Z:)D-0!3R\W)N\O#C!N=Q<"(5-(
MP "I4@*4U4>P:F""A3;NQ<LBNP9@IMR0I5?/]8]ZJ2L,QO,!ST81P%SB#[N?
MX*5AJ%P@I41T.\9BP<,."-;:%P%89EB4CS')\??]4$X$BC)J3YE ->QXA%)
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M,\N(4B 7(=,V()@_2Z:V@!/7[NP-4-02\2X[I,RXK&"4B,A@>Y>"$VOR@LC
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M%.$T:+"<=4$\+%ZAM K,:Y"WF_SN)95<'H!^E]/%LLY+*@(U+9R_U%6F@+S
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MV*Y\HXW$KI)8H)=2YLQJ#*<0&%'N54945E 2\PBR:I51>0X2R[.-O+C6Y?T
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M^[ \#O1>OK<EC_^OQ-7O]+#Q1\557- WL)[OJN5L4/7.J'JUX%]S!;8'8(8
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M_[UQZ35'"6L:.M& TC,&I47+/D0P) /Q3EO"!:,$Q,,!1AF;Q=P5P( ;4&I
M:=WC*AI0>L:@-.__\&!M%R'SQ*;BPYIFQ.A<$<:$0Y=(E!EO0*D!I74/NFA
MZ1F#TKR7".AQ[@M@2MQ*"J"4!_02:6)XD<58:*ZH:D!I643&?U)-QNGZW-,N
MM!]?Z71:\Z8KG=9-IW[VZJ9T]_UAQ#+_TGK"\]QB6Q-#3#2:9#;:S!=6N]S\
M_^R]:7/;2+(V^E<0?GMNV!$$&_MBG^,(M9=^/=>2W6[U]'5_Z2@ !0DV"7
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MS<!SO<A!/X=YEF%S%OEFY%O,=_<-<],G@AU,3"^:M)[N:IJE@S7+P)"U6!2
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MBN_ <DS?UT*-:;[O (<$L161W--+N:?W<J^#<F_I IO%OA'@M;7C&ZK%.$A
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M9TF$^9:X;6_8!*D-XV_9+ ^/( OOA,S^%BJXYLHEBX2!C4NC/W!8+/@-E)V
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M.<A0P>RLQA>+@LNBXK)2E0H<*8*"Z5K*3Z8Q=&L \NJC49Y<\12?D%@K!/]
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MG<H%:Q5YJ]YHP:$C-C:;QOC[#3=7'ZRY?ZM6 "^&G$=%;:R(@DF5#B?F @(
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M/JC"GZAK,JT^--SS-)?^'WZ7_1)/CRYXC;'F/)[YD0(Z_-6MWP1P*^82\OM
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M5)*0;FJ'ZXL ]4Z6'Z]S3H9*^$[UHM8;2%W9J(Z)[20$4MTV5<504BZR(4M
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M_;7N$@C8\ X>8D=@!#TI$Q;#-=4C1!-1!1RA]&ZE/49VL^-%+0"4L50=\X6
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ME@TK;)_0\AS:B=*Z$!9%1LFDHX:*BXE]+?(MD[3HR)5UU/+T0=+%L!-,>>1
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M9Z7U5(9NZAP\/ 83]J2(2@![Z#&B<.4U54"9\5GFH_#P*,2H+T6#U&U'N."
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MJ]&!AY8!# 7QE%V^YR\5/F:_IE"6JMM+/E'QC4E!O:"X)Y!QX9[/>_\P0@I
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M,/P%1TZZ&8SPQ](E/GV*D\"6IIG(_JR'CJ55PM&6$.\@GRH(-1@DY$'G)?(
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M>KF9IP*"/E0HAPPNEW#P^$5<B?I3:>\8_9>UOTDQ\D, <3BWK@A"'1@M-_Q
ML)BA!;VMG-.>;[AO&K[O53;5'=@*L^X9#!2_EE-9&KOE#K?3"ETE09Q7;;Y$
M,^*/C3>\HMZ4I8W[7J%J% S0R[)>89WMQ;RA"?I O3]_0W*[Z!.=1/2QC"C/
M+U >?:*#!<XJO&1%1R[.$:5T.$>):QP(O.<^7SFO((=*OI_0;\7^6+*'DA=2
M$'])8W+M":%6),)7N ?)#4ILCXE"_FK]T8+:>.7<K4WVOW;<\?R9VPFT_[$
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M':@K?APHI.(+__P.AP_^Q_NK0=&09;58U-O[KH@Q>__BA>+8[A9)A!9UV2;
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M(@_!D.DC)5B?Q1'0%-#PFE76KM!#V.#1A^MU+];G)0^.3QYM0PJ7B9]R.S!
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MD&_('(L'IT'!#J-F.=K_ 17M6?2FK> 63K+#;W&U#K$*.: !&K.95?L?I'I
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M7 Q1X3D(T;S!T]U._-()APC3.1XF9+N%]@J,IDZIL!D]APT;UK=<2H?>2NK
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M$EJO*-+MVNBL8^]5W >[8IKBZYUBJ;*X%A38N^D99OZ -X_T<Y)::%S36(S
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M!U*19XNF>L!<$;*.[&\4JE[U5_W78(PIK7.LI-I5>CU[$P^C.5>>OF5DJ)Q
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MMSFZ,454'SX]=Q7_ONGY?#K'>;Z"CR%9ES1($7)K.<J/#PH!-5B!;/M+W?U
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MA$#)^9;1'0%-;KV+,T9-E&OWF'27JC-YR!+C0]"FKZ@.L%B=G>8T02F*DKZ
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M7D=%2;1TK 2&EW((C!)DL&2#1FFZGZ/P;41CBEH<BCH=9=3O<)=3.*=%Q)?
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MK:62VN<7^8/[DKR.+36^@]Y&)8O!Y-FZ/\H#=4_S$A?K;QVM9-2,60'%\)H
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M09SQB#,81U)"E"8$4B)CF 1IHG]!(Z+<2A#9T9V:>MIFNZK87E>4JHH+:2F
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MN+$XYT4^","Q>*5GA;#5%[DT]P-+^44NRORKW-3D_BBUE?*9?J]=__KG2^/
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MVNTN--^TH&!;TB;J%NS*:E+&&VE!)>Z.1;\E\@"QN8--B^_07O^,ODYD\&"
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M\E5UDVF:J58%I1_D@FL]^B8O^;PHM36]O@>+42!YC$W*=L0@2E@ 24@$S*C
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MHXW<K:55SN5J69D?Y>WJBUQ^_D(7MW6]_K^8=J#E^T6=GSI34L4HED*?@DR
M,\\XQ$DJ(:6"81(3I%*W+-"1&)^:UKV7FO&\4@3U\>A9?S4E>#!,ZY_U[^0Y
MUH<@61H1CB7$$B<0$2X@SF($)8^2+$WT@5GPV5>Y9,7O^5/8%F"XC^$OOYM9
MM]O#ISB3 ^_Z'MKZK$]4:^E!)3Y8:?G!;=OEIX8 U%4GNNK/C-??I^>TO7:;
M'U>V?Q_=?GI.AK>F/WWI]S-\-OMH=?;\U>RB]Y]^;4(9TT@RDDH,N<R$20Y-
M()4IA@P'(4\2R3D/W#:I3GK3VUFVS(S:DU,Q#'[0++ON,=U(VVT,WM ;6)MW
MPC9 @R K7#RIRVY:H^HX*['W%9/=2_VTR:^EO%5MM]-RE@2<D8A0&%',33!6
M $D0*B@52;(XRK)829?#SN[P4SN2:.[,I<V:/S?UL >=G3[H#\C "F ?BW&J
MW1Z'P].ZWQM\U(5^7+#]E7WBJ9[U\(W5\;%8%&V&SOL%+QYEXW;9!).S("!8
M&P>IB/42%T1 )I(,!CPB*M/6 Y/4J3B^%=FI+?WZG)%7K((?FFKY/[I6R[=#
MW$XS^,=Q8(U10[C-,7C?X-DP_>,PA?6=@/)59=^.Z+@E]YV .*B_[_9VGW9E
M=&XRPXW-4H6;EZ;(7W-P^O6I6/QE691E>\^V:5 SX_I[RU)MA* L51#Q)-5G
MF ##*$EC;9V$A%%LW["L'Q-3TU=&C*JF1%V>A:]% 4^-3^59"P,>C#3@J1''
MI4]6S[FR"" 980:&=G4UX#>U<392K!U:1@Y0"0):2;8;9XTP$2XMRX:?D+&:
ME@TV,8Y]RRY#M+MS6<^Q1^Q==IGTN]W++ARKG^E\F.9^S7GQO%B5FC1E<SF+
M4IE&2C 8(&&*KH48$M-'ABF1HCA*PPQ;56&TICBU#:AES^PWAC\W2_D\P'9&
MLE?8!MXUCI6VR!=@#>3=&2"=#6-K<#S9Q.?IC6H.6XN_;PG;O]BS.V*Q$,6B
M:E#/Z.(?MTK)I13W^LC_X?W/M_>-/SE+XA1K/0+#,--6+Q,9Q$$40I4%(<\B
M24/N%&=@175J6J9F&JRY!@W;P/ -?J@X=_3BVZ%OIWZ\8SJP"K*"<P#OOA-.
MOKI?6M$<MRFF"PP'O3*=7KXP,WLK^=@$L/ZZ*%@IEU^-\GN_>'I>E??2R)S/
M\\JB-_]]7B[SQ<//M,S+M@K02S76+!"4<,$22)4P$5.1TO\*0YA%(A61*=3F
MYF$<A,NI:;YU"OX*+(L7.E^]@(+-\X<ZIJ(QNL"J &^_%O-G$[[^O- 3W3<?
MW.N$)S*@B"L%)>&)GG!N>LW+  9$990J(M,TFM6]@SZMZ'+U.YGV?8Z'F_PJ
M=;TJ87P%F'S(%POC3=4'6Y>&2P//<2B3F/ 8LCC+($*1_A=!&*:*AHF*4H$C
MW,SQVX7X7<UPR^\X\RL78EHS:V?ZO/I<#6PJ;:I'7&V7XJC3]K:%!+648%?,
M*["6$U2"7JUK%K[4PPY0>V*(J?!=L\(KCZ]3ZV((F$_6R!B$6,^2C)^_%<WQ
M*!0X37B 888P@R@B$C*.%.2*9Q2)0$8.M79WAIZ:'5;5V]'<.585W$!E<2/2
M&X"!=6 K>]_2BAL0'"LJ]@)CS$**71^$>]7$ W'/%DO<O#%NC<0#3@]*(QX^
MT=<%WY:XJN^A/\K5+",LX"@F4(8,0X1-A>^8IOH@F<1)3(.0(*O2(ATTIJ9^
MJO.^9K()37'ULA]B:.M7OPB9P3WI+7=-A,D5T SZ=)R?E-Z;J_R0PLC.\9,B
M'KK#3S_:,U>O;@[PH5@\&)51-;!0(0I3RAA,B2D;)*,44I4$, LR+$*6!-*N
M(7,'C:FM[6HGF1=4'Q86LFK_)_*RN0PR!?_6O4-X4;H6^CL&L=W2OQ"X@9=^
MV_O#L%?70C0,7IFP,V/WZH_48S;0:21\)>X<H3!NCLUI$0_283H>[7&>,.]O
M4F3:WJ_M=G>[F+^T519F0J613+,0(H7UMI]D 61:04 A0QJI%"E.K(+0'>E.
M35TT#9FUFLA;HZ#0[+8!7R[170[@6QQ?AH%T8$5BF-[*--SN=[VVN0SK;>30
M0/ Z'(R&@7FD4Y,_N-V.5^Z@=9Z]'(8;[V#F+N/.J:W'Z_W,ONWB#Q6!G=(0
MLRQ5B8I) ID( XBX_@/C#,,XXR%5&64DLRK8:D=N:MI]FUO0Y!^XF7QGX+6S
M_OR!-K#^WL&K4 =U9CPH$#=,/)F$9XB-:AW:";YO*%J^U=<M5*NE.YH+X\Y@
M1%&6!@(RB;72,-4I<2@DE$$88)J***/$S26T,_[4M,0-+;]H@R\70!7+M1WH
MZA7:A=#6(]0;F,&]08W]8%@SY:7X_+DJ"'U#G_(5G>?_79>AJAZZVFHE=LU7
M^5=//<3.P.3-;;0[^L@NHZ.B';J+CC_6;[V_I4L3^U"V_6O-K1:?T2!*E P1
MY($I1TLQ@C1+$501UW]%*A;<*?KZ*)6IK7T-)IA7Z3QM)^LKP RC7MI<'P?:
M3C=<#-_ &J+E;].Q^JJZE.?^UGTG!)Y6_W$:H^J 3C'W-4'WPSUCIZ6V(N3Q
MIH/K<\J;YZJJW&>-NYQ%G*(HBF*(8TP@PI)"3!F'3%'.*<]$PIR.%<X<3$V/
MZ.\J<0R9=@;=3F\,"N7 .J7F_6J_,^E6F,^5B<YDLC%+JO*6E1 >PZK[XN<K
MQ-J9_KCAUGWA.0B][CU0_[OOA9[ZE[K4QJ9!4\1CS+&,(4&9MGLDT79/DB7Z
M#TRB2*8J2IQZ8YTB-#65U?)IW6#Y+)*VAY[+\1G\]-.P.$Z!EG.(>+P?/TIF
M]$OR+F&/W91W/M_SNMQDOWXIYB:\OZXM-T-IQ(,$I=J4"3A$F4+&5XI@$C A
MI. $$SI;%?KT:Z<(#DDXJ8 UH0$ORPV-NMQ!P^?_^'<<A=G_;#IG.%Z/'T(:
M9C''F 6F-%X,D6D^B#'/8"1"%0J)I4+4/6GA,F#'RSCX>9UEP.C<!!U<C"?B
M(46)2B&*60*1"(1I4FLZR) LDD$<!ZET31#P@>;PT?V:@D\@[;:JRZ 9>)/:
M9NX_VC*OUZO5,F?/JS:1Z8YZ#M\XB8BOZ(U# N,&;YP4\"!VX_23_;:DNZ4T
M7NBF.-!-'7DS$V%(&2("1K'I2\UI#%F6Z:,VCVE PS1+LMC%/#U*96JV:<-D
M>V?G:* >!])NR5\,S\"KOD6F8? *W/B.T.I$P-,J/TYCU(7>*>;^6N]^>&K-
M%=X52R7SE6D!^S>9/WQ927']59^S'V15)/D-7<EU*LPL3E&<A4H??Y/,5 -+
M,DA1JB C$9>(9"B(G=S^TQ!K:@JMX;VIQG_IO<(T,'[ULOU#?1!#&VZC%?7?
M N@*M!"!!J.ZY#\P*(%-8N;OH>Y_GWF??%< )Z'^17H&])G(\3H*].*N;[/G
MZH:?FN )J0>FK=$:(91%D8R@XAF&*#3M8<-$PH 3D;&49 FSVIW/$9K:?EGS
M"K:8-8J*GK5VW=#MWL!\8C;T97Q/N'JTC>[&XH(6TB<&'KF==+=XAZVESSQ_
M>1*'.7E42LLDB)1OBD>:+V9<<)9%+(*Q<04@(07$,I0P3B@+:6ARQ:T2NVP)
M3DT]'$:^K[D&%=O@MYIQE^QJ&^"[-<80< ZL.5X-R?Y)&I<B^FK9&<[(7I26
MT0632S[&T7%>+1&C2ZJN#(S.]WIHZ=OO2C]K!OM0T,4[RJNXA;8R PHH$E$,
M8QQ3<U<30L)%!)G &5&*,198!5"?I30UO5SS6GW>P' +6G8=E$<GLA;ZUQ=>
M RO>DU#U*0S2_37::UI?V(VD8B_ T$VUVN#2J5,[!QA/F=K(L:-%K5[PWVZ=
MZ\_G>4[-B7LK\66&8Y&&) MA%&O;%X4DA#C%%"8RCB3*:"!I-EO(!_/B9S\=
MUX]S8K462+T6#O@9;CUL<;O3"-Q?(_83$V/G"1X(YPDT8"^O@#/V7CNO=\,W
M0M?U$PQ,IN-Z-T NW=;/C.2K.<(Z,K;)N%IWNM)?*D4T(C"E60"12D)(:6KZ
M)609I0D1F7"J_&M/>FK6YLT7X^.MFA;3:FZJ"B_S)H@XEZ5CJS&'2;!3>,-
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MK=>WRLIO2=B6F!=F\@XJQQ^6F]^K-@]^^US];I"4KR%GQ'=U>9\LODYQ^0%
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M>=6P/%\\5#7O<UE^R!?R_4H^EC.1X(10K52CR%3^82*#E$3(>-!8ED8!"N+
M.F"O@]#4M.6&5=#R"GXSW(**79<8LRYXN]6A3] &UG,CX>40B.<)MY&B[[:Q
MJOI"'@6TLOI]A=Y9 -09;]?U_GA!=A92[$36V3Q_X;5#-4N;<V^:XH"E,88T
MX0*BB!"(0Q[ E*>8B$"F*<%NS<N.TIF:!MWV5IA]K2CSML]O)<':4V'.N+69
M]+^?J2ER1U>UE:27P6,/#\:I>7"\X.B/[GC7'8/Z <X@X?L^9(_*Z]R.'!?U
MY%W)B<?[M@BBJ\K_<S.G97FK*A??]?>\G(4TS3)INJHSAB"* P)I:F)Q.<N0
MP(QSZN8Q/45I:CJDXF_M[@2_&1XM38GSJ%KZ(WU@-?05BQ-,/9JPG(' 6R^6
M4W1&;LER1MS#SBSG7KBX+.L[*6O/[]^H226>J5BE*""F.C-.]+$LXI!0K&"8
M!#)3H4@2Q7L69-TC-3654)6YS-?< B6U!5$[Q2O?5EY*T;MTZ#[,%L<S;^ -
MK"/VRH,"S6E[F5#SZ@VTWI56+P#O=6JL.H!X26G5$[@X%%7='^&URJF>D*2C
MD.JI-WJ7O2H>9>5)VVO*2K!@"1:0X(1#A$TS>LPEC!BC*@GB, F=+*Q3A*:F
M31M7M&;4O2OK"2CMS"H?  VL,3?8C-66M1L2?Y6GCI,9N\Y4I[!'JDIU/W_A
MF:LZR<VBA,HTD!0J%9@2)ZF$3(D 9B**,(EQS.S,JN/#3VWQK[D[ZUBTP<[Q
M..6,R,"KW1Z,_N>G'9E]'YKJP5_GI+0CV,GCT>Y34^MB]U=9KDR1ICJRX7PW
M,LD#I:TN!AD+ M,;-]&',9Y )10G*DQ1A)W"6B<CV=345,W^Q!O9N7X]EMIR
M*OQ.25&/ULZN^?#T=U>C]*_4TZ[G_$^^K9VK7/\BG>UZ3N=XS>WZ,MC/2MCU
M(50]LS3]>TWAK5*RZIZE&>'&8?0@9T$:A"&E!#*$N:EP+2!1>D]/2!Q':2R5
M2)T"!YVH3VVW7;-H-MF&1[=-U@U\NXUP,$C'];I>@99U8'C7.]$:[;OS:#MO
M'[U0\Z3BW6B/JH9[P;*O*OL-TC>RI"RE7)?1KJZ?[^5"?J-S4R)J%D9<8149
M[Z6IJL=BD^8J0ABK-""1^2')W"),.NE-364UK %-Z]$U5*0;6#OEY!&N@=51
MS>G55G'])IBDA?!S%X0](DBL@/$62=)-;>2($BO1#R-+[%YS;_O[IKDA^]_/
M=*D7ROSE7CX5R]5,!*DDB#*8,A5HW8$0Q$3%D!&C.:)$ZQ6KZ+0.&E/3%RV;
M8,TGJ!FU;_-["LUNA>$)HZ%M%F=XG-KZG@&@5T??4V..ULSWC%#;?7S//=K/
M1*A+RC?M@-=M8RA),>*(PB!-E5[<DD$L8P$YB3(>RD1@:A6]WTEE:LN[8:_I
MT>-F$!R'T<X,N!B<@==UVSFLQ6>(?CJ=&'C:YX_3&'5W[Q1S?T_O?KAGKN2.
MA=#6 '_YJ-EO>LWC-,UX&B8PC$0&41;$$,>$0HPD"Y,0T8PZM>TZ2W%J:F!C
MX\ZK</.M/EV.*8]GL;;3#UX1'%A7'!P0UNQ>@0W#'O,1;;'QE7%XEMZX.86V
MXA]D#5J_Z*9G2FW+WANG;Q4IG<2I"3%7,,DDATCP &(N(\AQAJ3@*:=9:*-+
M=D:=FKXPU]1YN<JY/@;O5!UV"#K?A:U;+?0&8X1 B!XX6"_YHW)W+6O]PM:2
MUO_;+.?=L499LD?9;Y?E\5_ZJ6V\5=ZWJ>X[RWBD.*.Q/KN+"**$<DC# ,,L
M2A*1$D:SR*DCTWF24UNTVS6/A8^:QT=01MJ,(EC#JDS6'D*IU-HO)1!Q#7:<
M8(EBU9:0'17GW=*Q_P)(V]E1?K_2@;7I8=7I'X[4Z3X=QG)Q">K3Z Q4COH(
MP5<M37T:@'-EJCO>[.FDJ7./RWO)95ZU8_HH5\W!<,9%R!,:4AA3I96+RA*(
M:1#"E*8,J2B5F#G%DW41FZ :KW@%RS6S5V A'35,)[R6/AQ/H WMRFGQNM_"
MBRH]557=MV]4KY2JBL#-4HI\!4P1D;7CQZ.WQP(M7TZ?+E+C^GXLA#YP =F\
M<VF=QHY6HW6$=II(E*$@UN@&#*(P#"&5H8!I&&=9C!/%8Z<X%WO24],W>VTY
M3W?I/5]SX]))L=-+PT ]]$G2'\H7%#&T!<Q[5<*SA%^IS* M(*?K!EJ/<&%2
M3AU56!4/69B@PLJK$@2AC!&5,,3<',)D"FFD J@2'#&.9,PCI^8^G=2FIKB:
MR.4-DY?51#@*L*5&\@7;P$K(&;'^Z3U=2/C.]CE*ZW62?[K$/ID+U/F2NZ_Z
M$Y<+NLR+7Q?ED^2YRO61K7C4I[E9G"A,,XI@F@9<&SU9!K%@@39Z&,4X)0$3
M5K%QG52FIB9:1L%O-7\.[NO32)YW9WO!9W"CQ!8:)X_V6=$O\'"?'GLTC_=9
M\;8]X.<?=E_@FS8Q-[24G_4 S5>)$H0RG$60IR$RG:48I&E&(9-)E@D4Z^_!
MZE#3161JRWNKSY%AM,<J/PGG^47N Z2!U[@S/DY+_1P %ZSTDT./MM#/";>]
MSL\^.W**;Y-J]/:[7/*\- >1O3RCYC?R;IES.2,\00EF'(9A*B%*J8 $!2$4
ME(HDB0,9L6B4!%XWOJ>FC YR(EMN0<7N%=B2ZW63>!V_#\MST/1F?6@+ZO($
MW'6*[9;T1[)K=[^D":35]INSUTZ:=>3Z]Y$2VV\JO"6\]B3?<T>4#X9P'2C>
M5BY^V2^\%" NPR@@ILTU-FFL%-(LC&"<Q)S*+ PBY!0-8D5U:KM1PS18<^VX
MMU@A;;DS^,9O:+V^#]TX9:^<8/*E2JUHCJL(76 X4&-.+_=/'GN7EYS._R[I
M\IW^23DC880)#HFVGL/8E#87^O =*XAYA*A,0GTRM_+%=]"8FH)99T?5? +#
M**@X=<\>VX>S6Z]X FE@+=(#GU[I8R<0N"A];'_,T=/'3@AU+'WLU*/]+ P3
MCD#++W?+XFLNI/CYY=?2W.VMP\NO34)[E3NQ3HHB D54X1CB!&MS(\XPI$S_
M@0G39V>5(H6<CL_N+$Q--1CV@9H7W\JZKWNQ3J*@:][=S)$>TV)GFPP+]L J
MQC3,JK!NV3>GS1^,!"!?_+B5W+Z18I!DM_X@>C)C>C PJDW3'Z!] ^>"D2Z,
M0?BP[CVDLA2'B(0PE$EL C05))(IR#,DPS#F64A1K\"##U-M@K55$_.#:RNG
M#B = PQZP3/T6<D-F?XQ!0?"^PXD^#!NSZ;S IX,&3A\<FHE1#\6BZ]5G;./
MSU7S=FT3X8QR"F7(*$229?#_I^Y-E^3&D3715Z'9C,VM-@OTX0*2P/2OU%8C
M&Y525U*=MF/Z$88UQ=N1$7F"#)6RG_X"7&(/!L  F%1;5U4J1=+=/Q ?'8 O
M)$H9(&F6,A9R%B*KNCRC:3XU(MJJ5Q\@U(<&Y61*?QZ/>D0R')-,C37'^D0Z
MH@"%D7*1\YC03$8HYF3^5-?!4^_VNOJ%Q_[8"G]OP"OQ4"QU5D9 R:(.;_\%
MW@3(DCQ+DQ0@'J< $BS5_(<(4$*BB,1Q)M*\?1/>+@USQR;\'G0V> SF6_)?
M[!7P?(CH<U"G?XQH6,=WBX'ZL49A B>)0P?NI<\2K?7^-4X3AP['> 5T+RDP
MS ?^3[(N]*&EKE?91GXAE$($!098^:8 AK%R8$@B@6 \(5Q"QNV2R4]%3,VK
M[#2L:[%:!M'U &E&^;?!XYF;+9&QILW+QCOBMS,"1B6BRP8>,T;/E0.Z!M;D
M0GOXAS[O+CD3SW"_J<J*U%[643S#9Z%U4[]_O5K6&VR;IB3E7@3$7,0D32,D
M04XUA3#=/B>&3!=.D(Q&+*68&W<E?%%3ID95)Z%16QN"/2/J\JW!4<2=/B(R
M]8]?'GB3EHN_S)LQB@=-#3UHVAN(MX?)F4"\GK=M#YI?YAVSZ%#YR[QK(W7
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M/=X&UXW6'VR$W?JL@:69VU)VA2BWQ>G?%"5;K,K-6LP91ESJST]*DQ1 BB%
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M%K06N:.U@<@YXCI;Z:,2X$!HCEEQZ&.<%^L[_G.3F#8G$4*"T!B$,80 2LH
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M>J,D+ZMY"KDD>8Z4,X'5ZC-,,,!(<! E-.<9X2C#;%ZM*K(P8PD+V5:\L=7
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MA G4=#,>EI>NZ79=T5^CIILQX,YJNIE+=!$VWY1HOMLFQ,X)CBGCB($P2R"
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M[LW<BI3O#9H!(-GOU/2!X&J[YJR,<?=L^LP\V;CIO=A%P?UM_](Y#C-"(6)
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ML:E8LN>VF=5=]9JLU\_JE_7&]QPG.,^H6DDADL8 )A0!Y7LA &DHXA0E^IS
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MUT'F:O#PL,"M052O+RQ>E*?\O)6'/^E.U#<<^Z5F<<L%E0!*K$*YG$E $TI
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M'$">"$ H9H!*)F.A_I<E1GQ7UI+GYO)/V@92"'UN7^F["'[JIC6'CJ8U(^?
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M?+X3PXG#?,^3:_8Q;_K>A\+,-_RM/&C>!0]LWJ,T^E*,>;HZ.[(?P2S#B4@
M16D&8)1!]1.B( TCDL HRE.66#7I:9<UM]?/2=5@?]1U,8P3J0MB,R?O"#C?
M"0LGS#XW,'/.G&2 AJMV.!V2IFU[TV_R57L;@T<&LC/3_5?]?UT2]DK7:MS]
MJ2FU_H4*Z,__H?')LCSL:<-VNM_.&U'^J?Y>1OLJ[/^J\X(_T8-X*Z5@AR5!
M#$D!*<AQE@(H<P0HRQ) H( Q2C*6Y"J4WA[HVLP+3:N^E6,[&N%OD3X6^NF]
M-5.6%?OQX@=QLM&287K:;X.9PYSO''OVP=H4'="J&6U8I"_8:F.#\B-ZXB_^
M\?R)$H6@AB'XI0;B7Q?!$8N@!B/0: 0E' YIN.\RC:XHOJ=5?EKZ\+M,S!4U
M^7VT&%K2_*C$[NCZ:</%C_\0/Y<TBFE,<0IHQJ5ZL4D(B,@88#R!FB8*JV#;
MKI3Y0L+<@NI2R>#QZ3]LBY4OH>M^"S@!Q+.CKK$H%0P*#0.EHLNBY!;K1Q0C
M7XXX<1%RBT'7Q<=M'QP6\#ZH,?EJ_7)8O8H3U=Q[-;M52XT\C3%'. <QD2I$
MQ;K34)()P!(JTI S+-+(9J/<)W!N"[NI[QF%I%9Y8.>27M#-(D&74'IV"2-1
MM(ZN3*%Q% _UBILT@C$U_C+F,'[.PVW_Q^UZQ7XNPS#",D\P0(QA78<D02X1
M!(Q$*,Y0'H;2RML8R)R;P^F[3[;<PYJ@[N"ZWA[+.U_+JUU@H7+P1_6GE[;7
M%IA-<>M>29S/[?HY!%:WZ!>/SHV%\/UV\UK01OV76'WYJOY\>!4[^D7\70U]
M>*-V7L?;D^;%*$M3&F--HXO3',"$(I")&($D3C,60TXEM.H1-3/[YN9K:]V#
M2OF@T#[0Z@>-SDMJ/UVR@<R%XW#8E\O,S<],ZQF]4J9C3#PBM0@,OZ(^&H+-
M])MP;XX;3];]-1AR_$[M=)2.X]1T7AWW[S]_H_^]W14-*8N^Q G,),]T.]@P
M4QLA3<U ='X"9Q1R1$6&$JN>L!:RY_:2[BR[VFN'6^@?E)U3;;I"#YD8P]0U
M/W#[3D)SB;3+,K8VS/R7JUU)GDM96ALD%N5GK4.,9Q#H<=O[-K]=%L'GN<Q9
MFB,0<I$!2$,(:,@RD"5)!#%.< 3E4+J!49K-S36>%]CKJ#/OC$[WI_ TOPY/
MQ],9C)MVP_W)/2;3]\[B:AZ[=QG[SFV&7VX%)YA[(&(8I]?=6!N<P-E%\>!&
MP(#*8]T#<;T6[/!"UQ]WV^]B=_CY9K7__G(0^_\K7EX%?:G*2DF2IYC%I.@[
M"""*$Y!E80YPF,N0R301J5$;0CNQ<W/F3<6#6O.@5GT15,I;U.^:ST"WZ_6'
MJV>_:@CID-IH<VPMBJ:]8#Q1-?78KZ]=>;4U4IUUU^:C35>0;6WA6:6V_=,#
M$Z:U)3HAI2C=6.W__^-.\-5!_Z0O<U$>BE1Y=,0!C'4_"\HP2%-)0P09RNPN
M<SMDS<V7:YWVQ=7C[TKGW8&N-D4YE_Z7,S-TQ%>:$>AG+/.3.\ W"Z8=0>K9
MC9\CII5;-$&;YBK7 "I7V;4=DJ9-A>TW^2IOU>"1$4VP'QC;O0C>*#A[?-GM
ME, E@E$,"68@EBP'4"()",\$2"D1(8UDQH75F4&WN+GYF_(2B9;JUJ5<EIDB
M/0";.11WL'GV*25BE:;-DEOE6DIE'?=T[@7%96?F=F'3]U?N-?QFE^3^IX:0
M81W4.^%IOU<#-]LHEUT8;E65+2',"$FR$" ,(8 A34".J&:=H5((SK/$+(89
M)GYN;D;K3M7,ZZB%;;]]TR6DVJ:BYFJ[V:AX4[^A_UP=O@;K6V6F]NUR!LZ;
MP8;6ZVSX/C L4"^5#TKMJZJF1=6W1M,(W*A9]0JZ#3V83_"GX@]S/@F6%&-#
M,>SF(+,>=4*2LJ$6G[.8#1YE6.1:<2+HD0KJ@V<U3'&7S&3*8TD0B AG #*9
MJYA5,! BEE&48)EF5DPZ;8+F]AIIZ%G1EFA-!UW=MV)K%JZZ0,RSJQ\&EG6,
MVH>$H^BT5<RD<6F?L9<1:>_GQQ*4Z$SGW:M89AR*!*<)X$FN/$*24Y!SE@#)
M<9A$.$>6-]]7$N;F"NH-V,UH<2@728VFF0\8A9'GQ?]V?UA]TSW=FX%$O2=R
M4%#9BX%SMI%Z_#MQC%R8U\XL<OG!H971=1EE@A)&8@A$%%$ ,0U!QF,&$A2A
M1.91S.+,KB!ZGN625>VO75WD%5K="W<,!K[7JZ'Y RJ>>PL730N=IRQ);%/_
MNJQY5(FA'N91#?*P$_1QR\4RH1&7!$.0)F$"H%!O5!J%.KR6:4P5*#DAILNM
M.?#<EIO6+=#*!5H[\]5V!E;_:AL*@>][(3/KK1;;+5,'+;:S@29;;+?4;RZV
MF[\?2!U0]C"HZDZ6H8BRB&@>/2S4&XY$!.1($H H))D0,(U2(\J/V\//;>$]
M?/[\]OFS9=G_.6!FT>EP&#POOBHIW$?AT6V;7=7JGP\^;67^3<.NZO!O?VK8
M*GWZ]IVN=GHW]4%>)H ?B:C_OMWR/U?K]1*KMV8"*0.8";7_5&L79+&D0)"8
MH#1"(6-6^T\KZ7-;XR?E]7W'ZE0/00O][1:_W3R8^09OZ'IV'>? 7A>:-!CS
M:^T=,N0/0LV1\[&3/:EO&@3+I>L:-LC T[/MYLNA;EZGAJCVCB0*<11'.4AS
MKOO'L1203+NP6&T :$HBF%GUC[LM9FZ^2FMY:DRYJ,Z(![$3M>!J>)@V&BW/
MOJ< ZMD6*/L#M4X<7)VJW18R[=%:IZ%7YVO=GQ[F"#ZJ[\97NA<?\G5U>+=,
MLP@G:N\/1!9% $+U4Z:34$/"<XC#-$\2J\W(M8BY.8!:PR(O8W4H^:GIM^V+
M[3'Z#33-EOXXC#PO^R,\)^W<+?9VRQTM]!L")EWD[09>+O".3PY<W&5)TO[7
M[>[S5A[^I#NQ%!D*(<D2$,N(Z%<\ 6J]$T!)%L5ARO1?EAOQ15^</%LL\FM1
M1M_@K/P&7PGTN/?F?%70& 2';<#H]]6!KE?_%#S85WI;+OD;&!NN^8&03;3H
M*^T"N=T%G_N@L5_V[<:[6O<W)$R[\-M-O%KY'1\=6%!^4.NIW$L4*3M?MVOU
M\+[D]C@>H\$,1RA%%&1QS'0_4P&R4(2 )S)'F"$JN1UEEHG4N;W]CTH7%<0-
MM?]/33ED<$XW8A+,O(5S:#W[#R>HVA=;VZ#DJI#:2.:T1=(V,%P50%L]/- ]
MO>3[%5_1W<_/M"BUUH**W#,B,.89"T$8HA1 G<!#DA""4%+,<$8SR*QV'ZV2
M9N>&:,5A4&3&#LGG:P?5T,6X@,JW6[%!R=Y]]"'@RF6TRIG63?29>^4:>A\8
M4%BBSS-.;&/O7W1E[0?YO*,;]E7LEVD:QSS+)4@3%@,82PYRF0@@((H1(X+Q
MU"C[QT#6W%Q"J9_^NA\J#2U*$'I@[78)CL'R[!2TH@U>R$5P N[9.7 6A1KN
M )RH*F,,D';U%V;0=!9;] PQ766%F2UG912&C[@DBS\V2E[2!(89IP0PF5/M
M42.0TU" /(X)2R12_\S'$\4?Y<W-JSYMP/>J?_C.8[?W$]YFT9=#%#V[VU9Z
M^%-G=M\L\%>P>&6 /TF; ?O[E>EFS._7CPUS+F_I;K/:?-%]LHJBKY(V0K-&
M%*012Y3S%!.: (Q1#B *,<@)#$&<4QX+2"A,K8Z4>N3-S;F\%X?@W5:YEH&\
MYWWPFOD2AZ!Y]B6UIB>\IF$D,43(D5OIDS:I6S$T_=*MF#XV/"'EN;K<_HT>
MJOXYG\3WZF3\@_RX6VW8ZKONWO5>"7W^4ZQ?Q6_;S>'K?HG"/(I"&@$2\T0Y
M'9[IKK $4(D%2G#(,#9*67>BS=Q<DOHV)O99+,,GP\Q%30:Q9P=VF1-3V?)S
M$?P_]18./FQ<=KAV@9G#_)GANDR>9C,:MEO9..,''=YI^]?U]L_WRG[UXU-!
MQZ]\LXKX?EUMU!Y2_\P.J]="IS>K/5MO=0WN\<HIAQFEC!.0$BH!3'&L2V4Y
M"/.8)8CG$8UC*W:YD0K-S64J.T#1_GI56U+L=61MB_IWN=U]ZTZ%\3-U9MYU
MR@GQ[&"+%M3:EJ*U2S$K3V>S<C0H.%D4G$SR<L_H"E^'/:5'J3-YEV@7X-WJ
M^^QD7)?]T)942)+S/ 61A 3 +%&^EL0(1%APFL@TPJ'=A>9-,7/SH,7-4$64
MSQIZNN@"-JH9UXP\VTT2^A.[^,G?55W[?'>G<GW)>5O(#'HUM5YO=G]ZF%OX
M3[I;:3IXW3&^N(P7N<QSFJ6 (\(!E!P#RA,",L9P+$BLHC$K:M]+ 7-S!;5^
M@59P4&+#%81F#F ,,)Z7OA4FULN[S7!'"_MJ^$F7=)MQEXNY]7-##ZCV^T>U
M>5,QA-BPGP7W#EW7B9M+B"&)XYP ABE3BYI%@*0T!21A>0QC@C&V>LMWBYO;
M$B].O-E)W9)-EZX70;T=MCV Z@3;](3)%83>CY 4>@U-@X<:O8]]Z TX0C(!
MQ=D94:>PB0^!3 R_/N4Q>FI<><;S]H']S\MJ)^IF Q_5U^.@=BTZY?)[R0[*
MH& X2M2N 4< DBP"-&,8)!@E+$N3%).XKMHP<S#FPHU6RGD=AV=W4Q?*['5B
MRO>Z788^"Q"UTL.*. QFPLSW.$9WXI*/PS:HU#XV(U&^2&N^*%!^VXORX'H0
M<\ <EXD8"+Y+]8@Y(&U%)18CN,PWJC:M=9LJ&&,:,<V+$:M-#^8<9"BB0.BN
M[9&(4DBM3IP-9,XM2/KD,=GH'&PS'^480L_.J37IJ%*XOP^5H]2CFP!Y33\Z
MESB#%*2;$)BE(=U^=%S.0!T./!ZKMQ^*VNUEE""1AHB!A*)0;<JH[FO"$( L
M$UQ&*9$Y'I(6T"9P;A[G1&SQW56%>R_F=K?_+I"<[(+_6 ?_V #QH1O$P7?\
M?<@XOL9O%7>7F_H^X]LNXWN?&^9H.OI J_%WA]4_BX/BRK==)<0(GA"H#X,P
MS%,5^Z02Y)JJ'L,H9YPB%-KE6X]39VY.RCX]:>1TF'FHZ4#V[+\Z&],OBO")
M:9+LIE4^DI?< .J_:[V),G-I9&\!G$5O>YM1!]3['<_3#I^V/^GZ\//$=Z*V
MK/K(_K#])-;Z'.DC5=O5NHE:'%/.H@0"DF2)BN:*B_1( -WO X=",LS,.QT/
M5&)NSO-D1K K[0BV1T/TX7MQR738!F]?M^N7??"K>AOJ8FZ+<KBAT]7M9J>:
M!,_.M8%_94*#)"GX>,*_,B,H[.AOD^=N&BS*%2>8CHGJ&'U-BUV-XT@\.XL?
MAXX]757D2.O/RB7'CM7VEFI.]#OUT]_^I?X7]1^=O/2W?_E?4$L#!!0    (
M $B(:%6X<GD7P(X  &UE!@ 5    96]L<RTR,#(R,#DS,%]P<F4N>&UL[+W9
MEILYDB9XWT\1DW,[EH%]J5/5?112*%O3BI!&4G1VSPT/%H/$3HI4D72%5$\_
M!I*^+Z*3^/G#LR>7")>[B[#E@\$,L.5?_\NWS[.?ON)R-5W,_^TO_*_L+S_A
M/"WR=/[QW_[RQX>7X/[R7_[S?_I/__I_ /R/7]Z]_NG%(IU]QOGZI^=+#&O,
M/_TY77_ZZ>\95__XJ2P7GW_Z^V+YC^G7 /"?-W_I^>++]^7TXZ?U3X()<?.G
MRW_QGME@<P:?@P:5@X3@N0$=O?26:2VR^;\^_DM60FJC TBF(BBA(X2B! 13
MK.!>HS-I\Z&SZ?P?_U+_$<,*?R+FYJO-'__M+Y_6ZR__\O//?_[YYU^_Q>7L
MKXOEQY\%8_+G\]_^R^[7O]WZ_3_EYK>Y]_[GS4\O?G4UO>L7Z6/YS__CM]?O
MTR?\'& Z7ZW#/-4%5M-_66V^^7J1PGHC\Q_2]=.]OU'_!.>_!O5;P 5(_M=O
MJ_R7__R??OII*X[E8H;OL/Q4__W'NU?7EL2OB]G9ZJ]I\?GG^N.?GR\(#$3H
MYB^NOW_!?_O+:OKYRPS/O_=IB>7?_H*+V0JJ1IF7K"[W?V[_XL^7JWY9XHJ
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MOAQWE_70ZONAH^.;S6:B[0DB;Q>K=9C]O],O&]?)"^39&0>6 BU03$IPRGI
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MZN@47*]6JS/BA$1C0RKD;-9F4\1)H- W(*3L R;+1+2M6]+>3\W85U\C@.H
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MJ*M%V54)T4]#35J\\J!:GU*;7:T^8LFAKEH/Y;K1U>OV??J"B OP>B,B>N5
M:^]!6<[!U;R;))(4FL!<9.L1'_>0<OP#X^X#/]0:ZXG &%14Y"4ZKFKLBV23
M501K*%@QK/C<OJCF&@7C7IBVT/?M5\6#)3SBJ;=:KFMCZGR6UA19X/+K-.&S
M;]/5)''R\%A] 7.U<JR^G7LRLE "RIR$5R;NY3;1 E?007^Z1,9]:W=RF7Z
M'A<-A=H'*#;OF%L.5B\6G\-T/F$R&8PN@'2&3G3!&869S ,O++K:)9:GO8HZ
M]T/&;0+&@4<;G=X&R)$"[L!AWC'R&WZ.N)Q(YYP7J*$DK,1+1<13U.@C,I_0
MQ-B\!N$: :.CXUB%WIX:<*!T.X#&3@X[XK.(CODZZ]8540NX)'@M+ 6"6((U
M68GF-SO7"!CG_6PX:!PNW1Z@<7[,4NR K^C+U40(%<F6>I A(5E2)%Q++<!I
MX[+W'K-JG;E[FXI.'ED/=SX:";@#B+S#KS@_P\O6U%PI.FVKS7.B5NI%HC\@
M0A )4S':"=DZ^>4F#9WXI@?J]%8>[1$"[@<@+TE.Y^TO_CY=?WI^MEI3>+>\
M&&11VY+3_W+-.Z^I JED!8X[\MDBR<NY^BI70BK)&!Y=ZY#^ #+'A=EQN+@;
M9(,IJ0,<7G3SV8T6O!2<8*%P+1/DH,B !Z<@; 8\Z6#0,%U[FS5&V[W$='*R
MM3%=;43> 7:>+U;K-Z5.6;GJ';Y?S/+$.D>'?2B *C!0R3H2C9,@>7:F6*.4
M;YV =C\UXUJD1NJ^];[01/8=H.AO%$O4V_%=Z\P/B\LF=N]QO9YM=MX$G5(F
M\@C*R%HT01%'I( 2BF#)1Z9E:9[1N!=AXUJF8;#57B./AYG?PFR.'S<D- SK
M9[,Z'PSG)+D9;9UG^?-T/JU26T^_XDZ.$R>E\44E($-/$:FN22FU":?RQ= 9
M[E6TK;M][T?9N#F/P^!M )UT8-=J!TXBX!/Q\X+\R-EB,S!SQ\REZYC^_6RZ
MZ3#U=KD@"[ZJAGWB98Y2(W&98QV]4*]6"M-@E#2UHB=DW1I^1Y [;K+D,)@\
ME?:Z!>H%2Q-+;!#1'-"%0&(TM;^0UI"++":C3%JT#@1^0-*X69.G!-QA6N@
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M12=P%A$21\-9RBRVKX'IL^_;<9K_0;NWQXBY X?[_C(@6?,KDE% ME*33(2
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MI?7TZ^T#!9FT1=5V_K;4'M:<..:>O)R2K6<%C>>M^P(<3_6X+D!G<!]0X4\
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M/;WE$>1U@KMFV+C92V0@176 P5]7Z^GG4)NL[L$;6IN9CAQJ[CFHHAQMY5(
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M=P":NQ,1?1!<RY(AQ$0V5[@(WB9RQYGQ#DE&.K6^CDYC\.1>FGUR\.0^8NX
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MQ9QTWF+K\4H#R#JE>HYC,-9:0QV";C<BXRWQ1?^RE/4LYBA#DJZ.M _D*Y'
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M=P"=NQ/W-8\*C4%(SM:2(7)./=<%M(F!"U6TS*V[IDYBK\%>BGURK\$^4NX
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M>WVUX-YIQPUS$:1Q"(KSRH2,M8PJ9(5>&3/H].]3#' ?(=..N1HK7WZ\S#L
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MV1B&Y1-X4>E%U:>,]CM9_C>;3[CZ\"DL[A7.3'-MG:4[2-4@5&7/($;GP)1
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MV#12Z66>M@^@RS@6QG#^!.'[$I0 EC,!]ME.C@'2P*\:^1O^H^1=K$/^6R;
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M,CW2N.!I ^OA,X2OHZV'_@ZA25DZ3-=KLRZUY_0S?!N#Z"" 0R2P1;+H8H_
M+ H\GIGAQUM"M\,6T>T[E<S++#B%\PS[C\H8M)Z+<*,J@Z-QHL &.B:H G#
M85,;I4B!^A[?OG_\[?CE&R+G=(]8OE*Z7"03N%+Y@H^H9YN#+DR7^&B]ASI)
M=Y__RHL994#G67=ALHF?4.J%&U8!/Q+!4&\.4K5TE,0AR\)=O#=$Q.=Q@:9[
MW+D;X$-$ZP2*\P(F/1)54@:TWUU'@X9AT\4D)B#,2L"KLPRZ($Y6(X>P9"*8
MB;Q<^#T/02Z-]$W_O8K&S&.S' T!\#4<NYR)_7*#BM/ OKUZPZS/_177@EL?
M+JAUZ?!P7"28&O&$-$MWF2Y)_E#@) Q[P'4C'1&X>HPB-*Q4!+P>!U:Z;, N
MQ ZO#!RJ-0:&CB6 _#@<D@)=)\[+63K.:(PAT"BX''  :\,)LB$0,1IJ04I+
MYCT!E)<.'MM+AJ6 "Q,QPV3&K*P80$B5=27,JKQH/IGN&U.C5<%+TX[9 [P]
MF;I I'G9ZR@*FJPW/&?YW)%ZS%!OYD@=!.1K25;(VFUP!+-YK.Z">10Y)HEU
MV'BS+0"HQ!1.9-$E)E6AHI?*<I[E7_BK:97&H5IH'/8"-,NI\W1A^!7M'XB$
MI)7AEV&(VE?!H@9Q2V^RWGK1SVK<54XC+]%[#V,KB&MF%8AW-W&&[!?E*3BK
M))8D8JY'L)(1NCYQK?R^)DX.U&VEEUSQS7W[BAC"'8%)/\"QO@&W]1*'H&$>
M^*OC_CO)]6!F8BQWD7A^V26=_[5(YF)1//D&40;[>RK.@$<QS']N&M!#I9<-
M"2M_G04 45[^O<87F*JP8G/C4'=B2*AI187'#^G>PW%>!-5,:31P]RJ0210K
MSJMRHJ5,(Q=HX@D/S$6>H_XF"Y< .A9CE"GBU+> (2_1X@7=7AA!C*Q^6SQ-
MARV22'$1SOH?/O8NKT^,M^FT=]E[>S'8$B]3U*KE7B?]GPJXJ=<"N/=&(RSV
M&@P(,^&*Y4%!@[S3X@I2!Y$&9*WPRUN0A8)?8,+HJ<$[/YC#4POH+JL*4@NR
M!-HM@IV_'QWN=V&6'93B@H4$>:8-UM66;) ;UR #9U#6Q#T3,9FK45;*(U*4
MZD9Y(ZGE<ES!VT#F98$FF;B8P/[ CN<9[CRJH"1Z"1)JV2#",B]9W%#>@O_N
M+0NXC2/+09"3<RTUNRT$.RAC)FBY&*%YBFWO)+B+-*W("(B"HTQ#/'4PEL/]
MPV>=5=/T)I-GH833*I>,(FCV$Q&1+&B3SK6V!BI)&GH%,:TBZXP2[Y4^B38I
MF%&<8NQF(:-N,*Q*%I2E^4KI 2#@L0D)M!SE;&W:"V60<@V&.$":-YK\R(J7
M2WB@+5ZT4QQQ*V[#=K KV2)V1?:J)S]?PS+M]M/@-$NK8J^F%V(( JQCC#H3
MV9!#28%4 1H1=^&D#_$M/-+]5!KJ;TC^N2'Y(.@SR6_+R?:FW883[L==X.J!
MK,P.VZ8PC(VN'1K-8;B'.\/.9F49XI'>5IIS2TP2^06LV//]( *-M-%0 XP$
M@Q_(@X'^ECB2D:=GK8Y=41(0L3=HFO09X*SL/[IP=2*0!HL1&27A>=A(2:8J
M=X<]+2F74Q&GQ<KP'V1@&5PXDIW8S[XTKU$,6A].&X?FV*'\IKKL@#C>_T_-
MM)I7D\(#(@JJA#Y3)>+= !N6$6S#]YYL.<]HLL4WF2U:';[9=$,4!4B?71.O
M-5+&)G9GP9.X+"PZ2%P7E('09EX(-IO?>WY+9]*UB(J /69L.HLDR"?QD",=
MVD ^CG?"C9(/V(8DFW<<6ZAV<&2D$M4<""S BE*O;A'?@GJS\QR8&A$7&\*6
M"+M7O=5[U:$C@;%7CLSHGT>R[2J3[M)!#':$RQG$,+N1'17D3+1H>1S-L37U
M@<$)WPYQ:]0><>O5WO[!>@/!":E!FQ=('A[549,2T6P98V@7AF^FC9H0JWR.
MRH1T#U0M]'2 ?#E+1-IERV7=\-G8HY%+M3+IM$42:A>OA0D@,.29U!L<(_K,
M3:B!I\JU15YMR^FP&3KLD0M*C)HH];HK?6"&5*U*T><&NCY\#YN$5&J!)I^0
MW'Y'^QW#A%U;PH[R]#$Q)NU>Y4G!PR^._]/$\I#P@_D;G6"(VK@.)79B:HC1
MBW 2RQME<A\%7^3"<S%CN$4H2!G'EE>[IU<>(+;4>-Y>'<+C[AJ=:G1U =>9
MU<\@'^LQ4/ \I1:\-XD-*(,$RK5[\'/MD67C$'R$OM#6KJ1@%*)P5AGNJ4A&
MP11V>^(R+IE&>DMH=>$EOG[$3KS^AD##\%@Q5^I^;X&"6GP=E\!FPGN<4BW(
M;U2\H%U+LQ7[M"QBHC](+(@ 52E:RKKN67Z4V)[\W/4]Y*PY2-*4RSBMLJI(
M%E8&+R=Y5HU9LE%J&>EY^HB[^[+:OO3H!G[R\^%6NH';(J6.VR.EWN'#ZOU1
M 4O?K'#Z=LFS8+DHLL@Q.J6#)(,Y(4MV)$',O(X*#''5EHDIJ4IE%GX!D85,
M$UV,(ROS.$3]BG]!,0:^=V4&YP<3H67:D[1(NTHFT;\V#8@"J=*"EKGC94A\
MG?JUH7-\D2(A3A6O:,XB42X>(XVMT4*[R^$*O+>&!V#X(09^S5HEJ?=GF\XD
M])*/KNQYOJ9C^XF.;1L\KE?7GUJARR@[,F^<L0&B)EOEX410?&=:4<HXTHN)
M4*Y&?3;AOR!*J^4U^L[?#[H'A\?H]0@H>=\1^1,1?MF]#B<92'G!C4@J:S]V
MSG.CQJ'[9"09UEO)P^O1,6J4M::I+"=9!"LZ5D&\15%--;&KZ4O8, ]GE&08
MONAX63UU!34E/1*F=YJZQBH@D?2',29KH&M7FZ6([KJFS >:I7";[KT3,<P4
M%<@J+RJD&S#!!08IX+%S[ AFOYZ]:-RM9_N[.%C$H  )!P,[.=?$]MYDX?!&
M\M"M;.1!+=G)5;O@=*YCW$M[J;0V36NO;YCSBHW997_]E!17<M33 A2SA+AP
M+M%*+LUG_I5W#"/<:!E4D*S2?JUZJX5_8B-J'AB"0C/ (/8\Q' ZL\-EC2BH
MHP+?7HHB$G\$&'>*>\=OH&"A=Q#CGN$7RO\1JH-5YU0Y_KS1U;K?H<P-_279
M==405$=TGV9H!XNTZ6Y=>[&B-OXSRM L&MI6X2CN:E#:D0"9ZS:>5E.R?U O
M$H9[L-]A?TW7/Q<@1^)>.%X)45BOFQ+,G#A=1<WH1-K(R:^V3V\,*LF[#_8N
MT(6!"T';P)8L- : I#O#*)D'^KR6?$+W#!6B(%%<:!T5I*D*LB7: 7-Q0Z C
M5<(93>B,H-@ANAW&_@JM)0E?8[1JP5VN<N7#<^)\S& :3ROU:H\0=H(K%0H.
M:&^0+LD.@ VO6P_7,. <MM5#( *NW$'+OW8HBL>V@PO"UP;:<][4WWOO>O=J
MF4K63P;;Q!D1J%)BM"+;-46'8W27*2UMYZC*V4W8%&P@:O$&PI@SFZ^C3K]I
M8%GFF:YVD+K(/#4^Z'F%D5P040^E7:U"$>T[)V]Y#!)7FF0]P;WI!ASN'[P(
M^M,T'E8%XH6I)C^BX;8MZ@6-$4?4!LD9F&8H9R4+"E[.D[T[M!.40ZI\-C'E
MXL &IS"8">:IJCV+*$65J0H2$Z#4QMJO6!)Q4DS:E;G-C^5!X,D<<?ZD/AQT
M:Y1PY*K\*\YQMDKRX@<K5.@I]()?Y[M8^N>1R8,71W#'H3-D]X[1K;EEM2=I
MH+"&/!9I7&=X\WT9ST[!'"NX8A\3C&E 64#RSHZJ$M-KO'>[*$20FMY 9%BV
MU!O4]:^VR3CRK> <(^&B5+C]Z9B)_Q; 7T!,Q.C0+0D*G/PP]K]3T )&('=O
MFWMZJ.8%PFPDK:X#.I\ 38+RV)?PE\CV1TRTD"GF^CUZ$-9X$)YMI0=A4U'$
M&LZFZ#;)]C53P,J@4LVEK>2J[@%YJ@L%Z[/0CF<Q1<2QIM#^%4$>M:CX+:'6
M<7NH]:N]YW<0[%\%9^&V V7 G(P;-2P.1R B2F$+*I)V9 DW1T0LV<Q,2U6!
MVB:E41(0@#W+J.HP8889 &%A;4&G>'0?3W?C9OW^(YWNWBVZSS:-@;2<3Y?+
M>#HD9  CB8Q(MS !9A8,2$T!%5A$)(M85M;QPBIEF.1H#!19?EKC/-X/!PG3
MBUCFOQ_?J!]Z:Z950[%S9>VGBA'](WV\8*O.RY?V7+"[;I>UH'VD-/7-7K,3
ME%^L,NN[79ID?L\; LKH$([F*C:B&4C722;LVNS(;I!7B<&900N_L92)"-1U
M=O3CI\=#CKN5M.>0W\U%+N#/:1J/XC:(2OTFR[^QCZOL4#)G-0/':!=. LPF
M6A@,"6WWU6&U]PBXX'L$PICC>J 'W.!>M-*B5LGV7&B]MI@.]--R;YD?A[/Z
M51I$(P@R*N$VF=9*DTKRLXH2)NU8VU(3N0A1TK06=MNLNJO<.J/<FN^26"AS
M9IP654Z\5&%ZD$ [8O .=]1P@R<ZM]XB'^_,)W&B\G]-1A2GAY0*_L?VY;@^
M.D:]TPZU.YSJ_KDQ=EL].NRXI,[YO*R;H7K5E;F1TI$-%OVNH8.XJG;'WRMS
M)(S5F#JEG4!7.[L,FFRH_$*IL/,80%;4(;_,]%><";QI>/B:?M/B"_N:6(1Y
M$'%N+T+)L_809T(H.1GL?KYX_SZP)7(8RF;0N_IP<<G ):>_!0AD<G+YVW8P
MR&E[]N#9G0QRX% 7"A=!R+N6610<"J=]&A[P( 4KI, %9S)$%D,4Q-?="(14
M3;4!H'N=0UDHCX_"_20R2*A*VG$*/)G\Z?0F0KPJ:%5:2I(=HQLBK?K!6L(H
M?$HS_0%[21*$WRNQ'?(?,3=98)['6)-!!BID&#P%9A=34R*/*6S%8,%"$R6M
M$PJ]VI9"<HB&!ZD!:[#UVG;EP@6B-!O/<-<(C\UG3<@8C!%F+WB+G53Y+"MT
M'^ZN==O@;]WX:5>^5B6I3*5(-=(K2T])DLUA*Q0BI^BHO9]J$#R5DB1"BEK
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MG$TX? ,K%.6[9.5?^)"<R  YB[$A-L@IR5;+&UAR<#?F;-$]S!+VM3NU;M9
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M+3(P,C(P.3,P+GAS9%!+ 0(4 Q0    ( $B(:%7E)?2_3QX  $<I 0 5
M          "  <S@ @!E;VQS+3(P,C(P.3,P7V-A;"YX;6Q02P$"% ,4
M" !(B&A5UM![1BUD   R700 %0              @ %._P( 96]L<RTR,#(R
M,#DS,%]D968N>&UL4$L! A0#%     @ 2(AH5:#2?JFSW   JSD) !4
M         ( !KF,# &5O;',M,C R,C Y,S!?;&%B+GAM;%!+ 0(4 Q0    (
M $B(:%6X<GD7P(X  &UE!@ 5              "  91 ! !E;VQS+3(P,C(P
M.3,P7W!R92YX;6Q02P$"% ,4    " !(B&A5X)YP$J,(  !6*0  %
M        @ &'SP0 97AH:6)I=#,Q,7$S,C R,BYH=&U02P$"% ,4    " !(
MB&A5^>>98(T(  !)*0  %               @ %<V 0 97AH:6)I=#,Q,G$S
M,C R,BYH=&U02P$"% ,4    " !(B&A5/N;_(&T%   .'@  %
M    @ $;X00 97AH:6)I=#,R,7$S,C R,BYH=&U02P$"% ,4    " !(B&A5
M9)-6G68W  !2:@$ '@              @ &ZY@0 <V%N9')A8F5A=F5R96UP
E;&]Y;65N=&%G<F4N:'1M4$L%!@     *  H G (  %P>!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
